FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Momand, JR Xu, GG Walter, CA AF Momand, Jamila R. Xu, Guogang Walter, Christi A. TI The Paternal Age Effect: A Multifaceted Phenomenon SO BIOLOGY OF REPRODUCTION LA English DT Review DE DNA repair; mutagenesis; paternal age; spermatogenic cells; spermatogonial stem cells ID DE-NOVO MUTATIONS; MALE GERM-CELLS; SPERMATOGONIAL STEM-CELLS; NUCLEOTIDE EXCISION-REPAIR; APERT-SYNDROME; OSTEOGENESIS IMPERFECTA; HETEROZYGOUS MICE; COSTELLO-SYNDROME; CROUZON-SYNDROME; FGFR2 MUTATIONS AB Birth rates for older fathers have increased 30% since 1980. When combined with the increased risk for genetic and multifactorial disorders in children conceived by older fathers, paternal age has become an important health issue for modern society. Laboratory research in this area has been minimal, perhaps because of significant experimental barriers, not the least of which is inadequate access to fresh, disease-free human testicular tissue. Regardless, progress has been made and intriguing models supported by experimental evidence have been proposed. The putative mechanisms range from reduced DNA repair activity, leading to increased mutagenesis, to positive selection of germ cells harboring specific disease-causing mutations. There remain many important venues for research in this increasingly relevant phenomenon that impacts future generations. C1 [Walter, Christi A.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Momand, Jamila R.; Xu, Guogang; Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA. RP Walter, CA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM walter@uthscsa.edu NR 101 TC 9 Z9 9 U1 1 U2 16 PU SOC STUDY REPRODUCTION PI MADISON PA 1691 MONROE ST,SUITE # 3, MADISON, WI 53711-2021 USA SN 0006-3363 J9 BIOL REPROD JI Biol. Reprod. PD APR PY 2013 VL 88 IS 4 AR 108 DI 10.1095/biolreprod.112.103440 PG 9 WC Reproductive Biology SC Reproductive Biology GA 138EF UT WOS:000318490800014 PM 23515674 ER PT J AU Velligan, DI Castillo, D Lopez, L Manaugh, B Davis, C Rodriguez, J Milam, AC Dassori, A Miller, AL AF Velligan, Dawn I. Castillo, Desiree Lopez, Linda Manaugh, Bren Davis, Charlotte Rodriguez, Juanita Milam, A. Camis Dassori, Albana Miller, Alexander L. TI A Case Control Study of the Implementation of Change Model Versus Passive Dissemination of Practice Guidelines for Compliance in Monitoring for Metabolic Syndrome SO COMMUNITY MENTAL HEALTH JOURNAL LA English DT Article DE Metabolic syndrome monitoring; Practice guidelines; Community mental health; Atypical antipsychotics; Implementation of change model; Serious mental illness ID ANTIPSYCHOTIC MEDICATIONS; VENOUS THROMBOEMBOLISM; HEALTH-CARE; SCHIZOPHRENIA; STATEMENT; CATIE; RISK AB We developed an intervention to improve compliance with guidelines for monitoring metabolic syndrome and compared compliance prior to intervention and three times post-intervention at three community mental health clinics in Texas. One test clinic received intervention and two other clinics served as controls. Fifty random charts were reviewed from each clinic for three specific, 1-2 weeks periods over the course of 18 months. There were significant improvements in the ordering of labs, the presence of lab results in the chart, and documentation of blood pressure, body mass index and waist circumference in the intervention clinic over time in comparison to the control clinics. Documented evidence of physician action with respect to out of range values remained low. Metabolic monitoring is a multi-step process. Removing barriers, creating specific procedures, and dedicating staff resources can improve compliance with monitoring. C1 [Velligan, Dawn I.; Castillo, Desiree; Milam, A. Camis; Miller, Alexander L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Lopez, Linda; Manaugh, Bren; Davis, Charlotte; Rodriguez, Juanita; Milam, A. Camis] Ctr Hlth Care Serv, Bexar Cty, TX USA. [Dassori, Albana] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. RP Velligan, DI (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, Mail Stop 7797,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM velligand@uthscsa.edu; castillod@uthscsa.edu; LLopez@chcsbc.org; BManaugh@chcsbc.org; Cdavis@chscbc.org; jlrodriguez@chcsbc.org; milama@uthscsa.edu; millera@uthscsa.edu FU NIMH NIH HHS [R24 MH072830] NR 18 TC 2 Z9 2 U1 0 U2 8 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0010-3853 J9 COMMUNITY MENT HLT J JI Community Ment. Health J. PD APR PY 2013 VL 49 IS 2 BP 141 EP 149 DI 10.1007/s10597-011-9472-z PG 9 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 136MS UT WOS:000318366600001 PM 22350562 ER PT J AU Jackevicius, CA Tu, JV Krumholz, HM AF Jackevicius, Cynthia A. Tu, Jack V. Krumholz, Harlan M. TI Statins: Is It Safe and Effective to Use Generic "Equivalents"? SO CANADIAN JOURNAL OF CARDIOLOGY LA English DT Editorial Material ID CARDIOVASCULAR-DISEASE; DRUGS; ATORVASTATIN; METAANALYSIS; PERCEPTIONS; EFFICACY; ADULTS; RISK C1 [Jackevicius, Cynthia A.] Western Univ Hlth Sci, Coll Pharm, Dept Pharm Practice & Adm, Pomona, CA 91766 USA. [Jackevicius, Cynthia A.; Tu, Jack V.] Inst Clin Evaluat Sci, Toronto, ON, Canada. [Jackevicius, Cynthia A.; Tu, Jack V.] Univ Toronto, Fac Med, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada. [Jackevicius, Cynthia A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Jackevicius, Cynthia A.] Univ Hlth Network, Toronto, ON, Canada. [Tu, Jack V.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Div Cardiol, Schulich Heart Ctr, Toronto, ON, Canada. [Krumholz, Harlan M.] Sect Cardiovasc Med, Dept Med, New Haven, CT USA. [Krumholz, Harlan M.] Yale Univ, Sch Med, Yale New Haven Hosp, Ctr Outcomes Res & Evaluat, New Haven, CT USA. [Krumholz, Harlan M.] Sect Hlth Policy & Adm, Dept Epidemiol & Publ Hlth, New Haven, CT USA. [Krumholz, Harlan M.] Robert Wood Johnson Clin Scholars Program, New Haven, CT USA. RP Jackevicius, CA (reprint author), Western Univ Hlth Sci, Coll Pharm, 309 E 2nd St, Pomona, CA 91766 USA. EM cjackevicius@westernu.edu OI Tu, Jack/0000-0003-0111-722X NR 17 TC 1 Z9 1 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0828-282X J9 CAN J CARDIOL JI Can. J. Cardiol. PD APR PY 2013 VL 29 IS 4 BP 408 EP 410 DI 10.1016/j.cjca.2012.08.012 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 133UQ UT WOS:000318166500002 PM 23062664 ER PT J AU Camp, ER Wang, C Little, EC Watson, PM Pirollo, KF Rait, A Cole, DJ Chang, EH Watson, DK AF Camp, E. R. Wang, C. Little, E. C. Watson, P. M. Pirollo, K. F. Rait, A. Cole, D. J. Chang, E. H. Watson, D. K. TI Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy SO CANCER GENE THERAPY LA English DT Article DE pancreatic cancer; transferrin; p53; nanoparticle ID SINGLE-INSTITUTION EXPERIENCE; CELLS IN-VITRO; 1423 PANCREATICODUODENECTOMIES; NANODELIVERY SYSTEM; INTERFERING RNA; CARCINOMA; IMMUNOLIPOPLEX; RESTORATION; XENOGRAFTS; EFFICACY AB To overcome gene therapy barriers such as low transfection efficiency and nonspecific delivery, liposomal nanoparticles targeted by a single-chain antibody fragment to the transferrin receptor (TfRscFv) delivering wild-type (wt) human p53 (SGT-53) were developed for tumor-specific targeting. We hypothesize that SGT-53 in combination with gemcitabine will demonstrate enhanced therapeutic benefit in an in vivo metastatic pancreatic cancer model. Intrasplenic injection of 1 x 10(6) Panc02 murine pancreatic cancer cells was used to generate in vivo hepatic metastatic tumors. Nanoparticle localization was assessed by tail vein injection of TfRscFv with fluorescently labeled oligonucleotides (6-carboxyfluorescein phosphoramidite (6FAM) ODN) imaged by Xenogen IVIS 200 scan. SGT-53 (equivalent to 30 mu g of p53 intravenously) and gemcitabine (20 mg/kg intraperitoneally) alone and in combination were administered biweekly and compared with untreated mice. Survival was determined by blinded daily assessment of morbidity. Human wtp53 expression and transferrin levels in the tumors were assessed by western blot analysis. Tumor burden was quantified by liver weight. Xenogen imaging demonstrated tumor-specific uptake of TfRscFv-6FAM ODN. Exogenous human wtp53 protein was detected in the SGT-53-treated tumors compared with control. Compared with untreated mice with metastatic tumors demonstrating median survival of 20 days, SGT-53, gemcitabine and the combination demonstrated improved median survival of 29, 30 and 37 days, respectively. The combination treatment prolonged median survival when compared with single drug treatment and decreased tumor burden. The tumor targeting liposomal-based SGT-53 nanoparticle is capable of sensitizing pancreatic cancer to conventional chemotherapy in pancreatic cancer models. This approach has the potential to be translated into a new, more effective therapy for pancreatic cancer. Further optimization is ongoing, moving towards a Phase 1B/2 clinical trial. Cancer Gene Therapy (2013) 20, 222-228; doi:10.1038/cgt.2013.9; published online 8 March 2013 C1 [Camp, E. R.; Wang, C.; Cole, D. J.] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA. [Camp, E. R.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Little, E. C.] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. [Watson, P. M.; Watson, D. K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Pirollo, K. F.; Rait, A.; Chang, E. H.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20007 USA. [Watson, D. K.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. RP Camp, ER (reprint author), Med Univ S Carolina, Dept Surg, 25 Courtenay Dr,Room 7018,MSC795, Charleston, SC 29425 USA. EM campe@musc.edu FU Hollings Cancer Center, Medical University of South Carolina [P30 CA138313]; National Institutes of Health [5R01CA123159-05, 1K08CA142904] FX This work was supported in part by the Flow Cytometry and Cell Sorting and Molecular imaging Shared Resource, Hollings Cancer Center, Medical University of South Carolina (P30 CA138313) and National Institutes of Health, 5R01CA123159-05 (DJC, DKW) and 1K08CA142904 (ERC). NR 30 TC 40 Z9 40 U1 2 U2 35 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0929-1903 J9 CANCER GENE THER JI Cancer Gene Ther. PD APR PY 2013 VL 20 IS 4 BP 222 EP 228 DI 10.1038/cgt.2013.9 PG 7 WC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity; Research & Experimental Medicine GA 131OT UT WOS:000318003700002 PM 23470564 ER PT J AU Brennan-Minnella, AM Shen, Y Swanson, RA AF Brennan-Minnella, A. M. Shen, Y. Swanson, R. A. TI Phosphoinositide 3-kinase couples NMDA receptors to superoxide release in excitotoxic neuronal death SO CELL DEATH & DISEASE LA English DT Article DE Calcium; glutamate; NADPH oxidase; protein kinase C zeta; protein kinase M ID PROTEIN-KINASE-C; D-ASPARTATE RECEPTOR; CEREBELLAR GRANULE CELLS; RAT HIPPOCAMPAL-NEURONS; LONG-TERM POTENTIATION; NITRIC-OXIDE; GLUTAMATE NEUROTOXICITY; NADPH-OXIDASE; OXIDATIVE STRESS; NR2B SUBUNIT AB Sustained activation of neuronal N-methly D-aspartate (NMDA)-type glutamate receptors leads to excitotoxic cell death in stroke, trauma, and neurodegenerative disorders. Excitotoxic neuronal death results in part from superoxide produced by neuronal NADPH oxidase (NOX2), but how NMDA receptors are coupled to neuronal NOX2 activation is not well understood. Here, we identify a signaling pathway coupling NMDA receptor activation to NOX2 activation in primary neuron cultures. Calcium influx through the NR2B subunit of NMDA receptors leads to the activation of phosphoinositide 3-kinase (PI3K). Formation of phosphatidylinositol (3,4,5)-triphosphate (PI(3,4,5)P3) by PI3K activates the atypical protein kinase C, PKC zeta (PKC xi), which in turn phosphorylates the p47(phox) organizing subunit of neuronal NOX2. Calcium influx through NR2B-containing NMDA receptors triggered mitochondrial depolarization, NOX2 activation, superoxide formation, and cell death. However, equivalent magnitude calcium elevations induced by ionomycin did not induce NOX2 activation or neuronal death, despite causing mitochondrial depolarization. The PI3K inhibitor wortmannin prevented NMDA-induced NOX2 activation and cell death, without preventing cell swelling, calcium elevation, or mitochondrial depolarization. The effects of wortmannin were circumvented by exogenous supply of the PI3K product, PI(3,4,5)P3, and by transfection with protein kinase M, a constitutively active form of PKC xi. These findings demonstrate that superoxide formation and excitotoxic neuronal death can be dissociated from mitochondrial depolarization, and identify a novel role for PI3K in this cell death pathway. Perturbations in this pathway may either increase or decrease superoxide production in response to NMDA receptor activation, and may thereby impact neurological disorders, in which excitotoxicity is a contributing factor. Cell Death and Disease (2013) 4, e580; doi:10.1038/cddis.2013.111; published online 4 April 2013 C1 [Brennan-Minnella, A. M.; Shen, Y.; Swanson, R. A.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Neurol, San Francisco, CA 94121 USA. RP Brennan-Minnella, AM (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Neurol, 4150 Clement St, San Francisco, CA 94121 USA. EM angela.brennan@ucsf.edu FU US National Institutes of Health [NS041421]; US Department of Veterans Affairs FX We thank J-Y Ahn, SM Massa, and S Finkbeiner for helpful discussions and C Hefner for technical assistance. This work was supported by funding from the US National Institutes of Health (NS041421) and by the US Department of Veterans Affairs. AMB-M designed and performed most of the experiments and prepared the initial manuscript. RAS conceived the project and prepared the final manuscript. The authors declare no competing financial interests. NR 60 TC 22 Z9 22 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-4889 J9 CELL DEATH DIS JI Cell Death Dis. PD APR PY 2013 VL 4 AR e580 DI 10.1038/cddis.2013.111 PG 10 WC Cell Biology SC Cell Biology GA 132NL UT WOS:000318075500014 PM 23559014 ER PT J AU Mazzoni, M De Giorgio, R Latorre, R Vallorani, C Bosi, P Trevisi, P Barbara, G Stanghellini, V Corinaldesi, R Forni, M Faussone-Pellegrini, MS Sternini, C Clavenzani, P AF Mazzoni, Maurizio De Giorgio, Roberto Latorre, Rocco Vallorani, Claudia Bosi, Paolo Trevisi, Paolo Barbara, Giovanni Stanghellini, Vincenzo Corinaldesi, Roberto Forni, Monica Faussone-Pellegrini, Maria S. Sternini, Catia Clavenzani, Paolo TI Expression and regulation of alpha-transducin in the pig gastrointestinal tract SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE LA English DT Article DE alpha-gustducin; taste receptors; enteroendocrine cells; chemosensing ID BITTER TASTE RECEPTORS; ENTEROENDOCRINE STC-1 CELLS; FOOD-INTAKE; ENDOCRINE RESPONSES; WEANLING PIGS; GUSTDUCIN; GHRELIN; SOMATOSTATIN; SECRETION; DEPRIVATION AB Taste signalling molecules are found in the gastrointestinal (GI) tract suggesting that they participate to chemosensing. We tested whether fasting and refeeding affect the expression of the taste signalling molecule, -transducin (Gtran), throughout the pig GI tract and the peptide content of Gtran cells. The highest density of Gtran-immunoreactive (IR) cells was in the pylorus, followed by the cardiac mucosa, duodenum, rectum, descending colon, jejunum, caecum, ascending colon and ileum. Most Gtran-IR cells contained chromogranin A. In the stomach, many Gtran-IR cells contained ghrelin, whereas in the upper small intestine many were gastrin/cholecystokinin-IR and a few somatostatin-IR. Gtran-IR and Ggust-IR colocalized in some cells. Fasting (24h) resulted in a significant decrease in Gtran-IR cells in the cardiac mucosa (29.3 +/- 0.8 versus 64.8 +/- 1.3, P<0.05), pylorus (98.8 +/- 1.7 versus 190.8 +/- 1.9, P<0.0l), caecum (8 +/- 0.01 versus 15.5 +/- 0.5, P<0.01), descending colon (17.8 +/- 0.3 versus 23 +/- 0.6, P<0.05) and rectum (15.3 +/- 0.3 versus 27.5 +/- 0.7, P<0.05). Refeeding restored the control level of Gtran-IR cells in the cardiac mucosa. In contrast, in the duodenum and jejunum, Gtran-IR cells were significantly reduced after refeeding, whereas Gtran-IR cells density in the ileum was not changed by fasting/refeeding. These findings provide further support to the concept that taste receptors contribute to luminal chemosensing in the GI tract and suggest they are involved in modulation of food intake and GI function induced by feeding and fasting. C1 [Mazzoni, Maurizio; Latorre, Rocco; Vallorani, Claudia; Forni, Monica; Clavenzani, Paolo] Univ Bologna, Dept Vet Med Sci, I-40126 Bologna, Italy. [De Giorgio, Roberto; Barbara, Giovanni; Stanghellini, Vincenzo; Corinaldesi, Roberto] Univ Bologna, Dept Med & Surg Sci, I-40126 Bologna, Italy. [Bosi, Paolo; Trevisi, Paolo] Univ Bologna, Dept Agri Food Protect & Improvement, I-40126 Bologna, Italy. [Faussone-Pellegrini, Maria S.] Univ Florence, Dept Anat Histol & Forens Med, Florence, Italy. [Sternini, Catia] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, CURE DDRC,Dept Med, Los Angeles, CA 90095 USA. [Sternini, Catia] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, CURE DDRC,Dept Neurobiol, Los Angeles, CA 90095 USA. [Sternini, Catia] Vet Adm Greater Los Angeles Hlth Syst, Los Angeles, CA USA. [De Giorgio, Roberto; Clavenzani, Paolo] Univ Bologna, CIRAU, I-40126 Bologna, Italy. RP Sternini, C (reprint author), Vet Adm Greater Los Angeles Hlth Syst, CURE Digest Dis Res Ctr, Bldg 115,Room 223,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM csternin@ucla.edu RI Mazzoni, Maurizio/J-1918-2016 OI Mazzoni, Maurizio/0000-0002-7384-5990; TREVISI, PAOLO/0000-0001-7019-6828; Forni, Monica/0000-0003-1310-6202 FU NIH [DK79155, 41301]; Italian Ministry of Education, University and Research (MIUR); 'Fondazione Del Monte di Bologna e Ravenna', Italy; University of Bologna FX Grant support: The present work was supported by NIH grants DK79155 and 41301 (C. S.), and grants from the Italian Ministry of Education, University and Research (MIUR) (PRIN2009) (R. De G.), from 'Fondazione Del Monte di Bologna e Ravenna', Italy and funds from the University of Bologna (R. De G. and P. C.). We are grateful to Dr. Chiara Bernardini, Department of Medical Veterinary Sciences, University of Bologna, for her valuable technical assistance with Western blot experiments. NR 33 TC 10 Z9 10 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1582-1838 J9 J CELL MOL MED JI J. Cell. Mol. Med. PD APR PY 2013 VL 17 IS 4 BP 466 EP 474 DI 10.1111/jcmm.12026 PG 9 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA 135KZ UT WOS:000318288300004 PM 23414137 ER PT J AU Grant, KW Walden, BE Summers, V Leek, MR AF Grant, Ken W. Walden, Brian E. Summers, Van Leek, Marjorie R. TI Auditory Models of Suprathreshold Distortion in Persons with Impaired Hearing Introduction SO JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY LA English DT Editorial Material ID SPEECH-RECEPTION THRESHOLD; NOISE; AID; LISTENERS; COGNITION; BENEFIT C1 [Grant, Ken W.; Summers, Van] Walter Reed Natl Mil Med Ctr, Sci & Clin Studies Sect, Audiol & Speech Ctr, Bethesda, MD USA. [Walden, Brian E.] Walter Reed Army Med Ctr, Washington, DC 20307 USA. [Leek, Marjorie R.] Portland VA Med Ctr, VA RR&D Natl Ctr Rehabil Auditory Res, Portland, OR USA. RP Grant, KW (reprint author), Walter Reed Natl Mil Med Ctr, Sci & Clin Studies Sect, Audiol & Speech Ctr, Bethesda, MD USA. NR 24 TC 4 Z9 4 U1 0 U2 2 PU AMER ACAD AUDIOLOGY PI RESTON PA 11730 PLAZA DR, STE 300, RESTON, VA 20190 USA SN 1050-0545 J9 J AM ACAD AUDIOL JI J. Am. Acad. Audiol. PD APR PY 2013 VL 24 IS 4 BP 254 EP 257 DI 10.3766/jaaa.24.4.2 PG 4 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 134JK UT WOS:000318206300002 PM 23636207 ER PT J AU Summers, V Makashay, MJ Theodoroff, SM Leek, MR AF Summers, Van Makashay, Matthew J. Theodoroff, Sarah M. Leek, Marjorie R. TI Suprathreshold Auditory Processing and Speech Perception in Noise: Hearing-Impaired and Normal-Hearing Listeners SO JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY LA English DT Article DE Compression; frequency selectivity; hearing impaired; hearing science; sensorineural hearing loss; speech perception; temporal fine structure sensitivity ID TEMPORAL FINE-STRUCTURE; FILTER SHAPES; FREQUENCY-SELECTIVITY; FLUCTUATING MASKERS; RECEPTION THRESHOLD; INTERFERING SPEECH; PHASE-LOCKING; INTELLIGIBILITY; NONLINEARITY; MODULATION AB Background: It is widely believed that suprathreshold distortions in auditory processing contribute to the speech recognition deficits experienced by hearing-impaired (HI). listeners in noise. Damage to outer hair cells and attendant reductions in peripheral compression and frequency selectivity may contribute to these deficits. In addition, reduced access to temporal fine structure (TFS) information in the speech waveform may play a role. Purpose: To examine how measures of peripheral compression, frequency selectivity, and TFS sensitivity relate to speech recognition performance by HI listeners. To determine whether distortions in processing reflected by these psychoacoustic measures are more closely associated with speech deficits in steady-state or modulated noise. Research Design: Normal-hearing (NH) and HI listeners were tested on tasks examining frequency selectivity (notched-noise task), peripheral compression (temporal masking curve task), and sensitivity to TFS information (frequency modulation [FM] detection task) in the presence of random amplitude modulation. Performance was tested at 500, 1000, 2000, and 4000 Hz at several presentation levels. The same listeners were tested on sentence recognition in steady-state and modulated noise at several signal-to-noise ratios. Study Sample: Ten NH and 18 HI listeners were tested. NH listeners ranged in age from 36 to 80 yr (M = 57.6). For HI listeners, ages ranged from 58 to 87 yr (M = 71.8). Results: Scores on the FM detection task at 1 and 2 kHz were significantly correlated with speech scores in both noise conditions. Frequency selectivity and compression measures were not as clearly associated with speech performance. Speech Intelligibility Index (SII) analyses indicated only small differences in speech audibility across subjects for each signal-to-noise ratio (SNR) condition that would predict differences in speech scores no greater than 10% at a given SNR. Actual speech scores varied by as much as 80% across subjects. Conclusions: The results suggest that distorted processing of audible speech cues was a primary factor accounting for differences in speech scores across subjects and that reduced ability to use TFS cues may be an important component of this distortion. The influence of TFS cues on speech scores was comparable in steady-state and modulated noise. Speech recognition was not related to audibility, represented by the SII, once high-frequency sensitivity differences across subjects (beginning at 5 kHz) were removed statistically. This might indicate that high-frequency hearing loss is associated with distortions in processing in lower-frequency regions. C1 [Summers, Van; Makashay, Matthew J.] Walter Reed Natl Mil Med Ctr, Sci & Clin Studies Sect, Audiol & Speech Ctr, Bethesda, MD 20889 USA. [Theodoroff, Sarah M.; Leek, Marjorie R.] Portland VA Med Ctr, VA RR&D Natl Ctr Rehabil Auditory Res, Portland, OR USA. RP Summers, V (reprint author), Walter Reed Natl Mil Med Ctr, Sci & Clin Studies Sect, Audiol & Speech Ctr, 8901 Wisconsin Ave, Bethesda, MD 20889 USA. EM vsummers6@gmail.com FU Oticon Foundation, Smorum, Denmark; Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service FX Supported by a grant from the Oticon Foundation, Smorum, Denmark. Additional support was provided by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service (Senior Research Career Scientist award [MRL]). The work was supported with resources and the use of facilities at the Portland VA Medical Center. NR 51 TC 14 Z9 16 U1 1 U2 25 PU AMER ACAD AUDIOLOGY PI RESTON PA 11730 PLAZA DR, STE 300, RESTON, VA 20190 USA SN 1050-0545 J9 J AM ACAD AUDIOL JI J. Am. Acad. Audiol. PD APR PY 2013 VL 24 IS 4 BP 274 EP 292 DI 10.3766/jaaa.24.4.4 PG 19 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 134JK UT WOS:000318206300004 PM 23636209 ER PT J AU Bernstein, JGW Mehraei, G Shamma, S Gallun, FJ Theodoroff, SM Leek, MR AF Bernstein, Joshua G. W. Mehraei, Golbarg Shamma, Shihab Gallun, Frederick J. Theodoroff, Sarah M. Leek, Marjorie R. TI Spectrotemporal Modulation Sensitivity as a Predictor of Speech Intelligibility for Hearing-Impaired Listeners SO JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY LA English DT Article DE Fine structure; frequency selectivity; hearing loss; model; modulation; sensorineural; spectral; speech intelligibility; temporal ID TEMPORAL FINE-STRUCTURE; AUDITORY FILTER SHAPES; FREQUENCY-SELECTIVITY; STRUCTURE INFORMATION; CARRIER FREQUENCY; PHASE-LOCKING; NERVE FIBERS; NOISE; RECEPTION; RECOGNITION AB Background: A model that can accurately predict speech intelligibility for a given hearing-impaired (HI) listener would be an important tool for hearing-aid fitting or hearing-aid algorithm development. Existing speech-intelligibility models do not incorporate variability in suprathreshold deficits that are not well predicted by classical audiometric measures. One possible approach to the incorporation of such deficits is to base intelligibility predictions on sensitivity to simultaneously spectrally and temporally modulated signals. Purpose: The likelihood of success of this approach was evaluated by comparing estimates of spectrotemporal modulation (STM) sensitivity to speech intelligibility and to psychoacoustic estimates of frequency selectivity and temporal fine-structure (TFS) sensitivity across a group of HI listeners. Research Design: The minimum modulation depth required to detect STM applied to an 86 dB SPL four-octave noise carrier was measured for combinations of temporal modulation rate (4, 12, or 32 Hz) and spectral modulation density (0.5, 1, 2, or 4 cycles/octave). STM sensitivity estimates for individual HI listeners were compared to estimates of frequency selectivity (measured using the notched-noise method at 500, 1000, 2000, and 4000 Hz), TFS processing ability (2 Hz frequency-modulation detection thresholds for 500, 1000, 2000, and 4000 Hz carriers) and sentence intelligibility in noise (at a 0 dB signal-to-noise ratio) that were measured for the same listeners in a separate study. Study Sample: Eight normal-hearing (NH) listeners and 12 listeners with a diagnosis of bilateral sensorineural hearing loss participated. Data Collection and Analysis: STM sensitivity was compared between NH and HI listener groups using a repeated-measures analysis of variance. A stepwise regression analysis compared STM sensitivity for individual HI listeners to audiometric thresholds, age, and measures of frequency selectivity and TFS processing ability. A second stepwise regression analysis compared speech intelligibility to STM sensitivity and the audiogrann-based Speech Intelligibility Index. Results: STM detection thresholds were elevated for the HI listeners, but only for low rates and high densities. STM sensitivity for individual HI listeners was well predicted by a combination of estimates of frequency selectivity at 4000 Hz and TFS sensitivity at 500 Hz but was unrelated to audiometric thresholds. STM sensitivity accounted for an additional 40% of the variance in speech intelligibility beyond the 40% accounted for by the audibility-based Speech Intelligibility Index. Conclusions: Impaired STM sensitivity likely results from a combination of a reduced ability to resolve spectral peaks and a reduced ability to use TFS information to follow spectral-peak movements. Combining STM sensitivity estimates with audiometric threshold measures for individual HI listeners provided a more accurate prediction of speech intelligibility than audiometric measures alone. These results suggest a significant likelihood of success for an STM-based model of speech intelligibility for HI listeners. C1 [Bernstein, Joshua G. W.] Walter Reed Natl Mil Med Ctr, Sci & Clin Studies Sect, Audiol & Speech Ctr, Bethesda, MD 20889 USA. [Mehraei, Golbarg] Harvard MIT Speech & Hearing Biosci & Technol Pro, Cambridge, MA USA. [Shamma, Shihab] Univ Maryland, Syst Res Inst, College Pk, MD 20742 USA. [Gallun, Frederick J.; Theodoroff, Sarah M.; Leek, Marjorie R.] Portland VA Med Ctr, VA RR&D Natl Ctr Rehabil Auditory Res, Portland, OR USA. RP Bernstein, JGW (reprint author), Walter Reed Natl Mil Med Ctr, Sci & Clin Studies Sect, Audiol & Speech Ctr, 8901 Wisconsin Ave, Bethesda, MD 20889 USA. EM joshua.g.bernstein.civ@health.mil FU Oticon Foundation, Swum, Denmark; VA Rehabilitation Research & Development Service FX Supported by a grant from the Oticon Foundation, Swum, Denmark (J.G.W.B. and M.R.L.). Additional support was provided by the VA Rehabilitation Research & Development Service (Career Development grant [F.J.G.], Senior Research Career Scientist award [M.R.L.]), and some resources and facilities were provided by the Portland VA Medical Center and Walter Reed Army Medical Center. NR 63 TC 19 Z9 19 U1 5 U2 28 PU AMER ACAD AUDIOLOGY PI RESTON PA 11730 PLAZA DR, STE 300, RESTON, VA 20190 USA SN 1050-0545 J9 J AM ACAD AUDIOL JI J. Am. Acad. Audiol. PD APR PY 2013 VL 24 IS 4 BP 293 EP 306 DI 10.3766/jaaa.24.4.5 PG 14 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 134JK UT WOS:000318206300005 PM 23636210 ER PT J AU Hempel, S Newberry, S Wang, Z Booth, M Shanman, R Johnsen, B Shier, V Saliba, D Spector, WD Ganz, DA AF Hempel, Susanne Newberry, Sydne Wang, Zhen Booth, Marika Shanman, Roberta Johnsen, Breanne Shier, Victoria Saliba, Debra Spector, William D. Ganz, David A. TI Hospital Fall Prevention: A Systematic Review of Implementation, Components, Adherence, and Effectiveness SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE fall prevention; implementation; hospital; systematic review ID QUALITY IMPROVEMENT; PATIENT SAFETY; CARE HOSPITALS; INTERVENTIONS; METAANALYSIS; INPATIENTS; WORK AB Objectives To systematically document the implementation, components, comparators, adherence, and effectiveness of published fall prevention approaches in U.S. acute care hospitals. Design Systematic review. Studies were identified through existing reviews, searching five electronic databases, screening reference lists, and contacting topic experts for studies published through August 2011. Setting U.S. acute care hospitals. Participants Studies reporting in-hospital falls for intervention groups and concurrent (e.g., controlled trials) or historic comparators (e.g., beforeafter studies). Intervention Fall prevention interventions. Measurements Incidence rate ratios (IRR, ratio of fall rate postintervention or treatment group to the fall rate preintervention or control group) and ratings of study details. Results Fifty-nine studies met inclusion criteria. Implementation strategies were sparsely documented (17% not at all) and included staff education, establishing committees, seeking leadership support, and occasionally continuous quality improvement techniques. Most interventions (81%) included multiple components (e.g., risk assessments (often not validated), visual risk alerts, patient education, care rounds, bed-exit alarms, and postfall evaluations). Fifty-four percent did not report on fall prevention measures applied in the comparison group, and 39% neither reported fidelity data nor described adherence strategies such as regular audits and feedback to ensure completion of care processes. Only 45% of concurrent and 15% of historic control studies reported sufficient data to compare fall rates. The pooled postintervention incidence rate ratio (IRR) was 0.77 (95% confidence interval=0.521.12, P=.17; eight studies; I2: 94%). Meta-regressions showed no systematic association between implementation intensity, intervention complexity, comparator information, or adherence levels and IRR. Conclusion Promising approaches exist, but better reporting of outcomes, implementation, adherence, intervention components, and comparison group information is necessary to establish evidence on how hospitals can successfully prevent falls. C1 [Hempel, Susanne; Newberry, Sydne; Wang, Zhen; Booth, Marika; Shanman, Roberta; Johnsen, Breanne; Shier, Victoria; Saliba, Debra; Ganz, David A.] RAND Corp, Santa Monica, CA 90407 USA. [Saliba, Debra; Ganz, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Saliba, Debra] Univ Calif Los Angeles, JH Borun Ctr, Los Angeles, CA USA. [Spector, William D.] Agcy Healthcare Res & Qual, Rockville, MD USA. [Ganz, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Hempel, S (reprint author), RAND Corp, Southern Calif Evidence Based Practice Ctr, 1776 Main St, Santa Monica, CA 90407 USA. EM susanne_hempel@rand.org RI Wang, Zhen/D-5991-2013 OI Wang, Zhen/0000-0002-9368-6149 FU AHRQ [HHSA290201000017I]; U.S. Department of Veterans Affairs, Veterans Health Administration, Veterans Affairs Health Services Research and Development (HSR&D) Service through the VA Greater Los Angeles HSR&D Center of Excellence [VA CD2 08-012-1] FX The editor in chief has reviewed the conflict of interest checklist provided by the authors and has determined that the authors have no financial or any other kind of personal conflicts with this paper. This project was funded under Contract HHSA290201000017I TO #1 from the AHRQ. Additional support was provided through the U.S. Department of Veterans Affairs, Veterans Health Administration, Veterans Affairs Health Services Research and Development (HSR&D) Service through the VA Greater Los Angeles HSR&D Center of Excellence (Project VA CD2 08-012-1 and a locally initiated project). NR 29 TC 30 Z9 30 U1 2 U2 25 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 IS 4 BP 483 EP 494 DI 10.1111/jgs.12169 PG 12 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 130IN UT WOS:000317907600001 PM 23527904 ER PT J AU Min, LL Wenger, N Walling, AM Blaum, C Cigolle, C Ganz, DA Reuben, D Shekelle, P Roth, C Kerr, EA AF Min, Lillian Wenger, Neil Walling, Anne M. Blaum, Caroline Cigolle, Christine Ganz, David A. Reuben, David Shekelle, Paul Roth, Carol Kerr, Eve A. TI When Comorbidity, Aging, and Complexity of Primary Care Meet: Development and Validation of the Geriatric CompleXity of Care Index SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE ambulatory care; utilization; comorbidity ID QUALITY-OF-CARE; VULNERABLE OLDER-PEOPLE; PRACTICE GUIDELINES; FUNCTIONAL DECLINE; ELDERS SURVEY; LAST YEAR; MULTIMORBIDITY; RISK; INTERVENTION; CONSEQUENCES AB Objectives To develop and validate the Geriatric CompleXity of Care Index (GXI), a comorbidity index of medical, geriatric, and psychosocial conditions that addresses disease severity and intensity of ambulatory care for older adults with chronic conditions. Design Development phase: variable selection and rating by clinician panel. Validation phase: medical record review and secondary data analysis. Setting Assessing the Care of Vulnerable Elders-2 study. Participants Six hundred forty-four older (75) individuals receiving ambulatory care. Measures Development: 32 conditions categorized according to severity, resulting in 117 GXI variables. A panel of clinicians rated each GXI variable with respect to the added difficulty of providing primary care for an individual with that condition. Validation: Modified versions of previously validated comorbidity measures (simple count, Charlson, Medicare Hierarchical Condition Category), longitudinal clinical outcomes (functional decline, survival), intensity of ambulatory care (primary, specialty care visits, polypharmacy, number of eligible quality indicators (NQI)) over 1year of care. Results The most-morbid individuals (according to quintiles of GXI) had more visits (7.0 vs 3.7 primary care, 6.2 vs 2.4 specialist), polypharmacy (14.3% vs 0% had 14 medications), and greater NQI (33 vs 25) than the least-morbid individuals. Of the four comorbidity measures, the GXI was the strongest predictor of primary care visits, polypharmacy, and NQI (P<.001, controlling for age, sex, function-based vulnerability). Conclusion Older adults with complex care needs, as measured by the GXI, have healthcare needs above what previously employed comorbidity measures captured. Healthcare systems could use the GXI to identify the most complex elderly adults and appropriately reimburse primary providers caring for older adults with the most complex care needs for providing additional visits and coordination of care. C1 [Min, Lillian; Cigolle, Christine] Univ Michigan, Dept Med, Div Geriatr, Sch Med, Ann Arbor, MI 48109 USA. [Min, Lillian; Cigolle, Christine] Vet Affairs Ann Arbor Healthcare Syst, Geriatr Res Educ & Clin Care Ctr, Ann Arbor, MI USA. [Wenger, Neil; Walling, Anne M.; Ganz, David A.; Shekelle, Paul] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Dept Med, Los Angeles, CA 90095 USA. [Wenger, Neil; Walling, Anne M.; Ganz, David A.; Shekelle, Paul; Roth, Carol] RAND Hlth, Santa Monica, CA USA. [Blaum, Caroline] NYU, Dept Med, Langone Med Ctr, New York, NY 10016 USA. [Blaum, Caroline] NYU, Dept Populat Hlth, Langone Med Ctr, New York, NY 10016 USA. [Ganz, David A.; Reuben, David] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Dept Med, Los Angeles, CA 90095 USA. [Ganz, David A.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. [Kerr, Eve A.] Univ Michigan, Div Gen Internal Med, Dept Med, Sch Med, Ann Arbor, MI 48109 USA. [Kerr, Eve A.] Vet Affairs Ann Arbor Healthcare Syst, Ctr Clin Management Res, Ann Arbor, MI USA. RP Min, LL (reprint author), Univ Michigan, Dept Med, Div Geriatr, 300 North Ingalls Bldg Wing E,Room 966, Ann Arbor, MI 48109 USA. EM lmin@med.umich.edu RI Kerr, Eve/I-3330-2013 FU Agency for Healthcare Research and Quality [Min R21 HS017621]; Claude Pepper Older Americans Independence Centers at the University of California at Los Angeles [NIA-K12 2006-2010]; University of Michigan; Hartford-AFAR Geriatric Scholars Research Outcomes Award; Veterans Affairs Greater Los Angeles Health Services Research and Development Center [CD208-012-1]; Pfizer, Inc FX This project was supported by the Agency for Healthcare Research and Quality (Min R21 HS017621). Dr. Min was supported by the Claude Pepper Older Americans Independence Centers at the University of California at Los Angeles (NIA-K12 2006-2010) and the University of Michigan (2010-2011) and a Hartford-AFAR Geriatric Scholars Research Outcomes Award (2005-2006). Dr. Ganz is funded by a Veterans Affairs Greater Los Angeles Health Services Research and Development Center of Excellence Career Development Award (CD208-012-1). The original ACOVE-2 study was supported by a contract from Pfizer, Inc. to RAND. These results were presented at the American Geriatrics Society and Society for General Internal Medicine Meetings in 2012. NR 41 TC 10 Z9 11 U1 3 U2 17 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 IS 4 BP 542 EP 550 DI 10.1111/jgs.12160 PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 130IN UT WOS:000317907600008 PM 23581912 ER PT J AU Andrews, JS Cenzer, IS Yelin, E Covinsky, KE AF Andrews, James S. Cenzer, Irena Stijacic Yelin, Edward Covinsky, Kenneth E. TI Pain as a Risk Factor for Disability or Death SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE pain; functional limitations; activities of daily living; disability; quality of life ID LIVING OLDER PERSONS; LOW-BACK-PAIN; LAST 2 YEARS; MUSCULOSKELETAL PAIN; FUNCTIONAL DECLINE; DISABLED WOMEN; HEALTH; LIFE; DIFFICULTY; ADULTS AB Objectives To determine whether pain predicts future activity of daily living (ADL) disability or death in individuals aged 60 and older. Design Prospective cohort study. Setting The 1998 to 2008 Health and Retirement Study (HRS), a nationally representative study of older community-living individuals. Participants Twelve thousand six hundred thirty-one participants in the 1998 HRS aged 60 and older who did not need help in any ADL. Measurements Participants reporting that they had moderate or severe pain most of the time were defined as having significant pain. The primary outcome was time to development of ADL disability or death over 10yrs, assessed at five successive 2-year intervals. ADL disability was defined as needing help performing any ADL: bathing, dressing, transferring, toileting, eating, or walking across a room. A discrete hazards survival model was used to examine the relationship between pain and incident disability over each 2-year interval using only participants who started the interval with no ADL disability. Several potential confounders were adjusted for at the start of each interval: demographic factors, seven chronic health conditions, and functional limitations (ADL difficulty and difficulty with five measures of mobility). Results At baseline, 2,283 (18%) participants had significant pain. Participants with pain were more likely (all P<.001) to be female (65% vs 54%), have ADL difficulty (e.g., transferring 12% vs 2%, toileting 11% vs 2%), have difficulty walking several blocks (60% vs 21%), and have difficulty climbing one flight of stairs (40% vs 12%). Over 10years, participants with pain were more likely to develop ADL disability or death (58% vs 43%, unadjusted hazard ratio (HR)=1.67, 95% confidence interval(CI)=1.571.79), although after adjustment for confounders, participants with pain were not at greater risk for ADL disability or death (HR=0.98, 95% CI=0.911.07). Adjustment for functional status almost entirely explained the difference between the unadjusted and adjusted results. Conclusion Although there are strong cross-sectional relationships between pain and functional limitations, individuals with pain are not at higher risk of subsequent disability or death after accounting for functional limitations. Like many geriatric syndromes, pain and disability may represent interrelated phenomena that occur simultaneously and require unified treatment paradigms. C1 [Yelin, Edward] Univ Calif San Francisco, Div Rheumatol, San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. [Andrews, James S.] Univ Calif San Francisco, Sch Med, San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. [Cenzer, Irena Stijacic; Covinsky, Kenneth E.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. RP Andrews, JS (reprint author), 400 Parnassus Ave,Floor B1, San Francisco, CA 94143 USA. EM james.andrews@ucsf.edu FU NIAMD; NIA [U01AG009740]; University of California at San Francisco Multidisciplinary Clinical Research Center from the National Institute of Arthritis and Musculoskeletal Diseases (NIAMD) [P60AR-053308]; National Institute on Aging (NIA) [K24 AG029812] FX Dr. Yelin receives grant support from the NIAMD. Dr. Covinsky receives grant support from the NIA. The HRS is funded by the NIA (U01AG009740).; Supported in part by the University of California at San Francisco Multidisciplinary Clinical Research Center from the National Institute of Arthritis and Musculoskeletal Diseases (NIAMD) (P60AR-053308) and a Midcareer Research and Mentoring Award from the National Institute on Aging (NIA) (K24 AG029812). NR 29 TC 15 Z9 16 U1 3 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 IS 4 BP 583 EP 589 DI 10.1111/jgs.12172 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 130IN UT WOS:000317907600014 PM 23521614 ER PT J AU Hazzard, WR AF Hazzard, William R. TI As a Gerontologist Enters Old Age SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE gerontologist; old age; successful aging C1 [Hazzard, William R.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr & Extended Care, Seattle, WA USA. RP Hazzard, WR (reprint author), VA Puget Sound Hlth Care Syst, Geriatr & Extended Care, 1660 S Columbian Way,S-182-GEC, Seattle, WA 98108 USA. EM william.hazzard@med.va.gov NR 0 TC 4 Z9 4 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 IS 4 BP 639 EP 640 DI 10.1111/jgs.12176 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 130IN UT WOS:000317907600020 PM 23581916 ER PT J AU Yoshida, M Dickey, MW Sturt, P AF Yoshida, Masaya Dickey, Michael Walsh Sturt, Patrick TI Predictive processing of syntactic structure: Sluicing and ellipsis in real-time sentence processing SO LANGUAGE AND COGNITIVE PROCESSES LA English DT Article DE Sluicing; Ellipsis; Prediction; Gender mismatch effects ID EYE-TRACKING; LANGUAGE COMPREHENSION; BRAIN POTENTIALS; CONSTRAINTS; INFORMATION; RECONSTRUCTION; DEPENDENCIES; PLAUSIBILITY; PARALLELISM; ASYMMETRIES AB This paper investigates the prediction of syntactic structure during sentence processing, using constructions that temporarily allow a sluicing interpretation in English. Making use of two well-known properties of sluicing and pronoun interpretation-connectivity effects and the local antecedent requirement on reflexives, respectively-we show that (1) the parser chooses a sluicing structure over other possible structures when sluicing is a possibility, and (2) the structure which the parser posits for sluicing involves detailed hierarchical syntactic structure. A self-paced reading experiment and three offline experiments (two acceptability rating studies and a sentence completion study) find evidence that readers immediately try to associate a reflexive pronoun embedded inside a wh-phrase with a potential antecedent in the preceding clause. However, this association is made only if a sluicing structure is a possible continuation of the sentence. This finding suggests that readers actively anticipated a sluicing structure when it was grammatically permissible, and that this structure is sufficiently detailed to license reflexive binding. This result adds to the increasing evidence that comprehenders make detailed predictions regarding upcoming linguistic structure. C1 [Yoshida, Masaya] Northwestern Univ, Dept Linguist, Evanston, IL USA. [Dickey, Michael Walsh] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA USA. [Dickey, Michael Walsh] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Sturt, Patrick] Univ Edinburgh, Dept Psychol, Sch Philosophy Psychol & Language Sci, Edinburgh EH8 9YL, Midlothian, Scotland. RP Yoshida, M (reprint author), Northwestern Univ, Dept Linguist, 2016 Sheridan Rd, Eanston, IL 60208 USA. EM m-yoshida@northwestern.edu OI Dickey, Michael Walsh/0000-0002-9068-3313 NR 75 TC 15 Z9 15 U1 1 U2 17 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 0169-0965 J9 LANG COGNITIVE PROC JI Lang. Cogn. Process. PD APR 1 PY 2013 VL 28 IS 3 SU S SI SI BP 272 EP 302 DI 10.1080/01690965.2011.622905 PG 31 WC Linguistics; Psychology, Experimental SC Linguistics; Psychology GA 113GE UT WOS:000316653800005 ER PT J AU Liu, J Lloyd, SG AF Liu, Jian Lloyd, Steven G. TI High-fat, low-carbohydrate diet alters myocardial oxidative stress and impairs recovery of cardiac function after ischemia and reperfusion in obese rats SO NUTRITION RESEARCH LA English DT Article DE Diet; Rat; Myocardial ischemia; Obesity; Mitochondria; Oxidative stress ID HIGH-PROTEIN-DIET; METABOLIC SYNDROME; MITOCHONDRIAL BIOGENESIS; NAD(P)H OXIDASE; ADIPONECTIN; IMPACT; DYSFUNCTION; HEART; ACCUMULATION; RECEPTORS AB Obesity is associated with elevated risk of heart disease. A solid understanding of the safety and potential adverse effects of high-fat, low-carbohydrate diet (HFLCD) similar to that used by humans for weight loss on the heart is crucial. High fat intake is known to promote increases in reactive oxygen species and mitochondrial damage. We hypothesized that. there would be adverse effects of HFLCD on myocardial ischemia/reperfusion injury through enhancing oxidative stress injury and impairing mitochondrial biogenesis in a nongenetic, diet-induced rat model of obesity. To test the hypothesis, 250-g male Sprague-Dawley rats were fed an obesity-promoting diet for 7 weeks to induce obesity, then switched to HFLCD or a low-fat control diet for 2 weeks. Isolated hearts underwent global low flow ischemia for 60 minutes and reperfusion for 60 minutes. High-fat, low-carbohydrate diet resulted in greater weight gain and lower myocardial glycogen, plasma adiponectin, and insulin. Myocardial antioxidant gene transcript and protein expression of superoxide dismutase and catalase were reduced in HFLCD, along with increased oxidative gene NADPH oxidase-4 transcript and xanthine oxidase activity, and a 37% increase in nitrated protein (nitrotyrosine) in HFLCD hearts. The cardiac expression of key mitochondrial regulatory factors such as nuclear respiratory factor-1 and transcription factor A-mitochondrial were inhibited and myocardial mitochondrial DNA copy number decreased. The cardiac expression of adiponectin and its receptors was down-regulated in HFLCD. High-fat, low-carbohydrate diet impaired recovery of left ventricular rate-pressure product after ischemia/reperfusion and led to 3.5-fold increased injury as measured by lactate dehydrogenase release. In conclusion, HFLCD leads to increased ischemic myocardial injury and impaired recovery of function after reperfusion and was associated with attenuation of mitochondrial biogenesis and enhanced oxidative stress in obese rats. These findings may have important implications for diet selection in obese patients with ischemic heart disease. Published by Elsevier Inc. C1 [Liu, Jian; Lloyd, Steven G.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Lloyd, Steven G.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Lloyd, SG (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. EM sglloyd@uab.edu FU Scientist Development Grant from the American Heart Association [0735212N]; NIH Grant [P30DK056336] FX The present study was supported by Scientist Development Grant 0735212N from the American Heart Association and, in part, by NIH Grant P30DK056336. The authors would like to thank Qinglin Yang and C. Roger White for assistance with the experiment. NR 42 TC 13 Z9 14 U1 0 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0271-5317 J9 NUTR RES JI Nutr. Res. PD APR PY 2013 VL 33 IS 4 BP 311 EP 321 DI 10.1016/j.nutres.2013.02.005 PG 11 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 134EI UT WOS:000318192500009 PM 23602249 ER PT J AU Darden, PM Thompson, DM Roberts, JR Hale, JJ Pope, C Naifeh, M Jacobson, RM AF Darden, Paul M. Thompson, David M. Roberts, James R. Hale, Jessica J. Pope, Charlene Naifeh, Monique Jacobson, Robert M. TI Reasons for Not Vaccinating Adolescents: National Immunization Survey of Teens, 2008-2010 SO PEDIATRICS LA English DT Article DE adolescent; preventive health services; vaccination; immunization; adolescent health services; preventive health services; vaccines; meningococcal vaccines; papillomavirus vaccines; tetanus vaccine; diphtheria-tetanus vaccine; attitude to health; patient acceptance of health care; treatment refusal ID HUMAN-PAPILLOMAVIRUS VACCINE; AGED 13-17 YEARS; UNITED-STATES; ADVISORY-COMMITTEE; PRACTICES ACIP; COVERAGE; RECOMMENDATIONS; PARENT; PERTUSSIS; COMMUNICATION AB OBJECTIVE: To determine the reasons adolescents are not vaccinated for specific vaccines and how these reasons have changed over time. METHODS: We analyzed the 2008-2010 National Immunization Survey of Teens examining reasons parents do not have their teens immunized. Parents whose teens were not up to date (Not-UTD) for Tdap/Td and MCV4 were asked the main reason they were not vaccinated. Parents of female teens Not-UTD for human papillomavirus vaccine (HPV) were asked their intent to give HPV, and those unlikely to get HPV were asked the main reason why not. RESULTS: The most frequent reasons for not vaccinating were the same for Tdap/Td and MCV4, including "Not recommended" and "Not needed or not necessary." For HPV, the most frequent reasons included those for the other vaccines as well as 4 others, including "Not sexually active" and "Safety concerns/Side effects." "Safety concerns/Side effects" increased from 4.5% in 2008 to 7.7% in 2009 to 16.4% in 2010 and, in 2010, approaching the most common reason "Not Needed or Not Necessary" at 17.4% (95% CI: 15.7-19.1). Although parents report that health care professionals increasingly recommend all vaccines, including HPV, the intent to not vaccinate for HPV increased from 39.8% in 2008 to 43.9% in 2010 (OR for trend 1.08, 95% CI: 1.04-1.13). CONCLUSIONS: Despite doctors increasingly recommending adolescent vaccines, parents increasingly intend not to vaccinate female teens with HPV. The concern about safety of HPV grew with each year. Addressing specific and growing parental concerns about HPV will require different considerations than those for the other vaccines. C1 [Darden, Paul M.; Hale, Jessica J.; Naifeh, Monique] Univ Oklahoma, Hlth Sci Ctr, Coll Med, Dept Pediat, Oklahoma City, OK 73190 USA. [Thompson, David M.] Univ Oklahoma, Hlth Sci Ctr, Dept Biostat & Epidemiol, Coll Publ Hlth, Oklahoma City, OK USA. [Darden, Paul M.; Roberts, James R.] Med Univ S Carolina, Coll Med, Dept Pediat, Charleston, SC 29425 USA. [Pope, Charlene] Med Univ S Carolina, Coll Nursing, Charleston, SC 29425 USA. [Pope, Charlene] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Jacobson, Robert M.] Mayo Clin, Dept Pediat & Adolescent Med, Rochester, MN USA. RP Darden, PM (reprint author), Suite 12400, Oklahoma City, OK 73104 USA. EM paul-darden@ouhsc.edu OI Jacobson, Robert/0000-0002-6355-8752 FU Pfizer; Novartis; Merck; US Department of Health and Human Services, Health Resources and Services Administration, Maternal and Child Health Research Program [R40 MC 21522] FX Dr Darden has been a consultant and served on an advisory board to Pfizer, Inc. in the past 3 years. Dr Jacobson has served in the past 3 years as a principal investigator for 2 multicenter vaccine studies funded by Pfizer as well as 1 funded by Novartis, all conducted at Mayo Clinic. He currently serves as a member of a safety review committee for 1 vaccine study as well as a member of a data and safety monitoring board for 2 other vaccine studies, all funded by Merck. The other authors have indicated they have no financial relationships relevant to this article to disclose.; Supported by grant R40 MC 21522 through the US Department of Health and Human Services, Health Resources and Services Administration, Maternal and Child Health Research Program. NR 30 TC 73 Z9 73 U1 3 U2 19 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD APR PY 2013 VL 131 IS 4 BP 645 EP 651 DI 10.1542/peds.2012-2384 PG 7 WC Pediatrics SC Pediatrics GA 135EF UT WOS:000318269500048 PM 23509163 ER PT J AU Stone, AEL Giugliano, S Schnell, G Cheng, LL Leahy, KF Golden-Mason, L Gale, M Rosen, HR AF Stone, Amy E. L. Giugliano, Silvia Schnell, Gretja Cheng, Linling Leahy, Katelyn F. Golden-Mason, Lucy Gale, Michael, Jr. Rosen, Hugo R. TI Hepatitis C Virus Pathogen Associated Molecular Pattern (PAMP) Triggers Production of Lambda-Interferons by Human Plasmacytoid Dendritic Cells SO PLOS PATHOGENS LA English DT Article ID ANTIVIRAL INNATE IMMUNITY; RIG-I; GENETIC-VARIATION; INFECTION; RECOGNITION; RNA; REPLICATION; IL28B; EXPRESSION; CLEARANCE AB Plasmacytoid Dendritic Cells (pDCs) represent a key immune cell in the defense against viruses. Through pattern recognition receptors (PRRs), these cells detect viral pathogen associated molecular patterns (PAMPs) and initiate an Interferon (IFN) response. pDCs produce the antiviral IFNs including the well-studied Type I and the more recently described Type III. Recent genome wide association studies (GWAS) have implicated Type III IFNs in HCV clearance. We examined the IFN response induced in a pDC cell line and ex vivo human pDCs by a region of the HCV genome referred to as the HCV PAMP. This RNA has been shown previously to be immunogenic in hepatocytes, whereas the conserved X-region RNA is not. We show that in response to the HCV PAMP, pDC-GEN2.2 cells upregulate and secrete Type III (in addition to Type I) IFNs and upregulate PRR genes and proteins. We also demonstrate that the recognition of this RNA is dependent on RIG-I-like Receptors (RLRs) and Toll-like Receptors (TLRs), challenging the dogma that RLRs are dispensable in pDCs. The IFNs produced by these cells in response to the HCV PAMP also control HCV replication in vitro. These data are recapitulated in ex vivo pDCs isolated from healthy donors. Together, our data shows that pDCs respond robustly to HCV RNA to make Type III Interferons that control viral replication. This may represent a novel therapeutic strategy for the treatment of HCV. C1 [Stone, Amy E. L.; Golden-Mason, Lucy; Rosen, Hugo R.] Univ Colorado, Integrated Dept Immunol, Denver, CO 80202 USA. [Stone, Amy E. L.; Golden-Mason, Lucy; Rosen, Hugo R.] Natl Jewish Hlth, Denver, CO USA. [Stone, Amy E. L.; Giugliano, Silvia; Cheng, Linling; Leahy, Katelyn F.; Golden-Mason, Lucy; Rosen, Hugo R.] Univ Colorado Denver, Hepatitis C Ctr, Dept Med, Div Gastroenterol & Hepatol, Aurora, CO USA. [Schnell, Gretja; Gale, Michael, Jr.] Univ Washington, Sch Med, Dept Immunol, Seattle, WA USA. [Rosen, Hugo R.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Stone, AEL (reprint author), Univ Colorado, Integrated Dept Immunol, Denver, CO 80202 USA. EM Hugo.Rosen@UCDENVER.edu OI Gale, Michael/0000-0002-6332-7436 FU VA Merit Review grant; NIH/NCATS Colorado CTSI [TL1 TR000155]; [U19 AI 1066328] FX This work was supported by U19 AI 1066328 and a VA Merit Review grant. Supported by NIH/NCATS Colorado CTSI Grant Number TL1 TR000155. Contents are the authors' sole responsibility and do not necessarily represent official NIH views. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 37 TC 35 Z9 35 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7374 J9 PLOS PATHOG JI PLoS Pathog. PD APR PY 2013 VL 9 IS 4 AR e1003316 DI 10.1371/journal.ppat.1003316 PG 13 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA 132MN UT WOS:000318072700053 PM 23637605 ER PT J AU Singh, JA Jensen, M Lewallen, D AF Singh, Jasvinder A. Jensen, Matthew Lewallen, David TI Predictors of periprosthetic fracture after total knee replacement An analysis of 21,723 cases SO ACTA ORTHOPAEDICA LA English DT Article ID SUPRACONDYLAR FRACTURE; TOTAL HIP; ARTHROPLASTY; FEMUR; OUTCOMES; MORBIDITY; MORTALITY; INDEX; RISK; PAIN AB Background and purpose Periprosthetic fracture is a devastating complication of total knee replacement (TKR). Most published studies have not comprehensively assessed clinical and demographic predictors. We wanted to determine the incidence and predictors of postoperative periprosthetic fracture after primary and revision TKR. Patients and methods We used prospectively collected data in the Mayo Clinic Total Joint Registry on all patients who underwent primary or revision TKR at the Mayo Clinic, Rochester, from 1989 through 2008. We assessed incidence of postoperative periprosthetic fractures and modifiable (comorbidity, body mass index) and unmodifiable factors (age, sex, operative diagnosis, ASA class, previous cardiac disease, and previous thromboembolic disease) as predictors of postoperative periprosthetic fractures. We used multivariable-adjusted Cox regression analyses separately for primary and revision TKR. Results 12,914 patients underwent 17,633 primary TKRs and 3,286 patients underwent 4,090 revision TKRs during the period 1989-2008. 1.1% of patients (188/17,633) after primary TKR and 2.5% of patients (104/4,090) after revision TKR sustained a postoperative periprosthetic fracture on or after postoperative day 1. Older age was associated with lower risk of periprosthetic fractures after primary TKR (p < 0.001). Compared to = 60 years, risk was lower for ages 61-70 years (hazard ratio (HR) = 0.5, 95% confidence interval (CI): 0.3-0.7)) and 71-80 years (HR = 0.6, CI: 0.4-0.8), but not for age > 80 years (HR = 0.9, CI: 0.5-1.6). In revision TKR cohort, a diagnosis of non-union (HR = 4.9, CI: 1.2-20), infection (HR = 2.9, CI: 1.3-6.4) or previous surgery with components removed (HR = 2.1, CI: 1.3-3.4) increased the risk of postoperative periprosthetic fracture, compared to a diagnosis of loosening/wear/osteolysis. Interpretation We identified significant risk factors for periprosthetic fracture after primary and revision TKR. Patients with these risk factors can be informed by their surgeons of increased risk of this uncommon, but serious complication of TKR. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Lewallen, David] Mayo Clin, Sch Med, Dept Orthoped Surg, Rochester, MN USA. [Jensen, Matthew] Mayo Clin, Sch Med, Dept Hlth Sci Res, Rochester, MN USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. EM Jasvinder.md@gmail.com OI singh, jasvinder/0000-0003-3485-0006 FU National Institutes of Health (NIH) Clinical Translational Science Award [1 KL2 RR024151-01] FX We thank Youlonda Lochler for assistance in identifying the cohort for analysis and Scott Harmsen for help with statistical analysis. This published material is the result of work supported by the National Institutes of Health (NIH) Clinical Translational Science Award 1 KL2 RR024151-01 (Mayo Clinic Center for Clinical and Translational Research) and of the resources and use of facilities at the Birmingham VA Medical Center, AL, USA. NR 28 TC 5 Z9 7 U1 0 U2 4 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 1745-3674 J9 ACTA ORTHOP JI Acta Orthop. PD APR PY 2013 VL 84 IS 2 BP 170 EP 177 DI 10.3109/17453674.2013.788436 PG 8 WC Orthopedics SC Orthopedics GA 126ZF UT WOS:000317661500009 PM 23530873 ER PT J AU Patel, SM Thames, AD Arbid, N Panos, SE Castellon, S Hinkin, CH AF Patel, Sapna M. Thames, April D. Arbid, Natalie Panos, Stella E. Castellon, Steven Hinkin, Charles H. TI The aggregate effects of multiple comorbid risk factors on cognition among HIV-infected individuals SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Article DE HIV; Neuropsychology; Comorbid risk factors; Aging; Cognition ID HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C VIRUS; INTIMA-MEDIA THICKNESS; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; ANTIRETROVIRAL THERAPY; MEDICATION ADHERENCE; DRUG-USE; METHAMPHETAMINE DEPENDENCE; NEUROCOGNITIVE DISORDERS; CARDIOVASCULAR-DISEASE AB This study developed and then cross-validated a novel weighting algorithm based on multiple comorbid risk factors (stimulant use, vascular disease, hepatitis C, HIV disease severity, cognitive reserve) to predict cognitive functioning among 366 HIV+ adults. The resultant risk severity score was used to differentially weight, as a function of age, the impact and magnitude of multiple risk factors on cognition. Among older adults (50 years) the risk severity index was differentially predictive of learning/memory and verbal fluency, whereas among younger adults it was linked to working memory and executive function. Cognitive reserve was found to be the most robust predictor of neurocognition. C1 [Patel, Sapna M.; Thames, April D.; Panos, Stella E.; Castellon, Steven; Hinkin, Charles H.] Univ Calif Los Angeles, Los Angeles, CA 90095 USA. [Patel, Sapna M.; Thames, April D.; Arbid, Natalie; Panos, Stella E.; Castellon, Steven; Hinkin, Charles H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Patel, SM (reprint author), Univ Calif Los Angeles, 760 Westwood Plaza,C8-746, Los Angeles, CA 90095 USA. EM smpatel@mednet.ucla.edu RI Thames, April/K-1964-2014 OI Thames, April/0000-0001-8414-7189 FU National Institute on Drug Abuse [R01 DA 13799]; National Institute of Mental Health [T32 MH19535]; NIMH [T32MH19535, K23MH095661] FX This study was supported by a grant from the National Institute on Drug Abuse (R01 DA 13799) and by the National Institute of Mental Health Training Grant (T32 MH19535; PI: Charles Hinkin). Dr. Patel and Dr. Panos are supported by the NIMH Institutional Training Grant (No. T32MH19535) and Dr. Thames is supported by NIMH Grant (No. K23MH095661). We would also like to acknowledge the help from members of our laboratory: Sara-Beth Lawrence, Tim Arentsen, and Vanessa Streiff. NR 89 TC 7 Z9 7 U1 3 U2 10 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1380-3395 J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PD APR 1 PY 2013 VL 35 IS 4 BP 421 EP 434 DI 10.1080/13803395.2013.783000 PG 14 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 129LR UT WOS:000317841600008 PM 23547924 ER PT J AU Cheng, G Servaes, S Zhuang, HM AF Cheng, Gang Servaes, Sabah Zhuang, Hongming TI Value of F-18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan versus diagnostic contrast computed tomography in initial staging of pediatric patients with lymphoma SO LEUKEMIA & LYMPHOMA LA English DT Article DE FDG PET/CT; lymphoma; Hodgkin disease; staging; pediatric ID FDG-PET; CHILDHOOD LYMPHOMA; HODGKINS-LYMPHOMA; MANAGEMENT; BONE; ADOLESCENTS; CHILDREN; UTILITY; IMPACT; CT AB Our objective was to evaluate the value of F-18-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) versus diagnostic contrast CT in the initial staging of pediatric Hodgkin disease (HD) and non-Hodgkin lymphoma (NHL). Thirty patients with HD and 21 patients with NHL were included in this retrospective study. On nodal lesion analysis, PET/CT detected 94.8% (HD) and 88.3% (NHL) of total lesions, respectively, in contrast to 82.6% (HD) and 69.1% (NHL), respectively, for diagnostic contrast CT. PET/CT also detected more extranodal lesions. On the patient level, PET/CT detected additional lesions in 50% of patients with HD and in 42.9% of patients with NHL. In contrast, diagnostic contrast CT detected additional lesions in 16.7% (HD) and 23.8% (NHL) of total cases. FDG PET/CT led to upstaging in seven cases of HD and seven cases of NHL, while diagnostic contrast CT upstaged two cases of NHL. We conclude that FDG PET/CT outperforms diagnostic contrast CT in the initial staging of pediatric patients with lymphoma. C1 [Cheng, Gang] Philadelphia VA Med Ctr, Dept Radiol, Philadelphia, PA 19104 USA. [Servaes, Sabah; Zhuang, Hongming] Childrens Hosp Philadelphia, Dept Radiol, Philadelphia, PA 19104 USA. RP Cheng, G (reprint author), Philadelphia VA Med Ctr, Dept Radiol, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM gangcheng99@yahoo.com; zhuang@email.chop.edu NR 21 TC 14 Z9 14 U1 0 U2 2 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1042-8194 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PD APR PY 2013 VL 54 IS 4 BP 737 EP 742 DI 10.3109/10428194.2012.727416 PG 6 WC Oncology; Hematology SC Oncology; Hematology GA 103EP UT WOS:000315898100014 PM 22957898 ER PT J AU Spindler, SR Mote, PL Flegal, JM Teter, B AF Spindler, Stephen R. Mote, Patricia L. Flegal, James M. Teter, Bruce TI Influence on Longevity of Blueberry, Cinnamon, Green and Black Tea, Pomegranate, Sesame, Curcumin, Morin, Pycnogenol, Quercetin, and Taxifolin Fed Iso-Calorically to Long-Lived, F1 Hybrid Mice SO REJUVENATION RESEARCH LA English DT Article ID LIFE-SPAN EXTENSION; CAENORHABDITIS-ELEGANS; OXIDATIVE STRESS; DROSOPHILA-MELANOGASTER; EXTRACT; HEALTH; ACID; EXPRESSION; CAFFEINE; SURVIVAL AB Phytonutrients reportedly extend the life span of Caenorhabditis elegans, Drosophila, and mice. We tested extracts of blueberry, pomegranate, green and black tea, cinnamon, sesame, and French maritime pine bark (Pycnogenol and taxifolin), as well as curcumin, morin, and quercetin for their effects on the life span of mice. While many of these phytonutrients reportedly extend the life span of model organisms, we found no significant effect on the life span of male F1 hybrid mice, even though the dosages used reportedly produce defined therapeutic end points in mice. The compounds were fed beginning at 12 months of age. The control and treatment groups were iso-caloric with respect to one another. A 40% calorically restricted and other groups not reported here did experience life span extension. Body weights were un-changed relative to controls for all but two supplemented groups, indicating most supplements did not change energy absorption or utilization. Tea extracts with morin decreased weight, whereas quercetin, taxifolin, and Pycnogenol together increased weight. These changes may be due to altered locomotion or fatty acid biosynthesis. Published reports of murine life span extension using curcumin or tea components may have resulted from induced caloric restriction. Together, our results do not support the idea that isolated phytonutrient anti-oxidants and anti-inflammatories are potential longevity therapeutics, even though consumption of whole fruits and vegetables is associated with enhanced health span and life span. C1 [Spindler, Stephen R.; Mote, Patricia L.] Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA. [Flegal, James M.] Univ Calif Riverside, Dept Stat, Riverside, CA 92521 USA. [Teter, Bruce] VA Greater Los Angeles Healthcare Syst, Dept Med, Sepulveda, CA USA. RP Spindler, SR (reprint author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA. EM spindler@ucr.edu OI Flegal, James/0000-0002-9960-8942 FU Alva, LLC FX The authors thank Ms. Carol Boyd for her invaluable help feeding and monitoring the mice. This work was funded by Alva, LLC, whose business is funding research. The funding organization and its members had no role in study design, data collection or analysis, decision to publish, or preparation of the manuscript. NR 60 TC 13 Z9 13 U1 3 U2 27 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1549-1684 J9 REJUV RES JI Rejuv. Res. PD APR PY 2013 VL 16 IS 2 BP 143 EP 151 DI 10.1089/rej.2012.1386 PG 9 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 129IM UT WOS:000317832600008 PM 23432089 ER PT J AU Khodneva, Y Pletcher, M Safford, M Schumacher, J Tucker, J Kertesz, S AF Khodneva, Yulia Pletcher, Mark Safford, Monika Schumacher, Joseph Tucker, Jalie Kertesz, Stefan TI Conjoint Trajectories of Drug Use and Trajectories of Depressive Symptoms in Adults: A 2-Decade Portrait of Comorbidity (the CARDIA study) SO SUBSTANCE ABUSE LA English DT Meeting Abstract C1 [Khodneva, Yulia; Tucker, Jalie; Kertesz, Stefan] Univ Alabama Birmingham, Birmingham, AL USA. [Pletcher, Mark; Safford, Monika; Schumacher, Joseph] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Kertesz, Stefan] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 J9 SUBST ABUS JI Subst. Abus. PD APR 1 PY 2013 VL 34 IS 2 BP 215 EP 215 PG 1 WC Substance Abuse SC Substance Abuse GA 128BI UT WOS:000317742700038 ER PT J AU Ottum, A Sethi, AK Jacobs, E Zerbel, S Gaines, ME Safdar, N AF Ottum, Andrew Sethi, Ajay K. Jacobs, Elizabeth Zerbel, Sara Gaines, Martha E. Safdar, Nasia TI Engaging patients in the prevention of health care-associated infections: A survey of patients' awareness, knowledge, and perceptions regarding the risks and consequences of infection with methicillin-resistant Staphylococcus aureus and Clostridium difficile SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE MRSA; Clostridium difficile; Awareness ID EDUCATION MODEL; HOSPITALS AB Background and objective: Methicillin-resistant Staphylococcus aureus (MRSA) infections and Clostridium difficile infections (CDI) are major health care-associated infections (HAIs). Little is known about patients' knowledge of these HAIs. Therefore, we surveyed patients to determine awareness, knowledge, and perceptions of MRSA infections and CDI. Design: An interviewer-administered questionnaire. Setting: A tertiary care academic medical center. Participants: Adult patients who met at least one of the following criteria: at risk of CDI or MRSA infection, current CDI or colonization or current MRSA infection or colonization, or history of CDI or MRSA infection. Methods: Two unique surveys were developed and administered to 100 patients in 2011. Results: Overall, 76% of patients surveyed were aware of MRSA, whereas 44% were aware of C difficile. The strongest predictor of patients' awareness of these infections was having a history of HAI. Patients with a history of HAI were significantly more likely to have heard of both MRSA (odds ratio, 13.29; 95% confidence interval, 2.84-62.14; P = .001) and C difficile (odds ratio, 9.78; 95% confidence interval, 2.66-35.95; P = .001), than those patients without a history of HAI. There was also a significant positive association between having a history of HAI and greater knowledge of the risk factors, health consequences, and prevention techniques relative to CDI and MRSA infections. Conclusions: There are additional opportunities to engage patients about the risks and consequences of MRSA and CDIs, particularly those without a history of HAI. Copyright (C) 2013 by the Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved. C1 [Ottum, Andrew; Sethi, Ajay K.; Jacobs, Elizabeth] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI USA. [Jacobs, Elizabeth; Safdar, Nasia] Univ Wisconsin, Dept Med, Madison, WI USA. [Zerbel, Sara; Safdar, Nasia] Univ Wisconsin, Univ Wisconsin Hosp & Clin, Madison, WI USA. [Gaines, Martha E.] Univ Wisconsin, Ctr Patient Partnerships, Madison, WI USA. [Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Safdar, N (reprint author), 5221 MFCB,1685 Highland Ave, Madison, WI 53705 USA. EM ns2@medicine.wisc.edu NR 12 TC 6 Z9 6 U1 0 U2 6 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD APR PY 2013 VL 41 IS 4 BP 322 EP 326 DI 10.1016/j.ajic.2012.04.334 PG 5 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 123UG UT WOS:000317416000008 PM 22884494 ER PT J AU Kramer, JR Fischbach, LA Richardson, P Alsarraj, A Fitzgerald, S Shaib, Y Abraham, NS Velez, M Cole, R Anand, B Verstovsek, G Rugge, M Parente, P Graham, DY El-Serag, HB AF Kramer, Jennifer R. Fischbach, Lori A. Richardson, Peter Alsarraj, Abeer Fitzgerald, Stephanie Shaib, Yasser Abraham, Neena S. Velez, Maria Cole, Rhonda Anand, Bhupinderjit Verstovsek, Gordana Rugge, Massimo Parente, Paola Graham, David Y. El-Serag, Hashem B. TI Waist-to-Hip Ratio, but Not Body Mass Index, Is Associated With an Increased Risk of Barrett's Esophagus in White Men SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE Visceral Obesity; Epidemiologic Study; Veterans Affairs; Risk Factors ID GASTROESOPHAGEAL-REFLUX DISEASE; GENERAL-POPULATION; METABOLIC SYNDROME; CENTRAL ADIPOSITY; HIATAL-HERNIA; FLAP VALVE; OBESITY; PREVALENCE; SYMPTOMS; ADENOCARCINOMA AB BACKGROUND & AIMS: Abdominal obesity increases the risk of gastroesophageal reflux disease (GERD) and also might contribute to the development of Barrett's esophagus (BE), although results are inconsistent. We examined the effects of waist-to-hip ratio (WHR) and body mass index (BMI) on the risk of BE and investigated whether race, GERD symptoms, or hiatus hernia were involved. METHODS: We conducted a case-control study using data from eligible patients who underwent elective esophagogastroduodenoscopy; 237 patients had BE and the other 1021 patients served as endoscopy controls. We also analyzed data and tissue samples from enrolled patients who were eligible for screening colonoscopies at a primary care clinic (colonoscopy controls, n = 479). All patients underwent esophagogastroduodenoscopy, completed a survey, and had anthropometric measurements taken. WHR was categorized as high if it was 0.9 or greater for men or 0.85 or greater for women. Data were analyzed with logistic regression. RESULTS: There was no association between BMI and BE. However, more patients with BE had a high WHR (92.4%) than endoscopy controls (79.5%) or colonoscopy controls (84.6%) (P < .001 and P = .008, respectively). In adjusted analysis, patients with BE were 2-fold more likely to have a high WHR than endoscopy controls (odds ratio [OR], 1.93; 95% confidence interval [CI], 1.1-3.5), this association was stronger for patients with long-segment BE (OR, 2.81; 95% CI, 1.0-7.9). A high WHR was associated significantly with BE only in whites (OR, 2.5; 95% CI, 1.2-5.4), but not in blacks or Hispanics. GERD symptoms, hiatus hernia, or gastroesophageal valve flap grade could not account for the association. CONCLUSIONS: High WHR, but not BMI, is associated with a significant increase in the risk of BE, especially long-segment BE and in whites. The association is not caused by GERD symptoms or hiatus hernia. C1 [Kramer, Jennifer R.; Richardson, Peter; Alsarraj, Abeer; Fitzgerald, Stephanie; Abraham, Neena S.; El-Serag, Hashem B.] Baylor Coll Med, Houston VA Hlth Serv Res & Dev Ctr Excellence, Houston, TX 77030 USA. [Abraham, Neena S.; Velez, Maria; Cole, Rhonda; Anand, Bhupinderjit; Graham, David Y.; El-Serag, Hashem B.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Verstovsek, Gordana] Baylor Coll Med, Dept Pathol, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Kramer, Jennifer R.; Richardson, Peter; Shaib, Yasser] Baylor Coll Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Shaib, Yasser; Abraham, Neena S.; Velez, Maria; Cole, Rhonda; Anand, Bhupinderjit; Graham, David Y.; El-Serag, Hashem B.] Baylor Coll Med, Dept Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA. [Verstovsek, Gordana] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. [Fischbach, Lori A.] Univ Arkansas Med Sci, Dept Epidemiol, Fay W Boozman Coll Publ Hlth, Little Rock, AR 72205 USA. [Rugge, Massimo] Univ Padua, Surg Pathol & Cytopathol Unit, Dept Med DIMED, Padua, Italy. [Parente, Paola] Casa Sollievo Sofferenza, Dept Pathol, San Giovanni Rotondo, Italy. RP Kramer, JR (reprint author), Michael E DeBakey VA Med Ctr, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM jennifer.kramer@va.gov RI Rugge, Massimo/K-7525-2016 FU National Institutes of Health grant National Cancer Institute [R01 116845]; Houston VA HSR&D Center of Excellence [HFP90-020]; Texas Digestive Disease Center National Institutes of Health [DK58338]; National Institute of Diabetes and Digestive and Kidney Diseases [K24-04-107] FX Supported in part by National Institutes of Health grant National Cancer Institute R01 116845, the Houston VA HSR&D Center of Excellence (HFP90-020), and the Texas Digestive Disease Center National Institutes of Health (DK58338). Also supported by the National Institute of Diabetes and Digestive and Kidney Diseases (K24-04-107 to H.B.E.-S.). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 37 TC 39 Z9 39 U1 1 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD APR PY 2013 VL 11 IS 4 BP 373 EP + DI 10.1016/j.cgh.2012.11.028 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 123TK UT WOS:000317413700012 PM 23220167 ER PT J AU Fett, N Neves, J AF Fett, Nicole Neves, Jennifer TI Multiple Eruptive Milia SO CUTIS LA English DT Article ID CLASSIFICATION; BOY AB Multiple eruptive milia (MEM) is a rare skin condition characterized by sudden onset of multiple milia occurring mainly on the head, neck, and trunk. Milia are small, benign, 1- to 4-mm, white keratinous cysts. The lesions generally are asymptomatic and may arise spontaneously or secondary to a number of processes. Multiple eruptive milia are cosmetically troublesome and difficult to treat. We report the case of a 40-year-old man with an abrupt onset of MEM on the face. Cutis. 2013; 91: 191-192. C1 [Fett, Nicole; Neves, Jennifer] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Fett, Nicole] Univ Penn, Dept Dermatol, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Fett, N (reprint author), Perelman Ctr Adv Med, Dept Dermatol, Ste 1-330A,3400 Civic Ctr Blvd, Philadelphia, PA 19104 USA. EM Nicole.fett@uphs.upenn.edu NR 7 TC 1 Z9 1 U1 0 U2 0 PU QUADRANT HEALTHCOM INC PI PARSIPPANY PA 7 CENTURY DRIVE, STE 302, PARSIPPANY, NJ 07054-4603 USA SN 0011-4162 J9 CUTIS JI Cutis PD APR PY 2013 VL 91 IS 4 BP 191 EP 192 PG 2 WC Dermatology SC Dermatology GA 127QB UT WOS:000317712400009 PM 23763079 ER PT J AU O'Donovan, A Rush, G Hoatam, G Hughes, BM McCrohan, A Kelleher, C O'Farrelly, C Malone, KM AF O'Donovan, Aoife Rush, Gavin Hoatam, Gerard Hughes, Brian M. McCrohan, AnnMaria Kelleher, Cecily O'Farrelly, Cliona Malone, Kevin M. TI SUICIDAL IDEATION IS ASSOCIATED WITH ELEVATED INFLAMMATION IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER SO DEPRESSION AND ANXIETY LA English DT Article DE depression; biological markers; mood disorders; stress; suicide; self-harm ID NATIONAL COMORBIDITY SURVEY; IMMUNE ACTIVATION; CANCER-PATIENTS; DSM-IV; INTERLEUKIN-6; STRESS; PREVALENCE; ATTEMPTERS; RESPONSES; CORTISOL AB Background Patients with major depressive disorder (MDD) who attempt or complete suicide have elevated inflammation compared to nonsuicidal patients with MDD. However, greater severity of depression and the medical lethality of suicide attempts could account for such elevated inflammation in suicide attempters and suicide completers. Methods To clarify, we measured inflammatory markers in patients with MDD with and without high levels of suicidal ideation and in nondepressed controls (N = 124). Levels of suicidal ideation, depression severity, and recent suicide attempts were assessed by structured clinical interviews. A composite score including the inflammatory markers tumor necrosis factor- (TNF-), interleukin-6 (IL-6), interleukin-10 (IL-10), and C-reactive protein (CRP) was used as an inflammatory index. Analysis of covariance models were used to assess group differences with adjustments for age and gender. Results Patients with MDD and high suicidal ideation had significantly higher inflammatory index scores than both controls, F(1,53) = 18.08, partial 2 = .25, P < .001, and patients with MDD and lower suicidal ideation F(1,44) = 7.59, partial 2 = .15, P = .009. In contrast, patients with lower suicidal ideation were not significantly different from controls on the inflammatory index, F(1,63) = .52, partial 2 = .01, P = .47. Follow-up analyses indicated that differences between patients with MDD and high versus lower suicidal ideation were independent of depression severity and recent suicide attempts. Conclusions Suicidal ideation may be uniquely associated with inflammation in depressed patients. C1 [O'Donovan, Aoife; Malone, Kevin M.] Univ Coll Dublin, Sch Med & Med Sci, Dublin 2, Ireland. [O'Donovan, Aoife; McCrohan, AnnMaria; Malone, Kevin M.] St Vincents Univ Hosp, Dept Psychiat Psychotherapy & Mental Hlth Res, Dublin 4, Ireland. [O'Donovan, Aoife] San Francisco VA Med Ctr, Stress & Hlth Res Program, San Francisco, CA USA. [O'Donovan, Aoife] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Rush, Gavin] St Patricks Univ Hosp, Dublin, Ireland. [Hoatam, Gerard] Creighton Univ, Sch Med, Omaha, NE USA. [Hughes, Brian M.] Natl Univ Ireland, Dept Psychol, Galway, Ireland. [Kelleher, Cecily] Univ Coll Dublin, Sch Publ Hlth Physiotherapy & Populat Sci, Dublin 2, Ireland. [O'Farrelly, Cliona] Trinity Coll Dublin, Sch Biochem & Immunol, Dublin, Ireland. RP O'Donovan, A (reprint author), Univ Calif San Francisco, Dept Psychiat, 3333 Calif St,Suite 465, San Francisco, CA 94143 USA. EM aoife.odonovan@ucsf.edu OI Malone, Kevin M/0000-0001-5665-4706 FU Craig Dobbin Newman Scholarship in Mental Health Research and Society in Science - The Branco Weiss Fellowship; Lundbeck Research Scholarship FX This study was supported by the Craig Dobbin Newman Scholarship in Mental Health Research and Society in Science - The Branco Weiss Fellowship to A.O.D. and by a Lundbeck Research Scholarship to G. R. The authors would like to thank Josh Woolley, M.D./Ph.D., Ashkan Ahmadian, B. A., and Kristen Nishimi, B. A., for helpful feedback on this manuscript. NR 44 TC 40 Z9 41 U1 0 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PD APR PY 2013 VL 30 IS 4 BP 307 EP 314 DI 10.1002/da.22087 PG 8 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 126GJ UT WOS:000317600800004 PM 23504697 ER PT J AU Bleich, S Nanda, NC Hage, FG AF Bleich, Steven Nanda, Navin C. Hage, Fadi G. TI The Incremental Value of Three-Dimensional Transthoracic Echocardiography in Adult Congenital Heart Disease SO ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES LA English DT Article DE three-dimensional echocardiography; congenital heart disease; atrial septal defect; ventricular septal defect; anomalous coronary artery; coarctation of aorta ID VENTRICULAR SEPTAL-DEFECTS; COR-TRIATRIATUM SINISTER; BICUSPID AORTIC-VALVE; OF-THE-ART; GREAT-ARTERIES; PULMONARY-ARTERY; FORAMEN-OVALE; MANAGEMENT; TRANSPOSITION; COARCTATION AB Imaging with echocardiography is useful in diagnosing congenital heart disease (CHD). Two-dimensional (2D) transthoracic echocardiography (TTE) has been the standard cardiac imaging modality, but it forces the reader to mentally create the three-dimensional (3D) cardiac anatomy to understand these complex diseases. 3D TTE, which has relatively recently emerged to address this limitation, is capable of providing clear and dynamic 3D views of these anatomic defects and offers more insight on how to manage them. This review article will address the benefit of utilizing 3D TTE for proper characterization of different types of CHD in the adult and as a guide to appropriate treatment. (Echocardiography 2013;30:483-494) C1 [Bleich, Steven] Univ Alabama Birmingham, Dept Med, Div Internal Med, Birmingham, AL 35249 USA. [Nanda, Navin C.; Hage, Fadi G.] Univ Alabama Birmingham, Div Cardiovasc Dis, Birmingham, AL 35249 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Div Cardiol, Birmingham, AL USA. RP Nanda, NC (reprint author), Univ Alabama Birmingham, Heart Stn SWB S102, 619 19th St South, Birmingham, AL 35249 USA. EM nanda@uab.edu OI Hage, Fadi/0000-0002-1397-4942 NR 51 TC 4 Z9 4 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0742-2822 J9 ECHOCARDIOGR-J CARD JI Echocardiography-J. Cardiovasc. Ultrasound Allied Tech. PD APR PY 2013 VL 30 IS 4 BP 483 EP 494 DI 10.1111/echo.12130 PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 123XS UT WOS:000317425900025 PM 23551608 ER PT J AU Yallampalli, R Wilde, EA Bigler, ED McCauley, SR Hanten, G Troyanskaya, M Hunter, JV Chu, ZL Li, XQ Levin, HS AF Yallampalli, Ragini Wilde, Elisabeth A. Bigler, Erin D. McCauley, Stephen R. Hanten, Gerri Troyanskaya, Maya Hunter, Jill V. Chu, Zili Li, Xiaoqi Levin, Harvey S. TI Acute White Matter Differences in the Fornix Following Mild Traumatic Brain Injury Using Diffusion Tensor Imaging SO JOURNAL OF NEUROIMAGING LA English DT Article DE Diffusion tensor imaging; mild traumatic brain injury; fornix ID AXONAL INJURY; HIPPOCAMPAL; CONCUSSION; RESPONSES; ATROPHY; MEMORY AB The integrity of the fornix using diffusion tensor imaging (DTI) in adolescent participants with acute mild traumatic brain injury (mTBI) compared to a demographically matched control group was examined. Fractional anisotropy (FA) in the fornix was elevated in the mild traumatic brain injured group. Performance on the Automated Neuropsychological Assessment Metrics (ANAM) was lower in the group with mTBI. A relation was found between lower performance on cognitive tasks and higher FA. The potential role of fornix injury as a basis of memory and processing speed deficits in mTBI is discussed. C1 [Yallampalli, Ragini; Wilde, Elisabeth A.; McCauley, Stephen R.; Hanten, Gerri; Troyanskaya, Maya; Li, Xiaoqi; Levin, Harvey S.] Baylor Coll Med, Phys Med & Rehabil Alliance, Houston, TX 77030 USA. [Yallampalli, Ragini; Wilde, Elisabeth A.; McCauley, Stephen R.; Hanten, Gerri; Troyanskaya, Maya; Li, Xiaoqi; Levin, Harvey S.] Univ Texas Houston, Sch Med, Houston, TX USA. [Wilde, Elisabeth A.; McCauley, Stephen R.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. [Wilde, Elisabeth A.; Hunter, Jill V.; Chu, Zili] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA. [McCauley, Stephen R.; Levin, Harvey S.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. [Wilde, Elisabeth A.; Hunter, Jill V.; Chu, Zili] Texas Childrens Hosp, Dept Pediat Radiol, Houston, TX 77030 USA. [Wilde, Elisabeth A.; McCauley, Stephen R.; Troyanskaya, Maya; Levin, Harvey S.] Univ Houston, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Yallampalli, Ragini] Univ Houston, Dept Psychol, Houston, TX USA. [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA. [Bigler, Erin D.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA. [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA. [Bigler, Erin D.] Univ Utah, Utah Brain Inst, Salt Lake City, UT USA. RP Wilde, EA (reprint author), Baylor Coll Med, 1709 Dryden Rd,Ste 1200, Houston, TX 77030 USA. EM ewilde@bcm.edu FU National Institutes of Health [NS056202-02] FX This research was supported by Grant NS056202-02 awarded to Harvey S. Levin by the National Institutes of Health. We would also like to acknowledge the generous support by Mission Connect of the TIRR Foundation. We would also like to thank the patients and their families for involvement in this study. The information in this manuscript and the manuscript itself has never been published either electronically or in print. None of the authors have any financial or other relationship(s) that could be construed as a conflict of interest with respect to the content of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 30 TC 23 Z9 23 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1051-2284 J9 J NEUROIMAGING JI J. Neuroimaging PD APR PY 2013 VL 23 IS 2 BP 224 EP 227 DI 10.1111/j.1552-6569.2010.00537.x PG 4 WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 126LN UT WOS:000317617800016 PM 21988147 ER PT J AU Collins, E Ebert, J Hentzen, K Johnson, D Stevenson, K AF Collins, E. Ebert, J. Hentzen, K. Johnson, D. Stevenson, K. TI Development of a telephone clinic for the management of neuropathic pain SO JOURNAL OF PAIN LA English DT Meeting Abstract C1 [Collins, E.; Ebert, J.; Hentzen, K.; Johnson, D.; Stevenson, K.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1526-5900 J9 J PAIN JI J. Pain PD APR PY 2013 VL 14 IS 4 SU 1 BP S39 EP S39 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 126RR UT WOS:000317639400154 ER PT J AU Prowse, RL Dalbeth, N Kavanaugh, A Adebajo, AO Gaffo, AL Terkeltaub, R Mandell, BF Suryana, BPP Goldenstein-Schainberg, C Diaz-Torne, C Khanna, D Liote, F Mccarthy, G Kerr, GS Yamanaka, H Janssens, H Baraf, HF Chen, JH Vazquez-Mellado, J Harrold, LR Stamp, LK Van de Laar, MA Janssen, M Doherty, M Boers, M Edwards, NL Gow, P Chapman, P Khanna, P Helliwell, PS Grainger, R Schumacher, HR Neogi, T Jansen, TL Louthrenoo, W Sivera, F Taylor, WJ AF Prowse, Rebecca L. Dalbeth, Nicola Kavanaugh, Arthur Adebajo, Adewale O. Gaffo, Angelo L. Terkeltaub, Robert Mandell, Brian F. Suryana, Bagus P. P. Goldenstein-Schainberg, Claudia Diaz-Torne, Cesar Khanna, Dinesh Liote, Frederic Mccarthy, Geraldine Kerr, Gail S. Yamanaka, Hisashi Janssens, Hein Baraf, Herbert F. Chen, Jiunn-Horng Vazquez-Mellado, Janitzia Harrold, Leslie R. Stamp, Lisa K. Van de Laar, Mart A. Janssen, Matthijs Doherty, Michael Boers, Maarten Edwards, N. Lawrence Gow, Peter Chapman, Peter Khanna, Puja Helliwell, Philip S. Grainger, Rebecca Schumacher, H. Ralph Neogi, Tuhina Jansen, Tim L. Louthrenoo, Worawit Sivera, Francisca Taylor, William J. TI A Delphi Exercise to Identify Characteristic Features of Gout - Opinions from Patients and Physicians, the First Stage in Developing New Classification Criteria SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE GOUT; CLASSIFICATION; CRITERIA; PATIENTS; PHYSICIANS ID DIAGNOSTIC-CRITERIA; FLUID ANALYSIS; RHEUMATOLOGY; PREVALENCE; ARTHRITIS; HEALTH AB Objective. To identify a comprehensive list of features that might discriminate between gout and other rheumatic musculoskeletal conditions, to be used subsequently for a case-control study to develop and test new classification criteria for gout. Methods. Two Delphi exercises were conducted using Web-based questionnaires: one with physicians from several countries who had an interest in gout and one with patients from New Zealand who had gout. Physicians rated a list of potentially discriminating features that were identified by literature review and expert opinion, and patients rated a list of features that they generated themselves. Agreement was defined by the RAND/UCLA disagreement index. Results. Forty-four experienced physicians and 9 patients responded to all iterations. For physicians, 71 items were identified by literature review and 15 more were suggested by physicians. The physician survey showed agreement for 26 discriminatory features and 15 as not discriminatory. The patients identified 46 features of gout, for which there was agreement on 25 items as being discriminatory and 7 items as not discriminatory. Conclusion. Patients and physicians agreed upon several key features of gout. Physicians emphasized objective findings, imaging, and patterns of symptoms, whereas patients emphasized severity, functional results, and idiographic perception of symptoms. (First Release Feb 15 2013; J Rheumatol 2013;40:498-505; doi:10.3899/jrheum.121037) C1 Univ Otago, Dunedin, New Zealand. [Dalbeth, Nicola] Univ Auckland, Auckland 1, New Zealand. [Kavanaugh, Arthur] Univ Calif San Diego, Vet Affairs Healthcare Syst, San Diego, CA 92103 USA. [Adebajo, Adewale O.] Univ Sheffield, Sheffield, S Yorkshire, England. Vet Affairs Med Ctr, Birmingham, AL USA. Univ Alabama Birmingham, Birmingham, AL USA. [Mandell, Brian F.] Case Western Reserve Univ, Cleveland Clin, CCF Lerner Coll Med, Cleveland, OH 44106 USA. Brawijaya Univ, Malang, Indonesia. Dr Saiful Anwar Hosp, Malang, Indonesia. Univ Sao Paulo, Fac Med, Sao Paulo, Brazil. Univ Sao Paulo, Fac Med, Hosp Clin, Sao Paulo, Brazil. [Diaz-Torne, Cesar] Hosp Santa Creu & Sant Pau, Barcelona, Spain. [Khanna, Dinesh; Stamp, Lisa K.] Univ Michigan, Ann Arbor, MI 48109 USA. Univ Paris Diderot, Paris, France. Hop Lariboisiere, F-75475 Paris, France. [Mccarthy, Geraldine] Univ Coll Dublin, Dublin 2, Ireland. Georgetown Univ, Vet Affairs Med Ctr, Washington, DC USA. [Kerr, Gail S.] Howard Univ, Vet Affairs Med Ctr, Washington, DC 20059 USA. [Yamanaka, Hisashi] Tokyo Womens Med Univ, Tokyo, Japan. [Janssens, Hein] Radboud Univ Nijmegen, Med Ctr, Dept Primary & Community Care, NL-6525 ED Nijmegen, Netherlands. [Baraf, Herbert F.] Arthrit & Rheumatism Associates, Ctr Rheumatol & Bone Res, Wheaton, MA USA. [Chen, Jiunn-Horng] China Med Univ, China Med Univ Hosp, Taichung, Taiwan. [Vazquez-Mellado, Janitzia] Hosp Gen Mexico City, Mexico City, DF, Mexico. [Harrold, Leslie R.] Univ Massachusetts, Sch Med, Worcester, MA USA. Univ Otago, Christchurch, New Zealand. [Van de Laar, Mart A.] Med Spectrum Twente, Dept Rheumatol & Clin Immunol, Enschede, Netherlands. [Janssen, Matthijs] Rijnstate, Dept Rheumatol, Arnhem, Netherlands. [Doherty, Michael] Univ Nottingham, Nottingham NG7 2RD, England. [Boers, Maarten] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands. [Edwards, N. Lawrence] Univ Florida, Gainesville, FL USA. [Gow, Peter] Counties Manukau Dist Hlth Board, Auckland, New Zealand. [Chapman, Peter] Canterbury Dist Hlth Board, Christchurch, New Zealand. [Helliwell, Philip S.] Univ Leeds, Leeds, W Yorkshire, England. Univ Otago, Wellington, New Zealand. Univ Penn, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. [Neogi, Tuhina] Boston Univ, Sch Med, Boston, MA 02118 USA. [Jansen, Tim L.] Radboud Univ Nijmegen, Med Centrum, Dept Rheumatol, NL-6525 ED Nijmegen, Netherlands. [Louthrenoo, Worawit] Chiang Mai Univ, Chiang Mai 50000, Thailand. Hosp Gen Elda, Alicante, Spain. Univ Miguel Hernandez, Alicante, Spain. RP Taylor, WJ (reprint author), Univ Otago Wellington, Dept Med, POB 7343, Wellington 6242, New Zealand. EM Will.taylor@otago.ac.nz RI Jansen, T.L.Th.A./L-4407-2015 OI Cesar, Diaz-Torne/0000-0001-6275-7699; Jansen, Tim/0000-0003-3026-3154; Neogi, Tuhina/0000-0002-9515-1711 FU Arthritis New Zealand FX R. Prowse was supported by a Summer Student Scholarship from Arthritis New Zealand. Dr. Kerr has participated in gout trials by Savient, Nuon, and Ardea. Dr. Doherty is a member of advisory boards for Ardea Biosciences, Ipsen, Menarini, Novartis, and Savient. NR 18 TC 14 Z9 16 U1 0 U2 7 PU J RHEUMATOL PUBL CO PI TORONTO PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA SN 0315-162X J9 J RHEUMATOL JI J. Rheumatol. PD APR PY 2013 VL 40 IS 4 BP 498 EP 505 DI 10.3899/jrheum.121037 PG 8 WC Rheumatology SC Rheumatology GA 125LF UT WOS:000317540600024 PM 23418379 ER PT J AU Tomov, S Lazarchick, J Self, SE Bruner, ET Budisavljevic, MN AF Tomov, S. Lazarchick, J. Self, S. E. Bruner, E. T. Budisavljevic, M. N. TI Kidney-limited thrombotic microangiopathy in patients with SLE treated with romiplostim SO LUPUS LA English DT Article DE Thrombotic microangiopathy; antiphospholipid syndrome; thrombotic thrombocytopenic purpura; romiplostim; acute renal failure; systemic lupus erythematosus; plasma exchange ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; HEMOLYTIC-UREMIC SYNDROME; THROMBOCYTOPENIC PURPURA; ANTIPHOSPHOLIPID SYNDROME; IMMUNE THROMBOCYTOPENIA; VASCULAR-LESIONS; NEPHRITIS; ADAMTS13; THROMBOPOIETIN; ANEMIA AB We present the case of a 19 year-old Caucasian female with history of systemic lupus erythematosus (SLE) and normal baseline kidney function who developed severe acute renal failure following treatment of thrombocytopenia with the thrombopoietic agent romiplostim. Percutaneous kidney biopsy revealed thrombotic microangiopathy (TMA) without immune complex lupus glomerulonephritis. We discuss pathogenesis and differential diagnosis of TMA in patients with SLE and raise concerns regarding the use of thrombopoietic agents in such patients. Based on favorable long-term outcome in our case aggressive treatment and in particular prolonged use of plasma exchange in these patients are advocated. Lupus (2013) 22, 504-509. C1 [Tomov, S.; Budisavljevic, M. N.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Lazarchick, J.; Self, S. E.; Bruner, E. T.] Pathol & Lab Med Med Univ South Carolina, Charleston, SC USA. [Budisavljevic, M. N.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Budisavljevic, MN (reprint author), Med Univ S Carolina, Div Nephrol, 171 Ashley Ave, Charleston, SC 29425 USA. EM budisamn@musc.edu NR 37 TC 1 Z9 1 U1 0 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0961-2033 J9 LUPUS JI Lupus PD APR PY 2013 VL 22 IS 5 BP 504 EP 509 DI 10.1177/0961203313477900 PG 6 WC Rheumatology SC Rheumatology GA 122TV UT WOS:000317341900014 PM 23554039 ER PT J AU DeKosky, ST Blennow, K Ikonomovic, MD Gandy, S AF DeKosky, Steven T. Blennow, Kaj Ikonomovic, Milos D. Gandy, Sam TI Acute and chronic traumatic encephalopathies: pathogenesis and biomarkers SO NATURE REVIEWS NEUROLOGY LA English DT Review ID POSTTRAUMATIC-STRESS-DISORDER; AMYLOID-BETA ACCUMULATION; PITTSBURGH COMPOUND-B; SEVERE BRAIN-INJURY; HEAD-INJURY; ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; PARKINSONS-DISEASE; COGNITIVE DECLINE; PRECURSOR PROTEIN AB Over the past decade, public awareness of the long-term pathological consequences of traumatic brain injury (TBI) has increased. Such awareness has been stimulated mainly by reports of progressive neurological dysfunction in athletes exposed to repetitive concussions in high-impact sports such as boxing and American football, and by the rising number of TBIs in war veterans who are now more likely to survive explosive blasts owing to improved treatment. Moreover, the entity of chronic traumatic encephalopathy (CTE)-which is marked by prominent neuropsychiatric features including dementia, parkinsonism, depression, agitation, psychosis, and aggression-has become increasingly recognized as a potential late outcome of repetitive TBI. Annually, about 1% of the population in developed countries experiences a clinically relevant TBI. The goal of this Review is to provide an overview of the latest understanding of CTE pathophysiology, and to delineate the key issues that are challenging clinical and research communities, such as accurate quantification of the risk of CTE, and development of reliable biomarkers for single-incident TBI and CTE. DeKosky, S. T. et al. Nat. Rev. Neurol. 9, 192-200 (2013); doi:10.1038/nrneurol.2013.36 C1 [DeKosky, Steven T.] Univ Virginia, Sch Med, Off Dean, Charlottesville, VA 22908 USA. [DeKosky, Steven T.] Univ Virginia, Sch Med, Dept Neurol, Charlottesville, VA 22908 USA. [Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Clin Neurochem Lab, Inst Neurosci & Physiol,Sahlgrenska Univ Hosp, SE-43180 Molndal, Sweden. [Ikonomovic, Milos D.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15213 USA. [Ikonomovic, Milos D.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. [Ikonomovic, Milos D.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA. [Gandy, Sam] James J Peters Med Ctr, Icahn Sch Med, Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Gandy, Sam] James J Peters Med Ctr, Icahn Sch Med, Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Gandy, Sam] James J Peters Med Ctr, Icahn Sch Med, Mt Sinai, Alzheimers Dis Res Ctr, New York, NY 10029 USA. RP DeKosky, ST (reprint author), Univ Virginia, Sch Med, Off Dean, Charlottesville, VA 22908 USA. EM dekosky@virginia.edu FU NIH [P01NS30318, P01AG14449, P50AG05133]; VA MERIT review grants [1I01BX000348, 1I01RX000511]; Cure Alzheimer's Fund; US NIH [P50 AG05138] FX The authors gratefully acknowledge the support of NIH grants P01NS30318, P01AG14449 and P50AG05133 (S. T. DeKosky and M. D. Ikonomovic), and VA MERIT review grants 1I01BX000348 (S. Gandy) and 1I01RX000511 (M. D. Ikonomovic). S. Gandy also acknowledges the support of the Cure Alzheimer's Fund and of US NIH P50 AG05138. The authors thank P. Davies (North Shore-Hofstra) for helpful discussions. NR 96 TC 80 Z9 82 U1 7 U2 66 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-4758 J9 NAT REV NEUROL JI Nat. Rev. Neurol. PD APR PY 2013 VL 9 IS 4 BP 192 EP 200 DI 10.1038/nrneurol.2013.36 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 121TV UT WOS:000317268100007 PM 23558985 ER PT J AU Villar, CC Lin, AL Cao, Z Zhao, XR Wu, LA Chen, S Sun, Y Yeh, CK AF Villar, C. C. Lin, A. L. Cao, Z. Zhao, X-R Wu, L-A Chen, S. Sun, Y. Yeh, C-K TI Anticandidal activity and biocompatibility of a rechargeable antifungal denture material SO ORAL DISEASES LA English DT Article DE anticandidal; rechargeable denture material; denture stomatitis; Candida albicans; epithelial cells ID ORAL EPITHELIAL-CELLS; SECRETED PROTEINASE GENES; CANDIDA-ALBICANS; IN-VITRO; TISSUE CONDITIONERS; BIOFILM FORMATION; SILVER-ZEOLITE; DRUG-RELEASE; MICONAZOLE; INFECTION AB OBJECTIVES: Candida-associated denture stomatitis is a recurrent and debilitating oral mucosal disease. Development of anticandidal denture materials represents a promising strategy to manage this condition. We have previously shown that miconazole incorporated in methacrylic acid (MAA) copolymerized diurethane dimethacrylate (UDMA) denture materials has long-term anticandidal activity. In this study, we examined the ability of culture medium conditioned with drug-free-or miconazole-MAA-UDMA discs to prevent Candida infection in an in vitro oral epithelial cell/Candida albicans coculture system. MATERIALS AND METHODS: Candida albicans (C. albicans)-induced OKF6/TERT-2 cell damage was quantified by the release of lactate dehydrogenase from epithelial cells, cytokine production was quantified using protein cytokine arrays, and the expression of C. albicans genes was measured by RT-qPCR. RESULTS: Candida albicans had limited growth with altered expression levels of secreted aspartyl proteinase-2 and -5 in culture medium conditioned by miconazole-MAA-UDMA discs. Significantly, the ability of C. albicans to induce oral epithelial cell damage and trigger epithelial proinflammatory cytokine production was also inhibited by miconazole disc conditioned media. CONCLUSION: Miconazole released from MAA-UDMA denture materials effectively prevents the development of candidal infection in an in vitro oral epithelial system. Further characterization of this drug-rechargeable denture material is warranted. Oral Diseases (2013) 19, 287--295 C1 [Villar, C. C.; Zhao, X-R] Univ Texas Hlth Sci Ctr San Antonio, Dept Periodont, San Antonio, TX 78229 USA. [Lin, A. L.; Yeh, C-K] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, San Antonio, TX 78229 USA. [Cao, Z.; Sun, Y.] Univ S Dakota, Dept Biomed Engn Program, Sioux Falls, SD USA. [Wu, L-A; Chen, S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Dev Dent, San Antonio, TX 78229 USA. [Yeh, C-K] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Audie L Murphy Div, San Antonio, TX 78229 USA. RP Yeh, CK (reprint author), South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr 182, Audie L Murphy Div, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM yeh@uthscsa.edu RI Villar, Cristina/D-6353-2013 OI Villar, Cristina/0000-0002-5905-5079 FU NIDCR/NIH [R01 DE021084, R01DE019892]; NCRR/NIH [UL1RR025767] FX We are grateful to Drs. Brian Wickes (Department of Microbiology, UTHSCSA) and Spencer Redding (Comprehensive Dentistry, UTHSCSA) for their support and useful discussion during this research. Cell line OKF6/TERT-2 was a gift from Dr. Jim. Rhienwald (Brigham and Women's Hospital, Harvard Medical. School, Boston, MA). We would also like to thank Ms. Shuko Lee for her assistance in statistical analysis. This research is support by NIDCR/NIH grants R01 DE021084 (Y. Sun and C-K. Yeh), R01DE019892 (S. Chen), and NCRR/NIH grant UL1RR025767 (C.C. Villar). Dr. Zhengbing Cao current address is Medetech Development Corporation, 12527 MUKILTEO SPEEDWAY STE 103 LYNNWOOD, WA 98087-1532, USA (zhengbing@medetech.com). NR 52 TC 4 Z9 4 U1 2 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1354-523X J9 ORAL DIS JI Oral Dis. PD APR PY 2013 VL 19 IS 3 BP 287 EP 295 DI 10.1111/odi.12000 PG 9 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 124TP UT WOS:000317490300008 PM 22957799 ER PT J AU Koolaee, RM Schumacher, H Shoemaker, MJ Mooar, SK Pullman-Mooar, S AF Koolaee, R. M. Schumacher, H., Jr. Shoemaker, M. J. Mooar, S. K. Pullman-Mooar, S. TI FACTORS PREDICTING THE EFFICACY OF VISCOSUPPLEMENTATION IN KNEE OSTEOARTHRITIS SO OSTEOARTHRITIS AND CARTILAGE LA English DT Meeting Abstract CT World Congress of the Osteoarthritis-Research-Society-International (OARSI) CY APR 18-21, 2013 CL Philadelphia, PA SP OsteoArthritis Res Soc Int (OARSI) C1 [Koolaee, R. M.; Schumacher, H., Jr.; Mooar, S. K.; Pullman-Mooar, S.] Univ Penn, Philadelphia, PA 19104 USA. [Koolaee, R. M.; Schumacher, H., Jr.; Mooar, S. K.; Pullman-Mooar, S.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Shoemaker, M. J.] Grand Valley State Univ, Grand Rapids, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1063-4584 J9 OSTEOARTHR CARTILAGE JI Osteoarthritis Cartilage PD APR PY 2013 VL 21 SU S BP S258 EP S258 PG 1 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA 130TF UT WOS:000317942300526 ER PT J AU Suri, P Hunter, DJ Rainville, J Guermazi, A Katz, JN AF Suri, P. Hunter, D. J. Rainville, J. Guermazi, A. Katz, J. N. TI ASSOCIATIONS BETWEEN SELF-REPORTED PHYSICAL ACTIVITY AND LUMBAR FACET JOINT OSTEOARTHRITIS: THE FRAMINGHAM STUDY SO OSTEOARTHRITIS AND CARTILAGE LA English DT Meeting Abstract CT World Congress of the Osteoarthritis-Research-Society-International (OARSI) CY APR 18-21, 2013 CL Philadelphia, PA SP OsteoArthritis Res Soc Int (OARSI) C1 [Suri, P.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Hunter, D. J.] Univ Sydney, Sydney, NSW 2006, Australia. [Rainville, J.] New England Baptist Hosp, Boston, MA USA. [Guermazi, A.] Boston Univ, Boston, MA 02215 USA. [Katz, J. N.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1063-4584 J9 OSTEOARTHR CARTILAGE JI Osteoarthritis Cartilage PD APR PY 2013 VL 21 SU S BP S279 EP S279 PG 1 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA 130TF UT WOS:000317942300576 ER PT J AU Dowben, JS Grant, JS Froelich, KD Keltner, NL AF Dowben, Jonathan S. Grant, Joan S. Froelich, Kimberly D. Keltner, Norman L. TI Biological Perspectives Hydroxyzine for Anxiety: Another Look at an Old Drug SO PERSPECTIVES IN PSYCHIATRIC CARE LA English DT Article DE Hydroxyzine; anxiety ID GENERALIZED ANXIETY; DISORDER; EFFICACY; PLACEBO C1 [Dowben, Jonathan S.] Brooke Army Med Ctr, Pediat & Adolescent Behav Hlth Serv, San Antonio, TX USA. [Grant, Joan S.; Keltner, Norman L.] Univ Alabama Birmingham, Birmingham, AL 35294 USA. [Froelich, Kimberly D.] Birmingham VA Med Ctr, Patient Care Serv, Birmingham, AL USA. RP Keltner, NL (reprint author), Univ Alabama Birmingham, Birmingham, AL 35294 USA. EM nkeltner@uab.edu OI Grant, Joan/0000-0001-6000-4060 NR 9 TC 6 Z9 6 U1 3 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0031-5990 J9 PERSPECT PSYCHIATR C JI Perspect. Psychiatr. Care PD APR PY 2013 VL 49 IS 2 BP 75 EP 77 DI 10.1111/ppc.12012 PG 3 WC Nursing; Psychiatry SC Nursing; Psychiatry GA 122DE UT WOS:000317295600002 PM 23557449 ER PT J AU Soni, RK Palevsky, PM AF Soni, Ritu K. Palevsky, Paul M. TI THE SMARTPHONE IN NEPHROLOGY: PRELIMINARY SURVEY ON CURRENT TRENDS AND PERCEIVED NEEDS SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT International Conference on Glomerular Diseases CY APR 27, 2012 CL Hofstra N Shore LIJ Sch Med, Div Kidney Dis & Hypertens, Great Neck, NY SP N Shore LIJ Hlth Syst, Natl Kidney Fdn HO Hofstra N Shore LIJ Sch Med, Div Kidney Dis & Hypertens C1 Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2013 VL 61 IS 4 MA 302 BP A91 EP A91 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 121WG UT WOS:000317274900304 ER PT J AU Chang, TI Li, SY Chen, SC Peralta, CA Shlipak, MG Fried, LF Whaley-Connell, AT McCullough, PA Tamura, MK AF Chang, Tara I. Li, Suying Chen, Shu-Cheng Peralta, Carmen A. Shlipak, Michael G. Fried, Linda F. Whaley-Connell, Adam T. McCullough, Peter A. Tamura, Manjula Kurella CA KEEP Investigators TI Risk Factors for ESRD in Individuals With Preserved Estimated GFR With and Without Albuminuria: Results From the Kidney Early Evaluation Program (KEEP) SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Albuminuria; blood pressure; chronic kidney disease; diabetes; dialysis risk factors; end-stage renal disease; public health. ID STAGE RENAL-DISEASE; BLOOD-PRESSURE CONTROL; GLOMERULAR-FILTRATION-RATE; COMPETING RISK; PROGRESSION; PROTEINURIA; FAILURE; TRIAL; NEPHROPATHY; POPULATION AB Background: Given the increasing costs and poor outcomes of end-stage renal disease (ESRD), we sought to identify risk factors for ESRD in people with preserved estimated glomerular filtration rate (eGFR), with or without albuminuria, who were at high risk of ESRD. Methods: This cohort study included participants in the National Kidney Foundation's Kidney Early Evaluation Program (KEEP) with eGFR >= 60 mL/min/1.73 m(2) at baseline stratified by the presence or absence of albuminuria. The Chronic Kidney Disease Epidemiology Collaboration equation was used to calculate eGFR. Urine was tested for albuminuria by semiquantitative dipstick. The outcome was the development of treated chronic kidney failure, defined as initiation of maintenance dialysis therapy or kidney transplantation, determined by linkage to the US Renal Data System. We used a Cox model with the Fine-Gray method to assess risk factors for treated chronic kidney failure while accounting for the competing risk of death. Results: During a median follow-up of 4.8 years, 126 of 13,923 participants with albuminuria (16/10,000 patient-years) and 56 of 109,135 participants without albuminuria (1.1/10,000 patient-years) developed treated chronic kidney failure. Diabetes was a strong risk factor for developing treated chronic kidney failure in participants with and without albuminuria (adjusted HRs of 9.3 [95% CI, 5.7-15.3] and 7.8 [95% CI, 4.1-14.8], respectively). Black race, lower eGFR, and higher systolic blood pressure also were associated with higher adjusted risks of developing treated chronic kidney failure. Conclusions: In a diverse high-risk cohort of KEEP participants with preserved eGFR, we showed that diabetes, higher systolic blood pressure, lower eGFR, and black race were risk factors for developing treated chronic kidney failure irrespective of albuminuria status, although the absolute risk of kidney failure in participants without albuminuria was very low. Our findings support testing for kidney disease in high-risk populations, which often have otherwise unrecognized kidney disease. Am J Kidney Dis. 61(4)(S2): S4-S11. (C) 2013 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. C1 [Chang, Tara I.; Tamura, Manjula Kurella] Stanford Univ, Sch Med, Div Nephrol, Dept Med, Palo Alto, CA 94304 USA. [Li, Suying; Chen, Shu-Cheng] Minneapolis Med Res Fdn Inc, Chron Dis Res Grp, Minneapolis, MN USA. [Peralta, Carmen A.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Shlipak, Michael G.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Fried, Linda F.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Fried, Linda F.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Whaley-Connell, Adam T.] Harry S Truman Mem Vet Hosp, Res Serv, Columbia, MO 65201 USA. [Whaley-Connell, Adam T.] Univ Missouri, Columbia Sch Med, Div Nephrol & Hypertens, Columbia, MO USA. [McCullough, Peter A.] St John Providence Hlth Syst, Providence Pk Heart Inst, Novi, MI USA. RP Chang, TI (reprint author), Stanford Univ, Sch Med, Div Nephrol, 777 Welch Rd,Ste DE,Rm D100, Palo Alto, CA 94304 USA. EM tichang@stanford.edu RI Kurella Tamura, Manjula/C-8284-2014 OI Kurella Tamura, Manjula/0000-0001-5227-2479; Whaley-Connell, Adam/0000-0001-8955-5560 FU National Kidney Foundation Inc; Abbott; Amgen; LifeScan; Siemens; Genentech; GMFoundation; Nephroceuticals; Pfizer; American Heart Association National Scientist Development Grant [12SDG11670032]; T. FranklinWilliams Scholarship Award [CDA-2 BB47, AG040638]; Atlantic Philanthropies Inc; John A. Hartford Foundation; ASP; ASN; Novartis Corp. FX KEEP is a program of the National Kidney Foundation Inc and is supported by Abbott, Amgen, LifeScan, Siemens, Genentech, GMFoundation, Nephroceuticals, and Pfizer. Dr Chang is supported by an American Heart Association National Scientist Development Grant (12SDG11670032). Department of Veterans Affairs CDA-2 BB47, National Institutes of Health AG040638, and the American Society of Nephrology- Association of Specialty Professors (ASN-ASP) Development Grant in Geriatric Nephrology to Dr Whaley-Connell are supported by a T. FranklinWilliams Scholarship Award, funding provided by Atlantic Philanthropies Inc, the John A. Hartford Foundation, the ASP, and the ASN. This research was also supported by Novartis Corp. NR 30 TC 17 Z9 17 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2013 VL 61 IS 4 SU 2 BP S4 EP S11 DI 10.1053/j.ajkd.2012.12.016 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 121US UT WOS:000317270600002 PM 23507268 ER PT J AU Birdsall, HH AF Birdsall, Holly H. TI Women as Leaders and Investigators in VA Research SO AMERICAN JOURNAL OF MEDICINE LA English DT Letter C1 [Birdsall, Holly H.] US Dept Vet Affairs, Washington, DC USA. [Birdsall, Holly H.] Baylor Coll Med, Houston, TX 77030 USA. RP Birdsall, HH (reprint author), US Dept Vet Affairs, Washington, DC USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD APR PY 2013 VL 126 IS 4 BP E9 EP E9 DI 10.1016/j.amjmed.2012.08.022 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 115IR UT WOS:000316806300004 PM 23507219 ER PT J AU McCarren, M Goldman, S AF McCarren, Madeline Goldman, Steven TI Women as Leaders and Investigators in VA Research Reply SO AMERICAN JOURNAL OF MEDICINE LA English DT Letter C1 [McCarren, Madeline] US Dept Vet Affairs, Pharm Benefits Management Serv 10P4P, Hines, IL USA. [Goldman, Steven] US Dept Vet Affairs, Southern Arizona VA Healthcare Syst 111C, Tucson, AZ USA. RP McCarren, M (reprint author), US Dept Vet Affairs, Pharm Benefits Management Serv 10P4P, Hines, IL USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD APR PY 2013 VL 126 IS 4 BP E11 EP E11 DI 10.1016/j.amjmed.2012.09.007 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 115IR UT WOS:000316806300005 PM 23507209 ER PT J AU Russo, AM Stainback, RF Bailey, SR Epstein, AE Heidenreich, PA Jessup, M Kapa, S Kremers, MS Lindsay, BD Stevenson, LW Bailey, SR Russo, AM Kapa, S Alexander, MB Bailey, SR Birgersdotter-Green, U Brown, AS Grimm, RA Hauptman, PJ Hunt, SA Lampert, R Lindenfeld, J Malenka, DJ Mani, K Marine, JE Martin, ET Page, RL Rich, MW Varosy, PD Walsh, MN Wolk, MJ Bailey, SR Doherty, JU Douglas, PS Hendel, RC Kramer, CM Min, JK Patel, MR Shaw, L Stainback, RF Allen, JM AF Russo, Andrea M. Stainback, Raymond F. Bailey, Steven R. Epstein, Andrew E. Heidenreich, Paul A. Jessup, Mariell Kapa, Suraj Kremers, Mark S. Lindsay, Bruce D. Stevenson, Lynne Warner Bailey, Steven R. Russo, Andrea M. Kapa, Suraj Alexander, Michael B. Bailey, Steven R. Birgersdotter-Green, Ulrika Brown, Alan S. Grimm, Richard A. Hauptman, Paul J. Hunt, Sharon A. Lampert, Rachel Lindenfeld, JoAnn Malenka, David J. Mani, Kartik Marine, Joseph E. Martin, Edward T. Page, Richard L. Rich, Michael W. Varosy, Paul D. Walsh, Mary Norine Wolk, Michael J. Bailey, Steven R. Doherty, John U. Douglas, Pamela S. Hendel, Robert C. Kramer, Christopher M. Min, James K. Patel, Manesh R. Shaw, Leslee Stainback, Raymond F. Allen, Joseph M. CA Amer Geriatrics Soc TI ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 Appropriate Use Criteria for Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance SO HEART RHYTHM LA English DT Article DE ACCF appropriate use criteria; CRT; electrophysiology; heart failure; ICD; implantable defibrillator; sudden death ID ACUTE MYOCARDIAL-INFARCTION; MONOMORPHIC VENTRICULAR-TACHYCARDIA; DUAL-CHAMBER; QRS DURATION; TASK-FORCE; NUCLEAR CARDIOLOGY; PRIMARY PREVENTION; UNIVERSAL DEFINITION; COMPLICATION RATES; THORACIC-SURGEONS AB The American College of Cardiology Foundation in collaboration with the Heart Rhythm Society and key specialty and subspecialty societies conducted a review of common clinical scenarios where implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT) are frequently considered. The clinical scenarios covered in this document address secondary prevention, primary prevention, comorbidities, generator replacement at elective replacement indicator, dual-chamber ICD, and CRT. The indications (clinical scenarios) were derived from common applications or anticipated uses, as well as from current clinical practice guidelines and results of studies examining device implantation. The 369 indications in this document were developed by a multidisciplinary writing group and scored by a separate independent technical panel on a scale of 1 to 9 to designate care that is Appropriate (median 7 to 9), May Be Appropriate (median 4 to 6), and Rarely Appropriate (median 1 to 3). The final ratings reflect the median score of the 17 technical panel members: 45% of the indications were rated as Appropriate, 33% were rated May Be Appropriate and 22% were rated Rarely Appropriate. In general, Appropriate designations were assigned to scenarios for which clinical trial evidence and/or clinical experience was available that supported device implantation. By contrast, scenarios for which clinical trial evidence was limited or device implantation seemed reasonable for extenuating reasons were categorized as May Be Appropriate. Scenarios for which there were data showing harm, or no data were available, and medical judgment deemed device therapy ill-advised were categorized as Rarely Appropriate. For example, comorbidities including life expectancy and cognitive function impacted appropriateness ratings. The Appropriate Use Criteria for ICD/CRT have the potential to enhance physician decision making, healthcare delivery, and reimbursement policy. Furthermore, recognition of clinical scenarios rated as May Be Appropriate facilitates the identification of areas that would benefit from future research. C1 [Russo, Andrea M.; Russo, Andrea M.] UMDNJ, Robert Wood Johnson Med Sch, Piscataway, NJ USA. [Russo, Andrea M.; Russo, Andrea M.] Cooper Univ Hosp, Cardiac Electrophysiol Serv, Camden, NJ USA. [Russo, Andrea M.; Russo, Andrea M.] Cooper Univ Hosp, Arrhythmia Serv, Camden, NJ USA. [Stainback, Raymond F.] St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX USA. [Stainback, Raymond F.] Baylor Coll Med, Houston, TX 77030 USA. [Bailey, Steven R.; Bailey, Steven R.] Univ Texas Hlth Sci Ctr San Antonio, Div Cardiol, San Antonio, TX 78229 USA. [Bailey, Steven R.; Bailey, Steven R.] Univ Texas Hlth Sci Ctr San Antonio, Janey Briscoe Distinguished Chair, San Antonio, TX 78229 USA. [Epstein, Andrew E.] Univ Penn, Electrophysiol Sect, Cardiovasc Div, Philadelphia, PA 19104 USA. [Epstein, Andrew E.] Philadelphia VA Med Ctr, Cardiol Sect, Philadelphia, PA USA. [Heidenreich, Paul A.] Stanford Univ, Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA. [Jessup, Mariell] Univ Penn, Heart & Vasc Ctr, Philadelphia, PA 19104 USA. [Kapa, Suraj; Kapa, Suraj] Univ Penn, Dept Med, Div Cardiol, Philadelphia, PA 19104 USA. [Kremers, Mark S.] Mid Carolina Cardiol, Charlotte, NC USA. [Lindsay, Bruce D.] Cleveland Clin Fdn Cardiovasc Med, Cleveland, OH USA. [Stevenson, Lynne Warner] Brigham & Womens Hosp, Cardiomyopathy & Heart Failure Program, Cardiovasc Div, Boston, MA 02115 USA. [Alexander, Michael B.] Cigna HealthCare, Blue Bell, PA USA. [Birgersdotter-Green, Ulrika] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA. [Birgersdotter-Green, Ulrika] Univ Calif San Diego, Med Ctr, Pacemaker & ICD Clin, La Jolla, CA 92093 USA. [Brown, Alan S.] Midwest Heart Dis Prevent Ctr, Naperville, IL USA. [Brown, Alan S.] Loyola Univ, Stritch Sch Med, Naperville, IL USA. [Grimm, Richard A.] Cleveland Clin, Sect Cardiovasc Imaging, Cardiovasc Med Heart & Vasc Inst, Cleveland, OH 44106 USA. [Hauptman, Paul J.] St Louis Univ Hosp, Heart Failure & Transplant Program, St Louis, MO USA. [Hauptman, Paul J.] St Louis Univ, Sch Publ Hlth, St Louis, MO 63103 USA. [Hunt, Sharon A.] Stanford Univ, Dept Cardiovasc Med, Stanford, CA 94305 USA. [Lampert, Rachel] Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT USA. [Lindenfeld, JoAnn] Univ Colorado, Hlth Sci Ctr, Cardiac Transplant Program, Aurora, CO USA. [Malenka, David J.] Dartmouth Inst Hlth Policy & Clin Practice, Dartmouth Med Sch, Lebanon, NH USA. [Mani, Kartik] Mercy Med Ctr, Roseburg, OR USA. [Marine, Joseph E.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Martin, Edward T.] Oklahoma Heart Inst, Cardiovasc MRI, Tulsa, OK USA. [Martin, Edward T.] Univ Oklahoma, Tulsa, OK USA. [Page, Richard L.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. [Rich, Michael W.] Washington Univ, Sch Med, St Louis, MO USA. [Varosy, Paul D.] VA Eastern Colorado Hlth Care Syst, Denver, CO USA. [Varosy, Paul D.] Univ Colorado, Denver, CO 80202 USA. [Walsh, Mary Norine] St Vincent Heart Ctr Indiana, Indianapolis, IN USA. Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA. VA Med Ctr, Heart Failure Program, Minneapolis, MN USA. Johns Hopkins Med Inst, Cardiac Elect Training Program, Baltimore, MD 21205 USA. Ctr Med Technol Policy, Baltimore, MD USA. Los Angeles Biomed Res Inst, Torrance, CA USA. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. Beth Israel Deaconess Med Ctr, Clin Electrophysiol Lab, Boston, MA 02215 USA. Cardiac Arrhythmia Serv, Baltimore, MD USA. Electrophysiol Lab, Baltimore, MD USA. Johns Hopkins ARVD C Program, Baltimore, MD USA. SUNY Buffalo, Dept Med, Buffalo, NY 14260 USA. RI Page, Richard/L-5501-2014 OI Page, Richard/0000-0001-5603-1330 NR 61 TC 48 Z9 49 U1 0 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1547-5271 J9 HEART RHYTHM JI Heart Rhythm PD APR PY 2013 VL 10 IS 4 BP E11 EP E58 DI 10.1016/j.hrthm.2013.01.008 PG 48 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 121XE UT WOS:000317277700001 PM 23473952 ER PT J AU Gurubhagavatula, I Fields, BG Morales, CR Hurley, S Pien, GW Wick, LC Staley, BA Townsend, RR Maislin, G AF Gurubhagavatula, Indira Fields, Barry G. Morales, Christian R. Hurley, Sharon Pien, Grace W. Wick, Lindsay C. Staley, Bethany A. Townsend, Raymond R. Maislin, Greg TI Screening for Severe Obstructive Sleep Apnea Syndrome in Hypertensive Outpatients SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Article ID POSITIVE AIRWAY PRESSURE; HIGH BLOOD-PRESSURE; DAYTIME SLEEPINESS; DIAGNOSTIC SYSTEM; CONTROLLED-TRIAL; ASSOCIATION; POLYSOMNOGRAPHY; PREVALENCE; MEN; POPULATION AB The authors attempted to validate a 2-stage strategy to screen for severe obstructive sleep apnea syndrome (s-OSAS) among hypertensive outpatients, with polysomnography (PSG) as the gold standard. Using a prospective design, outpatients with hypertension were recruited from medical outpatient clinics. Interventions included (1) assessment of clinical data; (2) home sleep testing (HST); and (3) 12-channnel, in-laboratory PSG. The authors developed models using clinical or HST data alone (single-stage models) or clinical data in tandem with HST (2-stage models) to predict s-OSAS. For each model, area under receiver operating characteristic curves (AUCs), sensitivity, specificity, negative likelihood ratio, and negative post-test probability (NPTP) were computed. Models were then rank-ordered based on AUC values and NPTP. HST used alone had limited accuracy (AUC=0.727, NPTP=2.9%). However, models that used clinical data in tandem with HST were more accurate in identifying s-OSAS, with lower NPTP: (1) facial morphometrics (AUC=0.816, NPTP=0.6%); (2) neck circumference (AUC=0.803, NPTP=1.7%); and Multivariable Apnea Prediction Score (AUC=0.799, NPTP=1.5%) where sensitivity, specificity, and NPTP were evaluated at optimal thresholds. Therefore, HST combined with clinical data can be useful in identifying s-OSAS in hypertensive outpatients, without incurring greater cost and patient burden associated with in-laboratory PSG. These models were less useful in identifying obstructive sleep apnea syndrome of any severity. C1 [Gurubhagavatula, Indira] Univ Penn, Med Ctr, Pulm & Crit Care & Sleep Sect, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Gurubhagavatula, Indira; Fields, Barry G.; Morales, Christian R.; Hurley, Sharon; Pien, Grace W.; Wick, Lindsay C.; Staley, Bethany A.; Maislin, Greg] Univ Penn, Med Ctr, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA. [Gurubhagavatula, Indira; Fields, Barry G.; Pien, Grace W.] Univ Penn, Med Ctr, Div Sleep Med, Renal Electrolyte & Hypertens Div, Philadelphia, PA 19104 USA. [Townsend, Raymond R.] Univ Penn, Med Ctr, Dept Med, Philadelphia, PA 19104 USA. RP Fields, BG (reprint author), Ctr Sleep & Circadian Neurobiol, 3624 Market St,Suite 205, Philadelphia, PA 19104 USA. EM barry.fields@uphs.upenn.edu FU National Institutes of Health [K23 RR16068, RO1-OH009149, T32 HL07713]; Veterans Integrated Services Network FX This work was supported by National Institutes of Health grant K23 RR16068, RO1-OH009149, T32 HL07713, and by the Veterans Integrated Services Network 4 Competitive Pilot Project Fund. ResMed, Inc provided an unrestricted loan for use of portable diagnostic sleep study equipment (AutoSet) and had no role in protocol development, data collection, storage, analysis, or manuscript preparation. NR 41 TC 9 Z9 10 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1524-6175 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD APR PY 2013 VL 15 IS 4 BP 279 EP 288 DI 10.1111/jch.12073 PG 10 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 119YK UT WOS:000317135700010 PM 23551728 ER PT J AU Belland, L Handel, D Yadav, K Heard, K Rivera, L Eisenberg, A Noble, M Mekala, S Valley, M Hwang, U AF Belland, L. Handel, D. Yadav, K. Heard, K. Rivera, L. Eisenberg, A. Noble, M. Mekala, S. Valley, M. Hwang, U. TI Disparities in the quality of pain care for geriatric patients in the Emergency Department (ED). SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2013 CL Grapevine, TX SP Amer Geriatr Soc C1 [Belland, L.; Rivera, L.; Hwang, U.] Mt Sinai Sch Med, New York, NY USA. [Hwang, U.] James J Peters VAMC, GRECC, Bronx, NY USA. [Heard, K.; Valley, M.] Univ Colorado, Sch Med, Denver, CO USA. [Yadav, K.; Eisenberg, A.] George Washington Univ, Washington, DC USA. [Handel, D.; Noble, M.; Mekala, S.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 SU 1 SI SI BP S83 EP S83 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 120QW UT WOS:000317187600238 ER PT J AU Bowling, B Sharma, P O'Hare, AM Allman, RM Muntner, P AF Bowling, B. Sharma, P. O'Hare, A. M. Allman, R. M. Muntner, P. TI Increasing Prevalence of Reduced Estimated Glomerular Filtration Rate among the Oldest-Old US Adults from 1988-1994 through 2005-2010. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2013 CL Grapevine, TX SP Amer Geriatr Soc C1 [Bowling, B.; Allman, R. M.] Birmingham VA Med Ctr, Birmingham, AL USA. [Sharma, P.; Muntner, P.] UAB, Birmingham, AL USA. [O'Hare, A. M.] VA Puget Sound, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 SU 1 SI SI BP S116 EP S116 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 120QW UT WOS:000317187600330 ER PT J AU Brown, RT Ahalt, C Steinman, MA Williams, BA AF Brown, R. T. Ahalt, C. Steinman, M. A. Williams, B. A. TI Hands on the Hood, Grandpa: Assessing the Need for Geriatrics Health Training among Police. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2013 CL Grapevine, TX SP Amer Geriatr Soc C1 [Brown, R. T.; Ahalt, C.; Steinman, M. A.; Williams, B. A.] Univ Calif San Francisco, Div Geriatr, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 SU 1 SI SI BP S15 EP S15 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 120QW UT WOS:000317187600041 ER PT J AU Carrejo, M DeWitt, M Tan, RS AF Carrejo, M. DeWitt, M. Tan, R. S. TI The Collaborative Model of Geriatrics & Mental Health Care for Older Veterans in a Nursing Home. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2013 CL Grapevine, TX SP Amer Geriatr Soc C1 [Carrejo, M.; DeWitt, M.; Tan, R. S.] VA Med Ctr, Houston, TX USA. [DeWitt, M.] Baylor Coll Med, Sect Geriatr, Houston, TX 77030 USA. [Tan, R. S.] Univ Texas Houston, Houston, TX USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 SU 1 SI SI BP S112 EP S113 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 120QW UT WOS:000317187600320 ER PT J AU Fung, CH Martin, J Jouldjian, S Dzierzewski, J Josephson, K Alessi, C AF Fung, C. H. Martin, J. Jouldjian, S. Dzierzewski, J. Josephson, K. Alessi, C. TI Mental health and sleep characteristics among older veterans with untreated obstructive sleep apnea and comorbid insomnia. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2013 CL Grapevine, TX SP Amer Geriatr Soc C1 [Fung, C. H.; Martin, J.; Alessi, C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Fung, C. H.; Martin, J.; Jouldjian, S.; Dzierzewski, J.; Josephson, K.; Alessi, C.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 SU 1 SI SI BP S94 EP S94 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 120QW UT WOS:000317187600266 ER PT J AU Gruenewald, D Virtue, J Hartmann, T Kopf, W Nason, E White, E AF Gruenewald, D. Virtue, J. Hartmann, T. Kopf, W. Nason, E. White, E. TI Outcomes For Outpatient Veterans With Cancer Receiving Care Coordination-Home Telehealth Services. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2013 CL Grapevine, TX SP Amer Geriatr Soc C1 [Gruenewald, D.; Virtue, J.; Hartmann, T.; Kopf, W.; Nason, E.; White, E.] VA Puget Sound Hlth Care Syst, Geriatr Extended Care, Seattle, WA USA. [Gruenewald, D.] Univ Washington, Sch Med, Seattle, WA USA. NR 0 TC 1 Z9 1 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 SU 1 SI SI BP S56 EP S56 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 120QW UT WOS:000317187600158 ER PT J AU Hanson, AJ Hernandez, H Bartholomew, LM Gabriel, AK Chapman, D Craft, S AF Hanson, A. J. Hernandez, H. Bartholomew, L. M. Gabriel, A. K. Chapman, D. Craft, S. TI APOE Genotype and Gender Influence Glucose Tolerance in Older Adults. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2013 CL Grapevine, TX SP Amer Geriatr Soc C1 [Hanson, A. J.; Hernandez, H.; Bartholomew, L. M.; Gabriel, A. K.; Chapman, D.; Craft, S.] Univ Washington, Seattle, WA 98195 USA. [Hanson, A. J.] VA Puget Sound HCS, GRECC, Seattle, WA USA. [Craft, S.] Wake Forest Univ, Sch Med, Sticht Ctr Aging, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 SU 1 SI SI BP S114 EP S114 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 120QW UT WOS:000317187600324 ER PT J AU Hung, WW Ross, JS Siu, AL AF Hung, W. W. Ross, J. S. Siu, A. L. TI Predictors of adverse events during acute medical hospital admission among older adults. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2013 CL Grapevine, TX SP Amer Geriatr Soc C1 [Hung, W. W.; Siu, A. L.] Mt Sinai Sch Med, New York, NY USA. [Hung, W. W.; Siu, A. L.] James J Peters VA Med Ctr, Bronx, NY USA. [Ross, J. S.] Yale Univ, Sch Med, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 SU 1 SI SI BP S171 EP S171 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 120QW UT WOS:000317187600491 ER PT J AU Kelley, E Nguyen, G Anjum, S Lee, S Sanchez-Reilly, S AF Kelley, E. Nguyen, G. Anjum, S. Lee, S. Sanchez-Reilly, S. TI Is PTSD a Geriatric Condition? Caring for Vietnam Era Older Adults Facing Terminal Illness. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2013 CL Grapevine, TX SP Amer Geriatr Soc C1 [Kelley, E.; Anjum, S.; Sanchez-Reilly, S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Kelley, E.; Nguyen, G.; Anjum, S.; Lee, S.; Sanchez-Reilly, S.] South Texas Vet Hlth Care Syst, GRECC GEC, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 SU 1 SI SI BP S227 EP S227 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 120QW UT WOS:000317187600654 ER PT J AU Kinosian, B Mann, E Hammond, J Haggerty, M Feinberg, A Casarett, D AF Kinosian, B. Mann, E. Hammond, J. Haggerty, M. Feinberg, A. Casarett, D. TI Hospital <@> Home as an Inter-agency Collaborative in the VA SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2013 CL Grapevine, TX SP Amer Geriatr Soc C1 [Kinosian, B.; Mann, E.; Casarett, D.] Univ Penn, Philadelphia, PA 19104 USA. [Kinosian, B.; Hammond, J.; Haggerty, M.; Feinberg, A.] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 SU 1 SI SI BP S9 EP S9 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 120QW UT WOS:000317187600024 ER PT J AU LaMantia, MA Jhanji, S Maina, M Nazir, A Alder, C Chodosh, J Boustani, M AF LaMantia, M. A. Jhanji, S. Maina, M. Nazir, A. Alder, C. Chodosh, J. Boustani, M. TI Redesigning Acute Care for Cognitively Impaired Older Adults: Optimizing Health Care Services for the 21st Century. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2013 CL Grapevine, TX SP Amer Geriatr Soc C1 [LaMantia, M. A.; Jhanji, S.; Maina, M.; Boustani, M.] Indiana Univ, Ctr Aging Res, Indianapolis, IN 46204 USA. [LaMantia, M. A.; Jhanji, S.; Maina, M.; Boustani, M.] Regenstrief Inst Inc, Indianapolis, IN USA. [Nazir, A.] Indiana Univ, Geriatr Program, Indianapolis, IN 46204 USA. [Alder, C.] Wishard Hlth Serv, Indianapolis, IN USA. [Chodosh, J.] VA Greater Los Angeles Hlth Syst, Los Angeles, CA USA. [Chodosh, J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 SU 1 SI SI BP S112 EP S112 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 120QW UT WOS:000317187600319 ER PT J AU Levy, C Edes, T Whitfield, E Kinosian, B AF Levy, C. Edes, T. Whitfield, E. Kinosian, B. TI Medical Foster Homes - Is this new model of care an effective substitute for nursing homes? SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2013 CL Grapevine, TX SP Amer Geriatr Soc C1 [Levy, C.; Whitfield, E.] Denver VA Med Ctr, Denver, CO USA. [Kinosian, B.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Edes, T.] Vet Affairs Cent Off, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 SU 1 SI SI BP S109 EP S110 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 120QW UT WOS:000317187600311 ER PT J AU Matsuwaka, S Jouldjian, S Martin, J Alessi, C AF Matsuwaka, S. Jouldjian, S. Martin, J. Alessi, C. TI Insomnia in Older Veterans: Prevalence, Self-Rated Health, and Talking to a Doctor about Sleep Problems. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2013 CL Grapevine, TX SP Amer Geriatr Soc C1 [Matsuwaka, S.] Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA. [Jouldjian, S.; Martin, J.; Alessi, C.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, North Hills, CA USA. [Martin, J.; Alessi, C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 SU 1 SI SI BP S205 EP S205 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 120QW UT WOS:000317187600590 ER PT J AU Methvin, BL Lee, S Sharp, C Sanchez-Reilly, S Ross, J AF Methvin, B. L. Lee, S. Sharp, C. Sanchez-Reilly, S. Ross, J. TI Caregiver Burden Among Family Caregivers Of Homebound Older Veterans. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2013 CL Grapevine, TX SP Amer Geriatr Soc C1 [Methvin, B. L.; Sanchez-Reilly, S.; Ross, J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Lee, S.; Sharp, C.; Sanchez-Reilly, S.; Ross, J.] South Texas Vet Hlth Care Syst, GEC GRECC, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 SU 1 SI SI BP S93 EP S93 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 120QW UT WOS:000317187600264 ER PT J AU Methvin, BL Lee, S Ross, J AF Methvin, B. L. Lee, S. Ross, J. TI Analysis of YouTube Resources for Caregivers of Aging Individuals SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2013 CL Grapevine, TX SP Amer Geriatr Soc C1 [Methvin, B. L.; Ross, J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Lee, S.; Ross, J.] South Texas Vet Hlth Care Syst, GEC GRECC, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 SU 1 SI SI BP S7 EP S7 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 120QW UT WOS:000317187600019 ER PT J AU Meziab, O Yaffe, K Brach, J Simonsick, EM Harris, TB Barnes, DE AF Meziab, O. Yaffe, K. Brach, J. Simonsick, E. M. Harris, T. B. Barnes, D. E. TI Changes in Physical Activity Before and After Development of Pre-Clinical Cognitive Impairment. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2013 CL Grapevine, TX SP Amer Geriatr Soc C1 [Meziab, O.] Univ Arizona, Coll Med, Tucson, AZ USA. [Yaffe, K.; Barnes, D. E.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Brach, J.] Univ Pittsburgh, Pittsburgh, PA USA. [Simonsick, E. M.; Harris, T. B.] NIA, Baltimore, MD 21224 USA. [Yaffe, K.; Barnes, D. E.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 SU 1 SI SI BP S115 EP S115 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 120QW UT WOS:000317187600327 ER PT J AU Moody, S Newsom, EM Covinsky, KE AF Moody, S. Newsom, E. M. Covinsky, K. E. TI Determinants Of Emotional Recovery And Perceived Change In Health Following A Disaster SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2013 CL Grapevine, TX SP Amer Geriatr Soc C1 [Moody, S.; Covinsky, K. E.] Univ Calif San Francisco, Med Div Geriatr, San Francisco, CA 94143 USA. [Moody, S.; Covinsky, K. E.] San Francisco VA Med Ctr, San Francisco, CA USA. [Newsom, E. M.] Univ Calif San Francisco, Inst Hlth & Aging, San Francisco, CA USA. [Moody, S.] Kameda Med Ctr, Grad Med Educ, Kamogawa City, Chiba, Japan. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 SU 1 SI SI BP S102 EP S102 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 120QW UT WOS:000317187600291 ER PT J AU Mori, T Greendale, GA Cauley, JA Han, W Huang, M Karlamangla, AS AF Mori, T. Greendale, G. A. Cauley, J. A. Han, W. Huang, M. Karlamangla, A. S. TI Dietary Phytoestrogens and Femoral Neck Strength: Findings from the Study of Women's Health Across the Nation. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2013 CL Grapevine, TX SP Amer Geriatr Soc C1 [Mori, T.] VA Greater Los Angeles Healthcare Syst, GRECC, Los Angeles, CA USA. [Mori, T.; Greendale, G. A.; Han, W.; Huang, M.; Karlamangla, A. S.] Univ Calif Los Angeles, Los Angeles, CA USA. [Cauley, J. A.] Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 SU 1 SI SI BP S87 EP S88 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 120QW UT WOS:000317187600249 ER PT J AU Nazir, A Lamantia, M Perkins, A Hui, S Campbell, N Khan, B Chodosh, J Boustani, M AF Nazir, A. Lamantia, M. Perkins, A. Hui, S. Campbell, N. Khan, B. Chodosh, J. Boustani, M. TI Impact of Cognitive Impairment on Rehospitalizations SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2013 CL Grapevine, TX SP Amer Geriatr Soc C1 [Nazir, A.] Indiana Univ, Geriatr Program, Indianapolis, IN 46204 USA. [Lamantia, M.; Perkins, A.; Hui, S.; Campbell, N.; Khan, B.; Boustani, M.] Indiana Univ, Ctr Aging Res, Regenstrief Inst Inc, Indianapolis, IN 46204 USA. [Chodosh, J.] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Los Angeles, CA 90095 USA. [Chodosh, J.] VA Greater Los Angeles Hlth Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 SU 1 SI SI BP S104 EP S104 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 120QW UT WOS:000317187600296 ER PT J AU Northern, J Beckjord, S Rossi, MI Thatcher, T Kendjelic, E AF Northern, J. Beckjord, S. Rossi, M. I. Thatcher, T. Kendjelic, E. TI The Efficacy of a Neuropsychological Test Battery used in a VA Driving Clinic on Assessing Driving Ability amongst Older Veterans. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2013 CL Grapevine, TX SP Amer Geriatr Soc C1 [Northern, J.; Rossi, M. I.; Thatcher, T.; Kendjelic, E.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Beckjord, S.] Apex Psychol Care & Memory Ctr, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 SU 1 SI SI BP S64 EP S64 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 120QW UT WOS:000317187600182 ER PT J AU O'Kula, S Gottesman, E Hung, W Boockvar, K AF O'Kula, S. Gottesman, E. Hung, W. Boockvar, K. TI The Spanish-English Language Barrier as a Factor in Veterans' Care Transitions SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2013 CL Grapevine, TX SP Amer Geriatr Soc C1 [O'Kula, S.; Hung, W.; Boockvar, K.] Mt Sinai Sch Med, New York, NY USA. [Gottesman, E.; Hung, W.; Boockvar, K.] James J Peters VA Med Ctr, GRECC, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 SU 1 SI SI BP S219 EP S219 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 120QW UT WOS:000317187600632 ER PT J AU Qiu, A Ortiz, J Cruz-Oliver, D Sanchez-Reilly, S AF Qiu, A. Ortiz, J. Cruz-Oliver, D. Sanchez-Reilly, S. TI Barriers to End of Life Care among Latino Elders: A Healthcare Provider Perspective. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2013 CL Grapevine, TX SP Amer Geriatr Soc C1 [Qiu, A.; Ortiz, J.; Sanchez-Reilly, S.] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Div Geriatr Gerontol & Palliat Med, San Antonio, TX 78229 USA. [Ortiz, J.; Sanchez-Reilly, S.] South Texas Vet Hlth Care Syst, GEC GRECC, San Antonio, TX USA. [Cruz-Oliver, D.] St Louis Univ, Dept Internal Med, Div Geriatr, St Louis, MO 63103 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 SU 1 SI SI BP S211 EP S212 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 120QW UT WOS:000317187600609 ER PT J AU Reed, ML AF Reed, M. L. TI A Case of Granuloma Annulare and Malignancy. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2013 CL Grapevine, TX SP Amer Geriatr Soc C1 [Reed, M. L.] VA Puget Sound, Geriatr, Tacoma, WA USA. [Reed, M. L.] Madigan Healthcare Syst, Family Med, Tacoma, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 SU 1 SI SI BP S80 EP S80 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 120QW UT WOS:000317187600228 ER PT J AU Rothrock, AG Sawyer, P Ford, CR Brown, CJ AF Rothrock, A. G. Sawyer, P. Ford, C. R. Brown, C. J. TI Can a Single Dose of Interprofessional Team Training Influence Medical Student Attitudes Toward Healthcare Teams? SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2013 CL Grapevine, TX SP Amer Geriatr Soc C1 [Rothrock, A. G.; Sawyer, P.; Ford, C. R.; Brown, C. J.] Univ Alabama Birmingham, Birmingham, AL USA. [Brown, C. J.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 SU 1 SI SI BP S145 EP S145 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 120QW UT WOS:000317187600417 ER PT J AU Siddiqui, A Hwang, UY AF Siddiqui, A. Hwang, U. Y. TI The Effects of Age on the Quality of ED Pain Care and Outcomes. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2013 CL Grapevine, TX SP Amer Geriatr Soc C1 [Siddiqui, A.; Hwang, U. Y.] Mt Sinai Sch Med, New York, NY USA. [Hwang, U. Y.] James J Peters VAMC, GRECC, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 SU 1 SI SI BP S83 EP S83 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 120QW UT WOS:000317187600237 ER PT J AU Su, C McMahan, R Sudore, R AF Su, C. McMahan, R. Sudore, R. TI Family Matters: Effects of Birth Order and Family Dynamics on Surrogate Decision Making SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2013 CL Grapevine, TX SP Amer Geriatr Soc C1 [Su, C.] Mt Sinai Sch Med, New York, NY USA. [McMahan, R.; Sudore, R.] San Francisco VA Med Ctr, San Francisco, CA USA. [McMahan, R.; Sudore, R.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 SU 1 SI SI BP S6 EP S6 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 120QW UT WOS:000317187600017 ER PT J AU Win, AZ Ceresa, C Allison, TA AF Win, A. Z. Ceresa, C. Allison, T. A. TI The Prevalence of Malnutrition in Frail Older Veterans. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2013 CL Grapevine, TX SP Amer Geriatr Soc C1 [Win, A. Z.; Ceresa, C.; Allison, T. A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Allison, T. A.] Univ San Francisco, Div Geriatr, Dept Med, San Francisco, CA 94117 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 SU 1 SI SI BP S159 EP S159 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 120QW UT WOS:000317187600456 ER PT J AU Hall, RK O'Hare, AM Anderson, RA Colon-Emeric, CS AF Hall, Rasheeda K. O'Hare, Ann M. Anderson, Ruth A. Colon-Emeric, Cathleen S. TI End-Stage Renal Disease in Nursing Homes: A Systematic Review SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Review DE Renal dialysis; skilled nursing facilities; aged ID EXTENDED-CARE FACILITY; LONG-TERM-CARE; PERITONEAL-DIALYSIS; PATIENT CHARACTERISTICS; STARTING DIALYSIS; HEMODIALYSIS; REHABILITATION; MORTALITY; PREVALENCE; EXPERIENCE AB Objectives/Introduction: Demand for nursing home (NH) care by patients with end-stage renal disease (ESRD) is likely to increase with growing numbers of older adults initiating chronic dialysis. We completed a systematic review to summarize the literature on NH residents with ESRD. Methods: MEDLINE, CINAHL, EMBASE, and relevant conference proceedings were searched to identify articles using the following MESH terms or related key words in the title or abstract: "residential facilities", "renal dialysis", "renal replacement therapy", and "chronic kidney failure". We selected case control, cohort studies, and clinical trials that included older adults with ESRD (defined as those receiving chronic dialysis or those with stage 5 chronic kidney disease) living in residential care facilities. We abstracted information on study design, quality, and results. Results: Of 198 unique citations identified by the search strategy, 14 articles met eligibility criteria. Most articles were multicenter studies that were conducted in the 1990s. One study focused on patients with stage 5 chronic kidney disease, and the remaining 13 studies focused on patients receiving chronic dialysis, of which eight studies included only those receiving peritoneal dialysis, four studies included patients receiving both peritoneal dialysis and hemodialysis, and one study included only patients receiving hemodialysis. All studies were observational, no clinical trials were identified, and study design limitations and heterogeneity within study populations were common. Summarizing results across these studies suggests that NH residents with ESRD have limited survival, particularly early after dialysis initiation. Functional impairment is highly prevalent in this population and independently associated with poor outcomes. Conclusions: NH residents with ESRD appear to be a particularly vulnerable population, but current information on their prevalence, characteristics, and outcomes is limited. Further research is needed to provide a better understanding of modifiable predictors of survival and functional decline in this population. Copyright (C) 2013 -American Medical Directors Association, Inc. C1 [Hall, Rasheeda K.] Duke Univ, Med Ctr, Dept Med, Div Nephrol, Durham, NC 27710 USA. [O'Hare, Ann M.] Univ Washington, Dept Med, Seattle, WA USA. [O'Hare, Ann M.] VA Puget Sound Healthcare Syst, Dept Med, Seattle, WA USA. [O'Hare, Ann M.] VA Puget Sound Healthcare Syst, HSR&D Ctr Excellence, Seattle, WA USA. [Anderson, Ruth A.] Duke Univ, Sch Nursing, Durham, NC 27710 USA. [Anderson, Ruth A.; Colon-Emeric, Cathleen S.] Duke Univ, Ctr Study Aging & Human Dev, Durham, NC 27710 USA. [Colon-Emeric, Cathleen S.] Duke Univ, Med Ctr, Dept Med, Div Geriatr, Durham, NC 27710 USA. [Colon-Emeric, Cathleen S.] Durham VA Med Ctr, Geriatr Res Educ & Clin Ctr, Durham, NC USA. RP Hall, RK (reprint author), Duke Univ, Med Ctr, Box DUMC 2747,2424 Erwin Rd,Suite 605, Durham, NC 27710 USA. EM rasheeda.stephens@duke.edu OI Anderson, Ruth/0000-0001-6640-644X FU Claude D. Pepper Older Americans Independence Center [NIH P30 AG028716]; Agency for Healthcare Research and Quality [T32HS019490] FX None of the authors report any potential conflicts of interest. This material is the result of work supported with resources and the use of facilities at the Durham VA Medical Center. This study is supported by the Claude D. Pepper Older Americans Independence Center (NIH P30 AG028716) and the Agency for Healthcare Research and Quality (T32HS019490). Some of the data reported here has been supplied by the United States Renal Data System (USRDS). The content is solely the responsibility of the authors and does not necessarily represent the official views of the Department of Veterans Affairs, the National Institutes of Health, or the United States government. NR 32 TC 4 Z9 4 U1 1 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD APR PY 2013 VL 14 IS 4 BP 242 EP 247 DI 10.1016/j.jamda.2013.01.004 PG 6 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 121YI UT WOS:000317281200005 PM 23375523 ER PT J AU Montgomery, EB AF Montgomery, Erwin B., Jr. TI Predictors of Parkinson's disease-not quite sound SO MOVEMENT DISORDERS LA English DT Editorial Material C1 [Montgomery, Erwin B., Jr.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA. [Montgomery, Erwin B., Jr.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Montgomery, EB (reprint author), Univ Alabama Birmingham, Dept Neurol, 1720 7th Ave South, Birmingham, AL 35294 USA. EM emontgom@uab.edu NR 5 TC 3 Z9 3 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD APR PY 2013 VL 28 IS 4 BP 413 EP 415 DI 10.1002/mds.25432 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 123CO UT WOS:000317366100002 PM 23483647 ER PT J AU Fisher, MB Mauck, RL AF Fisher, Matthew B. Mauck, Robert L. TI Starting with form, emerging with function: nanofibrous scaffolds for tissue engineering of orthopedic tissuesalternatives SO NANOMEDICINE LA English DT Editorial Material DE function; nanofibrous scaffold; orthopedics; structure; tissue engineering ID LIGAMENT AB "This is an exciting time for the tissue engineering and regenerative medicine field as the complexity and usefulness of scaffolds, including nanofibrous scaffolds, continues to increase." C1 [Fisher, Matthew B.; Mauck, Robert L.] Univ Penn, Perelman Sch Med, Dept Orthoped Surg, McKay Orthoped Res Lab, Philadelphia, PA 19104 USA. [Fisher, Matthew B.; Mauck, Robert L.] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Mauck, Robert L.] Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA. RP Mauck, RL (reprint author), Univ Penn, Perelman Sch Med, Dept Orthoped Surg, McKay Orthoped Res Lab, 36th St & Hamilton Walk, Philadelphia, PA 19104 USA. EM lemauck@mail.med.upenn.edu RI Fisher, Matthew/M-5809-2016 OI Fisher, Matthew/0000-0002-3212-0870 FU NIAMS NIH HHS [P30AR050950, R01AR056624]; NIBIB NIH HHS [R01EB02425] NR 21 TC 4 Z9 4 U1 0 U2 11 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1743-5889 J9 NANOMEDICINE-UK JI Nanomedicine PD APR PY 2013 VL 8 IS 4 SI SI BP 505 EP 508 DI 10.2217/NNM.13.18 PG 4 WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology SC Biotechnology & Applied Microbiology; Science & Technology - Other Topics GA 120NU UT WOS:000317178200002 PM 23560399 ER PT J AU Loh, AR Joseph, D Keenan, JD Lietman, TM Naseri, A AF Loh, Allison R. Joseph, Damien Keenan, Jeremy D. Lietman, Thomas M. Naseri, Ayman TI Predictors of Matching in an Ophthalmology Residency Program SO OPHTHALMOLOGY LA English DT Article ID SELECTION; DIRECTORS; SCORES AB Purpose: To examine the characteristics of US medical students applying for ophthalmology residency and to determine the predictors of matching. Design: A retrospective case series. Participants: A total of 3435 medical students from the United States who applied to an ophthalmology residency program from 2003 to 2008 were included. Methods: Matched and unmatched applicants were compared and stratified by predictor variables, including United States Medical Licensing Examination (USMLE) Step 1 score, Alpha Omega Alpha (AOA) status, medical school reputation, and medical school geographic region. Differences in proportions were analyzed using the Fisher exact test. Logistic regression was used to determine the predictors of successful matching. Main Outcome Measures: Successful matching to an ophthalmology program. Results: The majority of applicants (72%, 2486/3435) matched in ophthalmology. In multivariate analysis, AOA membership (odds ratio [OR], 2.6, P < 0.0001), USMLE score (OR, 1.6; P < 0.0001), presence of an ophthalmology residency at medical school (OR, 1.4; P = 0.01), top 25 medical school (OR, 1.4; P < 0.03), top 10 medical school (OR, 1.6; P < 0.02), and allopathic degree (OR, 4.0; P < 0.0001) were statistically significant predictors of matching. Approximately 60% (1442/2486) of applicants matched to the same geographic region as their medical school. Applicants were more likely to match at a program in the same geographic region as their medical school than would be predicted by chance alone (P < 0.0001). In multivariate analysis, higher USMLE score (OR, 0.9; P < 0.0001) and top 10 medical school (OR, 0.7; P = 0.027) were statistically significant predictors of matching to outside the geographic region as one's medical school. Conclusions: The majority of applicants applying for an ophthalmology residency position match successfully. Higher performance on quantitative metrics seems to confer an advantage for matching. The majority of applicants match at a residency program within the same geographic region as one's medical school. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2013;120:865-870 (C) 2013 by the American Academy of Ophthalmology. C1 [Loh, Allison R.; Keenan, Jeremy D.; Lietman, Thomas M.; Naseri, Ayman] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94121 USA. [Joseph, Damien] San Francisco Match Program, San Francisco, CA USA. [Keenan, Jeremy D.; Lietman, Thomas M.; Naseri, Ayman] Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94121 USA. [Naseri, Ayman] San Francisco Vet Adm Med Ctr, Dept Ophthalmol, San Francisco, CA USA. RP Naseri, A (reprint author), Univ Calif San Francisco, Dept Ophthalmol, 10 Koret Way, San Francisco, CA 94121 USA. EM Ayman.Naseri@va.gov NR 19 TC 6 Z9 6 U1 2 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0161-6420 J9 OPHTHALMOLOGY JI Ophthalmology PD APR PY 2013 VL 120 IS 4 BP 865 EP 870 DI 10.1016/j.ophtha.2012.09.028 PG 6 WC Ophthalmology SC Ophthalmology GA 122UL UT WOS:000317343500033 PM 23260256 ER PT J AU Saladin, ME Gray, KM McRae-Clark, AL LaRowe, SD Yeatts, SD Baker, NL Hartwell, KJ Brady, KT AF Saladin, Michael E. Gray, Kevin M. McRae-Clark, Aimee L. LaRowe, Steven D. Yeatts, Sharon D. Baker, Nathaniel L. Hartwell, Karen J. Brady, Kathleen T. TI A double blind, placebo-controlled study of the effects of post-retrieval propranolol on reconsolidation of memory for craving and cue reactivity in cocaine dependent humans SO PSYCHOPHARMACOLOGY LA English DT Article DE Reconsolidation; Retrieval; Craving; Cocaine dependence; Cue exposure; Human subjects ID BETA-ADRENERGIC-BLOCKADE; NORADRENERGIC BLOCKADE; RECEPTOR BLOCKADE; ERASING FEAR; DAILY-LIFE; EXTINCTION; CONSOLIDATION; ADDICTION; PREFERENCE; DISRUPTION AB This study examined the effects of propranolol vs. placebo, administered immediately after a "retrieval" session of cocaine cue exposure (CCE), on craving and physiological responses occurring 24 h later during a subsequent "test" session of CCE. It was hypothesized that compared to placebo-treated cocaine-dependent (CD) individuals, propranolol-treated CD individuals would evidence attenuated craving and physiological reactivity during the test session. Secondarily, it was expected that group differences identified in the test session would be evident at a 1-week follow-up CCE session. Exploratory analyses of treatment effects on cocaine use were also performed at follow-up. CD participants received either 40 mg propranolol or placebo immediately following a "retrieval" CCE session. The next day, participants received a "test" session of CCE that was identical to the "retrieval" session except no medication was administered. Participants underwent a "follow-up" CCE session 1 week later. Craving and other reactivity measures were obtained at multiple time points during the CCE sessions. Propranolol- vs. placebo-treated participants evidenced significantly greater attenuation of craving and cardiovascular reactivity during the test session. Analysis of the follow-up CCE session data did not reveal any group differences. Although there was no evidence of treatment effects on cocaine use during follow-up, this study was insufficiently powered to rigorously evaluate differential cocaine use. This double-blind, placebo-controlled laboratory study provides the first evidence that propranolol administration following CCE may modulate memories for learning processes that subserve cocaine craving/cue reactivity in CD humans. Alternative interpretations of the findings were considered, and implications of the results for treatment were noted. C1 [Saladin, Michael E.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Saladin, Michael E.; Gray, Kevin M.; McRae-Clark, Aimee L.; LaRowe, Steven D.; Yeatts, Sharon D.; Baker, Nathaniel L.; Hartwell, Karen J.; Brady, Kathleen T.] Med Univ S Carolina, Clin Neurosci Div, Charleston, SC 29425 USA. [Gray, Kevin M.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Youth Div, Charleston, SC 29425 USA. [Yeatts, Sharon D.; Baker, Nathaniel L.] Med Univ S Carolina, Div Biostat & Epidemiol, Charleston, SC 29425 USA. [LaRowe, Steven D.] Ralph H Johnson Vet Affairs Med Ctr, Subst Abuse Treatment Ctr, Charleston, SC USA. [Saladin, Michael E.] Med Univ S Carolina, Dept Hlth Sci & Res, Coll Hlth Profess, Charleston, SC 29425 USA. RP Saladin, ME (reprint author), Med Univ S Carolina, Dept Hlth Sci & Res, Coll Hlth Profess, 77 President St,Room 224,MSC700, Charleston, SC 29425 USA. EM saladinm@musc.edu RI McRae-Clark, Aimee/I-3341-2013 OI McRae-Clark, Aimee/0000-0002-9774-318X; LaRowe, Steven/0000-0002-7664-2451 FU NIDA grant [R21DA025155]; South Carolina Clinical & Translational Research (SCTR) Institute; NIH [UL1 RR029882, UL1 TR000062] FX This research was supported by NIDA grant R21DA025155 (Saladin, PI) and by the South Carolina Clinical & Translational Research (SCTR) Institute, with an academic home at the Medical University of South Carolina, through NIH Grant Numbers UL1 RR029882 and UL1 TR000062. The authors report no conflicts of interest pertaining to this study. NR 91 TC 24 Z9 25 U1 3 U2 20 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0033-3158 EI 1432-2072 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD APR PY 2013 VL 226 IS 4 BP 721 EP 737 DI 10.1007/s00213-013-3039-3 PG 17 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 122GL UT WOS:000317306200009 PM 23460266 ER PT J AU Schiros, CG Ahmed, MI Sanagala, T Zha, W McGiffin, DC Bamman, MM Gupta, H Lloyd, SG Denney, TS Dell'Italia, LJ AF Schiros, Chun G. Ahmed, Mustafa I. Sanagala, Thriveni Zha, Wei McGiffin, David C. Bamman, Marcas M. Gupta, Himanshu Lloyd, Steven G. Denney, Thomas S., Jr. Dell'Italia, Louis J. TI Importance of Three-Dimensional Geometric Analysis in the Assessment of the Athlete's Heart SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID ISOLATED MITRAL REGURGITATION; LEFT-VENTRICULAR TORSION; BETA-BLOCKADE; EXERCISE; VOLUME AB How the left ventricle remodels in response to a high-volume stimulus is important in evaluating the endurance athlete's heart. Marathoners and patients with isolated, moderate chronic compensated mitral regurgitation (MR) represent physiologic and pathologic forms of eccentric left ventricular (LV) remodeling in response to intermittent and chronic volume overload, respectively. Thus, in this study, magnetic resonance imaging with tissue tagging and 3-dimensional data analysis at rest were performed in 19 marathoners (mean age 39 +/- 10 years, 47% women), 17 patients with isolated MR without coronary artery disease or medical therapy (mean age 46 +/- 5 years, 53% women), and 24 controls (mean age 45 +/- 8 years, 50% women). Marathoners and patients with MR had approximately 35% greater LV end-diastolic volume indexes, approximately 50% greater end-systolic volume indexes, and approximately 34% greater LV stroke volume indexes (p < 0.0001) compared to controls. However, marathoners' hearts had increased long-axis length, while those of patients with MR did not differ from the hearts of controls. The hearts of patients with MR had greater LV global and apex sphericity compared to those of marathoners and controls (p < 0.0001). Marathoners had normal LV mass/volume ratios and wall thicknesses, whereas these were significantly decreased in the MR group. In marathoners, the baseline LV work rate was similar to that in controls and higher in patients with MR compared to controls. In conclusion, marathoners' hearts achieve elevated stroke volume at rest with adherence to an elliptical shape defined by 3-dimensional geometry and mass/volume ratio. Thus, a comprehensive evaluation of LV geometry and mass/volume ratio may be important in the evaluation of the athlete's heart. (C) 2013 Elsevier Inc. All rights reserved. (Am J Cardiol 2013;111:1067-1072) C1 [Schiros, Chun G.; Ahmed, Mustafa I.; McGiffin, David C.; Gupta, Himanshu; Lloyd, Steven G.; Dell'Italia, Louis J.] Univ Alabama Birmingham, Dept Med, Ctr Heart Failure Res, Birmingham, AL 35233 USA. [Bamman, Marcas M.] Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL USA. [Sanagala, Thriveni] Loyola Univ Chicago, Div Cardiol, Dept Med, Stritch Sch Med, Maywood, IL USA. [Zha, Wei; Denney, Thomas S., Jr.] Auburn Univ, Dept Elect & Comp Engn, Samuel Ginn Coll Engn, Auburn, AL 36849 USA. [Bamman, Marcas M.; Gupta, Himanshu; Lloyd, Steven G.; Dell'Italia, Louis J.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Dell'Italia, LJ (reprint author), Univ Alabama Birmingham, Dept Med, Ctr Heart Failure Res, Birmingham, AL 35233 USA. EM dell'italia@physiology.uab.edu FU National Heart, Lung, and Blood Institute Specialized Center for Clinically Oriented Research in Cardiac Dysfunction, Bethesda, Maryland [P50HL077100] FX This study was funded by Grant P50HL077100 from the National Heart, Lung, and Blood Institute Specialized Center for Clinically Oriented Research in Cardiac Dysfunction, Bethesda, Maryland. NR 22 TC 6 Z9 6 U1 0 U2 6 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD APR 1 PY 2013 VL 111 IS 7 BP 1067 EP 1072 DI 10.1016/j.amjcard.2012.12.027 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 117AE UT WOS:000316923700024 PM 23332597 ER PT J AU Pham, CM Syed, AA Siddiqui, HA Keller, RA Kowalewski, C AF Pham, Catherine M. Syed, Almas A. Siddiqui, Huma A. Keller, Richard A. Kowalewski, Catherine TI Case of Metastatic Basal Cell Carcinoma to Bone Marrow, Resulting in Myelophthisic Anemia SO AMERICAN JOURNAL OF DERMATOPATHOLOGY LA English DT Article DE metastatic; non-melanoma skin cancer; basal cell carcinoma ID CYTOTOXIC THERAPY; SKIN AB Background: While basal cell carcinoma (BCC) remains the most common skin cancer, the incidence of metastasis is rare. Most cases of metastatic BCC have been to regional lymph nodes. Metastasis to bone marrow with myelophthisic anemia is especially rare. To our knowledge, there have been only 5 reported cases in literature. We report a sixth case. Observations: A 46-year-old male patient presented with an 8 x 7-cm ulcerated plaque on his chest, found to be morpheaform basal cell on pathology. Laboratory findings were notable for normocytic anemia, thrombocytopenia, and elevated LDH. Further work up with bone marrow biopsy revealed tumor cells staining positive for CK AE1/AE3, BerEP4, CK7, CD56, and PIN-4. This confirmed the diagnosis of metastatic BCC (MBCC) to bone marrow. Conclusions: Although the rate of metastasis for BCC is rare, once it occurs, prognosis is poor. MBCC remains a challenge to treat. Therefore, it is critical to resolve the primary BCC and obtain vigilant follow-up, especially in patients with multiple risk factors for MBCC. C1 [Pham, Catherine M.; Syed, Almas A.] Univ Texas Hlth Sci Ctr San Antonio, Div Dermatol & Cutaneous Surg, San Antonio, TX 78229 USA. [Siddiqui, Huma A.] Audie L Murphy Mem Vet Adm Med Ctr, Dept Pathol, San Antonio, TX 78229 USA. [Keller, Richard A.; Kowalewski, Catherine] Audie L Murphy Mem Vet Adm Med Ctr, Div Dermatol, San Antonio, TX 78229 USA. RP Kowalewski, C (reprint author), Audie L Murphy Mem Vet Adm Med Ctr, South Texas Vet Hlth Care Serv, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. NR 19 TC 1 Z9 1 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0193-1091 J9 AM J DERMATOPATH JI Am. J. Dermatopathol. PD APR PY 2013 VL 35 IS 2 BP E34 EP E36 DI 10.1097/DAD.0b013e3182761362 PG 3 WC Dermatology SC Dermatology GA 117GJ UT WOS:000316941200004 PM 23147353 ER PT J AU Ahmad, FS Tsang, T AF Ahmad, Faraz S. Tsang, Thomas TI Diabetes Prevention, Health Information Technology, and Meaningful Use Challenges and Opportunities SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID PHYSICIAN ORDER ENTRY; RANDOMIZED CONTROLLED-TRIAL; CLINICAL DECISION-SUPPORT; CENTERED MEDICAL HOME; OF-THE-LITERATURE; HEART-FAILURE; RECORD USE; CARE; MANAGEMENT; QUALITY AB The U.S. health system has historically been poorly equipped to confront the growing impact of diabetes on the nation's health. The Affordable Care Act legislates a number of new strategies-such as innovative payment and delivery models and increased public health funding-intended to improve diabetes prevention and care quality. Health information technology (IT) is often cited as a critical part of these strategies. Through the Health Information Technology for Economic and Clinical Health (HITECH) Act of 2009, the federal government has been supporting the rapid adoption of health IT, and more specifically of electronic health records (EHRs) through the Centers for Medicare and Medicaid Services (CMS) EHR Incentive Program. Health IT has the potential to contribute to diabetes prevention and improved quality of care, but the evidence supporting its benefits is mixed. This article provides a brief overview of the CMS EHR Incentive Program and meaningful-use criteria. Then it examines health IT strategies for diabetes prevention in the context of current evidence and identifies areas of needed research and innovation. (Am J Prev Med 2013;44(4S4):S357-S363) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Ahmad, Faraz S.] Univ Penn, Perelman Sch Med, Ctr Therapeut Effectiveness Res, Ctr Healthcare Improvement & Patient Safety, Philadelphia, PA 19104 USA. [Ahmad, Faraz S.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Tsang, Thomas] Dupont Merck Pharmaceut Co, Strategy & Business Dev, Boston, MA USA. RP Ahmad, FS (reprint author), Hosp Univ Penn, 3400 Spruce St,100 Centrex, Philadelphia, PA 19104 USA. EM faraz.ahmad@uphs.upenn.edu FU Joslin Diabetes Center; Novo Nordisk FX Publication of this supplement was supported by Joslin Diabetes Center and Novo Nordisk. NR 61 TC 9 Z9 9 U1 4 U2 38 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD APR PY 2013 VL 44 IS 4 SU 4 BP S357 EP S363 DI 10.1016/j.amepre.2012.12.020 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 113NH UT WOS:000316674200011 PM 23498299 ER PT J AU Miller, SC Baktash, SH Webb, TS Whitehead, CR Maynard, C Wells, TS Otte, CN Gore, RK AF Miller, Shannon C. Baktash, Suzanne H. Webb, Timothy S. Whitehead, Casserly R. Maynard, Charles Wells, Timothy S. Otte, Clifford N. Gore, Russel K. TI Risk for Addiction-Related Disorders Following Mild Traumatic Brain Injury in a Large Cohort of Active-Duty US Airmen SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID ALCOHOL-USE; SUBSTANCE-ABUSE; HEAD-INJURY; DRUG-USE; AFGHANISTAN; DEPRESSION; IRAQ; POPULATION; PATTERNS; CARE AB Objective: Military personnel are at increased risk for traumatic brain injury (TBI) from combat and noncombat exposures. The sequelae of moderate to severe TBI are well described, but little is known regarding long-term performance decrements associated with mild TBI. Furthermore, while alcohol and drug use are well known to increase risk for TBI, little is known regarding the reverse pattern. The authors sought to assess possible associations between mild TBI and addiction-related disorders in active-duty U.S. military personnel. Method: A historical prospective study was conducted using electronically recorded demographic, medical, and military data for more than a half million active-duty U.S. Air Force service members. Cases were identified by ICD-9-CM codes considered by an expert panel to be indicative of mild TBI. Outcomes included ICD-9-CM diagnoses of selected addiction-related disorders. Cox proportional hazards modeling was used to calculate hazard ratios while controlling for varying lengths of follow-up and potential confounding variables. Results: Airmen with mild TBI were at increased risk for certain addiction-related disorders compared with a similarly injured non-mild TBI comparison group. Hazards for alcohol dependence, nicotine dependence, and nondependent abuse of drugs or alcohol were significantly elevated, with a consistent decrease over time. Conclusions: A novel finding of this study was the initial increased risk for addiction-related disorders that decreased with time, thus eroding war fighter performance in a military population. Moreover, these results suggest that mild TBI is distinguished from moderate to severe TBI in terms of timing of the risk, indicating that there is a need for screening and prevention of addiction-related disorders in mild TBI. Screening may be warranted in military troops as well as civilians at both short- and long-term milestones following mild TBI. (Am J Psychiatry 2013; 170:383-390) C1 [Whitehead, Casserly R.] Vet Affairs Med Ctr, Cincinnati, OH 45267 USA. Univ Cincinnati, Dept Psychiat & Behav Neurosci, Ctr Treatment Res & Educ Addict Disorders, Cincinnati, OH USA. Univ Tennessee, Dept Elect Engn & Comp Sci, Knoxville, TN USA. USAF, Res Lab, Vulnerabil Anal Branch, AFMC Human Performance Wing 711, Wright Patterson AFB, OH 45433 USA. Infoscitex Corp, Waltham, MA USA. VA Puget Sound, Epidemiol Res & Informat Ctr, Seattle, WA USA. Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. RP Whitehead, CR (reprint author), Vet Affairs Med Ctr, Cincinnati, OH 45267 USA. EM casserly.whitehead.ctr@wpafb.af.mil RI Maynard, Charles/N-3906-2015; Gore, Russell/N-8988-2016 OI Maynard, Charles/0000-0002-1644-7814; Gore, Russell/0000-0002-8012-1579 NR 37 TC 15 Z9 17 U1 1 U2 19 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD APR PY 2013 VL 170 IS 4 BP 383 EP 390 DI 10.1176/appi.ajp.2012.12010126 PG 8 WC Psychiatry SC Psychiatry GA 117AW UT WOS:000316925500008 PM 23429886 ER PT J AU Steele, JW Gandy, S AF Steele, John W. Gandy, Sam TI Latrepirdine (Dimebon (R)), a potential Alzheimer therapeutic, regulates autophagy and neuropathology in an Alzheimer mouse model SO AUTOPHAGY LA English DT Editorial Material DE Alzheimer; therapeutics; latrepirdine; dimebon; synuclein; macroautophagy; amyloid; lysosome; presenilin; neurodegeneration AB Alzheimer disease (AD) is a form of neurodegeneration that develops over the course of multiple decades and as a result of the accumulation of the pathogenic amyloid-beta (A beta) peptide, also known as A4. In late-stage AD, failure of autophagic clearance results in neuronal cell bodies that are almost entirely consumed by autophagic vacuoles (AVs). Previously, we have shown that the potential AD drug latrepirdine (aka Dimebon (R)), a Russian antihistamine that has shown mixed results in phase II clinical trials in AD, regulates metabolism of the amyloid-beta/A4 precursor protein (APP). In two Molecular Psychiatry papers in 2012, we sought to determine the mechanism through which latrepirdine regulates APP metabolism and to determine, using an Alzheimer mouse model, whether latrepirdine provides protection from the toxicity associated with the accumulation of A beta. In cultured cells, we provided evidence that latrepirdine stimulates MTOR- and ATG5-dependent autophagy, leading to the reduction of intracellular levels of APP metabolites, including A beta. Consistent with this finding, we found that chronic latrepirdine administration resulted in increased levels of the biomarkers thought to correlate with autophagy activation in the brains of TgCRND8 (APP K670M, N671L, V717F) or wild-type mice, and that treatment was associated with abrogation of behavioral deficit, reduction in A beta neuropathology, and prevention of autophagic failure among TgCRND8 mice. C1 [Steele, John W.] Rockefeller Univ, Elizabeth & Zachary Fisher Ctr Alzheimers Dis Res, New York, NY 10021 USA. [Steele, John W.] Rockefeller Univ, Lab Mol & Cellular Neurosci, New York, NY 10021 USA. [Gandy, Sam] Icahn Sch Med Mt Sinai, Dept Neurol, Ctr Cognit Hlth, New York, NY USA. [Gandy, Sam] Icahn Sch Med Mt Sinai, Dept Psychiat, Ctr Cognit Hlth, New York, NY USA. [Gandy, Sam] Icahn Sch Med Mt Sinai, Mt Sinai Alzheimers Dis Res Ctr, New York, NY USA. [Gandy, Sam] James J Peters VA Med Ctr, Bronx, NY USA. RP Gandy, S (reprint author), Icahn Sch Med Mt Sinai, Dept Neurol, Ctr Cognit Hlth, New York, NY USA. EM samuel.gandy@mssm.edu NR 0 TC 40 Z9 43 U1 1 U2 8 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1554-8627 J9 AUTOPHAGY JI Autophagy PD APR PY 2013 VL 9 IS 4 BP 617 EP 618 DI 10.4161/auto.23487 PG 2 WC Cell Biology SC Cell Biology GA 114HR UT WOS:000316732200018 PM 23380933 ER PT J AU Wang, TY Halaney, D Ho, D Feldman, MD Milner, TE AF Wang, Tianyi Halaney, David Ho, Derek Feldman, Marc D. Milner, Thomas E. TI Two-photon luminescence properties of gold nanorods SO BIOMEDICAL OPTICS EXPRESS LA English DT Article ID EXCITATION CROSS-SECTIONS; ASPECT RATIO; METAL NANOPARTICLES; CORONARY PLAQUE; IN-VITRO; PHOTOLUMINESCENCE; ABSORPTION; FIELD; ENHANCEMENT; SIMULATION AB Gold nanorods can be internalized by macrophages (an important early cellular marker in atherosclerosis and cancer) and used as an imaging contrast agent for macrophage targeting. Objective of this study is to compare two-photon luminescence (TPL) properties of four aspect ratios of gold nanorods with surface plasmon resonance at 700, 756, 844 and 1060 nm respectively. TPL from single nanorods and Rhodamine 6G particles was measured using a laser-scanning TPL microscope. Nanorod TPL emission spectrum was recorded by a spectrometer. Quadratic dependence of luminescence intensity on excitation power (confirming a TPL process) was observed below a threshold (e. g., <1.6 mW), followed by photobleaching at higher power levels. Dependence of nanorod TPL intensity on excitation wavelength indicated that the two-photon action cross section (TPACS) is plasmon-enhanced. Largest TPACS of a single nanorod (12271 GM) was substantially larger than a single Rhodamine 6G particle (25 GM) at 760 nm excitation. Characteristics of nanorod TPL emission spectrum can be explained by plasmon-enhanced interband transition of gold. Comparison results of TPL brightness, TPACS and emission spectrum of nanorods can guide selection of optimal contrast agent for selected imaging applications. (C) 2013 Optical Society of America C1 [Wang, Tianyi; Ho, Derek; Milner, Thomas E.] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA. [Halaney, David; Feldman, Marc D.] Univ Texas Hlth Sci Ctr San Antonio, Div Cardiol, San Antonio, TX 78229 USA. [Halaney, David; Feldman, Marc D.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Wang, TY (reprint author), Univ Texas Austin, Dept Biomed Engn, 1 Univ Stn C0800, Austin, TX 78712 USA. EM Tianyi.Wang@utexas.edu OI Halaney, David/0000-0003-4437-0516 FU VA Merit grant; Clayton Foundation for Biomedical Research; Janey and Dolph Briscoe Center for Cardiovascular Research; Cigarrora Endowed Professorship; Marion E. Forsman Professorship in Engineering; American Society for Laser Medicine and Surgery FX The authors would like to acknowledge the technical support from Nanopartz, Inc, Mr. John Alford from Andor Technology, PLC, and kind supply of the objective patent and model by Drs. Fabian F. Voigt and Fritjof Helmchen from University of Zurich. This work is supported by a VA Merit grant, the Clayton Foundation for Biomedical Research, Janey and Dolph Briscoe Center for Cardiovascular Research, a Cigarrora Endowed Professorship (M. D. F.), a Marion E. Forsman Professorship in Engineering (T. E. M.), and a travel grant from the American Society for Laser Medicine and Surgery (T. W.). NR 53 TC 23 Z9 25 U1 4 U2 94 PU OPTICAL SOC AMER PI WASHINGTON PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA SN 2156-7085 J9 BIOMED OPT EXPRESS JI Biomed. Opt. Express PD APR 1 PY 2013 VL 4 IS 4 BP 584 EP 595 PG 12 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 117GW UT WOS:000316942500011 PM 23577293 ER PT J AU Merkow, RP Kmiecik, TE Bentrem, DJ Winchester, DP Stewart, AK Ko, CY Bilimoria, KY AF Merkow, Ryan P. Kmiecik, Thomas E. Bentrem, David J. Winchester, David P. Stewart, Andrew K. Ko, Clifford Y. Bilimoria, Karl Y. TI Effect of including cancer-specific variables on models examining short-term outcomes SO CANCER LA English DT Article DE colorectal cancer; outcomes; risk-adjustment; outcomes; American College of Surgeons National Surgical Quality Improvement Program; National Cancer Data Base; cancer stage; neoadjuvant therapy ID SURGICAL QUALITY IMPROVEMENT; RISK PREDICTION MODELS; RECTAL-CANCER; ABDOMINOPERINEAL RESECTION; PREOPERATIVE RADIOTHERAPY; SURGERY; SAFETY; CARE; COMPLICATIONS; PROGRAM AB BACKGROUND: The American College of Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) generally has not collected cancer-specific variables. Because increasing numbers of studies are using ACS NSQIP data to study cancer surgery, the objectives of the current study were 1) to examine differences between existing ACS NSQIP variables and cancer registry variables, and 2) to determine whether the addition of cancer-specific variables improves modeling of short-term outcomes. METHODS: Data from patients in the ACS NSQIP and National Cancer Data Base (NCDB) who underwent colorectal resection for cancer were linked (2006-2008). By using regression methods, the relative importance of cancer staging and neoadjuvant therapy variables were assessed along with their effects on morbidity, serious morbidity, and mortality. RESULTS: From 146 hospitals, 11,405 patients were identified who underwent surgery for colorectal cancer (colon, 85%; rectum, 15%). The NCDB metastatic cancer variable and the ACS NSQIP disseminated cancer variables agreed marginally (Cohen kappa coefficient, 0.454). For mortality, only the ACS NSQIP disseminated cancer variable and the NCDB stage IV variable were identified as important predictors; whereas the variables stage I through III, tumor (T)-classification, and lymph node (N)-classification were not selected. Cancer stage variables were inconsistently important for serious morbidity (stage IV, T-classification), superficial surgical site infection (N-classification), venous thromboembolism (metastatic cancer), and pneumonia (T-classification). With respect to neoadjuvant therapy, ACS NSQIP and NCDB variables agreed moderately (kappa, 0.570) and predicted superficial surgical site infection, serious morbidity, and organ space surgical site infection. The model fit was similar regardless of the inclusion of stage and neoadjuvant therapy variables. CONCLUSIONS: Although advanced disease stage and neoadjuvant therapy variables were predictors of short-term outcomes, their inclusion did not improve the models. Cancer 2013. (c) 2012 American Cancer Society. C1 [Merkow, Ryan P.; Winchester, David P.; Stewart, Andrew K.; Ko, Clifford Y.; Bilimoria, Karl Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA. [Merkow, Ryan P.; Kmiecik, Thomas E.; Bentrem, David J.; Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Surg Outcomes & Qual Improvement Ctr, Chicago, IL 60611 USA. [Merkow, Ryan P.; Kmiecik, Thomas E.; Bentrem, David J.; Bilimoria, Karl Y.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Northwestern Inst Comparat Effectiveness Res Onco, Chicago, IL 60611 USA. [Merkow, Ryan P.] Univ Colorado Denver, Dept Surg, Aurora, CO USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Bilimoria, KY (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 North St Clair St,22nd Floor, Chicago, IL 60611 USA. EM kbilimoria@facs.org FU American Cancer Society; Agency for Healthcare Research and Quality; Northwestern Institute for Comparative Effectiveness Research in Oncology FX This study was supported by the American Cancer Society, the Agency for Healthcare Research and Quality, and the Northwestern Institute for Comparative Effectiveness Research in Oncology. NR 36 TC 14 Z9 14 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X J9 CANCER-AM CANCER SOC JI Cancer PD APR 1 PY 2013 VL 119 IS 7 BP 1412 EP 1419 DI 10.1002/cncr.27891 PG 8 WC Oncology SC Oncology GA 115KU UT WOS:000316811900018 PM 23184472 ER PT J AU Armstrong, EJ Kwa, AT Yeo, KK Mahmud, E Javed, U Patel, M Shunk, KA MacGregor, JS Low, RI Rogers, JH AF Armstrong, Ehrin J. Kwa, Andrew T. Yeo, Khung Keong Mahmud, Ehtisham Javed, Usman Patel, Mitul Shunk, Kendrick A. MacGregor, John S. Low, Reginald I. Rogers, Jason H. TI Angiographically confirmed stent thrombosis in contemporary practice: Insights from intravascular ultrasound SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Article DE stent thrombosis; intravascular ultrasound; acute coronary syndrome (ACS); intravascular ultrasound (IVUS); thrombosis (THRM) ID PERCUTANEOUS CORONARY INTERVENTION; ACUTE MYOCARDIAL-INFARCTION; DRUG-ELUTING STENTS; IMPLANTATION; PREDICTORS; MALAPPOSITION; FRACTURE; IMPACT; DEPLOYMENT; OUTCOMES AB Objective: We hypothesized that patients presenting with stent thrombosis (ST) have a high prevalence of stent underexpansion and malapposition when assessed by intravascular ultrasound (IVUS). Background: IVUS can provide mechanistic insight into mechanical factors, including stent underexpansion, malapposition, and fracture that may predispose to ST. Methods: All consecutive cases of angiographically confirmed ST from a multicenter registry (from 2005 to 2010) were reviewed. All IVUS images were reviewed off-line for the presence of stent underexpansion, malapposition, and fracture. KaplanMeier analysis was used to determine whether use of IVUS at the time of ST was associated with long-term mortality and major adverse cardiovascular events. Results: IVUS was performed in 32 of 173 subjects with ST (18%). Stent underexpansion was present in 82% of cases and in all cases of early ST, with a mean stent expansion of 0.7 +/- 0.23 by MUSIC criteria. Stent malapposition was most frequently observed in very late ST (40%). In-hospital mortality was similar between subjects who had IVUS performed at the time of ST when compared with the non-IVUS group (3.2% vs. 4.3%, P = 0.8). Subjects who had IVUS performed at the time of ST had lower rates of mortality (HR 0.4, 95% CI 0.1-1.6, P =0.2) and major adverse cardiovascular events (HR 0.5, 95% CI 0.21.4, P =0.2) at follow-up, but these values were not statistically significant. Conclusions: There is a high prevalence of stent underexpansion in early ST, while the prevalence of malapposition is higher in very late ST. Use of IVUS during treatment for ST may identify mechanisms underlying the development of ST. (c) 2012 Wiley Periodicals, Inc. C1 [Armstrong, Ehrin J.; Kwa, Andrew T.; Yeo, Khung Keong; Javed, Usman; Low, Reginald I.; Rogers, Jason H.] Calif State Univ Sacramento, Davis Med Ctr, Sacramento, CA 95819 USA. [Mahmud, Ehtisham; Patel, Mitul] Univ Calif San Diego, San Diego Med Ctr, San Diego, CA 92103 USA. [Shunk, Kendrick A.] Univ Calif San Francisco, San Francisco Med Ctr, San Francisco, CA 94143 USA. [Shunk, Kendrick A.] San Francisco VA Med Ctr, San Francisco, CA USA. [MacGregor, John S.] San Francisco Gen Hosp, San Francisco, CA 94110 USA. RP Rogers, JH (reprint author), 4860 Y St,Suite 2820, Sacramento, CA 95817 USA. EM jason.rogers@ucdmc.ucdavis.edu FU Boston Scientific; Abbott Vascular; Sanofi Aventis FX Drs. Armstrong, Kwa, Javed, Patel, Shunk, and MacGregor have no disclosures. Dr Low is on the advisory board of Abbott Vascular and Boston Scientific. Dr Rogers is a consultant for Volcano, Medtronic, Cordis, and Boston Scientific. Dr Mahmud is on the Speakers Bureau for Medtronic and Eli Lilly; is a consultant for Eli Lilly; and has research support from Boston Scientific, Abbott Vascular and Sanofi Aventis. NR 31 TC 9 Z9 9 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1522-1946 J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD APR PY 2013 VL 81 IS 5 BP 782 EP 790 DI 10.1002/ccd.24460 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 113TL UT WOS:000316691300010 PM 22511567 ER PT J AU Chen, BB Mallampalli, RK AF Chen, Bill B. Mallampalli, Rama K. TI F-box protein substrate recognition A new insight SO CELL CYCLE LA English DT Editorial Material ID IDENTIFICATION; DEGRADATION; ARREST; FBXL2 C1 [Chen, Bill B.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Chen, BB (reprint author), Univ Pittsburgh, Pittsburgh, PA 15260 USA. EM chenb@upmc.edu; mallampallirk@upmc.edu FU BLRD VA [I01 BX002200]; NHLBI NIH HHS [R01 HL098174, R01 HL116472, R01 HL096376] NR 10 TC 5 Z9 5 U1 2 U2 6 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1538-4101 J9 CELL CYCLE JI Cell Cycle PD APR 1 PY 2013 VL 12 IS 7 BP 1009 EP 1010 DI 10.4161/cc.23071 PG 2 WC Cell Biology SC Cell Biology GA 117HJ UT WOS:000316943900001 PM 23255120 ER PT J AU Palevsky, PM AF Palevsky, Paul M. TI Introduction: Perspectives on Integrated Nephrology Care SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Editorial Material C1 [Palevsky, Paul M.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA. [Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA. RP Palevsky, PM (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Mail Stop 111 F-U,Univ Dr, Pittsburgh, PA 15240 USA. EM palevsky@pitt.edu OI Palevsky, Paul/0000-0002-7334-5400 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD APR PY 2013 VL 8 IS 4 BP 681 EP 681 DI 10.2215/CJN.00230113 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 118KB UT WOS:000317023300024 PM 23564886 ER PT J AU Horner, MD Mintzer, JE Turner, TH Edmiston, KR Brawman-Mintzer, O AF Horner, Michael David Mintzer, Jacobo E. Turner, Travis H. Edmiston, Keith R. Brawman-Mintzer, Olga TI Attentional functioning in patients with posttraumatic stress disorder: a preliminary study SO CNS SPECTRUMS LA English DT Article DE PTSD; neuropsychology; attention; cognition ID INTIMATE PARTNER VIOLENCE; COMBAT VETERANS; MEMORY FUNCTION; PTSD; SYMPTOMS; SURVIVORS; DEFICITS; WAR AB Objective. To compare patients with posttraumatic stress disorder (PTSD) to patients without psychiatric or cognitive disorders on neuropsychological measures of attention. Methods. The sample included 19 patients with PTSD and 22 participants with no cognitive or psychiatric diagnosis. All had been referred for clinical neuropsychological evaluation at a VA Medical Center. None were diagnosed with dementia, delirium, or current substance dependence except nicotine or caffeine, and none had a history of stroke or of traumatic brain injury with loss of consciousness. Patients were excluded if they failed to exert adequate effort on testing. Results. PTSD patients performed significantly more poorly than patients without psychiatric diagnoses on Digit Span. Conclusion. PTSD patients were impaired relative to participants without psychiatric diagnoses on a measure of focused attention. Several factors, including the small sample size, suggest that the results should be considered preliminary. C1 [Horner, Michael David; Mintzer, Jacobo E.; Turner, Travis H.; Brawman-Mintzer, Olga] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. [Horner, Michael David; Mintzer, Jacobo E.; Turner, Travis H.; Brawman-Mintzer, Olga] Med Univ S Carolina, Charleston, SC 29425 USA. [Edmiston, Keith R.] Coll Charleston, Charleston, SC 29401 USA. RP Horner, MD (reprint author), Ralph H Johnson VA Med Ctr, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM hornermd@musc.edu RI Kilic, Cengiz/I-9145-2013 FU Department of Veterans Affairs; Pfizer; NIH/NIA; Genentech; University of San Diego; Novartis, Inc.; Janssen; Wyeth, Inc.; Lilly Research Labs; Eli Lilly Company; CSP [545]; Elan Pharmaceuticals; BioPharma Connex; Takeda; Shire; Novartis FX This study was supported in part by the Department of Veterans Affairs.; Jacobo Mintzer has the following disclosures: Pfizer: research support (grant); NIH/NIA: research support (grant); Genentech: research support (grant); University of San Diego: research support (grant); Novartis, Inc.: research support (grant); Janssen: research support (grant); Wyeth, Inc.: research support (grant); Lilly Research Labs: research support (grant); Eli Lilly & Company: research support (grant); CSP #545: research support (grant); Elan Pharmaceuticals: research support (grant); BioPharma Connex: founder and chair (salary); NeuroQuest: consultant. Olga Brawman-Mintzer has the following disclosures: Takeda: research support (grant); Shire: research support (grant); Novartis: research support (grant). The remaining authors have nothing to disclose. NR 30 TC 4 Z9 4 U1 0 U2 14 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1092-8529 J9 CNS SPECTRUMS JI CNS Spectr. PD APR PY 2013 VL 18 IS 2 BP 90 EP 94 DI 10.1017/S1092852912000909 PG 5 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 119WO UT WOS:000317130200006 PM 23298713 ER PT J AU Krmpotich, TD Tregellas, JR Thompson, LL Banich, MT Klenk, AM Tanabe, JL AF Krmpotich, Theodore D. Tregellas, Jason R. Thompson, Laetitia L. Banich, Marie T. Klenk, Amanda M. Tanabe, Jody L. TI Resting-state activity in the left executive control network is associated with behavioral approach and is increased in substance dependence SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Substance dependence; Approach; Avoidance; Resting-state; Executive control network; Laterality ID INTRINSIC CONNECTIVITY NETWORKS; DEFAULT-MODE; FUNCTIONAL CONNECTIVITY; ACTIVATION SYSTEMS; INHIBITION SYSTEM; HEALTHY-SUBJECTS; DECISION-MAKING; USE DISORDERS; ADDICTION; REWARD AB Background: Individuals with drug addictions report increased willingness to approach rewards. Approach behaviors are thought to involve executive control processes and are more strongly represented in the left compared to right prefrontal cortex. A direct link between approach tendencies and left hemisphere activity has not been shown in the resting brain. We hypothesized that compared to controls, substance dependent individuals (SDI) would have greater left hemisphere activity in the left executive control network (ECN) at rest. Methods: Twenty-five SDI and 25 controls completed a Behavioral Inhibition System/Behavioral Activation System (BIS/BAS) questionnaire and underwent a resting-state fMRI scan. Group independent component analysis was performed. We used template matching to identify the left and right ECN separately and compared the corresponding components across groups. Across group, BAS scores were correlated with signal fluctuations in the left ECN and BIS scores with right ECN. Results: BAS scores were higher in SDI compared to controls (p < .003) and correlated with signal fluctuation in the left ECN. SDI showed significantly more activity than controls in the left prefrontal cortex of the left ECN. Conversely, SDI showed less activity than controls in the right prefrontal cortex of the right ECN. Conclusions: Results from this study suggest that approach tendencies are related to the left ECN, even during rest. Higher resting-state signal in the left ECN may play a role in heightened approach tendencies that contribute to drug-seeking behavior. Published by Elsevier Ireland Ltd. C1 [Krmpotich, Theodore D.; Klenk, Amanda M.; Tanabe, Jody L.] Univ Colorado Denver, Dept Radiol, Denver, CO USA. [Tregellas, Jason R.; Thompson, Laetitia L.; Banich, Marie T.; Tanabe, Jody L.] Univ Colorado Denver, Dept Psychiat, Denver, CO USA. [Banich, Marie T.] Univ Colorado Boulder, Inst Cognit Sci, Boulder, CO USA. [Tregellas, Jason R.] Denver Vet Affairs Med Ctr, Res Serv, Denver, CO USA. RP Tanabe, JL (reprint author), 12700 E 17th Ave,C278, Aurora, CO 80045 USA. EM Jody.Tanabe@ucdenver.edu RI Tregellas, Jason/J-3637-2015 FU NIDA [R01 DA024104, DA027748] FX Funding for this study was provided by NIDA grants R01 DA024104 and DA027748; NIDA had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. NR 45 TC 17 Z9 18 U1 0 U2 17 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD APR 1 PY 2013 VL 129 IS 1-2 BP 1 EP 7 DI 10.1016/j.drugalcdep.2013.01.021 PG 7 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 115QS UT WOS:000316827600001 PM 23428318 ER PT J AU Shen, XYY Kosten, TA Lopez, AY Kinsey, BM Kosten, TR Orson, FM AF Shen, Xiaoyun Y. Kosten, Therese A. Lopez, Angel Y. Kinsey, Berma M. Kosten, Thomas R. Orson, Frank M. TI A vaccine against methamphetamine attenuates its behavioral effects in mice SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Conjugate vaccine; Keyhole limpet hemocyanin; Monophosphoryl lipid A; Serum antibody titers; Locomotor activity; Conditioned place preference ID CONDITIONED PLACE PREFERENCE; ACTIVE IMMUNIZATION; MONOCLONAL-ANTIBODIES; COCAINE; RATS; AMPHETAMINE; (+)-METHAMPHETAMINE; NICOTINE; IMMUNOGENICITY; NEUROTOXICITY AB Background: Vaccines have treatment potential for methamphetamine (MA) addiction. We tested whether a conjugate vaccine against MA (succinyl-methamphetamine-keyhole limpet hemocyanin carrier protein; SMA-KLH) would generate MA antibodies and alter MA-induced behaviors. Methods: Mice were injected with SMA-KLH and received booster administrations 3 and 20 weeks later. Serum antibody titers reached peak levels by 4-6 weeks, remained at a modest level through 18 weeks, peaked again at 22 weeks after the second boost, and were still elevated at 35 weeks. At 7 weeks, groups of vaccinated and non-vaccinated mice were administered one of three MA doses (1, 2 or 3 mg/kg) to assess locomotor activity. Results: Non-vaccinated mice showed dose-dependent effects of MA with hypolocomotion at the lowest dose and elevated activity levels at the highest dose. Both dose effects were reduced in SMA-KLH groups, particularly low dose-induced hypolocomotion at later times post MA administration. Separate groups of vaccinated and non-vaccinated mice were trained in MA place conditioning at 30 weeks with either 0 (vehicle) or 0.5 mg/kg MA. Although times spent in the MA-paired side did not differ between groups on test vs. baseline sessions, SMA-KLH mice conditioned with MA showed reduced conditioned approach behaviors and decreased conditioned activity levels compared to control groups. Conclusion: These data suggest SMA-KLH attenuates the ability of MA to support place conditioning and reduces or delays its locomotor effects. Overall, results support SMA-KLH as a candidate MA vaccine. (C) 2012 Elsevier Ireland Ltd. All rights reserved. C1 [Shen, Xiaoyun Y.; Lopez, Angel Y.; Kinsey, Berma M.; Orson, Frank M.] Michael E Debakey Vet Med Affairs Ctr, Dept Med, Houston, TX 77030 USA. [Kosten, Therese A.; Kosten, Thomas R.] Baylor Coll Med, Michael E Debakey Vet Med Affairs Ctr, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. RP Kosten, TA (reprint author), Michael E Debakey VAMC, Res Serv Line 151, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM tkosten@bcm.edu FU National Institute on Drug Abuse (NIDA) [DP1DA033502, U01023898]; NIH; Department of Veterans Affairs FX This research was supported by grants DP1DA033502 and U01023898 from The National Institute on Drug Abuse (NIDA). NIDA had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. Drs. T.A. Kosten, T.R. Kosten, and Orson have received funding from the NIH and the Department of Veterans Affairs. NR 41 TC 18 Z9 18 U1 0 U2 4 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD APR 1 PY 2013 VL 129 IS 1-2 BP 41 EP 48 DI 10.1016/j.drugalcdep.2012.09.007 PG 8 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 115QS UT WOS:000316827600006 PM 23022610 ER PT J AU Mentz, RJ Hernandez, AF Stebbins, A Ezekowitz, JA Felker, GM Heizer, GM Atar, D Teerlink, JR Califf, RM Massie, BM Hasselblad, V Starling, RC O'Connor, CM Ponikowski, P AF Mentz, Robert J. Hernandez, Adrian F. Stebbins, Amanda Ezekowitz, Justin A. Felker, G. Michael Heizer, Gretchen M. Atar, Dan Teerlink, John R. Califf, Robert M. Massie, Barry M. Hasselblad, Vic Starling, Randall C. O'Connor, Christopher M. Ponikowski, Piotr TI Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Article DE Acute heart failure; Dyspnoea relief; Prognosis; Outcomes ID EUROPEAN-SOCIETY; NESIRITIDE; NITROGLYCERIN; REGISTRY; PROTECT; UPDATE; TRIAL AB To examine the characteristics associated with early dyspnoea relief during acute heart failure (HF) hospitalization, and its association with 30-day outcomes. ASCEND-HF was a randomized trial of nesiritide vs. placebo in 7141 patients hospitalized with acute HF in which dyspnoea relief at 6 h was measured on a 7-point Likert scale. Patients were classified as having early dyspnoea relief if they experienced moderate or marked dyspnoea improvement at 6 h. We analysed the clinical characteristics, geographical variation, and outcomes (mortality, mortality/HF hospitalization, and mortality/hospitalization at 30 days) associated with early dyspnoea relief. Early dyspnoea relief occurred in 2984 patients (43). In multivariable analyses, predictors of dyspnoea relief included older age and oedema on chest radiograph; higher systolic blood pressure, respiratory rate, and natriuretic peptide level; and lower serum blood urea nitrogen (BUN), sodium, and haemoglobin (model mean C index 0.590). Dyspnoea relief varied markedly across countries, with patients enrolled from Central Europe having the lowest risk-adjusted likelihood of improvement. Early dyspnoea relief was associated with lower risk-adjusted 30-day mortality/HF hospitalization [hazard ratio (HR) 0.81; 95 confidence interval (CI) 0.680.96] and mortality/hospitalization (HR 0.85; 95 CI 0.740.99), but similar mortality. Clinical characteristics such as respiratory rate, pulmonary oedema, renal function, and natriuretic peptide levels are associated with early dyspnoea relief, and moderate or marked improvement in dyspnoea was associated with a lower risk for 30-day outcomes. C1 [Mentz, Robert J.; Hernandez, Adrian F.; Felker, G. Michael; Califf, Robert M.; O'Connor, Christopher M.] Duke Univ, Med Ctr, Durham, NC USA. [Hernandez, Adrian F.; Stebbins, Amanda; Felker, G. Michael; Heizer, Gretchen M.; Califf, Robert M.; Hasselblad, Vic; O'Connor, Christopher M.] Duke Clin Res Inst, Durham, NC 27715 USA. [Ezekowitz, Justin A.] Univ Alberta, Edmonton, AB, Canada. [Atar, Dan] Oslo Univ Hosp, Oslo, Norway. [Teerlink, John R.; Massie, Barry M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Teerlink, John R.; Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Starling, Randall C.; Ponikowski, Piotr] Cleveland Clin, Cleveland, OH 44106 USA. [Starling, Randall C.; Ponikowski, Piotr] Kardiol Klin, Wroclaw, Poland. RP Hernandez, AF (reprint author), Duke Clin Res Inst, POB 17969, Durham, NC 27715 USA. EM adrian.hernandez@duke.edu RI Ezekowitz, Justin/C-4579-2013; Ponikowski, Piotr/O-6454-2015; Hernandez, Adrian F./A-7818-2016 OI Ezekowitz, Justin/0000-0002-2724-4086; Ponikowski, Piotr/0000-0002-3391-7064; Hernandez, Adrian F./0000-0003-3387-9616 FU Johnson and Johnson; Scios Inc.; Amgen; Bayer; Corthera; Cytokinetics; Novartis; Trevena; Johnson Johnson; DCRI; Otsuka; Roche Diagnostics; Merck; BG Medicine; NIH FX Johnson and Johnson provided funding for the overall ASCEND-HF trial.; J.R.T. has received research grants for his role as a Steering committee member in ASCEND-HF from Scios Inc., the sponsor of this trial. He received research support and/or consultation fees from Amgen, Bayer, Corthera, Cytokinetics, Novartis, and Trevena. R. C. has received research grants and consulting fees from Johnson & Johnson. All other industry relations are publicly displayed at www.dcri.org/about-us. J.E. is currently conducting research sponsored by Johnson & Johnson. B. M. has received consulting fees/honoraria from DCRI. G. M. F. has received consulting fees from Amgen, Trevena, Otsuka, Roche Diagnostics, Novartis, Merck, and BG Medicine, and research funding from NIH, Amgen, Otsuka, and Roche Diagnostics. P. P. has received fees in respect of consultancy and speaker's bureau from Scios Inc., Corthera, Novartis, Johnson & Johnson, and Bayer. All other authors declare no conflict of interest. NR 24 TC 19 Z9 19 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1388-9842 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD APR PY 2013 VL 15 IS 4 BP 456 EP 464 DI 10.1093/eurjhf/hfs188 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 117LR UT WOS:000316955400014 PM 23159547 ER PT J AU Pistilli, EE Quinn, LS AF Pistilli, Emidio E. Quinn, LeBris S. TI From Anabolic to Oxidative: Reconsidering the Roles of IL-15 and IL-15R alpha in Skeletal Muscle SO EXERCISE AND SPORT SCIENCES REVIEWS LA English DT Review DE cytokines; myokines; fatigue; oxidative muscle; atrophy; hypertrophy ID TUMOR-BEARING RATS; INTERLEUKIN-15 RECEPTOR; CARBOHYDRATE INGESTION; CYTOKINE; EXERCISE; PROTEIN; ALPHA; DIFFERENTIATION; EXPRESSION; ELEVATION AB PISTILLI, E. E. and L. S. QUINN. From anabolic to oxidative: reconsidering the roles of IL-15 and IL-15R alpha in skeletal muscle. Exerc. Sport Sci. Rev., Vol. 41, No. 2, pp. 100-106, 2013. Interleukin 15 (IL-15) and its receptor IL-15 receptor-alpha (IL-15R alpha) are suggested to function in the determination of skeletal muscle phenotypes, with IL-15 originally proposed as an anabolic cytokine. This review will focus on recent work demonstrating that manipulation of IL-15 and IL-15R alpha in vivo promotes changes in exercise capacity, muscle fatigue, and gene expression indicative of a more oxidative skeletal muscle phenotype. C1 [Pistilli, Emidio E.] W Virginia Univ, Div Exercise Physiol, Sch Med, Morgantown, WV 26506 USA. [Pistilli, Emidio E.] W Virginia Univ, Ctr Cardiovasc & Resp Sci, Sch Med, Morgantown, WV 26506 USA. [Quinn, LeBris S.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Quinn, LeBris S.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. RP Pistilli, EE (reprint author), W Virginia Univ, Div Exercise Physiol, Sch Med, Morgantown, WV 26506 USA. EM epistilli2@hsc.wvu.edu FU National Institute of Arthritis and Musculoskeletal and Skin Diseases [5T32AR053461]; Department of Veterans Affairs [BX001026] FX This work was supported by a Ruth L. Kirschstein National Research Service Award (5T32AR053461) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (to E. E. Pistilli) and Merit Review BX001026 from the Department of Veterans Affairs (to L. S. Quinn), with resources from the VA Puget Sound Health Care System. NR 35 TC 9 Z9 9 U1 1 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0091-6331 J9 EXERC SPORT SCI REV JI Exerc. Sport Sci. Rev. PD APR PY 2013 VL 41 IS 2 BP 100 EP 106 DI 10.1097/JES.0b013e318275d230 PG 7 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 114IA UT WOS:000316733100006 PM 23072822 ER PT J AU Deepa, SS Pulliam, D Hill, S Shi, Y Walsh, ME Salmon, A Sloane, L Zhang, N Zeviani, M Viscomi, C Musi, N Van Remmen, H AF Deepa, Sathyaseelan S. Pulliam, Daniel Hill, Shauna Shi, Yun Walsh, Michael E. Salmon, Adam Sloane, Lauren Zhang, Ning Zeviani, Massimo Viscomi, Carlo Musi, Nicolas Van Remmen, Holly TI Improved insulin sensitivity associated with reduced mitochondrial complex IV assembly and activity SO FASEB JOURNAL LA English DT Article DE fatty acid oxidation; PGC-1 alpha; longevity; Surf1 ID CYTOCHROME-C-OXIDASE; ACTIVATED RECEPTOR-ALPHA; FATTY-ACID OXIDATION; ADIPOSE-TISSUE; LIFE-SPAN; GLUCOSE-METABOLISM; SKELETAL-MUSCLE; GROWTH-HORMONE; KNOCKOUT MICE; UP-REGULATION AB Mice lacking Surf1, a complex IV assembly protein, have similar to 50-70% reduction in cytochrome c oxidase activity in all tissues yet a paradoxical increase in lifespan. Here we report that Surf1(-/-) mice have lower body (15%) and fat (20%) mass, in association with reduced lipid storage, smaller adipocytes, and elevated indicators of fatty acid oxidation in white adipose tissue (WAT) compared with control mice. The respiratory quotient in the Surf1(-/-) mice was significantly lower than in the control animals (0.83-0.93 vs. 0.90-0.98), consistent with enhanced fat utilization in Surf1(-/-) mice. Elevated fat utilization was associated with increased insulin sensitivity measured as insulin-stimulated glucose uptake, as well as an increase in insulin receptor levels (similar to 2-fold) and glucose transporter type 4 (GLUT4; similar to 1.3-fold) levels in WAT in the Surf1(-/-) mice. The expression of peroxisome proliferator-activated receptor gamma-coactivator 1-alpha (PGC-1 alpha) mRNA and protein was up-regulated by 2.5- and 1.9-fold, respectively, in WAT from Surf1(-/-) mice, and the expression of PGC-1 alpha target genes and markers of mitochondrial biogenesis was elevated. Together, these findings point to a novel and unexpected link between reduced mitochondrial complex IV activity, enhanced insulin sensitivity, and increased mitochondrial biogenesis that may contribute to the increased longevity in the Surf1(-/-) mice.-Deepa, S. S., Pulliam, D., Hill, S., Shi, Y., Walsh, M. E., Salmon, A., Sloane, L., Zhang, N., Zeviani, M., Viscomi, C., Musi, N., Van Remmen, H. Improved insulin sensitivity associated with reduced mitochondrial complex IV assembly and activity. FASEB J. 27, 1371-1380 (2013). www.fasebj.org C1 [Deepa, Sathyaseelan S.; Pulliam, Daniel; Hill, Shauna; Shi, Yun; Walsh, Michael E.; Salmon, Adam; Sloane, Lauren; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. [Deepa, Sathyaseelan S.; Pulliam, Daniel; Hill, Shauna; Walsh, Michael E.; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78245 USA. [Zhang, Ning; Musi, Nicolas] Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, San Antonio, TX 78245 USA. [Salmon, Adam; Musi, Nicolas; Van Remmen, Holly] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. [Zeviani, Massimo; Viscomi, Carlo] Ist Ricovero & Cura Carattere Sci, Fdn Ist Neurol Carlo Besta, Unit Mol Neurogenet, Milan, Italy. RP Van Remmen, H (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, 15355 Lambda Dr,Mail Code 5566, San Antonio, TX 78245 USA. EM vanremmen@uthscsa.edu RI Zeviani, Massimo/K-2891-2014; Viscomi, Carlo/R-1940-2016 FU Ellison Medical Foundation; Telethon grant [GPP10005]; Italian Ministry of Health [GR2010-2306756] FX The authors thank Yuhong Liu, Li Yan, Marian Sabia, Amanda Jernigan, and Barbara Hunter for technical support. This work was supported by an Ellison Medical Foundation Senior Scholar award to H. V. R. Telethon grant GPP10005 to M.Z. and Italian Ministry of Health grant GR2010-2306756 to C.V. are also acknowledged. The authors report no conflicts of interest. NR 47 TC 14 Z9 14 U1 0 U2 7 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 IS 4 BP 1371 EP 1380 DI 10.1096/fj.12-221879 PG 10 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 117GF UT WOS:000316940800010 PM 23241310 ER PT J AU Kutner, N Zhang, R Johansen, K Bliwise, D AF Kutner, Nancy Zhang, Rebecca Johansen, Kirsten Bliwise, Donald TI Associations among nocturnal sleep, daytime intradialytic sleep, and mortality risk in patients on daytime conventional hemodialysis: US Renal Data System special study data SO HEMODIALYSIS INTERNATIONAL LA English DT Article DE Sleep; sleep quality; sleepiness; hemodialysis; mortality risk ID QUALITY-OF-LIFE; CARDIOVASCULAR-DISEASE; NAP HABITS; LONG-SLEEP; DIALYSIS; DURATION; SIESTA; POPULATION; HEALTH; DEPRESSION AB Fragmented nocturnal sleep is commonly reported by patients undergoing daytime conventional hemodialysis (CHD) and may be associated with higher mortality risk. Subjective sleepiness during CHD is also frequently observed. We examined the association of reported sleep fragmentation and nocturnal and daytime (intradialytic) sleep durations with survival in a national cohort of 1440 CHD patients who were interviewed in 20052007 in a phone survey conducted by the US Renal Data System. Patient survival was followed through September 30, 2010 in the US Renal Data System. A total of 76% of patients reported that they typically dozed off or slept during their treatment, and intradialytic dozing was especially common among patients whose treatment shift started before 1000 hours. There was a trend for patients who reported dozing during CHD to report nocturnal sleep fragmentation (60.4% vs. 55.1%; P=0.07). With adjustment for intradialytic sleep and other covariates, nocturnal sleep fragmentation was not associated with survival. Mortality risk was higher for patients who reported sleeping 9 or more hours/night compared with the referent category of nocturnal sleep equal to 67 hours (hazard ratio: 1.50 [95% confidence interval: 1.042.17]; P=0.03). Continued investigation of the association of timing and duration of sleep with hemodialysis patient outcomes is warranted. C1 [Kutner, Nancy; Zhang, Rebecca; Johansen, Kirsten; Bliwise, Donald] Emory Univ, US Renal Data Syst, Rehabil Qual Life Special Studies Ctr, Atlanta, GA 30322 USA. [Bliwise, Donald] Emory Univ, Dept Neurol, Atlanta, GA 30322 USA. [Johansen, Kirsten] Univ Calif San Francisco, Nephrol Sect, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Johansen, Kirsten] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. RP Kutner, N (reprint author), Emory Univ, Dept Rehabil Med, Atlanta, GA 30322 USA. EM nkutner@emory.edu FU National Institutes of Health [HHSN267200715004C]; ADB [N01-DK-7-5004] FX This study was supported by National Institutes of Health contract HHSN267200715004C, ADB No. N01-DK-7-5004 (Dr. Kutner). The interpretation and reporting of the data presented here are the responsibility of the authors and in no way should be seen as an official policy or interpretation of the US government. NR 28 TC 5 Z9 5 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1492-7535 J9 HEMODIAL INT JI Hemodial. Int. PD APR PY 2013 VL 17 IS 2 BP 223 EP 229 DI 10.1111/hdi.12005 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 117PX UT WOS:000316966700004 PM 23216956 ER PT J AU Williams, AB Wang, HH Burgess, J Li, XH Danvers, K AF Williams, Ann B. Wang, Honghong Burgess, Jane Li, Xianhong Danvers, Karina TI Cultural adaptation of an evidence-based nursing intervention to improve medication adherence among people living with HIV/AIDS (PLWHA) in China SO INTERNATIONAL JOURNAL OF NURSING STUDIES LA English DT Article DE Cultural adaptation; Nursing intervention; Medication adherence; HIV/AIDS; China ID ACTIVE ANTIRETROVIRAL THERAPY; SELF-REPORTED ADHERENCE; HOME VISITS; HIV; DISSEMINATION; CHALLENGES; ISSUES AB Background: Adapting nursing interventions to suit the needs and culture of a new population (cultural adaptation) is an important early step in the process of implementation and dissemination. While the need for cultural adaptation is widely accepted, research-based strategies for doing so are not well articulated. Non-adherence to medications for chronic disease is a global problem and cultural adaptation of existing evidence-based interventions could be useful. Objectives: This paper aims to describe the cultural adaptation of an evidence-based nursing intervention to improve medication adherence among people living with HIV/AIDS and to offer recommendations for adaptation of interventions across cultures and borders. Site: The intervention, which demonstrated efficacy in a randomized controlled trial in North America, was adapted for the cultural and social context of Hunan Province, in south central China. Sources of data: The adaptation process was undertaken by intervention stakeholders including the original intervention study team, the proposed adaptation team, and members of a Community Advisory Board, including people living with HIV/AIDS, family members, and health care workers at the target clinical sites. Procedures: The adaptation process was driven by quantitative and qualitative data describing the new population and context and was guided by principles for cultural adaptation drawn from prevention science research. Results: The primary adaptation to the intervention was the inclusion of family members in intervention activities, in response to the cultural and social importance of the family in rural China. In a pilot test of the adapted intervention, self-reported medication adherence improved significantly in the group receiving the intervention compared to the control group (p = 0.01). Recommendations for cultural adaptation of nursing interventions include (1) involve stakeholders from the beginning; (2) assess the population, need, and context; (3) evaluate the intervention to be adapted with attention to details of the original studies that demonstrated efficacy; (4) compare important elements of the original intervention with those of the proposed new population and context to identify primary points for adaptation; (5) explicitly identify sources of tension between intervention fidelity and cultural adaptive needs; (6) document the process of adaptation, pilot the adapted intervention, and evaluate its effectiveness before moving to dissemination and implementation on a large scale. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Williams, Ann B.] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. [Wang, Honghong; Li, Xianhong] Cent S Univ, Sch Nursing, Changsha, Hunan, Peoples R China. [Burgess, Jane] VA Greater Los Angeles Healthcare Syst, QUERI HIV Hepatitis, Los Angeles, CA 90024 USA. [Danvers, Karina] Yale Univ, Connecticut AIDS Educ & Training Ctr, Sch Nursing, New Haven, CT 06610 USA. RP Williams, AB (reprint author), Univ Calif Los Angeles, Sch Nursing, 10880 Wilshire Blvd,Suite 550, Los Angeles, CA 90024 USA. EM awilliams@sonnet.ucla.edu; Honghong_wang@tom.com; Jane.Burgess@VA.gov; Xianhong_li228@hotmail.com; Karina.Danvers@yale.edu FU National Institute of Mental Health, USA FX Partial funding provided by the National Institute of Mental Health, USA, which had no role in the conduct of the work. NR 26 TC 3 Z9 5 U1 4 U2 38 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0020-7489 J9 INT J NURS STUD JI Int. J. Nurs. Stud. PD APR PY 2013 VL 50 IS 4 SI SI BP 487 EP 494 DI 10.1015/j.ijnurstu.2012.08.018 PG 8 WC Nursing SC Nursing GA 117UC UT WOS:000316977600006 PM 22981372 ER PT J AU Yun, X Maximov, VD Yu, J Zhu, H Vertegel, AA Kindy, MS AF Yun, Xiang Maximov, Victor D. Yu, Jin Zhu, Hong Vertegel, Alexey A. Kindy, Mark S. TI Nanoparticles for targeted delivery of antioxidant enzymes to the brain after cerebral ischemia and reperfusion injury SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE anti-oxidants; antibody; cerebral ischemia; nanoparticles; superoxide dismutase ID CONJUGATED SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; OXYGEN RADICALS; LIPID-PEROXIDATION; FOREBRAIN ISCHEMIA; EDEMA FORMATION; FOCAL ISCHEMIA; IN-VIVO; RATS; BARRIER AB Stroke is one of the major causes of death and disability in the United States. After cerebral ischemia and reperfusion injury, the generation of reactive oxygen species (ROS) and reactive nitrogen species may contribute to the disease process through alterations in the structure of DNA, RNA, proteins, and lipids. We generated various nanoparticles (liposomes, polybutylcyanoacrylate (PBCA), or poly(lactide-co-glycolide) (PLGA)) that contained active superoxide dismutase (SOD) enzyme (4,000 to 20,000 U/kg) in the mouse model of cerebral ischemia and reperfusion injury to determine the impact of these molecules. In addition, the nanoparticles were untagged or tagged with nonselective antibodies or antibodies directed against the N-methyl-D-aspartate (NMDA) receptor 1. The nanoparticles containing SOD protected primary neurons in vitro from oxygen-glucose deprivation (OGD) and limited the extent of apoptosis. The nanoparticles showed protection against ischemia and reperfusion injury when applied after injury with a 50% to 60% reduction in infarct volume, reduced inflammatory markers, and improved behavior in vivo. The targeted nanoparticles not only showed enhanced protection but also showed localization to the CA regions of the hippocampus. Nanoparticles alone were not effective in reducing infarct volume. These studies show that targeted nanoparticles containing protective factors may be viable candidates for the treatment of stroke. Journal of Cerebral Blood Flow & Metabolism (2013) 33, 583-592; doi:10.1038/jcbfm.2012.209; published online 6 February 2013 C1 [Yun, Xiang; Maximov, Victor D.; Vertegel, Alexey A.; Kindy, Mark S.] Clemson Univ, Dept Bioengn, Clemson, SC USA. [Yu, Jin; Zhu, Hong; Kindy, Mark S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Kindy, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Kindy, Mark S.] CU MUSC Bioengn Res Program, Charleston, SC USA. RP Kindy, MS (reprint author), Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. EM kindyms@musc.edu RI Maximov, Victor/G-2991-2013 FU National Institutes of Health [R01 ES016774-01, 5 P20 RR016461, 8P20GM103444-04, 5P20RR021949-03]; VA Merit Award; National Science Foundation [IIP-917987] FX This work was partially supported by grants from the National Institutes of Health (R01 ES016774-01, 5 P20 RR016461, 8P20GM103444-04, and 5P20RR021949-03), VA Merit Award, and a grant from the National Science Foundation (IIP-917987). Dr Kindy is a Research Career Scientist in the VA. NR 49 TC 34 Z9 35 U1 6 U2 42 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0271-678X J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD APR PY 2013 VL 33 IS 4 BP 583 EP 592 DI 10.1038/jcbfm.2012.209 PG 10 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA 117CR UT WOS:000316930200015 PM 23385198 ER PT J AU Smits, MM Ioannou, GN Boyko, EJ Utzschneider, KM AF Smits, Mark M. Ioannou, George N. Boyko, Edward J. Utzschneider, Kristina M. TI Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: Results of a US national survey in three ethnic groups SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE factor analysis; insulin resistance; NAFLD; obesity ID INSULIN-RESISTANCE ATHEROSCLEROSIS; CONFIRMATORY FACTOR-ANALYSIS; NUTRITION EXAMINATION SURVEY; HEPATIC STEATOSIS; POPULATION; PREVALENCE; HEALTH; RISK; PATHOPHYSIOLOGY; STEATOHEPATITIS AB Background and Aim The metabolic syndrome (MetS) and each of its components are strongly associated with non-alcoholic fatty liver disease (NAFLD). This has led many investigators to suggest that NAFLD is an independent component of the MetS. We formally tested this hypothesis using confirmatory factor analysis, which allows comparison of different models, with or without including NAFLD as a component of the MetS. Methods We analyzed data from 3846 subjects of the Third National Health and Nutrition Examination Survey (19881994). NAFLD was defined by increased liver fat measured by ultrasonography. Results MetS by Adult Treatment Panel III criteria was present in 20.5%, and 30.2% had NAFLD, defined as mild, moderate, or severe ultrasonographic steatosis. Using confirmatory factor analysis, a basic model representing the MetS using its currently accepted components (glucose, waist, triglyceride/high-density lipoprotein ratio, and mean arterial pressure) showed excellent goodness-of-fit statistics. Addition of NAFLD to the model as a fifth independent variable decreased model fit, suggesting that NAFLD is not an additional independent component of the MetS. Analysis by ethnicity showed that addition of NAFLD decreased model fit in Whites but resulted in minor improvements in non-Hispanic Blacks and Mexican Americans. Conclusions The MetS is strongly associated with NAFLD. However, we found no evidence that NAFLD is an independent component or manifestation of the MetS. Interestingly, ethnic differences might be important in this relationship and require further study. C1 [Smits, Mark M.; Utzschneider, Kristina M.] VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Ioannou, George N.] VA Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, Seattle, WA USA. [Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA. [Boyko, Edward J.] Univ Washington, Seattle, WA 98195 USA. [Smits, Mark M.] Vrije Univ Amsterdam, Med Ctr, Ctr Diabet, Dept Internal Med, Amsterdam, Netherlands. RP Utzschneider, KM (reprint author), VA Puget Sound Hlth Care Syst 151, 1660 S Columbian Way, Seattle, WA 98108 USA. EM kutzschn@u.washington.edu RI Smits, Mark/E-6573-2014 OI Smits, Mark/0000-0001-8236-8842; Boyko, Edward/0000-0002-3695-192X FU Department of Veterans Affairs FX The Department of Veterans Affairs provided support in part for the involvement of Drs Utzschneider, Ioannou, and Boyko in this research. NR 41 TC 42 Z9 42 U1 0 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0815-9319 J9 J GASTROEN HEPATOL JI J. Gastroenterol. Hepatol. PD APR PY 2013 VL 28 IS 4 BP 664 EP 670 DI 10.1111/jgh.12106 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 115MV UT WOS:000316817300013 PM 23286209 ER PT J AU Almog, DM Padberg, FT Carmel, G Friedlander, AH AF Almog, Dov M. Padberg, Frank T., Jr. Carmel, Gwendolyhn Friedlander, Arthur H. TI Previously Unappreciated Carotid Artery Stenosis Diagnosed by Cone Beam Computerized Tomography SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article ID PANORAMIC RADIOGRAPHS; HEART-DISEASE; ENDARTERECTOMY; ASSOCIATION; SOCIETY; TRIAL AB Stroke is the third leading cause of death in the western world. Calcification noted on cone beam computerized tomography, frequently used to evaluate the maxillofacial structures for extent of tumor, trauma, and implant placement, may indicate atherosclerotic disease in the carotid artery. Internal carotid artery stenosis is a recognized risk factor for stroke; multiple, large randomized controlled trials have demonstrated a decreased risk of stroke after repair of the stenotic artery. Recognition of calcified carotid artery plaque, on cone beam computerized tomography during the course of surgical care may offer the opportunity for stroke risk reduction. Published by Elsevier Inc on behalf of the American Association of Oral and Maxillofacial Surgeons J Oral Maxillofac Surg 71:702-705, 2013 C1 [Almog, Dov M.] Univ Med & Dent New Jersey, New Jersey Med Sch, Vet Affairs New Jersey Healthcare Syst, Dent Serv, Newark, NJ 07103 USA. [Padberg, Frank T., Jr.] Vet Affairs New Jersey Healthcare Syst, Newark, NJ USA. [Padberg, Frank T., Jr.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, Div Vasc Surg, Newark, NJ 07103 USA. [Carmel, Gwendolyhn] Vet Affairs New Jersey Healthcare Syst, Dept Surg, Vasc Lab, E Orange, NJ USA. [Friedlander, Arthur H.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Friedlander, Arthur H.] Hosp Dent Serv Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA. [Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. RP Friedlander, AH (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM arthur.friedlander@va.gov NR 20 TC 3 Z9 3 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0278-2391 J9 J ORAL MAXIL SURG JI J. Oral Maxillofac. Surg. PD APR PY 2013 VL 71 IS 4 BP 702 EP 705 DI 10.1016/j.joms.2012.09.021 PG 4 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 114MP UT WOS:000316745800018 PM 23245518 ER PT J AU Leigh, AE Burgio, KL Williams, BR Kvale, E Bailey, FA AF Leigh, Alexandra E. Burgio, Kathryn L. Williams, Beverly R. Kvale, Elizabeth Bailey, F. Amos TI Hospice Emergency Kit for Veterans: A Pilot Study SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID MEDICATION MANAGEMENT; HOME; CAREGIVERS; DIE AB Background: Although the provision of hospice emergency kits (HEKs) by home hospice agencies is thought to be widespread, little is known about their use, safety, and impact. Objective: This study evaluated HEK medication utilization, safety, diversion, and perceived impact. Design: Evaluation consisted of a retrospective patient chart abstraction and an anonymous questionnaire for home hospice nurses. Setting/subjects: Chart abstraction examined the computerized records of deceased veterans discharged to home hospice in 2009 (N = 76). The questionnaire was completed by 78 home hospice nurses from 16 agencies. Measurements: Chart abstraction examined HEK medication utilization, symptoms addressed, and safety / diversion concerns. The hospice nurse questionnaire assessed their perceptions of HEK utilization, safety, and impact, including efficacy for preventing emergency department (ED) visits and hospitalizations. Results: Of patients who received an HEK, its use was documented in 50% of cases. The most used items were morphine concentrate and antibiotics. Nurses estimated that the HEK was utilized in 66.3% of cases, with the most frequently used medications being morphine, lorazepam, promethazine, and haloperidol. Fifty-nine percent of nurses felt HEKs were helpful 100% of the time (mean = 84.2%; median = 100% of the time) and 93% felt that an emergency department (ED) visit or hospitalization was avoided by having the kit in the home. Eighteen percent believed that medications in the kit are used by someone other than the patient. Conclusions: HEKs have value as a means to alleviate many symptoms that emerge predictably in home hospice patients and may avoid unwanted hospitalizations and ED visits. C1 [Leigh, Alexandra E.] Birmingham VA Med Ctr, Birmingham, AL 35233 USA. [Burgio, Kathryn L.; Williams, Beverly R.; Kvale, Elizabeth; Bailey, F. Amos] Birmingham VA Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Birmingham, AL 35233 USA. [Burgio, Kathryn L.; Williams, Beverly R.; Kvale, Elizabeth; Bailey, F. Amos] Univ Alabama Birmingham, Birmingham, AL USA. RP Burgio, KL (reprint author), Birmingham VA Med Ctr, Geriatr Res Educ & Clin Ctr, 11G 700 South 19th St, Birmingham, AL 35233 USA. EM kburgio@uabmc.edu FU Birmingham/Atlanta Geriatric Research, Education, and Clinical Center (GRECC) FX This researh was supported by the Birmingham/Atlanta Geriatric Research, Education, and Clinical Center (GRECC). The authors thank Donna Hix, RN, the Hospice and Palliative Care Coordinator for the BVAMC, and Shanette Granstaff, MPH, for analytic support. NR 18 TC 2 Z9 2 U1 1 U2 4 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD APR PY 2013 VL 16 IS 4 BP 356 EP 361 DI 10.1089/jpm.2012.0304 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 116BJ UT WOS:000316857000009 PM 23445251 ER PT J AU Winter, L AF Winter, Laraine TI Patient Values and Preferences for End-of-Life Treatments: Are Values Better Predictors Than a Living Will? SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID ADVANCE DIRECTIVES; OLDER-ADULTS; DECISION-MAKING; CARE; VALIDATION; QUALITY; HISTORY; BURDEN; HEALTH AB Background: Advance care planning is widely considered important for good treatment decision making. Patient values have been proposed as superior to standard living wills as guides to end-of-life (EOL) care decisions on behalf of decisionally incapacitated patients. Little research has examined whether values outperform living wills as predictors of treatment preferences. Objective: The study aimed to test whether patient values are associated with treatment preferences, compare values and preferences to responses from a standard living will, and determine whether some values are better predictors than others. Design: Community-dwelling elderly men and women (n = 304) were interviewed in their homes by telephone. The interview consisted of an eight-item EOL values scale, a standard living will question, preferences for four life-prolonging treatments in each of six scenarios, and sociodemographic questions. Results: Principal components analysis of the EOL values revealed two factors: (1) dignity, pain management, and reluctance to burden others; and (2) religiosity and desire for longevity and following family wishes. In regression analyses, stronger preferences for life-prolonging treatments were correlated with higher scores on factor 1 and lower scores on factor 2. But when living will responses were also entered into the regression model, only religiosity, longevity, and following family wishes predicted treatment preferences independently of the living will responses. Conclusions: Providing better guidance than a living will in determining a patient's EOL treatment preferences are (1) knowledge about a patient's religiosity, (2) patient's wishes for longevity, and (3) patient's wishes for following family preferences. Wishes for dignity and pain management and reluctance to burden others do not offer better guidance than a living will. C1 Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Winter, L (reprint author), Philadelphia VA Med Ctr, 3800 Woodland Ave, Philadelphia, PA 19104 USA. EM Laraine.winter@gmail.com NR 34 TC 3 Z9 3 U1 6 U2 30 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD APR PY 2013 VL 16 IS 4 BP 362 EP 368 DI 10.1089/jpm.2012.0303 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 116BJ UT WOS:000316857000010 PM 23442042 ER PT J AU Dominguez, JR Shlipak, MG Whooley, MA Ix, JH AF Dominguez, Julie R. Shlipak, Michael G. Whooley, Mary A. Ix, Joachim H. TI Fractional Excretion of Phosphorus Modifies the Association between Fibroblast Growth Factor-23 and Outcomes SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID CHRONIC KIDNEY-DISEASE; GELATINASE-ASSOCIATED LIPOCALIN; INJURY MOLECULE-1 KIM-1; CORONARY-HEART-DISEASE; CARDIOVASCULAR EVENTS; CYSTATIN-C; ATHEROSCLEROSIS; COMMUNITY; KLOTHO; HEALTH AB Fibroblast growth factor-23 (FGF23) induces phosphaturia through its effects on renal tubules. Higher levels of FGF23 associate with cardiovascular disease (CVD) events and all-cause mortality, but it is unknown whether these associations differ by the degree of phosphaturia. Here, we measured serum FGF23 and 24-hour urine fractional excretion of phosphorus (FePi) in 872 outpatients with stable CVD and a mean estimated G FR of 71 ml/nnin per 1.73 m(2). During an average 7.5 years of follow-up, there were 337 deaths and 199 CVD events. Urinary Fe Pi significantly modified the association of FGF23 with each outcome (P interaction<0.001 for all-cause mortality and P P interaction<0.05 for CVD events). In models adjusted for CVD risk factors, kidney function, and PTH, those patients who had FGF23 above the median (>= 42.3 relative units [RU]/ml) but FePi below the median (<15.7%) had the highest risks of both all-cause mortality (HR=1.98, 95% CI=1.42-2.77) and CVD events (HR=1.92, 95% CI=1.25-2.94) compared with those patients who had low concentrations of FGF23 and low FePi. In summary, associations of FGF23 with mortality and CVD events are stronger in persons with lower FePi independent of PTH and kidney function. In such individuals, the renal tubular response to FGF23 may be suboptimal. J Am Soc Nephrol 24: 647-654, 2013. doi: 10.1681/ASN.2012090894 C1 [Dominguez, Julie R.; Ix, Joachim H.] Univ Calif San Diego, Dept Med, Div Nephrol & Hypertens, San Diego, CA 92161 USA. [Ix, Joachim H.] Univ Calif San Diego, Dept Family & Prevent Med, Div Prevent Med, San Diego, CA 92161 USA. [Dominguez, Julie R.; Ix, Joachim H.] Vet Affairs San Diego Healthcare Syst, Nephrol Sect, San Diego, CA USA. [Shlipak, Michael G.; Whooley, Mary A.] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. [Shlipak, Michael G.; Whooley, Mary A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Shlipak, Michael G.; Whooley, Mary A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Ix, JH (reprint author), Univ Calif San Diego, Dept Med, Div Nephrol & Hypertens, 3350 La Jolla Village Dr,Mail Code 111-H, San Diego, CA 92161 USA. EM joeix@ucsd.edu FU National Heart, Lung, and Blood Institute Training Grant [T32 HL007261]; National Heart, Lung, and Blood Institute [R01HL096851]; Department of Veterans Epidemiology Merit Review Program; Department of Veterans Affairs Health Services Research and Development Service, National Heart, Lung, and Blood Institute [R01 HL079235]; National Heart, Lung, and Blood Institute; American Federation for Aging Research (Paul Beeson Scholars Program); Robert Wood Johnson Foundation (Generalist Physician Faculty Scholars Program); Ischemia Research and Education Foundation; American Heart Association; Sandra A. Daugherty Foundation; Veterans Affairs San Diego Healthcare System FX J.R.D. was supported by National Heart, Lung, and Blood Institute Training Grant T32 HL007261. J.H.I. was supported by National Heart, Lung, and Blood Institute Grant R01HL096851. The Heart and Soul Study was supported by the Department of Veterans Epidemiology Merit Review Program, the Department of Veterans Affairs Health Services Research and Development Service, National Heart, Lung, and Blood Institute Grant R01 HL079235, the American Federation for Aging Research (Paul Beeson Scholars Program), the Robert Wood Johnson Foundation (Generalist Physician Faculty Scholars Program), and the Ischemia Research and Education Foundation. This ancillary study was supported by the American Heart Association and the National Heart, Lung, and Blood Institute. Fibroblast growth factor-23 and urine measurements were supported by grants from the American Heart Association and the Sandra A. Daugherty Foundation. This material is the result of work supported with resources of the Veterans Affairs San Diego Healthcare System. NR 31 TC 40 Z9 40 U1 0 U2 5 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD APR PY 2013 VL 24 IS 4 BP 647 EP 654 DI 10.1681/ASN.2012090894 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 116ZK UT WOS:000316921700016 PM 23520205 ER PT J AU Baruch, L Sherman, O AF Baruch, Lawrence Sherman, Olga TI Utilization of laboratory testing to optimize dabigatran dosing in 5 octogenarians: Focus on the 75-mg BID dose SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS LA English DT Meeting Abstract C1 [Baruch, Lawrence; Sherman, Olga] James J Peters VA Med Ctr, Bronx, NY USA. [Baruch, Lawrence] Mt Sinai Sch Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0929-5305 J9 J THROMB THROMBOLYS JI J. Thromb. Thrombolysis PD APR PY 2013 VL 35 IS 3 SI SI BP 404 EP 405 PG 2 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 115OQ UT WOS:000316822100032 ER PT J AU Mallipattu, SK Liu, RJ Zhong, YF Chen, EY D'Agati, V Kaufman, L Ma'ayan, A Klotman, PE Chuang, PY He, JC AF Mallipattu, Sandeep K. Liu, Ruijie Zhong, Yifei Chen, Ed Y. D'Agati, Vivette Kaufman, Lewis Ma'ayan, Avi Klotman, Paul E. Chuang, Peter Y. He, John C. TI Expression of HIV transgene aggravates kidney injury in diabetic mice SO KIDNEY INTERNATIONAL LA English DT Article DE diabetic nephropathy; glomerulopathy; HIV ID ACQUIRED IMMUNODEFICIENCY SYNDROME; HIV-1-ASSOCIATED NEPHROPATHY; INFECTED PATIENTS; RENAL-DISEASE; MOUSE KIDNEY; GLOMERULOSCLEROSIS; GENES; PODOCYTES; PROTEIN; BIOPSY AB With the widespread use of combination antiretroviral agents, the incidence of HIV-associated nephropathy has decreased. Currently, HIV-infected patients live much longer and often suffer from comorbidities such as diabetes mellitus. Recent epidemiological studies suggest that concurrent HIV infection and diabetes mellitus may have a synergistic effect on the incidence of chronic kidney disease. To address this, we determined whether HIV-1 transgene expression accelerates diabetic kidney injury using a diabetic HIV-1 transgenic (Tg26) murine model. Diabetes was initially induced with low-dose streptozotocin in both Tg26 and wildtype mice on a C57BL/6 background, which is resistant to classic HIV-associated nephropathy. Although diabetic nephropathy is minimally observed on the C57BL/6 background, diabetic Tg26 mice exhibited a significant increase in glomerular injury compared with nondiabetic Tg26 mice and diabetic wild-type mice. Validation of microarray gene expression analysis from isolated glomeruli showed a significant upregulation of proinflammatory pathways in diabetic Tg26 mice. Thus, our study found that expression of HIV-1 genes aggravates diabetic kidney disease. Kidney International (2013) 83, 626-634; doi:10.1038/ki.2012.445; published online 16 January 2013 C1 [Mallipattu, Sandeep K.; Liu, Ruijie; Kaufman, Lewis; Chuang, Peter Y.; He, John C.] Mt Sinai Sch Med, Dept Med, Div Nephrol, New York, NY 10029 USA. [Liu, Ruijie; He, John C.] James J Peters VA Med Ctr, Renal Sect, New York, NY USA. [Zhong, Yifei] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Dept Nephrol, Shanghai, Peoples R China. [Chen, Ed Y.; Ma'ayan, Avi; He, John C.] Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA. [D'Agati, Vivette] Columbia Univ, Dept Pathol, New York, NY USA. [Klotman, Paul E.] Baylor Coll Med, Houston, TX 77030 USA. RP He, JC (reprint author), Mt Sinai Sch Med, Dept Med Nephrol, 1 Gustave L Levy Pl,Box 1243, New York, NY 10029 USA. EM cijiang.he@mssm.edu RI Mallipattu , Sandeep/M-7009-2014 FU NIH/NIDDK [1R01DK078897-01, 2012CB517601, P01DK056492, 5K08DK082760, T32 DK07757-12, 1F32 DK094635-01] FX We thank Dr A Gharavi for use of the backcrossed Tg26 mice. This work was supported by funds from the NIH/NIDDK (1R01DK078897-01 and 973 fund 2012CB517601 to JCH, P01DK056492 to PEK and JCH, 5K08DK082760 to PYC, and T32 DK07757-12 and 1F32 DK094635-01 to SKM). NR 41 TC 19 Z9 19 U1 1 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD APR PY 2013 VL 83 IS 4 BP 626 EP 634 DI 10.1038/ki.2012.445 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 117HY UT WOS:000316945400014 PM 23325078 ER PT J AU Bonawitz, SC Duvvuri, U AF Bonawitz, Steven C. Duvvuri, Umamaheswar TI Robotic-assisted FAMM flap for soft palate reconstruction SO LARYNGOSCOPE LA English DT Article DE FAMM flap; robotic; oropharyngeal ID ARTERY MUSCULOMUCOSAL FLAP; NECK-CANCER; SURGERY TORS; HEAD; DEFECTS AB Objectives/Hypothoses: TORS (Trans Oral Robotic Surgery) has been demonstrated to be an acceptable alternative to chemoradiation for the treatment of early stage malignant lesions of the oropharynx, with equivalent tumor control and enhanced functional outcomes. Surgical ablation of tumors of the oropharynx under conditions of limited access, however, creates the need to adapt the robotic platform to surgical reconstruction and to assess reconstructive outcomes. We present our experience with the Facial Artery Musculomucosal (FAMM) flap with robotic assistance for the reconstruction of defects of the soft palate. Methods: We reviewed the records of five patients who underwent combined robot-assisted resection of malignant lesions of the oropharynx with immediate reconstruction. The reconstructions included four ispilateral and one bilateral FAMM flaps. Patients were assessed for complications and functional results. Results: Successful closure of the defect was achieved in all five patients. There were no major complications; however, three patients developed minor wound dehiscence and two were revised at the time of planned subsequent lymphadenectomy. All five patients achieved a good functional outcome. Conclusions: The FAMM flap is reliable and easy to raise and transfer, with the surgical robot making it a good candidate for reconstruction of moderate-sized defects created by TORS applied to malignancies of the soft palate. Minor wound dehiscence is not infrequent, but reconstructive outcomes are nevertheless good. A unilateral FAMM flap will reach to the contralateral border of the uvula and is best limited to defects with a width of 2 cm or less. C1 [Bonawitz, Steven C.] Johns Hopkins Univ, Sch Med, Dept Plast & Reconstruct Surg, Baltimore, MD USA. [Duvvuri, Umamaheswar] Univ Pittsburgh, Med Ctr, Vet Affairs Pittsburgh Hlth Syst, Dept Otolaryngol,Eye & Ear Inst, Pittsburgh, PA 15213 USA. RP Duvvuri, U (reprint author), Univ Pittsburgh, Med Ctr, Dept Head & Neck Surg, Inst Eye & Ear, Suite 500,200 Lothrop St, Pittsburgh, PA 15213 USA. EM duvvuriu@upmc.edu NR 17 TC 8 Z9 8 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD APR PY 2013 VL 123 IS 4 BP 870 EP 874 DI 10.1002/lary.23578 PG 5 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 115KZ UT WOS:000316812400012 PM 23529879 ER PT J AU Dalal, SR Shekelle, PG Hempel, S Newberry, SJ Motala, A Shetty, KD AF Dalal, Siddhartha R. Shekelle, Paul G. Hempel, Susanne Newberry, Sydne J. Motala, Aneesa Shetty, Kanaka D. TI A Pilot Study Using Machine Learning and Domain Knowledge to Facilitate Comparative Effectiveness Review Updating SO MEDICAL DECISION MAKING LA English DT Review DE machine learning; comparative effectiveness reviews; text classification ID SYSTEMATIC REVIEWS; TEXT CATEGORIZATION; CONTROLLED-TRIAL; CONCEPT DRIFT; DOUBLE-BLIND; OSTEOPOROSIS; OLANZAPINE; REGRESSION; MODELS AB Background. Comparative effectiveness and systematic reviews require frequent and time-consuming updating. Results of earlier screening should be useful in reducing the effort needed to screen relevant articles. Methods. We collected 16,707 PubMed citation classification decisions from 2 comparative effectiveness reviews: interventions to prevent fractures in low bone density (LBD) and off-label uses of atypical antipsychotic drugs (AAP). We used previously written search strategies to guide extraction of a limited number of explanatory variables pertaining to the intervention, outcome, and study design. We empirically derived statistical models (based on a sparse generalized linear model with convex penalties [GLMnet] and a gradient boosting machine [GBM]) that predicted article relevance. We evaluated model sensitivity, positive predictive value (PPV), and screening workload reductions using 11,003 PubMed citations retrieved for the LBD and AAP updates. Results. GLMnet-based models performed slightly better than GBM-based models. When attempting to maximize sensitivity for all relevant articles, GLMnet-based models achieved high sensitivities (0.99 and 1.0 for AAP and LBD, respectively) while reducing projected screening by 55.4% and 63.2%. The GLMnet-based model yielded sensitivities of 0.921 and 0.905 and PPVs of 0.185 and 0.102 when predicting articles relevant to the AAP and LBD efficacy/effectiveness analyses, respectively (using a threshold of P >= 0.02). GLMnet performed better when identifying adverse effect relevant articles for the AAP review (sensitivity = 0.981) than for the LBD review (0.685). The system currently requires MEDLINE-indexed articles. Conclusions. We evaluated statistical classifiers that used previous classification decisions and explanatory variables derived from MEDLINE indexing terms to predict inclusion decisions. This pilot system reduced workload associated with screening 2 simulated comparative effectiveness review updates by more than 50% with minimal loss of relevant articles. C1 [Dalal, Siddhartha R.; Shekelle, Paul G.; Hempel, Susanne; Newberry, Sydne J.; Motala, Aneesa; Shetty, Kanaka D.] RAND Corp, Southern Calif Evidence Based Practice Ctr, Santa Monica, CA 90401 USA. [Shekelle, Paul G.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. RP Dalal, SR (reprint author), RAND Corp, 1776 Main St, Santa Monica, CA 90401 USA. EM sdalal@rand.org FU RAND Corporation; Agency for Healthcare Research and Quality [290-2007-10062-I] FX Received 21 March 2012 from Southern California Evidence-based Practice Center, RAND Corporation, Santa Monica, CA (SRD, PGS, SH, SJN, AM, KDS); and the Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, CA (PGS). This work was largely produced under Agency for Healthcare Research and Quality Contract No. 290-2007-10062-I. The funding agreement ensured the authors' independence in designing the study, interpreting the data, and writing and publishing the report. This work was also funded by an internal grant from the RAND Corporation. The RAND Corporation played no role in the design or conduct of the study. Revision accepted for publication 29 May 2012. NR 40 TC 5 Z9 5 U1 1 U2 9 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0272-989X J9 MED DECIS MAKING JI Med. Decis. Mak. PD APR PY 2013 VL 33 IS 3 SI SI BP 343 EP 355 DI 10.1177/0272989X12457243 PG 13 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA 113RH UT WOS:000316685000006 PM 22961102 ER PT J AU Gellhorn, AC Katz, JN Suri, P AF Gellhorn, Alfred C. Katz, Jeffrey N. Suri, Pradeep TI Osteoarthritis of the spine: the facet joints SO NATURE REVIEWS RHEUMATOLOGY LA English DT Review ID LOW-BACK-PAIN; BONE-MARROW LESIONS; LUMBAR ZYGAPOPHYSEAL JOINTS; COMMUNITY-BASED POPULATION; CERVICAL-SPINE; DISC DEGENERATION; LONGITUDINAL ASSESSMENT; KNEE OSTEOARTHRITIS; CLINICAL-FEATURES; PREVALENCE AB Osteoarthritis (OA) of the spine involves the facet joints, which are located in the posterior aspect of the vertebral column and, in humans, are the only true synovial joints between adjacent spinal levels. Facet joint osteoarthritis (FJ OA) is widely prevalent in older adults, and is thought to be a common cause of back and neck pain. The prevalence of facet-mediated pain in clinical populations increases with increasing age, suggesting that FJ OA might have a particularly important role in older adults with spinal pain. Nevertheless, to date FJ OA has received far less study than other important OA phenotypes such as knee OA, and other features of spine pathoanatomy such as degenerative disc disease. This Review presents the current state of knowledge of FJ OA, including relevant anatomy, biomechanics, epidemiology, and clinical manifestations. We present the view that the modern concept of FJ OA is consonant with the concept of OA as a failure of the whole joint, and not simply of facet joint cartilage. Gellhorn, A. C. et al. Nat. Rev. Rheumatol. 9, 216-224 (2013); published online 13 November 2012; doi:10.1038/nrrheum.2012.199 C1 [Gellhorn, Alfred C.] Univ Washington, Dept Rehabil Med, Med Ctr, Seattle, WA 98105 USA. [Katz, Jeffrey N.] Harvard Univ, Dept Orthoped Surg, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Suri, Pradeep] VA Puget Sound Healthcare Syst, Div Rehabil Care Serv, Seattle, WA 98108 USA. RP Suri, P (reprint author), VA Puget Sound Healthcare Syst, Div Rehabil Care Serv, 1660 S Columbian Way, Seattle, WA 98108 USA. EM pradeep.suri@va.gov FU NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases [P60 AR 47782] FX J. N. Katz's work is supported in part by a grant (P60 AR 47782) from the NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases. NR 97 TC 36 Z9 38 U1 6 U2 43 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-4790 J9 NAT REV RHEUMATOL JI Nat. Rev. Rheumatol. PD APR PY 2013 VL 9 IS 4 BP 216 EP 224 DI 10.1038/nrrheum.2012.199 PG 9 WC Rheumatology SC Rheumatology GA 117KR UT WOS:000316952600005 PM 23147891 ER PT J AU Morasco, BJ Lovejoy, TI Lu, M Turk, DC Lewis, L Dobscha, SK AF Morasco, Benjamin J. Lovejoy, Travis I. Lu, Mary Turk, Dennis C. Lewis, Lynsey Dobscha, Steven K. TI The relationship between PTSD and chronic pain: Mediating role of coping strategies and depression SO PAIN LA English DT Article DE Chronic pain; Chronic pain coping inventory; Coping strategies; Mediation; Posttraumatic stress disorder; Quality of life ID POSTTRAUMATIC-STRESS-DISORDER; COMORBID CHRONIC PAIN; MUTUAL MAINTENANCE; FIT INDEXES; BACK-PAIN; VETERANS; SYMPTOMS; INVENTORY; BELIEFS; MODELS AB People with chronic pain and comorbid posttraumatic stress disorder (PTSD) report more severe pain and poorer quality of life than those with chronic pain alone. This study evaluated the extent to which associations between PTSD and chronic pain interference and severity are mediated by pain-related coping strategies and depressive symptoms. Veterans with chronic pain were divided into 2 groups, those with (n = 65) and those without (n = 136) concurrent PTSD. All participants completed measures of pain severity, interference, emotional functioning, and coping strategies. Those with current PTSD reported significantly greater pain severity and pain interference, had more symptoms of depression, and were more likely to meet diagnostic criteria for a current alcohol or substance use disorder (all p-values <.01). Participants with PTSD reported more use of several coping strategies, including guarding, resting, relaxation, exercise/stretching, and coping self-statements. Illness-focused pain coping (i.e., guarding, resting, and asking for assistance) and depressive symptoms jointly mediated the relationship between PTSD and both pain interference (total indirect effect = 0.194, p < .001) and pain severity (total indirect effect = 0.153, p = .004). Illness-focused pain coping also evidenced specific mediating effects, independent of depression. In summary, specific pain coping strategies and depressive symptoms partially mediated the relationship between PTSD and both pain interference and severity. Future research should examine whether changes in types of coping strategies after targeted treatments predict improvements in pain-related function for chronic pain patients with concurrent PTSD. Published by Elsevier B.V. on behalf of International Association for the Study of Pain. C1 [Morasco, Benjamin J.; Lovejoy, Travis I.; Lu, Mary; Dobscha, Steven K.] Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR USA. [Morasco, Benjamin J.; Lu, Mary; Lewis, Lynsey; Dobscha, Steven K.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Morasco, Benjamin J.; Lu, Mary; Dobscha, Steven K.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Med & Psychiat, Portland, OR USA. [Turk, Dennis C.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA. RP Morasco, BJ (reprint author), Portland VA Med Ctr R&D99, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM benjamin.morasco@va.gov FU National Institute on Drug Abuse [K23DA023467]; Endo; Johnson Johnson; Philips Respironics; National Institutes of Health; Eli Lilly; Empi; Pfizer; SK Life Science FX This study was supported in part by award K23DA023467 from the National Institute on Drug Abuse to Dr. Morasco. The work was supported with resources and the use of facilities at the Portland VA Medical Center. During the past 12 months, Dr. Turk has received research support from Endo, Johnson & Johnson, Philips Respironics, and the National Institutes of Health, and consulting fees from Eli Lilly, Empi, Johnson & Johnson, Pfizer, Philips Respironics, and SK Life Science. He is also a Special Government Employee of the US Food and Drug Administration. No other author reports having any potential conflict of interest with this study. The authors appreciate the assistance of Susan Gritzner, Renee Cavanagh, and Aysha Crain with data collection, and Jonathan Duckart, MPS, for extracting data from the electronic medical record. NR 55 TC 15 Z9 15 U1 2 U2 34 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-3959 J9 PAIN JI Pain PD APR PY 2013 VL 154 IS 4 BP 609 EP 616 DI 10.1016/j.pain.2013.01.001 PG 8 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA 113HW UT WOS:000316658200013 PM 23398939 ER PT J AU Smucny, J Rojas, DC Eichman, LC Tregellas, JR AF Smucny, Jason Rojas, Donald C. Eichman, Lindsay C. Tregellas, Jason R. TI Neural Effects of Auditory Distraction on Visual Attention in Schizophrenia SO PLOS ONE LA English DT Article ID FUSIFORM FACE AREA; DORSOLATERAL PREFRONTAL CORTEX; WORD FORM AREA; BOTTOM-UP; HEMODYNAMIC-RESPONSE; NEURONAL MECHANISMS; NEGATIVE SYMPTOMS; ODDBALL TASK; FMRI; MEMORY AB Sensory flooding, particularly during auditory stimulation, is a common problem for patients with schizophrenia. The functional consequences of this impairment during cross-modal attention tasks, however, are unclear. The purpose of this study was to examine how auditory distraction differentially affects task-associated response during visual attention in patients and healthy controls. To that end, 21 outpatients with schizophrenia and 23 healthy comparison subjects performed a visual attention task in the presence or absence of distracting, environmentally relevant "urban'' noise while undergoing functional magnetic resonance imaging at 3T. The task had two conditions (difficult and easy); task-related neural activity was defined as difficult - easy. During task performance, a significant distraction (noise or silence) by group (patient or control) interaction was observed in the left dorsolateral prefrontal cortex, right hippocampus, left temporoparietal junction, and right fusiform gyrus, with patients showing relative hypoactivation during noise compared to controls. In patients, the ability to recruit the dorsolateral prefrontal cortex during the task in noise was negatively correlated with the effect of noise on reaction time. Clinically, the ability to recruit the fusiform gyrus during the task in noise was negatively correlated with SANS affective flattening score, and hippocampal recruitment during the task in noise was positively correlated with global functioning. In conclusion, schizophrenia may be associated with abnormalities in neural response during visual attention tasks in the presence of cross-modal noise distraction. These response differences may predict global functioning in the illness, and may serve as a biomarker for therapeutic development. C1 [Smucny, Jason; Rojas, Donald C.; Tregellas, Jason R.] Univ Colorado, Neurosci Program, Aurora, CO 80045 USA. [Smucny, Jason; Rojas, Donald C.; Eichman, Lindsay C.; Tregellas, Jason R.] Univ Colorado, Dept Psychiat, Aurora, CO USA. [Rojas, Donald C.; Eichman, Lindsay C.; Tregellas, Jason R.] Denver VA Med Ctr, Res Serv, Denver, CO USA. RP Tregellas, JR (reprint author), Univ Colorado, Neurosci Program, Anschutz Med Campus, Aurora, CO 80045 USA. EM Jason.Tregellas@ucdenver.edu RI Tregellas, Jason/J-3637-2015 OI Rojas, Don/0000-0001-6560-9616; Smucny, Jason/0000-0001-5656-7987 FU National Institute of Mental Health [MH-061412]; NIMH [MH-086383]; Brain & Behavior Research Foundation; United States Department of Veterans Affairs; Blowitz-Ridgeway Foundation FX Funding came from National Institute of Mental Health Grant MH-061412 (http://www.nimh.nih.gov/index.shtml); NIMH Grant MH-086383; National Alliance for Research on Schizophrenia and Depression, now Brain & Behavior Research Foundation (No Grant Number) (bbrfoundation.org); United States Department of Veterans Affairs (No Grant Number) (www.va.gov); and Blowitz-Ridgeway Foundation (No Grant Number) (http://www.blowitzridgeway.org/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 66 TC 3 Z9 3 U1 3 U2 15 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 1 PY 2013 VL 8 IS 4 AR e60606 DI 10.1371/journal.pone.0060606 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 117CY UT WOS:000316930900071 PM 23560100 ER PT J AU Albert, RK Connett, J Bailey, WC Casaburi, R Cooper, JAD Criner, GJ Curtis, JL Dransfield, MT Han, MK Lazarus, SC Make, B Marchetti, N Martinez, FJ Madinger, NE Mcevoy, C Niewoehner, DE Porsasz, J Price, CS Reilly, J Scanlon, PD Sciurba, FC Scharf, SM Washko, GR Woodruff, PG Anthonisen, NR AF Albert, R. K. Connett, J. Bailey, W. C. Casaburi, R. Cooper, J. A. D., Jr. Criner, G. J. Curtis, J. L. Dransfield, M. T. Han, M. K. Lazarus, S. C. Make, B. Marchetti, N. Martinez, F. J. Madinger, N. E. Mcevoy, C. Niewoehner, D. E. Porsasz, J. Price, C. S. Reilly, J. Scanlon, P. D. Sciurba, F. C. Scharf, S. M. Washko, G. R. Woodruff, P. G. Anthonisen, N. R. CA COPD Clinical Res Network TI LONG-TERM AZITHROMYCIN DECREASES COPD EXACERBATIONS SO RESPIROLOGY LA English DT Meeting Abstract C1 [Albert, R. K.; Price, C. S.] Denver Hlth, Med Serv, Denver, CO USA. [Albert, R. K.; Price, C. S.] Univ Colorado Denver, Dept Med, Denver, CO USA. [Connett, J.] Univ Minnesota, Div Biostat, Sch Publ Hlth, Minneapolis, MN 55455 USA. [Bailey, W. C.] Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, Dept Med, Birmingham, AL USA. [Casaburi, R.; Porsasz, J.] Harbor UCLA Med Ctr, Dept Med, Div Resp & Crit Care Physiol & Med, Torrance, CA 90509 USA. [Cooper, J. A. D., Jr.; Dransfield, M. T.] Birmingham VA Med Ctr, Pulm Sect, Birmingham, AL USA. [Criner, G. J.; Marchetti, N.] Temple Univ, Div Pulm & Crit Care Med, Dept Med, Philadelphia, PA 19122 USA. [Curtis, J. L.; Martinez, F. J.] Ann Arbor VA Med Ctr, Div Pulm & Crit Care Med, Ann Arbor, MI USA. [Han, M. K.] Univ Michigan, Dept Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA. [Lazarus, S. C.; Woodruff, P. G.] Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care Med, San Francisco, CA USA. [Lazarus, S. C.; Woodruff, P. G.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA. [Make, B.] Natl Jewish Hlth, Div Pulm Med, Denver, CO USA. [Madinger, N. E.] Univ Colorado Denver, Dept Med, Div Infect Dis, Denver, CO USA. [Mcevoy, C.] HealthPartners Res Fdn, Pulm Crit Care & Sleep Dept, St Paul, MN USA. [Niewoehner, D. E.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA. [Niewoehner, D. E.] Minneapolis Vet Affairs VA Med Ctr, Med Serv, Div Pulm Med, Minneapolis, MN USA. [Reilly, J.; Washko, G. R.] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA. [Scanlon, P. D.] Mayo Clin, Div Pulm & Crit Care Med, Rochester, MN USA. [Sciurba, F. C.] Univ Pittsburgh, Div Pulm & Crit Care Med, Dept Med, Pittsburgh, PA 15260 USA. [Scharf, S. M.] Univ Maryland, Dept Med, Div Pulm & Crit Care, Baltimore, MD 21201 USA. [Anthonisen, N. R.] Resp Hosp, Winnipeg, MB, Canada. NR 0 TC 0 Z9 0 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1323-7799 J9 RESPIROLOGY JI Respirology PD APR PY 2013 VL 18 SU 1 SI SI BP 5 EP 5 PG 1 WC Respiratory System SC Respiratory System GA 114RO UT WOS:000316760200011 ER PT J AU Malhotra, A Younes, M Kuna, ST Benca, R Kushida, CA Walsh, J Hanlon, A Staley, B Pack, AI Pien, GW AF Malhotra, Atul Younes, Magdy Kuna, Samuel T. Benca, Ruth Kushida, Clete A. Walsh, James Hanlon, Alexandra Staley, Bethany Pack, Allan I. Pien, Grace W. TI Performance of an Automated Polysomnography Scoring System Versus Computer-Assisted Manual Scoring SO SLEEP LA English DT Article DE apnea-hypopnea index; lung; polysomnography; reliability; scoring; sleep ID SLEEP CLASSIFICATION; SIESTA DATABASE; SOMNOLYZER 24X7; VARIABILITY; RELIABILITY; RECORDINGS; ADULTS; DISORDERS; AGREEMENT; INSOMNIA AB Study Objectives: Manual scoring of polysomnograms (PSG) is labor intensive and has considerable variance between scorers. Automation of scoring could reduce cost and improve reproducibility. The purpose of this study was to compare a new automated scoring system (YST-Limited, Winnipeg, Canada) with computer-assisted manual scoring. Design: Technical assessment. Setting: Five academic medical centers. Participants: N/A. Interventions: N/A. Measurements and Results: Seventy PSG files were selected at University of Pennsylvania (Penn) and distributed to five US academic sleep centers. Two blinded technologists from each center scored each file. Automatic scoring was performed at Penn by a YST Limited technician using a laptop containing the software. Variables examined were sleep stages, arousals, and apnea-hypopnea index (AHI) using three methods of identifying hypopneas. Automatic scores were not edited and were compared to the average scores of the 10 technologists. Intraclass correlation coefficient (ICC) was obtained for the 70 pairs and compared to across-sites ICCs for manually scored results. ICCs for automatic versus manual scoring were > 0.8 for total sleep time, stage N2, and nonrapid eye movement arousals and > 0.9 for AHI scored by primary and secondary American Academy of Sleep Medicine criteria. ICCs for other variables were not as high but were comparable to the across-site ICCs for manually scored results. Conclusion: The automatic system yielded results that were similar to those obtained by experienced technologists. Very good ICCs were obtained for many primary PSG outcome measures. This automated scoring software, particularly if supplemented with manual editing, may increase laboratory efficiency and standardize PSG scoring results within and across sleep centers. C1 [Malhotra, Atul] Harvard Univ, Dept Med, Boston, MA 02115 USA. [Younes, Magdy] Univ Manitoba, Dept Med, Winnipeg, MB, Canada. [Kuna, Samuel T.; Hanlon, Alexandra; Staley, Bethany; Pack, Allan I.; Pien, Grace W.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Kuna, Samuel T.; Hanlon, Alexandra; Staley, Bethany; Pack, Allan I.; Pien, Grace W.] Univ Penn, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA. [Kuna, Samuel T.] Philadelphia VA Med Ctr, Dept Med, Philadelphia, PA USA. [Benca, Ruth] Univ Wisconsin, Dept Med, Madison, WI USA. [Kushida, Clete A.] Stanford Univ, Dept Psychiat, Palo Alto, CA 94304 USA. [Walsh, James] St Lukes Hosp, Sleep Med & Res Ctr, Chesterfield, MO USA. RP Malhotra, A (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. EM amalhotra1@partners.org FU NIH [R01 HL085695]; Academic Alliance for Sleep Research (Philips-Respironics Foundation); Philips Respironics Foundation; Philips Respironics; SHC; SGS; Apnex Medical; Pfizer; Apnicure; Merck; Sanofi-Aventis; NovoNordisk; Vanda; Ventus; ResMed; Pacific Medico; Cephalon; Ventus Medical; Jazz Pharmaceuticals; Apnex; Philips-Respironics FX Scorers at the University of Pennsylvania: Haideliza Soto-Calderon, Mary Jones-Parker, RPSGT; scorers at Harvard University: Mary MacDonald, RPSGT, Pam DeYoung, RPSGT; scorers at the University of Wisconsin at Madison: Jennifer Noe, RPSGT, Rebecca Weise, RPSGT; scorers at Stanford University: Martin Ukockis, RPSGT; scorers at St. Luke's Hospital: Hilary Simon, RPSGT, Laura Rahubka, RPSGT. Eileen O'Leary, RPSGT coordinated activity at Stanford University and assisted in data export at the sites using Alice software. Sources of support: NIH R01 HL085695; Academic Alliance for Sleep Research (Philips-Respironics Foundation); This study was funded in part by the Philips Respironics Foundation. Dr. Malhotra had previously received (prior to May 2012) consulting and/or research income from Philips Respironics, SHC, SGS, Apnex Medical, Pfizer and Apnicure. Dr. Kuna receives grant support from Philips-Respironics. Dr. Benca has received consulting income from Merck and Sanofi-Aventis. Dr. Walsh has received research support from Apnex, NovoNordisk, Merck, Phillips-Respironics, Vanda, and Ventus. Dr. Younes is the owner of YRT a research and development company. Dr. Kushida receives research support from ResMed, Pacific Medico, Merck, Cephalon, Ventus Medical, and Jazz Pharmaceuticals. He receives royalties from Philips-Respironics. The other authors have indicated no financial conflicts of interest. NR 26 TC 20 Z9 20 U1 2 U2 14 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD APR 1 PY 2013 VL 36 IS 4 BP 573 EP 582 DI 10.5665/sleep.2548 PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 117FN UT WOS:000316939000017 PM 23565003 ER PT J AU Kuna, ST Benca, R Kushida, CA Walsh, J Younes, M Staley, B Hanlon, A Pack, AI Pien, GW Malhotra, A AF Kuna, Samuel T. Benca, Ruth Kushida, Clete A. Walsh, James Younes, Magdy Staley, Bethany Hanlon, Alexandra Pack, Allan I. Pien, Grace W. Malhotra, Atul TI Agreement in Computer-Assisted Manual Scoring of Polysomnograms across Sleep Centers SO SLEEP LA English DT Article DE Apnea-hypopnea index; polysomnography; reliability; scoring ID APNEA-HYPOPNEA INDEX; VARIABILITY; RELIABILITY; AROUSAL; RECOMMENDATIONS; RECORDINGS; DISORDERS; IMPACT AB Study Objectives: To determine intersite agreement in respiratory event scoring of polysomnograms (PSGs) using different hypopnea definitions. Design: Technical assessment. Setting: Five academic medical centers. Participants: N/A. Interventions: N/A. Measurements and Results: Seventy good-quality PSGs performed in middle-aged women were manually scored by two experienced technologists at each of the five sleep centers using the particular laboratory's own software system. Studies were scored once by each scorer using American Academy of Sleep Medicine (AASM) standards for scoring sleep stages, arousals, and apneas. Hypopneas were then scored using three different AASM criteria: recommended, alternate, and research (Chicago). Means of each PSG variable for the scorers at each site were used to calculate an across-site intraclass correlation coefficient (ICC). Average AHI across the 10 scorers was 7.4 +/- 12.3 (standard deviation) events/h using recommended criteria (ICC 0.984; 95% confidence interval [CI] 0.977-0.990), 12.1 +/- 13.3 events/h using alternate criteria (ICC 0.947; 95% CI 0.889-0.972), and 15.1 +/- 13.9 events/h with Chicago criteria (ICC 0.800; 95% CI 0.768-0.828). ICC across sites was 0.870 (95% CI = 0.847-0.889) for total sleep time, 0.861 (95% CI 0.837-0.881) for number of obstructive apneas and 0.683 (95% CI 0.640-0.722) for number of central apneas. ICCs across sites for hypopneas were very good using recommended criteria (ICC 0.843; 95% CI 0.820-0.870) but decreased when alternate criteria (ICC 0.728; 95% CI 0.689-0.763) and Chicago criteria (ICC 0.535; 95% CI 0.485-0.583) were used. Conclusion: Experienced scorers at different laboratories have very good agreement in hypopnea and AHI results when good-quality PSGs are scored using AASM-recommended criteria. Substantial degradation of reliability was observed for alternative definitions of hypopneas, particularly that proposed for research. C1 [Kuna, Samuel T.; Staley, Bethany; Hanlon, Alexandra; Pack, Allan I.; Pien, Grace W.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Kuna, Samuel T.; Staley, Bethany; Hanlon, Alexandra; Pack, Allan I.; Pien, Grace W.] Univ Penn, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA. [Kuna, Samuel T.] Philadelphia VA Med Ctr, Dept Med, Philadelphia, PA 19104 USA. [Benca, Ruth] Univ Wisconsin, Dept Med, Madison, WI USA. [Kushida, Clete A.] Stanford Univ, Dept Psychiat, Palo Alto, CA 94304 USA. [Walsh, James] St Lukes Hosp, Sleep Med & Res Ctr, Chesterfield, MO USA. [Younes, Magdy] Univ Manitoba, Dept Med, Winnipeg, MB, Canada. [Malhotra, Atul] Harvard Univ, Dept Med, Boston, MA 02115 USA. RP Kuna, ST (reprint author), Philadelphia VA Med Ctr, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM skuna@mail.med.upenn.edu FU NIH [R01 HL085695, 1PO1-1HL094307]; Academic Alliance for Sleep Research (Philips-Respironics Foundation); Philips-Respironics; Merck; Sanofi-Aventis; Philips Respironics; SHC; SGS; Apnex Medical; Pfizer; Apnicure; ResMed; Pacific Medico; Cephalon; Ventus Medical; Jazz Pharmaceuticals; Apnex; NovoNordisk; Vanda; Ventus FX Scorers at the University of Pennsylvania: Haideliza Soto-Calderon, Mary Jones-Parker, RPSGT; scorers at Harvard University: Mary MacDonald, RPSGT, Pam DeYoung, RPSGT; scorers at the University of Wisconsin at Madison: Jennifer Noe, RPSGT, Rebecca Weise, RPSGT; scorers at Stanford University: Martin Ukockis, RPSGT, Julianne Blythe; scorers at St. Luke's Hospital: Hilary Field, RPSGT, Laura Rahubka, RPSGT. Eileen O'Leary, RPSGT coordinated activity at Stanford University and assisted in data export at the sites using Alice software. Sources of support: NIH R01 HL085695; NIH 1PO1-1HL094307; Academic Alliance for Sleep Research (Philips-Respironics Foundation).; This was not an industry supported study. Dr. Kuna receives grant support from Philips-Respironics. Dr. Benca has received consulting income from Merck and Sanofi-Aventis. Dr. Malhotra had previously received (prior to May 2012) consulting and/or research income from Philips Respironics, SHC, SGS, Apnex Medical, Pfizer and Apnicure. Dr. Kushida receives research support from ResMed, Pacific Medico, Merck, Cephalon, Ventus Medical, and Jazz Pharmaceuticals. He receives royalties from Philips-Respironics. Dr. Younes is the owner of YRT a research and development company. Dr. Walsh has received research support from Apnex, NovoNordisk, Merck, Phillips-Respironics, Vanda, and Ventus. The other authors have indicated no financial conflicts of interest. NR 25 TC 20 Z9 20 U1 1 U2 3 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD APR 1 PY 2013 VL 36 IS 4 BP 583 EP 589 DI 10.5665/sleep.2550 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 117FN UT WOS:000316939000018 PM 23565004 ER PT J AU Janzen, DM Cheng, DH Schafenacker, AM Paik, DY Goldstein, AS Witte, ON Jaroszewicz, A Pellegrini, M Memarzadeh, S AF Janzen, Deanna M. Cheng, Donghui Schafenacker, Amanda M. Paik, Daniel Y. Goldstein, Andrew S. Witte, Owen N. Jaroszewicz, Artur Pellegrini, Matteo Memarzadeh, Sanaz TI Estrogen and progesterone together expand murine endometrial epithelial progenitor cells SO STEM CELLS LA English DT Article DE Endometrial epithelial progenitors; Progesterone; Estrogen; Paracrine signaling ID LABEL-RETAINING CELLS; LARGE GENE LISTS; STEM-CELLS; PROSTATE-CANCER; SELF-RENEWAL; POSTMENOPAUSAL WOMEN; UTERINE EPITHELIUM; MOUSE ENDOMETRIUM; COLON-CARCINOMA; CD44 ISOFORMS AB Synchronous with massive shifts in reproductive hormones, the uterus and its lining the endometrium expand to accommodate a growing fetus during pregnancy. In the absence of an embryo the endometrium, composed of epithelium and stroma, undergoes numerous hormonally regulated cycles of breakdown and regeneration. The hormonally mediated regenerative capacity of the endometrium suggests that signals that govern the growth of endometrial progenitors must be regulated by estrogen and progesterone. Here, we report an antigenic profile for isolation of mouse endometrial epithelial progenitors. These cells are EpCAM+CD44+ITGA6hiThy1PECAM1PTPRCTer119, comprise a minor subpopulation of total endometrial epithelia and possess a gene expression profile that is unique and different from other cells of the endometrium. The epithelial progenitors of the endometrium could regenerate in vivo, undergo multilineage differentiation and proliferate. We show that the number of endometrial epithelial progenitors is regulated by reproductive hormones. Coadministration of estrogen and progesterone dramatically expanded the endometrial epithelial progenitor cell pool. This effect was not observed when estrogen or progesterone was administered alone. Despite the remarkable sensitivity to hormonal signals, endometrial epithelial progenitors do not express estrogen or progesterone receptors. Therefore, their hormonal regulation must be mediated through paracrine signals resulting from binding of steroid hormones to the progenitor cell niche. Discovery of signaling defects in endometrial epithelial progenitors or their niche can lead to development of better therapies in diseases of the endometrium. STEM CELLS 2013;31:808822 C1 [Janzen, Deanna M.; Schafenacker, Amanda M.; Paik, Daniel Y.; Memarzadeh, Sanaz] Univ Calif Los Angeles, Dept Obstet & Gynecol, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Goldstein, Andrew S.; Witte, Owen N.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Goldstein, Andrew S.] Univ Calif Los Angeles, Dept Urol, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Cheng, Donghui; Witte, Owen N.] Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90024 USA. [Goldstein, Andrew S.; Witte, Owen N.; Pellegrini, Matteo; Memarzadeh, Sanaz] Univ Calif Los Angeles, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Los Angeles, CA 90024 USA. [Witte, Owen N.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90024 USA. [Jaroszewicz, Artur; Pellegrini, Matteo] Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90024 USA. [Memarzadeh, Sanaz] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. RP Memarzadeh, S (reprint author), Univ Calif Los Angeles, Dept Obstet & Gynecol, David Geffen Sch Med, Los Angeles, CA 90024 USA. EM smemarzadeh@mednet.ucla.edu OI Goldstein, Andrew/0000-0003-0434-9149 FU VA CDA-2 Career Development Award; Mary Kay Foundation Award; PCF Young Investigators Award; STOP Cancer Award; Broad Stem Cell Research Center, Research Award; U54 CA 143,931 award; Kimmel Translational Scholar Award; Joe and Ali Torre-Prostate Cancer Foundation Young Investigator Award FX SM is supported by a VA CDA-2 Career Development Award, a gift from the Scholars in Translational Medicine Program, Mary Kay Foundation Award, PCF Young Investigators Award, STOP Cancer Award, the Broad Stem Cell Research Center, Research Award, the U54 CA 143,931 award and a Kimmel Translational Scholar Award. ASG is supported by the Joe and Ali Torre-Prostate Cancer Foundation Young Investigator Award. ONW is a Howard Hughes Medical Institute investigator. NR 84 TC 10 Z9 10 U1 1 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1066-5099 EI 1549-4918 J9 STEM CELLS JI Stem Cells PD APR PY 2013 VL 31 IS 4 BP 808 EP 822 DI 10.1002/stem.1337 PG 15 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology GA 112WG UT WOS:000316624300018 PM 23341289 ER PT J AU Ma, RS Latif, R Davies, TF AF Ma, Risheng Latif, Rauf Davies, Terry F. TI Thyroid Follicle Formation and Thyroglobulin Expression in Multipotent Endodermal Stem Cells SO THYROID LA English DT Article ID SYNERGISTICALLY ACTIVATE; GENE-EXPRESSION; TRANSCRIPTION; DIFFERENTIATION; MOUSE; PAX8; PRESERVATION; ORGANOIDS AB Objective: The aim of this study was to assess the impact of transcriptional induction on thyroid follicular cell (TFC) differentiation from endodermally matured embryonic stem (ES) cells. The thyroid transcription factors-NKx2 homeobox 1 (NKx2-1, formerly called TTF-1) and Paired box gene 8 (Pax8)-are known to associate biochemically and synergistically in the activation of thyroid functional genes including the sodium/iodide symporter (NIS), thyrotropin (TSH) receptor (TSHR), thyroglobulin (Tg), and thyroid peroxidase (TPO) genes. In this study, we investigated the ability of ectopically expressed Pax8 and NKx2-1 to further the induction and differentiation of murine ES cells into potential TFCs. Methods: ES cells were stably transfected with either the Pax8 gene, the NKx2-1 gene, or both genes to study the induction of NIS, TSHR, Tg, and TPO genes as assessed using both quantitative reverse-transcription polymerase chain reaction (qRT-PCR) and protein expression. The derived cells were cultured with or without the presence of activin A to allow their differentiation into multipotent endodermal cells. Results: The four thyroid-specific genes NIS, TSHR, Tg, and TPO were all significantly activated by expressing both transcription factors within the same ES cell. In contrast, significant but much lower transcriptional activity of the TSHR, Tg, and TPO genes was detected in cells expressing just NKx2-1, and only the NIS and TSHR genes responded to Pax8 alone. No Tg protein expression could be detected prior to their development into endodermal derivatives. However, after further differentiation of postembryoid body ES cells with activin A and TSH into endodermal cell lines, those cells with dual transfection of Pax8 and NKx2-1 demonstrated greatly enhanced expression of the NIS, TSHR, Tg, and TPO genes to such a degree that it was similar to that found in control thyroid cells. Furthermore, these same cells formed three-dimensional neofollicles in vitro and expressed Tg protein, but these phenomena were absent from lines expressing only Pax8 or NKx2-1. Conclusion: These findings provide further evidence that co-expression of Pax8 and NKx2-1 in murine ES cells may induce the differentiation of thyroid-specific gene expression within endodermally differentiated ES cells and commit them to form three-dimensional neofollicular structures. C1 [Ma, Risheng; Latif, Rauf; Davies, Terry F.] Icahn Sch Med Mt Sinai, Dept Med, Thyroid Res Unit, New York, NY USA. [Ma, Risheng; Latif, Rauf; Davies, Terry F.] James J Peters VA Med Ctr, Dept Med, New York, NY USA. RP Ma, RS (reprint author), VA Med Ctr, Room 2F-27,130 West Kingsbridge Rd, New York, NY 10468 USA. EM risheng.ma@mssm.edu OI latif, rauf/0000-0002-4226-3728 FU National Institutes of Health [DK080459, DK069713, DK052464]; VA Merit Review Program FX This work was supported in part by DK080459, DK069713, and DK052464 from the National Institutes of Health and the VA Merit Review Program. NR 14 TC 16 Z9 17 U1 1 U2 13 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1050-7256 EI 1557-9077 J9 THYROID JI Thyroid PD APR PY 2013 VL 23 IS 4 BP 385 EP 391 DI 10.1089/thy.2012.0644 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 115FT UT WOS:000316798700003 PM 23360087 ER PT J AU Sealock, RJ Kramer, JR Verstovsek, G Richardson, P Rugge, M Parente, P Vela, M El-Serag, HB AF Sealock, R. J. Kramer, J. R. Verstovsek, G. Richardson, P. Rugge, M. Parente, P. Vela, M. El-Serag, H. B. TI The prevalence of oesophageal eosinophilia and eosinophilic oesophagitis: a prospective study in unselected patients presenting to endoscopy SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID CONSENSUS RECOMMENDATIONS; BARRETTS-ESOPHAGUS; ADULTS; POPULATION; DYSPHAGIA; CHILDREN AB Background Oesophageal eosinophilia (EE) is encountered in clinical practice as oesophageal biopsies are being obtained in patients with GI symptoms other than classical symptoms of eosinophilic oesophagitis (EoE). The prevalence, determinants and clinical relevance of EE identified irrespective of symptoms are unclear. Aim To determine the prevalence and risk factors of EE with or without EoE in a nonselected group of patients undergoing endoscopy and in primary care patients. Methods A cross-sectional study in a single VA centre in which we obtained at least one oesophageal biopsy from patients presenting to elective endoscopy, as well as a sample of patients eligible for screening colonoscopy recruited from primary care clinics. EE was defined by >15 eosinophils in a single HPF; and EoE was defined as definite, probable or none depending on the presence of EE, acid-suppressive therapy and oesophageal symptoms. Results EE was identified in 33 of 1357 patients (2.4%, 95% CI: 1.73.4); of whom 9 had definite EoE (0.66%, 95% CI: 0.231.10), 17 had probable EoE (1.25%), and the only 7 patients had EE without EoE. The prevalence of EE was 2.3% among patients undergoing elective endoscopy and 0.1% among patients eligible for screening colonoscopy. Seasonal allergies (adjusted OR: 2.78; 95% CI: 1.266.11) and oesophageal strictures (4.50; 0.9022.40) were associated with EE. Conclusions The prevalence of EE was 2.3% among unselected patients presenting to endoscopy most of whom have EoE. EE was present in 0.1% in primary care patients none of whom had EoE. C1 [Sealock, R. J.; El-Serag, H. B.] Michael E DeBakey VA Med Ctr, Gastroenterol Sect, Houston, TX USA. [Sealock, R. J.; Vela, M.; El-Serag, H. B.] Baylor Coll Med, Dept Med, Gastroenterol Sect, Houston, TX 77030 USA. [Kramer, J. R.; Richardson, P.; El-Serag, H. B.] Michael E DeBakey VA Med Ctr, Houston VA Hlth Serv, Res & Dev Ctr Excellence, Houston, TX USA. [Kramer, J. R.; Richardson, P.] Baylor Coll Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Verstovsek, G.] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. [Rugge, M.] Univ Padua, Dept Med DIMED, Surg Pathol & Cytopathol Unit, Padua, Italy. [Parente, P.] Casa Sollievo della Sofferenza, Dept Pathol, San Giovanni Rotondo, Italy. RP El-Serag, HB (reprint author), VA Med Ctr, 152,2002 Holcombe Blvd, Houston, TX 77030 USA. EM hasheme@bcm.tmc.edu RI Rugge, Massimo/K-7525-2016 FU National Institutes of Health (NIH) [NCI R01 116845]; Houston VA HSR&D Center of Excellence [HFP90-020]; Texas Digestive Disease Center NIH [DK58338]; NIDDK [K24-04-107] FX This work is funded in part by National Institutes of Health (NIH) grant NCI R01 116845, the Houston VA HSR&D Center of Excellence (HFP90-020), and the Texas Digestive Disease Center NIH DK58338. Dr El-Serag is also supported by NIDDK K24-04-107. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs, the US government, the NIH or Baylor College of Medicine. The NIH had no role in the design and conduct of the study; the collection, management, analysis and interpretation of the data; or the preparation, review or approval of the manuscript. NR 23 TC 9 Z9 9 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-2813 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD APR PY 2013 VL 37 IS 8 BP 825 EP 832 DI 10.1111/apt.12268 PG 8 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 108WC UT WOS:000316325900008 PM 23441936 ER PT J AU Suhler, EB Lowder, CY Goldstein, DA Giles, T Lauer, AK Kurz, PA Pasadhika, S Lee, ST de Saint Sardos, A Butler, NJ Tessler, HH Smith, JR Rosenbaum, JT AF Suhler, Eric B. Lowder, Careen Y. Goldstein, Debra A. Giles, Tracy Lauer, Andreas K. Kurz, Paul A. Pasadhika, Sirichai Lee, Shelly T. de Saint Sardos, Alexandre Butler, Nicholas J. Tessler, Howard H. Smith, Justine R. Rosenbaum, James T. TI Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial SO BRITISH JOURNAL OF OPHTHALMOLOGY LA English DT Article ID NECROSIS-FACTOR-ALPHA; ANTERIOR UVEITIS; INFLIXIMAB THERAPY; PREVALENCE; CHILDHOOD; EFFICACY; DISEASES AB Objective Tumour necrosis factor (TNF) blockers have been demonstrated to be effective in the treatment of systemic and ocular inflammatory diseases. We conducted a prospective, multicentre, open-label Phase II clinical trial to assess the effectiveness and safety of adalimumab, a fully human anti-TNF monoclonal antibody, in treating refractory uveitis. Methods Subjects with non-infectious uveitis refractory to corticosteroids and at least one other immunosuppressive medication were enrolled. Treatment outcome was ascertained by a composite endpoint comprised of visual acuity, intraocular inflammation, ability to taper immunosuppressives, and posterior segment imaging. Clinical response was defined by improvement in at least one parameter, worsening in none, and well controlled intraocular inflammation. Week 10 responders were permitted to continue receiving adalimumab for the study duration of 50 weeks. Results Twenty-one of 31 patients (68%) were characterised as clinical responders at 10 weeks, of whom 12 patients (39%) exhibited durable response after 50 weeks. The most common reason for study termination was primary or secondary inefficacy. No patients experienced treatment-limiting toxicity clearly related to study therapy. Conclusions Adalimumab was safe and effective in 68% of refractory uveitis patients 10 weeks after study enrolment, and maintained in 39% after 1 year. Ongoing study is required to determine the place of adalimumab and other TNF blockers in the treatment of uveitis. C1 [Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA. [Suhler, Eric B.; Giles, Tracy; Lauer, Andreas K.; Kurz, Paul A.; Pasadhika, Sirichai; Lee, Shelly T.; de Saint Sardos, Alexandre; Butler, Nicholas J.; Smith, Justine R.; Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Casey Eye Inst, Portland, OR 97239 USA. [Suhler, Eric B.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA. [Lowder, Careen Y.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA. [Goldstein, Debra A.; Tessler, Howard H.] Univ Illinois, Dept Ophthalmol, Chicago, IL 60680 USA. [Tessler, Howard H.] Northwestern Univ, Dept Ophthalmol, Chicago, IL 60611 USA. [Smith, Justine R.; Rosenbaum, James T.] Oregon Hlth & Sci Univ, Depatment Cell Biol, Portland, OR 97239 USA. [Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA. [Rosenbaum, James T.] Devers Eye Inst, Portland, OR USA. RP Suhler, EB (reprint author), Oregon Hlth & Sci Univ, Dept Ophthalmol, Casey Eye Inst, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA. EM suhlere@ohsu.edu FU Abbott (Chicago, IL) [HUM05-029]; Department of Veterans' Affairs; Research to Prevent Blindness; University of Illinois-Chicago; Rosenfeld Family Trust; William and Mary Bauman Foundation; William C Kuzell Foundation; Abbott; Bristol-Myers-Squibb; EyeGate; Genentech; LuxBio; Novartis FX This work was supported by Abbott (Chicago, IL) protocol number HUM05-029. Research support was provided by the Department of Veterans' Affairs (EBS), Research to Prevent Blindness (unrestricted grant to Casey Eye Institute and University of Illinois-Chicago, Senior Scholar Award to JTR), the Rosenfeld Family Trust (JTR), the William and Mary Bauman Foundation, and the William C Kuzell Foundation. Dr Suhler has served as a paid consultant to LuxBio. Dr Rosenbaum has served as a paid consultant to Amgen, LuxBio, Xoma, Centocor, Genentech, Pfizer and Abbott. Dr Suhler, Dr Rosenbaum and Ms Giles have received research support from Abbott, Bristol-Myers-Squibb, EyeGate, Genentech, LuxBio and Novartis. Dr Goldstein has served as a paid consultant to Bausch and Lomb, Allergan, GSK, Santen, LuxBio, and serves on an IDMC for Abbott. Dr Lowder serves on an advisory board for Allergan. Authorship is based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. NR 30 TC 28 Z9 29 U1 0 U2 5 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0007-1161 EI 1468-2079 J9 BRIT J OPHTHALMOL JI Br. J. Ophthalmol. PD APR PY 2013 VL 97 IS 4 BP 481 EP 486 DI 10.1136/bjophthalmol-2012-302292 PG 6 WC Ophthalmology SC Ophthalmology GA 107ZM UT WOS:000316259900022 PM 23376607 ER PT J AU Lorincz, IS Lawson, BCT Long, JA AF Lorincz, Ilona S. Lawson, Brittany C. T. Long, Judith A. TI Provider and Patient Directed Financial Incentives to Improve Care and Outcomes for Patients with Diabetes SO CURRENT DIABETES REPORTS LA English DT Article DE Diabetes mellitus; Reimbursement; Incentives; Pay for performance; Economics; Behavioral ID PAY-FOR-PERFORMANCE; WEIGHT-LOSS; BARIATRIC SURGERY; RANDOMIZED-TRIAL; MEDICAL THERAPY; UNITED-KINGDOM; QUALITY; MANAGEMENT; IMPACT; ENGLAND AB Incentive programs directed at both providers and patients have become increasingly widespread. Pay-for-performance (P4P) where providers receive financial incentives to carry out specific care or improve clinical outcomes has been widely implemented. The existing literature indicates they probably spur initial gains which then level off or partially revert if incentives are withdrawn. The literature also indicates that process measures are easier to influence through P4P programs but that intermediate outcomes such as glucose, blood pressure, and cholesterol control are harder to influence, and the long-term impact of P4P programs on health is largely unknown. Programs directed at patients show greater promise as a means to influence patient behavior and intermediate outcomes such as weight loss; however, the evidence for long-term effects are lacking. In combination, both patient and provider incentives are potentially powerful tools but whether they are cost-effective has yet to be determined. C1 [Lorincz, Ilona S.] Univ Penn, Perelman Sch Med, Dept Med, Div Endocrine, Philadelphia, PA 19104 USA. [Lawson, Brittany C. T.; Long, Judith A.] Univ Penn, Perelman Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Long, Judith A.] Philadelphia VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Long, Judith A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Long, JA (reprint author), Univ Penn, Perelman Sch Med, Dept Med, Div Gen Internal Med, 1021 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM Ilona.Lorincz@uphs.upenn.edu; blaws@mail.med.upenn.edu; jalong@mail.med.upenn.edu FU NIDDK FX I.S. Lorincz: none; B.C.T. Lawson: none; J.A. Long: has received grant support from NIDDK. NR 45 TC 3 Z9 3 U1 1 U2 15 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1534-4827 J9 CURR DIABETES REP JI Curr. Diabetes Rep. PD APR PY 2013 VL 13 IS 2 BP 188 EP 195 DI 10.1007/s11892-012-0353-9 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 105KZ UT WOS:000316069500004 PM 23225214 ER PT J AU Pisprasert, V Ingram, KH Lopez-Davila, MF Munoz, AJ Garvey, WT AF Pisprasert, Veeradej Ingram, Katherine H. Lopez-Davila, Maria F. Munoz, A. Julian Garvey, W. Timothy TI Limitations in the Use of Indices Using Glucose and Insulin Levels to Predict Insulin Sensitivity Impact of race and gender and superiority of the indices derived from oral glucose tolerance test in African Americans SO DIABETES CARE LA English DT Article ID BETA-CELL FUNCTION; HOMEOSTASIS MODEL ASSESSMENT; NON-HISPANIC WHITES; CLAMP TECHNIQUE; RESISTANCE ATHEROSCLEROSIS; CHECK INDEX; IN-VIVO; SECRETION; BLACK; CLEARANCE AB OBJECTIVE-To examine the utility of commonly used insulin sensitivity indices in nondiabetic European Americans (EAs) and African Americans (AAs). RESEARCH DESIGN AND METHODS-Two-hundred forty nondiabetic participants were studied. Euglycemic-hyperinsulinemic clamp was the gold standard approach to assess glucose disposal rates (GDR) normalized by lean body mass. The homeostatic model assessment for insulin resistance (HOMA-IR) and the quantitative insulin sensitivity check index (QUICKI) were calculated from fasting plasma glucose and insulin (FIL). Oral glucose tolerance test (OGTT) was performed to determine Matsuda index, the simple index assessing insulin sensitivity (SI(is)OGTT), Avignon index, and Stomvoll index. Relationships among these indices with GDR were analyzed by multiple regression. RESULTS-GDR values were similar in EA and AA subgroups; even so, AA exhibited higher FIL and were insulin-resistant compared with EA, as assessed by HOMA-IR, QUICKI, Matsuda index, SIisOGTT, Avignon index, and Stumvoll index. In the overall study population, GDR was significantly correlated with all studied insulin sensitivity indices (/r/ = 0.381-0.513); however, these indices were not superior to FIL in predicting GDR. Race and gender affected the strength of this relationship. In AA males, FIL and HOMA-IR were not correlated with GDR. In contrast, Matsuda index and SI(is)OGTT were significantly correlated with GDR in AA males, and Matsuda index was superior to HOMA-IR and QUICKI in AAs overall. CONCLUSIONS-Insulin sensitivity indices based on glucose and insulin levels should be used cautiously as measures of peripheral insulin sensitivity when comparing mixed gender and mixed race populations. Matsuda index and SI(is)OGTT are reliable in studies that include AA males. Diabetes Care 36:845-853, 2013 C1 [Pisprasert, Veeradej; Lopez-Davila, Maria F.; Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Ingram, Katherine H.] Kennesaw State Univ, Dept Exercise Sci & Sport Management, Kennesaw, GA USA. [Munoz, A. Julian] Univ S Carolina, Sch Med, Div Endocrinol, Columbia, SC USA. [Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Pisprasert, V (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. EM veeradej@uab.edu FU National Institutes of Health [DK-083562, DK-038764]; Merit Review program of the U.S. Department of Veterans Affairs; UAB Diabetes Research and Training Center [P60-DK079626] FX This work was supported from grants from the National Institutes of Health (DK-083562 and DK-038764 to W.T.G.) and by the Merit Review program of the U.S. Department of Veterans Affairs (W.T.G.).; The authors are grateful to Dr. Barbara Gower (Department of Nutrition Sciences, University of Alabama at Birmingham) and Dr. Mark Beasley (Department of Biostatistics, University of Alabama at Birmingham) for insightful discussions regarding these data. The authors thank the support of the research core facilities of the UAB Diabetes Research and Training Center (P60-DK079626) and their research volunteers. NR 40 TC 90 Z9 90 U1 0 U2 7 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD APR PY 2013 VL 36 IS 4 BP 845 EP 853 DI 10.2337/dc12-0840 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 110RG UT WOS:000316462400028 PM 23223406 ER PT J AU Cummings, DE Cohen, RV AF Cummings, David E. Cohen, Ricardo V. TI Response to Comment on: Cohen et al. Effects of Gastric Bypass Surgery in Patients With Type 2 Diabetes and Only Mild Obesity. Diabetes Care 2012;35:1420-1428 SO DIABETES CARE LA English DT Letter ID BARIATRIC SURGERY; MEDICAL THERAPY C1 [Cummings, David E.] Univ Washington, Sch Med, Diabet & Obes Ctr Excellence, Seattle, WA 98195 USA. [Cummings, David E.] Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Cohen, Ricardo V.] Oswaldo Cruz Hosp, Ctr Excellence Bariatr & Metab Surg, Sao Paulo, Brazil. [Cohen, Ricardo V.] Marcia Maria Braido Hosp, Sao Paulo, Brazil. RP Cummings, DE (reprint author), Univ Washington, Sch Med, Diabet & Obes Ctr Excellence, Seattle, WA 98195 USA. EM davidec@u.washington.edu NR 6 TC 1 Z9 1 U1 0 U2 2 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD APR PY 2013 VL 36 IS 4 BP E59 EP E59 DI 10.2337/dc12-2243 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 110RG UT WOS:000316462400012 PM 23520383 ER PT J AU Rountree, AM Reed, BJ Cummings, BP Jung, SR Stanhope, KL Graham, JL Griffen, SC Hull, RL Havel, PJ Sweet, IR AF Rountree, A. M. Reed, B. J. Cummings, B. P. Jung, S. -R. Stanhope, K. L. Graham, J. L. Griffen, S. C. Hull, R. L. Havel, P. J. Sweet, I. R. TI Loss of coupling between calcium influx, energy consumption and insulin secretion associated with development of hyperglycaemia in the UCD-T2DM rat model of type 2 diabetes SO DIABETOLOGIA LA English DT Article DE Calcium; Hyperglycaemia; Insulin secretion; Islets; Oxygen consumption ID PANCREATIC BETA-CELLS; PYRUVATE-CARBOXYLASE; ENDOPLASMIC-RETICULUM; OXYGEN-CONSUMPTION; B-CELLS; GLUCOSE; ISLETS; CHANNELS; RELEASE; MITOCHONDRIA AB Previous studies on isolated islets have demonstrated tight coupling between calcium (Ca2+) influx and oxygen consumption rate (OCR) that is correlated with insulin secretion rate (ISR). To explain these observations, we have proposed a mechanism whereby the activation of a highly energetic process (Ca2+/metabolic coupling process [CMCP]) by Ca2+ mediates the stimulation of ISR. The aim of the study was to test whether impairment of the CMCP could play a role in the development of type 2 diabetes. Glucose- and Ca2+-mediated changes in OCR and ISR in isolated islets were compared with the time course of changes of plasma insulin concentrations observed during the progression to hyperglycaemia in a rat model of type-2 diabetes (the University of California at Davis type 2 diabetes mellitus [UCD-T2DM] rat). Islets were isolated from UCD-T2DM rats before, 1 week, and 3 weeks after the onset of hyperglycaemia. Glucose stimulation of cytosolic Ca2+ and OCR was similar for islets harvested before and 1 week after the onset of hyperglycaemia. In contrast, a loss of decrement in islet OCR and ISR in response to Ca2+ channel blockade coincided with decreased fasting plasma insulin concentrations observed in rats 3 weeks after the onset of hyperglycaemia. These results suggest that phenotypic impairment of diabetic islets in the UCD-T2DM rat is downstream of Ca2+ influx and involves unregulated stimulation of the CMCP. The continuously elevated levels of CMCP induced by chronic hyperglycaemia in these islets may mediate the loss of islet function. C1 [Rountree, A. M.; Reed, B. J.; Jung, S. -R.; Sweet, I. R.] Univ Washington, Diabet & Obes Ctr Excellence, Seattle, WA 98109 USA. [Cummings, B. P.; Stanhope, K. L.; Graham, J. L.; Havel, P. J.] Univ Calif Davis, Dept Mol Biosci, Sch Vet Med, Davis, CA 95616 USA. [Cummings, B. P.; Stanhope, K. L.; Graham, J. L.; Havel, P. J.] Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA. [Griffen, S. C.] Bristol Myers Squibb Co, Princeton, NJ USA. [Hull, R. L.] VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA. [Hull, R. L.] Univ Washington, Seattle, WA 98109 USA. RP Sweet, IR (reprint author), Univ Washington, Diabet & Obes Ctr Excellence, 850 Republican St, Seattle, WA 98109 USA. EM isweet@u.washington.edu OI Hull, Rebecca/0000-0001-9690-4087 FU Merck Investigator Initiated Sponsored Program [33171]; National Institutes of Health [DK17047, DK063986, R01 HL075675, R01 HL091333, AT002599, AT002993, AT003645]; Washington State Life Sciences Discovery Fund; American Diabetes Association FX This research was funded by grants from Merck Investigator Initiated Sponsored Program (No. 33171), the National Institutes of Health (DK17047 and DK063986) and the Washington State Life Sciences Discovery Fund. P. J. Havel's laboratory also receives, or received, support during the time the experiments were conducted from NIH grants R01 HL075675, R01 HL091333, AT002599, AT002993, AT003645 and the American Diabetes Association. NR 35 TC 6 Z9 6 U1 0 U2 13 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X J9 DIABETOLOGIA JI Diabetologia PD APR PY 2013 VL 56 IS 4 BP 803 EP 813 DI 10.1007/s00125-012-2808-6 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 105MX UT WOS:000316076300014 PM 23404441 ER PT J AU Tyler, JA Fox, JP Desai, MM Perry, WB Glasgow, SC AF Tyler, Joshua A. Fox, Justin P. Desai, Mayur M. Perry, W. Brian Glasgow, Sean C. TI Outcomes and Costs Associated With Robotic Colectomy in the Minimally Invasive Era SO DISEASES OF THE COLON & RECTUM LA English DT Article DE Robotic surgery; Colectomy; Laparoscopic colectomy; Colon cancer ID SHORT-TERM OUTCOMES; MRC CLASICC TRIAL; COLON-CANCER; RANDOMIZED-TRIAL; ASSISTED SURGERY AB BACKGROUND: Robotic-assisted surgery has become increasingly common; however, it is unclear if its use for colectomy improves in-hospital outcomes compared with the laparoscopic approach. OBJECTIVE: The aim of the study is to compare in-hospital outcomes and costs between patients undergoing robotic or laparoscopic colectomy. DESIGN: This study is a retrospective review of the 2008 to 2009 Nationwide Inpatient Sample. SETTINGS, PATIENTS, INTERVENTIONS: All adult patients who underwent an elective robotic or laparoscopic colectomy in hospitals performing both procedures (N = 2583 representing an estimated 12,732 procedures) were included. MAIN OUTCOME MEASURES: Outcomes included intraoperative and postoperative complications, length of stay, and direct costs of care. Regression models were used to compare these outcomes between procedural approaches while controlling for baseline differences in patient characteristics. RESULTS: Overall, 6.1% of patients underwent a robotic procedure. Factors associated with robotic-assisted colectomy included younger age, benign diagnoses, and treatment at a lower-volume center. Patients undergoing robotic and laparoscopic procedures experienced similar rates of intraoperative (3.0% vs 3.3%; adjusted OR = 0.88 (0.35-2.22)) and postoperative (21.7% vs 21.6%; adjusted OR = 0.84 (0.54-1.30)) complications, as well as risk-adjusted average lengths of stay (5.4 vs 5.5 days, p = 0.66). However, robotic-assisted colectomy resulted in significantly higher costs of care ($19,231 vs $ 15,807, p < 0.001). Although the overall postoperative morbidity rate was similar between groups, the individual complications experienced by each group were different. LIMITATIONS: A limitation of this study is the potential miscoding of robotic cases in administrative data. CONCLUSIONS: Robotic-assisted colectomy significantly increases the costs of care without providing clear reductions in overall morbidity or length of stay. As the use of robotic technology in colon surgery continues to evolve, critical appraisal of the benefits offered in comparison with the resources consumed is required. C1 [Tyler, Joshua A.; Glasgow, Sean C.] San Antonio Mil Med Ctr, Dept Surg, San Antonio, TX USA. [Fox, Justin P.; Desai, Mayur M.] Yale Univ, Sch Med, Robert Wood Johnson Fdn, Clin Scholars Program, New Haven, CT USA. [Desai, Mayur M.] Yale Univ, Sch Publ Hlth, Dept Chron Dis Epidemiol, New Haven, CT USA. [Perry, W. Brian] South Texas Vet Hlth Care Syst, Dept Gen Surg, San Antonio, TX USA. RP Tyler, JA (reprint author), San Antonio Mil Med Ctr, Dept Gen Surg, 3851 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA. EM Joshua.Tyler.1@us.af.mil FU Robert Wood Johnson Foundation FX Drs Fox and Desai are involved with the Clinical Scholars Program, which is supported by the Robert Wood Johnson Foundation. NR 25 TC 28 Z9 29 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0012-3706 J9 DIS COLON RECTUM JI Dis. Colon Rectum PD APR PY 2013 VL 56 IS 4 BP 458 EP 466 DI 10.1097/DCR.0b013e31827085ec PG 9 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 106ZB UT WOS:000316183200467 PM 23478613 ER PT J AU Rosenberg, DE Huang, DL Simonovich, SD Belza, B AF Rosenberg, Dori E. Huang, Deborah L. Simonovich, Shannon D. Belza, Basia TI Outdoor Built Environment Barriers and Facilitators to Activity among Midlife and Older Adults with Mobility Disabilities SO GERONTOLOGIST LA English DT Article DE Ambulation; Neighborhood; Physical function; Walkability; Physical activity; Disability ID PHYSICAL-ACTIVITY; NEIGHBORHOOD ENVIRONMENT; QUALITATIVE RESEARCH; METROPOLITAN-AREAS; PEOPLE; HEALTH; WALKABILITY; VALIDATION; FRAMEWORK; ACCESS AB Purpose: To gain better understanding of how the built environment impacts neighborhood-based physical activity among midlife and older adults with mobility disabilities. Design and methods: We conducted in-depth interviews with 35 adults over age 50, which used an assistive device and lived in King County, Washington, U.S. In addition, participants wore Global Positioning Systems (GPS) devices for 3 days prior to the interview. The GPS maps were used as prompts during the interviews. Open coding of the 35 interviews using latent content analysis resulted in key themes and subthemes that achieved consensus between coders. Two investigators independently coded the text of each interview. Results: Participants were on average of 67 years of age (range: 5086) and predominantly used canes (57%), walkers (57%), or wheelchairs (46%). Key themes pertained to curb ramp availability and condition, sidewalk availability and condition, hills, aesthetics, lighting, ramp availability, weather, presence and features of crosswalks, availability of resting places and shelter on streets, paved or smooth walking paths, safety, and traffic on roads. Implications: A variety of built environment barriers and facilitators to neighborhood-based activity exist for midlife and older adults with mobility disabilities. Preparing our neighborhood environments for an aging population that uses assistive devices will be important to foster independence and health. C1 [Rosenberg, Dori E.] Grp Hlth Res Inst, Seattle, WA 98101 USA. [Huang, Deborah L.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr S 182, Seattle, WA USA. [Simonovich, Shannon D.; Belza, Basia] Univ Washington, Sch Nursing, Seattle, WA 98195 USA. [Belza, Basia] Univ Washington, Hlth Promot Res Ctr, Seattle, WA 98195 USA. RP Rosenberg, DE (reprint author), Grp Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA. EM rosenberg.d@ghc.org FU NCCDPHP CDC HHS [U48-DP001911] NR 38 TC 39 Z9 39 U1 2 U2 67 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD APR PY 2013 VL 53 IS 2 BP 268 EP 279 DI 10.1093/geront/gns119 PG 12 WC Gerontology SC Geriatrics & Gerontology GA 106MR UT WOS:000316148600009 PM 23010096 ER PT J AU Navathe, AS Silber, JH Small, DS Rosen, AK Romano, PS Even-Shoshan, O Wang, YL Zhu, JS Halenar, MJ Volpp, KG AF Navathe, Amol S. Silber, Jeffrey H. Small, Dylan S. Rosen, Amy K. Romano, Patrick S. Even-Shoshan, Orit Wang, Yanli Zhu, Jingsan Halenar, Michael J. Volpp, Kevin G. TI Teaching Hospital Financial Status and Patient Outcomes Following ACGME Duty Hour Reform SO HEALTH SERVICES RESEARCH LA English DT Article DE Resident duty hour reform; quality of care; hospital financial health; patient outcomes; health policy ID QUALITY-OF-CARE; RESIDENTS WORK HOURS; ADMINISTRATIVE DATA; MEDICARE BENEFICIARIES; COMORBIDITY MEASURES; COST IMPLICATIONS; SAFETY; MORTALITY; STAY; REIMBURSEMENT AB Objective To examine whether hospital financial health was associated with differential changes in outcomes after implementation of 2003 ACGME duty hour regulations. Data Sources/Study Setting Observational study of 3,614,174 Medicare patients admitted to 869 teaching hospitals from July 1, 2000 to June 30, 2005. Study Design Interrupted time series analysis using logistic regression to adjust for patient comorbidities, secular trends, and hospital site. Outcomes included 30-day mortality, AHRQ Patient Safety Indicators (PSIs), failure-to-rescue (FTR) rates, and prolonged length of stay (PLOS). Principal Findings All eight analyses measuring the impact of duty hour reform on mortality by hospital financial health quartile, in postreform year 1 (Post 1) or year 2 (Post 2) versus the prereform period, were insignificant: Post 1 OR range 1.001.02 and Post 2 OR range 0.991.02. For PSIs, all six tests showed clinically insignificant effect sizes. The FTR rate analysis demonstrated nonsignificance in both postreform years (OR 1.00 for both). The PLOS outcomes varied significantly only for the combined surgical sample in Post 2, but this effect was very small, OR 1.03 (95% CI 1.02, 1.04). Conclusions The impact of 2003 ACGME duty hour reform on patient outcomes did not differ by hospital financial health. This finding is somewhat reassuring, given additional financial pressure on teaching hospitals from 2011 duty hour regulations. C1 [Navathe, Amol S.; Silber, Jeffrey H.; Small, Dylan S.; Even-Shoshan, Orit; Volpp, Kevin G.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Navathe, Amol S.; Zhu, Jingsan; Halenar, Michael J.; Volpp, Kevin G.] Univ Penn, Dept Med, Sch Med, Philadelphia, PA 19104 USA. [Navathe, Amol S.; Silber, Jeffrey H.; Volpp, Kevin G.] Univ Penn, Wharton Sch, Dept Hlth Care Management & Econ, Philadelphia, PA 19104 USA. [Navathe, Amol S.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Silber, Jeffrey H.; Even-Shoshan, Orit; Wang, Yanli] Childrens Hosp Philadelphia, Ctr Outcomes Res, Philadelphia, PA 19104 USA. [Silber, Jeffrey H.] Univ Penn, Dept Pediat, Sch Med, Philadelphia, PA 19104 USA. [Silber, Jeffrey H.] Univ Penn, Dept Anesthesiol & Crit Care, Sch Med, Philadelphia, PA 19104 USA. [Small, Dylan S.] Univ Penn, Wharton Sch, Dept Stat, Philadelphia, PA 19104 USA. [Rosen, Amy K.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. [Rosen, Amy K.] Vet Adm Hosp, Ctr Org Leadership & Management Res, Boston, MA USA. [Romano, Patrick S.] Univ Calif Davis, Div Gen Med, Sch Med, Sacramento, CA 95817 USA. [Romano, Patrick S.] Univ Calif Davis, Ctr Healthcare Policy & Res, Sch Med, Sacramento, CA 95817 USA. [Halenar, Michael J.; Volpp, Kevin G.] Vet Adm Hosp, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Navathe, AS (reprint author), Univ Penn, Leonard Davis Inst Hlth Econ, 3641 Locust Walk,Room 202, Philadelphia, PA 19104 USA. EM amol@wharton.upenn.edu RI Romano, Patrick/N-4225-2014 OI Romano, Patrick/0000-0001-6749-3979; Halenar, Michael/0000-0002-8703-3811 FU National Heart, Lung, and Blood Institute (NHLBI) [R01 HL082637] FX This study was supported by grant R01 HL082637 from the National Heart, Lung, and Blood Institute (NHLBI), "Impact of Resident Work Hour Rules on Errors and Quality." NR 48 TC 4 Z9 4 U1 0 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD APR PY 2013 VL 48 IS 2 BP 476 EP 498 DI 10.1111/j.1475-6773.2012.01453.x PN 1 PG 23 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 106CW UT WOS:000316120200008 PM 22862427 ER PT J AU Ghaffarzadegan, N Epstein, AJ Martin, EG AF Ghaffarzadegan, Navid Epstein, Andrew J. Martin, Erika G. TI Practice Variation, Bias, and Experiential Learning in Cesarean Delivery: A Data-Based System Dynamics Approach SO HEALTH SERVICES RESEARCH LA English DT Article DE Cesarean delivery; practice variation; experiential learning; simulation; system dynamics ID IDENTIFY INDICATIONS; DECISION-MAKING; HEALTH; MODEL; FEEDBACK; OUTCOMES; AGREEMENT; PHYSICIAN; SELECTION; SERVICES AB Objectives To simulate physician-driven dynamics of delivery mode decisions (scheduled cesarean delivery [CD] vs. vaginal delivery [VD] vs. unplanned CD after labor), and to evaluate a behavioral theory of how experiential learning leads to emerging bias toward more CD and practice variation across obstetricians. Data Sources/Study Setting Hospital discharge data on deliveries performed by 300 randomly selected obstetricians in Florida who finished obstetrics residency and started practice after 1991. Study Design We develop a system dynamics simulation model of obstetricians' delivery mode decision based on the literature of experiential learning. We calibrate the model and investigate the extent to which the model replicates the data. Principal Findings Our learning-based simulation model replicates the empirical data, showing that physicians are more likely to schedule CD as they practice longer. Variation in CD rates is related to the way that physicians learn from outcomes of past decisions and accumulate experience. Conclusions The repetitive nature of medical decision making, learning from past practice, and accumulating experience can account for increases in CD decisions and practice variation across physicians. Policies aimed at improving medical decision making should account for providers' feedback-based learning mechanisms. C1 [Ghaffarzadegan, Navid] MIT, Engn Syst Div, Cambridge, MA 02139 USA. [Epstein, Andrew J.] Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Epstein, Andrew J.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Martin, Erika G.] SUNY Albany, Rockefeller Coll Publ Affairs & Policy, Albany, NY 12222 USA. [Martin, Erika G.] SUNY Albany, Nelson A Rockefeller Inst Govt, Albany, NY 12222 USA. RP Ghaffarzadegan, N (reprint author), MIT, Engn Syst Div, 77 Massachusetts Ave, Cambridge, MA 02139 USA. EM navidg@mit.edu NR 52 TC 6 Z9 6 U1 1 U2 19 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD APR PY 2013 VL 48 IS 2 BP 713 EP 734 DI 10.1111/1475-6773.12040 PN 2 PG 22 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 106CZ UT WOS:000316120600004 PM 23398502 ER PT J AU Lindrooth, RC Konetzka, RT Navathe, AS Zhu, JS Chen, W Volpp, K AF Lindrooth, Richard C. Konetzka, R. Tamara Navathe, Amol S. Zhu, Jingsan Chen, Wei Volpp, Kevin TI The Impact of Profitability of Hospital Admissions on Mortality SO HEALTH SERVICES RESEARCH LA English DT Article DE Hospital quality; medicare reimbursement; hospital finances ID ACUTE MYOCARDIAL-INFARCTION; PROSPECTIVE PAYMENT; HEALTH-CARE; QUALITY INFORMATION; COMPETITION; REIMBURSEMENT; MEDICARE; OUTCOMES; INCENTIVES; NONPROFIT AB Background Fiscal constraints faced by Medicare are leading to policies designed to reduce expenditures. Evidence of the effect of reduced reimbursement on the mortality of Medicare patients discharged from all major hospital service lines is limited. Methods We modeled risk-adjusted 30-day mortality of patients discharged from 21 hospital service lines as a function of service line profitability, service line time trends, and hospital service line and year-fixed effects. We simulated the effect of alternative revenue-neutral reimbursement policies on mortality. Our sample included all Medicare discharges from PPS-eligible hospitals (1997, 2001, and 2005). Results The results reveal a statistically significant inverse relationship between changes in profitability and mortality. A $0.19 average reduction in profit per $1.00 of costs led to a 0.0100.020 percentage-point increase in mortality rates (p<.001). Mortality in newly unprofitable service lines is significantly more sensitive to reduced payment generosity than in service lines that remain profitable. Policy simulations that target service line inequities in payment generosity result in lower mortality rates, roughly 70013,000 fewer deaths nationally. Conclusions The policy simulations raise questions about the trade-offs implicit in universal reductions in reimbursement. The effect of reduced payment generosity on mortality could be mitigated by targeting highly profitable services only for lower reimbursement. C1 [Lindrooth, Richard C.] Univ Colorado, Colorado Sch Publ Hlth, Aurora, CO 80045 USA. [Konetzka, R. Tamara] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA. [Navathe, Amol S.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Zhu, Jingsan; Chen, Wei] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Volpp, Kevin] Univ Penn, Perelman Sch Med, Leonard Davis Inst, Philadelphia VA Med Ctr,Ctr Hlth Incent & Behav E, Philadelphia, PA 19104 USA. [Volpp, Kevin] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. RP Lindrooth, RC (reprint author), Univ Colorado, Colorado Sch Publ Hlth, Anschutz Med Campus,13001 E 17th Pl,Campus Box B1, Aurora, CO 80045 USA. EM richard.lindrooth@ucdenver.edu OI Lindrooth, Richard/0000-0001-9538-9749 FU Robert Wood Johnson Foundation's Health Care Financing and Organization Initiative; Agency for Healthcare Research and Quality FX Joint Acknowledgment/Disclosure Statement: We thank Robert Wood Johnson Foundation's Health Care Financing and Organization Initiative and the Agency for Healthcare Research and Quality for funding this research. We also thank Jeff Stensland for helpful comments on a previous draft of this manuscript. NR 34 TC 7 Z9 7 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD APR PY 2013 VL 48 IS 2 BP 792 EP 809 DI 10.1111/1475-6773.12026 PN 2 PG 18 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 106CZ UT WOS:000316120600008 PM 23346946 ER PT J AU Williams, DL Goldstein, G Minshew, NJ AF Williams, Diane L. Goldstein, Gerald Minshew, Nancy J. TI The Modality Shift Experiment in Adults and Children with High Functioning Autism SO JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS LA English DT Article DE Autism; Attentional shifting; Speed of processing; Perceptual development ID DIAGNOSTIC OBSERVATION SCHEDULE; SPECTRUM DISORDER; COGNITIVE-STYLE; YOUNG-CHILDREN; ATTENTION; DISENGAGEMENT; DYSFUNCTION; INTERVIEW; DEFICITS AB This study used the modality shift experiment, a relatively simple reaction time measure to visual and auditory stimuli, to examine attentional shifting within and across modalities in 33 children and 42 adults with high-functioning autism as compared to matched numbers of age- and ability-matched typical controls. An exaggerated "modality shift effect" relative to the TD children occurred for the children with autism in conditions involving the reaction time when shifting from sound to light but not from light to sound. No exaggerated MSE was found for the adults with autism; rather, their responses were characterized by a generalized slowness relative to the adults with TD. These results suggest a lag in maturational development in autism in basic information processing mechanisms. C1 [Williams, Diane L.] Duquesne Univ, Dept Speech Language Pathol, Pittsburgh, PA 15219 USA. [Goldstein, Gerald] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA. [Goldstein, Gerald] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15206 USA. [Minshew, Nancy J.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15206 USA. [Minshew, Nancy J.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15206 USA. RP Goldstein, G (reprint author), VA Pittsburgh Healthcare Syst, 7180 Highland Dr 151R, Pittsburgh, PA 15206 USA. EM williamsd2139@duq.edu; ggold@nb.net RI Williams, Diane/B-4128-2017 FU NICHD NIH HHS [HD055748, HD35469, P01 HD035469, P50 HD055748, U19 HD035469]; NIDCD NIH HHS [K23 DC006691, K23DC006691]; NINDS NIH HHS [R01 NS033355] NR 52 TC 7 Z9 7 U1 2 U2 12 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0162-3257 J9 J AUTISM DEV DISORD JI J. Autism Dev. Disord. PD APR PY 2013 VL 43 IS 4 BP 794 EP 806 DI 10.1007/s10803-012-1618-5 PG 13 WC Psychology, Developmental SC Psychology GA 109KG UT WOS:000316365400005 PM 22865151 ER PT J AU Cidav, Z Lawer, L Marcus, SC Mandell, DS AF Cidav, Zuleyha Lawer, Lindsay Marcus, Steven C. Mandell, David S. TI Age-Related Variation in Health Service Use and Associated Expenditures Among Children with Autism SO JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS LA English DT Article DE Autism; Economics; Cost; Expenditures; Utilization; Medicaid; Age variation ID PSYCHOTROPIC MEDICATION USE; SPECTRUM DISORDERS; PSYCHIATRIC-HOSPITALIZATION; CARE EXPENDITURES; ELIGIBLE CHILDREN; ENROLLED CHILDREN; ADULTS; DIAGNOSIS; COSTS; INDIVIDUALS AB This study examined differences by age in service use and associated expenditures during 2005 for Medicaid-enrolled children with autism spectrum disorders. Aging was associated with significantly higher use and costs for restrictive, institution-based care and lower use and costs for community-based therapeutic services. Total expenditures increased by 5 % with each year of age; by 23 % between 3-5 and 6-11 year olds, 23 % between 6-11 and 12-16, and 14 % between 12-16 and 17-20 year olds. Use of and expenditures for long-term care, psychiatric medications, case management, medication management, day treatment/partial hospitalization, and respite services increased with age; use of and expenditures for occupational/physical therapy, speech therapy, mental health services, diagnostic/assessment services, and family therapy declined. C1 [Cidav, Zuleyha; Lawer, Lindsay; Mandell, David S.] Univ Penn, Childrens Hosp Philadelphia, Ctr Mental Hlth Policy & Serv Res, Ctr Autism Res,Perelman Sch Med, Philadelphia, PA 19104 USA. [Marcus, Steven C.] Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia Vet Affairs Med Ctr, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. RP Cidav, Z (reprint author), Univ Penn, Childrens Hosp Philadelphia, Ctr Mental Hlth Policy & Serv Res, Ctr Autism Res,Perelman Sch Med, Philadelphia, PA 19104 USA. EM zcidav@upenn.edu RI Mandell, David/H-2730-2012 OI Mandell, David/0000-0001-8240-820X FU NIMH NIH HHS [R01 MH077000] NR 39 TC 21 Z9 21 U1 2 U2 31 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0162-3257 J9 J AUTISM DEV DISORD JI J. Autism Dev. Disord. PD APR PY 2013 VL 43 IS 4 BP 924 EP 931 DI 10.1007/s10803-012-1637-2 PG 8 WC Psychology, Developmental SC Psychology GA 109KG UT WOS:000316365400017 PM 22941343 ER PT J AU Ai, AL Hall, D Pargament, K Tice, TN AF Ai, Amy L. Hall, Daniel Pargament, Kenneth Tice, Terrence N. TI Posttraumatic growth in patients who survived cardiac surgery: the predictive and mediating roles of faith-based factors SO JOURNAL OF BEHAVIORAL MEDICINE LA English DT Article DE Posttraumatic growth; Cardiovascular diseases and surgery; Religion; faith; and spiritual support; Social support; Optimism and hope ID PERCEIVED SOCIAL SUPPORT; CORONARY-HEART-DISEASE; BREAST-CANCER PATIENTS; ARTERY-BYPASS SURGERY; QUALITY-OF-LIFE; PSYCHOLOGICAL ADJUSTMENT; RELIGIOUS INVOLVEMENT; DEPRESSIVE SYMPTOMS; COPING STRATEGIES; GRAFT-SURGERY AB Despite the growing knowledge of posttraumatic growth, only a few studies have examined personal growth in the context of cardiac health. Similarly, longitudinal research is lacking on the implications of religion/spirituality for patients with advanced cardiac diseases. This paper aims to explore the effect of preoperative religious coping on long-term postoperative personal growth and potential mediation in this effect. Analyses capitalized on a preoperative survey and medical indices from the Society of Thoracic Surgeons' National Database of patients undergoing cardiac surgery. Participants in the current follow-up study completed a mailed survey 30 months after surgery. Hierarchical regression analysis was performed to evaluate the extent to which preoperative use of religious coping predicted growth at follow-up, after controlling for key demographics, medical indices, mental health, and protective factors. Predictors of posttraumatic growth at follow-up were positive religious coping and a living status without a partner. Medical indices, optimistic expectations, social support, and other religious factors were unrelated to posttraumatic growth. Including religious factors diminished effects of gender, age, and race. Including perceived spiritual support completely eliminated the role of positive religious coping, indicating mediation. Preoperative positive religious coping may have a long-term effect on postoperative personal growth, explainable by higher spiritual connections as a part of significance-making. These results suggest that spirituality may play a favorable role in cardiac patients' posttraumatic growth after surviving a life-altering operation. The elimination of demographic effects may help explain previously mixed findings concerning the association between these factors and personal growth. C1 [Ai, Amy L.] Florida State Univ, Tallahassee, FL 32306 USA. [Hall, Daniel] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Pargament, Kenneth] Bowling Green State Univ, Bowling Green, OH 43403 USA. [Tice, Terrence N.] Iliff Univ Theol, Denver, CO USA. RP Ai, AL (reprint author), Florida State Univ, FL 2313,Univ Ctr Bldg C, Tallahassee, FL 32306 USA. EM amyai8@gmail.com RI Hall, Daniel/H-4843-2013 OI Hall, Daniel/0000-0001-6382-0522 FU NCCIH NIH HHS [P50 AT00011]; PHS HHS [1 RO3 AGO 15686-01] NR 70 TC 6 Z9 7 U1 3 U2 20 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0160-7715 J9 J BEHAV MED JI J. Behav. Med. PD APR PY 2013 VL 36 IS 2 BP 186 EP 198 DI 10.1007/s10865-012-9412-6 PG 13 WC Psychology, Clinical SC Psychology GA 109RG UT WOS:000316385600008 PM 22460360 ER PT J AU Meszaros, ZS Abdul-Malak, Y Dimmock, JA Wang, DL Ajagbe, TO Batki, SL AF Meszaros, Zsuzsa Szombathyne Abdul-Malak, Ynesse Dimmock, Jacqueline A. Wang, Dongliang Ajagbe, Tolani O. Batki, Steven L. TI Varenicline Treatment of Concurrent Alcohol and Nicotine Dependence in Schizophrenia A Randomized, Placebo-Controlled Pilot Trial SO JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY LA English DT Article DE varenicline; schizophrenia; alcohol; nicotine; smoking ID CONSENSUS COGNITIVE BATTERY; USE DISORDERS; SCHIZOAFFECTIVE DISORDER; SUBSTANCE USE; SMOKING; SCALE; STANDARDIZATION; INTERVENTIONS; OUTPATIENTS; PREVALENCE AB Alcohol and nicotine dependence are common in schizophrenia. Varenicline is effective in smoking cessation and has also been shown to decrease alcohol consumption in smokers. The present pilot study assessed the safety and effectiveness of varenicline for treatment of concurrent nicotine and alcohol dependence in schizophrenia. Outpatients with schizophrenia or schizoaffective disorder and concurrent alcohol and nicotine dependence were enrolled in this 8-week, double-blind, randomized, placebo-controlled trial. Alcohol use and smoking were assessed using self-report (Timeline Follow-Back) and biological measures. Adverse events were recorded. Changes in the number of standard drinks per week and cigarettes per week were compared in the 2 groups. Because of safety concerns or loss to follow-up, of 55 patients enrolled, only 10 started study medication, 5 each on varenicline and placebo. Gastrointestinal adverse effects, such as severe abdominal pain, limited study completion to only 4 subjects. Number of standard alcoholic drinks consumed per week decreased by [mean (SD)] 16.6 (20.1) in the varenicline group and by 2.4 (27.4) in the placebo group. Mean (SD) number of cigarettes smoked per week decreased by 66 (65) its the varenicline group and by 47 (77) in the placebo group. Varenicline treatment of concurrent alcohol and nicotine dependence in schizophrenia may be problematic because of safety concerns limiting recruitment and poor tolerability (gastrointestinal adverse effects) limiting retention. There was no increased number of serious neuropsychiatric adverse events in the varenicline group. Based on this small sample, concurrent alcohol and nicotine dependence in schizophrenia may present special obstacles to successful treatment with varenicline. C1 [Meszaros, Zsuzsa Szombathyne; Abdul-Malak, Ynesse; Dimmock, Jacqueline A.; Ajagbe, Tolani O.; Batki, Steven L.] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY 13210 USA. [Wang, Dongliang] SUNY Upstate Med Univ, Dept Publ Hlth & Prevent Med, Syracuse, NY 13210 USA. [Batki, Steven L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Batki, Steven L.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Meszaros, ZS (reprint author), SUNY Upstate Med Univ, Dept Psychiat, 750 E Adams St,IHP 3302, Syracuse, NY 13210 USA. EM meszaroz@upstate.edu FU Brain & Behavior Research Foundation (NARSAD) Young Investigator Award; NIH/NIAAA [R01 AA013655]; Alkermes, Inc. FX This research was supported by the Brain & Behavior Research Foundation (NARSAD) 2008 Young Investigator Award to Dr Szombathyne Meszaros. Dr Batki has received research funding from NIH/NIAAA (R01 AA013655) and Alkermes, Inc. The authors alone are responsible for the content and writing of the paper. NR 41 TC 11 Z9 11 U1 3 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0271-0749 J9 J CLIN PSYCHOPHARM JI J. Clin. Psychopharmacol. PD APR PY 2013 VL 33 IS 2 BP 243 EP 247 DI 10.1097/JCP.0b013e3182870551 PG 5 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 108NX UT WOS:000316303700018 PM 23422399 ER PT J AU True, G Butler, AE Lamparska, BG Lempa, ML Shea, JA Asch, DA Werner, RM AF True, Gala Butler, Anneliese E. Lamparska, Bozena G. Lempa, Michele L. Shea, Judy A. Asch, David A. Werner, Rachel M. TI Open Access in the Patient-Centered Medical Home: Lessons from the Veterans Health Administration SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE patient-centered access; primary care; continuity of care; veterans health; qualitative evaluation ID PRIMARY-CARE; READINESS AB The Veterans Health Administration (VHA) has undertaken a 5-year initiative to transform to a patient-centered medical home model. An early focus of implementation was on creating open access, defined as continuity and capacity in primary care. We describe the impact of readiness for implementation on efforts of pilot teams to make changes to improve access and identify successful strategies used by early adopters to overcome barriers to change. A qualitative, formative evaluation of the first 18 months of implementation in one Veterans Integrated Service Network (VISN) spread across six states. Members of local implementation teams including administrators, primary care providers, and staff from primary care clinics located at 10 medical centers and 45 outpatient clinics. We conducted site visits during the first 6 months of implementation, observations at Learning Collaboratives, semi-structured interviews, and review of internal organizational documents. All data collection took place between April 2010 and December 2011. Early adopters employed various strategies to enhance access, with a focus on decreasing demand for face-to-face care, increasing supply of different types of primary care encounters, and improving clinic efficiencies. Our interviews with key contacts revealed three important areas where readiness for implementation (or lack thereof) had an impact on interventions to improve access: leadership engagement, staffing resources, and access to information and knowledge. Key factors related to readiness for implementation had an impact on which interventions pilot teams could put into place, as well as the viability and sustainability of access gains. Wide variations in interventions to improve access occurring across sites situated within one organization have important implications for efforts to measure the impact of enhanced access on patient outcomes, costs, and other systems-level indicators of the Medical Home. C1 [True, Gala; Butler, Anneliese E.; Lamparska, Bozena G.; Lempa, Michele L.; Shea, Judy A.; Asch, David A.; Werner, Rachel M.] Philadelphia Vet Affairs Med Ctr, CEPACT, Philadelphia, PA 19104 USA. [True, Gala; Shea, Judy A.; Asch, David A.; Werner, Rachel M.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. RP True, G (reprint author), Philadelphia Vet Affairs Med Ctr, CEPACT, Bldg 4100,Univ & Woodland Aves, Philadelphia, PA 19104 USA. EM Jennifer.True2@va.gov OI Asch, David/0000-0002-7970-286X FU Office of Primary Care, Veterans Health Administration, Department of Veterans Affairs FX The authors wish to thank the staff of the Center for Evaluation of Patient Aligned Care Teams (CEPACT), members of the CEPACT Advisory Board and the VISN 4 PACT Steering Committee, the VISN 4 Offices, and staff at VISN 4 Medical Facilities. We are also grateful for the insightful comments and suggestions from the three anonymous reviewers. Funding for the VISN 4 Center for Evaluation of PACT is through the Office of Primary Care, Veterans Health Administration, Department of Veterans Affairs. The views expressed in this paper do not necessarily represent the official views of the Department of Veterans Affairs. NR 20 TC 18 Z9 18 U1 3 U2 37 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2013 VL 28 IS 4 BP 539 EP 545 DI 10.1007/s11606-012-2279-y PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 109VV UT WOS:000316398400010 PM 23192447 ER PT J AU Schleifer, JW Centor, RM Heudebert, GR Estrada, CA Morris, JL AF Schleifer, J. William Centor, Robert M. Heudebert, Gustavo R. Estrada, Carlos A. Morris, Jason L. TI NSTEMI or Not: A 59-Year-Old Man with Chest Pain and Troponin Elevation SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID AORTIC DISSECTION; FREQUENCY AB A 59-year-old African-American man with a history of hypertension, hyperlipidemia, and cerebrovascular disease presented to the emergency department complaining of chest pain. He stated that the pain began suddenly while he was seated at home several hours prior to presentation. He described the pain as throbbing, 9 out of 10 in intensity, substernal, and associated with nausea, diaphoresis, and dyspnea. He stated that the pain radiated to his left leg but not to his arm or jaw. The pain resolved spontaneously after an hour, but then recurred 3 hours later. He had never experienced pain like this before. He initially delayed coming to the hospital, expecting the chest pain to subside spontaneously again; but finally his family brought him in when he became disoriented and confused. C1 [Schleifer, J. William; Heudebert, Gustavo R.; Morris, Jason L.] Univ Alabama Birmingham, Tinsley Harrison Internal Med Residency Program, Birmingham, AL 35294 USA. [Centor, Robert M.; Heudebert, Gustavo R.; Estrada, Carlos A.; Morris, Jason L.] Univ Alabama Birmingham, Div Gen Internal Med, Birmingham, AL 35294 USA. [Centor, Robert M.] Univ Alabama Birmingham, Huntsville, AL USA. [Centor, Robert M.; Heudebert, Gustavo R.; Estrada, Carlos A.; Morris, Jason L.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Estrada, Carlos A.] Vet Affairs Natl Qual Scholars Program, Birmingham, AL USA. [Morris, Jason L.] Univ Alabama Birmingham, Birmingham, AL 35294 USA. RP Morris, JL (reprint author), Univ Alabama Birmingham, Tinsley Harrison Internal Med Residency Program, BDB 345,1720 2nd Ave South, Birmingham, AL 35294 USA. EM jlmorris@uab.edu OI Schleifer, John/0000-0002-2074-108X NR 14 TC 2 Z9 2 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2013 VL 28 IS 4 BP 583 EP 590 DI 10.1007/s11606-012-2236-9 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 109VV UT WOS:000316398400019 PM 23054926 ER PT J AU Shen, KZ Johnson, SW AF Shen, Ke-Zhong Johnson, Steven W. TI Group I mGluRs Evoke K-ATP Current by Intracellular Ca2+ Mobilization in Rat Subthalamus Neurons SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS LA English DT Article ID METABOTROPIC GLUTAMATE RECEPTORS; SENSITIVE POTASSIUM CHANNELS; DOPAMINERGIC MIDBRAIN NEURONS; PARKINSONS-DISEASE; NITRIC-OXIDE; SUBSTANTIA-NIGRA; GLOBUS-PALLIDUS; BASAL GANGLIA; NUCLEUS; ACTIVATION AB We reported previously that Ca2+ influx through N-methly-D-aspartate- gated channels evokes ATP-sensitive K+ (K-ATP) currents in rat subthalamic nucleus (STN) neurons. By using whole-cell patch clamp recordings in brain slices, we investigated the ability of (RS)-3,5-dihydroxyphenylglycine (DHPG), a group I metabotropic glutamate receptor (mGluR) agonist, to evoke K-ATP currents. DHPG (20 mu M) evoked outward current at -70 mV and was associated with a positive slope conductance of 2.7 nS. The sulfonylurea agent tolbutamide (100 mu M) converted the positive slope to negative slope conductance, indicating mediation by K-ATP channels (ATP-sensitive K+ channels). Currents evoked by DHPG were significantly reduced by a combination of mGluR1 and mGluR5 negative allosteric modulators. DHPG-evoked outward current was blocked by cyclopiazonic acid and thapsigargin and mimicked by caffeine, suggesting mediation by release of intracellular Ca2+. DHPG outward current was also blocked by ryanodine and 2-aminoethoxydiphenylborane, suggesting mediation by ryanodine-and inositol 1,4,5-triphosphate-sensitive Ca2+ release. The nitric oxide synthase inhibitor N-G-nitro-L-arginine methyl ester and inhibitors of protein kinase G activity also suppressed DHPG-induced outward current. Voltage recordings showed that tolbutamide prolonged depolarizing plateau potentials and increased the spontaneous firing rate of STN neurons recorded in the presence of DHPG. These results show that group I mGluR stimulation generates K-ATP current by a nitric oxide-and protein kinase G-dependent process that is mediated by release of Ca2+ from intracellular stores. Because burst firing is linked to symptoms of Parkinson's disease, we suggest that K-ATP channels might provide a physiologically important inhibitory influence on STN neuronal activity. C1 [Shen, Ke-Zhong; Johnson, Steven W.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Johnson, Steven W.] Portland VA Med Ctr, Portland, OR 97207 USA. RP Johnson, SW (reprint author), Portland VA Med Ctr, RD 61,3710 SW US Vet Hosp Rd, Portland, OR 97207 USA. EM johnsost@ohsu.edu FU National Institutes of Health National Institute of Neurological Disorders and Stroke [NS38715]; Portland Veterans Affairs Parkinson's Disease Research, Education, and Clinical Center FX This work was supported by the National Institutes of Health National Institute of Neurological Disorders and Stroke [Grant NS38715]; and by the Portland Veterans Affairs Parkinson's Disease Research, Education, and Clinical Center. NR 54 TC 3 Z9 3 U1 1 U2 3 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0022-3565 EI 1521-0103 J9 J PHARMACOL EXP THER JI J. Pharmacol. Exp. Ther. PD APR PY 2013 VL 345 IS 1 BP 139 EP 150 DI 10.1124/jpet.112.201566 PG 12 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 109KT UT WOS:000316367000016 PM 23335392 ER PT J AU Wang, L Porter, B Maynard, C Evans, G Bryson, C Sun, HL Gupta, I Lowy, E McDonell, M Frisbee, K Nielson, C Kirkland, F Fihn, SD AF Wang, Li Porter, Brian Maynard, Charles Evans, Ginger Bryson, Christopher Sun, Haili Gupta, Indra Lowy, Elliott McDonell, Mary Frisbee, Kathleen Nielson, Christopher Kirkland, Fred Fihn, Stephan D. TI Predicting Risk of Hospitalization or Death Among Patients Receiving Primary Care in the Veterans Health Administration SO MEDICAL CARE LA English DT Article DE primary care; statistical models; hospitalization; death ID READMISSION; MODEL; REGRESSION AB Background: Statistical models that identify patients at elevated risk of death or hospitalization have focused on population subsets, such as those with a specific clinical condition or hospitalized patients. Most models have limitations for clinical use. Our objective was to develop models that identified high-risk primary care patients. Methods: Using the Primary Care Management Module in the Veterans Health Administration (VHA)'s Corporate Data Warehouse, we identified all patients who were enrolled and assigned to a VHA primary care provider on October 1, 2010. The outcome variable was the occurrence of hospitalization or death during the subsequent 90 days and 1 year. We extracted predictors from 6 categories: sociodemographics, medical conditions, vital signs, prior year use of health services, medications, and laboratory tests and then constructed multinomial logistic regression models to predict outcomes for over 4.6 million patients. Results: In the predicted 95th risk percentiles, observed 90-day event rates were 19.6%, 6.2%, and 22.6%, respectively, for hospitalization, death, and either hospitalization or death, compared with population averages of 2.7%, 0.7%, and 3.4%, respectively; 1-year event rates were 42.3%, 19.4%, and 51.3%, respectively, compared with population averages of 8.2%, 2.6%, and 10.8%, respectively. The C-statistics for 90-day outcomes were 0.83, 0.86, and 0.81, respectively, for hospitalization, death, and either hospitalization or death and were 0.81, 0.85, and 0.79, respectively, for 1-year outcomes. Conclusions: Prediction models using electronic clinical data accurately identified patients with elevated risk for hospitalization or death. This information can enhance the coordination of care for patients with complex clinical conditions. C1 [Wang, Li; Maynard, Charles; Evans, Ginger; Bryson, Christopher; Sun, Haili; Gupta, Indra; Lowy, Elliott] VA Puget Sound Hlth Care Syst, Seattle, WA 98101 USA. [Porter, Brian; Evans, Ginger; Bryson, Christopher; Fihn, Stephan D.] Univ Washington, Dept Med, Seattle, WA USA. [Maynard, Charles] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [McDonell, Mary; Frisbee, Kathleen; Nielson, Christopher; Kirkland, Fred; Fihn, Stephan D.] VHA Off Informat & Analyt Analyt & Business Intel, Washington, DC USA. RP Maynard, C (reprint author), VA Puget Sound Hlth Care Syst, HSR&D 1100 Olive Way Suite 1400, Seattle, WA 98101 USA. EM cmaynard@u.washington.edu RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 NR 19 TC 33 Z9 33 U1 0 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD APR PY 2013 VL 51 IS 4 BP 368 EP 373 DI 10.1097/MLR.0b013e31827da95a PG 6 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 107HS UT WOS:000316207100013 PM 23269113 ER PT J AU Herzig, MCS Hildreth, K Huamani, J Perez, M Goins, BA McMahan, CA Reddick, RL Walter, CA AF Herzig, Maryanne C. S. Hildreth, Kim Huamani, Jessica Perez, Marissa Goins, Beth A. McMahan, C. Alex Reddick, Robert L. Walter, Christi A. TI Human O-6-methylguanine-DNA methyltransferase containing C145A does not prevent hepatocellular carcinoma in C3HeB/FeJ transgenic mice SO MOLECULAR CARCINOGENESIS LA English DT Article DE liver cancer; DNA repair; mouse model; computed tomography; imaging ID HUMAN O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; DNA-REPAIR PROTEIN; HUMAN LIVER-CANCER; MOUSE MODELS; ESCHERICHIA-COLI; TUMORS; DIMETHYLNITROSAMINE; EXPRESSION; MUTATIONS; APOPTOSIS AB The prevalence of hepatocellular carcinoma (HCC) was diminished from 60% to 18% at 15 months of age in C3HeB/FeJ male transgenic mice expressing hMGMT in our previous studies. To directly test if the methyltransferase activity is required for diminished tumor prevalence, two separate lines of transgenic mice bearing an enzymatically inactive form of hMGMT were used. In these lines, cysteine 145 was substituted with alanine (C145A). Expression of the hMGMT C145A transgene in liver was demonstrated by Northern blots and Western blots. Immunohistochemistry revealed predominantly nuclear localization of the hMGMT C145A protein. hMGMT C145A transgenic mice were crossed with lacI transgenic mice to assess mutant frequencies in the presence of the mutant protein. Mutant frequencies were similar among livers of lacIxhMGMT C145A bi-transgenic mice and lacIxwild-type (WT) mice. DNA sequence analysis of recovered lacI mutants revealed similar mutation spectra for hMGMT C145A and WT mice. The prevalence of HCC was also similar for the two tested lines of hMGMT C145A mice, 45% and 48% prevalence with median tumor sizes of 11 and 8mm, and WT mice, 40% prevalence and median tumor size of 10mm. These results provide evidence that residue C145 in hMGMT is required to reduce the prevalence of HCC in C3HeB/FeJ mice transgenic for hMGMT. (c) 2011 Wiley Periodicals, Inc. C1 [Herzig, Maryanne C. S.; Hildreth, Kim; Perez, Marissa; Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Huamani, Jessica] Childrens Healthcare Atlanta, Dept Radiol, Atlanta, GA USA. [Goins, Beth A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. [McMahan, C. Alex; Reddick, Robert L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Walter, Christi A.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Walter, Christi A.] Barshop Inst Longev & Aging Studies, San Antonio, TX USA. [Walter, Christi A.] Canc Therapy & Res Inst, San Antonio, TX USA. RP Walter, CA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. FU VA Merit Award FX This study was supported by a VA Merit Award (to C.A.W.). The generous gift of the hMGMT C145A cDNA from Dr Anthony Pegg is gratefully acknowledged. We would like to thank Dr. LuZhe Sun and Dr. Thomas J. Slaga for their helpful comments in reviewing this article. We thank Dr. Anu Soundararajan and Dr. Max Amurao for their technical assistance during microCT image acquisition. We also thank Ms. Rebecca Garcia for excellent technical assistance. NR 71 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0899-1987 J9 MOL CARCINOGEN JI Mol. Carcinog. PD APR PY 2013 VL 52 IS 4 BP 275 EP 285 DI 10.1002/mc.21855 PG 11 WC Biochemistry & Molecular Biology; Oncology SC Biochemistry & Molecular Biology; Oncology GA 112CQ UT WOS:000316570000004 PM 22213062 ER PT J AU Nambiar, AM AF Nambiar, Anoop M. TI Procalcitonin in acute exacerbations of interstitial pneumonia: Another tool in the toolbox? SO RESPIROLOGY LA English DT Editorial Material DE acute respiratory distress syndrome; interstitial; lung disease; pneumonia; pulmonary fibrosis ID IDIOPATHIC PULMONARY-FIBROSIS; DIAGNOSIS C1 Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, Dept Med, Audie L Murphy Div,Div Pulm Dis & Crit Care Med, San Antonio, TX 78229 USA. RP Nambiar, AM (reprint author), Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, Dept Med, Audie L Murphy Div,Div Pulm Dis & Crit Care Med, San Antonio, TX 78229 USA. OI Nambiar, Anoop/0000-0003-2778-0433 NR 13 TC 1 Z9 1 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1323-7799 J9 RESPIROLOGY JI Respirology PD APR PY 2013 VL 18 IS 3 BP 389 EP 390 DI 10.1111/resp.12055 PG 2 WC Respiratory System SC Respiratory System GA 112ZV UT WOS:000316636000001 PM 23336530 ER PT J AU Porcel, JM Leung, CC Restrepo, MI Takahashi, K Lee, P AF Porcel, Jose M. Leung, Chi Chiu Restrepo, Marcos I. Takahashi, Kazuhisa Lee, Pyng TI Year in review 2012: Lung cancer, respiratory infections, tuberculosis, pleural diseases, bronchoscopic intervention and imaging SO RESPIROLOGY LA English DT Review DE bronchoscopic intervention and imaging; lung cancer; pleural disease; respiratory infection; tuberculosis ID COMMUNITY-ACQUIRED PNEUMONIA; DRUG-RESISTANT TUBERCULOSIS; OBSTRUCTIVE PULMONARY-DISEASE; EPITHELIAL-MESENCHYMAL TRANSITIONS; C-REACTIVE PROTEIN; ENDOBRONCHIAL ULTRASOUND; PARAPNEUMONIC EFFUSIONS; CONSENSUS GUIDELINES; PREDICTING MORTALITY; THORACIC-SOCIETY C1 [Porcel, Jose M.] Arnau de Vilanova Univ Hosp, Dept Internal Med, Pleural Dis Unit, Biomed Res Inst Lleida, Lleida 25198, Spain. [Leung, Chi Chiu] Dept Hlth, TB & Chest Serv, Hong Kong, Hong Kong, Peoples R China. [Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. [Restrepo, Marcos I.] Vet Evidence Based Res Disseminat & Implement Ctr, San Antonio, TX USA. [Takahashi, Kazuhisa] Juntendo Univ, Grad Sch Med, Dept Resp Med, Tokyo, Japan. [Lee, Pyng] Natl Univ Singapore Hosp, Dept Med, Singapore 117548, Singapore. RP Porcel, JM (reprint author), Arnau de Vilanova Univ Hosp, Dept Internal Med, Avda Alcalde Rovira Roure 80, Lleida 25198, Spain. EM jporcelp@yahoo.es RI Restrepo, Marcos/H-4442-2014 FU National Heart, Lung, and Blood Institute [K23HL096054] FX M.I.R.'s time is partially protected by Award Number K23HL096054 from the National Heart, Lung, and Blood Institute. The content of M.I.R.'s contribution on respiratory infections is solely the responsibility of the author and does not necessarily represent the official views of the National Heart, Lung, And Blood Institute, the National Institutes of Health or the Department of Veterans Affairs. NR 82 TC 2 Z9 2 U1 0 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1323-7799 EI 1440-1843 J9 RESPIROLOGY JI Respirology PD APR PY 2013 VL 18 IS 3 BP 573 EP 583 DI 10.1111/resp.12048 PG 11 WC Respiratory System SC Respiratory System GA 112ZV UT WOS:000316636000028 PM 23317457 ER PT J AU Anaya, HD Butler, JN Solomon, JL Knapp, H Hoang, T Kan, V Rodriguez-Barradas, MC Hare, KA Kertz, B Bokhour, B AF Anaya, Henry D. Butler, Jaimi N. Solomon, Jeffrey L. Knapp, Herschel Hoang, Tuyen Kan, Virginia Rodriguez-Barradas, Maria C. Hare, Katherine A. Kertz, Barbara Bokhour, Barbara TI Implementation of Nurse-Initiated Rapid HIV Testing at High-Prevalence Primary Care Sites Within the US Veterans Affairs Health Care System SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID UNITED-STATES; IMMUNIZATION; DISEASE; RISK AB Nurse-initiated HIV rapid testing (NRT) increases testing/receipt of results compared with traditional testing. We implemented NRT in primary care clinics at 2 Veterans Affairs hospitals. At site 1, 2364 tests were conducted; 5 HIV positives were identified. At site 2, 2522 tests were conducted; 9 HIV positives were identified. Success varied across demographic/clinical strata. C1 [Anaya, Henry D.; Butler, Jaimi N.; Knapp, Herschel; Hoang, Tuyen] VA Greater Los Angeles Healthcare Syst, Vet Affairs VA Qual Enhancement Res Initiat HIV &, Los Angeles, CA USA. [Anaya, Henry D.; Butler, Jaimi N.; Knapp, Herschel; Hoang, Tuyen] VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Provider Behav, VA Greater Los Angeles Hlth Serv Res & Dev Ctr Ex, Los Angeles, CA USA. [Anaya, Henry D.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med, Los Angeles, CA 90095 USA. [Anaya, Henry D.] VA Chicago Healthcare Syst, VA Ctr Management Complex Chron Condit, Chicago, IL USA. [Anaya, Henry D.] VA Chicago Healthcare Syst, Qual Enhancement Res Initiat Spinal Cord Injury S, Chicago, IL USA. [Solomon, Jeffrey L.; Bokhour, Barbara] VA New England Healthcare Syst, Bedford, MA USA. [Kan, Virginia; Hare, Katherine A.] VA Med Ctr, Washington, DC USA. [Kan, Virginia] George Washington Univ, Infect Dis Sect, Washington, DC USA. [Rodriguez-Barradas, Maria C.; Kertz, Barbara] Michael E DeBakey VA Med Ctr, Infect Dis Sect, Houston, TX USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. RP Anaya, HD (reprint author), 11301Wilshire Blvd 111G, Los Angeles, CA 90073 USA. EM henry.anaya@va.gov OI Bokhour, Barbara/0000-0001-8238-0745 FU VA Quality Enhancement Research Initiative (QUERI) [SDP07-318]; Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service; Veterans Health Administration FX This research was funded by VA Quality Enhancement Research Initiative (QUERI) grant SDP07-318 awarded to the first author and supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service. The authors thank the primary care clinics and all the nurses who participated in these testing efforts; their participation, dedication, support, and patience were invaluable. The views and opinions expressed in this article are those of the authors and do not necessarily represent the views of the US Department of Veterans Affairs. The Veterans Health Administration supported this study but had no input in the design or reporting, or decision to submit this manuscript for publication. This study was reviewed and sanctioned by a US Department of Veterans Affairs institutional review board process. NR 18 TC 6 Z9 6 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD APR PY 2013 VL 40 IS 4 BP 341 EP 345 DI 10.1097/OLQ.0b013e31828417a5 PG 5 WC Infectious Diseases SC Infectious Diseases GA 107CQ UT WOS:000316192700018 PM 23486502 ER PT J AU Kadauke, S Picarelli, A Di Tola, M Parikh, RK Naylor, P Zhou, WL Bowman, J Bullock, D Tobi, M AF Kadauke, S. Picarelli, A. Di Tola, M. Parikh, R. K. Naylor, P. Zhou, W. -L. Bowman, J. Bullock, D. Tobi, M. TI Letter: Adnab-9 as a potential non-invasive biomarker for prediction of malignancy in coeliac disease SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Letter ID MONOCLONAL-ANTIBODY ADNAB-9; SMALL-INTESTINE; MARKER; CANCER C1 [Kadauke, S.] Perelman Sch Med, Med Scientist Training Program, Philadelphia, PA 19104 USA. [Picarelli, A.; Di Tola, M.] Univ Roma La Sapienza, Dept Internal Med & Med Special, Rome, Italy. [Parikh, R. K.; Naylor, P.; Zhou, W. -L.; Bowman, J.; Bullock, D.; Tobi, M.] Wayne State Univ, Sch Med, John D Dingell VAMC Dept Med, Detroit, MI USA. [Tobi, M.] Philadelphia Vet Affairs Med Ctr, Div Gastroenterol, Gastroenterol Sect, Philadelphia, PA USA. [Tobi, M.] Perelman Sch Med, Philadelphia, PA USA. RP Kadauke, S (reprint author), Perelman Sch Med, Med Scientist Training Program, Philadelphia, PA 19104 USA. EM martin.tobi@va.gov OI Picarelli, Antonio/0000-0002-6104-8193 NR 8 TC 2 Z9 2 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-2813 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD APR PY 2013 VL 37 IS 7 BP 761 EP 762 DI 10.1111/apt.12231 PG 2 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 100ZC UT WOS:000315743300023 PM 23458541 ER PT J AU Ross, SA Allen, DN Goldstein, G AF Ross, Sylvia An Allen, Daniel N. Goldstein, Gerald TI Factor Structure of the Halstead-Reitan Neuropsychological Battery: A Review and Integration SO APPLIED NEUROPSYCHOLOGY-ADULT LA English DT Article DE factor analysis; Halstead-Reitan Neuropsychological Battery; neuropsychological assessment ID BRAIN-DAMAGE; WAIS-R; TESTS; PERFORMANCE; DYSFUNCTION; ATTENTION; VALIDITY; MATRIX; SKILLS AB The Halstead-Reitan Neuropsychological Battery (HRNB) was the first factor-analyzed neuropsychological battery. It was based on a series of tests studied in Ward Halstead's laboratory at the University of Chicago, was accomplished in collaboration with a group of eminent statisticians, and was published in 1947. Four factors were extracted based on Halstead's tests called central integrative field, abstraction, power, and directional and constituted what was described as biological intelligence. Since this original analysis, Reitan's additions to the battery, and the proposal of Reitan and Wolfson's model of neuropsychological functioning, this factor-analytic research continued. This article reviews factor-analytic research concluding that Halstead's analysis has held up reasonably well and there is support for the Reitan and Wolfson model. However, Reitan's revisions of the battery added tests that form a distinct language factor and the sensory-perceptual tests that generally form a separate factor. Other tests and scoring methods used in individual studies modified the core battery and produced somewhat differing solutions. The complexity of the tests prevents the HRNB from being a factorially pure battery, and simple structure is rarely, if ever, reached. Current versions of the HRNB appear to evaluate both biological and psychometric intelligence, which appear to load on separate factors. C1 [Ross, Sylvia An; Allen, Daniel N.] Univ Nevada, Dept Psychol, Las Vegas, NV 89154 USA. [Goldstein, Gerald] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Allen, DN (reprint author), Univ Nevada, Dept Psychol, 4505 Maryland Pkwy, Las Vegas, NV 89154 USA. EM daniel.allen@unlv.edu FU Mental Illness Research, Education, and Clinical Center (MIRECC), VA Pittsburgh Healthcare System; Medical Research Service, Department of Veterans Affairs FX Indebtedness is expressed to the Mental Illness Research, Education, and Clinical Center (MIRECC), VA Pittsburgh Healthcare System, and the Medical Research Service, Department of Veterans Affairs for support of this research. NR 49 TC 0 Z9 0 U1 1 U2 5 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 0908-4282 J9 APPL NEUROPSYCH-ADUL JI Appl. Neuropsychol.-Adult PD APR 1 PY 2013 VL 20 IS 2 BP 120 EP 135 DI 10.1080/09084282.2012.690798 PG 16 WC Clinical Neurology; Psychology SC Neurosciences & Neurology; Psychology GA 100EA UT WOS:000315677400006 PM 23397998 ER PT J AU Parmelee, PA Harralson, TL McPherron, JA Schumacher, HR AF Parmelee, Patricia A. Harralson, Tina L. McPherron, Jesse A. Schumacher, H. Ralph TI The structure of affective symptomatology in older adults with osteoarthritis SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE affective symptoms; comorbidity; depression; anxiety; osteoarthritis ID GENERALIZED ANXIETY DISORDER; PRIMARY-CARE PATIENTS; SELF-RATED HEALTH; SOMATIC SYMPTOMS; ELDERLY-PATIENTS; STATUS QUESTIONNAIRE; PHYSICAL SYMPTOMS; MIXED ANXIETY; DEPRESSION; PAIN AB Objective To examine the structure of symptoms of affective disorder among older adults with a chronic health problem (osteoarthritis) and to explore cross-sectional and longitudinal associations of obtained affective symptom clusters with key health outcomes (pain, functional disability, perceived health). Methods One-year longitudinal study of older adults with diagnosed osteoarthritis of the knee. Symptoms of DSM depression and anxiety were assessed in a research diagnostic interview by using a DSM-IV symptom checklist; self-reports captured demographic characteristics, objective health, pain, disability, and perceived health. Confirmatory factor analysis tested comparability of affective symptom structure in this sample to findings of previous research; ordinary least squares regression examined cross-sectional and longitudinal associations of affective symptoms with health outcomes, controlling for demographics and objective health. Results The current sample displayed an affective symptom structure comparable with that observed in previous research, with symptoms clustering into depressed mood (DM), somatic symptoms (SS), and psychic anxiety (PA) factors. DM was cross-sectionally associated with pain and disability and marginally with perceived health; SS predicted current pain and perceived health. Only DM predicted 1year change in disability and perceived health (but not pain). Conclusions This research confirms the role of SS of distress in fueling disability and perceived ill health among older adults who are chronically ill. However, it is DM that drives changes in perceived health and functional ability. Copyright (c) 2012 John Wiley & Sons, Ltd. C1 [Parmelee, Patricia A.; McPherron, Jesse A.] Univ Alabama, Ctr Mental Hlth & Aging, Tuscaloosa, AL 35487 USA. [Parmelee, Patricia A.; McPherron, Jesse A.] Univ Alabama, Dept Psychol, Tuscaloosa, AL USA. [Harralson, Tina L.] Polaris Hlth Care, Philadelphia, PA USA. [Schumacher, H. Ralph] Vet Affairs Med Ctr, Philadelphia, PA USA. [Schumacher, H. Ralph] Univ Penn, Sch Med, Dept Rheumatol, Philadelphia, PA 19104 USA. RP Parmelee, PA (reprint author), Univ Alabama, Ctr Mental Hlth & Aging, Tuscaloosa, AL 35487 USA. EM pparmelee@ua.edu FU National Institute of Mental Health [1-R01-MH51800] FX This research was supported by the National Institute of Mental Health grant 1-R01-MH51800 to the first author for research conducted at the Philadelphia Geriatric Center and the University of Pennsylvania. We thank Lori Smith for project management, James Hollander, Meredith Olderman, and Beth Chmar for collecting the data, Hui Wu and Yunqi Zhang for data management, and Elaine Benoff and Susan Gallagher for administrative support. NR 55 TC 4 Z9 7 U1 2 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-6230 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD APR PY 2013 VL 28 IS 4 BP 393 EP 401 DI 10.1002/gps.3837 PG 9 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 103ZR UT WOS:000315958800009 PM 22653754 ER PT J AU Maust, DT Mavandadi, S Benson, A Streim, JE DiFilippo, S Snedden, T Weber, AL Oslin, DW AF Maust, Donovan T. Mavandadi, Shahrzad Benson, Amy Streim, Joel E. DiFilippo, Suzanne Snedden, Thomas Weber, Anita L. Oslin, David W. TI Telephone-based care management for older adults initiated on psychotropic medication SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE care management; telepsychiatry; psychotropics; depression ID LATE-LIFE DEPRESSION; RANDOMIZED CONTROLLED-TRIAL; MENTAL-HEALTH; RISK; BENZODIAZEPINE; VALIDATION; DISABILITY; SEVERITY; SYMPTOMS; VALIDITY AB Objective This study aimed to explore the longitudinal, 6-month symptom course of older adults newly started on an antidepressant or anxiolytic by non-psychiatrist physicians and enrolled in a care management program. Method This is a naturalistic cohort study of older adults (age 65years) receiving pharmacotherapy and telephone-based care management. Participants are non-institutionalized adults participating in Pennsylvania's Pharmaceutical Assistance Contract for the Elderly who completed telephone-based clinical assessments including demographic data, self-report on history of psychiatric treatment and adherence, and standardized symptom scales. Results A total of 162 participants with an average age of 77.2years (SD 6.8) were followed and, for analysis, split into two groups by PHQ-9 score: 75 (46.3%) scoring 04 (minimally symptomatic group, MSG) and 87 (53.7%) scoring 5 (symptomatic group, SG). Over 6months, the SG improved with PHQ-9 scores beginning on average at 10.0 (SD 4.6) and falling to 5.4 (SD 4.2) (F(1, 86)=29.53, p<0.0001). The MSG had no significant change in depressive symptoms. Emotional health as measured by SF-12 Mental Composite Score mirrored the PHQ-9 change and lack thereof in the SG and MSG, respectively. No clinical or demographic features were associated with symptom improvement in the SG although they were more likely to report medication adherence (66.7% vs. 44.0%, 2(1)=8.4, p=0.0037) compared with the MSG. Conclusions Participation of symptomatic older adults initiated on psychotropic medication in a telephone-based care management program was associated with improvement in depressive symptoms and overall emotional well-being, notable findings given participants' advanced age, state-wide distribution, and history of limited utilization of mental health care. Copyright (c) 2012 John Wiley & Sons, Ltd. C1 [Maust, Donovan T.; Mavandadi, Shahrzad; Benson, Amy; Streim, Joel E.; DiFilippo, Suzanne; Oslin, David W.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Mavandadi, Shahrzad; Streim, Joel E.; DiFilippo, Suzanne; Oslin, David W.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Mavandadi, Shahrzad; Streim, Joel E.; DiFilippo, Suzanne; Oslin, David W.] VISN 4 Mental Illness Res Educ & Clin Ctr MIRECC, Philadelphia, PA USA. [Snedden, Thomas] Penn Dept Aging, PACE Program, Harrisburg, PA USA. [Weber, Anita L.] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Maust, DT (reprint author), Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. EM Donovan.Maust@uphs.upenn.edu FU PACE Program, Pennsylvania Department of Aging, Harrisburg, PA, USA; NIMH [R25-MH060490] FX This study has been supported by the PACE Program, Pennsylvania Department of Aging, Harrisburg, PA, USA. D. T. M. was supported by the NIMH-funded Clinical Research Scholars Program (R25-MH060490) of the Department of Psychiatry, University of Pennsylvania. NR 39 TC 5 Z9 5 U1 5 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-6230 EI 1099-1166 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD APR PY 2013 VL 28 IS 4 BP 410 EP 416 DI 10.1002/gps.3839 PG 7 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 103ZR UT WOS:000315958800011 PM 22678956 ER PT J AU Katz, DL Grant, DL McGuire, TJ McQuigg, S Voci, K Volpp, K AF Katz, David L. Grant, Deborah Lewison McGuire, Todd J. McQuigg, Scott Voci, Karen Volpp, Kevin TI Working on the Health of Families: Where Children Fit in Worksite Health Promotion Efforts SO CHILDHOOD OBESITY LA English DT Editorial Material ID GLOBAL CAPACITY C1 [Katz, David L.] Yale Univ, Prevent Res Ctr, Griffin Hosp, Derby, CT 06418 USA. [Grant, Deborah Lewison] FoodFight, New York, NY USA. [McGuire, Todd J.] IncentaHLTH LLC, Denver, CO USA. [McQuigg, Scott] HealthTeacher Inc, Nashville, TN USA. [Voci, Karen] Harvard Pilgrim Hlth Care Fdn, Harvard Pilgrim Hlth Care, Wellesley, MA USA. [Volpp, Kevin] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Volpp, Kevin] Leonard Davis Inst, Ctr Hlth Incent & Behav Econ, Philadelphia, PA USA. [Volpp, Kevin] Penn CMU Roybal Ctr Behav Econ & Hlth P30, Philadelphia, PA USA. [Volpp, Kevin] UPHS Ctr Innovat Hlth Care Financing, Philadelphia, PA USA. [Volpp, Kevin] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Volpp, Kevin] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. RP Katz, DL (reprint author), Yale Univ, Prevent Res Ctr, Griffin Hosp, 2nd Floor 130 Div St, Derby, CT 06418 USA. EM david.katz@yale.edu OI Katz, David/0000-0001-6845-6192 NR 6 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2153-2168 EI 2153-2176 J9 CHILD OBES JI Child Obes. PD APR PY 2013 VL 9 IS 2 BP 95 EP 103 DI 10.1089/chi.2013.9202 PG 9 WC Pediatrics SC Pediatrics GA AI4PB UT WOS:000336846200003 PM 23517280 ER PT J AU Halford, C Gau, V Churchill, BM Haake, DA AF Halford, Colin Gau, Vincent Churchill, Bernard M. Haake, David A. TI Bacterial Detection & Identification Using Electrochemical Sensors SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS LA English DT Article DE Bioengineering; Issue 74; Microbiology; Genetics; Molecular Biology; Cellular Biology; Biochemistry; Biomedical Engineering; Medicine; Immunology; Bacteria; Electrochemical sensor; ribosomal RNA; rRNA; 16S RNA; DNA; probe; assay AB Electrochemical sensors are widely used for rapid and accurate measurement of blood glucose and can be adapted for detection of a wide variety of analytes. Electrochemical sensors operate by transducing a biological recognition event into a useful electrical signal. Signal transduction occurs by coupling the activity of a redox enzyme to an amperometric electrode. Sensor specificity is either an inherent characteristic of the enzyme, glucose oxidase in the case of a glucose sensor, or a product of linkage between the enzyme and an antibody or probe. Here, we describe an electrochemical sensor assay method to directly detect and identify bacteria. In every case, the probes described here are DNA oligonucleotides. This method is based on sandwich hybridization of capture and detector probes with target ribosomal RNA (rRNA). The capture probe is anchored to the sensor surface, while the detector probe is linked to horseradish peroxidase (HRP). When a substrate such as 3,3', 5,5'-tetramethylbenzidine (TMB) is added to an electrode with capture-target-detector complexes bound to its surface, the substrate is oxidized by HRP and reduced by the working electrode. This redox cycle results in shuttling of electrons by the substrate from the electrode to HRP, producing current flow in the electrode. C1 [Halford, Colin] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. [Halford, Colin; Churchill, Bernard M.; Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. [Gau, Vincent] GeneFluidics, Duarte, CA USA. [Haake, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA USA. [Haake, David A.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA. RP Haake, DA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. EM dhaake@ucla.edu FU National Institute of Allergy and Infectious Diseases [AI075565]; Wendy and Ken Ruby Fund for Excellence in Pediatric Urology Research FX This study was supported by Cooperative Agreement Award AI075565 (to D.A.H.) from the National Institute of Allergy and Infectious Diseases and by the Wendy and Ken Ruby Fund for Excellence in Pediatric Urology Research. B.M.C. is the Judith and Robert Winston Chair in Pediatric Urology. NR 12 TC 0 Z9 0 U1 2 U2 14 PU JOURNAL OF VISUALIZED EXPERIMENTS PI CAMBRIDGE PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA SN 1940-087X J9 JOVE-J VIS EXP JI J. Vis. Exp. PD APR PY 2013 IS 74 AR UNSP e4282 DI 10.3791/4282 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA V36QY UT WOS:000209227100006 PM 23644406 ER PT J AU La Fountaine, MF Wecht, JM Bauman, WA AF La Fountaine, M. F. Wecht, J. M. Bauman, W. A. TI Acute nitric oxide synthase inhibition and cardiac conduction in persons with spinal cord injury: a short report SO PHARMAZIE LA English DT Article ID AUTONOMIC NERVOUS-SYSTEM; HEART-RATE-VARIABILITY; BLOOD-PRESSURE; INCREASED SUSCEPTIBILITY; VENTRICULAR-ARRHYTHMIAS; SARCOPLASMIC-RETICULUM; EXCHANGER EXPRESSION; PARAPLEGIC RATS; RATE RESPONSE; TETRAPLEGIA AB N-G-nitro L-arginine methyl ester (L-NAME) is a potent and non-specific inhibitor of nitric oxide synthase (NOS). NOS inhibition with L-NAME has been shown to adversely prolong electrocardiogram (ECG) intervals in an animal model, an observation which has yet to be evaluated in humans. We determined the effects of several weight-based L-NAME doses on ECG intervals in persons with tetraplegia and a neurologically-intact control group. This two-part investigation determined the effects of different weight-based doses of L-NAME in the supine (Study 1) and orthostatic position (Study 2). Subjects completed an open-label trial with intravenous administration of L-NAME at specific doses [i.e., 0, 1, 2 or 4 mg.kg(-1)] in the supine position. The SCI group completed an orthostatic challenge with or without L-NAME [i.e., 0, 1 or 2 mg.kg(-1)] and controls completed only a single visit [0 mg-kg(-1)]. Digital ECGs were obtained at baseline (BL), after infusion (60 minutes) and 1 hour post-infusion (120 minutes) in Study 1, and at BL, 60 minutes and at two, 10 minute post-infusion time points after head up tilt (Post-Tilt 1 and 2) in Study 2. Heart rate, PQ, QT, and heart rate corrected QT (QTC) intervals were determined. The groups were matched for demographics. Seven subjects with tetraplegia and 6 controls participated in Study 1; 7 subjects with tetraplegia and 7 controls participated in Study 2. No statistical differences were noted between or within groups at baseline on each study visit for the ECG variables. L-NAME, regardless of dose, did not significantly change any ECG interval. NOS inhibition with L-NAME, at the weight-based doses tested do not induce hypertensive crises and, did not adversely affect any ECG interval in persons with SCI or neurologically intact control subjects during supine rest or orthostatic provocation. C1 [La Fountaine, M. F.; Wecht, J. M.; Bauman, W. A.] James J Peters VA Med Ctr, VA RR&D Natl Ctr Excellence Med Consequences Spin, Bronx, NY 10468 USA. [La Fountaine, M. F.; Wecht, J. M.; Bauman, W. A.] James J Peters VA Med Ctr, Med Serv, Bronx, NY 10468 USA. [La Fountaine, M. F.; Bauman, W. A.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [La Fountaine, M. F.] Seton Hall Univ, Sch Hlth & Med Sci, Dept Phys Therapy, S Orange, NJ 07079 USA. [Wecht, J. M.; Bauman, W. A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. RP La Fountaine, MF (reprint author), James J Peters VA Med Ctr, VA RR&D Natl Ctr Excellence Med Consequences Spin, Room 7A-13 M,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM michael.lafountaine@va.gov FU Veteran Affairs Rehabilitation Research and Development Service [B9212C, B3600R, B3346 V]; James J. Peters VA Medical Center FX This research was supported by the Veteran Affairs Rehabilitation Research and Development Service (#B9212C, #B3600R, and #B3346 V) and the James J. Peters VA Medical Center. NR 35 TC 2 Z9 2 U1 0 U2 1 PU GOVI-VERLAG PHARMAZEUTISCHER VERLAG GMBH PI ESCHBORN PA PHARMAZEUTISCCARL MANNICH STR 26, D-65760 ESCHBORN, GERMANY SN 0031-7144 J9 PHARMAZIE JI Pharmazie PD APR PY 2013 VL 68 IS 4 BP 245 EP 250 DI 10.1691/ph.2013.2794 PG 6 WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy SC Pharmacology & Pharmacy; Chemistry GA AE8NZ UT WOS:000334259900003 PM 23700789 ER PT J AU Maselli, DJ Adams, SG Peters, JI Levine, SM AF Maselli, Diego J. Adams, Sandra G. Peters, Jay I. Levine, Stephanie M. TI Management of asthma during pregnancy SO THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE LA English DT Review DE asthma; management of asthma; pregnancy ID RANDOMIZED CONTROLLED-TRIAL; PROTON-PUMP INHIBITORS; SEVERE ALLERGIC-ASTHMA; DOUBLE-BLIND-TRIAL; PERINATAL OUTCOMES; CONGENITAL-MALFORMATIONS; INHALED BECLOMETHASONE; NEDOCROMIL SODIUM; MATERNAL ASTHMA; MODERATE ASTHMA AB Asthma is an inflammatory lung condition that is the most common chronic disease affecting pregnancy. The changes in pulmonary physiology during pregnancy include increased minute ventilation, decreased functional residual capacity, increased mucus production, and airway mucosa hyperemia and edema. Pregnancy is also associated with a physiological suppression of the immune system. Many studies have described the heterogeneous immune system response in women with asthma during pregnancy, which partly explains why asthma has been shown to worsen, improve, or remain stable in equal proportions of women during pregnancy. Asthma may be associated with poor maternal and fetal outcomes. However, better maternal and fetal outcomes are observed with better asthma control. Asthma controller medications are generally thought to be safe during pregnancy, but limited data are available for some of the medicines. Newer medications like omalizumab open avenues for the treatment of asthma, but also pose a challenge, as there is limited experience with their use. Therefore, a multidisciplinary approach, including obstetricians, asthma specialists, and pediatricians should collaborate with the patient to carefully weigh the risks and benefits to determine an optimal management plan for each individual patient. The aim of this review article is to summarize the most recent literature about the immunological changes that occur during pregnancy, physiological and clinical implications of asthma on pregnancy, and asthma management and medication use in pregnant women. C1 [Maselli, Diego J.; Adams, Sandra G.; Peters, Jay I.; Levine, Stephanie M.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm Dis & Crit Care, San Antonio, TX 78229 USA. [Adams, Sandra G.; Peters, Jay I.; Levine, Stephanie M.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Maselli, DJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Pulm Dis & Crit Care, 7400 Merton Minter MC 111E, San Antonio, TX 78229 USA. EM masellicacer@uthscsa.edu NR 82 TC 10 Z9 10 U1 0 U2 5 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1753-4658 EI 1753-4666 J9 THER ADV RESPIR DIS JI Ther. Adv. Respir. Dis. PD APR PY 2013 VL 7 IS 2 BP 87 EP 100 DI 10.1177/1753465812464287 PG 14 WC Respiratory System SC Respiratory System GA AH3KU UT WOS:000336023000003 PM 23129568 ER PT J AU Restrepo, MI Faverio, P Anzueto, A AF Restrepo, Marcos I. Faverio, Paola Anzueto, Antonio TI Long-term prognosis in community-acquired pneumonia SO CURRENT OPINION IN INFECTIOUS DISEASES LA English DT Review DE biomarkers; community-acquired pneumonia; outcome ID RESPIRATORY-DISTRESS-SYNDROME; PRACTICE POPULATION COHORT; GERMAN COMPETENCE NETWORK; ACUTE CORONARY SYNDROMES; OLD MANS FRIEND; FOLLOW-UP; INFLAMMATORY MARKERS; SEVERITY ASSESSMENT; ELDERLY-PATIENTS; ACUTE INFECTION AB Purpose of review Pneumonia is considered the leading infectious diseases cause of death and the seventh leading cause of death overall in the US. There is significant interest in understanding the relationship between community-acquired pneumonia (CAP) and mortality. Recent findings Most clinical studies examining patients with CAP have used an arbitrary in-hospital or 30-day mortality as a short-term mortality clinical end point. However, long-term mortality (arbitrary >3 months) factors, incidence, prediction, and implications on patient care are important issues that require further evaluation in patients with CAP. This review focuses on the most recent literature assessing the importance and the frequency of long-term associated outcomes in patients with CAP, the risk factors, and possible implications for future strategies. Multiple risk factors that include age, sex, comorbid conditions, type of pneumonia, and severity of illness are associated with higher long-term mortality. In addition, several biomarkers were demonstrated to be independently associated with long-term mortality. Summary Despite advances in the understanding of long-term mortality among CAP patients, there is still a high unacceptable long-term mortality. Public health programs should address this important gap, considering the high level of complexity factors in patients with CAP. C1 [Restrepo, Marcos I.; Faverio, Paola; Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Restrepo, Marcos I.; Anzueto, Antonio] S Texas Vet Healthcare Syst, Audie L Murphy Div, San Antonio, TX USA. [Restrepo, Marcos I.] Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX USA. [Faverio, Paola] Univ Milano Bicocca, Monza, Italy. [Faverio, Paola] San Gerardo Hosp, Dept Resp Med, Monza, Italy. RP Restrepo, MI (reprint author), 7400 Merton Minter Blvd 11C6, San Antonio, TX 78229 USA. EM restrepom@uthscsa.edu RI Restrepo, Marcos/H-4442-2014 FU National Heart, Lung, and Blood Institute [K23HL096054] FX Dr Restrepo time is partially protected by Award Number K23HL096054 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, And Blood Institute or the National Institutes of Health. The funding agencies had no role in the preparation, review, or approval of the manuscript. The views expressed in this article are those of the author and do not necessarily represent the views of the Department of Veterans Affairs. NR 85 TC 30 Z9 31 U1 0 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0951-7375 J9 CURR OPIN INFECT DIS JI Curr. Opin. Infect. Dis. PD APR PY 2013 VL 26 IS 2 BP 151 EP 158 DI 10.1097/QCO.0b013e32835ebc6d PG 8 WC Infectious Diseases SC Infectious Diseases GA 097IY UT WOS:000315468400008 PM 23426328 ER PT J AU Babson, KA Boden, MT Harris, AH Stickle, TR Bonn-Miller, MO AF Babson, Kimberly A. Boden, Matthew Tyler Harris, Alex H. Stickle, Timothy R. Bonn-Miller, Marcel O. TI Poor sleep quality as a risk factor for lapse following a cannabis quit attempt SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE Sleep; Marijuana; Cannabis; Lapse ID MARIJUANA DEPENDENCE; ANXIETY SENSITIVITY; SEEKING TREATMENT; COPING MOTIVES; WITHDRAWAL; ALCOHOL; USERS; PREVALENCE; SYMPTOMS; NICOTINE AB Treatments for cannabis dependence are associated with high rates of lapse/relapse, underscoring the importance of identifying malleable risk factors that are associated with quit failure. Whereas research has demonstrated that poor sleep quality following cannabis discontinuation is related to subsequent use, there has yet to be an examination of whether poor sleep quality prior to a quit attempt results in a similar pattern of lapse. The present study addressed this gap by examining the role of pre-quit sleep quality on early lapse to cannabis use following a self-guided quit attempt, among 55 cannabis dependent military veterans. Results indicated that participants who experienced poor pre-quit sleep quality had greater risk for lapse within the first 2 days (out of 7) following their quit attempt. Findings are discussed in terms of improving treatments for individuals who report poor sleep quality prior to a cannabis quit attempt. Published by Elsevier Inc. C1 [Babson, Kimberly A.] Stanford Univ, Ctr Hlth Care Evaluat, Vet Affairs Palo Alto Hlth Care Syst, Menlo Pk, CA 94025 USA. [Babson, Kimberly A.] Stanford Univ, Dept Psychiat & Behav Sci, Menlo Pk, CA 94025 USA. [Boden, Matthew Tyler; Harris, Alex H.] Vet Affairs Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA 94025 USA. [Stickle, Timothy R.] Univ Vermont, Dept Psychol, Burlington, VT 05405 USA. [Bonn-Miller, Marcel O.] Philadelphia Vet Affairs Med Ctr, Ctr Excellence Substance Abuse Treatment & Educ, Philadelphia, PA 19104 USA. [Bonn-Miller, Marcel O.] Vet Affairs Palo Alto Hlth Care Syst, Natl Ctr PTSD, Menlo Pk, CA 94025 USA. [Bonn-Miller, Marcel O.] Vet Affairs Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA 94025 USA. RP Babson, KA (reprint author), 795 Willow Rd 152 MPD, Menlo Pk, CA 94025 USA. EM Kimberly.Babson@va.gov OI Babson, Kimberly/0000-0002-9233-8230 NR 46 TC 11 Z9 11 U1 0 U2 16 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD APR PY 2013 VL 44 IS 4 BP 438 EP 443 DI 10.1016/j.jsat.2012.08.224 PG 6 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 096TD UT WOS:000315426300011 PM 23098380 ER PT J AU Wang, Q Wu, PC Dong, DZ Ivanova, I Chu, E Zeliadt, S Vesselle, H Wu, DY AF Wang, Qin Wu, Peter C. Dong, David Z. Ivanova, Iana Chu, Elizabeth Zeliadt, Steven Vesselle, Hubert Wu, Daniel Y. TI Polyploidy road to therapy-induced cellular senescence and escape SO INTERNATIONAL JOURNAL OF CANCER LA English DT Article DE polyploidy; cellular senescence; Cdc2; Cdk1; cancer therapeutics ID ADRIAMYCIN-INDUCED SENESCENCE; BREAST-TUMOR CELLS; MITOTIC CATASTROPHE; CANCER CELLS; GIANT-CELLS; DNA-DAMAGE; ACTIVATION; KINASE; APOPTOSIS; DIVISION AB Therapy-induced cellular senescence (TCS), characterized by prolonged cell cycle arrest, is an in vivo response of human cancers to chemotherapy and radiation. Unfortunately, TCS is reversible for a subset of senescent cells, leading to cellular reproliferation and ultimately tumor progression. This invariable consequence of TCS recapitulates the clinical treatment experience of patients with advanced cancer. We report the findings of a clinicopathological study in patients with locally advanced non-small cell lung cancer demonstrating that marker of in vivo TCS following neoadjuvant therapy prognosticate adverse clinical outcome. In our efforts to elucidate key molecular pathways underlying TCS and cell cycle escape, we have previously shown that the deregulation of mitotic kinase Cdk1 and its downstream effectors are important mediators of survival and cell cycle reentry. We now report that aberrant expression of Cdk1 interferes with apoptosis and promotes the formation of polyploid senescent cells during TCS. These polyploid senescent cells represent important transition states through which escape preferentially occurs. The Cdk1 pathway is in part modulated differentially by p21 and p27 two members of the KIP cyclin-dependent kinase inhibitor family during TCS. Altogether, these studies underscore the importance of TCS in cancer therapeutics. C1 [Wang, Qin; Wu, Peter C.; Ivanova, Iana; Chu, Elizabeth; Wu, Daniel Y.] VA Puget Sound Hlth Care Syst, Seattle Inst Biomed & Clin Res, Seattle, WA 98108 USA. [Wu, Peter C.] VA Puget Sound Hlth Care Syst, Dept Surg, Seattle, WA 98108 USA. [Wu, Peter C.] Univ Washington, Dept Surg, Seattle, WA 98195 USA. [Dong, David Z.] VA Puget Sound Hlth Care Syst, Dept Pathol, Seattle, WA 98108 USA. [Zeliadt, Steven] VA Puget Sound Hlth Care Syst, Dept Hlth Serv, Seattle, WA 98108 USA. [Vesselle, Hubert] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. [Wu, Daniel Y.] Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195 USA. [Wu, Daniel Y.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. RP Wang, Q (reprint author), VA Puget Sound Hlth Care Syst, Seattle Inst Biomed & Clin Res, 1660 S Columbian Way, Seattle, WA 98108 USA. EM proteins@hotmail.com FU National Cancer Institute [R01-CA113892-01]; Veteran Affairs Office of Research and Development Medical Research Service; Veteran Affairs Office of Research & Development Medical Research Service (Biomedical Laboratory R&D Career Development Award-2) FX Grant sponsor: National Cancer Institute; Grant number: R01-CA113892-01; Grant sponsor: Veteran Affairs Office of Research and Development Medical Research Service; This material is based upon work supported by the National Cancer Institute (R01-CA113892-01, D. Wu) and Veteran Affairs Office of Research & Development Medical Research Service (Biomedical Laboratory R&D Career Development Award-2, P. Wu). The authors thank Dr. Liu Yang for his critical reading of our manuscript and his insightful suggestions. They also thank Dr. Chris Guthrie for assisting to obtain the time lapse images. NR 49 TC 21 Z9 21 U1 0 U2 27 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0020-7136 J9 INT J CANCER JI Int. J. Cancer PD APR 1 PY 2013 VL 132 IS 7 BP 1505 EP 1515 DI 10.1002/ijc.27810 PG 11 WC Oncology SC Oncology GA 079NN UT WOS:000314177500003 PM 22945332 ER PT J AU Cacciola, JS Alterman, AI DePhilippis, D Drapkin, ML Valadez, C Fala, NC Oslin, D Mckay, JR AF Cacciola, John S. Alterman, Arthur I. DePhilippis, Dominick Drapkin, Michelle L. Valadez, Charles, Jr. Fala, Natalie C. Oslin, David Mckay, James R. TI Development and initial evaluation of the Brief Addiction Monitor (BAM) SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE Addiction; Substance abuse; Reliability; Validity; Assessment ID SUBSTANCE-ABUSE TREATMENT; RECOVERY MANAGEMENT CHECKUPS; USE DISORDERS; FOLLOW-UP; TREATMENT RETENTION; ARBITRARY METRICS; SEVERITY INDEX; ALCOHOL-USE; RELIABILITY; VALIDITY AB This project developed and tested a 17-item monitoring instrument covering important substance use related behaviors to support measurement-based care and outcomes assessment. The study consisted of two phases, an instrument development phase and an initial study to examine its psychometric properties. Participants were 175 patients entering VA outpatient substance abuse treatment. The findings revealed that this Brief Addiction Monitor (BAM) exhibited acceptable characteristics. Exploratory factor analysis yielded three summary factors; recovery protection, physical and psychological problems, and substance use and risk. The root mean square error of approximation estimate was acceptable and the factors had alpha values exceeding or approaching 0.70. All three factors were sensitive to change and had excellent test-retest reliability. Predictive validity was demonstrated for two factors; recovery protection, and substance use and risk. At the item level, there was little indication of inappropriate response patterns. Change over time was significant for most items, and test-retest reliability was acceptable for nearly all items. Additional research is warranted to further establish the BAM's reliability, validity and usefulness. (C) 2013 Elsevier Inc. All rights reserved. C1 [Cacciola, John S.] Treatment Res Inst, Philadelphia, PA 19106 USA. [Cacciola, John S.; Alterman, Arthur I.; DePhilippis, Dominick; Drapkin, Michelle L.; Oslin, David; Mckay, James R.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [DePhilippis, Dominick; Drapkin, Michelle L.; Oslin, David; Mckay, James R.] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Valadez, Charles, Jr.] La Salle Univ, Philadelphia, PA 19141 USA. [Fala, Natalie C.] Florida Inst Technol, Melbourne, FL 32901 USA. RP Cacciola, JS (reprint author), Treatment Res Inst, 600 Publ Ledger Bldg,150 S Independence Mall W, Philadelphia, PA 19106 USA. EM jcacciola@tresearch.org FU NIDA NIH HHS [K24 DA029062, R01 DA021154, R01 DA21154]; PHS HHS [NIDA K24DA029062] NR 55 TC 26 Z9 26 U1 2 U2 24 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD APR PY 2013 VL 44 IS 3 BP 256 EP 263 DI 10.1016/j.jsat.2012.07.013 PG 8 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 077EQ UT WOS:000314011100002 PM 22898042 ER PT J AU Leshner, AF Tom, SR Kern, RS AF Leshner, Anna F. Tom, Shelley R. Kern, Robert S. TI Errorless learning and social problem solving ability in schizophrenia: An examination of the compensatory effects of training SO PSYCHIATRY RESEARCH LA English DT Article DE Cognitive rehabilitation; Errorless learning; Compensatory; Memory; Severe mental illness ID OF-THE-LITERATURE; COGNITIVE REHABILITATION; NEUROCOGNITIVE DEFICITS; RETROGRADE-AMNESIA; ALZHEIMERS-DISEASE; MEMORY; INDIVIDUALS; PERFORMANCE; METAANALYSIS; REMEDIATION AB Compensatory approaches to cognitive rehabilitation in schizophrenia aim to improve functioning by bypassing or compensating for impaired areas of cognition. At present, there is little empirical evidence that these approaches actually compensate for neurocognitive impairments in improving community functioning. This study examined the effects of errorless learning (EL), a compensatory cognitive rehabilitation approach, on social problem solving ability in schizophrenia. The study included 60 outpatients who met DSM-IV criteria for schizophrenia or schizoaffective disorder. Participants received a baseline battery to assess explicit and implicit memory functioning. Participants were stratified according to gender and level of memory functioning and then randomized to EL or symptom management training. Training was conducted over two days lasting a total of 6 h for each group. Assessment of social problem-solving ability, using the Assessment of Interpersonal Problem Solving Skills (AIPSS), was conducted after completion of training and at a 3-month follow-up without further intervention. Results from hierarchical multiple regression and analysis of covariance each supported the compensatory effects of training. These findings indicate that EL facilitates learning of new skills across varying levels of memory impairment. Future efforts may aim to explore the specific neurocognitive mechanisms involved in EL Published by Elsevier Ireland Ltd. C1 [Leshner, Anna F.; Tom, Shelley R.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Kern, Robert S.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA. [Kern, Robert S.] VISN 22 Mental Illness Res Educ & Clin Ctr, Dept Vet Affairs, Los Angeles, CA USA. RP Kern, RS (reprint author), VA Greater Los Angeles Healthcare Ctr MIRECC 210, Bldg 210,Room 116,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM rkern@ucla.edu FU Stanley Medical Research Institute; NIMH [R01 MH082939]; VA Merit Award FX This project was supported in part by Stanley Medical Research Institute, the NIMH Grant R01 MH082939, and a VA Merit Award received by R. Kern (Principal Investigator). NR 46 TC 6 Z9 6 U1 2 U2 26 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD MAR 30 PY 2013 VL 206 IS 1 BP 1 EP 7 DI 10.1016/j.psychres.2012.10.007 PG 7 WC Psychiatry SC Psychiatry GA 124DB UT WOS:000317442900001 PM 23158835 ER PT J AU Pilkonis, PA Choi, SW Salsman, JM Butt, Z Moore, TL Lawrence, SM Zill, N Cyranowski, JM Kelly, MAR Knox, SS Cella, D AF Pilkonis, Paul A. Choi, Seung W. Salsman, John M. Butt, Zeeshan Moore, Tara L. Lawrence, Suzanne M. Zill, Nicholas Cyranowski, Jill M. Kelly, Morgen A. R. Knox, Sarah S. Cella, David TI Assessment of self-reported negative affect in the NIH Toolbox SO PSYCHIATRY RESEARCH LA English DT Article DE Sadness; Fear; Anger; Item response theory; Measurement ID ITEM RESPONSE THEORY; QUALITY-OF-LIFE; DEPRESSIVE SYMPTOMS; TRIPARTITE MODEL; EMOTIONAL DISORDERS; CHILDRENS REPORTS; ANXIETY; MOTHERS; SCALES; PARENT AB We report on the selection of self-report measures for inclusion in the NIH Toolbox that are suitable for assessing the full range of negative affect including sadness, fear, and anger. The Toolbox is intended to serve as a "core battery" of assessment tools for cognition, sensation, motor function, and emotional health that will help to overcome the lack of consistency in measures used across epidemiological, observational, and intervention studies. A secondary goal of the NIH Toolbox is the identification of measures that are flexible, efficient, and precise, an agenda best fulfilled by the use of item banks calibrated with models from item response theory (IRT) and suitable for adaptive testing. Results from a sample of 1763 respondents supported use of the adult and pediatric item banks for emotional distress from the Patient-Reported Outcomes Measurement Information System (PROMIS) as a starting point for capturing the full range of negative affect in healthy individuals. Content coverage for the adult Toolbox was also enhanced by the development of a scale for somatic arousal using items from the Mood and Anxiety Symptom Questionnaire (MASQ) and scales for hostility and physical aggression using items from the Buss-Perry Aggression Questionnaire (BPAQ). (C) 2012 Elsevier Ireland Ltd. All rights reserved. C1 [Pilkonis, Paul A.; Moore, Tara L.; Lawrence, Suzanne M.; Cyranowski, Jill M.; Kelly, Morgen A. R.] Univ Pittsburgh, Western Psychiat Inst & Clin, Med Ctr, Dept Psychiat, Pittsburgh, PA 15213 USA. [Choi, Seung W.; Salsman, John M.; Butt, Zeeshan; Cella, David] Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, Chicago, IL 60611 USA. [Salsman, John M.; Butt, Zeeshan; Cella, David] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. [Butt, Zeeshan] Northwestern Univ, Feinberg Sch Med, Comprehens Transplant Ctr, Chicago, IL 60611 USA. [Butt, Zeeshan; Cella, David] Northwestern Univ, Feinberg Sch Med, Inst Healthcare Studies, Chicago, IL 60611 USA. [Zill, Nicholas] Westat Corp, Rockville, MD USA. [Kelly, Morgen A. R.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Knox, Sarah S.] W Virginia Univ, Sch Med, Dept Community Med, Morgantown, WV 26506 USA. RP Pilkonis, PA (reprint author), Univ Pittsburgh, Western Psychiat Inst & Clin, Med Ctr, Dept Psychiat, 3811 OHara St, Pittsburgh, PA 15213 USA. EM pilkonispa@upmc.edu FU Federal funds from the Blueprint for Neuroscience Research; Office of Behavioral and Social Sciences Research, National Institutes of Health [HHS-N-260-2006-00007-C] FX This project is funded in whole or in part with Federal funds from the Blueprint for Neuroscience Research and the Office of Behavioral and Social Sciences Research, National Institutes of Health, under Contract no. HHS-N-260-2006-00007-C. NR 67 TC 5 Z9 5 U1 5 U2 19 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD MAR 30 PY 2013 VL 206 IS 1 BP 88 EP 97 DI 10.1016/j.psychres.2012.09.034 PG 10 WC Psychiatry SC Psychiatry GA 124DB UT WOS:000317442900015 PM 23083918 ER PT J AU Roussos, P McClure, MM Hazlett, EA New, AS Siever, LJ Bitsios, P Giakoumaki, SG AF Roussos, Panos McClure, Margaret M. Hazlett, Erin A. New, Antonia S. Siever, Larry J. Bitsios, Panos Giakoumaki, Stella G. TI CACNA1C as a risk factor for schizotypal personality disorder and schizotypy in healthy individuals SO PSYCHIATRY RESEARCH LA English DT Letter ID BIPOLAR DISORDER; ASSOCIATION ANALYSIS; SCHIZOPHRENIA; ANK3 C1 [Roussos, Panos; McClure, Margaret M.; Hazlett, Erin A.; New, Antonia S.; Siever, Larry J.] Mt Sinai Sch Med, Dept Psychiat, Bronx, NY 10468 USA. [Roussos, Panos; McClure, Margaret M.; Hazlett, Erin A.; New, Antonia S.; Siever, Larry J.] James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr VISN 3, Bronx, NY USA. [Roussos, Panos; Bitsios, Panos; Giakoumaki, Stella G.] Univ Crete, Fac Med, Dept Psychiat & Behav Sci, Iraklion, Crete, Greece. RP Roussos, P (reprint author), Mt Sinai Sch Med, Dept Psychiat, Room 4F-21,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM panagiotis.roussos@mssm.edu RI Roussos, Panos/J-7090-2013 OI Roussos, Panos/0000-0002-4640-6239 FU NIMH NIH HHS [R01 MH056140] NR 10 TC 16 Z9 16 U1 0 U2 10 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD MAR 30 PY 2013 VL 206 IS 1 BP 122 EP 123 DI 10.1016/j.psychres.2012.08.039 PG 2 WC Psychiatry SC Psychiatry GA 124DB UT WOS:000317442900021 PM 22985546 ER PT J AU Foland-Ross, LC Thompson, PM Sugar, CA Narr, KL Penfold, C Vasquez, RE Townsend, J Fischer, J Saharan, P Bearden, CE Altshuler, LL AF Foland-Ross, Lara C. Thompson, Paul M. Sugar, Catherine A. Narr, Katherine L. Penfold, Conor Vasquez, Roxanne E. Townsend, Jennifer Fischer, Jeffrey Saharan, Priya Bearden, Carrie E. Altshuler, Lori L. TI Three-dimensional mapping of hippocampal and amygdalar structure in euthymic adults with bipolar disorder not treated with lithium SO PSYCHIATRY RESEARCH-NEUROIMAGING LA English DT Article DE Mood disorder; Magnetic resonance imaging; Hippocampus; Amygdala; Lithium; Bipolar disorder ID FACIAL EMOTION RECOGNITION; TEMPORAL-LOBE STRUCTURES; RATING-SCALE; WHITE-MATTER; YOUNG-ADULTS; MRI; VOLUME; SCHIZOPHRENIA; BRAIN; MANIA AB Structural neuroimaging studies of the amygdala and hippocampus in bipolar disorder have been largely inconsistent. This may be due in part to differences in the proportion of subjects taking lithium or experiencing an acute mood state, as both factors have recently been shown to influence gray matter structure. To avoid these problems, we evaluated euthymic subjects not currently taking lithium. Thirty-two subjects with bipolar type I disorder and 32 healthy subjects were scanned using magnetic resonance imaging. Subcortical regions were manually traced, and converted to three-dimensional meshes to evaluate the main effect of bipolar illness on radial distance. Statistical analyses found no evidence for a main effect of bipolar illness in either region, although exploratory analyses found a significant age by diagnosis interaction in the right amygdala, as well as positive associations between radial distance of the left amygdala and both prior hospitalizations for mania and current medication status. These findings suggest that, when not treated with lithium or in an acute mood state, patients with bipolar disorder exhibit no structural abnormalities of the amygdala or hippocampus. Future studies, nevertheless, that further elucidate the impact of age, course of illness, and medication on amygdala structure in bipolar disorder are warranted. Published by Elsevier Ireland Ltd. C1 [Foland-Ross, Lara C.; Thompson, Paul M.; Saharan, Priya] Univ Calif Los Angeles, Sch Med, Dept Neurol, Lab Neuro Imaging, Los Angeles, CA 90024 USA. [Sugar, Catherine A.; Narr, Katherine L.; Penfold, Conor; Vasquez, Roxanne E.; Townsend, Jennifer; Fischer, Jeffrey; Bearden, Carrie E.; Altshuler, Lori L.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Sugar, Catherine A.] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA USA. [Altshuler, Lori L.] West Los Angeles Healthcare Ctr, Dept Psychiat, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Altshuler, LL (reprint author), UCLA Mood Disorders Res Program, Dept Psychiat & Biobehav Sci, 300 Med Plaza,Suite 1544,Box 957057, Los Angeles, CA 90095 USA. EM laltshuler@mednet.ucla.edu FU National Institute of Mental Health [MH078556, MH075944, MH01848]; National Association for Research on Schizophrenia and Affective Disorders (NARSAD); Brain Mapping Medical Research Organization; Brain Mapping Support Foundation; Pierson-Lovelace Foundation; Ahmanson Foundation; William M. and Linda R. Dietel Philanthropic Fund at the Northern Piedmont Community Foundation; Tamkin Foundation; Jennifer Jones-Simon Foundation; Capital Group Companies Charitable Foundation; Robson Family; Northstar Fund; National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [RR12169, RR13642, RR00865] FX This work was supported by Grants from the National Institute of Mental Health (MH078556 to LCFR, and MH075944 and MH01848 to LLA). Additional support for algorithm development was provided by the NIA, NIBIB, and the National Center for Research Resources (AG016570, EB01651, RR019771 to PT). For their generous support, the authors also thank the National Association for Research on Schizophrenia and Affective Disorders (NARSAD), Brain Mapping Medical Research Organization, Brain Mapping Support Foundation, Pierson-Lovelace Foundation, The Ahmanson Foundation, William M. and Linda R. Dietel Philanthropic Fund at the Northern Piedmont Community Foundation, Tamkin Foundation, Jennifer Jones-Simon Foundation, Capital Group Companies Charitable Foundation, Robson Family and Northstar Fund. The project was also supported by Grants RR12169, RR13642 and RR00865 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH). NR 54 TC 7 Z9 7 U1 0 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0925-4927 J9 PSYCHIAT RES-NEUROIM JI Psychiatry Res. Neuroimaging PD MAR 30 PY 2013 VL 211 IS 3 BP 195 EP 201 DI 10.1016/j.pscychresns.2012.08.002 PG 7 WC Clinical Neurology; Neuroimaging; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 123HN UT WOS:000317379100002 PM 23149020 ER PT J AU Stefater, JA Rao, S Bezold, K Aplin, AC Nicosia, RF Pollard, JW Ferrara, N Lang, RA AF Stefater, James A., III Rao, Sujata Bezold, Katie Aplin, Alfred C. Nicosia, Roberto F. Pollard, Jeffrey W. Ferrara, Napoleone Lang, Richard A. TI Macrophage Wnt-Calcineurin-Flt1 signaling regulates mouse wound angiogenesis and repair SO BLOOD LA English DT Article ID IMMUNOSUPPRESSED MICE; INFLAMMATORY CELLS; TGF-BETA; VEGF; RECEPTOR; CALCINEURIN; PROTEIN; INHIBITION; LETHALITY; SECRETION AB The treatment of festering wounds is one of the most important aspects of medical care. Macrophages are important components of wound repair, both in fending off infection and in coordinating tissue repair. Here we show that macrophages use a Wnt-Calcineurin-Flt1 signaling pathway to suppress wound vasculature and delay repair. Conditional mutants deficient in both Wntless/GPR177, the secretory transporter of Wnt ligands, and CNB1, the essential component of the nuclear factor of activated T cells dephosporylation complex, displayed enhanced angiogenesis and accelerated repair. Furthermore, in myeloid-like cells, we show that noncanonical Wnt activates Flt1, a naturally occurring inhibitor of vascular endothelial growth factor-A-mediated angiogenesis, but only when calcineurin function is intact. Then, as expected, conditional deletion of Flt1 in macrophages resulted in enhanced wound angiogenesis and repair. These results are consistent with the published link between enhanced angiogenesis and enhanced repair, and establish novel therapeutic approaches for treatment of wounds. C1 [Stefater, James A., III; Rao, Sujata; Bezold, Katie; Lang, Richard A.] Cincinnati Childrens Hosp Med Ctr, Div Pediat Ophthalmol, Visual Syst Grp, Cincinnati, OH 45229 USA. [Stefater, James A., III; Rao, Sujata; Bezold, Katie; Lang, Richard A.] Cincinnati Childrens Hosp Med Ctr, Div Dev Biol, Cincinnati, OH 45229 USA. [Stefater, James A., III; Rao, Sujata; Bezold, Katie; Lang, Richard A.] Univ Cincinnati, Dept Ophthalmol, Cincinnati, OH USA. [Aplin, Alfred C.; Nicosia, Roberto F.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Aplin, Alfred C.; Nicosia, Roberto F.] VA Puget Sound Hlth Care Syst, Pathol & Lab Med, Seattle, WA USA. [Pollard, Jeffrey W.] Yeshiva Univ, Albert Einstein Coll Med, Bronx, NY USA. [Ferrara, Napoleone] Genentech Inc, San Francisco, CA 94080 USA. RP Lang, RA (reprint author), Cincinnati Childrens Hosp Med Ctr, Div Pediat Ophthalmol, 3333 Burnet Ave, Cincinnati, OH 45229 USA. EM richard.lang@cchmc.org FU National Institutes of Health [R01CA131270, T32GM063483-08S1] FX This work was supported by grants from the National Institutes of Health (R01CA131270) (J.P. and R. A. L) and (T32GM063483-08S1) (J.A.S). NR 40 TC 20 Z9 20 U1 1 U2 5 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD MAR 28 PY 2013 VL 121 IS 13 BP 2574 EP 2578 DI 10.1182/blood-2012-06-434621 PG 5 WC Hematology SC Hematology GA 182RT UT WOS:000321762400029 PM 23303818 ER PT J AU Epstein, AJ Srinivas, SK Nicholson, S Herrin, J Asch, DA AF Epstein, Andrew J. Srinivas, Sindhu K. Nicholson, Sean Herrin, Jeph Asch, David A. TI Association between physicians' experience after training and maternal obstetrical outcomes: cohort study SO BMJ-BRITISH MEDICAL JOURNAL LA English DT Article ID LEARNING-CURVE; MORTALITY; SURGEONS; CARE AB Objective To assess the association between obstetricians' years of experience after training and the maternal complications of their patients during their first 40 years of post-residency practice. Design Retrospective cohort analysis. Setting Obstetrical discharges from acute care hospitals in Florida and New York between academic years 1992 and 2009. Population 6 704 311 deliveries performed by 5175 obstetricians. Main outcome measure Three composite measures of maternal complication rates per physician year from vaginal and cesarean births separately and combined, adjusted for secular trends. Results Obstetricians' maternal complication rates declined during the first three decades after completion of residency. The improvement was largest in the first decade and diminished thereafter. For all deliveries, the change was -0.21 (95% confidence interval -0.23 to -0.19) percentage points per year in the first decade, -0.11 (-0.13 to -0.09) percentage points per year in the second decade, and -0.05 (-0.08 to -0.01) percentage points in the third decade (P<0.001 for second to first decade comparison; P=0.001 for third to second decade comparison). The patterns were comparable for cesarean deliveries and vaginal deliveries and across several sensitivity checks. Conclusions Among obstetricians practicing in Florida and New York, those with more years of experience had fewer maternal complications. This association persisted over the first three decades of practice but diminished in magnitude. C1 [Epstein, Andrew J.; Asch, David A.] Philadelphia Vet Affairs Med Ctr, Dept Vet Affairs, Ctr Hlth Equity Res & Promot, Philadelphia, PA 19104 USA. [Epstein, Andrew J.; Asch, David A.] Univ Penn, Div Gen Internal Med, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Epstein, Andrew J.; Srinivas, Sindhu K.; Asch, David A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Srinivas, Sindhu K.] Univ Penn, Dept Obstet & Gynecol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Nicholson, Sean] Cornell Univ, Dept Policy Anal & Management, Coll Human Ecol, Ithaca, NY 14853 USA. [Herrin, Jeph] Yale Univ, Sect Cardiovasc Med, Dept Med, Sch Med, New Haven, CT 06510 USA. [Herrin, Jeph] Hlth Res & Educ Trust, Chicago, IL 60606 USA. RP Epstein, AJ (reprint author), Philadelphia Vet Affairs Med Ctr, Dept Vet Affairs, Ctr Hlth Equity Res & Promot, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM eandrew@mail.med.upenn.edu OI Asch, David/0000-0002-7970-286X NR 17 TC 2 Z9 2 U1 0 U2 5 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1756-1833 J9 BMJ-BRIT MED J JI BMJ-British Medical Journal PD MAR 28 PY 2013 VL 346 AR f1596 DI 10.1136/bmj.f1596 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 117XI UT WOS:000316986200003 PM 23538919 ER PT J AU Utzschneider, KM Bayer-Carter, JL Arbuckle, MD Tidwell, JM Richards, TL Craft, S AF Utzschneider, Kristina M. Bayer-Carter, Jennifer L. Arbuckle, Matthew D. Tidwell, Jaime M. Richards, Todd L. Craft, Suzanne TI Beneficial effect of a weight-stable, low-fat/low-saturated fat/low-glycaemic index diet to reduce liver fat in older subjects SO BRITISH JOURNAL OF NUTRITION LA English DT Article DE Non-alcoholic fatty liver; Dietary fat; Glycaemic index; Saturated fat ID MAGNETIC-RESONANCE-SPECTROSCOPY; HIGH-CARBOHYDRATE DIET; HEPATIC STEATOSIS; NONALCOHOLIC STEATOHEPATITIS; INSULIN SENSITIVITY; ACID SYNTHESIS; GLUCOSE; DISEASE; OBESE; RESISTANCE AB Non-alcoholic fatty liver disease is associated with insulin resistance and dyslipidaemia and can progress to steatohepatitis and cirrhosis. We sought to determine whether dietary fat and saturated fat content alter liver fat in the absence of weight change in an older population. Liver fat was quantified by magnetic resonance spectroscopy before and after 4 weeks on an isoenergetic low-fat/low-saturated fat/low-glycaemic index (LGI) (LSAT: 23% fat/7% saturated fat/GI < 55) or a high-fat/high-saturated fat/high-GI (HSAT: 43% fat/24% saturated fat/GI > 70) diet in older subjects. In the present study, twenty subjects (seven males/thirteen females; age 69.3 (SEM 1.6) years, BMI 26.9 (SEM 0.8) kg/m(2)) were randomised to the LSAT diet and fifteen subjects (six males/nine females; age 68.6 (SEM 1.8) years, BMI 28.1 (SEM 0.9) kg/m(2)) to the HSAT diet. Weight remained stable. Liver fat decreased significantly on the LSAT diet (median 2.2 (interquartile range (IQR) 3.1) to 1.7 (IQR 1.8) %, P = 0.002) but did not change on the HSAT diet (median 1.2 (IQR 4.1) to 1.6 (IQR 3.9) %). The LSAT diet lowered fasting glucose and total cholesterol, HDL-cholesterol and LDL-cholesterol and raised TAG (P<0.05), while the HSAT diet had no effect on glucose or HDL-cholesterol but increased total cholesterol and LDL-cholesterol (P<0.05). Fasting insulin and homeostasis model of insulin resistance did not change significantly on either diet, but the Matsuda index of insulin sensitivity improved on the LSAT diet (P<0.05). Assignment to the LSAT v. HSAT diet was a predictor of changes in lipid parameters but not liver fat. We conclude that diet composition may be an important factor in the accumulation of liver fat, with a low-fat/low-saturated fat/LGI diet being beneficial. C1 [Utzschneider, Kristina M.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. [Utzschneider, Kristina M.] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. [Bayer-Carter, Jennifer L.; Arbuckle, Matthew D.; Tidwell, Jaime M.; Craft, Suzanne] VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA 98108 USA. [Bayer-Carter, Jennifer L.; Craft, Suzanne] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Richards, Todd L.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. RP Utzschneider, KM (reprint author), VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, 1660 South Columbian Way, Seattle, WA 98108 USA. EM kutzschn@u.washington.edu FU VA Office of Research and Development Medical Research Service [R37 AG-10880, UL1RR025014, P30 DK017047]; University of Washington Diagnostic Imaging Science Center FX We are grateful to the study participants for their contribution and time. This study was supported in part by the VA Office of Research and Development Medical Research Service, grant no. R37 AG-10880, UL1RR025014, P30 DK017047 and the University of Washington Diagnostic Imaging Science Center. The funding agencies had no role in the design, implementation, analysis or interpretation of the data. The authors' responsibilities were as follows: K. M. U. designed the MRS sub-study, analysed the data and wrote the manuscript; J. L. B.-C. designed the diet interventions; M. D. A. and J. M. T. coordinated the study and data entry; T. L. R. designed the MRS protocol and interpreted the scans; S. C. designed the parent study and assisted with the data analysis. All authors read and approved the final manuscript. None of the authors had a conflict of interest to disclose. NR 53 TC 21 Z9 21 U1 1 U2 11 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 0007-1145 J9 BRIT J NUTR JI Br. J. Nutr. PD MAR 28 PY 2013 VL 109 IS 6 BP 1096 EP 1104 DI 10.1017/S0007114512002966 PG 9 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 107GE UT WOS:000316202300015 PM 22849970 ER PT J AU Kettl, P AF Kettl, Paul TI The NRA Let Me Down SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material C1 Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Kettl, P (reprint author), Philadelphia VA Med Ctr, Philadelphia, PA USA. EM paul.kettl@va.gov NR 2 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 27 PY 2013 VL 309 IS 12 BP 1239 EP 1240 DI 10.1001/jama.2013.1302 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 112WO UT WOS:000316625200023 PM 23532239 ER PT J AU Wilson, LB Rojas, DC Shatti, S Tregellas, JR AF Wilson, Lisa B. Rojas, Donald C. Shatti, Shireen Tregellas, Jason R. TI Greater neuronal responses during automatic semantic processing in schizophrenia SO NEUROREPORT LA English DT Article DE functional magnetic resonance imaging; fusiform gyrus; schizophrenia; semantic priming; superior temporal gyrus ID MRC PSYCHOLINGUISTIC DATABASE; ACTIVATION; BRAIN AB A core feature of schizophrenia is a disturbance of associative processes. To date, no functional MRI studies have investigated semantic priming in schizophrenia under experimental conditions that measure automatic, as opposed to strategic, processing. The present study's focus was to investigate hemodynamic responses during indirect semantic priming at a short stimulus onset asynchrony (i.e. 350 ms), conditions which are considered to be a particularly sensitive measure of automatic spreading activation during semantic processing and of the associative disturbances in schizophrenia. Seventeen individuals with DSM-IV, schizophrenia and 15 comparison participants underwent functional scanning while performing a lexical decision task on directly related, indirectly related, unrelated, and word/nonword pairs. A random-effects region of interest analysis within a priori temporal and frontal regions was performed. Whereas comparison individuals exhibited hemodynamic suppression in response to priming, individuals with schizophrenia exhibited hemodynamic enhancement. Relative to the comparison group, these enhancements were observed in the left fusiform and superior temporal gyri for indirectly related word pairs relative to unrelated pairs. Greater priming-related responses within temporal regions may reflect increased and prolonged automatic spreading activation during semantic processing in schizophrenia. NeuroReport 24:212-216 (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins. C1 [Wilson, Lisa B.; Rojas, Donald C.; Shatti, Shireen; Tregellas, Jason R.] Univ Colorado Denver, Dept Psychiat, Aurora, CO 80045 USA. [Tregellas, Jason R.] Denver VA Med Ctr, Res Serv, Denver, CO USA. RP Wilson, LB (reprint author), Univ Colorado Denver, Dept Psychiat, 13001 East 17th Pl, Aurora, CO 80045 USA. EM lisa.wilson@ucdenver.edu RI Tregellas, Jason/J-3637-2015 OI Rojas, Don/0000-0001-6560-9616 FU National Institute of Mental Health (NIMH) [MH60214]; National Institute of Child Health and Human Development (NICHHD) [HD041697]; Brain and Behavior Research Foundation; Blowitz-Ridgeway Foundation FX Funding for this study was provided by the National Institute of Mental Health (NIMH) Grant MH60214, the National Institute of Child Health and Human Development (NICHHD) Grant HD041697 the Brain and Behavior Research Foundation and the Blowitz-Ridgeway Foundation. NR 24 TC 4 Z9 4 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0959-4965 J9 NEUROREPORT JI Neuroreport PD MAR 27 PY 2013 VL 24 IS 5 BP 212 EP 216 DI 10.1097/WNR.0b013e32835eb688 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 103VD UT WOS:000315946700002 PM 23399997 ER PT J AU Brizendine, KD Baddley, JW Pappas, PG AF Brizendine, Kyle D. Baddley, John W. Pappas, Peter G. TI Predictors of Mortality and Differences in Clinical Features among Patients with Cryptococcosis According to Immune Status SO PLOS ONE LA English DT Article ID ORGAN TRANSPLANT RECIPIENTS; VIRUS-NEGATIVE PATIENTS; AMPHOTERICIN-B; PULMONARY CRYPTOCOCCOSIS; NEOFORMANS INFECTION; RANDOMIZED-TRIAL; MENINGITIS; FLUCYTOSINE; FLUCONAZOLE; DISEASE AB Introduction: Cryptococcosis is an invasive fungal infection causing substantial morbidity and mortality. Prognostic factors are largely derived from trials conducted prior to the modern era of antifungal and potent combination antiretroviral therapies, immunosuppression, and transplantation. Data describing the clinical features and predictors of mortality in a modern cohort are needed. Methods: We conducted a retrospective cohort study of patients at our institution diagnosed with cryptococcosis from 1996 through 2010. Data included demographics, clinical features, diagnostics, treatment, and outcomes. Results: We identified 302 individuals: 108 (36%) human immunodeficiency virus (HIV)-positive, 84 (28%) organ transplant recipients (OTRs), and 110 (36%) non-HIV, non-transplant (NHNT) patients including 39 with no identifiable immunodeficiency. Mean age was 49 years, 203 (67%) were male and 170 (56%) were white. All-cause mortality at 90 days was 21%. In multivariable logistic regression analyses, cryptococcemia (OR 5.09, 95% CI 2.54-10.22) and baseline opening pressure >25 cmH(2)O (OR 2.93, 95% CI 1.25-6.88) were associated with increased odds of mortality; HIV-positive patients (OR 0.46, 95% CI 0.19-1.16) and OTRs (OR 0.46, 95% CI 0.21-1.05) had lower odds of death compared to NHNT patients. Conclusions: Predictors of mortality from cryptococcosis in the modern period include cryptococcemia, high intracranial pressure, and NHNT status while drug(s) used for induction and historical prognostic factors including organ failure syndromes and hematologic malignancy were not associated with mortality. C1 [Brizendine, Kyle D.] Cleveland Clin, Dept Infect Dis, Cleveland, OH 44106 USA. [Baddley, John W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Baddley, John W.; Pappas, Peter G.] Univ Alabama Birmingham, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA. RP Brizendine, KD (reprint author), Cleveland Clin, Dept Infect Dis, Cleveland, OH 44106 USA. EM brizenk@ccf.org; pappas@uab.edu FU National Institutes of Health [T32AI520699] FX KDB acknowledges National Institutes of Health mentored training grant, T32AI520699. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 31 TC 36 Z9 37 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 26 PY 2013 VL 8 IS 3 AR e60431 DI 10.1371/journal.pone.0060431 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 123VE UT WOS:000317418500134 PM 23555970 ER PT J AU Atkinson, C Floerchinger, B Qiao, F Casey, S Williamson, T Moseley, E Stoica, S Goddard, M Ge, XP Tullius, SG Tomlinson, S AF Atkinson, Carl Floerchinger, Bernhard Qiao, Fei Casey, Sarah Williamson, Tucker Moseley, Ellen Stoica, Serban Goddard, Martin Ge, Xupeng Tullius, Stefan G. Tomlinson, Stephen TI Donor Brain Death Exacerbates Complement-Dependent Ischemia/Reperfusion Injury in Transplanted Hearts SO CIRCULATION LA English DT Article DE inflammation; ischemia; reperfusion injury; transplantation ID ISCHEMIA-REPERFUSION INJURY; P-SELECTIN LIGAND; LIVER-REGENERATION; ACTIVATION; RAT; C3A; ALLOGRAFT; C5A; MEDIATORS; KIDNEY AB Background-Brain death (BD) can immunologically prime the donor organ and is thought to lead to exacerbated ischemia/reperfusion injury after transplantation. Using a newly developed mouse model of BD, we investigated the effect of donor BD on posttransplantation cardiac ischemia/reperfusion injury. We further investigated the therapeutic effect of a targeted complement inhibitor in recipients of BD donor hearts and addressed the clinical relevance of these studies by analyzing human heart biopsies from BD and domino (living) donors. Methods and Results-Hearts from living or BD donor C57BL/6 mice were transplanted into C57BL/6 or BALB/c recipients. Recipient mice were treated with the complement inhibitor CR2-Crry or vehicle control (n=6). Isografts were analyzed 48 hours after transplantation for injury, inflammation, and complement deposition, and allografts were monitored for graft survival. Human cardiac biopsies were analyzed for complement deposition and inflammatory cell infiltration. In the murine model, donor BD exacerbated ischemia/reperfusion injury and graft rejection, as demonstrated by increased myocardial injury, serum cardiac troponin, cellular infiltration, complement deposition, inflammatory chemokine and cytokine levels, and by decreased graft survival. CR2-Crry treatment of recipients significantly reduced all measured outcomes in grafts from both BD and living donors compared with controls. Analysis of human samples documented the relevance of our experimental findings and revealed exacerbated complement deposition and inflammation in grafts from BD donors compared with grafts from living donors. Conclusions-BD exacerbates posttransplantation cardiac ischemia/reperfusion injury in mice and humans and decreases survival of mouse allografts. Furthermore, targeted complement inhibition in recipient mice ameliorates BD-exacerbated ischemia/reperfusion injury. (Circulation. 2013; 127: 1290-1299.) C1 [Atkinson, Carl; Qiao, Fei; Casey, Sarah; Williamson, Tucker; Tomlinson, Stephen] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. [Floerchinger, Bernhard; Tullius, Stefan G.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Transplant Surg, Boston, MA 02115 USA. [Floerchinger, Bernhard; Tullius, Stefan G.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Transplant Surg Res Lab, Boston, MA 02115 USA. [Floerchinger, Bernhard] Univ Med Ctr Regensburg, Dept Cardiothorac Surg, Regensburg, Germany. [Moseley, Ellen; Stoica, Serban; Goddard, Martin] Papworth Hosp NHS Trust, Dept Pathol, Cambridge, England. [Stoica, Serban] Bristol Childrens Hosp, Bristol, Avon, England. [Stoica, Serban] Inst Heart, Bristol, Avon, England. [Ge, Xupeng] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. [Tomlinson, Stephen] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Tomlinson, S (reprint author), Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. EM stullius@partners.org; tomlinss@musc.edu FU National Institutes of Health [RO1 HL 86562, HL082485]; US Department of Veterans Affairs [1BX001218]; American Heart Association [SDG AHA 065100]; Fundacion Carlos Slim de la Salud; Deutsche Forschungsgemeinschaft [DFG/FL 703/1-1]; University of Regensburg; South Carolina Clinical & Translational Research Institute, Medical University of South Carolina's CTSA, National Institutes of Health/National Center for Advancing Translational Sciences [UL1TR000062] FX This study was supported by grants from the National Institutes of Health (RO1 HL 86562 and HL082485 to Dr Tomlinson), the US Department of Veterans Affairs (1BX001218 to Dr Tomlinson), the American Heart Association (SDG AHA 065100 to Dr Atkinson), the Fundacion Carlos Slim de la Salud (to Dr Tullius), Deutsche Forschungsgemeinschaft (DFG/FL 703/1-1) and the University of Regensburg (to Dr Floerchinger), and South Carolina Clinical & Translational Research Institute, Medical University of South Carolina's CTSA, National Institutes of Health/National Center for Advancing Translational Sciences grant UL1TR000062. NR 36 TC 17 Z9 18 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAR 26 PY 2013 VL 127 IS 12 BP 1290 EP + DI 10.1161/CIRCULATIONAHA.112.000784 PG 12 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 113NQ UT WOS:000316675100021 PM 23443736 ER PT J AU Shunk, RL AF Shunk, Rebecca Lesto TI Professionalism A Piercing Dilemma SO JAMA INTERNAL MEDICINE LA English DT Editorial Material C1 [Shunk, Rebecca Lesto] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Shunk, Rebecca Lesto] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Shunk, RL (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM rebecca.shunk@va.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 J9 JAMA INTERN MED JI JAMA Intern. Med. PD MAR 25 PY 2013 VL 173 IS 6 BP 406 EP 406 DI 10.1001/jamainternmed.2013.2744 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 154NA UT WOS:000319681400001 PM 23420355 ER PT J AU Singh, H Giardina, TD Meyer, AND Forjuoh, SN Reis, MD Thomas, EJ AF Singh, Hardeep Giardina, Traber Davis Meyer, Ashley N. D. Forjuoh, Samuel N. Reis, Michael D. Thomas, Eric J. TI Types and Origins of Diagnostic Errors in Primary Care Settings SO JAMA INTERNAL MEDICINE LA English DT Article ID ADVERSE EVENTS; MALPRACTICE CLAIMS; CANCER-DIAGNOSIS; MISSED OPPORTUNITIES; MULTISITE SURVEY; GENERAL-PRACTICE; MEDICAL ERRORS; INTERVENTIONS; PHYSICIANS; HARM AB Importance: Diagnostic errors are an understudied aspect of ambulatory patient safety. Objectives: To determine the types of diseases missed and the diagnostic processes involved in cases of confirmed diagnostic errors in primary care settings and to determine whether record reviews could shed light on potential contributory factors to inform future interventions. Design: We reviewed medical records of diagnostic errors detected at 2 sites through electronic health record-based triggers. Triggers were based on patterns of patients' unexpected return visits after an initial primary care index visit. Setting: A large urban Veterans Affairs facility and a large integrated private health care system. Participants: Our study focused on 190 unique instances of diagnostic errors detected in primary care visits between October 1, 2006, and September 30, 2007. Main Outcome Measures: Through medical record reviews, we collected data on presenting symptoms at the index visit, types of diagnoses missed, process breakdowns, potential contributory factors, and potential for harm from errors. Results: In 190 cases, a total of 68 unique diagnoses were missed. Most missed diagnoses were common conditions in primary care, with pneumonia (6.7%), decompensated congestive heart failure (5.7%), acute renal failure (5.3%), cancer (primary) (5.3%), and urinary tract infection or pyelonephritis (4.8%) being most common. Process breakdowns most frequently involved the patient-practitioner clinical encounter (78.9%) but were also related to referrals (19.5%), patient-related factors (16.3%), follow-up and tracking of diagnostic information (14.7%), and performance and interpretation of diagnostic tests (13.7%). A total of 43.7% of cases involved more than one of these processes. Patient-practitioner encounter breakdowns were primarily related to problems with history-taking (56.3%), examination (47.4%), and/or ordering diagnostic tests for further workup (57.4%). Most errors were associated with potential for moderate to severe harm. Conclusions and Relevance: Diagnostic errors identified in our study involved a large variety of common diseases and had significant potential for harm. Most errors were related to process breakdowns in the patient-practitioner clinical encounter. Preventive interventions should target common contributory factors across diagnoses, especially those that involve data gathering and synthesis in the patient-practitioner encounter. C1 [Singh, Hardeep; Giardina, Traber Davis; Meyer, Ashley N. D.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston VA Hlth Serv Res & Dev Ctr Excellence, Houston, TX 77030 USA. [Singh, Hardeep; Giardina, Traber Davis; Meyer, Ashley N. D.] Baylor Coll Med, Sect Hlth Serv Res, Dept Med, Houston, TX USA. [Forjuoh, Samuel N.; Reis, Michael D.] Texas A&M Hlth Sci Ctr, Coll Medi, Dept Family & Community Med, Temple, TX USA. [Thomas, Eric J.] Univ Texas Houston, Mem Hermann Ctr Health care Qual & Safety, Houston, TX USA. [Thomas, Eric J.] Univ Texas Houston, Div Gen Med, Dept Med, Sch Med, Houston, TX USA. RP Singh, H (reprint author), Michael E DeBakey Vet Affairs Med Ctr 152, Houston VA Hlth Serv Res & Dev Ctr Excellence, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hrdeeps@bcm.edu OI Davis Giardina, Traber/0000-0002-9184-6524; Meyer, Ashley/0000-0001-7993-8584 FU National Institutes of Health K23 Career Development Award [K23CA125585]; Agency for Health Care Research and Quality Health Services Research Demonstration and Dissemination grant [R18HS17244-02]; Houston VA HSR&D Center of Excellence [HFP90-020]; VA Office of Academic Affiliations Fellowship Program FX The study was supported by National Institutes of Health K23 Career Development Award K23CA125585 to Dr Singh, by Agency for Health Care Research and Quality Health Services Research Demonstration and Dissemination grant R18HS17244-02 to Dr Thomas, and in part by Houston VA HSR&D Center of Excellence grant HFP90-020 and the VA Office of Academic Affiliations Fellowship Program to Dr Meyer. NR 38 TC 71 Z9 71 U1 2 U2 18 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 J9 JAMA INTERN MED JI JAMA Intern. Med. PD MAR 25 PY 2013 VL 173 IS 6 BP 418 EP 425 DI 10.1001/jamainternmed.2013.2777 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 154NA UT WOS:000319681400004 PM 23440149 ER PT J AU Beach, MC Fitzgerald, A Saha, S AF Beach, Mary Catherine Fitzgerald, April Saha, Somnath TI White Coat Hype: Branding Physicians With Professional Attire SO JAMA INTERNAL MEDICINE LA English DT Editorial Material ID APPEARANCE C1 [Beach, Mary Catherine; Fitzgerald, April] Johns Hopkins Univ Hosp, Div Gen Internal Med, Baltimore, MD 21287 USA. [Saha, Somnath] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Sect Gen Internal Med, Portland, OR 97201 USA. RP Beach, MC (reprint author), Johns Hopkins Univ Hosp, Div Gen Internal Med, 2024 Monument St,Room 2-511, Baltimore, MD 21287 USA. EM mcbeach@jhmi.edu NR 10 TC 3 Z9 3 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 J9 JAMA INTERN MED JI JAMA Intern. Med. PD MAR 25 PY 2013 VL 173 IS 6 BP 467 EP 468 DI 10.1001/jamainternmed.2013.3766 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 154NA UT WOS:000319681400017 PM 23420503 ER PT J AU Gao, Y Geng, LY Orson, F Kinsey, B Kosten, TR Shen, XY Brimijoin, S AF Gao, Yang Geng, Liyi Orson, Frank Kinsey, Berma Kosten, Thomas R. Shen, Xiaoyun Brimijoin, Stephen TI Effects of anti-cocaine vaccine and viral gene transfer of cocaine hydrolase in mice on cocaine toxicity including motor strength and liver damage SO CHEMICO-BIOLOGICAL INTERACTIONS LA English DT Article; Proceedings Paper CT International Meeting on Cholinesterases CY JUN 04-09, 2012 CL Kazan, RUSSIA DE Cocaine toxicity; Anti-cocaine vaccine; Mouse; Alanine transaminase; Histopathology; Grip strength ID HUMAN BUTYRYLCHOLINESTERASE; INDUCED HEPATOTOXICITY; ABUSE; INTERCEPTION AB In developing an vivo drug-interception therapy to treat cocaine abuse and hinder relapse into drug seeking provoked by re-encounter with cocaine, two promising agents are: (1) a cocaine hydrolase enzyme (CocH) derived from human butyrylcholinesterase and delivered by gene transfer; (2) an anti-cocaine antibody elicited by vaccination. Recent behavioral experiments showed that antibody and enzyme work in a complementary fashion to reduce cocaine-stimulated locomotor activity in rats and mice. Our present goal was to test protection against liver damage and muscle weakness in mice challenged with massive doses of cocaine at or near the LD50 level (100-120 mg/kg, i.p.). We found that, when the interceptor proteins were combined at doses that were only modestly protective in isolation (enzyme, 1 mg/kg; antibody, 8 mg/kg), they provided complete protection of liver tissue and motor function. When the enzyme levels were similar to 400-fold higher, after in vivo transduction by adeno-associated viral vector, similar protection was observed from CocH alone. (C) 2012 Elsevier Ireland Ltd. All rights reserved. C1 [Gao, Yang; Geng, Liyi; Brimijoin, Stephen] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA. [Orson, Frank; Kinsey, Berma; Shen, Xiaoyun] Dept Med, Houston, TX USA. [Kosten, Thomas R.] Dept Psychiat & Neurosci, Houston, TX USA. [Orson, Frank; Kosten, Thomas R.] Dept Pathol & Immunol, Houston, TX USA. [Orson, Frank; Kinsey, Berma; Kosten, Thomas R.; Shen, Xiaoyun] Dept Vet Affairs Med Ctr, Houston, TX USA. RP Brimijoin, S (reprint author), Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA. EM brimijoin@mayo.edu FU NIDA [DP1 DA031340, R01 DA023979, R01 DA023979 S1]; Mayo Foundation FX We thank Drs D. Baltimore and S. J. Russell for generously providing crucial viral vectors for this research. Our work was supported by NIDA grants DP1 DA031340, R01 DA023979, and R01 DA023979 S1, and by Mayo Foundation. NR 21 TC 8 Z9 8 U1 0 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0009-2797 EI 1872-7786 J9 CHEM-BIOL INTERACT JI Chem.-Biol. Interact. PD MAR 25 PY 2013 VL 203 IS 1 SI SI BP 208 EP 211 DI 10.1016/j.cbi.2012.08.006 PG 4 WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology GA 134HU UT WOS:000318201800042 PM 22935511 ER PT J AU Beidas, RS Aarons, G Barg, F Evans, A Hadley, T Hoagwood, K Marcus, S Schoenwald, S Walsh, L Mandell, DS AF Beidas, Rinad S. Aarons, Gregory Barg, Frances Evans, Arthur Hadley, Trevor Hoagwood, Kimberly Marcus, Steven Schoenwald, Sonja Walsh, Lucia Mandell, David S. TI Policy to implementation: evidence-based practice in community mental health - study protocol SO IMPLEMENTATION SCIENCE LA English DT Article DE Evidence-based practice; Community mental health; Policy; Implementation; Fidelity; Organizational variables ID CHILD-WELFARE SYSTEMS; SOCIAL-CONTEXT OSC; ORGANIZATIONAL READINESS; SERVICES; CLIMATE; LEADERSHIP; THERAPY; INTERVENTIONS; ATTITUDES; FIDELITY AB Background: Evidence-based treatments (EBTs) are not widely available in community mental health settings. In response to the call for implementation of evidence-based treatments in the United States, states and counties have mandated behavioral health reform through policies and other initiatives. Evaluations of the impact of these policies on implementation are rare. A systems transformation about to occur in Philadelphia, Pennsylvania, offers an important opportunity to prospectively study implementation in response to a policy mandate. Methods/design: Using a prospective sequential mixed-methods design, with observations at multiple points in time, we will investigate the responses of staff from 30 community mental health clinics to a policy from the Department of Behavioral Health encouraging and incentivizing providers to implement evidence-based treatments to treat youth with mental health problems. Study participants will be 30 executive directors, 30 clinical directors, and 240 therapists. Data will be collected prior to the policy implementation, and then at two and four years following policy implementation. Quantitative data will include measures of intervention implementation and potential moderators of implementation (i.e., organizational-and leader-level variables) and will be collected from executive directors, clinical directors, and therapists. Measures include self-reported therapist fidelity to evidence-based treatment techniques as measured by the Therapist Procedures Checklist-Revised, organizational variables as measured by the Organizational Social Context Measurement System and the Implementation Climate Assessment, leader variables as measured by the Multifactor Leadership Questionnaire, attitudes towards EBTs as measured by the Evidence-Based Practice Attitude Scale, and knowledge of EBTs as measured by the Knowledge of Evidence-Based Services Questionnaire. Qualitative data will include semi-structured interviews with a subset of the sample to assess the implementation experience of high-, average-, and low-performing agencies. Mixed methods will be integrated through comparing and contrasting results from the two methods for each of the primary hypotheses in this study. Discussion: Findings from the proposed research will inform both future policy mandates around implementation and the support required for the success of these policies, with the ultimate goal of improving the quality of treatment provided to youth in the public sector. C1 [Beidas, Rinad S.; Evans, Arthur; Hadley, Trevor; Walsh, Lucia; Mandell, David S.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Aarons, Gregory] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Barg, Frances] Univ Penn, Dept Family Med & Community Hlth, Perelman Sch Med, Philadelphia, PA 19104 USA. [Evans, Arthur] Dept Behav Hlth & Intellectual DisAbil Serv, Philadelphia, PA USA. [Hoagwood, Kimberly] NYU, Dept Psychiat, New York, NY 10016 USA. [Marcus, Steven] Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia Vet Affairs Med Ctr, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. [Schoenwald, Sonja] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. RP Beidas, RS (reprint author), Univ Penn, Dept Psychiat, Perelman Sch Med, 3535 Market St,3rd Floor, Philadelphia, PA 19104 USA. EM rbeidas@upenn.edu RI Mandell, David/H-2730-2012 OI Mandell, David/0000-0001-8240-820X FU Department of Behavioral Health and Intellectual DisAbility Services; Evidence Based Practice and Innovation (EPIC) group; NIMH [K23 MH099179]; National Institute of Mental Health [R25 MH080916]; Quality Enhancement Research Initiative (QUERI); Department of Veterans Affairs Contract; Veterans Health Administration; Office of Research & Development, Health Services Research & Development Service FX We are especially grateful for the support the Department of Behavioral Health and Intellectual DisAbility Services has provided for this project, and for the Evidence Based Practice and Innovation (EPIC) group. Funding for this research project was supported by the following grants from NIMH: (K23 MH099179, Beidas). Additionally, the preparation of this article was supported in part by the Implementation Research Institute (IRI), at the George Warren Brown School of Social Work, Washington University in St. Louis; through an award from the National Institute of Mental Health (R25 MH080916) and Quality Enhancement Research Initiative (QUERI), Department of Veterans Affairs Contract, Veterans Health Administration, Office of Research & Development, Health Services Research & Development Service. Dr. Beidas is an IRI fellow. We would like to thank the following experts who provided their time and input on this project: Dr. Marc Atkins, Dr. Ross Brownson, Dr. David Chambers, Dr. Charles Glisson, Dr. Nicholas Ialongo, Dr. John Landsverk, and Dr. Enola Proctor. We are also grateful for the time and effort provided by Steven Lucas and Margaret Mary Downey with this project. NR 38 TC 13 Z9 14 U1 4 U2 39 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD MAR 24 PY 2013 VL 8 AR 38 DI 10.1186/1748-5908-8-38 PG 9 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 137EU UT WOS:000318419100001 PM 23522556 ER PT J AU Crabtree, D Boyer-Guittaut, M Ouyang, XS Fineberg, N Zhang, JH AF Crabtree, Donna Boyer-Guittaut, Michael Ouyang, Xiaosen Fineberg, Naomi Zhang, Jianhua TI Dopamine and its metabolites in cathepsin D heterozygous mice before and after MPTP administration SO NEUROSCIENCE LETTERS LA English DT Article DE MPTP; Monoamine; Lysosome; Heterozygotes; Behavioral assessment ID ALPHA-SYNUCLEIN; RAT-BRAIN; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; TRANSFERASE; RESISTANCE; MECHANISM; TRANSPORT; TOXICITY; OXIDASE; ENZYMES AB Cathepsin D (CD) is a lysosomal aspartyl protease which plays an important role in alpha-synuclein degradation, and neuronal survival. CD knockout mice die by post-natal day 25 +/- 1 due to intestinal necrosis. We analyzed the young adult male heterozygous mice, and found no behavior abnormalities in the heterozygous mice compared to wildtype littermates. LC3-II, p62, and alpha-synuclein levels are similar, while LAMP1 is higher in the striatum in CD heterozygous compared to wildtype mice. Interestingly, we found that dopamine and metabolites in the striatum and olfactory bulbs are at higher levels than wildtype littermates, while the DOPAC/DA and HVA/DA ratio remain similar between wildtype and CD heterozygous mice. In response to sub-chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration, dopamine, DOPAC, and HVA are depleted to similar levels in the striatum in both heterozygous and wildtype mice. Dopamine synthesizing enzyme tyrosine hydroxylase, metabolic enzyme monoamine oxidase, and catechol-O-methyltransferase (COMT) levels are similar in the striatum in wild-type and heterozygous mice. These studies provide valuable information regarding how lysosomal function may contribute to neurochemical homeostasis in animal models. (C) 2013 Elsevier Ireland Ltd. All rights reserved. C1 [Crabtree, Donna; Boyer-Guittaut, Michael; Ouyang, Xiaosen; Zhang, Jianhua] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Boyer-Guittaut, Michael; Ouyang, Xiaosen; Zhang, Jianhua] Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL USA. [Ouyang, Xiaosen; Zhang, Jianhua] Birmingham VA Med Ctr, Dept Vet Affairs, Birmingham, AL USA. [Fineberg, Naomi] UAB Sch Publ Hlth, Dept Biostat, Birmingham, AL USA. [Boyer-Guittaut, Michael] Univ Franche Comte, Biochim Lab, SFR IBCT,FED 4234, UFR Sci & Tech,EA3922, F-25030 Besancon, France. RP Zhang, JH (reprint author), Univ Alabama Birmingham, Dept Pathol, BMRII-534,901 19th St S, Birmingham, AL 35294 USA. EM zhanja@uab.edu RI di Ronza, Alberto/H-7674-2016 OI di Ronza, Alberto/0000-0002-9813-5143; Zhang, Jianhua/0000-0002-2128-9574 FU Michael J Fox Foundation; VA merit award; UAB Behavioral Assessment Core [P30 NS47466]; [NIHR01-NS064090] FX We thank members of the Zhang Laboratory for technical help and discussions. We thank Dr. Paul Saftig for the cathepsin D knockout mice, Dr. Thomas Van Groen for his help and expertise with the behavioral assessments. This work was supported by Michael J Fox Foundation, NIHR01-NS064090 and a VA merit award (to JZ), and in part by P30 NS47466 (UAB Behavioral Assessment Core). NR 21 TC 4 Z9 4 U1 0 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD MAR 22 PY 2013 VL 538 BP 3 EP 8 DI 10.1016/j.neulet.2013.01.035 PG 6 WC Neurosciences SC Neurosciences & Neurology GA 120FH UT WOS:000317155700002 PM 23391753 ER PT J AU Aguirre, JD Clark, HM McIlvin, M Vazquez, C Palmere, SL Grab, DJ Seshu, J Hart, PJ Saito, M Culotta, VC AF Aguirre, J. Dafhne Clark, Hillary M. McIlvin, Matthew Vazquez, Christine Palmere, Shaina L. Grab, Dennis J. Seshu, J. Hart, P. John Saito, Mak Culotta, Valeria C. TI A Manganese-rich Environment Supports Superoxide Dismutase Activity in a Lyme Disease Pathogen, Borrelia burgdorferi SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID SACCHAROMYCES-CEREVISIAE; STAPHYLOCOCCUS-AUREUS; ESCHERICHIA-COLI; LEUCINE AMINOPEPTIDASE; NEISSERIA-GONORRHOEAE; OXIDATIVE STRESS; BINDING PROTEIN; TYROSINE 34; IRON; RESISTANCE AB The Lyme disease pathogen Borrelia burgdorferi represents a novel organism in which to study metalloprotein biology in that this spirochete has uniquely evolved with no requirement for iron. Not only is iron low, but we show here that B. burgdorferi has the capacity to accumulate remarkably high levels of manganese. This high manganese is necessary to activate the SodA superoxide dismutase (SOD) essential for virulence. Using a metalloproteomic approach, we demonstrate that a bulk of B. burgdorferi SodA directly associates with manganese, and a smaller pool of inactive enzyme accumulates as apoprotein. Other metalloproteins may have similarly adapted to using manganese as co-factor, including the BB0366 aminopeptidase. Whereas B. burgdorferi SodA has evolved in a manganese-rich, iron-poor environment, the opposite is true for Mn-SODs of organisms such as Escherichia coli and bakers' yeast. These Mn-SODs still capture manganese in an iron-rich cell, and we tested whether the same is true for Borrelia SodA. When expressed in the iron-rich mitochondria of Saccharomyces cerevisiae, B. burgdorferi SodA was inactive. Activity was only possible when cells accumulated extremely high levels of manganese that exceeded cellular iron. Moreover, there was no evidence for iron inactivation of the SOD. B. burgdorferi SodA shows strong overall homology with other members of the Mn-SOD family, but computer-assisted modeling revealed some unusual features of the hydrogen bonding network near the enzyme's active site. The unique properties of B. burgdorferi SodA may represent adaptation to expression in the manganese-rich and iron-poor environment of the spirochete. C1 [Aguirre, J. Dafhne; Clark, Hillary M.; Vazquez, Christine; Palmere, Shaina L.; Culotta, Valeria C.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA. [McIlvin, Matthew; Saito, Mak] Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA. [Grab, Dennis J.] Johns Hopkins Univ, Sch Med, Div Med Microbiol, Dept Pathol, Baltimore, MD 21205 USA. [Seshu, J.] Univ Texas San Antonio, Dept Biol, San Antonio, TX 78249 USA. [Hart, P. John] South Texas Vet Hlth Care Syst, Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. [Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. RP Culotta, VC (reprint author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA. EM vculotta@jhsph.edu FU National Institutes of Health [R01 ES08996, GM50016, SC1 AI078559, T32 GM080189]; Johns Hopkins University NIEHS, National Institutes of Health, center; Robert A. Welch Foundation [AQ-1399]; Veterans Affairs Department Grant, South Texas Veterans Health Care System [I01BX000506]; Gordon and Betty Moore Foundation Marine Microbiology Program; National Science Foundation Chemical Oceanography Grant [OCE-1031271] FX This work was supported, in whole or in part, by National Institutes of Health Grants R01 ES08996 and GM50016 (to V. C. C.) and SC1 AI078559 (to J. S.). This work was also supported in part by the Johns Hopkins University NIEHS, National Institutes of Health, center, by Robert A. Welch Foundation Grant AQ-1399, and in part by Veterans Affairs Department Grant I01BX000506, South Texas Veterans Health Care System (to P. J. H.). Metalloproteomic studies were funded by the Gordon and Betty Moore Foundation Marine Microbiology Program and National Science Foundation Chemical Oceanography Grant OCE-1031271 (to M. A. S.).; Supported by National Institutes of Health Grant T32 GM080189. NR 57 TC 29 Z9 29 U1 2 U2 49 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD MAR 22 PY 2013 VL 288 IS 12 BP 8468 EP 8478 DI 10.1074/jbc.M112.433540 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 112AS UT WOS:000316564500044 PM 23376276 ER PT J AU Contreras-Shannon, V Heart, DL Paredes, RM Navaira, E Catano, G Maffi, SK Walss-Bass, C AF Contreras-Shannon, Veronica Heart, Dylan L. Paredes, R. Madelaine Navaira, Erica Catano, Gabriel Maffi, Shivani Kaushal Walss-Bass, Consuelo TI Clozapine-Induced Mitochondria Alterations and Inflammation in Brain and Insulin-Responsive Cells SO PLOS ONE LA English DT Article ID INDUCED METABOLIC ALTERATIONS; OXIDATIVE STRESS; RAT-BRAIN; ANTIPSYCHOTIC MEDICATIONS; POSSIBLE MECHANISM; ENERGY-METABOLISM; OBESITY; DYSFUNCTION; RESISTANCE; SCHIZOPHRENIA AB Background: Metabolic syndrome (MetS) is a constellation of factors including abdominal obesity, hyperglycemia, dyslipidemias, and hypertension that increase morbidity and mortality from diabetes and cardiovascular diseases and affects more than a third of the population in the US. Clozapine, an atypical antipsychotic used for the treatment of schizophrenia, has been found to cause drug-induced metabolic syndrome (DIMS) and may be a useful tool for studying cellular and molecular changes associated with MetS and DIMS. Mitochondria dysfunction, oxidative stress and inflammation are mechanisms proposed for the development of clozapine-related DIMS. In this study, the effects of clozapine on mitochondrial function and inflammation in insulin responsive and obesity-associated cultured cell lines were examined. Methodology/Principal Findings: Cultured mouse myoblasts (C2C12), adipocytes (3T3-L1), hepatocytes (FL-83B), and monocytes (RAW 264.7) were treated with 0, 25, 50 and 75 mu M clozapine for 24 hours. The mitochondrial selective probe TMRM was used to assess membrane potential and morphology. ATP levels from cell lysates were determined by bioluminescence assay. Cytokine levels in cell supernatants were assessed using a multiplex array. Clozapine was found to alter mitochondria morphology, membrane potential, and volume, and reduce ATP levels in all cell lines. Clozapine also significantly induced the production of proinflammatory cytokines IL-6, GM-CSF and IL12-p70, and this response was particularly robust in the monocyte cell line. Conclusions/ Significance: Clozapine damages mitochondria and promotes inflammation in insulin responsive cells and obesity-associated cell types. These phenomena are closely associated with changes observed in human and animal studies of MetS, obesity, insulin resistance, and diabetes. Therefore, the use of clozapine in DIMS may be an important and relevant tool for investigating cellular and molecular changes associated with the development of these diseases in the general population. C1 [Contreras-Shannon, Veronica; Heart, Dylan L.] St Marys Univ, Dept Biol Sci, San Antonio, TX USA. [Paredes, R. Madelaine; Navaira, Erica; Walss-Bass, Consuelo] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Catano, Gabriel] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Catano, Gabriel] Univ Texas Hlth Sci Ctr San Antonio, Vet Adm Ctr Personalized Med, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Maffi, Shivani Kaushal] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA. [Maffi, Shivani Kaushal] Reg Acad Hlth Ctr Edinburg, Div Med Res, Edinburg, TX USA. RP Walss-Bass, C (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. EM walss@uthscsa.edu FU St. Mary's University Undergraduate Research Office, Biaggini Undergraduate Research Scholarships, St. Mary's University; Department of Psychiatry, University of Texas Health Science Center at San Antonio FX Summer Undergraduate Research Fellowship from the St. Mary's University Undergraduate Research Office, Biaggini Undergraduate Research Scholarships, St. Mary's University. Friends for Psychiatric Research Grant from the Department of Psychiatry, University of Texas Health Science Center at San Antonio. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 54 TC 24 Z9 24 U1 1 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 20 PY 2013 VL 8 IS 3 AR e59012 DI 10.1371/journal.pone.0059012 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 125SW UT WOS:000317562600051 PM 23527073 ER PT J AU Scimemi, A Meabon, JS Woltjer, RL Sullivan, JM Diamond, JS Cook, DG AF Scimemi, Annalisa Meabon, James S. Woltjer, Randall L. Sullivan, Jane M. Diamond, Jeffrey S. Cook, David G. TI Amyloid-beta(1-42) Slows Clearance of Synaptically Released Glutamate by Mislocalizing Astrocytic GLT-1 SO JOURNAL OF NEUROSCIENCE LA English DT Article ID ALZHEIMERS-DISEASE; TRANSPORTER GLT-1; BRAIN; BETA; NEURODEGENERATION; EXPRESSION; MECHANISM; NEURONS; PATHWAY; PROTECT AB GLT-1, the major glutamate transporter in the adult brain, is abundantly expressed in astrocytic processes enveloping synapses. By limiting glutamate escape into the surrounding neuropil, GLT-1 preserves the spatial specificity of synaptic signaling. Here we show that the amyloid-beta peptide A beta(1-42) markedly prolongs the extracellular lifetime of synaptically released glutamate by reducing GLT-1 surface expression in mouse astrocytes and that this effect is prevented by the vitamin E derivative Trolox. These findings indicate that astrocytic glutamate transporter dysfunction may play an important role in the pathogenesis of Alzheimer's disease and suggest possible mechanisms by which several current treatment strategies could protect against the disease. C1 [Scimemi, Annalisa; Diamond, Jeffrey S.] NINDS, Synapt Physiol Sect, NIH, Bethesda, MD 20892 USA. [Meabon, James S.] Univ Washington, Dept Psychiat, Seattle, WA 98108 USA. [Cook, David G.] Univ Washington, Dept Med, Seattle, WA 98108 USA. [Cook, David G.] Univ Washington, Dept Pharmacol, Seattle, WA 98108 USA. [Sullivan, Jane M.] Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA. [Meabon, James S.; Cook, David G.] VA Puget Sound Hlth Care Syst, Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Woltjer, Randall L.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97239 USA. RP Cook, DG (reprint author), VA Med Ctr, GRECC, 1660 S Columbian Way, Seattle, WA 98108 USA. EM dgcook@u.washington.edu RI Scimemi, Annalisa/O-5396-2014; Diamond, Jeffrey/C-1835-2015 OI Scimemi, Annalisa/0000-0003-4975-093X; Diamond, Jeffrey/0000-0002-1770-2629 FU Veteran's Affairs Office of Research and Development Medical Research Service; NIH [T32 AG000258, RO1 NS055804]; NINDS [NS002986] FX This work was supported by the Veteran's Affairs Office of Research and Development Medical Research Service (D. G. C.), NIH (Grants T32 AG000258, J.S.M.; and RO1 NS055804, J.M.S.), and NINDS Intramural Research Program (Grant NS002986, J.S.D.). We thank Mike Ahlquist, Ping Zhu, and Ning Li for excellent technical assistance. NR 28 TC 30 Z9 31 U1 1 U2 10 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD MAR 20 PY 2013 VL 33 IS 12 BP 5312 EP 5318 DI 10.1523/JNEUROSCI.5274-12.2013 PG 7 WC Neurosciences SC Neurosciences & Neurology GA 111XB UT WOS:000316553800023 PM 23516295 ER PT J AU Wang, Z Ocampo, MA Pang, RD Bota, M Bradesi, S Mayer, EA Holschneider, DP AF Wang, Zhuo Ocampo, Marco A. Pang, Raina D. Bota, Mihail Bradesi, Sylvie Mayer, Emeran A. Holschneider, Daniel P. TI Alterations in Prefrontal-Limbic Functional Activation and Connectivity in Chronic Stress-Induced Visceral Hyperalgesia SO PLOS ONE LA English DT Article ID BRAIN-GUT AXIS; IRRITABLE-BOWEL-SYNDROME; CHRONIC RESTRAINT STRESS; CENTRAL-NERVOUS-SYSTEM; DENDRITIC REORGANIZATION; VOLUNTARY SUPPRESSION; PERIAQUEDUCTAL GRAY; CEREBRAL ACTIVATION; PYRAMIDAL NEURONS; FOS EXPRESSION AB Repeated water avoidance stress (WAS) induces sustained visceral hyperalgesia (VH) in rats measured as enhanced visceromotor response to colorectal distension (CRD). This model incorporates two characteristic features of human irritable bowel syndrome (IBS), VH and a prominent role of stress in the onset and exacerbation of IBS symptoms. Little is known regarding central mechanisms underlying the stress-induced VH. Here, we applied an autoradiographic perfusion method to map regional and network-level neural correlates of VH. Adult male rats were exposed to WAS or sham treatment for 1 hour/day for 10 days. The visceromotor response was measured before and after the treatment. Cerebral blood flow (CBF) mapping was performed by intravenous injection of radiotracer ([C-14]-iodoantipyrine) while the rat was receiving a 60-mmHg CRD or no distension. Regional CBF-related tissue radioactivity was quantified in autoradiographic images of brain slices and analyzed in 3-dimensionally reconstructed brains with statistical parametric mapping. Compared to sham rats, stressed rats showed VH in association with greater CRD-evoked activation in the insular cortex, amygdala, and hypothalamus, but reduced activation in the prelimbic area (PrL) of prefrontal cortex. We constrained results of seed correlation analysis by known structural connectivity of the PrL to generate structurally linked functional connectivity (SLFC) of the PrL. Dramatic differences in the SLFC of PrL were noted between stressed and sham rats under distension. In particular, sham rats showed negative correlation between the PrL and amygdala, which was absent in stressed rats. The altered pattern of functional brain activation is in general agreement with that observed in IBS patients in human brain imaging studies, providing further support for the face and construct validity of the WAS model for IBS. The absence of prefrontal cortex-amygdala anticorrelation in stressed rats is consistent with the notion that impaired corticolimbic modulation acts as a central mechanism underlying stress-induced VH. C1 [Wang, Zhuo; Ocampo, Marco A.; Holschneider, Daniel P.] Univ So Calif, Dept Psychiat & Behav Sci, Los Angeles, CA 93385 USA. [Pang, Raina D.; Holschneider, Daniel P.] Univ So Calif, Program Neurosci, Los Angeles, CA USA. [Bota, Mihail] Univ So Calif, Dept Biol Sci, Los Angeles, CA 90089 USA. [Holschneider, Daniel P.] Univ So Calif, Dept Neurol, Los Angeles, CA USA. [Bradesi, Sylvie; Mayer, Emeran A.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Bradesi, Sylvie; Mayer, Emeran A.; Holschneider, Daniel P.] Univ Calif Los Angeles, Dept Med, Ctr Neurobiol Stress, Los Angeles, CA 90024 USA. [Mayer, Emeran A.] Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90024 USA. [Mayer, Emeran A.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA. [Mayer, Emeran A.] Univ Calif Los Angeles, Dept Biobehav Sci, Los Angeles, CA USA. RP Holschneider, DP (reprint author), Univ So Calif, Dept Psychiat & Behav Sci, Los Angeles, CA 93385 USA. EM holschne@usc.edu FU United States National Institutes of Health [P50DK064539, R24AT002681] FX The research was supported by United States National Institutes of Health grants P50DK064539 (Mayer) and R24AT002681 (Mayer). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 81 TC 13 Z9 13 U1 2 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 19 PY 2013 VL 8 IS 3 AR e59138 DI 10.1371/journal.pone.0059138 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 125SR UT WOS:000317562100082 PM 23527114 ER PT J AU Xiao, WC Peng, YY Liu, Y Li, Z Li, SL Zheng, XF AF Xiao, Weichun Peng, Yanyan Liu, Yong Li, Zhi Li, Senlin Zheng, Xiaofeng TI HSCARG Inhibits NADPH Oxidase Activity through Regulation of the Expression of p47phox SO PLOS ONE LA English DT Article ID NF-KAPPA-B; SENSOR PROTEIN; TUMOR-CELLS; ACTIVATION; DIPHENYLENEIODONIUM; MODULATION; INDUCTION; APOPTOSIS; INCREASE; ASSAY AB Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase catalyzes the transfer of electrons from NADPH to O-2, which is the main source of reactive oxygen species (ROS) in nonphagocytic cells. Excess ROS are toxic; therefore, keeping ROS in homeostasis in cells can protect cells from oxidative damage. It is meaningful to further understand the molecular mechanism by which ROS homeostasis is mediated. Human protein HSCARG is a newly identified oxidative sensor and a negative regulator of NF-kappa B. Here, we find that HSCARG represses the cellular ROS generation through inhibiting mRNA and protein expression of p47phox, a subunit of NADPH oxidase. In contrast, shRNA-mediated HSCARG knockdown increases endogenous p47phox expression level. And HSCARG has no obvious effect on ROS production in p47phox-depleted cells. Furthermore, HSCARG regulates p47phox through inhibition of NF-kappa B activity. Our findings identify HSCARG as a novel regulator in regulation of the activity of NADPH oxidase and ROS homeostasis. C1 [Xiao, Weichun; Peng, Yanyan; Liu, Yong; Li, Zhi; Zheng, Xiaofeng] State Key Lab Prot & Plant Gene Res, Beijing, Peoples R China. [Xiao, Weichun; Peng, Yanyan; Liu, Yong; Li, Zhi; Zheng, Xiaofeng] Peking Univ, Sch Life Sci, Dept Biochem & Mol Biol, Beijing 100871, Peoples R China. [Li, Senlin] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Li, Senlin] South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Zheng, XF (reprint author), State Key Lab Prot & Plant Gene Res, Beijing, Peoples R China. EM xiaofengz@pku.edu.cn FU National Science Foundation of China [30930020, 31170709]; National High Technology and Development Program of China 973 programs [2010CB911800]; International Centre for Genetic Engineering and Biotechnology [CRP/CHN09-01] FX This work was supported by grants from the National Science Foundation of China (30930020 and 31170709) the National High Technology and Development Program of China 973 programs (No. 2010CB911800), and the International Centre for Genetic Engineering and Biotechnology (Project No. CRP/CHN09-01). The funders had no roles in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 33 TC 2 Z9 3 U1 0 U2 12 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 19 PY 2013 VL 8 IS 3 AR e59301 DI 10.1371/journal.pone.0059301 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 125SR UT WOS:000317562100101 PM 23527155 ER PT J AU Adams, SG Peters, JI AF Adams, Sandra G. Peters, Jay I. TI Amoxicillin/clavulanate vs placebo: more exacerbation cures, fewer recurrences in mild-to-moderate COPD SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material C1 [Adams, Sandra G.] Univ Texas San Antonio, Hlth Sci Ctr, San Antonio, TX 78249 USA. South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Adams, SG (reprint author), Univ Texas San Antonio, Hlth Sci Ctr, San Antonio, TX 78249 USA. OI Miravitlles, Marc/0000-0002-9850-9520 NR 2 TC 0 Z9 0 U1 0 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAR 19 PY 2013 VL 158 IS 6 AR JC3 DI 10.7326/0003-4819-158-6-201303190-02003 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 112AY UT WOS:000316565100002 PM 23552686 ER PT J AU Aneja, A Esquitin, R Shah, K Iyengar, R Nisenbaum, R Melo, M Matthewkutty, S Sethi, SS Mamdani, M Farkouh, ME AF Aneja, Ashish Esquitin, Ricardo Shah, Kshitij Iyengar, Rupa Nisenbaum, Rosane Melo, Magda Matthewkutty, Shiny Sethi, Sanjum S. Mamdani, Muhammad Farkouh, Michael E. TI Authors' Self-Declared Financial Conflicts of Interest Do Not Impact the Results of Major Cardiovascular Trials SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE cardiovascular; clinical trial; conflicts of interest; financial; industry; randomized controlled trials ID CLINICAL-TRIALS; PHARMACEUTICAL-INDUSTRY; INTEREST DISCLOSURE; DRUG TRIALS; ASSOCIATION; OUTCOMES; TIES AB Objectives This study assessed whether the results of major, potentially practice-altering cardiovascular trials were influenced by the authors' self-declared financial conflicts of interest (FCOI). Secondary objectives included assessment of trial outcomes by source of funding, by FCOI subtype, and by trial endpoints. Background Financial conflicts of interest, ubiquitous in cardiovascular medicine because of significant investigator-industry collaborations, potentially can influence trial outcomes. Methods A MEDLINE search was performed using the MeSH term cardiovascular disease limited to randomized controlled trials and clinical trials published from January 1, 2000, through April 15, 2008, in 3 high-impact journals. Two reviewers independently abstracted data from the published article. Chi-square tests, Fisher exact tests, and multivariate logistic regression were used to assess the associations between FCOI and study characteristics and between FCOI and trial outcomes. Results Of the 550 articles reviewed, 51.1% satisfied FCOI criteria, including at least one of the following: stock ownership, employee, speaker's bureau, and consultant). Of the 538 articles providing sponsorship information, 34.6% reported funding solely by nonprofit organizations, 48.3% reported funding solely by industry, and 17.1% reported funding by a combination. Prevalence of FCOI significantly increased with level of industry funding: 21.5% (none), 50.0% (shared), 75.0% (industry solely, n = 281, p < 0.0001). However, no differences in reporting of favorable results were detected when articles were analyzed by self-declared FCOI (60.5% vs. 59.5% in those with and without, odds ratio: 1.04, p = 0.81). This result was upheld in multivariate analysis. Conclusions Authors' self-declared FCOI and source of funding do not seem to impact outcomes in major cardiovascular clinical trials. (J Am Coll Cardiol 2013;61:1137-43) (C) 2013 by the American College of Cardiology Foundation C1 [Aneja, Ashish] Case Western Reserve Univ, Heart & Vasc Ctr, Cleveland, OH 44106 USA. [Esquitin, Ricardo] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Cardiol, Boston, MA 02215 USA. [Shah, Kshitij] James J Peters VA Med Ctr, Dept Med, Bronx, NY USA. [Iyengar, Rupa; Matthewkutty, Shiny; Sethi, Sanjum S.; Farkouh, Michael E.] Mt Sinai Sch Med, Zena & Michael A Weiner Cardiovasc Inst, New York, NY 10029 USA. [Nisenbaum, Rosane] Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Ctr Res Inner City Hlth,Keenan Res Ctr, Toronto, ON M5B 1W8, Canada. [Nisenbaum, Rosane] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada. [Nisenbaum, Rosane; Melo, Magda; Mamdani, Muhammad; Farkouh, Michael E.] Univ Toronto, Li Ka Shing Knowledge Inst, Appl Hlth Res Ctr, Toronto, ON, Canada. [Farkouh, Michael E.] Univ Toronto, Peter Munk Cardiac Ctr, Toronto, ON, Canada. RP Farkouh, ME (reprint author), Mt Sinai Sch Med, Cardiovasc Inst, 1 Gustave L Levy Pl,Box 1074, New York, NY 10029 USA. EM Michael.Farkouh@mssm.edu OI Esquitin, Ricardo/0000-0002-3475-3671 NR 30 TC 9 Z9 10 U1 0 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 19 PY 2013 VL 61 IS 11 BP 1137 EP 1143 DI 10.1016/j.jacc.2012.10.056 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 103UO UT WOS:000315945200003 PM 23395075 ER PT J AU Ganz, PA Bower, JE Kwan, L Castellon, SA Silverman, DHS Geist, C Breen, EC Irwin, MR Cole, SW AF Ganz, Patricia A. Bower, J. E. Kwan, L. Castellon, S. A. Silverman, D. H. S. Geist, C. Breen, E. C. Irwin, M. R. Cole, S. W. TI Does tumor necrosis factor-alpha (TNF-alpha) play a role in post-chemotherapy cerebral dysfunction? SO BRAIN BEHAVIOR AND IMMUNITY LA English DT Article DE Breast cancer; Cognitive complaints; Chemotherapy; Proinflammatory cytokines; TNF-alpha; Neuropsychological testing; Brain imaging ID BREAST-CANCER SURVIVORS; FATIGUE SYMPTOM INVENTORY; QUALITY-OF-LIFE; ADJUVANT CHEMOTHERAPY; COGNITIVE FUNCTION; INFLAMMATORY BIOMARKERS; LONGITUDINAL ASSESSMENT; CHEMORADIATION THERAPY; SYSTEMIC CHEMOTHERAPY; POSTMENOPAUSAL WOMEN AB Post-chemotherapy treated cancer patients frequently report cognitive difficulties. The biology of this phenomenon is poorly understood, with uncertainty about possible direct toxic effects on the brain, secondary effects from systemic inflammation, host factors/genetic predisposition to cognitive complaints, or hormonal changes influencing cognitive function. To elucidate possible mechanisms associated with post-treatment cognitive dysfunction among breast cancer survivors, in 2007 we established a prospective, longitudinal, observational cohort study of early stage breast cancer patients, recruited at the end of initial treatments (primary treatment exposure included surgery, +/- radiation, +/- chemotherapy), and prior to the initiation of adjuvant endocrine therapy. We assessed cognitive complaints, neuropsychological (NP) test performance, markers of inflammation, and brain imaging at baseline, 6 months and 12 months after enrollment. In this analysis of data from the first 93 patients enrolled in the cohort study, we focus on the relationship of circulating levels of proinflammatory cytokines to cerebral functioning and chemotherapy exposure. Among the proinflammatory cytokines tested (IL-1ra, sTNE-RII, CRP, and IL-6) at baseline, only sTNE-RII was increased among chemotherapy exposed patients, with a significant decline in the year after treatment (p = 0.003). Higher baseline sTNE-RII in chemotherapy patients was significantly associated with increased memory complaints. In chemotherapy exposed patients, the longitudinal decline in sTNE-RII was significantly correlated with fewer memory complaints over 12 months (r = -0.34, p = 0.04). Higher baseline sTNE-RII was also associated with relatively diminished brain metabolism in the inferior frontal cortex (r = -0.55, p = 0.02), as well as relatively increased inferior frontal metabolism after 1 year, in chemotherapy-exposed subjects. These preliminary findings suggest that post-chemotherapy increases in TNF-alpha, may be playing an important role in the manifestations of cognitive complaints in breast cancer survivors. (C) 2012 Elsevier Inc. All rights reserved. C1 [Ganz, Patricia A.] Univ Calif Los Angeles, Dept Hlth Policy & Management, Fielding Sch Publ Hlth, Los Sangeles, CA USA. [Ganz, Patricia A.; Cole, S. W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Ganz, Patricia A.; Bower, J. E.; Kwan, L.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Div Canc Prevent & Control Res, Los Angeles, CA 90095 USA. [Bower, J. E.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. [Bower, J. E.; Breen, E. C.; Irwin, M. R.; Cole, S. W.] Semel Inst Neurosci, Cousins Ctr Psychoneuroimmunol, Los Angeles, CA USA. [Castellon, S. A.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Silverman, D. H. S.; Geist, C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med & Mol Pharmacol, Los Angeles, CA 90095 USA. [Breen, E. C.; Irwin, M. R.; Cole, S. W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. RP Ganz, PA (reprint author), Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Div Canc Prevent & Control Res, A2-125 CHS,650 Charles Young Dr South,Box 956900, Los Angeles, CA 90095 USA. EM pganz@mednet.ucla.edu RI Irwin, Michael/H-4870-2013 OI Irwin, Michael/0000-0002-1502-8431 FU Breast Cancer Research Foundation (BCRF) [NIH/NCI R01 CA 109650]; an American Society Clinical Research Professorship; UCLA Older Americans Independence Center (OAIC); OAIC Inflammatory Biology Core [NIH/NIA P30-AG028748]; Norman Cousins Center [PNI. R01-AG034588, R01-AG026364, R01-CA119159, R01-HL079955, R01-HL095799, P30-AG028748, UL RR 033176] FX NIH/NCI R01 CA 109650; the Breast Cancer Research Foundation (BCRF); an American Society Clinical Research Professorship to Dr. Ganz; the UCLA Older Americans Independence Center (OAIC) and the OAIC Inflammatory Biology Core (NIH/NIA P30-AG028748); the Norman Cousins Center for PNI. R01-AG034588; R01-AG026364; R01-CA119159; R01-HL079955; R01-HL095799; P30-AG028748; UL RR 033176 to Dr. Irwin. NR 60 TC 50 Z9 51 U1 2 U2 24 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0889-1591 J9 BRAIN BEHAV IMMUN JI Brain Behav. Immun. PD MAR 15 PY 2013 VL 30 SI SI BP S99 EP S108 DI 10.1016/j.bbi.2012.07.015 PG 10 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA 111GW UT WOS:000316510800012 PM 22884417 ER PT J AU Das, F Ghosh-Choudhury, N Bera, A Dey, N Abboud, HE Kasinath, BS Choudhury, GG AF Das, Falguni Ghosh-Choudhury, Nandini Bera, Amit Dey, Nirmalya Abboud, Hanna E. Kasinath, Balakuntalam S. Choudhury, Goutam Ghosh TI Transforming Growth Factor beta Integrates Smad 3 to Mechanistic Target of Rapamycin Complexes to Arrest Deptor Abundance for Glomerular Mesangial Cell Hypertrophy SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID MESSENGER-RNA TRANSLATION; PLASMINOGEN-ACTIVATOR INHIBITOR-1; SMOOTH-MUSCLE-CELLS; RICTOR-MTOR COMPLEX; HIGH GLUCOSE; DIABETIC-NEPHROPATHY; SIGNAL-TRANSDUCTION; MAMMALIAN TARGET; FIBRONECTIN EXPRESSION; MESENCHYMAL TRANSITION AB In many renal diseases, transforming growth factor beta (TGF beta)-stimulated canonical Smad 3 and noncanonical mechanistic target of rapamycin (mTOR) promote increased protein synthesis and mesangial cell hypertrophy. The cellular underpinnings involving these signaling molecules to regulate mesangial cell hypertrophy are not fully understood. Deptor has recently been identified as an mTOR interacting protein and functions as an endogenous inhibitor of the kinase activity for both TORC1 and TORC2. Prolonged incubation of mesangial cells with TGF beta reduced the levels of deptor concomitant with an increase in TORC1 and TORC2 activity. Sustained TGF beta activation was required to inhibit association of deptor with mTOR, whereas rapid activation had no effect. Using the mTOR inhibitor PP242, we found that TGF beta-induced both early and sustained activation of TORC1 and TORC2 was necessary for deptor suppression. PP242-induced reversal of deptor suppression by TGF beta was associated with a significant inhibition of TGF beta-stimulated protein synthesis and hypertrophy. Interestingly, expression of siRNA against Smad 3 or Smad 7, which blocks TGF beta receptor-specific Smad 3 signaling, prevented TGF beta-induced suppression of deptor abundance and TORC1/2 activities. Furthermore, overexpression of Smad 3 decreased deptor expression similar to TGF beta stimulation concomitant with increased TORC1 and TORC2 activities. Finally, knockdown of deptor reversed Smad 7-mediated inhibition of protein synthesis and mesangial cell hypertrophy induced by TGF beta. These data reveal the requirement of both early and late activation of mTOR for TGF beta-induced protein synthesis. Our results support that TGF beta-stimulated Smad 3 acts as a key node to instill a feedback loop between deptor down-regulation and TORC1/2 activation in driving mesangial cell hypertrophy. C1 [Ghosh-Choudhury, Nandini; Abboud, Hanna E.; Kasinath, Balakuntalam S.; Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, Vet Affairs Res, San Antonio, TX 78229 USA. [Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. [Das, Falguni; Bera, Amit; Dey, Nirmalya; Abboud, Hanna E.; Kasinath, Balakuntalam S.; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. RP Choudhury, GG (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. EM choudhuryg@uthscsa.edu FU National Institutes of Health [RO1 DK50190, RO1 AR 52425, RO1 DK 78971, RO1 DK 077295, RC2A 036613]; Veterans Affairs Merit Review grants; Ronald P. Williams Orthopedic Oncology Developmental Research Award from the Cancer Therapy and Research Center, San Antonio; Juvenile Diabetes Research Foundation; Veterans Affairs Research Service; Veterans Affairs Senior Research Career Scientist Award; Juvenile Diabetes Research Foundation [1-2008-185] FX This work was supported, in whole or in part, by National Institutes of Health Grant RO1 DK50190 and Veterans Affairs Merit Review grants (to G. G. C.).; Supported by National Institutes of Health Grant RO1 AR 52425, Veterans Affairs Merit Review grants, and a Ronald P. Williams Orthopedic Oncology Developmental Research Award from the Cancer Therapy and Research Center, San Antonio.; Supported by National Institutes of Health Grant RO1 DK 78971 and Veterans Affairs Merit Review and Juvenile Diabetes Research Foundation grants.; Supported by National Institutes of Health Grants RO1 DK 077295 and RC2A 036613 and the Veterans Affairs Research Service.; Recipient of Veterans Affairs Senior Research Career Scientist Award and supported by Juvenile Diabetes Research Foundation Grant 1-2008-185. NR 65 TC 11 Z9 13 U1 2 U2 4 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD MAR 15 PY 2013 VL 288 IS 11 BP 7756 EP 7768 DI 10.1074/jbc.M113.455782 PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 110OW UT WOS:000316455300031 PM 23362262 ER PT J AU Wong, ES Liu, CF AF Wong, Edwin S. Liu, Chuan-Fen TI The relationship between local area labor market conditions and the use of Veterans Affairs health services SO BMC HEALTH SERVICES RESEARCH LA English DT Article DE Health services; Utilization; Veterans; Socioeconomic factors ID QUALITY-OF-CARE; BEHAVIORAL-MODEL; MEDICAL-CARE; SYSTEM; ACCESS; VA; ALCOHOL; TRENDS AB Background: In the U.S., economic conditions are intertwined with labor market decisions, access to health care, health care utilization and health outcomes. The Veterans Affairs (VA) health care system has served as a safety net provider by supplying free or reduced cost care to qualifying veterans. This study examines whether local area labor market conditions, measured using county-level unemployment rates, influence whether veterans obtain health care from the VA. Methods: We used survey data from the Behavioral Risk Factor Surveillance System in years 2000, 2003 and 2004 to construct a random sample of 73,964 respondents self-identified as veterans. VA health service utilization was defined as whether veterans received all, some or no care from the VA. Hierarchical ordered logistic regression was used to address unobserved state and county random effects while adjusting for individual characteristics. Local area labor market conditions were defined as the average 12-month unemployment rate in veterans' county of residence. Results: The mean unemployment rate for veterans receiving all, some and no care was 5.56%, 5.37% and 5.24%, respectively. After covariate adjustment, a one percentage point increase in the unemployment rate in a veteran's county of residence was associated with an increase in the probability of receiving all care (0.34%, p-value = 0.056) or some care (0.29%, p-value = 0.023) from the VA. Conclusions: Our findings suggest that the important role of the VA in providing health care services to veterans is magnified in locations with high unemployment. C1 [Wong, Edwin S.; Liu, Chuan-Fen] VA Puget Sound Hlth Care Syst, Northwest Ctr Outcomes Res Older Adults, Seattle, WA 98101 USA. [Wong, Edwin S.; Liu, Chuan-Fen] Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA 98195 USA. RP Wong, ES (reprint author), VA Puget Sound Hlth Care Syst, Northwest Ctr Outcomes Res Older Adults, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM edwin.wong@va.gov FU VA Health Services Research and Development Postdoctoral Fellowship [TPP 61-024] FX Dr. Wong is supported by VA Health Services Research and Development Postdoctoral Fellowship TPP 61-024. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs and the University of Washington. NR 41 TC 0 Z9 0 U1 1 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6963 J9 BMC HEALTH SERV RES JI BMC Health Serv. Res. PD MAR 13 PY 2013 VL 13 AR 96 DI 10.1186/1472-6963-13-96 PG 10 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 119QI UT WOS:000317112000001 ER PT J AU Perederiy, JV Luikart, BW Washburn, EK Schnell, E Westbrook, GL AF Perederiy, Julia V. Luikart, Bryan W. Washburn, Eric K. Schnell, Eric Westbrook, Gary L. TI Neural Injury Alters Proliferation and Integration of Adult-Generated Neurons in the Dentate Gyrus SO JOURNAL OF NEUROSCIENCE LA English DT Article ID ENTORHINAL CORTEX LESION; ELECTRON-MICROSCOPIC ANALYSIS; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; RAT FASCIA-DENTATA; GRANULE CELLS; HIPPOCAMPAL NEUROGENESIS; INDUCED SYNAPTOGENESIS; VESICULAR GLUTAMATE; RECEPTOR ACTIVATION AB Neural plasticity following brain injury illustrates the potential for regeneration in the central nervous system. Lesioning of the perforant path, which innervates the outer two-thirds of the molecular layer of the dentate gyrus, was one of the first models to demonstrate structural plasticity of mature granule cells (Parnavelas et al., 1974; Caceres and Steward, 1983; Diekmann et al., 1996). The dentate gyrus also harbors a continuously proliferating population of neuronal precursors that can integrate into functional circuits and show enhanced short-term plasticity (Schmidt-Hieber et al., 2004; Abrous et al., 2005). To examine the response of adult-generated granule cells to unilateral complete transection of the perforant path in vivo, we tracked these cells using transgenic POMC-EGFP mice or by retroviral expression of GFP. Lesioning triggered a marked proliferation of newborn neurons. Subsequently, the dendrites of newborn neurons showed reduced complexity within the denervated zone, but dendritic spines still formed in the absence of glutamatergic nerve terminals. Electron micrographs confirmed the lack of intact presynaptic terminals apposing spines on mature cells and on newborn neurons. Newborn neurons, but not mature granule cells, had a higher density of dendritic spines in the inner molecular layer postlesion accompanied by an increase in miniature EPSC amplitudes and rise times. Our results indicate that injury causes an increase in newborn neurons and lamina-specific synaptic reorganization indicative of enhanced plasticity. The presence of de novo dendritic spines in the denervated zone suggests that the postlesion environment provides the necessary signals for spine formation. C1 [Perederiy, Julia V.; Luikart, Bryan W.; Washburn, Eric K.; Westbrook, Gary L.] OHSU, Vollum Inst, Portland, OR 97239 USA. [Schnell, Eric] Portland VA Med Ctr, Portland, OR 97239 USA. [Schnell, Eric] OHSU Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA. RP Perederiy, JV (reprint author), OHSU, Vollum Inst, L474,3181 Southwest Sam Jackson Pk Rd, Portland, OR 97239 USA. EM perederi@ohsu.edu OI Schnell, Eric/0000-0002-5623-5015 FU NIH [MH46613, P30 NS06180]; Oregon Partnership for Alzheimer's Research Tax Check-Off Grant FX This work was supported by NIH Grant MH46613 and by Oregon Partnership for Alzheimer's Research Tax Check-Off Grant. We thank Oswald Steward for training in the perforant path lesion procedure. We thank Stephanie Kaech-Petrie with the Jungers Center Microscopy Core for assistance with imaging parameters and Sue Aicher, Melissa Williams, Lisa Dirling, and Robert Kayton with the Electron Microscopy Core for tissue preparation and assistance with imaging equipment (supported by NIH Grant P30 NS06180). NR 82 TC 15 Z9 15 U1 0 U2 9 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD MAR 13 PY 2013 VL 33 IS 11 BP 4754 EP 4767 DI 10.1523/JNEUROSCI.4785-12.2013 PG 14 WC Neurosciences SC Neurosciences & Neurology GA 106CO UT WOS:000316119200011 PM 23486947 ER PT J AU Chhatriwalla, AK Amin, AP Kennedy, KF House, JA Cohen, DJ Rao, SV Messenger, JC Marso, SP AF Chhatriwalla, Adnan K. Amin, Amit P. Kennedy, Kevin F. House, John A. Cohen, David J. Rao, Sunil V. Messenger, John C. Marso, Steven P. CA Natl Cardiovasc Data Registry TI Association Between Bleeding Events and In-hospital Mortality After Percutaneous Coronary Intervention SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID GLYCOPROTEIN IIB/IIIA INHIBITION; CARDIOVASCULAR DATA REGISTRY; MYOCARDIAL-INFARCTION; CLINICAL-OUTCOMES; ACUITY TRIAL; ANTITHROMBOTIC THERAPY; ECONOMIC-EVALUATION; PROGNOSTIC IMPACT; PROPENSITY SCORE; ISCHEMIC EVENTS AB Importance Bleeding is the most common complication after percutaneous coronary intervention (PCI) and is associated with increased morbidity and health care costs. The incidence of bleeding-related mortality after PCI has not been described in a nationally representative population. Furthermore, the relationships among bleeding risk, bleeding site, and mortality are unclear. Objectives To describe the association between bleeding events and in-hospital mortality after PCI and to estimate the adjusted population attributable risk (estimated as the proportion of mortality risk associated with bleeding events), risk difference, and number needed to harm (NNH) for bleeding-related in-hospital mortality after PCI. Design, Setting, and Patients Data from 3 386 688 procedures in the CathPCI Registry performed in the United States between 2004 and 2011 were analyzed. The population attributable risk was calculated after adjustment for baseline demographic, clinical, and procedural variables. To calculate the NNH for bleeding-related mortality, a propensity-matched analysis was performed. Main Outcome Measures In-hospital mortality. Results There were 57 246 bleeding events (1.7%) and 22 165 in-hospital deaths (0.65%) in 3 386 688 PCI procedures. The adjusted population attributable risk for mortality related to major bleeding was 12.1% (95% CI, 11.4%-12.7%) in the entire CathPCI cohort. The propensity-matched population consisted of 56 078 procedures with a major bleeding event and 224 312 controls. In this matched cohort, major bleeding was associated with increased in-hospital mortality (5.26% vs 1.87%; risk difference, 3.39% [95% CI, 3.20%-3.59%]; NNH=29 [95% CI, 28-31]; P < .001). The association between major bleeding and in-hospital mortality was observed in all strata of preprocedural bleeding risk (low: 1.62% vs 0.17%; risk difference, 1.45% [95% CI, 1.13%-1.77%], NNH=69 [95% CI, 57-88], P < .001; intermediate: 3.27% vs 0.71%; risk difference, 2.56% [95% CI, 2.33%-2.79%], NNH=39 [95% CI, 36-43], P < .001; and high: 8.16% vs 3.45%; risk difference, 4.71% [95% CI, 4.35%-5.07%], NNH=21 [95% CI, 20-23], P < .001). Although both access-site and non-access-site bleeding were associated with increased in-hospital mortality (2.73% vs 1.87%; risk difference, 0.86% [95% CI, 0.66%-1.05%], NNH=117 [95% CI, 95-151], P < .001; and 8.25% vs 1.87%; risk difference, 6.39% [95% CI, 6.04%-6.73%], NNH=16 [95% CI, 15-17], P < .001, respectively), the NNH was lower for nonaccess bleeding. Conclusions and Relevance In a large registry of patients undergoing PCI, post-procedural bleeding events were associated with increased risk of in-hospital mortality, with an estimated 12.1% of deaths related to bleeding complications. JAMA. 2013;309(10):1022-1029 www.jama.com C1 [Kennedy, Kevin F.; House, John A.] St Lukes Mid Amer Heart Inst, Dept Biostat, Kansas City, MO 64111 USA. [Chhatriwalla, Adnan K.; Cohen, David J.; Marso, Steven P.] St Lukes Mid Amer Heart Inst, Kansas City, MO 64111 USA. [Chhatriwalla, Adnan K.; Cohen, David J.; Marso, Steven P.] Univ Missouri Kansas City, Sch Med, Dept Internal Med, Div Cardiol, Kansas City, MO USA. [Amin, Amit P.] Washington Univ, Sch Med, Dept Internal Med, Div Cardiol, St Louis, MO 63110 USA. [Rao, Sunil V.] Duke Clin Res Inst, Dept Internal Med, Div Cardiol, Durham, NC USA. [Messenger, John C.] Univ Colorado Denver, Dept Internal Med, Div Cardiol, Denver, CO USA. [Messenger, John C.] Denver VA Med Ctr, Denver, CO USA. RP Chhatriwalla, AK (reprint author), St Lukes Mid Amer Heart Inst, 4300 Wornall Rd,Ste 2000, Kansas City, MO 64111 USA. EM achhatri-walla@saint-lukes.org FU Medtronic; Edwards Lifesciences; Abbott Vascular; Boston Scientific; Eli Lilly; AstraZeneca; Biomet Inc; Daiichii Sankyo; Medicines Company; Novo Nordisk; Amylin Pharmaceuticals; Volcano Corporation; Terumo Medical; American College of Cardiology Foundation's National Cardiovascular Data Registry (NCDR) FX All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Chhatriwalla reports that he will be receiving speaking honoraria from Edwards Lifesciences to be paid directly to Saint Luke's Hospital Foundation of Kansas City. Mr House reports receiving consulting honoraria from Vita Solutions and KU Medical Center. Dr Cohen reports medical board membership for Medtronic and Abbott Vascular and reports receiving research support from Medtronic, Edwards Lifesciences, Abbott Vascular, Boston Scientific, Eli Lilly, AstraZeneca, Biomet Inc, and Daiichii Sankyo; consultant honoraria from AstraZeneca, Eli Lilly, Merck, and Janssen Pharmaceuticals; and speaking honoraria from St Jude Medical and Eli Lilly. Dr Rao reports receiving research support and consultant honoraria from The Medicines Company. Dr Marso reports that all compensation for research activities, including research grants and consulting fees from The Medicines Company, Novo Nordisk, Abbott Vascular, Amylin Pharmaceuticals, Boston Scientific, Volcano Corporation, and Terumo Medical, was paid directly to the Saint Luke's Hospital Foundation of Kansas City. No other disclosures were reported.; This research was supported by the American College of Cardiology Foundation's National Cardiovascular Data Registry (NCDR). NR 33 TC 88 Z9 92 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 13 PY 2013 VL 309 IS 10 BP 1022 EP 1029 DI 10.1001/jama.2013.1556 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 103SH UT WOS:000315938700031 PM 23483177 ER PT J AU Chandrashekhar, R Akers, S Vakilipour, A Shiva-Kumar, P Haines, P Jain, S Saif, H Witschey, W Ferrari, VA Chirinos, JA AF Chandrashekhar, Rahul Akers, Scott Vakilipour, Amin Shiva-Kumar, Prithvi Haines, Philip Jain, Snigdha Saif, Hassam Witschey, Walter Ferrari, Victor A. Chirinos, Julio A. TI TIME-RESOLVED LEFT VENTRICULAR MYOCARDIAL STRESS IN HEART FAILURE WITH REDUCED EJECTION FRACTION REVEALS A MARKED INCREASE IN LATE SYSTOLIC MYOCARDIAL LOAD SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 62nd Annual Scientific Session of the American-College-of-Cardiology CY MAR 09-11, 2013 CL San Francisco, CA SP Amer Coll Cardiol C1 Philadelphia VA Med Ctr, Philadelphia, PA USA. Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 12 PY 2013 VL 61 IS 10 SU S BP E613 EP E613 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 111XO UT WOS:000316555200613 ER PT J AU Chirinos, JA Shiva-Kumar, P Chandrashekhar, R Haines, P Vakilipour, A Saif, H Witschey, W Pandya, N Segers, P Ferrari, V Akers, S AF Chirinos, Julio A. Shiva-Kumar, Prithvi Chandrashekhar, Rahul Haines, Philip Vakilipour, Amin Saif, Hassam Witschey, Walter Pandya, Nirzari Segers, Patrick Ferrari, Victor Akers, Scott TI RELATIONSHIP BETWEEN ARTERIAL LOAD AND LV CONCENTRIC HYPERTROPHY ASSESSED WITH MRI SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 62nd Annual Scientific Session of the American-College-of-Cardiology CY MAR 09-11, 2013 CL San Francisco, CA SP Amer Coll Cardiol C1 Philadelphia VA Med Ctr, Philadelphia, PA USA. Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 12 PY 2013 VL 61 IS 10 SU S BP E1473 EP E1473 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 111XO UT WOS:000316555201578 ER PT J AU Le Elizabeth, DT Pascotto, M Leong-Poi, H Sari, I Micari, A Kaul, S AF Le Elizabeth, Dai-Trang Pascotto, Marco Leong-Poi, Howard Sari, Ibrahim Micari, Antonio Kaul, Sanjiv TI ANTI-INFLAMMATORY AND PRO-ANGIOGENIC EFFECTS OF BETA-BLOCKERS IN A CANINE MODEL OF CHRONIC ISCHEMIC CARDIOMYOPATHY: COMPARISON BETWEEN CARVEDILOL AND METOPROLOL SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 62nd Annual Scientific Session of the American-College-of-Cardiology CY MAR 09-11, 2013 CL San Francisco, CA SP Amer Coll Cardiol C1 Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 12 PY 2013 VL 61 IS 10 SU S BP E1175 EP E1175 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 111XO UT WOS:000316555201280 ER PT J AU Niesor, EJ Schwartz, G Suchankova, G Benghozi, R Abt, M Kallend, D AF Niesor, Eric J. Schwartz, Gregory Suchankova, Gabriela Benghozi, Renee Abt, Markus Kallend, David TI STATIN-INDUCED DECREASE IN ABCA1 EXPRESSION VIA MIR33 INDUCTION MAY COUNTERACT CHOLESTEROL EFFLUX BY HIGH-DENSITY LIPOPROTEINS RAISED WITH THE CHOLESTERYL ESTER TRANSFER PROTEIN MODULATOR DALCETRAPIB SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 62nd Annual Scientific Session of the American-College-of-Cardiology CY MAR 09-11, 2013 CL San Francisco, CA SP Amer Coll Cardiol C1 F Hoffmann La Roche Ltd, Basel, Switzerland. Denver VA Med Ctr, Denver, CO USA. NR 0 TC 2 Z9 2 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 12 PY 2013 VL 61 IS 10 SU S BP E2032 EP E2032 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 111XO UT WOS:000316555202236 ER PT J AU Saha, S Beatty, A Mishra, R Whooley, M Schiller, N AF Saha, Sandeep Beatty, Alexis Mishra, Rakesh Whooley, Mary Schiller, Nelson TI AN ECHOCARDIOGRAPHIC COMPOSITE CARDIAC CALCIFICATION SCORE PREDICTS MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE: THE HEART AND SOUL STUDY SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 62nd Annual Scientific Session of the American-College-of-Cardiology CY MAR 09-11, 2013 CL San Francisco, CA SP Amer Coll Cardiol C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 12 PY 2013 VL 61 IS 10 SU S BP E1024 EP E1024 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 111XO UT WOS:000316555201129 ER PT J AU Chiyomaru, T Yamamura, S Fukuhara, S Hidaka, H Majid, S Saini, S Arora, S Deng, GR Shahryari, V Chang, I Tanaka, Y Tabatabai, ZL Enokida, H Seki, N Nakagawa, M Dahiya, R AF Chiyomaru, Takeshi Yamamura, Soichiro Fukuhara, Shinichiro Hidaka, Hideo Majid, Shahana Saini, Sharanjot Arora, Sumit Deng, Guoren Shahryari, Varahram Chang, Inik Tanaka, Yuichiro Tabatabai, Z. Laura Enokida, Hideki Seki, Naohiko Nakagawa, Masayuki Dahiya, Rajvir TI Genistein Up-Regulates Tumor Suppressor MicroRNA-574-3p in Prostate Cancer SO PLOS ONE LA English DT Article ID GROWTH-FACTOR RECEPTOR; MATRIX-METALLOPROTEINASE TYPE-2; INHIBITS CELL-PROLIFERATION; ANDROGEN-INDEPENDENCE; ENRICHMENT ANALYSIS; SIGNALING PATHWAY; INDUCED APOPTOSIS; GENE-EXPRESSION; BLADDER-CANCER; TARGETING EGFR AB Genistein has been shown to inhibit cancers both in vitro and in vivo, by altering the expression of several microRNAs (miRNAs). In this study, we focused on tumor suppressor miRNAs regulated by genistein and investigated their function in prostate cancer (PCa) and target pathways. Using miRNA microarray analysis and real-time RT-PCR we observed that miR-574-3p was significantly up-regulated in PCa cells treated with genistein compared with vehicle control. The expression of miR-574-3p was significantly lower in PCa cell lines and clinical PCa tissues compared with normal prostate cells (RWPE-1) and adjacent normal tissues. Low expression level of miR-574-3p was correlated with advanced tumor stage and higher Gleason score in PCa specimens. Re-expression of miR-574-3p in PCa cells significantly inhibited cell proliferation, migration and invasion in vitro and in vivo. miR-574-3p restoration induced apoptosis through reducing Bcl-xL and activating caspase-9 and caspase-3. Using GeneCodis software analysis, several pathways affected by miR-574-3p were identified, such as 'Pathways in cancer', 'Jak-STAT signaling pathway', and 'Wnt signaling pathway'. Luciferase reporter assays demonstrated that miR-574-3p directly binds to the 39 UTR of several target genes (such as RAC1, EGFR and EP300) that are components of 'Pathways in cancer'. Quantitative real-time PCR and Western analysis showed that the mRNA and protein expression levels of the three target genes in PCa cells were markedly down-regulated with miR-574-3p. Loss-of-function studies demonstrated that the three target genes significantly affect cell proliferation, migration and invasion in PCa cell lines. Our results show that genistein up-regulates tumor suppressor miR-574-3p expression targeting several cell signaling pathways. These findings enhance understanding of how genistein regulates with miRNA in PCa. C1 [Chiyomaru, Takeshi; Yamamura, Soichiro; Fukuhara, Shinichiro; Majid, Shahana; Saini, Sharanjot; Arora, Sumit; Deng, Guoren; Shahryari, Varahram; Chang, Inik; Tanaka, Yuichiro; Dahiya, Rajvir] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA 94121 USA. [Chiyomaru, Takeshi; Yamamura, Soichiro; Fukuhara, Shinichiro; Majid, Shahana; Saini, Sharanjot; Arora, Sumit; Deng, Guoren; Shahryari, Varahram; Chang, Inik; Tanaka, Yuichiro; Tabatabai, Z. Laura; Dahiya, Rajvir] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Hidaka, Hideo; Enokida, Hideki; Nakagawa, Masayuki] Kagoshima Univ, Dept Urol, Grad Sch Med & Dent Sci, Kagoshima 890, Japan. [Tabatabai, Z. Laura] San Francisco VA Med Ctr, Dept Pathol, San Francisco, CA USA. [Seki, Naohiko] Chiba Univ, Grad Sch Med, Dept Funct Genom, Chiba, Japan. RP Dahiya, R (reprint author), San Francisco VA Med Ctr, Dept Urol, San Francisco, CA 94121 USA. EM rdahiya@urology.ucsf.edu FU National Center for Research Resources of the National Institutes of Health [R01CA160079, R01CA138642, T32DK007790]; VA Merit Review; VA Program Project FX This research was supported by the National Center for Research Resources of the National Institutes of Health through Grant Numbers R01CA160079, R01CA138642, T32DK007790 and VA Merit Review and VA Program Project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 55 TC 49 Z9 52 U1 0 U2 12 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 12 PY 2013 VL 8 IS 3 AR e58929 DI 10.1371/journal.pone.0058929 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 107WV UT WOS:000316252500058 PM 23554959 ER PT J AU Iskandrian, AE Hage, FG AF Iskandrian, Ami E. Hage, Fadi G. TI Declining Frequency of Ischemia Detection Using Stress Myocardial Perfusion Imaging SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Editorial Material DE coronary artery disease risk factors; myocardial ischemia; perfusion; prognosis ID AMERICAN-HEART-ASSOCIATION; CORONARY-ARTERY-DISEASE; OPTIMAL MEDICAL THERAPY; COMPUTED-TOMOGRAPHY; NUCLEAR CARDIOLOGY; TRIAL; OUTCOMES; RISK C1 [Iskandrian, Ami E.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Div Cardiol, Birmingham, AL USA. RP Iskandrian, AE (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, 318 LHRB,1900 Univ Blvd, Birmingham, AL 35294 USA. EM aiskand@uab.edu OI Hage, Fadi/0000-0002-1397-4942 NR 17 TC 10 Z9 11 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 12 PY 2013 VL 61 IS 10 BP 1066 EP 1068 DI 10.1016/j.jacc.2012.12.009 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 100HA UT WOS:000315687300006 PM 23473412 ER PT J AU Knight, SJ AF Knight, Sara J. TI Bridging the Gap at the Center of Patient Centeredness Individual Patient Preferences in Health Care Decision Making SO JAMA INTERNAL MEDICINE LA English DT Editorial Material ID MEN C1 [Knight, Sara J.] US Dept Vet Affairs, Hlth Serv Res & Dev Serv, Off Res & Dev, Vet Hlth Adm, Washington, DC 20420 USA. [Knight, Sara J.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Knight, Sara J.] Univ Calif San Francisco, Dept Urol, San Francisco, CA USA. RP Knight, SJ (reprint author), US Dept Vet Affairs, Hlth Serv Res & Dev Serv, Off Res & Dev, Vet Hlth Adm, 180 Vermont Ave NW, Washington, DC 20420 USA. EM sara.knight@va.gov NR 9 TC 1 Z9 1 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 J9 JAMA INTERN MED JI JAMA Intern. Med. PD MAR 11 PY 2013 VL 173 IS 5 BP 369 EP 370 DI 10.1001/jamainternmed.2013.3370 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 153OY UT WOS:000319613100009 PM 23400376 ER PT J AU Prochazka, AV Caverly, T AF Prochazka, Allan V. Caverly, Tanner TI General Health Checks in Adults for Reducing Morbidity and Mortality From Disease Summary Review of Primary Findings and Conclusions SO JAMA INTERNAL MEDICINE LA English DT Editorial Material C1 [Prochazka, Allan V.] Denver VA Med Ctr, Dept Ambulatory Care, Denver, CO 80220 USA. Univ Colorado, Sch Med, Div Gen Internal Med, Denver, CO USA. RP Prochazka, AV (reprint author), Denver VA Med Ctr, Dept Ambulatory Care, 11B,1055 Clermont, Denver, CO 80220 USA. EM allan.prochazka@va.gov NR 8 TC 6 Z9 7 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 J9 JAMA INTERN MED JI JAMA Intern. Med. PD MAR 11 PY 2013 VL 173 IS 5 BP 371 EP 372 DI 10.1001/jamainternmed.2013.3187 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 153OY UT WOS:000319613100010 PM 23318544 ER PT J AU Dodson, JA Fried, TR Van Ness, PH Goldstein, NE Lampert, R AF Dodson, John A. Fried, Terri R. Van Ness, Peter H. Goldstein, Nathan E. Lampert, Rachel TI Patient Preferences for Deactivation of Implantable Cardioverter-Defibrillators SO JAMA INTERNAL MEDICINE LA English DT Letter ID LIFE; END; MANAGEMENT C1 [Dodson, John A.; Lampert, Rachel] Yale Univ, Sch Med, Cardiol Sect, Dept Internal Med, New Haven, CT 06520 USA. [Dodson, John A.; Fried, Terri R.; Van Ness, Peter H.] Yale Univ, Sch Med, Sect Geriatr, Dept Internal Med, New Haven, CT 06520 USA. Mt Sinai Sch Med, Dept Geriatr & Palliat Care, New York, NY USA. [Goldstein, Nathan E.] James J Peters VA Med Ctr, Bronx, NY USA. RP Lampert, R (reprint author), Yale Univ, Sch Med, Cardiol Sect, 789 Howard Ave,Dana 3,Room 319, New Haven, CT 06520 USA. EM rachel.lampert@yale.edu FU NIA NIH HHS [K24 AG028443, K24AG028443, P30 AG021342, P30AG021342, T32 AG019134] NR 9 TC 18 Z9 18 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 J9 JAMA INTERN MED JI JAMA Intern. Med. PD MAR 11 PY 2013 VL 173 IS 5 BP 377 EP 379 DI 10.1001/jamainternmed.2013.1883 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 153OY UT WOS:000319613100013 PM 23358714 ER PT J AU Steinman, MA AF Steinman, Michael A. TI Reaching Out to Patients to Identify Adverse Drug Reactions and Nonadherence: Necessary but Not Sufficient SO JAMA INTERNAL MEDICINE LA English DT Editorial Material ID MEDICATION; CARE C1 [Steinman, Michael A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Steinman, Michael A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Steinman, MA (reprint author), San Francisco VA Med Ctr, POB 181G,4150 Clement St, San Francisco, CA 94121 USA. EM mike.steinman@ucsf.edu FU NIA NIH HHS [1K23-AG030999., K23 AG030999] NR 8 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD MAR 11 PY 2013 VL 173 IS 5 BP 384 EP 385 DI 10.1001/jamainternmed.2013.2965 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 153OY UT WOS:000319613100017 PM 23381677 ER PT J AU Kampa-Schittenhelm, KM Heinrich, MC Akmut, F Dohner, H Dohner, K Schittenhelm, MM AF Kampa-Schittenhelm, Kerstin Maria Heinrich, Michael Charles Akmut, Figen Doehner, Hartmut Doehner, Konstanze Schittenhelm, Marcus Matthias TI Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms SO MOLECULAR CANCER LA English DT Article DE AC220; Quizartinib; Leukemia; KIT; FLT3; PDGFR ID ACUTE MYELOID-LEUKEMIA; GASTROINTESTINAL STROMAL TUMOR; INTERNAL TANDEM DUPLICATIONS; LIGAND-INDEPENDENT ACTIVATION; MAST-CELL LEUKEMIA; C-KIT; MYELODYSPLASTIC SYNDROME; FLT3 GENE; WILD-TYPE; SYSTEMIC MASTOCYTOSIS AB Background: Activating mutations of class III receptor tyrosine kinases (RTK) FLT3, PDGFR and KIT are associated with multiple human neoplasms including hematologic malignancies, for example: systemic mast cell disorders (KIT), non-CML myeloproliferative neoplasms (PDGFR) and subsets of acute leukemias (FLT3 and KIT). First generation tyrosine kinase inhibitors (TKI) are rapidly being integrated into routine cancer care. However, the expanding spectrum of TK-mutations, bioavailability issues and the emerging problem of primary or secondary TKI-therapy resistance have lead to the search for novel second generation TKIs to improve target potency and to overcome resistant clones. Quizartinib was recently demonstrated to be a selective FLT3 inhibitor with excellent pharmacokinetics and promising in vivo activity in a phase II study for FLT3 ITD + AML patients. In vitro kinase assays have suggested that in addition to FLT3, quizartinib also targets related class III RTK isoforms. Methods: Various FLT3 or KIT leukemia cell lines and native blasts were used to determine the antiproliferative and proapoptotic efficacy of quizartinib. To better compare differences between the mutant kinase isoforms, we generated an isogenic BaF3 cell line expressing different FLT3, KIT or BCR/ABL isoforms. Using immunoblotting, we examined the effects of quizartinib on activation of mutant KIT or FLT3 isoforms. Results: Kinase inhibition of (mutant) KIT, PDGFR and FLT3 isoforms by quizartinib leads to potent inhibition of cellular proliferation and induction of apoptosis in in vitro leukemia models as well as in native leukemia blasts treated ex vivo. However, the sensitivity patterns vary widely depending on the underlying (mutant)-kinase isoform, with some isoforms being relatively insensitive to this agent (e. g. FLT3 D835V and KIT codon D816 mutations). Evaluation of sensitivities in an isogenic cellular background confirms a direct association with the underlying mutant-TK isoform - which is further validated by immunoblotting experiments demonstrating kinase inhibition consistent with the cellular sensitivity/resistance to quizartinib. Conclusion: Quizartinib is a potent second-generation class III receptor TK-inhibitor - but specific, mutation restricted spectrum of activity may require mutation screening prior to therapy. C1 [Kampa-Schittenhelm, Kerstin Maria; Akmut, Figen; Schittenhelm, Marcus Matthias] Univ Tubingen Hosp, Dept Hematol Oncol Rheumatol Immunol & Pulmol, Tubingen, Germany. [Heinrich, Michael Charles] Portland VA Med Ctr, Dept Med, Div Hematol & Med Oncol, Portland, OR USA. [Heinrich, Michael Charles] OHSU Knight Canc Inst, Portland, OR USA. [Doehner, Hartmut; Doehner, Konstanze] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany. RP Kampa-Schittenhelm, KM (reprint author), Univ Tubingen Hosp, Dept Hematol Oncol Rheumatol Immunol & Pulmol, Tubingen, Germany. EM kerstin.kampa-schittenhelm@med.uni-tuebingen.de FU Deutsche Krebshilfe Foundation; IZKF Program of the Medical Faculty Tubingen; Carreras Scholarship Program; Leukemia and Lymphoma Society; Department of Veterans Affairs; Deutsche Forschungsgemeinschaft; Open Access Publishing Fund of Tubingen University FX Grant support in part by the Deutsche Krebshilfe Foundation (MMS, KKS), the IZKF Program of the Medical Faculty Tubingen (MMS) and the Carreras Scholarship Program (KKS), a grant from the Leukemia and Lymphoma Society (MCH) and a Merit Review Grant from the Department of Veterans Affairs (MCH). We acknowledge support by Deutsche Forschungsgemeinschaft and Open Access Publishing Fund of Tubingen University. NR 52 TC 27 Z9 28 U1 0 U2 16 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1476-4598 J9 MOL CANCER JI Mol. Cancer PD MAR 7 PY 2013 VL 12 AR 19 DI 10.1186/1476-4598-12-19 PG 15 WC Biochemistry & Molecular Biology; Oncology SC Biochemistry & Molecular Biology; Oncology GA 133BS UT WOS:000318113000001 PM 23497317 ER PT J AU Chatzaki, E Anton, PA Million, M Lambropoulou, M Constantinidis, T Kolios, G Tache, Y Grigoriadis, DE AF Chatzaki, Ekaterini Anton, Peter A. Million, Mulugeta Lambropoulou, Maria Constantinidis, Theodoros Kolios, George Tache, Yvette Grigoriadis, Dimitri E. TI Corticotropin-releasing factor receptor subtype 2 in human colonic mucosa: Down-regulation in ulcerative colitis SO WORLD JOURNAL OF GASTROENTEROLOGY LA English DT Article DE Colonic mucosa; Corticotropin-releasing factor; Corticotropin-releasing factor receptor; Human immunodeficiency virus; Ulcerative colitis; Urocortin ID INFLAMMATORY-BOWEL-DISEASE; STRESS-RELATED ALTERATIONS; ENTERIC NERVOUS-SYSTEM; FACTOR CRF RECEPTOR; GUT MOTOR FUNCTION; GASTROINTESTINAL-TRACT; RHEUMATOID-ARTHRITIS; PSYCHOLOGICAL STRESS; RAT-BRAIN; UROCORTIN AB AIM: To assess corticotropin-releasing factor receptor 2 (CRF2) expression in the colon of healthy subjects and patients with ulcerative colitis (UC). METHODS: We examined CRF2 gene and protein expression in the distal/sigmoid colonic mucosal biopsies from healthy subjects and patients with UC (active or disease in remission), human immunodeficiency virus (HIV) and functional bowel disease (FBD) by reverse transcription-polymerase chain reaction and immunofluorescence. RESULTS: Gene expression of CRF2 was demonstrated in the normal human colonic biopsies, but not in the human colorectal adenocarcinoma cell line Caco2. Receptor protein localization showed immunoreactive CRF2 receptors in the lamina propria and in the epithelial cells of the distal/sigmoid biopsy samples. Interestingly, CRF2 immunoreactivity was no longer observed in epithelial cells of patients with mild-moderately active UC and disease in remission, while receptor protein expression did not change in the lamina propria. No differences in CRF2 expression profile were observed in distal/sigmoid intestinal biopsies from HIV infection and FBD patients, showing no signs of inflammation. CONCLUSION: The down-regulation of the CRF2 receptor in the distal/sigmoid biopsies of UC patients is indicative of change in CRF2 signalling associated with the process of inflammation. (C) 2013 Baishideng. All rights reserved. C1 [Chatzaki, Ekaterini; Grigoriadis, Dimitri E.] Neurocrine Biosci Inc, San Diego, CA 92121 USA. [Chatzaki, Ekaterini; Kolios, George] Democritus Univ Thrace, Pharmacol Lab, Fac Med, Dragana 68100, Alexandroupolis, Greece. [Anton, Peter A.] Univ Calif Los Angeles, Ctr HIV Prevent Res, Div Digest Dis, Los Angeles, CA 90073 USA. [Anton, Peter A.; Million, Mulugeta; Tache, Yvette] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Anton, Peter A.; Million, Mulugeta; Tache, Yvette] Univ Calif Los Angeles, Digest Dis Res Ctr, Los Angeles, CA 90073 USA. [Anton, Peter A.; Million, Mulugeta; Tache, Yvette] Univ Calif Los Angeles, Ctr Neurobiol Stress, Div Digest Dis, Los Angeles, CA 90073 USA. [Lambropoulou, Maria] Democritus Univ Thrace, Lab Histol Embryol, Fac Med, Dragana 68100, Alexandroupolis, Greece. [Constantinidis, Theodoros] Democritus Univ Thrace, Lab Hyg & Environm Protect, Fac Med, Dragana 68100, Alexandroupolis, Greece. RP Chatzaki, E (reprint author), Democritus Univ Thrace, Pharmacol Lab, Fac Med, Dragana 68100, Alexandroupolis, Greece. EM achatzak@med.duth.gr RI Kolios, George/N-6641-2013 OI Kolios, George/0000-0002-2066-4782 FU National Institute of Diabetes and Digestive and Kidney Diseases R01 grant [DK-57238]; Veteran Administration Research Career Scientist Award; NIH [DK-78676]; [DK-41301] FX Supported by The National Institute of Diabetes and Digestive and Kidney Diseases R01 grant DK-57238; Center Grant DK-41301 (Clinical core); Veteran Administration Research Career Scientist Award (YT); and NIH DK-78676 (MM) NR 55 TC 9 Z9 9 U1 0 U2 1 PU BAISHIDENG PUBL GRP CO LTD PI WANCHAI PA ROOM 1701, 17-F, HENAN BUILDING, NO. 90, JAFFE RD, WANCHAI, HONG KONG 100025, PEOPLES R CHINA SN 1007-9327 J9 WORLD J GASTROENTERO JI World J. Gastroenterol. PD MAR 7 PY 2013 VL 19 IS 9 BP 1416 EP 1423 DI 10.3748/wjg.v19.i9.1416 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 104NT UT WOS:000316001700012 PM 23539366 ER PT J AU Tarter, L Yazdany, J Moyers, B Barnett, C Dhaliwal, G AF Tarter, Laura Yazdany, Jinoos Moyers, Brian Barnett, Christopher Dhaliwal, Gurpreet TI The Heart of the Matter SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; LIBMAN-SACKS ENDOCARDITIS; ANTIPHOSPHOLIPID ANTIBODIES; VALVE REPLACEMENT; DISEASE; INVOLVEMENT C1 [Tarter, Laura] Stanford Univ, Med Ctr, Dept Med, Div Rheumatol & Immunol, Palo Alto, CA 94304 USA. [Yazdany, Jinoos] Univ Calif San Francisco, Div Rheumatol, San Francisco, CA USA. [Moyers, Brian; Barnett, Christopher] Univ Calif San Francisco, Div Cardiol, San Francisco, CA USA. [Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Barnett, Christopher] San Francisco Gen Hosp, San Francisco, CA 94110 USA. [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, San Francisco, CA USA. RP Tarter, L (reprint author), Stanford Univ, Med Ctr, Dept Med, Div Rheumatol & Immunol, 1000 Welch Rd,Suite 203, Palo Alto, CA 94304 USA. EM tarter@gmail.com NR 15 TC 1 Z9 2 U1 0 U2 5 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAR 7 PY 2013 VL 368 IS 10 BP 944 EP 950 DI 10.1056/NEJMcps1114207 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 100BG UT WOS:000315669100012 PM 23465105 ER PT J AU Rosenbaum, L AF Rosenbaum, Lisa TI The Whole Ball Game - Overcoming the Blind Spots in Health Care Reform SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID LOW-BACK-PAIN; TRIAL C1 [Rosenbaum, Lisa] Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Rosenbaum, Lisa] Univ Penn, Robert Wood Johnson Fdn Clin Scholars Program, Philadelphia, PA 19104 USA. RP Rosenbaum, L (reprint author), Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. NR 11 TC 10 Z9 10 U1 0 U2 4 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAR 7 PY 2013 VL 368 IS 10 BP 959 EP 962 DI 10.1056/NEJMms1301576 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 100BG UT WOS:000315669100015 PM 23465107 ER PT J AU Singh, JA Lewallen, DG AF Singh, Jasvinder A. Lewallen, David G. TI Income and patient-reported outcomes (PROs) after primary total knee arthroplasty SO BMC MEDICINE LA English DT Article DE arthroplasty; income; joint replacement; patient-reported outcomes; risk factor; total knee replacement ID TOTAL HIP-ARTHROPLASTY; SEVERE FUNCTIONAL LIMITATION; TOTAL JOINT ARTHROPLASTY; CLINICAL RATING SYSTEM; SOCIOECONOMIC-STATUS; REPLACEMENT SURGERY; HEALTH-CARE; PAIN; PREDICTORS; EXPECTATIONS AB Background: To assess whether income is associated with patient-reported outcomes (PROs) after primary total knee arthroplasty (TKA). Methods: We used prospectively collected data from the Mayo Clinic Total Joint Registry to assess the association of income with index knee functional improvement, moderate to severe pain and moderate to severe activity limitation at 2-year and 5-year follow-up after primary TKA using multivariable-adjusted logistic regression analyses. Results: There were 7, 139 primary TKAs at 2 years and 4, 234 at 5 years. In multivariable-adjusted analyses, at 2-year follow-up, compared to income > US$45, 000, lower incomes of <= US$35, 000 and > US$35, 000 to 45, 000 were associated (1) significantly with moderate to severe pain with an odds ratio (OR) 0.61 (95% CI 0.40 to 0.94) (P = 0.02) and 0.68 (95% CI 0.49 to 0.94) (P = 0.02); and (2) trended towards significance for moderate to severe activity limitation with OR 0.78 (95% CI 0.60 to 1.02) (P = 0.07) and no significant association with OR 0.96 (95% CI 0.78 to 1.20) (P = 0.75), respectively. At 5 years, odds were not statistically significantly different by income, although numerically they favored lower income. In multivariable-adjusted analyses, overall improvement in knee function was rated as 'better' slightly more often at 2 years by patients with income in the <= US$35, 000 range compared to patients with income > US$45, 000, with an OR 1.9 (95% CI 1.0 to 3.6) (P = 0.06). Conclusions: We found that patients with lower income had better pain outcomes compared to patients with higher income. There was more improvement in knee function, and a trend towards less overall activity limitation after primary TKA in lower income patients compared to those with higher incomes. Insights into mediators of these relationships need to be investigated to understand how income influences outcomes after TKA. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, C SMART, Birmingham, AL 35233 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Lewallen, David G.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN 55905 USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, 700 19th St S, Birmingham, AL 35233 USA. EM jasvinder.md@gmail.com OI singh, jasvinder/0000-0003-3485-0006 FU Takeda; Savient; URL pharmaceuticals; Regeneron; Allergan; Ardea; Novartis; Zimmer; Orthosonic; Osteotech; Pipeline Biomedical; DePuy; Stryker; Biomet; Mayo Clinic Orthopedic Surgery research funds; Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs); National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS); National Institute of Aging (NIA); National Cancer Institute (NCI) FX The authors report no financial conflicts related directly to this study. JAS has received research grants from Takeda and Savient; and consultant fees from URL pharmaceuticals, Savient, Takeda, Regeneron, Allergan, Ardea and Novartis. DGL has received royalties/speaker fees from Zimmer, Orthosonic and Osteotech, has been a paid consultant to and owns stock in Pipeline Biomedical and has received institutional research funds from DePuy, Stryker, Biomet and Zimmer.; This material is the result of work supported by Mayo Clinic Orthopedic Surgery research funds and the resources and use of facilities at the Birmingham VA Medical Center, Alabama, USA. JAS is also supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs), National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS), National Institute of Aging (NIA) and National Cancer Institute (NCI). NR 53 TC 5 Z9 5 U1 1 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1741-7015 J9 BMC MED JI BMC Med. PD MAR 6 PY 2013 VL 11 AR 62 DI 10.1186/1741-7015-11-62 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 137LE UT WOS:000318436600001 PM 23497272 ER PT J AU Shao, LJ Zhou, ZS Cai, Y Castro, P Dakhov, O Shi, P Bai, YX Ji, HX Shen, WH Wang, JH AF Shao, Longjiang Zhou, Zhansong Cai, Yi Castro, Patricia Dakhov, Olga Shi, Ping Bai, Yaoxia Ji, Huixiang Shen, Wenhao Wang, Jianghua TI Celastrol Suppresses Tumor Cell Growth through Targeting an AR-ERG-NF-kappa B Pathway in TMPRSS2/ERG Fusion Gene Expressing Prostate Cancer SO PLOS ONE LA English DT Article ID TRANSCRIPTIONAL ACTIVITY; SIGNALING PATHWAYS; IKK-EPSILON; P65 SUBUNIT; NUDE-MICE; GOD VINE; PHOSPHORYLATION; PROGRESSION; ACTIVATION; KINASE AB The TMPRSS2/ERG (T/E) fusion gene is present in the majority of all prostate cancers (PCa). We have shown previously that NF-kappa B signaling is highly activated in these T/E fusion expressing cells via phosphorylation of NF-kB p65 Ser536 (p536). We therefore hypothesize that targeting NF-kB signaling may be an efficacious approach for the subgroup of PCas that carry T/E fusions. Celastrol is a well known NF-kB inhibitor, and thus may inhibit T/E fusion expressing PCa cell growth. We therefore evaluated Celastrol's effects in vitro and in vivo in VCaP cells, which express the T/E fusion gene. VCaP cells were treated with different concentrations of Celastrol and growth inhibition and target expression were evaluated. To test its ability to inhibit growth in vivo, 0.5 mg/kg Celastrol was used to treat mice bearing subcutaneous VCaP xenograft tumors. Our results show Celastrol can significantly inhibit the growth of T/E fusion expressing PCa cells both in vitro and in vivo through targeting three critical signaling pathways: AR, ERG and NF-kB in these cells. When mice received 0.5 mg/kg Celastrol for 4 times/week, significant growth inhibition was seen with no obvious toxicity or significant weight loss. Therefore, Celastrol is a promising candidate drug for T/E fusion expressing PCa. Our findings provide a novel strategy for the targeted therapy which may benefit the more than half of PCa patients who have T/E fusion expressing PCas. C1 [Shao, Longjiang; Cai, Yi; Castro, Patricia; Dakhov, Olga; Wang, Jianghua] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA. [Shao, Longjiang; Cai, Yi; Castro, Patricia; Dakhov, Olga; Wang, Jianghua] Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX USA. [Zhou, Zhansong; Shi, Ping; Bai, Yaoxia; Ji, Huixiang; Shen, Wenhao] South West Hosp, Dept Urol, Chongqing, Peoples R China. RP Wang, JH (reprint author), Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA. EM jwang1@bcm.edu FU Department of Defense Prostate Cancer Research program [DOD W81XWH-08-1-0055]; NCI; Duncan Cancer Center Human Tissue and Pathology Core [NCI: P30CA125123] FX This work was supported by the Department of Defense Prostate Cancer Research program (DOD W81XWH-08-1-0055; JW) and the NCI to the Dan L. Duncan Cancer Center Human Tissue and Pathology Core (NCI: P30CA125123). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 50 TC 19 Z9 20 U1 1 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 6 PY 2013 VL 8 IS 3 AR e58391 DI 10.1371/journal.pone.0058391 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 117EP UT WOS:000316936100115 PM 23554889 ER PT J AU Shekelle, PG Pronovost, PJ Wachter, RM McDonald, KM Schoelles, K Dy, SM Shojania, K Reston, JT Adams, AS Angood, PB Bates, DW Bickman, L Carayon, P Donaldson, L Duan, NH Farley, DO Greenhalgh, T Haughom, JL Lake, E Lilford, R Lohr, KN Meyer, GS Miller, MR Neuhauser, DV Ryan, G Saint, S Shortell, SM Stevens, DP Walshe, K AF Shekelle, Paul G. Pronovost, Peter J. Wachter, Robert M. McDonald, Kathryn M. Schoelles, Karen Dy, Sydney M. Shojania, Kaveh Reston, James T. Adams, Alyce S. Angood, Peter B. Bates, David W. Bickman, Leonard Carayon, Pascale Donaldson, Liam Duan, Naihua Farley, Donna O. Greenhalgh, Trisha Haughom, John L. Lake, Eileen Lilford, Richard Lohr, Kathleen N. Meyer, Gregg S. Miller, Marlene R. Neuhauser, Duncan V. Ryan, Gery Saint, Sanjay Shortell, Stephen M. Stevens, David P. Walshe, Kieran TI The Top Patient Safety Strategies That Can Be Encouraged for Adoption Now SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material ID SYSTEMATIC REVIEWS C1 [Shekelle, Paul G.] RAND Corp, Santa Monica, CA 90401 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Stanford Ctr Hlth Policy, Stanford, CA USA. Ctr Primary Care & Outcomes Res, Stanford, CA USA. Kaiser Permanente, Oakland, CA 94612 USA. Univ Calif Berkeley, Berkeley, CA 94720 USA. Johns Hopkins Univ, Baltimore, MD 21231 USA. Johns Hopkins Childrens Ctr, Baltimore, MD 21287 USA. ECRI Inst, Plymouth Meeting, PA 19462 USA. RAND Corp, Pittsburgh, PA 15213 USA. Univ Penn, Philadelphia, PA 19104 USA. Univ Toronto, Ottawa, ON, Canada. Natl Qual Forum, Washington, DC USA. Harvard Univ, Brigham & Womens Hosp, Boston, MA 02115 USA. Vanderbilt Univ, Peabody Coll, Nashville, TN 37203 USA. Univ Wisconsin, Madison, WI 53706 USA. Univ London Imperial Coll Sci Technol & Med, London W2 1NY, England. Univ London, London, England. Univ Birmingham, Birmingham B15 2TT, W Midlands, England. Univ Manchester, Manchester Business Sch, Manchester M15 6PB, Lancs, England. New York State Psychiat Inst & Hosp, New York, NY 10032 USA. PeaceHlth Med Grp, Eugene, OR USA. Res Triangle Inst Int, Res Triangle Pk, NC 27709 USA. Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH 03766 USA. Case Western Reserve Univ, Cleveland, OH 44106 USA. Vet Affairs Ann Arbor Healthcare Syst, Ann Arbor, MI 48105 USA. Univ Michigan, Ann Arbor, MI 48109 USA. RP Shekelle, PG (reprint author), RAND Corp, 1776 Main St, Santa Monica, CA 90401 USA. EM shekelle@rand.org RI Greenhalgh, Trisha/B-1825-2015 OI Greenhalgh, Trisha/0000-0003-2369-8088; Bickman, Leonard/0000-0002-0746-3791 FU PHS HHS [HHSA-290-2007-10062I] NR 10 TC 98 Z9 99 U1 1 U2 15 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAR 5 PY 2013 VL 158 IS 5 BP 365 EP + DI 10.7326/0003-4819-158-5-201303051-00001 PN 2 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 105HX UT WOS:000316058600001 PM 23460091 ER PT J AU Miake-Lye, IM Hempel, S Ganz, DA Shekelle, PG AF Miake-Lye, Isomi M. Hempel, Susanne Ganz, David A. Shekelle, Paul G. TI Inpatient Fall Prevention Programs as a Patient Safety Strategy A Systematic Review SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; ACUTE-CARE; MULTIFACTORIAL INTERVENTION; METHODOLOGICAL QUALITY; RISK-ASSESSMENT; ADVERSE EVENTS; HOSPITALS; INJURIES; MULTIDISCIPLINARY; IMPLEMENTATION AB Falls are common among inpatients. Several reviews, including 4 meta-analyses involving 19 studies, show that multicomponent programs to prevent falls among inpatients reduce relative risk for falls by as much as 30%. The purpose of this updated review is to reassess the benefits and harms of fall prevention programs in acute care settings and to identify factors associated with successful implementation of these programs. We searched for new evidence using PubMed from 2005 to September 2012. Two new, large, randomized, controlled trials supported the conclusions of the existing meta-analyses. An optimal bundle of components was not identified. Harms were not systematically examined, but potential harms included increased use of restraints and sedating drugs and decreased efforts to mobilize patients. Eleven studies showed that the following themes were associated with successful implementation: leadership support, engagement of front-line staff in program design, guidance of the prevention program by a multidisciplinary committee, pilot-testing interventions, use of information technology systems to provide data about falls, staff education and training, and changes in nihilistic attitudes about fall prevention. Future research would advance knowledge by identifying optimal bundles of component interventions for particular patients and by determining whether effectiveness relies more on the mix of the components or use of certain implementation strategies. Ann Intern Med. 2013;158:390-396. www.annals.org C1 Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Shekelle, Paul G.] RAND Corp, Santa Monica, CA 90401 USA. RP Shekelle, PG (reprint author), RAND Corp, Santa Monica, CA 90401 USA. EM shekelle@rand.org FU AHRQ, U.S. Department of Health and Human Services [HHSA-290-2007-10062I, HHSA-290-2010-00017I, HHSA-290-32001T]; Veterans Affairs Health Services Research & Development Service, Veterans Health Administration, U.S. Department of Veterans Affairs through the Veterans Affairs Greater Los Angeles Health Services Research & Development Center of Excellence [VA CD2 08-012-1]; AHRQ; AHRQ, Veterans Affairs Health Services Research and Development Service; Veterans Affairs; Centers for Medicare & Medicaid Services; National Institute of Nursing Research; Office of the National Coordinator FX Financial Support: From the AHRQ, U.S. Department of Health and Human Services (contracts HHSA-290-2007-10062I, HHSA-290-2010-00017I, and HHSA-290-32001T). Dr. Ganz was supported by a Career Development Award from the Veterans Affairs Health Services Research & Development Service, Veterans Health Administration, U.S. Department of Veterans Affairs through the Veterans Affairs Greater Los Angeles Health Services Research & Development Center of Excellence (project VA CD2 08-012-1).; Potential Conflicts of Interest: Dr. Hempel: Grant (money to institution): AHRQ. Dr. Ganz: Grant (money to institution): AHRQ, Veterans Affairs Health Services Research and Development Service. Dr. Shekelle: Consultancy: ECRI Institute; Employment: Veterans Affairs; Grants/grants pending: AHRQ, Veterans Affairs, Centers for Medicare & Medicaid Services, National Institute of Nursing Research, Office of the National Coordinator; Royalties: UpToDate. Ms. Miake-Lye: None disclosed. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum = M12-2569. NR 57 TC 49 Z9 52 U1 0 U2 26 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAR 5 PY 2013 VL 158 IS 5 BP 390 EP + DI 10.7326/0003-4819-158-5-201303051-00005 PN 2 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 105HX UT WOS:000316058600005 PM 23460095 ER PT J AU Shekelle, PG AF Shekelle, Paul G. TI Nurse-Patient Ratios as a Patient Safety Strategy A Systematic Review SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID INTENSIVE-CARE-UNIT; STAFFING LEVELS; HOSPITAL MORTALITY; JOB DISSATISFACTION; OUTCOMES EVIDENCE; 30-DAY MORTALITY; HEALTH-CARE; QUALITY; COST; ASSOCIATION AB A small percentage of patients die during hospitalization or shortly thereafter, and it is widely believed that more or better nursing care could prevent some of these deaths. The author systematically reviewed the evidence about nurse staffing ratios and in-hospital death through September 2012. From 550 titles, 87 articles were reviewed and 15 new studies that augmented the 2 existing reviews were selected. The strongest evidence supporting a causal relationship between higher nurse staffing levels and decreased inpatient mortality comes from a longitudinal study in a single hospital that carefully accounted for nurse staffing and patient comorbid conditions and a meta-analysis that found a "dose-response relationship" in observational studies of nurse staffing and death. No studies reported any serious harms associated with an increase in nurse staffing. Limiting any stronger conclusions is the lack of an evaluation of an intervention to increase nurse staffing ratios. The formal costs of increasing the nurse-patient ratio cannot be calculated because there has been no evaluation of an intentional change in nurse staffing to improve patient outcomes. Ann Intern Med. 2013;158:404-409. www.annals.org C1 [Shekelle, Paul G.] RAND Corp, Santa Monica, CA 90401 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Shekelle, PG (reprint author), RAND Corp, 1776 Main St, Santa Monica, CA 90401 USA. EM shekelle@rand.org FU Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services [HHSA-290-2007-10062I]; Agency for Healthcare Research and Quality; Veterans Affairs; Centers for Medicare & Medicaid Services; National Institute of Nursing Research; Office of the National Coordinator FX Financial Support: From the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services (contract HHSA-290-2007-10062I).; Potential Conflicts of Interest: Consultancy: ECRI Institute; Employment: Veterans Affairs; Grants/grants pending: Agency for Healthcare Research and Quality, Veterans Affairs, Centers for Medicare & Medicaid Services, National Institute of Nursing Research, Office of the National Coordinator; Royalties: UpToDate. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M12-257 4. NR 46 TC 26 Z9 27 U1 4 U2 42 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAR 5 PY 2013 VL 158 IS 5 BP 404 EP + DI 10.7326/0003-4819-158-5-201303051-00007 PN 2 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 105HX UT WOS:000316058600007 PM 23460097 ER PT J AU Wachter, RM Pronovost, PJ Shekelle, PG AF Wachter, Robert M. Pronovost, Peter J. Shekelle, Paul G. TI Strategies to Improve Patient Safety: The Evidence Base Matures SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material C1 [Wachter, Robert M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Pronovost, Peter J.] Johns Hopkins Med Patient Safety & Qual, Baltimore, MD USA. [Shekelle, Paul G.] W Los Angeles Vet Affairs Med Ctr, Santa Monica, CA USA. [Shekelle, Paul G.] RAND Corp, Santa Monica, CA USA. RP Wachter, RM (reprint author), Univ Calif San Francisco, Room M-994,505 Parnassus Ave, San Francisco, CA 94143 USA. EM bobw@medicine.ucsf.edu NR 25 TC 12 Z9 14 U1 0 U2 13 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAR 5 PY 2013 VL 158 IS 5 BP 350 EP + DI 10.7326/0003-4819-158-5-201303050-00010 PN 1 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 105HP UT WOS:000316057700008 PM 23460060 ER PT J AU Achildi, O Leong, SH Maust, DT Streim, JE Oslin, DW AF Achildi, Olga Leong, Shirley H. Maust, Donovan T. Streim, Joel E. Oslin, David W. TI Patterns of Newly-Prescribed Benzodiazepines in Late Life SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry CY MAR 14-17, 2013 CL Los Angeles, CA SP Amer Assoc Geriatr Psychiat C1 [Achildi, Olga; Leong, Shirley H.; Maust, Donovan T.; Streim, Joel E.; Oslin, David W.] Univ Penn, Philadelphia, PA 19104 USA. [Achildi, Olga; Leong, Shirley H.; Maust, Donovan T.; Streim, Joel E.; Oslin, David W.] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2013 VL 21 IS 3 SU S BP S90 EP S91 PG 3 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 298XQ UT WOS:000330358400089 ER PT J AU Asbury, M Helstrom, A Benson, A Leong, SH Zimmerman, J Streim, JE Oslin, DW AF Asbury, Melanie Helstrom, Amy Benson, Amy Leong, Shirley H. Zimmerman, Jacob Streim, Joel E. Oslin, David W. TI Experience of Pain in the Elderly in Relation to Mood, Anxiety and Physical Quality of Life in a PACE/BHL Program SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry CY MAR 14-17, 2013 CL Los Angeles, CA SP Amer Assoc Geriatr Psychiat C1 [Asbury, Melanie; Helstrom, Amy; Benson, Amy; Zimmerman, Jacob; Streim, Joel E.; Oslin, David W.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Helstrom, Amy; Benson, Amy; Leong, Shirley H.; Streim, Joel E.; Oslin, David W.] Philadelphia VA Med Ctr, VISN Mental Illness Res Educ & Clin Ctr 4, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2013 VL 21 IS 3 SU S BP S109 EP S110 PG 3 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 298XQ UT WOS:000330358400118 ER PT J AU Beristianos, M Yaffe, K Neylan, T Covinsky, K Byers, AL AF Beristianos, Matthew Yaffe, Kristine Neylan, Thomas Covinsky, Kenneth Byers, Amy L. TI Late-Life PTSD, Comorbid Psychiatric and Behavioral Disorders and Risk of Mortality among Veterans SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry CY MAR 14-17, 2013 CL Los Angeles, CA SP Amer Assoc Geriatr Psychiat C1 [Beristianos, Matthew; Yaffe, Kristine; Neylan, Thomas; Covinsky, Kenneth; Byers, Amy L.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Beristianos, Matthew; Yaffe, Kristine; Neylan, Thomas; Covinsky, Kenneth; Byers, Amy L.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2013 VL 21 IS 3 SU S BP S89 EP S90 PG 3 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 298XQ UT WOS:000330358400088 ER PT J AU Byers, AL Barry, LC Okereke, OI Yaffe, K AF Byers, Amy L. Barry, Lisa C. Okereke, Olivia I. Yaffe, Kristine TI NEW EPIDEMIOLOGICAL EVIDENCE FOR MENTAL HEALTH PREDICTING LATE-LIFE COGNITIVE AND FUNCTIONAL DECLINE SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry CY MAR 14-17, 2013 CL Los Angeles, CA SP Amer Assoc Geriatr Psychiat C1 [Byers, Amy L.; Yaffe, Kristine] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Byers, Amy L.; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Barry, Lisa C.] Univ Connecticut, Ctr Hlth, Ctr Aging, Farmington, CT USA. [Okereke, Olivia I.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Okereke, Olivia I.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. RI Okereke, Olivia/R-9934-2016 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2013 VL 21 IS 3 SU S BP S25 EP S26 PG 3 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 298XQ UT WOS:000330358400032 ER PT J AU Cohen, CI Kasckow, J Rajji, T Vahia, I AF Cohen, Carl I. Kasckow, John Rajji, Tarek Vahia, Ipsit TI ADVANCES IN LATE LIFE SCHIZOPHRENIA RESEARCH SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry CY MAR 14-17, 2013 CL Los Angeles, CA SP Amer Assoc Geriatr Psychiat C1 [Rajji, Tarek] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Rajji, Tarek] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Kasckow, John] Suny Downstate Med Ctr, New York, NY USA. [Cohen, Carl I.] Univ Toronto, Toronto, ON, Canada. [Vahia, Ipsit] Univ Calif San Diego, San Diego, CA 92103 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2013 VL 21 IS 3 SU S BP S5 EP S6 PG 3 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 298XQ UT WOS:000330358400003 ER PT J AU DeWitt, MA Barnes, DE Kunik, ME Gordon, SM AF DeWitt, Marie A. Barnes, Deborah E. Kunik, Mark E. Gordon, Sharon M. TI VA SYMPOSIUM: LINKS TO DEMENTIA SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry CY MAR 14-17, 2013 CL Los Angeles, CA SP Amer Assoc Geriatr Psychiat C1 [DeWitt, Marie A.; Kunik, Mark E.] Michael E DeBakey VAMC, Houston, TX USA. [Barnes, Deborah E.] San Francisco VA Med Ctr, San Francisco, CA USA. [Gordon, Sharon M.] VA Tennessee Valley Hlth Care Syst, Nashville, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2013 VL 21 IS 3 SU S BP S40 EP S41 PG 3 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 298XQ UT WOS:000330358400053 ER PT J AU Ege, MA Messias, E Krain, L Thapa, PB AF Ege, Margaret A. Messias, Erick Krain, Lewis Thapa, Puru B. TI AAGP Annual Meeting 2013 SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry CY MAR 14-17, 2013 CL Los Angeles, CA SP Amer Assoc Geriatr Psychiat C1 [Ege, Margaret A.; Messias, Erick; Krain, Lewis; Thapa, Puru B.] Univ Arkansas Med Sci, Dept Psychiat, Little Rock, AR 72205 USA. [Krain, Lewis] US Dept Vet Affairs, Dept Psychiat, North Little Rock, AR USA. [Thapa, Puru B.] Arkansas Mental Hlth Res & Training Inst, Little Rock, AR USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2013 VL 21 IS 3 SU S BP S63 EP S63 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 298XQ UT WOS:000330358400054 ER PT J AU Fischer, C Sweet, RA Ismail, Z AF Fischer, Corinne Sweet, Robert A. Ismail, Zahinoor TI FITTING A SQUARE PEG INTO A ROUND HOLE: UNDERSTANDING PSYCHOTIC SYMPTOMS IN ALZHEIMER'S DISEASE SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry CY MAR 14-17, 2013 CL Los Angeles, CA SP Amer Assoc Geriatr Psychiat C1 [Fischer, Corinne] St Michaels Hosp, Toronto, ON M5B 1W8, Canada. [Ismail, Zahinoor] Ctr Addict & Mental Hlth, Toronto, ON, Canada. [Fischer, Corinne; Ismail, Zahinoor] Univ Toronto, Toronto, ON, Canada. [Sweet, Robert A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. OI Fischer, Corinne/0000-0002-1047-0167 NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2013 VL 21 IS 3 SU S BP S16 EP S16 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 298XQ UT WOS:000330358400018 ER PT J AU Lanctot, K Chau, S Herrmann, N Drye, L Rosenberg, P Scherer, RW Vaidya, V Black, S Mintzer, J AF Lanctot, Krista Chau, Sarah Herrmann, Nathan Drye, Lea Rosenberg, Paul Scherer, Roberta W. Vaidya, Vijay Black, Sandra Mintzer, Jacobo TI Effects of Methylphenidate on Attention and Association with Apathy in AD patients SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry CY MAR 14-17, 2013 CL Los Angeles, CA SP Amer Assoc Geriatr Psychiat C1 [Lanctot, Krista; Chau, Sarah; Herrmann, Nathan; Black, Sandra] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada. [Drye, Lea; Rosenberg, Paul; Scherer, Roberta W.; Vaidya, Vijay] Johns Hopkins Univ, Baltimore, MD USA. [Mintzer, Jacobo] Med Univ S Carolina, Charleston, SC 29425 USA. [Mintzer, Jacobo] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2013 VL 21 IS 3 SU S BP S158 EP S159 PG 3 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 298XQ UT WOS:000330358400179 ER PT J AU Maust, DT Oslin, DW Marcus, S AF Maust, Donovan T. Oslin, David W. Marcus, Steven TI The Association of Age and Clinical Factors in Psychotropic Prescribing Nationwide SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry CY MAR 14-17, 2013 CL Los Angeles, CA SP Amer Assoc Geriatr Psychiat C1 [Maust, Donovan T.; Oslin, David W.; Marcus, Steven] Univ Penn, Philadelphia, PA 19104 USA. [Oslin, David W.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2013 VL 21 IS 3 SU S BP S114 EP S116 PG 4 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 298XQ UT WOS:000330358400124 ER PT J AU Sasaki, DA Takahashi, NY Feil, D AF Sasaki, Dean A. Takahashi, Nancy Y. Feil, Denise TI A Qualitative Study of Medical Student Attitudes About Individualizing Diabetes Care in Vulnerable Elders SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry CY MAR 14-17, 2013 CL Los Angeles, CA SP Amer Assoc Geriatr Psychiat C1 [Sasaki, Dean A.] UCSF, San Francisco, CA USA. [Sasaki, Dean A.; Takahashi, Nancy Y.; Feil, Denise] Univ Calif Los Angeles, Los Angeles, CA USA. [Takahashi, Nancy Y.; Feil, Denise] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2013 VL 21 IS 3 SU S BP S110 EP S110 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 298XQ UT WOS:000330358400119 ER PT J AU Streim, JE Oslin, DW Liptzin, B Moak, GS AF Streim, Joel E. Oslin, David W. Liptzin, Benjamin Moak, Gary S. TI EVOLVING ROLES FOR GERIATRIC MENTAL HEALTH PROVIDERS IN THE 21ST CENTURY HEALTHCARE SYSTEM SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry CY MAR 14-17, 2013 CL Los Angeles, CA SP Amer Assoc Geriatr Psychiat C1 [Streim, Joel E.; Oslin, David W.] Univ Penn, Philadelphia, PA 19104 USA. [Streim, Joel E.; Oslin, David W.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Liptzin, Benjamin] Baystate Med Ctr, Springfield, MA USA. [Liptzin, Benjamin] Tufts Univ, Boston, MA 02111 USA. [Moak, Gary S.] Moak Ctr Hlth Aging, Westborough, MA USA. [Moak, Gary S.] Univ Massachusetts, Worcester, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2013 VL 21 IS 3 SU S BP S14 EP S15 PG 4 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 298XQ UT WOS:000330358400016 ER PT J AU Streim, JE Oslin, DW Maust, DT Mavandadi, S AF Streim, Joel E. Oslin, David W. Maust, Donovan T. Mavandadi, Shahrzad TI A STATE-WIDE PROGRAM OF COLLABORATIVE CARE: WORKING TOWARDS GERIATRIC MENTAL HEALTHCARE REFORM SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry CY MAR 14-17, 2013 CL Los Angeles, CA SP Amer Assoc Geriatr Psychiat C1 [Streim, Joel E.; Oslin, David W.; Maust, Donovan T.; Mavandadi, Shahrzad] Univ Penn, Philadelphia, PA 19104 USA. [Streim, Joel E.; Oslin, David W.; Maust, Donovan T.; Mavandadi, Shahrzad] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2013 VL 21 IS 3 SU S BP S5 EP S5 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 298XQ UT WOS:000330358400002 ER PT J AU Sultzer, DL Leskin, LP Jacobs, ZM Melrose, RJ Harwood, DG Narvaez, TA Ando, TK Mandelkern, MA AF Sultzer, David L. Leskin, Lorraine P. Jacobs, Zachary M. Melrose, Rebecca J. Harwood, Dylan G. Narvaez, Theresa A. Ando, Timothy K. Mandelkern, Mark A. TI Cognitive, behavioral, and emotional domains of apathy in Alzheimer's disease: clinical and neurobiological features SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry CY MAR 14-17, 2013 CL Los Angeles, CA SP Amer Assoc Geriatr Psychiat C1 [Sultzer, David L.; Leskin, Lorraine P.; Jacobs, Zachary M.; Melrose, Rebecca J.; Harwood, Dylan G.; Narvaez, Theresa A.; Ando, Timothy K.] VA Greater Los Angeles Healthcare Syst, Brain Behav & Aging Res Ctr, Los Angeles, CA USA. [Sultzer, David L.; Melrose, Rebecca J.; Harwood, Dylan G.] UCLA Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. [Mandelkern, Mark A.] VA Greater Los Angeles Healthcare Syst, Nucl Med Serv, Los Angeles, CA USA. [Mandelkern, Mark A.] UC Irvine, Dept Phys, Irvine, CA USA. NR 0 TC 3 Z9 3 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2013 VL 21 IS 3 SU S BP S144 EP S145 PG 3 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 298XQ UT WOS:000330358400160 ER PT J AU Yoder, M Kasckow, J Thorp, SR Magruder, KM AF Yoder, Matthew Kasckow, John Thorp, Steven R. Magruder, Kathryn M. TI PSYCHOSOCIAL INTERVENTIONS FOR OLDER PATIENTS WITH POST TRAUMATIC STRESS DISORDER SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry CY MAR 14-17, 2013 CL Los Angeles, CA SP Amer Assoc Geriatr Psychiat C1 [Kasckow, John] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Kasckow, John] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Yoder, Matthew; Magruder, Kathryn M.] Med Univ S Carolina, Charleston, SC 29425 USA. [Thorp, Steven R.] Univ Calif San Diego, San Diego, CA 92103 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2013 VL 21 IS 3 SU S BP S29 EP S30 PG 3 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 298XQ UT WOS:000330358400038 ER PT J AU Hoang, JK Massoglia, DP Apostol, MA Lascola, CD Eastwood, JD Kranz, PG AF Hoang, J. K. Massoglia, D. P. Apostol, M. A. Lascola, C. D. Eastwood, J. D. Kranz, P. G. TI CT-Guided Cervical Transforaminal Steroid Injections: Where Should the Needle Tip Be Located? SO AMERICAN JOURNAL OF NEURORADIOLOGY LA English DT Article ID NERVE ROOT BLOCKS; RADICULOPATHY AB BACKGROUND AND PURPOSE: The aim of CT-guided CTSI is to inject medication into the foraminal region where the nerve root is inflamed. The optimal location for needle placement and therapeutic delivery, however, remain uncertain. The purpose of this study was to investigate how needle positioning and angle of approach impact the transforaminal distribution of injectate. MATERIALS AND METHODS: We retrospectively reviewed fluoroscopic images from 90 CT-guided CTSI procedures for needle-tip location, needle angle, and contrast distribution. Needle-tip position was categorized as either foraminal zone, junctional, or extraforaminal. Distribution of contrast injected immediately before steroid administration was categorized as central epidural, intraforaminal, or extraforaminal in location. Needle-tip location and angle were correlated with contrast distribution. RESULTS: The needle tip was most commonly placed in the junctional position (36 cases, 40%), followed by foraminal (30 cases, 33%) and extraforaminal (24 cases, 27%) locations. Intraforaminal contrast distribution was highest when the needle location was foraminal (30/30, 100%) or junctional (35/36, 97%), compared with extraforaminal (7/24, 29%) (P value <.0001). There was no relationship between needle angle and contrast distribution. CONCLUSIONS: Needle-tip location at the outer edge of the neural foramen (junctional location) correlated well with intraforaminal distribution of contrast for CT-guided CTSI and compared favorably with injectate distribution following foraminal zone needle positioning. Junctional needle positioning may be preferred over the foraminal zone by some proceduralists. Extraforaminal needle positioning resulted in less favorable contrast distribution, which may significantly diminish the therapeutic efficacy of CTSI. C1 [Hoang, J. K.; Lascola, C. D.; Eastwood, J. D.; Kranz, P. G.] Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA. [Hoang, J. K.] Duke Univ, Med Ctr, Div Neuroradiol, Durham, NC 27710 USA. [Hoang, J. K.] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA. [Massoglia, D. P.] Ralph Johnson VA Med Ctr, Dept Radiol, Charleston, SC USA. [Apostol, M. A.] Clin Radiologists SC, Springfield, IL USA. RP Hoang, JK (reprint author), Duke Univ, Med Ctr, Dept Radiol, Box 3808,Erwin Rd, Durham, NC 27710 USA. EM jennykh@gmail.com RI Hoang, Jenny/B-7779-2016; Kranz, Peter/B-2471-2016; Lascola, Christopher/B-9126-2017 OI Hoang, Jenny/0000-0002-6715-0922; Kranz, Peter/0000-0001-5410-7135; Lascola, Christopher/0000-0002-8031-782X NR 12 TC 7 Z9 7 U1 0 U2 1 PU AMER SOC NEURORADIOLOGY PI DENVILLE PA PO BOX 3000, DENVILLE, NJ 07834-9349 USA SN 0195-6108 EI 1936-959X J9 AM J NEURORADIOL JI Am. J. Neuroradiol. PD MAR PY 2013 VL 34 IS 3 BP 688 EP 692 DI 10.3174/ajnr.A3266 PG 5 WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 291RN UT WOS:000329846900039 PM 22954742 ER PT J AU Jonker, SS Louey, S Thornburg, KL Faber, JJ Giraud, GD AF Jonker, Sonnet S. Louey, Samantha Thornburg, Kent L. Faber, J. Job Giraud, George D. TI Cardiac Myocyte Growth Dynamics Change at Birth SO REPRODUCTIVE SCIENCES LA English DT Meeting Abstract CT 60th Annual Scientific Meeting of the Society-for-Gynecologic-Investigation (SGI) CY MAR 20-23, 2013 CL Orlando, FL SP Soc Gynecol Invest C1 [Jonker, Sonnet S.; Louey, Samantha; Thornburg, Kent L.; Faber, J. Job; Giraud, George D.] OHSU, Heart Res Ctr, Portland, OR USA. [Jonker, Sonnet S.; Louey, Samantha; Thornburg, Kent L.; Giraud, George D.] OHSU, Portland, OR 97201 USA. [Giraud, George D.] Portland VA Med Ctr, Portland, OR 97201 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1933-7191 EI 1933-7205 J9 REPROD SCI JI Reprod. Sci. PD MAR PY 2013 VL 20 IS S3 SU 3 BP 212A EP 212A PG 1 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 287LK UT WOS:000329543100508 ER PT J AU Sherman, ME Knudsen, KJ Sweeney, HA Tam, K Musuuza, J Koroukian, SM AF Sherman, Marion E. Knudsen, Kraig J. Sweeney, Helen Anne Tam, Kwok Musuuza, Jackson Koroukian, Siran M. TI Analysis of Causes of Death for All Decedents in Ohio With and Without Mental Illness, 2004-2007 SO PSYCHIATRIC SERVICES LA English DT Article ID PREMATURE MORTALITY; MEDICAID POPULATION; CARE; DISORDERS; QUALITY; CANCER; INJURY AB Objective: This study compared causes of death, crude mortality rates, and standardized mortality ratios (SMRs) between decedents with mental illness in Ohio's publicly funded mental health system ("mental illness decedents") and all Ohio decedents. Methods: Ohio death certificates and Ohio Department of Mental Health service utilization data were used to assess mortality among decedents from 2004 to 2007. Age-adjusted SMRs and age-adjusted mortality rates were calculated across race and sex strata. Results: Mental illness decedents accounted for 3.3% of all 438,749 Ohio deaths. Age-adjusted SMRs varied widely across the race and sex strata and by cause of death. Nonblacks with or without mental illness showed higher SMRs than blacks. Nonblack females with mental illness showed the highest SMRs in injury-related deaths. Higher SMRs were found for deaths associated with substance abuse; mental illness; diabetes; issues related to the nervous, cardiovascular, or respiratory systems; and injury. With and without mental illness, the top cause of death was violence for youths and cardiovascular disease for adults >35. Conclusions: Deaths from injury and violence, especially among those <35, should be specifically addressed to reduce excess mortality for persons with mental illness. Mental health care should be integrated with primary care to better manage chronic disease, especially cardiovascular disease. Methodological contributions included use of linked files to compare SMR and leading causes of death between mental illness decedents and all Ohio decedents. More research is needed on patterns in cause of death and any interactions from demographic characteristics and mental illness. Health care data silos must be bridged between private and public sectors and the Departments of Veterans Affairs and Defense. C1 [Sherman, Marion E.] VA Gulf Coast Vet Hlth Care Syst, US Dept Vet Affairs, Biloxi, MS 39531 USA. [Knudsen, Kraig J.; Sweeney, Helen Anne] Case Western Reserve Univ, Ohio Dept Mental Hlth, Dept Res & Evaluat, Cleveland, OH 44106 USA. [Musuuza, Jackson] Case Western Reserve Univ, Dept Epidemiol & Biostatist, Cleveland, OH 44106 USA. [Musuuza, Jackson] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53706 USA. RP Sherman, ME (reprint author), VA Gulf Coast Vet Hlth Care Syst, US Dept Vet Affairs, 400 Vet Ave, Biloxi, MS 39531 USA. EM marion.sherman@va.gov FU ODMH; Clinical and Translational Science Collaborative of Cleveland; National Center for Advancing Translational Sciences component of the National Institutes of Health (NIH) [UL1TR000439]; NIH Roadmap for Medical Research FX Dr. Koroukian was funded in part by a contract from ODMH, by a pilot grant from the Clinical and Translational Science Collaborative of Cleveland, by grant UL1TR000439 from the National Center for Advancing Translational Sciences component of the National Institutes of Health (NIH), and by an NIH Roadmap for Medical Research. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of NIH. The authors thank Meatal Patel, M. P. H., M. B. A. candidate, for her assistance in manuscript preparation. NR 20 TC 2 Z9 2 U1 1 U2 8 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD MAR PY 2013 VL 64 IS 3 BP 245 EP 251 DI 10.1176/appi.ps.201100238 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 255UM UT WOS:000327265600008 PM 23318767 ER PT J AU Drapalski, AL Lucksted, A Perrin, PB Aakre, JM Brown, CH DeForge, BR Boyd, JE AF Drapalski, Amy L. Lucksted, Alicia Perrin, Paul B. Aakre, Jennifer M. Brown, Clayton H. DeForge, Bruce R. Boyd, Jennifer E. TI A Model of Internalized Stigma and Its Effects on People With Mental Illness SO PSYCHIATRIC SERVICES LA English DT Article ID SCHIZOPHRENIA SPECTRUM DISORDERS; STRESS-COPING MODEL; SELF-EFFICACY SCALE; PERCEIVED DISCRIMINATION; EUROPEAN COUNTRIES; GAMIAN-EUROPE; OUTPATIENTS; EMPOWERMENT; DEPRESSION; VALIDATION AB Objectives: The investigators aimed to examine the prevalence of internalized stigma among individuals with serious mental illness and to construct and test a hypothesized model of the interrelationships among internalized stigma, self-concept, and psychiatric symptoms. Methods: One hundred individuals, most of whom were African American and had a diagnosis of serious mental illness, were receiving mental health services from one of three community outpatient mental health programs or one Veterans Affairs medical center. They completed an interview that included measures of internalized stigma, psychiatric symptoms, self-esteem, self-efficacy, and recovery orientation. Structural equation modeling (SEM) was used to examine the interrelationships among these variables. Results: Thirty-five percent of participants reported moderate to severe levels of internalized stigma, which was not significantly associated with any demographic variable or diagnosis. However, greater internalized stigma was associated with lower levels of self-esteem, self-efficacy, and recovery orientation, as well as with more severe psychiatric symptoms. The SEM produced a nonsignificant chi square statistic and other fit indices indicative of a good model fit (goodness-of-fit index=.96, root mean square error of approximation=.011). Conclusions: Results suggest that internalized stigma was prevalent and problematic among individuals with serious mental illness. There may be multiple pathways through which stigma and discrimination lead to negative outcomes, suggesting that interventions to reduce internalized stigma need to target multiple points along these pathways in order to be effective. C1 [Drapalski, Amy L.; Lucksted, Alicia; Aakre, Jennifer M.; Brown, Clayton H.] VA Maryland Healthcare Syst, MIRECC Annex, Mental Illness Res Educ & Clin Ctr, Vet Affairs VA Capitol Network,Vet Integrated Ser, Baltimore, MD 21201 USA. [Lucksted, Alicia] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA. [Brown, Clayton H.] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA. [Perrin, Paul B.] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA. [DeForge, Bruce R.] Univ Maryland, Sch Social Work, Baltimore, MD 21201 USA. [Boyd, Jennifer E.] San Francisco VA Med Ctr, Dept Psychiat, San Francisco, CA USA. [Boyd, Jennifer E.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Drapalski, AL (reprint author), VA Maryland Healthcare Syst, MIRECC Annex, Mental Illness Res Educ & Clin Ctr, Vet Affairs VA Capitol Network,Vet Integrated Ser, 7th Floor,10 N Greene St, Baltimore, MD 21201 USA. EM amy.drapalski@va.gov FU VA Capitol Network (Veterans Integrated Service Network 5) Mental Illness Research, Education and Clinical Center FX This article is the result of work supported by the VA Capitol Network (Veterans Integrated Service Network 5) Mental Illness Research, Education and Clinical Center. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the U.S. Department of Veterans Affairs or the U.S. government. NR 32 TC 43 Z9 43 U1 3 U2 33 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD MAR PY 2013 VL 64 IS 3 BP 264 EP 269 DI 10.1176/appi.ps.001322012 PG 6 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 255UM UT WOS:000327265600011 PM 23573532 ER PT J AU Anderson, DM Pesaturo, KA Casavant, J Ramsey, EZ AF Anderson, Debra M. Pesaturo, Kimberly A. Casavant, Jonathan Ramsey, E. Zachary TI Alteplase for the Treatment of Catheter Occlusion in Pediatric Patients SO ANNALS OF PHARMACOTHERAPY LA English DT Article ID TISSUE-PLASMINOGEN ACTIVATOR; CENTRAL VENOUS CATHETERS; ACCESS DEVICES; LINES; RESTORATION; EFFICACY; TRIAL AB OBJECTIVE: To review the literature pertaining to the efficacy of alteplase for restoration of patency of occluded venous and dialysis catheters in pediatric patients. DATA SOURCES: A MEDLINE search was conducted and cross-referenced with an EMBASE search through November 2012. Search terms included alteplase, tissue plasminogen activator, and catheter. STUDY SELECTION AND DATA EXTRACTION: Search results were limited to humans, English language, and ages from neonates to 18 years. Pertinent studies discussing efficacy of alteplase for restoration of occluded venous or dialysis catheter function were included. Case reports, review articles, and studies that specified inclusion of hemophilia patients or more than 75% of children with malignancy were excluded. DATA SYNTHESIS: Fibrinolytics are the drug class of choice for restoration of patency (defined as the ability to withdraw a blood sample) of thrombus-occluded catheters. The trials used to support Food and Drug Administration approval of alteplase for central venous catheter (CVC) occlusions generally had low pediatric enrollment; however, additional small studies are available that support use of alteplase for this indication in children. Alteplase doses of 0.5-2 mg instilled into the lumen of a CVC with dwell times ranging from 30 to more than 240 minutes plus the potential for repeat dosing were reported. Overall efficacy ranged from approximately 50% to 90%, with greater efficacy generally reported with larger doses and longer dwell times. Alteplase doses of 2-2.5 mg with dwell times of 60120 minutes were observed in 2 studies of occluded peritoneal or hemodialysis catheters, in which efficacy was reported in 57-100% of cases. Limitations of current studies of alteplase for catheter occlusion in children include small study populations and relative lack of pediatric-specific prospective trials. CONCLUSIONS: Alteplase appears to show efficacy for treatment of thrombus-related venous catheter occlusion in pediatric patients; however, data regarding its use in occluded dialysis catheters are limited. C1 [Anderson, Debra M.] Harrington Mem Hosp, Dept Pharm, Southbridge, MA USA. [Pesaturo, Kimberly A.] Massachusetts Coll Pharm & Hlth Sci, Dept Pharm Practice, Boston, MA USA. [Casavant, Jonathan] VA Puget Sound Hlth Care Syst, Dept Pharm, Seattle, WA USA. [Ramsey, E. Zachary] Childrens Hosp Philadelphia, Dept Pharm, Philadelphia, PA USA. RP Anderson, DM (reprint author), Harrington Mem Hosp, Dept Pharm, Southbridge, MA USA. EM danderso@harringtonhospital.org NR 17 TC 5 Z9 5 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1060-0280 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD MAR PY 2013 VL 47 IS 3 BP 405 EP 410 DI 10.1345/aph.1Q483 PG 6 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 225TZ UT WOS:000324987200016 PM 23463740 ER PT J AU Mechanick, JI Youdim, A Jones, DB Garvey, WT Hurley, DL McMahon, MM Heinberg, LJ Kushner, R Adams, TD Shikora, S Dixon, JB Brethauer, S AF Mechanick, Jeffrey I. Youdim, Adrienne Jones, Daniel B. Garvey, W. Timothy Hurley, Daniel L. McMahon, M. Molly Heinberg, Leslie J. Kushner, Robert Adams, Ted D. Shikora, Scott Dixon, John B. Brethauer, Stacy TI Clinical Practice Guidelines for the Perioperative Nutritional, Metabolic, and Nonsurgical Support of the Bariatric Surgery Patient-2013 Update: Cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery SO OBESITY LA English DT Article DE Bariatric surgery; Obesity; Metabolic surgery; Diabetes surgery; Metabolic syndrome; Clinical practice guidelines; Best practice guidelines; Weight loss surgery ID Y-GASTRIC-BYPASS; LAPAROSCOPIC-SLEEVE-GASTRECTOMY; TYPE-2 DIABETES-MELLITUS; WEIGHT-LOSS SURGERY; BODY-MASS INDEX; PROSPECTIVE-RANDOMIZED-TRIAL; OF-THE-LITERATURE; OUTCOMES LONGITUDINAL DATABASE; HELICOBACTER-PYLORI INFECTION; CARDIOVASCULAR RISK-FACTORS AB The development of these updated guidelines was commissioned by the AACE, TOS, and ASMBS Board of Directors and adheres to the AACE 2010 protocol for standardized production of clinical practice guidelines (CPG). Each recommendation was re-evaluated and updated based on the evidence and subjective factors per protocol. Examples of expanded topics in this update include: the roles of sleeve gastrectomy, bariatric surgery in patients with type-2 diabetes, bariatric surgery for patients with mild obesity, copper deficiency, informed consent, and behavioral issues. There are 74 recommendations (of which 56 are revised and 2 are new) in this 2013 update, compared with 164 original recommendations in 2008. There are 403 citations, of which 33 (8.2%) are EL 1, 131 (32.5%) are EL 2, 170 (42.2%) are EL 3, and 69 (17.1%) are EL 4. There is a relatively high proportion (40.4%) of strong (EL 1 and 2) studies, compared with only 16.5% in the 2008 AACE-TOS-ASMBS CPG. These updated guidelines reflect recent additions to the evidence base. Bariatric surgery remains a safe and effective intervention for select patients with obesity. A team approach to perioperative care is mandatory with special attention to nutritional and metabolic issues. C1 [Mechanick, Jeffrey I.] Icahn Sch Med Mt Sinai, New York, NY USA. [Youdim, Adrienne] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Jones, Daniel B.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. [Garvey, W. Timothy] Univ Alabama Birmingham, Birmingham VA Med Ctr, AACE, Birmingham, AL USA. [Hurley, Daniel L.; McMahon, M. Molly] Mayo Clin, Div Endocrinol Diabet Metab & Nutr, AACE, Rochester, MN USA. [Heinberg, Leslie J.] Cleveland Clin, Lerner Coll Med, BMI Director Behav Serv, TOS, Cleveland, OH 44106 USA. [Kushner, Robert] Northwestern Univ, Feinberg Sch Med, TOS, Chicago, IL 60611 USA. [Adams, Ted D.] Univ Utah, Sch Med, TOS, Hlth & Fitness Inst,Intermt Healthcare & Cardiova, Salt Lake City, UT USA. [Shikora, Scott] Harvard Univ, Brigham & Womens Hosp, Sch Med, ASMBS,Ctr Metab Hlth & Bariatr Surg, Boston, MA 02115 USA. [Dixon, John B.] Baker IDI Heart & Diabet Inst, Melbourne, Vic, Australia. [Brethauer, Stacy] Cleveland Clin, Bariatr & Metab Inst, Cleveland Clin Lerner Coll Med, Cleveland, OH 44106 USA. RP Mechanick, JI (reprint author), Icahn Sch Med Mt Sinai, New York, NY USA. EM jeffreymechanick@gmail.com RI Dixon, John/A-5318-2011 OI Dixon, John/0000-0001-5391-4082 FU NIDDK NIH HHS [P30 DK079626] NR 395 TC 186 Z9 193 U1 7 U2 39 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 EI 1930-739X J9 OBESITY JI Obesity PD MAR PY 2013 VL 21 SU 1 BP S1 EP S27 DI 10.1002/oby.20461 PG 27 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 187TB UT WOS:000322141500001 PM 23529939 ER PT J AU Lima, MMO Pareja, JC Alegre, SM Geloneze, SR Kahn, SE Astiarraga, BD Chaim, EA Baracat, J Geloneze, B AF Lima, Marcelo M. O. Pareja, Jose C. Alegre, Sarah M. Geloneze, Sylka R. Kahn, Steven E. Astiarraga, Brenno D. Chaim, Elinton A. Baracat, Jamal Geloneze, Bruno TI Visceral Fat Resection in Humans: Effect on Insulin Sensitivity, Beta-Cell Function, Adipokines, and Inflammatory Markers SO OBESITY LA English DT Article ID TYPE-2 DIABETES-MELLITUS; Y GASTRIC BYPASS; METABOLIC SYNDROME; SURGICAL REMOVAL; OBESE-PATIENTS; RESISTANCE; OMENTECTOMY; PATHOGENESIS; ADIPOSITY; RISK AB Objective: The visceral fat is linked to insulin resistance, the metabolic syndrome, type 2 diabetes and an increased cardiovascular risk, but it is not clear whether it has a causative role. Design and Methods: Surgical resection of this fat depot is a research model to address this issue. Twenty premenopausal women with metabolic syndrome and grade III obesity were randomized to undergo Roux-en-Y gastric bypass (RYGBP) either alone or combined with omentectomy. Insulin sensitivity (IS; euglycemic-hyperinsulinemic clamp), acute insulin response to glucose (AIR; intravenous glucose tolerance test), disposition index (DI = AIR x IS measured by clamp), lipid profile, adipokine profile (leptin, adiponectin, resistin, visfatin, interleukin-6, TNF-alpha, MCP-1), ultra-sensitive C-reactive protein (CRP), body composition, and abdominal fat echography were assessed prior to surgery and 1, 6, and 12 months post-surgery. Results: Omentectomy was associated with greater weight loss at all time points. IS improved similarly in both groups. Omentectomy was associated to lower CRP after 12 months, but it did not influence adipokines and other metabolic parameters. Among non-diabetic subjects, omentectomy was associated with a preservation of baseline AIR after 12 months (as opposed to deterioration in the control group) and a greater DI after 6 and 12 months. Conclusion: Although omentectomy did not enhance the effect of RYGBP on insulin sensitivity and adipokines, it was associated with a preservation of insulin secretion, a greater weight loss, and lower CRP. C1 [Lima, Marcelo M. O.; Pareja, Jose C.; Geloneze, Sylka R.; Astiarraga, Brenno D.; Geloneze, Bruno] State Univ Campinas UNICAMP, Lab Invest Metab & Diabet LIMED Gastrocent, Campinas, SP, Brazil. [Pareja, Jose C.; Chaim, Elinton A.] State Univ Campinas UNICAMP, Dept Surg, Campinas, SP, Brazil. [Alegre, Sarah M.; Astiarraga, Brenno D.] State Univ Campinas UNICAMP, Dept Internal Med, Campinas, SP, Brazil. [Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. [Baracat, Jamal] State Univ Campinas UNICAMP, Dept Radiol, Campinas, SP, Brazil. RP Lima, MMO (reprint author), State Univ Campinas UNICAMP, Lab Invest Metab & Diabet LIMED Gastrocent, Campinas, SP, Brazil. EM endo.marcelolima@gmail.com OI Kahn, Steven/0000-0001-7307-9002 FU Fundacao de Apoio a Pesquisa do Estado de Sao Paulo (FAPESP), Sao Paulo, Brazil [05/58627-2]; US Department of Veterans Affairs FX Funding agencies: This study was funded by Fundacao de Apoio a Pesquisa do Estado de Sao Paulo (FAPESP), Sao Paulo, Brazil (Protocol 05/58627-2) and supported in part by funding from the US Department of Veterans Affairs. NR 25 TC 12 Z9 13 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 J9 OBESITY JI Obesity PD MAR PY 2013 VL 21 IS 3 BP E182 EP E189 DI 10.1002/oby.20030 PG 8 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 187AK UT WOS:000322087600002 PM 23404948 ER PT J AU Rahimy, E Sarraf, D AF Rahimy, Ehsan Sarraf, David TI Cystoid Macular Edema Secondary to Nanoparticle Albumin-Bound Paclitaxel Therapy SO OPHTHALMIC SURGERY LASERS & IMAGING LA English DT Article ID MACULOPATHY AB The authors report a case of nanoparticle albumin-bound paclitaxel-induced cystoid macular edema (CME) without fluorescein angiographic leakage in a patient being treated for metastatic breast cancer. The CME briskly improved 3 weeks after the chemotherapeutic agent was discontinued and was completely resolved after 6 weeks. Patients receiving taxane therapy must be counseled to report any vision problems during their treatment period because early recognition of this rare but severe adverse event can facilitate appropriate intervention to reverse visual compromise and minimize any potential long-term ophthalmologic sequelae. C1 [Rahimy, Ehsan; Sarraf, David] Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90095 USA. [Sarraf, David] VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA USA. RP Sarraf, D (reprint author), Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, 100 Stein Plaza, Los Angeles, CA 90095 USA. EM dsarraf@ucla.edu FU Karl Kirchgessner Foundation at the Jules Stein Eye Institute FX Supported by a grant from the Karl Kirchgessner Foundation at the Jules Stein Eye Institute. NR 9 TC 5 Z9 5 U1 1 U2 4 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 1542-8877 J9 OPHTHAL SURG LAS IM JI Ophthalmic Surg. Lasers Imaging PD MAR-APR PY 2013 VL 44 IS 2 BP 187 EP 189 DI 10.3928/23258160-20130212-02 PG 3 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA 172PS UT WOS:000321017200015 PM 23421925 ER PT J AU Woods, SS Schwartz, E Tuepker, A Press, NA Nazi, KM Turvey, CL Nichol, P AF Woods, Susan S. Schwartz, Erin Tuepker, Anais Press, Nancy A. Nazi, Kim M. Turvey, Carolyn L. Nichol, Paul TI Patient Experiences With Full Electronic Access to Health Records and Clinical Notes Through the My HealtheVet Personal Health Record Pilot: Qualitative Study SO JOURNAL OF MEDICAL INTERNET RESEARCH LA English DT Article DE personal health records; eHealth; patient access to records; veterans; patient participation ID MEDICAL-RECORD; INVITING PATIENTS; GENERAL-PRACTICE; DOCTORS NOTES; CARE RECORD; COMMUNICATION; EXPECTATIONS; INFORMATION; ATTITUDES; TRIAL AB Background: Full sharing of the electronic health record with patients has been identified as an important opportunity to engage patients in their health and health care. The My HealtheVet Pilot, the initial personal health record of the US Department of Veterans Affairs, allowed patients and their delegates to view and download content in their electronic health record, including clinical notes, laboratory tests, and imaging reports. Objective: A qualitative study with purposeful sampling sought to examine patients' views and experiences with reading their health records, including their clinical notes, online. Methods: Five focus group sessions were conducted with patients and family members who enrolled in the My HealtheVet Pilot at the Portland Veterans Administration Medical Center, Oregon. A total of 30 patients enrolled in the My HealtheVet Pilot, and 6 family members who had accessed and viewed their electronic health records participated in the sessions. Results: Four themes characterized patient experiences with reading the full complement of their health information. Patients felt that seeing their records positively affected communication with providers and the health system, enhanced knowledge of their health and improved self-care, and allowed for greater participation in the quality of their care such as follow-up of abnormal test results or decision-making on when to seek care. While some patients felt that seeing previously undisclosed information, derogatory language, or inconsistencies in their notes caused challenges, they overwhelmingly felt that having more, rather than less, of their health record information provided benefits. Conclusions: Patients and their delegates had predominantly positive experiences with health record transparency and the open sharing of notes and test results. Viewing their records appears to empower patients and enhance their contributions to care, calling into question common provider concerns about the effect of full record access on patient well-being. While shared records may or may not impact overall clinic workload, it is likely to change providers' work, necessitating new types of skills to communicate and partner with patients. C1 [Woods, Susan S.; Schwartz, Erin; Tuepker, Anais] Portland VA Med Ctr, Portland, OR 97239 USA. [Woods, Susan S.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA. [Press, Nancy A.] Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97201 USA. [Press, Nancy A.] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97201 USA. [Nazi, Kim M.] Vet Hlth Adm, Vet & Consumers Hlth Informat Off, Off Informat & Analyt, Washington, DC USA. [Turvey, Carolyn L.] Iowa City VA Hlth Care Syst, Ctr Comprehens Access & Delivery Res & Evaluat, Iowa City, IA USA. [Nichol, Paul] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Woods, SS (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd P3HSRD, Portland, OR 97239 USA. EM susan.woods@va.gov NR 26 TC 47 Z9 47 U1 4 U2 23 PU JMIR PUBLICATIONS, INC PI TORONTO PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA SN 1438-8871 J9 J MED INTERNET RES JI J. Med. Internet Res. PD MAR PY 2013 VL 15 IS 3 BP 182 EP 191 DI 10.2196/jmir.2356 PG 10 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA 151EA UT WOS:000319442300015 PM 23535584 ER PT J AU Tannock, LR AF Tannock, Lisa R. TI U-500: A CONVENIENT INSULIN FOR A CONVENIENCE FOOD NATION SO ENDOCRINE PRACTICE LA English DT Editorial Material ID DIABETES-MELLITUS C1 [Tannock, Lisa R.] Univ Kentucky, US Dept Vet Affairs, Lexington, KY 40536 USA. [Tannock, Lisa R.] Univ Kentucky, Div Endocrinol & Mol Med, Lexington, KY 40536 USA. RP Tannock, LR (reprint author), Univ Kentucky, Room 553,Wethington Bldg,900 S Limestone St, Lexington, KY 40536 USA. EM Lisa.Tannock@uky.edu NR 9 TC 1 Z9 1 U1 0 U2 1 PU AMER ASSOC CLINICAL ENDOCRINOLOGISTS PI JACKSONVILLE PA 245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA SN 1530-891X J9 ENDOCR PRACT JI Endocr. Pract. PD MAR-APR PY 2013 VL 19 IS 2 BP 194 EP 195 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 154JX UT WOS:000319672400005 PM 23598533 ER PT J AU Mechanick, JI Youdim, A Jones, DB Garvey, WT Hurley, DL McMahon, MM Heinberg, LJ Kushner, R Adams, TD Shikora, S Dixon, JB Brethauer, S AF Mechanick, Jeffrey I. Youdim, Adrienne Jones, Daniel B. Garvey, W. Timothy Hurley, Daniel L. McMahon, M. Molly Heinberg, Leslie J. Kushner, Robert Adams, Ted D. Shikora, Scott Dixon, John B. Brethauer, Stacy TI CLINICAL PRACTICE GUIDELINES FOR THE PERIOPERATIVE NUTRITIONAL, METABOLIC, AND NONSURGICAL SUPPORT OF THE BARIATRIC SURGERY PATIENT-2013 UPDATE: COSPONSORED BY AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, THE OBESITY SOCIETY, AND AMERICAN SOCIETY FOR METABOLIC & BARIATRIC SURGERY SO ENDOCRINE PRACTICE LA English DT Article ID Y-GASTRIC-BYPASS; LAPAROSCOPIC-SLEEVE-GASTRECTOMY; TYPE-2 DIABETES-MELLITUS; WEIGHT-LOSS SURGERY; BODY-MASS INDEX; PROSPECTIVE-RANDOMIZED-TRIAL; OF-THE-LITERATURE; OUTCOMES LONGITUDINAL DATABASE; HELICOBACTER-PYLORI INFECTION; CARDIOVASCULAR RISK-FACTORS AB The development of these updated guidelines was commissioned by the AACE, TOS, and ASMBS Board of Directors and adheres to the AACE 2010 protocol for standardized production of clinical practice guidelines (CPG). Each recommendation was re-evaluated and updated based on the evidence and subjective factors per protocol. Examples of expanded topics in this update include: the roles of sleeve gastrectomy, bariatric surgery in patients with type-2 diabetes, bariatric surgery for patients with mild obesity, copper deficiency, informed consent, and behavioral issues. There are 74 recommendations (of which 56 are revised and 2 are new) in this 2013 update, compared with 164 original recommendations in 2008. There are 403 citations, of which 33 (8.2%) are EL 1, 131 (32.5%) are EL 2, 170 (42.2%) are EL 3, and 69 (17.1%) are EL 4. There is a relatively high proportion (40.4%) of strong (EL 1 and 2) studies, compared with only 16.5% in the 2008 AACE- TOS-ASMBS CPG. These updated guidelines reflect recent additions to the evidence base. Bariatric surgery remains a safe and effective intervention for select patients with obesity. A team approach to perioperative care is mandatory with special attention to nutritional and metabolic issues. C1 [Mechanick, Jeffrey I.] Icahn Sch Med Mt Sinai, New York, NY 10128 USA. [Youdim, Adrienne] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Jones, Daniel B.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. [Garvey, W. Timothy] Univ Alabama Birmingham, Birmingham VA Med Ctr, AACE, Birmingham, AL USA. [Hurley, Daniel L.; McMahon, M. Molly] Mayo Clin, Div Endocrinol Diabet Metab & Nutr, AACE, Rochester, MN USA. [Heinberg, Leslie J.] Cleveland Clin, Lerner Coll Med, TOS, Cleveland, OH 44106 USA. [Kushner, Robert] Northwestern Univ, Feinberg Sch Med, TOS, Chicago, IL 60611 USA. [Adams, Ted D.] Univ Utah, Sch Med, Intermt Healthcare & Cardiovasc Genet Div, Hlth & Fitness Inst,TOS, Salt Lake City, UT USA. [Shikora, Scott] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Metab Hlth & Bariatr Surg,ASMBS, Boston, MA 02115 USA. [Dixon, John B.] Monash Univ, Baker IDI Heart & Diabet Inst, ASMBS, Melbourne, Vic 3004, Australia. [Brethauer, Stacy] Cleveland Clin, Bariatr & Metab Inst, ASMBS, Cleveland, OH 44106 USA. RP Mechanick, JI (reprint author), Icahn Sch Med Mt Sinai, 1192 Pk Ave, New York, NY 10128 USA. EM jeffreymechanick@gmail.com NR 387 TC 38 Z9 39 U1 1 U2 10 PU AMER ASSOC CLINICAL ENDOCRINOLOGISTS PI JACKSONVILLE PA 245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA SN 1530-891X J9 ENDOCR PRACT JI Endocr. Pract. PD MAR-APR PY 2013 VL 19 IS 2 BP 338 EP 372 PG 35 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 154JX UT WOS:000319672400025 ER PT J AU Mack, J Okai, D Brown, RG Askey-Jones, S Chaudhuri, KR Martin, A Samuel, M David, AS AF Mack, Joel Okai, David Brown, Richard G. Askey-Jones, Sally Chaudhuri, K. Ray Martin, Anne Samuel, Michael David, Anthony S. TI The Role of Self-Awareness and Cognitive Dysfunction in Parkinson's Disease With and Without Impulse-Control Disorder SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Article ID DOPAMINE DYSREGULATION; PSYCHOTIC SYMPTOMS; HALLUCINATIONS; STIMULATION; PREVALENCE; DYSKINESIAS; INVENTORY; DIAGNOSIS; RATINGS; SCALE AB The aim of this study was to investigate the clinical, neuropsychological, and self-awareness correlates of impulse-control disorder (ICD) in a group of 17 Parkinson's disease (PD) subjects with an active ICD and a comparison group of 17 PD subjects without ICD. Self-awareness was assessed with the Beck Cognitive Insight Scale and patient-caregiver discrepancy scores from ratings on the Dysexecutive Questionnaire and the Everyday Memory Questionnaire-Revised. Self-awareness was comparable or increased in those with ICD, versus those without, and measures of neuropsychological functioning did not differ between the two groups. Those with ICD had more motor complications of PD therapy and were more likely to be on an antidepressant than those without ICD, whereas dopaminergic medication profiles were comparable between the two groups. In this group, PD patients with current ICDs were aware of their impulsivity. Although executive dysfunction may contribute to ICD behavior, it is not a necessary component. The awareness of the inability to resist these motivated behaviors may be a source of increased depression. C1 Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. Portland VA Med Ctr, Dept Psychiat, Portland, OR USA. Portland VA Med Ctr, Northwest Parkinsons Dis Res Educ & Clin Ctr, Portland, OR USA. Kings Coll London, Inst Psychiat, Sect Cognit Neuropsychiat, London WC2R 2LS, England. Imperial Healthcare NHS Trust, London, England. West London Mental Hlth Trust, London, England. Kings Coll London, Inst Psychiat, Dept Psychol, London WC2R 2LS, England. Kings Coll London, Dept Mental Hlth & Specialist Care, Florence Nightingale Sch Nursing & Midwifery, London, England. Kings Hlth Partners, Kings Coll Hosp, Dept Neurol, Natl Parkinson Fdn Ctr Excellence, London, England. East Kent Hosp Univ NHS Fdn Trust, William Harvey Hosp, Ashford, Kent, England. RP Mack, J (reprint author), Portland VA Med Ctr, Portland, OR USA. EM mack@ohsu.edu RI Brown, Richard/A-9599-2010; David, Anthony/C-1315-2011 OI Brown, Richard/0000-0001-9021-0172; David, Anthony/0000-0003-0967-774X; Okai, David/0000-0002-0298-2031; Ray Chaudhuri, K/0000-0003-2815-0505 FU Parkinson's UK; National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London; Maudsley NHS Foundation Trust and King's College, London; Medtronic, Inc.; St. Judes, Inc.; Ipsen Pharmaceuticals; Solvay Pharmaceuticals; UCB Pharma, Britannia; GSK; Abbott; Teva; Medtronic; Boehringer Ingelheim; UCB Pharma; Britannia FX The authors acknowledge support from: Parkinson's UK; Authors RGB and ASD acknowledge support from the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College, London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.; Relevant conflicts of interest/financial disclosures: RGB has received honoraria for speaking at conferences and educational events from UCB Pharma, GSK, Lundbeck, and is an Advisory Board member for UCB Pharma. MS has received lecture fees from Medtronic, Inc., St. Judes, Inc., unrestricted educational grants from Ipsen and Solvay Pharmaceuticals, and sponsorship for educational meetings from Boehringer Ingelheim. KRC serves as the European Editor of Basal Ganglia, as an editorial board member of Parkinsonism and Related Disorders, and The Journal of Parkinson's Disease, and, as the Liaison and PR Committee Chairman of the Movement Disorders Society, has received honoraria for academic lectures at sponsored symposiums from UCB Pharma, Britannia, GSK, Abbott, Teva, Medtronic, and Boehringer Ingelheim, and has received educational grants for research from UCB Pharma, Abbott, Boehringer Ingelheim, and Britannia. NR 51 TC 5 Z9 5 U1 1 U2 14 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0895-0172 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD SPR PY 2013 VL 25 IS 2 BP 141 EP 149 PG 9 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 156FX UT WOS:000319808300048 PM 23686032 ER PT J AU Daniels, LB Grady, D Mosca, L Collins, P Mitlak, BH Amewou-Atisso, MG Wenger, NK Barrett-Connor, E AF Daniels, Lori B. Grady, Deborah Mosca, Lori Collins, Peter Mitlak, Bruce H. Amewou-Atisso, Messan G. Wenger, Nanette K. Barrett-Connor, Elizabeth CA Raloxifene Use Heart RUTH Trial In TI Is Diabetes Mellitus a Heart Disease Equivalent in Women? Results From an International Study of Postmenopausal Women in the Raloxifene Use for the Heart (RUTH) Trial SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE diabetes mellitus; heart diseases; randomized trial; risk factors; women ID PRIOR MYOCARDIAL-INFARCTION; FACTOR INTERVENTION TRIAL; CARDIOVASCULAR-DISEASE; FOLLOW-UP; DOPPLER ECHOCARDIOGRAPHY; NONDIABETIC INDIVIDUALS; RISK EQUIVALENT; MORTALITY; POPULATION; IMPACT AB Background-Several studies have concluded that diabetes mellitus and heart disease carry similar risk for future cardiovascular disease (CVD). Most of these studies were too small to quantify independent risks specific to women. The purpose of this study was to determine whether diabetes mellitus is a coronary heart disease (CHD) risk equivalent for prediction of future CHD and CVD events in women. Methods and Results-The Raloxifene Use for the Heart (RUTH) trial was an international, multicenter, double-blind, randomized, placebo-controlled trial of raloxifene and CVD outcomes in 10 101 postmenopausal women selected for high CHD risk. Of these, 3672 had a history of diabetes mellitus without known CHD, and 3265 had a history of CHD without known diabetes mellitus. Cox proportional hazard models were used to compare cardiovascular outcomes in these 2 groups. Mean age at baseline was 67.5 years; median follow-up was 5.6 years. There were 725 deaths, including 450 cardiovascular deaths. In age-adjusted analyses, diabetic women had an increased risk of all-cause mortality compared with women with CHD. Although the overall risk of CHD and CVD was lower in diabetic women compared with women with CHD, the risk of fatal CHD, fatal CVD, and all-cause mortality was similar (hazard ratio [95% confidence interval]: 0.85 [0.65-1.12], 0.99 [0.78-1.25], and 1.18 [0.98-1.42], respectively, after adjusting for age, lifestyle factors, CHD risk factors, statin use, and treatment assignment). Conclusions-In the RUTH trial, diabetes mellitus was a CHD risk equivalent in women for fatal, but not nonfatal, CHD and CVD. C1 [Daniels, Lori B.] UC San Diego Hlth Syst, Dept Med, Div Cardiol, La Jolla, CA USA. [Barrett-Connor, Elizabeth] UC San Diego Hlth Syst, Dept Family & Prevent Med, Div Epidemiol, La Jolla, CA USA. [Grady, Deborah] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Grady, Deborah] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Grady, Deborah] San Francisco VA Med Ctr, San Francisco, CA USA. [Mosca, Lori] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA. [Collins, Peter] Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Dept Cardiac Med, London, England. [Collins, Peter] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England. [Mitlak, Bruce H.; Amewou-Atisso, Messan G.] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA. [Wenger, Nanette K.] Emory Univ, Sch Med, Atlanta, GA USA. RP Daniels, LB (reprint author), Univ Calif San Diego, Div Cardiol, Mail Code 7411,9444 Med Ctr Dr, La Jolla, CA 92037 USA. EM lbdaniels@ucsd.edu RI Suryapranata, H./H-8095-2014; Gurevich, Victor/H-2935-2013 OI Gurevich, Victor/0000-0002-6815-444X; Maggioni, Aldo Pietro/0000-0003-2764-6779 FU Eli Lilly and Company, Indianapolis, IN FX This study was sponsored by Eli Lilly and Company, Indianapolis, IN. NR 42 TC 9 Z9 9 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7705 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD MAR PY 2013 VL 6 IS 2 BP 164 EP + DI 10.1161/CIRCOUTCOMES.112.966986 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 150LO UT WOS:000319392100007 PM 23481531 ER PT J AU Merchant, RM Asch, DA Hershey, JC Griffis, HM Hill, S Saynisch, O Leung, AC Asch, JM Lozada, K Nadkarni, LD Kilaru, A Branas, CC Stone, EM Starr, L Shofer, F Nichol, G Becker, LB AF Merchant, Raina M. Asch, David A. Hershey, John C. Griffis, Heather M. Hill, Shawndra Saynisch, Olivia Leung, Alison C. Asch, Jeremy M. Lozada, Kirk Nadkarni, Lindsay D. Kilaru, Austin Branas, Charles C. Stone, Eric M. Starr, Larry Shofer, Frances Nichol, Graham Becker, Lance B. TI A Crowdsourcing Innovation Challenge to Locate and Map Automated External Defibrillators SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE cardiopulmonary resuscitation; crowdsourcing; defibrillator; heart arrest ID HOSPITAL CARDIAC-ARREST; PUBLIC-ACCESS DEFIBRILLATION; AMERICAN-HEART-ASSOCIATION; UNITED-STATES; SURVIVAL; OUTCOMES; CARE C1 [Merchant, Raina M.; Griffis, Heather M.; Saynisch, Olivia; Leung, Alison C.; Asch, Jeremy M.; Lozada, Kirk; Nadkarni, Lindsay D.; Stone, Eric M.; Shofer, Frances; Becker, Lance B.] Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA. [Merchant, Raina M.; Asch, David A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Asch, David A.; Hershey, John C.; Hill, Shawndra] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [Branas, Charles C.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Nichol, Graham] Univ Washington, Dept Med, Univ Washington Harborview Ctr Prehosp Emergency, Seattle, WA USA. RP Merchant, RM (reprint author), Univ Penn, Perelman Sch Med, 423 Guardian St,1022 Blockley, Philadelphia, PA 19104 USA. EM raina.merchant@uphs.upenn.edu OI Asch, David/0000-0002-7970-286X FU Robert Wood Johnson Foundation Health and Society Scholars Program at the University of Pennsylvania, National Institutes of Health (NIH) [10714038]; Physio-Control, Seattle, WA; Zoll Medical, Boston, MA; Cardiac Science, Bothell, WA; Philips Medical, Seattle, WA; Medtronic Foundation Heart Rescue Project; Penn University Research Fund; McCabe Fund FX This study was supported by the Robert Wood Johnson Foundation Health and Society Scholars Program at the University of Pennsylvania, National Institutes of Health (NIH), K23 Grant 10714038, and pilot funding from Physio-Control, Seattle, WA; Zoll Medical, Boston, MA; Cardiac Science, Bothell, WA; and Philips Medical, Seattle, WA, as well as The Medtronic Foundation Heart Rescue Project; The Penn University Research Fund; and the McCabe Fund. No funders played a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. NR 25 TC 18 Z9 18 U1 2 U2 14 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7705 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD MAR PY 2013 VL 6 IS 2 BP 229 EP + DI 10.1161/CIRCOUTCOMES.113.000140 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 150LO UT WOS:000319392100016 PM 23481522 ER PT J AU Styskal, J Nwagwu, FA Watkins, YN Liang, H Richardson, A Musi, N Salmon, AB AF Styskal, JennaLynn Nwagwu, Florence A. Watkins, Yvonne N. Liang, Hanyu Richardson, Arlan Musi, Nicolas Salmon, Adam B. TI Methionine sulfoxide reductase A affects insulin resistance by protecting insulin receptor function SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE Oxidative stress; Methionine sulfoxide; Diabetes; Obesity; Glucose homeostasis; Protein oxidation ID HUMAN SKELETAL-MUSCLE; OXIDATIVE STRESS; HYDROGEN-PEROXIDE; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; GLUT4 TRANSLOCATION; 3T3-L1 ADIPOCYTES; ADIPOSE-TISSUE; OBESITY; PHOSPHORYLATION AB Oxidative stress plays a significant role in the development of insulin resistance; however, the cellular targets of oxidation that cause insulin resistance have yet to be fully elucidated. Methionine sulfoxide reductases reduce oxidized methionine residues, thereby repairing and protecting proteins from oxidation. Recently, several genome-wide analyses have found human obesity to be strongly correlated with polymorphisms near the methionine sulfoxide reductase A (MsrA) locus. In this study, we tested whether modulation of MsrA expression significantly alters the development of obesity and/or insulin resistance in mice. We show that mice lacking MsrA (MsrA(-/-)) are prone to the development of high-fat-diet-induced insulin resistance and a reduced physiological insulin response compared to high-fat-fed wild-type mice. We also show that oxidative stress in C2C12 cell cultures reduces both insulin-stimulated phosphorylation and autophosphorylation of the insulin receptor. Tissues from high-fat-fed mice show similar reduction in insulin receptor function and increase in insulin receptor oxidation, which are further exacerbated by the lack of MsrA. Together, these data demonstrate for the first time that MsrA and protein oxidation play a role in the regulation of glucose homeostasis. In addition, these data support a novel hypothesis that obesity-induced insulin resistance is caused in part by reduced function of insulin signaling proteins arising from protein oxidation. Published by Elsevier Inc. C1 [Styskal, JennaLynn; Nwagwu, Florence A.; Watkins, Yvonne N.; Richardson, Arlan; Musi, Nicolas; Salmon, Adam B.] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Styskal, JennaLynn; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Nwagwu, Florence A.; Watkins, Yvonne N.; Liang, Hanyu; Musi, Nicolas] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Liang, Hanyu; Musi, Nicolas] Univ Texas Hlth Sci Ctr San Antonio, Div Diabet, San Antonio, TX 78229 USA. [Salmon, Adam B.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA. [Richardson, Arlan; Musi, Nicolas; Salmon, Adam B.] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. RP Salmon, AB (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, 15355 Lambda Dr, San Antonio, TX 78245 USA. EM salmona@uthscsa.edu FU National Institutes of Health (NIH) [T32 AG021890-05]; NIH MERIT [R37AG026557]; Mitochondrial Function and Oxidative Damage Core Facility of the San Antonio Nathan Shock Center of Excellence in the Basic Biology of Aging FX The authors thank Rodney Levine, Geumsoo Kim, and Hang Zhao from the NIH/NHLBI Laboratory of Biochemistry for sharing MsrA-/- mice to generate our breeding colonies. This study was supported by National Institutes of Health (NIH) Training Grant T32 AG021890-05, NIH MERIT Grant R37AG026557, and the Mitochondrial Function and Oxidative Damage Core Facility of the San Antonio Nathan Shock Center of Excellence in the Basic Biology of Aging. NR 49 TC 17 Z9 17 U1 1 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD MAR PY 2013 VL 56 BP 123 EP 132 DI 10.1016/j.freeradbiomed.2012.10.544 PG 10 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 154BY UT WOS:000319647700012 PM 23089224 ER PT J AU Kaatz, A Vogelman, PN Carnes, M AF Kaatz, Anna Vogelman, Paul N. Carnes, Molly TI Are Men More Likely than Women To Commit Scientific Misconduct? Maybe, Maybe Not SO MBIO LA English DT Editorial Material ID GENDER; STEREOTYPES; SUCCESS AB In their study published in January 2013 in mBio, Fang et al. reviewed records from the Office of Research Integrity (ORI) and found more cases of scientific misconduct committed by men than women, particularly by faculty (F. C. Fang, J. W. Bennett, and A. Casadevall, mBio 4:1-3, 2013). Powerful social norms shape the way men and women behave, and implicit gender schemas can lead to different evaluation standards for men and women for tasks stereotypically linked to one gender. It is possible that norms for acceptable male and female behavior could lead to a lower threshold for men than women to engage in the risky behavior of scientific misconduct. It is also possible that women and men commit scientific fraud at the same rate but that, because crime is a male-gendered domain, evaluators require more proof of the criminal "competence" of women for an investigation to rise to the level of an ORI case or that female gender norms for likeability and a lower apology threshold more often prevent escalation of women's fraud beyond a local level. Male scientists also have more opportunity to commit fraud than female scientists because they receive more NIH research funding-a finding that may also be influenced by gender schemas. We cannot conclude from the ORI data that men are more likely than women to risk the consequences of committing scientific misconduct simply because risk taking aligns with male gender stereotypes. Neither can we conclude that because men are more likely than women to commit fraud in other contexts, men are also more likely than women to commit scientific fraud. We can conclude, however, that scientific misconduct, regardless of who commits it, diminishes all who contribute to the scientific enterprise. C1 [Kaatz, Anna; Carnes, Molly] Univ Wisconsin Madison, Ctr Womens Hlth Res, Madison, WI 53706 USA. [Carnes, Molly] Univ Wisconsin Madison, Dept Med, Madison, WI USA. [Carnes, Molly] Univ Wisconsin Madison, Dept Ind & Syst Engn, Madison, WI USA. [Carnes, Molly] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Carnes, M (reprint author), Univ Wisconsin Madison, Ctr Womens Hlth Res, Madison, WI 53706 USA. EM mlcarnes@wisc.edu NR 23 TC 2 Z9 2 U1 7 U2 21 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 2150-7511 J9 MBIO JI mBio PD MAR-APR PY 2013 VL 4 IS 2 AR e00156-13 DI 10.1128/mBio.00156-13 PG 2 WC Microbiology SC Microbiology GA 137JI UT WOS:000318431500025 ER PT J AU Blouin, AM Fried, I Wilson, CL Staba, RJ Behnke, EJ Lam, HA Maidment, NT Karlsson, KAE Lapierre, JL Siegel, JM AF Blouin, Ashley M. Fried, Itzhak Wilson, Charles L. Staba, Richard J. Behnke, Eric J. Lam, Hoa A. Maidment, Nigel T. Karlsson, Karl A. E. Lapierre, Jennifer L. Siegel, Jerome M. TI Human hypocretin and melanin-concentrating hormone levels are linked to emotion and social interaction SO NATURE COMMUNICATIONS LA English DT Article ID IN-VIVO MICRODIALYSIS; SLEEP-WAKING CYCLE; CEREBROSPINAL-FLUID; PARKINSONS-DISEASE; NARCOLEPTIC DOGS; OREXIN NEURONS; REM-SLEEP; CATAPLEXY; NUCLEUS; RELEASE AB The neurochemical changes underlying human emotions and social behaviour are largely unknown. Here we report on the changes in the levels of two hypothalamic neuropeptides, hypocretin-1 and melanin-concentrating hormone, measured in the human amygdala. We show that hypocretin-1 levels are maximal during positive emotion, social interaction and anger, behaviours that induce cataplexy in human narcoleptics. In contrast, melanin-concentrating hormone levels are minimal during social interaction, but are increased after eating. Both peptides are at minimal levels during periods of postoperative pain despite high levels of arousal. Melanin-concentrating hormone levels increase at sleep onset, consistent with a role in sleep induction, whereas hypocretin-1 levels increase at wake onset, consistent with a role in wake induction. Levels of these two peptides in humans are not simply linked to arousal, but rather to specific emotions and state transitions. Other arousal systems may be similarly emotionally specialized. C1 [Blouin, Ashley M.; Lam, Hoa A.; Maidment, Nigel T.; Karlsson, Karl A. E.; Lapierre, Jennifer L.; Siegel, Jerome M.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Blouin, Ashley M.] Johns Hopkins Univ, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA. [Fried, Itzhak; Behnke, Eric J.] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA 90095 USA. [Fried, Itzhak; Wilson, Charles L.; Maidment, Nigel T.; Siegel, Jerome M.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA. [Wilson, Charles L.; Staba, Richard J.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA. [Karlsson, Karl A. E.] Reykjavik Univ, Sch Sci & Engn, IS-101 Reykjavik, Iceland. [Siegel, Jerome M.] Vet Adm Greater Los Angeles Healthcare Syst, North Hills, CA 91343 USA. RP Siegel, JM (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. EM JSiegel@ucla.edu FU NIH [MH064109, NS14610, NS33310, NS02808]; Medical Research Service of the Department of Veterans Affairs FX These studies were supported by NIH Grants MH064109, NS14610, NS33310 and NS02808, and the Medical Research Service of the Department of Veterans Affairs. We thank Joyel Alamajano, Grace Barber, Josephine Ruidera and Sandeep Sood for assistance with sample collection, and Larry Ackerson, Tony Fields, Jo Hsieh, Yuval Nir, Ronald McGregor, Lalini Ramanathan and M.F. Wu for technical assistance. NR 58 TC 75 Z9 77 U1 2 U2 33 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD MAR PY 2013 VL 4 AR 1547 DI 10.1038/ncomms2461 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 143NJ UT WOS:000318873900001 PM 23462990 ER PT J AU Ripoll, LH Snyder, R Steele, H Siever, LJ AF Ripoll, Luis H. Snyder, Rebekah Steele, Howard Siever, Larry J. TI The Neurobiology of Empathy in Borderline Personality Disorder SO CURRENT PSYCHIATRY REPORTS LA English DT Article DE Borderline personality disorder; BPD; Personality; Empathy; Attachment theory; Social cognition; Aggression; Social affectivity; Neuropeptides; Neurobiology; Psychiatry ID REJECTION SENSITIVITY; EMOTION RECOGNITION; SOCIAL EXCLUSION; FACIAL EMOTION; SELF-INJURY; ATTACHMENT; OXYTOCIN; PAIN; FMRI; CHILDHOOD AB We present a neurobiological model of empathic dysfunction in borderline personality disorder (BPD) to guide future empirical research. Empathy is a necessary component of interpersonal functioning, involving two distinct, parallel neural networks. One form of empathic processing relies on shared representations (SR) of others' mental states, while the other is associated with explicit mental state attribution (MSA). SR processing is visceral and automatic, contributing to attunement, but also emotional contagion. MSA processing contributes to deliberate, perspectival forms of empathic understanding. Empathic dysfunction in BPD may involve hyper-reactivity of SR networks and impairment of MSA networks. Nevertheless, this empathic dysfunction is subtle, but contributes to interpersonal difficulties. Interaction between genetic factors and traumatic attachment stressors may contribute to development of BPD, with painful attachment insecurity and disorganization affecting SR and MSA network functioning. Future avenues for BPD research will include developmental assessment of attachment and neurobiological functioning under varying conditions. C1 [Ripoll, Luis H.; Siever, Larry J.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Ripoll, Luis H.] New York Psychoanalyt Inst, New York, NY USA. [Snyder, Rebekah] Columbia Univ, Dept Psychol, Barnard Coll, New York, NY 10027 USA. [Steele, Howard] New Sch Social Res, Dept Psychol, New York, NY 10011 USA. [Siever, Larry J.] Mental Illness Res Educ & Clin Ctr MIRECC, James J Peters VA Med Ctr, Bronx, NY USA. RP Ripoll, LH (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA. EM Luis.ripoll@mssm.edu NR 99 TC 14 Z9 15 U1 4 U2 40 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3812 J9 CURR PSYCHIAT REP JI Curr. Psychiatry Rep. PD MAR PY 2013 VL 15 IS 3 AR 344 DI 10.1007/s11920-012-0344-1 PG 11 WC Psychiatry SC Psychiatry GA 141XU UT WOS:000318760700002 PM 23389774 ER PT J AU Deacon, BJ Lickel, JJ Farrell, NR Kemp, JJ Hipol, LJ AF Deacon, Brett J. Lickel, James J. Farrell, Nicholas R. Kemp, Joshua J. Hipol, Leilani J. TI Therapist perceptions and delivery of interoceptive exposure for panic disorder SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE Interoceptive exposure; Panic disorder; Diaphragmatic breathing; Treatment ID COGNITIVE-BEHAVIORAL TREATMENT; POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; ANXIETY; COMBINATION; AGORAPHOBIA; IMIPRAMINE; EFFICACY AB Interoceptive exposure (IE) is widely regarded as an essential procedure in the cognitive-behavioral treatment of panic disorder (PD). However, treatment manuals differ substantially in their prescribed delivery of IE, and little research exists to inform the optimal manner of its implementation. The present study examined therapists' perceptions and delivery of IE for PD. Results revealed substantial variability in how clinicians provide IE. In contrast to the prolonged and intense manner in which exposure techniques are traditionally applied, many therapists reported delivering a low dose of IE accompanied by controlled breathing strategies. Concerns about the potential adverse effects of IE were common despite the fact that participants reported the actual occurrence of negative outcomes of IE in their own practice to be extremely infrequent. It is possible that some therapists deliver IE in a cautious manner in an attempt to minimize the perceived risks associated with this treatment. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Deacon, Brett J.; Farrell, Nicholas R.; Kemp, Joshua J.; Hipol, Leilani J.] Univ Wyoming, Dept 3415, Dept Psychol, Laramie, WY 82071 USA. [Lickel, James J.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. RP Deacon, BJ (reprint author), Univ Wyoming, Dept 3415, Dept Psychol, 1000 East Univ Ave, Laramie, WY 82071 USA. EM bdeacon@uwyo.edu NR 41 TC 20 Z9 20 U1 2 U2 18 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 J9 J ANXIETY DISORD JI J. Anxiety Disord. PD MAR PY 2013 VL 27 IS 2 BP 259 EP 264 DI 10.1016/j.janxdis.2013.02.004 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 136UA UT WOS:000318387700013 PM 23549110 ER PT J AU Farnsworth, SL Qiu, ZF Mishra, A Hornsby, PJ AF Farnsworth, Steven L. Qiu, Zhifang Mishra, Anuja Hornsby, Peter J. TI Directed neural differentiation of induced pluripotent stem cells from non-human primates SO EXPERIMENTAL BIOLOGY AND MEDICINE LA English DT Article DE induced pluripotent stem cells; non-human primates; differentiation; cell therapy ID REGENERATIVE MEDICINE; FATE; INDUCTION; BIOLOGY; GENERATION; CONVERSION; INHIBITOR; DISCOVERY; NEURONS; SIGNALS AB Induced pluripotent stem cells (iPS cells) are important for the future development of regenerative medicine involving autologous cell therapy. Before autologous cell therapy can be applied to human patients, suitable animal models must be developed, and in this context non-human primate models are critical. We previously characterized several lines of marmoset iPS cells derived from newborn skin fibroblasts. In the present studies, we explored methods for the directed differentiation of marmoset iPS cells in the neuroectodermal lineage. In this process we used an iterative process in which combinations of small molecules and protein factors were tested for their effects on mRNA levels of genes that are markers for the neuroectodermal lineage. This iterative process identified combinations of chemicals/factors that substantially improved the degree of marker gene expression over the initially tested combinations. This approach should be generally valuable in the directed differentiation of pluripotent cells for experimental cell therapy. C1 [Farnsworth, Steven L.; Qiu, Zhifang; Mishra, Anuja; Hornsby, Peter J.] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. [Farnsworth, Steven L.; Qiu, Zhifang; Mishra, Anuja; Hornsby, Peter J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78245 USA. [Farnsworth, Steven L.; Qiu, Zhifang; Mishra, Anuja; Hornsby, Peter J.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. RP Hornsby, PJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, 15355 Lambda Dr, San Antonio, TX 78245 USA. EM hornsby@uthscsa.edu RI Qiu, Zhifang/P-8313-2014 OI Qiu, Zhifang/0000-0001-9196-032X FU Department of Veterans Affairs [I01BX001454]; Ted Nash Long Life Foundation; Owens Medical Foundation; COSTAR [T32DE014318]; [F30DE022494] FX This work was supported by grant I01BX001454 from the Department of Veterans Affairs to PJH, and also by grants from the Ted Nash Long Life Foundation and the Owens Medical Foundation. SLF was supported by an individual fellowship (F30DE022494) and by the COSTAR training grant T32DE014318. NR 30 TC 5 Z9 5 U1 0 U2 9 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 1535-3702 J9 EXP BIOL MED JI Exp. Biol. Med. PD MAR PY 2013 VL 238 IS 3 BP 276 EP 284 DI 10.1177/1535370213482442 PG 9 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 134DA UT WOS:000318188900004 PM 23598973 ER PT J AU Liao, JM Singh, H AF Liao, Joshua M. Singh, Hardeep TI Reviving the Autopsy as a Diagnostic Error-Reduction Tool SO LABMEDICINE LA English DT Article DE diagnostic errors; autopsy; medical error; patient safety; pathology AB Errors are estimated to occur in 10% to 15% of all diagnoses and can lead to significant harm and costs. An autopsy can reveal clinically significant diagnoses missed before death. Multiple studies have reported poor concordance between clinical and autopsy diagnoses; thus, autopsy remains a powerful tool for the study of diagnostic errors. Although there are benefits to autopsy in the era of advanced diagnostic technology, many barriers exist. In this article, we discuss the role of autopsy in reducing diagnostic errors and make several recommendations of how to invigorate efforts to support autopsy as a potential diagnostic error reduction tool. A resurgence of autopsy as a learning tool will require not only focus on the actions of requesting physicians or pathologists, but also a systems-based approach, including nonphysician personnel, health information technology, reimbursement initiatives, and incentives to promote the use of autopsy. C1 [Liao, Joshua M.] Harvard Univ, Brigham & Womens Hosp, Dept Med, Sch Med, Boston, MA 02115 USA. [Singh, Hardeep] Baylor Coll Med, Houston VA Hlth Serv Res & Dev HSR&D, Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Singh, Hardeep] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. RP Singh, H (reprint author), Baylor Coll Med, Houston VA Hlth Serv Res & Dev HSR&D, Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. EM hardeeps@bcm.edu FU Houston VA Health Services Research and Development Center of Excellence at the Michael E. DeBakey VA Medical Center, Houston, TX [HFP90-020] FX The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. This paper is supported with resources and the use of facilities at the Houston VA Health Services Research and Development Center of Excellence (HFP90-020) at the Michael E. DeBakey VA Medical Center, Houston, TX. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL PATHOLOGY PI CHICAGO PA 2100 W HARRISON ST, CHICAGO, IL 60612 USA SN 0007-5027 J9 LABMEDICINE JI Labmedicine PD SPR PY 2013 VL 44 IS 2 BP 186 EP 190 DI 10.1309/LMI9N2TS8YTQLBDI PG 5 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 132HK UT WOS:000318058300017 ER PT J AU Carrion, IV Nedjat-Haiem, FR AF Carrion, Iraida V. Nedjat-Haiem, Frances R. TI Caregiving for Older Latinos at End of Life: Perspectives From Paid and Family (Unpaid) Caregivers SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE LA English DT Article DE Latinos; end of life; family (unpaid) caregiving; paid caregiving; hospice; settings ID OF-LIFE; QUALITATIVE RESEARCH; INFORMAL CAREGIVERS; HEALTH-CARE; CANCER CAREGIVERS; DECISION-MAKING; UNMET NEEDS; ISSUES; DETERMINANTS; CONSTRUCTION AB This study examined the various settings in which caregiving occurred for terminally ill older Latinos. Qualitative data were collected in Central Florida through in-depth, semi-structured, open-ended interviews. 20 Latinos caring for terminally ill Latinos participated in the study. N = 9 Latino family (unpaid) caregivers provided care in the terminally ill person's home, while N = 4 provided care to a family member in the caregiver's home. N = 4 paid caregivers provided care to terminally ill Latinos who reside in the caregiver's private home and N = 3 in an assisted-living facility. The themes indicate that family (unpaid) caregivers experienced changes in their financial status; they both encountered English language barriers. Geographical distance made caregiving more challenging. Paid caregivers adapted to cultural expectations and their higher income enabled them to hire assistance. C1 [Carrion, Iraida V.] Univ S Florida, Sch Social Work, Tampa, FL 33612 USA. [Nedjat-Haiem, Frances R.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Carrion, IV (reprint author), Univ S Florida, Coll Behav & Community Sci, Sch Social Work, 13301 Bruce B Downs Blvd,MHC 1438, Tampa, FL 33612 USA. EM icarrion@usf.edu OI Carrion, Iraida/0000-0003-4076-6644 NR 57 TC 6 Z9 6 U1 3 U2 8 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-9091 J9 AM J HOSP PALLIAT ME JI Am. J. Hosp. Palliat. Med. PD MAR PY 2013 VL 30 IS 2 BP 183 EP 191 DI 10.1177/1049909112448227 PG 9 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 127CQ UT WOS:000317673400013 PM 22637704 ER PT J AU Jones, C Missanelli, M Dure, L Funkhouser, E Kaffka, J Kilgore, M Saag, K Yu, F Safford, MM AF Jones, Charlotte Missanelli, Megan Dure, Leon Funkhouser, Ellen Kaffka, Jaimee Kilgore, Meredith Saag, Kenneth Yu, Feliciano Safford, Monika M. TI Anticonvulsant Medication Errors in Children With Epilepsy During the Home-to-Hospital Transition SO JOURNAL OF CHILD NEUROLOGY LA English DT Article DE patient safety; medication errors; epilepsy; transitions ID ADVERSE DRUG EVENTS; CHRONIC HEALTH CONDITIONS; SEVERE ACUTE ILLNESS; PEDIATRIC INPATIENTS; CARE TRANSITIONS; PATIENT SAFETY AB Children with epilepsy are at risk of having their anticonvulsant regimens disrupted during the home-to-hospital transition. We sought to estimate the frequency of anticonvulsant medication errors during transition into the hospital in children with epilepsy hospitalized for reasons other than seizures, and to examine factors associated with the occurrence of such errors. We examined the medical records to identify errors related to anticonvulsant administration during the transition into the hospital and we examined potential risk factors for error occurrence. Errors were classified as relating to dosing quantity or missing a dose. Among 120 children, 29 (24%) experienced an anticonvulsant medication error. In a multivariable model, the risk factors of changes in responsibility for anticonvulsant administration and frequency of anticonvulsant administration were strongly associated with increased odds of errors. Anticonvulsant medication errors during the home-to-hospital transition may be unacceptably common in children with epilepsy hospitalized for reasons other than seizures. C1 [Jones, Charlotte] Ohio State Univ, Dept Pediat, Div Pediat Neurol, Nationwide Childrens Hosp, Columbus, OH 43205 USA. [Missanelli, Megan] Univ S Alabama, Coll Med, Mobile, AL USA. [Dure, Leon] Univ Alabama Birmingham, Sch Med, Dept Pediat, Div Pediat Neurol, Birmingham, AL USA. [Funkhouser, Ellen] Univ Alabama Birmingham, Sch Med, Dept Med, Ctr Outcomes & Effectiveness Res & Educ, Birmingham, AL USA. [Funkhouser, Ellen] Birmingham VA Med Ctr, VA Res Enhancement Award Program, Birmingham, AL USA. [Kaffka, Jaimee] Univ Alabama Birmingham, Med Sch Birmingham, Div Continuing Med Educ, Birmingham, AL USA. [Kilgore, Meredith] Univ Alabama Birmingham, Sch Publ Hlth, Sch Med, Ctr Outcomes & Effectiveness Res & Educ, Birmingham, AL 35294 USA. [Saag, Kenneth] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol,Sch Med, Ctr Educ & Res Therapeut CERTS Musculoskeletal Di, Dept Med,Ctr Outcomes & Effectiveness Res & Educ, Birmingham, AL USA. [Yu, Feliciano] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA. [Safford, Monika M.] Univ Alabama Birmingham, Sch Med, Ctr Outcomes & Effectiveness Res & Educ, Dept Med,Div Prevent Med,Div Continuing Med Educ, Birmingham, AL USA. RP Jones, C (reprint author), Ohio State Univ, Dept Pediat, Div Pediat Neurol, Nationwide Childrens Hosp, 700 Childrens Dr ED 520, Columbus, OH 43205 USA. EM Charlotte.Jones@Nationwidechildrens.org FU Agency for Healthcare Research and Quality [5T32HS013852-08]; Center for Outcomes and Effectiveness Research at the University of Alabama, Birmingham, Alabama FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Dr Jones was supported by a grant (No. 5T32HS013852-08) from the Agency for Healthcare Research and Quality and funding was provided by the Center for Outcomes and Effectiveness Research at the University of Alabama, Birmingham, Alabama. NR 25 TC 7 Z9 7 U1 1 U2 13 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0883-0738 J9 J CHILD NEUROL JI J. Child Neurol. PD MAR PY 2013 VL 28 IS 3 BP 314 EP 320 DI 10.1177/0883073812446632 PG 7 WC Clinical Neurology; Pediatrics SC Neurosciences & Neurology; Pediatrics GA 127ER UT WOS:000317680100006 PM 22752478 ER PT J AU Lund, BC Charlton, ME Steinman, MA Kaboli, PJ AF Lund, Brian C. Charlton, Mary E. Steinman, Michael A. Kaboli, Peter J. TI Regional Differences in Prescribing Quality Among Elder Veterans and the Impact of Rural Residence SO JOURNAL OF RURAL HEALTH LA English DT Article DE geography; geriatrics; pharmacy; quality; rural ID INAPPROPRIATE MEDICATION USE; ADVERSE DRUG-REACTIONS; OLDER-ADULTS; BEERS CRITERIA; EXPLICIT CRITERIA; UNITED-STATES; RISK; CARE; POPULATION; PRESCRIPTION AB Purpose: Medication safety is a critical concern for older adults. Regional variation in potentially inappropriate prescribing practices may reflect important differences in health care quality. Therefore, the objectives of this study were to characterize prescribing quality variation among older adults across geographic region, and to compare prescribing quality across rural versus urban residence. Methods: Cross-sectional study of 1,549,824 older adult veterans with regular Veterans Affairs (VA) primary care and medication use during fiscal year 2007. Prescribing quality was measured by 4 indicators of potentially inappropriate prescribing: Zhan criteria drugs to avoid, Fick criteria drugs to avoid, therapeutic duplication, and drug-drug interactions. Frequency differences across region and rural-urban residence were compared using adjusted odds-ratios. Findings: Significant regional variation was observed for all indicators. Zhan criteria frequencies ranged from 13.2% in the Northeast to 21.2% in the South. Nationally, rural veterans had a significantly increased risk for inappropriate prescribing according to all quality indicators. However, regional analyses revealed this effect was limited to the South and Northeast, whereas rural residence was neutral in the Midwest and protective in the West. Conclusions: Significant regional variation in prescribing quality was observed among older adult veterans, mirroring recent findings among Medicare beneficiaries. The association between rurality and prescribing quality is heterogeneous, and relying solely on national estimates may yield misleading conclusions. Although we documented important variations in prescribing quality, the underlying factors driving these trends remain unknown, and they are a vital area for future research affecting older adults in both VA and non-VA health systems. C1 [Lund, Brian C.; Charlton, Mary E.; Kaboli, Peter J.] VA Iowa City Hlth Care Syst, Vet Rural Hlth Resource Ctr Cent Reg, Iowa City, IA 52246 USA. [Lund, Brian C.; Kaboli, Peter J.] VA Iowa City Hlth Care Syst, Ctr Comprehens Access & Delivery Res & Evaluat, Iowa City, IA 52246 USA. [Lund, Brian C.] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA. [Steinman, Michael A.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA. [Steinman, Michael A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Kaboli, Peter J.] Univ Iowa, Dept Internal Med, Div Gen Internal Med, Carver Coll Med, Iowa City, IA 52242 USA. RP Lund, BC (reprint author), VA Iowa City Hlth Care Syst, Mailstop 152,601 Hwy 6 West, Iowa City, IA 52246 USA. EM Brian.Lund@va.gov FU Veterans Rural Health Resource Center-Central Region [IMV 04-066-1]; Center for Comprehensive Access & Delivery Research and Evaluation [REA 09-220]; Agency for Healthcare Research and Quality Centers for Education and Research on Therapeutics [5 U18 HSO16094]; Career Development Award from the Health Services Research and Development Service, Department of Veterans Affairs [CDA 10-017]; National Institute on Aging; American Federation for Aging Research [K23-AG030999] FX This research was supported by the Veterans Rural Health Resource Center-Central Region (IMV 04-066-1) and the Center for Comprehensive Access & Delivery Research and Evaluation (REA 09-220). This study was also supported in part by an Agency for Healthcare Research and Quality Centers for Education and Research on Therapeutics cooperative agreement #5 U18 HSO16094. Dr. Lund was supported by a Career Development Award from the Health Services Research and Development Service, Department of Veterans Affairs (CDA 10-017). Dr. Steinman was supported by an award from the National Institute on Aging and the American Federation for Aging Research (K23-AG030999). NR 47 TC 12 Z9 12 U1 3 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0890-765X EI 1748-0361 J9 J RURAL HEALTH JI J. Rural Health PD SPR PY 2013 VL 29 IS 2 BP 172 EP 179 DI 10.1111/j.1748-0361.2012.00428.x PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 119CB UT WOS:000317073400006 PM 23551647 ER PT J AU Ahmad, S Wei, CC Tallaj, J Dell'Italia, LJ Moniwa, N Varagic, J Ferrario, CM AF Ahmad, Sarfaraz Wei, Chih-Chang Tallaj, Jose Dell'Italia, Louis J. Moniwa, Norihito Varagic, Jasmina Ferrario, Carlos M. TI Chymase mediates angiotensin-(1-12) metabolism in normal human hearts SO JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION LA English DT Article DE ACE2; cardiac myocytes; angiotensin-converting enzyme inhibitors; angiotensin II; heart disease; proangiotensin 12; angiotensin-(1-7) ID II-FORMING CHYMASE; CONVERTING ENZYME; INDEPENDENT MECHANISMS; PROANGIOTENSIN-12 PA12; CARBOXYPEPTIDASE ACE2; MITRAL REGURGITATION; ATRIAL-FIBRILLATION; PEPTIDE METABOLISM; SYSTEM; INHIBITION AB Identification of angiotensin-(1-12) [Ang-(1-12)] in forming angiotensin II (Ang II) by a non-renin dependent mechanism has increased knowledge on the paracrine/autocrine mechanisms regulating cardiac expression of Ang peptides. This study now describes in humans the identity of the enzyme accounting for Ang-(1-12) metabolism in the left ventricular (LV) tissue of normal subjects. Reverse phase HPLC characterized the products of I-125-Ang-(1-12) metabolism in plasma membranes (PMs) from human LV in the absence and presence of inhibitors for chymase (chymostatin), angiotensin-converting enzyme (ACE) 1 (lisinopril) and 2 (MLN-4760), and neprilysin (SHC39370). In the presence of the inhibitor cocktail, >= 98% +/- 2% of cardiac I-125-Ang-(1-12) remained intact, whereas exclusion of chymostatin from the inhibitor cocktail led to significant conversion of Ang-(1-12) into Ang II. In addition, chymase-mediated hydrolysis of I-125-Ang I was higher compared with Ang-(1-12). Negligible Ang-(1-12) hydrolysis occurred by ACE, ACE2, and neprilysin. A high chymase activity was detected for both I-125-Ang-(1-12) and I-125-Ang I substrates. Chymase accounts for the conversion of Ang-(1-12) and Ang I to Ang II in normal human LV. These novel findings expand knowledge of the alternate mechanism by which Ang-(1-12) contributes to the production of cardiac angiotensin peptides. J Am Soc Hypertens 2013;7(2):128-136. (C) 2013 American Society of Hypertension. All rights reserved. C1 [Ahmad, Sarfaraz; Moniwa, Norihito; Varagic, Jasmina; Ferrario, Carlos M.] Wake Forest Univ, Bowman Gray Sch Med, Div Surg Sci, Winston Salem, NC 27157 USA. [Wei, Chih-Chang; Tallaj, Jose; Dell'Italia, Louis J.] Univ Alabama Birmingham, Med Ctr, Birmingham Vet Affair Med Ctr, Birmingham, AL 35294 USA. [Wei, Chih-Chang; Tallaj, Jose; Dell'Italia, Louis J.] Univ Alabama Birmingham, Med Ctr, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Varagic, Jasmina] Wake Forest Univ, Bowman Gray Sch Med, Hypertens & Vasc Res Ctr, Winston Salem, NC 27157 USA. [Varagic, Jasmina; Ferrario, Carlos M.] Wake Forest Univ, Bowman Gray Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA. [Ferrario, Carlos M.] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC 27157 USA. RP Ferrario, CM (reprint author), Wake Forest Univ, Bowman Gray Sch Med, Dept Surg, Med Ctr Blvd, Winston Salem, NC 27157 USA. EM cferrari@wakehealth.edu FU Heart, Lung, Blood Institute of the National Institutes of Health [HL-051952]; Farley-Hudson Foundation, Jacksonville, NC FX Supported by a grant (HL-051952) from the Heart, Lung, Blood Institute of the National Institutes of Health. We also acknowledge partial support provided by the Farley-Hudson Foundation, Jacksonville, NC. NR 47 TC 17 Z9 17 U1 0 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1933-1711 J9 J AM SOC HYPERTENS JI J. Am. Soc. Hypertens. PD MAR-APR PY 2013 VL 7 IS 2 BP 128 EP 136 DI 10.1016/j.jash.2012.12.003 PG 9 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 120KI UT WOS:000317168800004 PM 23312967 ER PT J AU Malte, CA McFall, M Chow, B Beckham, JC Carmody, TP Saxon, AJ AF Malte, Carol A. McFall, Miles Chow, Bruce Beckham, Jean C. Carmody, Timothy P. Saxon, Andrew J. TI Survey of Providers' Attitudes Toward Integrating Smoking Cessation Treatment Into Posttraumatic Stress Disorder Care SO PSYCHOLOGY OF ADDICTIVE BEHAVIORS LA English DT Article DE smoking cessation; posttraumatic stress disorder; veterans; mental health providers; provider survey; implementation ID MENTAL-HEALTH-CARE; TOBACCO CESSATION; NICOTINE DEPENDENCE; PARIHS FRAMEWORK; VETERANS; IMPLEMENTATION; PREVALENCE; ADDICTION; ILLNESS AB A survey was administered anonymously to 45 mental health providers who delivered smoking cessation treatment integrated into posttraumatic stress disorder care (integrated care) as part of a multisite clinical trial. Survey items assessed key factors associated with successful implementation of research-based practices from the perspective of treating providers. Factors assessed included prior experiences with cessation treatment, compatibility of integrated care with current practices, feasibility of adopting integrated care into regular practice, and adequacy of training. More than half of respondents reported that integrated care delivery was feasible, and they would be considerably or extremely likely to continue delivery in routine practice. Positive prestudy beliefs and more experience delivering cessation care were associated with stronger endorsement of delivering integrated care after the study. The most frequently cited obstacle to delivering integrated care involved time limitations. Future efforts should focus on developing treatment adaptations that address provider-identified barriers and identifying clinic- and administrative-level supports that facilitate delivery of integrated care and assist providers who incorporate integrated care into clinical practice. C1 [Malte, Carol A.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Excellence Substance Abuse Treatment & Educ, Seattle, WA USA. [McFall, Miles; Saxon, Andrew J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [McFall, Miles; Saxon, Andrew J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Chow, Bruce] Vet Affairs Palo Alto Hlth Care Syst, Vet Affairs Cooperat Studies Program, Palo Alto, CA USA. [Beckham, Jean C.] Vet Affairs Mid Atlantic Reg Mental Illness Res E, Durham Vet Affairs Med Ctr, Durham, NC USA. [Beckham, Jean C.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27706 USA. [Carmody, Timothy P.] Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Carmody, Timothy P.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Malte, CA (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-116 ATC, Seattle, WA 98108 USA. EM carol.malte@va.gov NR 29 TC 2 Z9 2 U1 0 U2 3 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0893-164X J9 PSYCHOL ADDICT BEHAV JI Psychol. Addict. Behav. PD MAR PY 2013 VL 27 IS 1 BP 249 EP 255 DI 10.1037/a0028484 PG 7 WC Substance Abuse; Psychology, Multidisciplinary SC Substance Abuse; Psychology GA 107RH UT WOS:000316238000029 PM 22642854 ER PT J AU Emery, MJ Eveland, RL Min, JH Hildebrandt, J Swenson, ER AF Emery, Michael J. Eveland, Randy L. Min, Jin-Hye Hildebrandt, Jacob Swenson, Erik R. TI CO2 relaxation of the rat lung parenchymal strip SO RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY LA English DT Article DE Alveolar; Pulmonary mechanics; Ventilation-to-perfusion matching; Myosin ID AIRWAY SMOOTH-MUSCLE; HYPOXIC PULMONARY VASOCONSTRICTION; STIMULUS-RESPONSE; TISSUE RESISTANCE; MYOSIN-V; CALCIUM; DISSOCIATION; CONTRACTION; TENSION; OXYGEN AB Evidence from liquid-filled rat lungs supported the presence of CO2-dependent, active relaxation of parenchyma under normoxia by unknown mechanisms (Emery et al., 2007). This response may improve matching of alveolar ventilation ((V) over dot(A)) to perfusion ((Q) over dot) by increasing compliance and (V) over dot(A) in overperfused (high CO2) regions, and decrease (V) over dot(A) in underperfused regions. Here, we have more directly studied CO2-dependent parenchymal relaxation and tested a hypothesized role for actin-myosin interaction in this effect. Lung parenchymal strips (similar to 1.5 mm x 1.5 mm x 15 mm) from 16 rats were alternately exposed to normoxic hypocapnia (P-CO2 approximate to 20 mmHg) or hypercapnia (P-CO2 approximate to 53 mmHg). Seven specimens were used to construct length-tension curves, and nine were tested with and without the myosin blocker 2,3-butanedione monoxime (BDM). The results demonstrate substantial, reversible CO2-dependent changes in parenchyma strip recoil (up to 23%) and BDM eliminates this effect, supporting a potentially important role for parenchymal myosin in (V) over dot(A)/(Q) over dot matching. Published by Elsevier B.V. C1 [Emery, Michael J.; Eveland, Randy L.; Min, Jin-Hye; Swenson, Erik R.] VA Puget Sound Hlth Care Syst, Pulm & Crit Care Med S PULM 111, Seattle, WA 98108 USA. [Hildebrandt, Jacob; Swenson, Erik R.] Univ Washington, Sch Med, Dept Physiol & Biophys, Seattle, WA 98195 USA. [Hildebrandt, Jacob; Swenson, Erik R.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. RP Emery, MJ (reprint author), VA Puget Sound Hlth Care Syst, Pulm & Crit Care Med S PULM 111, 1660 S Columbian Way, Seattle, WA 98108 USA. EM mjemery@u.washington.edu; jackhil@u.washington.edu; eswenson@u.washington.edu FU VA Merit Review FX The authors gratefully acknowledge Steve Lai-Fook for important conversations concerning quantification of lung mechanical characteristics, Linda Wordeman for important conversations concerning inhibition of contractile proteins, and Albert Gordon for use of essential test equipment. Support for this project was provided by a VA Merit Review awarded to Erik R. Swenson. NR 39 TC 2 Z9 2 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1569-9048 J9 RESP PHYSIOL NEUROBI JI Respir. Physiol. Neuro. PD MAR 1 PY 2013 VL 186 IS 1 BP 33 EP 39 DI 10.1016/j.resp.2012.12.014 PG 7 WC Physiology; Respiratory System SC Physiology; Respiratory System GA 124EW UT WOS:000317447600005 PM 23305910 ER PT J AU Cordell, CB Borson, S Boustani, M Chodosh, J Reuben, D Verghese, J Thies, W Fried, LB AF Cordell, Cyndy B. Borson, Soo Boustani, Malaz Chodosh, Joshua Reuben, David Verghese, Joe Thies, William Fried, Leslie B. CA Medicare Detection Cognitive TI Alzheimer's Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting SO ALZHEIMERS & DEMENTIA LA English DT Article DE Annual Wellness Visit; AWV; Cognitive impairment; Assessment; Screen; Dementia; Alzheimer's disease; Medicare; Algorithm; Patient Protection and Affordable Care Act ID MINI-MENTAL-STATE; MEMORY IMPAIRMENT; SCREENING-TEST; VULNERABLE ELDERS; CONTROLLED-TRIAL; DEMENTIA CARE; OLDER-ADULTS; INFORMANT; DISEASE; VALIDATION AB The Patient Protection and Affordable Care Act added a new Medicare benefit, the Annual Wellness Visit (AWV), effective January 1, 2011. The AWV requires an assessment to detect cognitive impairment. The Centers for Medicare and Medicaid Services (CMS) elected not to recommend a specific assessment tool because there is no single, universally accepted screen that satisfies all needs in the detection of cognitive impairment. To provide primary care physicians with guidance on cognitive assessment during the AWV, and when referral or further testing is needed, the Alzheimer's Association convened a group of experts to develop recommendations. The resulting Alzheimer's Association Medicare Annual Wellness Visit Algorithm for Assessment of Cognition includes review of patient Health Risk Assessment (HRA) information, patient observation, unstructured queries during the AWV, and use of structured cognitive assessment tools for both patients and informants. Widespread implementation of this algorithm could be the first step in reducing the prevalence of missed or delayed dementia diagnosis, thus allowing for better healthcare management and more favorable outcomes for affected patients and their families and caregivers. (c) 2013 The Alzheimer's Association. All rights reserved. C1 [Cordell, Cyndy B.; Thies, William] Alzheimers Assoc, Chicago, IL 60601 USA. [Borson, Soo] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Borson, Soo] Univ Washington, Sch Med, Memory Disorders Clin, Seattle, WA USA. [Borson, Soo] Univ Washington, Sch Med, Dementia Hlth Serv, Seattle, WA USA. [Boustani, Malaz] Indiana Univ, Ctr Aging Res, Indianapolis, IN 46204 USA. [Boustani, Malaz] Regenstrief Inst Inc, Indianapolis, IN USA. [Boustani, Malaz] Indiana Univ Sch Med, Dept Med, Indianapolis, IN USA. [Chodosh, Joshua] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Chodosh, Joshua; Reuben, David] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Los Angeles, CA 90095 USA. [Verghese, Joe] Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA. [Fried, Leslie B.] Amer Bar Assoc, Washington, DC 20013 USA. [Fried, Leslie B.] Alzheimers Assoc Medicare Advocacy Project, Washington, DC USA. RP Cordell, CB (reprint author), Alzheimers Assoc, Chicago, IL 60601 USA. EM cyndy.cordell@alz.org OI Chodosh, Joshua/0000-0001-7784-4306 NR 60 TC 83 Z9 84 U1 5 U2 16 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD MAR PY 2013 VL 9 IS 2 BP 141 EP 150 DI 10.1016/j.jalz.2012.09.011 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA 119JD UT WOS:000317092700006 PM 23265826 ER PT J AU Mooney, LJ Nielsen, S Saxon, A Hillhouse, M Thomas, C Hasson, A Stablein, D McCormack, J Lindblad, R Ling, W AF Mooney, Larissa J. Nielsen, Suzanne Saxon, Andrew Hillhouse, Maureen Thomas, Christie Hasson, Albert Stablein, Don McCormack, Jennifer Lindblad, Robert Ling, Walter TI Cocaine Use Reduction with Buprenorphine (CURB): Rationale, design, and methodology SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE Cocaine dependence; Buprenorphine; Naltrexone; Clinical Trials Network; Methods; Kappa antagonist ID OF-LIFE ASSESSMENT; PSYCHOMETRIC PROPERTIES; OPIOID DEPENDENCE; ANTAGONIST; SUBSTANCE; TRIAL; TIME AB Background: Effective medications to treat cocaine dependence have not been identified. Recent pharmacotherapy trials demonstrate the potential efficacy of buprenorphine (BUP) (alone or with naltrexone) for reducing cocaine use. The National Institute on Drug Abuse Clinical Trials Network (CTN) launched the Cocaine Use Reduction with Buprenorphine (CURB) investigation to examine the safety and efficacy of sublingual BUP (as Suboxone (R)) in the presence of extended-release injectable naltrexone (XR-NTX, as Vivitrol (R)) for the treatment of cocaine dependence. This paper describes the design and rationale for this study. Methods: This multi-site, double-blind, placebo-controlled study will randomize 300 participants across 11 sites. Participants must meet the DSM-IV criteria for cocaine dependence and past or current opioid dependence or abuse. Participants are inducted onto XR-NTX after self-reporting at least 7 days of abstinence from opioids and tolerating a naloxone challenge followed by oral naltrexone and are then randomly assigned to one of three medication conditions (4 mg BUP, 16 mg BUP, or placebo) for 8 weeks. Participants receive a second injection of XR-NTX 4 weeks after the initial injection, and follow-up visits are scheduled at 1 and 3 months post-treatment. Participants receive weekly cognitive behavioral therapy (CBT). Recruitment commenced in September, 2011. Enrollment, active medication, and follow-up phases are ongoing, and recruitment is exceeding targeted enrollment rates. Conclusions: This research using 2 medications will demonstrate whether BUP, administered in the presence of XR-NTX, reduces cocaine use in adults with cocaine dependence and opioid use disorders and will demonstrate if XR-NTX prevents development of physiologic dependence on BUP. (C) 2012 Elsevier Inc. All rights reserved. C1 [Mooney, Larissa J.; Hillhouse, Maureen; Thomas, Christie; Hasson, Albert; Ling, Walter] Univ Calif Los Angeles, Integrated Subst Abuse Programs, Los Angeles, CA 90025 USA. [Nielsen, Suzanne] Univ Sydney, Drug Hlth Serv C39, Sydney, NSW 2006, Australia. [Saxon, Andrew] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Saxon, Andrew] Univ Washington, Seattle, WA 98108 USA. [Stablein, Don; McCormack, Jennifer; Lindblad, Robert] EMMES Corp, Rockville, MD 20850 USA. RP Mooney, LJ (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Integrated Subst Abuse Programs, 1640 S Sepulveda Blvd,Suite 120, Los Angeles, CA 90025 USA. EM lmooney@mednet.ucla.edu; suzanne.nielsen@sydney.edu.au; andrew.saxon@va.gov; hillhous@ucla.edu; cthomas@friendsresearch.org; alhasson@ucla.edu; dstablein@emmes.com; jmccormack@emmes.com; rlindblad@emmes.com; lwalter@ucla.edu RI Nielsen, Suzanne/C-3256-2015 OI Nielsen, Suzanne/0000-0001-5341-1055 FU National Institute on Drug Abuse Clinical Trials Network [U10DA013045, U10DA01714]; NIDA [N01DA92217, N01DA102221] FX This work was supported by the National Institute on Drug Abuse Clinical Trials Network Grants U10DA013045 (ISAP, Pacific Region Node); U10DA01714 (RCKC, Pacific Northwest Node); and NIDA Contracts N01DA92217 and N01DA102221 (The EMMES Corporation). We thank the staff and participants at the community treatment programs and regional research and training centers of the National Institute on Drug Abuse Clinical Trials Network for their involvement in this project, including Albert Einstein College of Medicine (Greater New York Node), Bellevue Hospital Center (Greater New York Node), Addiction Research & Treatment Services (Western States Node), CODA, Inc. (Western States Node), Atlanta VA Medical Center (Southern Consortium Node), Howard University (Mid-Atlantic Node), Maryhaven (Ohio Valley Node), Recovery Centers of King County (Pacific Northwest Node), South Texas Veterans Health Care System (Texas Node), Bay Area Addiction Research and Treatment (Pacific Region Node), and UCLA Integrated Substance Abuse Programs (Pacific Region Node). We also thank the staff of the Clinical Coordinating Center and the Data Coordinating Center (The EMMES Corporation, Rockville, MD), and the staff of the Center for the Clinical Trials Network at the National Institute on Drug Abuse (Rockville, MD) for their work on this project. NR 30 TC 11 Z9 13 U1 0 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD MAR PY 2013 VL 34 IS 2 BP 196 EP 204 DI 10.1016/j.cct.2012.11.002 PG 9 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA 120KL UT WOS:000317169100002 PM 23159524 ER PT J AU Rice, T Dobry, Y Wang, E Novakovic, V Sher, L AF Rice, Timothy Dobry, Yuriy Wang, Eugene Novakovic, Vladan Sher, Leo TI Cognitive effects of quetiapine in a patient with dementia with Lewy bodies SO PSYCHOGERIATRICS LA English DT Article DE atypical antipsychotics; CATIE-AD; cognition; dementia with Lewy bodies; neurodegenerative disorders; quetiapine ID VISUAL HALLUCINATIONS; NEUROLEPTIC SENSITIVITY; ALZHEIMERS-DISEASE; BODY DEMENTIA; SCHIZOPHRENIA; METAANALYSIS; OLANZAPINE; PSYCHOSIS; SYMPTOMS; EFFICACY AB A recent large-scale randomized controlled clinical trial, the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease study, found a significant worsening of cognitive functioning in a sample of patients with Alzheimer's disease. To date there have been no equally powered studies examining the cognitive effects of atypical antipsychotics in patients with dementia with Lewy bodies, the second most prevalent neurodegenerative disorder. This case report describes a significant cognitive improvement observed through the use of an atypical antipsychotic in a patient with dementia with Lewy bodies. The observed divergence in cognitive responsiveness is discussed mechanistically on both the clinical and neuromolecular level. Limitations to this case study design are presented and discussed. The prudence of caution in importing the results of the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease study to the dementia with Lewy bodies population is summarized and presented for psychiatrists, neurologists and primary care providers, with an intent to stimulate discussion and further research. C1 [Rice, Timothy; Dobry, Yuriy; Wang, Eugene; Novakovic, Vladan; Sher, Leo] Mt Sinai Sch Med, New York, NY 10029 USA. [Rice, Timothy; Dobry, Yuriy; Novakovic, Vladan; Sher, Leo] James J Peters Vet Adm Med Ctr, Bronx, NY USA. RP Rice, T (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1425 Madison Ave,Box 1230, New York, NY 10029 USA. EM timothy.rice@mssm.edu NR 33 TC 1 Z9 1 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1346-3500 J9 PSYCHOGERIATRICS JI Psychogeriatrics PD MAR PY 2013 VL 13 IS 1 BP 52 EP 57 DI 10.1111/j.1479-8301.2012.00414.x PG 6 WC Geriatrics & Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 117QG UT WOS:000316967600009 PM 23551413 ER PT J AU Tobin, MJ AF Tobin, M. J. TI Hypercapnia: keeping therapy and diagnosis distinct SO ANAESTHESIA AND INTENSIVE CARE LA English DT Editorial Material ID RESPIRATORY-DISTRESS-SYNDROME; DEAD SPACE; VENTILATION; MORTALITY; VOLUME C1 [Tobin, M. J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Div Pulm & Crit Care Med, Hines, IL 60141 USA. [Tobin, M. J.] Loyola Univ Chicago, Stritch Sch Med, Hines, IL USA. RP Tobin, MJ (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Div Pulm & Crit Care Med, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. NR 11 TC 0 Z9 0 U1 0 U2 0 PU AUSTRALIAN SOC ANAESTHETISTS PI EDGECLIFF PA P O BOX 600, EDGECLIFF, NSW 2027, AUSTRALIA SN 0310-057X J9 ANAESTH INTENS CARE JI Anaesth. Intensive Care PD MAR PY 2013 VL 41 IS 2 BP 149 EP 150 PG 2 WC Anesthesiology; Critical Care Medicine SC Anesthesiology; General & Internal Medicine GA 115TP UT WOS:000316835100002 PM 23577370 ER PT J AU Blum, MA Singh, JA Lee, GC Richardson, D Chen, W Ibrahim, SA AF Blum, Marissa A. Singh, Jasvinder A. Lee, Gwo-Chin Richardson, Diane Chen, Wei Ibrahim, Said A. TI Patient Race and Surgical Outcomes After Total Knee Arthroplasty: An Analysis of a Large Regional Database SO ARTHRITIS CARE & RESEARCH LA English DT Article ID QUALITY-OF-LIFE; MYOCARDIAL-INFARCTION MORTALITY; JOINT REPLACEMENT SURGERY; TOTAL HIP; AFRICAN-AMERICAN; THE-LITERATURE; UNITED-STATES; RIGHT TOOL; APR-DRGS; RISK AB Objective. To examine racial differences in surgical complications, mortality, and revision rates after total knee arthroplasty. Methods. We studied patients undergoing primary total knee arthroplasty using 2001-2007 Pennsylvania Health Care Cost Containment Council data. We conducted bivariate analyses to assess the risk of complications such as myocardial infarction, venous thromboembolism, wound infections, and failure of prosthesis, as well as 30-day and 1-year overall mortality after elective total knee arthroplasty, between racial groups. We estimated Kaplan-Meier 1- and 5-year surgical revision rates, and fit multivariable Cox proportional hazards models to compare surgical revision by race, incorporating 5 years of followup. We adjusted for patient age, sex, length of hospital stay, surgical risk of death, type of health insurance, hospital surgical volume, and hospital teaching status. Results. In unadjusted analyses, there were no significant differences by racial group for either overall 30-day or in-hospital complication rates, or 30-day and 1-year mortality rates. Adjusted Cox models incorporating 5 years of followup showed an increased risk of revisions for African American patients (hazard ratio [HR] 1.39, 95% confidence interval [95% CI] 1.08-1.80), younger patients (HR 2.30, 95% CI 1.96-2.69), and lower risk for female patients (HR 0.81, 95% CI 0.71-0.92). Conclusion. In this sample of patients who underwent knee arthroplasty, we found no significant racial differences in major complication rates or mortality. However, African American patients, younger patients, and male patients all had significantly higher rates of revision based on 5 years of followup. C1 [Blum, Marissa A.] Temple Univ, Sch Med, Philadelphia, PA USA. [Singh, Jasvinder A.] VA Med Ctr, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL USA. [Singh, Jasvinder A.] Mayo Clin, Sch Med, Rochester, MN USA. [Lee, Gwo-Chin; Ibrahim, Said A.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Richardson, Diane; Chen, Wei; Ibrahim, Said A.] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Blum, MA (reprint author), 3322 North Broad St,Suite 205, Philadelphia, PA 19140 USA. EM Marissa.blum@tuhs.temple.edu OI singh, jasvinder/0000-0003-3485-0006 FU NIH [1-KL2-RR-024151-01]; NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases [1-K24-AR-055259-06]; Zimmer and Smith Nephew FX Dr. Singh's work was supported by the NIH (Clinical Translational Science Award 1-KL2-RR-024151-01). Dr. Ibrahim's work was supported by the NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant 1-K24-AR-055259-06). Dr. Lee's work was supported by Zimmer and Smith & Nephew. NR 34 TC 13 Z9 13 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X J9 ARTHRIT CARE RES JI Arthritis Care Res. PD MAR PY 2013 VL 65 IS 3 BP 414 EP 420 DI 10.1002/acr.21834 PG 7 WC Rheumatology SC Rheumatology GA 116UE UT WOS:000316907700010 PM 22933341 ER PT J AU Johnson, KA Baig, M Ramsey, D Lisanby, SH Avery, D McDonald, WM Li, XB Bernhardt, ER Haynor, DR Holtzheimer, PE Sackeim, HA George, MS Nahas, Z AF Johnson, Kevin A. Baig, Mirza Ramsey, Dave Lisanby, Sarah H. Avery, David McDonald, William M. Li, Xingbao Bernhardt, Elisabeth R. Haynor, David R. Holtzheimer, Paul E., III Sackeim, Harold A. George, Mark S. Nahas, Ziad TI Prefrontal rTMS for treating depression: Location and intensity results from the OPT-TMS multi-site clinical trial SO BRAIN STIMULATION LA English DT Article DE Transcranial magnetic stimulation (TMS); Imaging (MRI); Motor cortex; Prefrontal cortex; Depression; Classifications; Transcranial Magnetic Stimulation (TMS); Psychiatry ID TRANSCRANIAL MAGNETIC STIMULATION; MOTOR-EVOKED-POTENTIALS; ANTIDEPRESSANT RESPONSE; RESISTANT DEPRESSION; RANDOMIZED-TRIAL; HAND PREFERENCE; CORTEX DISTANCE; COIL PLACEMENT; HUMAN-BRAIN; THRESHOLD AB Background: Motor cortex localization and motor threshold determination often guide Transcranial Magnetic Stimulation (TMS) placement and intensity settings for non-motor brain stimulation. However, anatomic variability results in variability of placement and effective intensity. Objective: Post-study analysis of the OPT-TMS Study reviewed both the final positioning and the effective intensity of stimulation (accounting for relative prefrontal scalp-cortex distances). Methods: We acquired MRI scans of 185 patients in a multi-site trial of left prefrontal TMS for depression. Scans had marked motor sites (localized with TMS) and marked prefrontal sites (5 cm anterior of motor cortex by the "5 cm rule"). Based on a visual determination made before the first treatment, TMS therapy occurred either at the 5 cm location or was adjusted 1 cm forward. Stimulation intensity was 120% of resting motor threshold. Results: The "5 cm rule" would have placed stimulation in premotor cortex for 9% of patients, which was reduced to 4% with adjustments. We did not find a statistically significant effect of positioning on remission, but no patients with premotor stimulation achieved remission (0/7). Effective stimulation ranged from 93 to 156% of motor threshold, and no seizures were induced across this range. Patients experienced remission with effective stimulation intensity ranging from 93 to 146% of motor threshold, and we did not find a significant effect of effective intensity on remission. Conclusions: Our data indicates that individualized positioning methods are useful to reduce variability in placement. Stimulation at 120% of motor threshold, unadjusted for scalp-cortex distances, appears safe for a broad range of patients. (C) 2013 Elsevier Inc. All rights reserved. C1 [Johnson, Kevin A.; Baig, Mirza; Li, Xingbao; George, Mark S.; Nahas, Ziad] Med Univ S Carolina, Charleston, SC 29425 USA. [Lisanby, Sarah H.; Bernhardt, Elisabeth R.; Sackeim, Harold A.] Columbia Univ, New York, NY 10027 USA. [Avery, David; Haynor, David R.] Univ Washington, Seattle, WA 98195 USA. [McDonald, William M.; Holtzheimer, Paul E., III] Emory Univ, Atlanta, GA 30322 USA. [Johnson, Kevin A.] Stanford Univ, Stanford, CA 94305 USA. [Lisanby, Sarah H.; Bernhardt, Elisabeth R.] Duke Univ, Durham, NC 27706 USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Johnson, KA (reprint author), Med Univ S Carolina, Charleston, SC 29425 USA. EM johnsk@stanford.edu RI Holtzheimer, Paul/B-6212-2015 OI Holtzheimer, Paul/0000-0002-3552-3296 FU National Institute of Mental Health [5R01 MH069929, 5R01MH069887, 5R01MH 069896, 5R01MH069895, 5R01 MH069886] FX This study was supported by the National Institute of Mental Health as the Optimization of TMS for the Treatment of Depression Study (OPT-TMS) involving grants 5R01 MH069929 (Dr. Avery), 5R01MH069887 (Dr. George), 5R01MH 069896 (Dr. George), 5R01MH069895 (Dr. Lisanby), and 5R01 MH069886 (Dr. McDonald). Following a competitive bid and request involving all TMS manufacturers at the time of trial initiation, Neuronetics Inc was selected and loaned the TMS devices, head holders, and coils for the trial and allowed use of the safety Investigational Device Exemption for their device. NR 61 TC 25 Z9 27 U1 6 U2 26 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X J9 BRAIN STIMUL JI Brain Stimul. PD MAR PY 2013 VL 6 IS 2 BP 108 EP 117 DI 10.1016/j.brs.2012.02.003 PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 115VM UT WOS:000316840000003 PM 22465743 ER PT J AU Tobi, M Kim, M Weinstein, DH Rambus, MA Hatfield, J Adsay, NV Levi, E Evans, D Lawson, MJ Fligiel, S AF Tobi, Martin Kim, Mijin Weinstein, Douglas H. Rambus, Mary Ann Hatfield, James Adsay, N. Volkan Levi, Edi Evans, Douglas Lawson, Michael J. Fligiel, Suzanne TI Prospective Markers for Early Diagnosis and Prognosis of Sporadic Pancreatic Ductal Adenocarcinoma SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Pancreatic ductal adenocarcinoma (PDA); Adnab-9 monoclonal antibody; K-ras; Her-2/neu ID MONOCLONAL-ANTIBODY ADNAB-9; COLORECTAL NEOPLASIA; MOLECULAR MARKERS; REG-I; CANCER; RISK; CARCINOMA; LESIONS; GENE; PRECURSORS AB Sporadic pancreatic ductal adenocarcinoma (PDA) is a highly lethal cancer. No proven screening strategies are available and frequent cross-sectional imaging studies (CT/MRI) are impractical even in patients thought to be at higher risk than the general population. Few PDA biomarkers have been studied prospectively for screening. Here, we prospectively evaluated the Adnab-9 monoclonal antibody in stool, pancreaticobiliary secretions, and tissue for screening and prognostic value in sporadic PDA. We also evaluated the prognostic value of characterized early biomarkers in pancreaticobiliary secretions. Adnab-9 diagnostic ability was tested in stool in 249 and 1,132 patients from China and the US, respectively. Immunohistochemistry was performed in 22 tissue samples with Adnab-9 antibody and anti-Defensin 5, a constituent of Paneth cells. Pancreatobiliary secretions were collected from 12 PDA patients and 9 controls. The enriched PCR method was performed to detect K-ras mutations. ELISA was performed with Adnab-9, anti-Her-2/neu, and monoclonal antibody D4 (anti-Reg I). Adnab-9 alone was diagnostic and prognostic when measured in pancreatic secretions, feces, and tissues of PDA patients compared to controls (p < 0.05). Significantly, Adnab-9 fecal binding can precede the clinical diagnosis by 2.3 years, potentially allowing earlier clinical intervention. In pancreatic secretions, a combination of K-ras and Her-2/neu when appropriately standardized can be diagnostic in 75 % of PDA. Our study suggests that Adnab-9 may be an effective marker for diagnosis and prognosis of PDA. Adnab-9 may be reflective of the presence of Paneth cells confirmed by Defensin-5 staining. These cells may modulate the biological activity of the cancer and confer a better prognosis. C1 [Tobi, Martin; Weinstein, Douglas H.] Philadelphia Vet Affairs Med Ctr, Gastroenterol Sect, Philadelphia, PA USA. [Tobi, Martin; Kim, Mijin] Univ Penn, Sch Med, Dept Med, Div Gastroenterol,PVAMC Med GI 3, Philadelphia, PA 19104 USA. [Tobi, Martin; Rambus, Mary Ann; Hatfield, James; Adsay, N. Volkan; Levi, Edi; Fligiel, Suzanne] Wayne State Univ, Sch Med, John D Dingell Vet Affairs Med Ctr, Dept Med & Pathol, Detroit, MI USA. [Evans, Douglas] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Lawson, Michael J.] Univ Calif, Kaiser Permanente, Sacramento, CA USA. RP Tobi, M (reprint author), Univ Penn, Sch Med, Dept Med, Div Gastroenterol,PVAMC Med GI 3, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM Martin.Tobi@va.gov FU Veterans Administration; Kaiser Permanente Research Foundation FX The authors wish to thank Dr. Vaitkevicius and Pat Arluskas for providing tissue blocks, and Dr. M.N. Ehrinpreis for his assistance with the preparation of this manuscript. We are grateful to Drs. Ralph Hruban, James Abbruzzese, Mei Yuan and Daniel Longnecker for study material and Dr. Ben Stanger for the internal review of this manuscript. This paper is dedicated to the memory of Chaim "Denis" Tobiansky. This study was supported in part by grants from the Veterans Administration and the Kaiser Permanente Research Foundation. NR 40 TC 2 Z9 3 U1 1 U2 7 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD MAR PY 2013 VL 58 IS 3 BP 744 EP 750 DI 10.1007/s10620-012-2387-x PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 119DF UT WOS:000317076700024 PM 23001406 ER PT J AU Tolstykh, GP Cavazos, JE AF Tolstykh, Gleb P. Cavazos, Jose E. TI Potential mechanisms of sudden unexpected death in epilepsy SO EPILEPSY & BEHAVIOR LA English DT Review DE SUDEP; Neuron loss; NTS; Nucleus of the solitary tract; KCNK channels ID BLOOD-PRESSURE VARIABILITY; NUCLEUS-TRACTUS-SOLITARIUS; FIBER SYNAPTIC REORGANIZATION; LIMBIC CORTICAL SEIZURES; KCNQ POTASSIUM CHANNELS; KAINIC ACID; BAROREFLEX SENSITIVITY; ORGAN DAMAGE; HEART-RATE; CARDIAC REPOLARIZATION AB Sudden unexpected death in epilepsy (SUDEP) accounts for 15% of all deaths in people with epilepsy and 50% in refractory epilepsy. The underlying mechanisms are not well understood, but seizure-induced cardiac and respiratory arrests are involved. The cardiovascular and respiratory systems are subject to precise reflex regulation to ensure appropriate oxygen supply under a wide range of circumstances. Barosensory and chemosensory afferents project into the nucleus tractus solitarius (NTS), which relays systemic data to higher brain centers for integration of homeostatic responses in heart rate, peripheral resistance, respiration, and other autonomic reactions. Being the afferent autonomic gatekeeper, NTS plays a critical role in cardiovascular and respiratory regulation. In the course of studying the kainic acid model, we became aware of progressive neuronal loss in the NTS and noted SUDEP-like deaths in rats with frequent convulsions. Increased autonomic susceptibility with inhalation anesthetics was also observed, often seen after impairment of baroreceptor and chemoreceptor reflex loops. Seizure-induced neuron loss in NTS may play a role impairing the integrative functions of NTS resulting in poor homeostatic responses during seizures and leading to SUDEP. This article is part of a Special Issue entitled "The Future of Translational Epilepsy Research". Published by Elsevier Inc. C1 [Tolstykh, Gleb P.; Cavazos, Jose E.] South Texas Vet Hlth Care Syst, Res Div ALM VAMC, San Antonio, TX USA. [Tolstykh, Gleb P.; Cavazos, Jose E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA. [Tolstykh, Gleb P.; Cavazos, Jose E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Tolstykh, Gleb P.; Cavazos, Jose E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Cavazos, Jose E.] South Texas Vet Hlth Care Syst, San Antonio VA Epilepsy Ctr Excellence, San Antonio, TX USA. [Cavazos, Jose E.] South Texas Vet Hlth Care Syst, Div Res, San Antonio, TX USA. RP Cavazos, JE (reprint author), Audie L Murphy VA Hosp, Neurol Sect, Mail Code 111D,7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM cavazosj@uthscsa.edu RI Cavazos, Jose/J-4122-2016 OI Cavazos, Jose/0000-0001-5777-2608 NR 95 TC 22 Z9 22 U1 1 U2 10 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-5050 J9 EPILEPSY BEHAV JI Epilepsy Behav. PD MAR PY 2013 VL 26 IS 3 BP 410 EP 414 DI 10.1016/j.yebeh.2012.09.017 PG 5 WC Behavioral Sciences; Clinical Neurology; Psychiatry SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry GA 113JU UT WOS:000316663900026 PM 23305781 ER PT J AU Bergman, J Brook, RH Litwin, MS AF Bergman, Jonathan Brook, Robert H. Litwin, Mark S. TI A Call to Action Improving Value by Emphasizing Patient-Centered Care at the End of Life SO JAMA SURGERY LA English DT Editorial Material C1 [Bergman, Jonathan; Litwin, Mark S.] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA 90095 USA. [Litwin, Mark S.] Univ Calif Los Angeles, Dept Hlth Serv, Los Angeles, CA 90095 USA. [Litwin, Mark S.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. [Bergman, Jonathan] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Bergman, Jonathan] Univ Calif Los Angeles, Robert Wood Johnson Clin Scholars Program, Los Angeles, CA USA. [Brook, Robert H.] RAND Corp, Santa Monica, CA USA. RP Bergman, J (reprint author), Univ Calif Los Angeles, Dept Urol, POB 951738, Los Angeles, CA 90095 USA. EM jbergman@mednet.ucla.edu NR 8 TC 3 Z9 3 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6254 J9 JAMA SURG JI JAMA Surg. PD MAR PY 2013 VL 148 IS 3 BP 215 EP 216 PG 2 WC Surgery SC Surgery GA 113QG UT WOS:000316682000001 PM 23552885 ER PT J AU Roth, MY Nya-Ngatchou, JJS Lin, K Page, ST Anawalt, BD Matsumoto, AM Marck, BT Bremner, WJ Amory, JK AF Roth, M. Y. Nya-Ngatchou, J. J. S. Lin, K. Page, S. T. Anawalt, B. D. Matsumoto, A. M. Marck, B. T. Bremner, W. J. Amory, J. K. TI Androgen Synthesis in the Gonadotropin-Suppressed Human Testes Can Be Markedly Suppressed by Ketoconazole SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID INTRATESTICULAR STEROID-LEVELS; HUMAN CHORIONIC-GONADOTROPIN; NORMAL MEN; NONOBSTRUCTIVE AZOOSPERMIA; TESTOSTERONE ENANTHATE; CONTRACEPTIVE EFFICACY; HORMONE ANTAGONIST; DOSE KETOCONAZOLE; MALE-INFERTILITY; YOUNG MEN AB Context: The concentration of intratesticular testosterone (IT-T) required for human spermatogenesis is unknown because spermatogenesis can persist despite the markedly reduced IT-T concentrations observed with LH suppression. Methods to lower IT-T further are needed to determine the relationship between IT-T and spermatogenesis. Objective: The objective of the study was to determine the effect of inhibiting the synthesis and metabolism of testosterone (T) on IT-T in gonadotropin-suppressed human testes. Design/Setting/Patients: Forty normal men participated in a blinded, placebo-controlled, randomized trial at an academic center. Intervention/Outcome Measures: All men were first administered the GnRH antagonist acyline to suppress LH. Forty-eight hours after acyline administration, subjects were randomly assigned to placebo, ketoconazole (to inhibit T synthesis) at 400 or 800 mg, dutasteride (to inhibit T metabolism) 2.5 mg, or anastrazole (to inhibit T metabolism) 1 mg, daily for 7 days (n = 8/group). Intratesticular steroid concentrations were measured 48 hours after acyline administration alone and again after 7 days of combination treatment. Results: After 7 days of combination treatment, the median IT-T (25th, 75th percentile) in the placebo group was 14 (8.0, 21.2) ng/mL. IT-T was reduced to 3.7 (2.5, 7.1) ng/mL in the ketoconazole 400 mg group and 1.7 (0.8, 4.0) ng/mL in the ketoconazole 800 mg group (P < .001 vs placebo for both comparisons). IT-T concentrations in the dutasteride and anastrazole groups were similar to placebo. Conclusion: Combining inhibition of steroidogenesis with gonadotropin suppression lowers IT-T more than gonadotropin suppression alone. This combination might be useful to determine the minimum IT-T concentration necessary for human spermatogenesis, information essential for developing male hormonal contraceptives. (J Clin Endocrinol Metab 98: 1198-1206, 2013) C1 [Roth, M. Y.; Nya-Ngatchou, J. J. S.; Page, S. T.; Anawalt, B. D.; Matsumoto, A. M.; Bremner, W. J.; Amory, J. K.] Univ Washington, Dept Internal Med, Seattle, WA 98195 USA. [Lin, K.] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA. [Roth, M. Y.; Nya-Ngatchou, J. J. S.; Page, S. T.; Anawalt, B. D.; Matsumoto, A. M.; Bremner, W. J.; Amory, J. K.] Univ Washington, Ctr Res Reprod & Contracept, Seattle, WA 98195 USA. [Matsumoto, A. M.; Marck, B. T.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. RP Roth, MY (reprint author), Univ Washington, 1959 NE Pacific St,Box 357138, Seattle, WA 98195 USA. EM mylang@u.washington.edu FU Eunice Kennedy Shriver National Institute of Child Health and Human Development as part of the Cooperative Contraceptive Research Centers Program [U54 HD-42454]; Eunice Kennedy Shriver National Institute of Child Health and Human Development Grant [K12 HD053984]; National Institute of Diabetes and Digestive and Kidney Diseases [5T32 DK007247-35]; Department of Veterans Affairs FX This work was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development through Cooperative Agreement U54 HD-42454 as part of the Cooperative Contraceptive Research Centers Program. M.Y.R. is supported, in part, by the Eunice Kennedy Shriver National Institute of Child Health and Human Development Grant K12 HD053984. J.J.S.N. is supported by the National Institute of Diabetes and Digestive and Kidney Diseases training grant 5T32 DK007247-35. A.M.M. is supported by the Department of Veterans Affairs. NR 30 TC 4 Z9 4 U1 0 U2 7 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD MAR PY 2013 VL 98 IS 3 BP 1198 EP 1206 DI 10.1210/jc.2012-3527 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 110BN UT WOS:000316417200071 PM 23348398 ER PT J AU Wecht, JM Bauman, WA AF Wecht, Jill M. Bauman, William A. TI Decentralized cardiovascular autonomic control and cognitive deficits in persons with spinal cord injury SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Review DE Spinal cord injuries; Cerebral blood flow; Brain injury; Traumatic; Cognitive dysfunction; Arterial pressure; Heart rate; Arterial stiffness; Autonomic dysreflexia; Tetraplegia; Paraplegia; Neuropsychological testing; Rehabilitation ID PULSE-WAVE VELOCITY; LOW BLOOD-PRESSURE; SLEEP-APNEA SYNDROME; CONTINGENT NEGATIVE-VARIATION; INCREASED ARTERIAL STIFFNESS; HEART-RATE-VARIABILITY; ORTHOSTATIC HYPOTENSION; RISK-FACTORS; INTERNATIONAL STANDARDS; SUSTAINED ATTENTION AB Spinal cord injury (SCI) results in motor and sensory impairments that can be identified with the American Spinal Injury Association (ASIA) Impairment Scale (AIS). Although, SCI may disrupt autonomic neural transmission, less is understood regarding the clinical impact of decentralized autonomic control. Cardiovascular regulation may be altered following SCI and the degree of impairment may or may not relate to the level of AIS injury classification. In general, persons with lesions above T1 present with bradycardia, hypotension, and orthostatic hypotension; functional changes which may interfere with rehabilitation efforts. Although many individuals with SCI above T1 remain overtly asymptomatic to hypotension, we have documented deficits in memory and attention processing speed in hypotensive individuals with SCI compared to a normotensive SCI cohort. Reduced resting cerebral blood flow (CBF) and diminished CBF responses to cognitive testing relate to test performance in hypotensive non-SCI, and preliminary evidence suggests a similar association in individuals with SCI. Persons with paraplegia below T7 generally present with a normal cardiovascular profile; however, our group and others have documented persistently elevated heart rate and increased arterial stiffness. In the non-SCI literature there is evidence supporting a link between increased arterial stiffness and cognitive deficits. Preliminary evidence suggests increased incidence of cognitive impairment in individuals with paraplegia, which we believe may relate to adverse cardiovascular changes. This report reviews relevant literature and discusses findings related to the possible association between decentralized cardiovascular autonomic control and cognitive dysfunction in persons with SCI. C1 [Wecht, Jill M.; Bauman, William A.] James J Peters VA Med Ctr, Bronx, NY USA. [Wecht, Jill M.; Bauman, William A.] Mt Sinai Sch Med, Ctr Excellence & Med Serv, New York, NY USA. [Wecht, Jill M.; Bauman, William A.] Dept Med, New York, NY USA. [Wecht, Jill M.; Bauman, William A.] Dept Rehabil Med, New York, NY USA. RP Wecht, JM (reprint author), James J Peters VA Med Ctr, Room 1E-02,130 West Kingsbridge Rd, Bronx, NY USA. EM jm.wecht@va.gov FU Veterans Affairs Rehabilitation Research and Development Service [A6161W, B3203R, B4162C] FX This research was supported by the Veterans Affairs Rehabilitation Research and Development Service (Grants: A6161W, B3203R, and B4162C). NR 97 TC 5 Z9 6 U1 1 U2 16 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD MAR PY 2013 VL 36 IS 2 BP 74 EP 81 DI 10.1179/2045772312Y.0000000056 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 112RT UT WOS:000316611400002 PM 23809520 ER PT J AU Carbone, LD Chin, AS Lee, TA Burns, SP Svircev, JN Hoenig, HM Akhigbe, T Weaver, FM AF Carbone, Laura D. Chin, Amy S. Lee, Todd A. Burns, Stephen P. Svircev, Jelena N. Hoenig, Helen M. Akhigbe, Titilola Weaver, Frances M. TI The association of opioid use with incident lower extremity fractures in spinal cord injury SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE Fractures; Opioids; Bone mineral density; Osteoporosis; Spinal cord injuries; Rehabilitation; Veterans ID RANDOMIZED CONTROLLED-TRIAL; BONE-MINERAL DENSITY; CHRONIC PAIN; OLDER-ADULTS; PHARMACOLOGICAL-TREATMENTS; CALCIUM SUPPLEMENTATION; LONG-TERM; RISK; MEN; OSTEOPOROSIS AB Objective: To determine the association between opioid use and lower extremity fracture risk in men with spinal cord injury (SCI). Design: Retrospective cohort study. Setting: Veterans Affairs Healthcare System. Participants: In total, 7447 male Veterans with a history of a traumatic SCI identified from the Veterans Affairs (VA) Spinal Cord Dysfunction Registry (SCD) from September 2002 through October 2007 and followed through October 2010. Outcome measures: Incident lower extremity fractures by use of opioids. Results: In individuals identified from the VA SCD Registry 2002-2007, opioid use was quite common, with approximately 70% of the cohort having received a prescription for an opioid. Overall, there were 892 incident lower extremity fractures over the time period of this study (597 fractures in the opioid users and 295 fractures in the non-opioid users). After adjusting for covariates, there was a statistically significant relationship between opioid use and increased risk for lower extremity fractures (hazard ratio 1.82 (95% confidence interval 1.59-2.09)). Shorter duration of use (<6 months) and higher doses were positively related to fracture risk (P < 0.0001). Conclusions: Opioid use is quite common in SCI and is associated with an increased risk for lower extremity fractures. Careful attention to fracture prevention is warranted in patients with SCI, particularly upon initiation of an opioid prescription and when higher doses are used. C1 [Carbone, Laura D.; Akhigbe, Titilola] Vet Affairs Med Ctr, Dept Res, Memphis, TN USA. [Carbone, Laura D.; Akhigbe, Titilola] Univ Tennessee, Ctr Hlth Sci, Div Connect Tissues Disorders, Dept Med, Memphis, TN 38163 USA. [Chin, Amy S.; Weaver, Frances M.] Edward Hines Jr VA Hosp, Spinal Cord Injury Qual Enhancement Res Initiat, Hines, IL USA. [Lee, Todd A.] Univ Illinois, Chicago, IL USA. [Burns, Stephen P.; Svircev, Jelena N.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Burns, Stephen P.; Svircev, Jelena N.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Hoenig, Helen M.] Durham Vet Affairs Med Ctr, Durham, NC USA. RP Carbone, LD (reprint author), Univ Tennessee, Ctr Hlth Sci, 956 Court Ave,Rm G326, Memphis, TN 38163 USA. EM lcarbone@uthsc.edu FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development [IIR 08-033] FX This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development #IIR 08-033. The authors thank Catherine Plunkett for her technical assistance in preparation of this manuscript. NR 53 TC 7 Z9 8 U1 0 U2 1 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD MAR PY 2013 VL 36 IS 2 BP 91 EP 96 DI 10.1179/2045772312Y.0000000060 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 112RT UT WOS:000316611400004 PM 23809522 ER PT J AU Harel, NY Asselin, PK Fineberg, DB Pisano, TJ Bauman, WA Spungen, AM AF Harel, Noam Y. Asselin, Pierre K. Fineberg, Drew B. Pisano, Thomas J. Bauman, William A. Spungen, Ann M. TI Adaptation of computerized posturography to assess seated balance in persons with spinal cord injury SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE Spinal cord injuries; Paraplegia; Rehabilitation; Disability; Assistive technology; Berg balance scale; Limits of stability; Modified functional reach test; Posturography ID POSTURAL CONTROL; SCALE; RELIABILITY; VALIDITY; PERFORMANCE; STROKE AB Background: The ability to retain or improve seated balance function after spinal cord injury (SCI) may mean the difference between independence and requiring assistance for basic activities of daily living. Compared with assessments of standing and walking balance, seated balance assessments remain relatively underemphasized and under-utilized. Objective: To optimize tools for assessing seated balance deficits and recovery in SCI. Design: Cross-sectional observational study of different methods for assessing seated balance function. Setting: Veterans Affairs Center of Excellence for the Medical Consequences of Spinal Cord Injury. Participants: Seven able-bodied volunteers, seven participants with chronic motor-complete thoracic SCI. Interventions: A computerized pressure-plate apparatus designed for testing standing balance was adapted into a seated balance assessment system. Outcome measures: Seated section of Berg Balance Scale; modified functional reach test; and two posturography tests: limits of stability and clinical test of sensory integration on balance. Results: Seated posturography demonstrated improved correlation with neurological level of lesion compared to that of routinely applied subjective clinical tests. Conclusion: Seated posturography represents an appealing outcome measure that may be applied toward the measurement of functional changes in response to various rehabilitation interventions in individuals with paralysis. C1 [Harel, Noam Y.; Asselin, Pierre K.; Fineberg, Drew B.; Pisano, Thomas J.; Bauman, William A.; Spungen, Ann M.] James J Peters Vet Affairs Med Ctr, VA RR&D Ctr Excellence Med Consequences Spinal Co, Bronx, NY 10468 USA. [Harel, Noam Y.] Mt Sinai Sch Med, Dept Neurol, New York, NY USA. [Harel, Noam Y.; Bauman, William A.; Spungen, Ann M.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. [Pisano, Thomas J.] Robert Wood Johnson Med Sch, Piscataway, NJ USA. [Bauman, William A.; Spungen, Ann M.] Mt Sinai Med Ctr, Dept Med, New York, NY 10029 USA. RP Harel, NY (reprint author), James J Peters Vet Affairs Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM noam.harel@va.gov FU VA Rehabilitation Research & Development (RRD) Service; RR&D National Center of Excellence for the Medical Consequences of Spinal Cord Injury [B9212-C]; James J. Peters Veterans Affairs Medical Center (JJPVAMC); Mount Sinai School of Medicine Department of Neurology FX The authors wish to thank the VA Rehabilitation Research & Development (RR&D) Service, the RR&D National Center of Excellence for the Medical Consequences of Spinal Cord Injury (#B9212-C), the James J. Peters Veterans Affairs Medical Center (JJPVAMC), and the Mount Sinai School of Medicine Department of Neurology for providing research and salary support. We would also like to specifically thank Steven Knezevic for his assistance, and the Audiology Service, JJPVAMC, for generously providing us access to the Smart EquiTest apparatus. NR 19 TC 3 Z9 3 U1 3 U2 15 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD MAR PY 2013 VL 36 IS 2 BP 127 EP 133 DI 10.1179/2045772312Y.0000000053 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 112RT UT WOS:000316611400009 PM 23809527 ER PT J AU Gamazon, ER Badner, JA Cheng, L Zhang, C Zhang, D Cox, NJ Gershon, ES Kelsoe, JR Greenwood, TA Nievergelt, CM Chen, C McKinney, R Shilling, PD Schork, NJ Smith, EN Bloss, CS Nurnberger, JI Edenberg, HJ Foroud, T Koller, DL Scheftner, WA Coryell, W Rice, J Lawson, WB Nwulia, EA Hipolito, M Byerley, W McMahon, FJ Schulze, TG Berrettini, WH Potash, JB Zandi, PP Mahon, PB McInnis, MG Zollner, S Zhang, P Craig, DW Szelinger, S Barrett, TB Liu, C AF Gamazon, E. R. Badner, J. A. Cheng, L. Zhang, C. Zhang, D. Cox, N. J. Gershon, E. S. Kelsoe, J. R. Greenwood, T. A. Nievergelt, C. M. Chen, C. McKinney, R. Shilling, P. D. Schork, N. J. Smith, E. N. Bloss, C. S. Nurnberger, J. I. Edenberg, H. J. Foroud, T. Koller, D. L. Scheftner, W. A. Coryell, W. Rice, J. Lawson, W. B. Nwulia, E. A. Hipolito, M. Byerley, W. McMahon, F. J. Schulze, T. G. Berrettini, W. H. Potash, J. B. Zandi, P. P. Mahon, P. B. McInnis, M. G. Zoellner, S. Zhang, P. Craig, D. W. Szelinger, S. Barrett, T. B. Liu, C. TI Enrichment of cis-regulatory gene expression SNPs and methylation quantitative trait loci among bipolar disorder susceptibility variants SO MOLECULAR PSYCHIATRY LA English DT Article DE bipolar disorder; eQTL; GWAS; mQTL ID GENOME-WIDE ASSOCIATION; HUMAN-DISEASE; EPIGENETICS AB We conducted a systematic study of top susceptibility variants from a genome-wide association (GWA) study of bipolar disorder to gain insight into the functional consequences of genetic variation influencing disease risk. We report here the results of experiments to explore the effects of these susceptibility variants on DNA methylation and mRNA expression in human cerebellum samples. Among the top susceptibility variants, we identified an enrichment of cis regulatory loci on mRNA expression (eQTLs), and a significant excess of quantitative trait loci for DNA CpG methylation, hereafter referred to as methylation quantitative trait loci (mQTLs). Bipolar disorder susceptibility variants that cis regulate both cerebellar expression and methylation of the same gene are a very small proportion of bipolar disorder susceptibility variants. This finding suggests that mQTLs and eQTLs provide orthogonal ways of functionally annotating genetic variation within the context of studies of pathophysiology in brain. No lymphocyte mQTL enrichment was found, suggesting that mQTL enrichment was specific to the cerebellum, in contrast to eQTLs. Separately, we found that using mQTL information to restrict the number of single-nucleotide polymorphisms studied enhances our ability to detect a significant association. With this restriction a priori informed by the observed functional enrichment, we identified a significant association (rs12618769, P-bonferroni < 0.05) from two other GWA studies (TGen + GAIN; 2191 cases and 1434 controls) of bipolar disorder, which we replicated in an independent GWA study (WTCCC). Collectively, our findings highlight the importance of integrating functional annotation of genetic variants for gene expression and DNA methylation to advance the biological understanding of bipolar disorder. Molecular Psychiatry (2013) 18, 340-346; doi:10.1038/mp.2011.174; published online 3 January 2012 C1 [Gamazon, E. R.; Cox, N. J.] Univ Chicago, Dept Med, Chicago, IL 60637 USA. [Badner, J. A.; Gershon, E. S.] Univ Chicago, Dept Psychiat, Chicago, IL 60637 USA. [Cheng, L.; Zhang, C.; Chen, C.; Liu, C.] Univ Illinois, Dept Psychiat, Chicago, IL 60607 USA. [Zhang, D.] Zhejiang Univ, Sch Med, Hangzhou, Zhejiang, Peoples R China. [Kelsoe, J. R.; Greenwood, T. A.; Nievergelt, C. M.; McKinney, R.; Shilling, P. D.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Schork, N. J.; Smith, E. N.; Bloss, C. S.] Scripps Genom Med & Scripps Translat Sci Inst, La Jolla, CA USA. [Nurnberger, J. I.; Koller, D. L.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN USA. [Edenberg, H. J.; Foroud, T.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN USA. [Scheftner, W. A.] Rush Univ, Dept Psychiat, Chicago, IL 60612 USA. [Coryell, W.] Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA. [Rice, J.] Washington Univ, Div Biostat, St Louis, MO USA. [Lawson, W. B.; Nwulia, E. A.; Hipolito, M.] Howard Univ, Dept Psychiat, Washington, DC 20059 USA. [Byerley, W.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [McMahon, F. J.; Schulze, T. G.] NIMH, Genet Basis Mood & Anxiety Disorders Unit, Intramural Res Program, NIH,US Dept HHS, Bethesda, MD 20892 USA. [Schulze, T. G.] Cent Inst Mental Hlth, Dept Genet Epidemiol Psychiat, Mannheim, Germany. [Berrettini, W. H.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Potash, J. B.; Zandi, P. P.; Mahon, P. B.] Johns Hopkins Sch Med, Dept Psychiat, Baltimore, MD USA. [McInnis, M. G.; Zoellner, S.; Zhang, P.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. [Craig, D. W.; Szelinger, S.] Translat Genom Res Inst, Neurogen Div, Phoenix, AZ USA. [Barrett, T. B.] Portland VA Med Ctr, Dept Psychiat, Portland, OR USA. RP Liu, C (reprint author), Univ Illinois, Dept Psychiat, 900 S Ashland Ave,Room 1006, Chicago, IL 60607 USA. EM cliu@psych.uic.edu RI Schulze, Thomas/H-2157-2013; Zhang, Peng/N-2920-2014 OI Zhang, Peng/0000-0003-1182-1392; Nievergelt, Caroline/0000-0001-5766-8923; Lawson, William/0000-0002-9324-7090; McMahon, Francis/0000-0002-9469-305X; Greenwood, Tiffany/0000-0002-6080-6503; Nurnberger, John/0000-0002-7674-1767; Edenberg, Howard/0000-0003-0344-9690; Gamazon, Eric/0000-0003-4204-8734 FU PAAR (Pharmacogenetics of Anti-cancer Agents Research) [U01 GM61393]; ENDGAMe (ENhancing Development of Genome-wide Association Methods) initiative [U01 HL084715]; Genotype-Tissue Expression project (GTeX) [R01 MH090937]; [5R01MH080425] FX This work was funded by 5R01MH080425 (to CL), PAAR (Pharmacogenetics of Anti-cancer Agents Research; U01 GM61393), ENDGAMe (ENhancing Development of Genome-wide Association Methods) initiative (U01 HL084715), and the Genotype-Tissue Expression project (GTeX) (R01 MH090937) (to NJC). NR 28 TC 57 Z9 57 U1 2 U2 19 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 EI 1476-5578 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD MAR PY 2013 VL 18 IS 3 BP 340 EP 346 DI 10.1038/mp.2011.174 PG 7 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA 112BZ UT WOS:000316568100011 PM 22212596 ER PT J AU Goetz, CG Stebbins, GT Chung, KA Hauser, RA Miyasaki, JM Nicholas, AP Poewe, W Seppi, K Rascol, O Stacy, MA Nutt, JG Tanner, CM Urkowitz, A Jaglin, JA Ge, S AF Goetz, Christopher G. Stebbins, Glenn T. Chung, Kathryn A. Hauser, Robert A. Miyasaki, Janis M. Nicholas, Anthony P. Poewe, Werner Seppi, Klaus Rascol, Olivier Stacy, Mark A. Nutt, John G. Tanner, Caroline M. Urkowitz, Alison Jaglin, Jean A. Ge, Song TI Which dyskinesia scale best detects treatment response? SO MOVEMENT DISORDERS LA English DT Article DE dyskinesia; Parkinson's disease; rating scales; clinimetrics; amantadine; clinical trials ID PARKINSONS-DISEASE; RATING-SCALE; PD; THERAPIES; TRIALS; UPDATE; DRUGS AB Numerous scales assess dyskinesia in Parkinson's disease (PD), variably focusing on anatomical distribution, phenomenology, time, severity, and disability. No study has compared these scales and their relative ability to detect change related to an established treatment. We conducted a randomized placebo-controlled trial of amantadine, assessing dyskinesia at baseline and at 4 and 8 weeks using the following scales: Unified Dyskinesia Rating Scale (UDysRS), Lang-Fahn Activities of Daily Living Dyskinesia Rating Scale (LF), 26-Item Parkinson's Disease Dyskinesia scale (PDD-26), patient diaries, modified Abnormal Involuntary Movements Scale (AIMS), Rush Dyskinesia Rating Scale (RDRS), dyskinesia items from the Movement Disorder Societysponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS), and Clinical Global Impression (severity and change: CGI-S, CGI-C). Scale order was randomized at each visit, but raters were aware of each scale as it was administered. Sensitivity to treatment was assessed using effect size. Sixty-one randomized dyskinetic PD subjects (31 amantadine, 30 placebo) completed the study. Four of the 8 scales (CGI-C, LF, PDD-26, and UDysRS) detected a significant treatment. The UDysRS Total Score showed the highest effect size (2 = 0.138) for detecting treatment-related change, with all other scales having effect sizes < 0.1. No scale was resistant to placebo effects. This study resolves 2 major issues useful for future testing of new antidyskinesia treatments: among tested scales, the UDysRS, having both subjective and objective dyskinesia ratings, is superior for detecting treatment effects; and the magnitude of the UDysRS effect size from amantadine sets a clear standard for comparison for new agents. (c) 2012 Movement Disorder Society C1 [Goetz, Christopher G.; Stebbins, Glenn T.; Jaglin, Jean A.; Ge, Song] Rush Univ, Dept Neurol Sci, Med Ctr, Chicago, IL 60612 USA. [Chung, Kathryn A.; Nutt, John G.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR USA. [Chung, Kathryn A.; Nutt, John G.] Portland VA Med Ctr, Portland, OR USA. [Hauser, Robert A.] Univ S Florida, Dept Neurol, Tampa, FL 33620 USA. [Miyasaki, Janis M.] Univ Toronto, Edmond J Safra Program Parkinsons Dis, Toronto, ON, Canada. [Nicholas, Anthony P.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA. [Nicholas, Anthony P.] Birmingham VA Med Ctr, Birmingham, AL USA. [Poewe, Werner; Seppi, Klaus] Med Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria. [Rascol, Olivier] Univ Hosp Toulouse, Clin Invest Ctr CIC9302, Toulouse, France. [Rascol, Olivier] Univ Hosp Toulouse, INSERM, Dept Clin Pharmacol, Toulouse, France. [Rascol, Olivier] Univ Hosp Toulouse, INSERM, Dept Neurosci, Toulouse, France. [Rascol, Olivier] Univ Toulouse 3, F-31062 Toulouse, France. [Stacy, Mark A.] Duke Univ, Dept Neurol, Durham, NC USA. [Tanner, Caroline M.] Parkinsons Inst, Sunnyvale, CA USA. [Tanner, Caroline M.] Ctr Clin, Sunnyvale, CA USA. [Urkowitz, Alison] Michael J Fox Fdn Parkinsons Res, New York, NY USA. RP Goetz, CG (reprint author), Rush Presbyterian St Lukes Med Ctr, Suite 755,1725 W Harrison St, Chicago, IL 60612 USA. EM cgoetz@rush.edu OI Miyasaki, Janis/0000-0002-6372-6007 FU Michael J. Fox Foundation for Parkinson's Research; Parkinson's Disease Foundation FX The trial was sponsored by a grant from the Michael J. Fox Foundation for Parkinson's Research. The Rush Movement Disorder Program is also supported by the Parkinson's Disease Foundation. NR 26 TC 20 Z9 20 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD MAR PY 2013 VL 28 IS 3 BP 341 EP 346 DI 10.1002/mds.25321 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 113VF UT WOS:000316696700020 PM 23390076 ER PT J AU Weiser, TG Porter, MP Maier, RV AF Weiser, Thomas G. Porter, Michael P. Maier, Ronald V. TI Safety in the operating theatre-a transition to systems-based care SO NATURE REVIEWS UROLOGY LA English DT Review ID SURGICAL-SITE INFECTIONS; RANDOMIZED CONTROLLED-TRIAL; SUPPLEMENTAL PERIOPERATIVE OXYGEN; IN-HOSPITAL MORTALITY; ARTERY-BYPASS-SURGERY; INTERMITTENT PNEUMATIC COMPRESSION; ASSESSMENT PROGRAM SCOAP; BETA-BLOCKER WITHDRAWAL; CRITICALLY-ILL PATIENTS; WOUND-INFECTION AB All surgeons want the best, safest care for their patients, but providing this requires the complex coordination of multiple disciplines to ensure that all elements of care are timely, appropriate, and well organized. Quality-improvement initiatives are beginning to lead to improvements in the quality of care and coordination amongst teams in the operating room. As the population ages and patients present with more complex disease pathology, the demands for efficient systematization will increase. Although evidence suggests that postoperative mortality rates are declining, there is substantial room for improvement. Multiple quality metrics are used as surrogates for safe care, but surgical teams including surgeons, anaesthetists, and nurses must think beyond these simple interventions if they are to effectively communicate and coordinate in the face of increasing demands. Weiser, T. G. et al. Nat. Rev. Urol. 10, 161-173; published online 19 February 2013; doi:10.1038/nrurol.2013.13 C1 [Weiser, Thomas G.] Stanford Univ, Med Ctr, Dept Surg, Stanford, CA 94305 USA. [Porter, Michael P.] Univ Washington, Dept Urol, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Maier, Ronald V.] Univ Washington, Harborview Med Ctr, Dept Surg, Seattle, WA 98104 USA. RP Weiser, TG (reprint author), Stanford Univ, Med Ctr, Dept Surg, 300 Pasteur Dr S067, Stanford, CA 94305 USA. EM tweiser@stanford.edu NR 169 TC 0 Z9 0 U1 0 U2 6 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-4812 EI 1759-4820 J9 NAT REV UROL JI Nat. Rev. Urol. PD MAR PY 2013 VL 10 IS 3 BP 161 EP 173 DI 10.1038/nrurol.2013.13 PG 13 WC Urology & Nephrology SC Urology & Nephrology GA 114AQ UT WOS:000316712500007 PM 23419492 ER PT J AU Baca, CB Vickrey, BG Vassar, S Hauptman, JS Dadour, A Oh, T Salamon, N Vinters, HV Sankar, R Mathern, GW AF Baca, Christine B. Vickrey, Barbara G. Vassar, Stefanie Hauptman, Jason S. Dadour, Andrew Oh, Taemin Salamon, Noriko Vinters, Harry V. Sankar, Raman Mathern, Gary W. TI Time to pediatric epilepsy surgery is related to disease severity and nonclinical factors SO NEUROLOGY LA English DT Article ID TEMPORAL-LOBE EPILEPSY; RACIAL DISPARITIES; REFERRAL PATTERNS; INFANTILE SPASMS; UNITED-STATES; CHILDREN; OUTCOMES; SEIZURE; RECOMMENDATIONS; ADOLESCENTS AB Objective: To identify clinical and nonclinical factors associated with time from epilepsy onset to surgical evaluation and treatment among a cohort of children having epilepsy surgery. Methods: Data were abstracted from records of 430 children (younger than 18 years) who had epilepsy neurosurgery at the University of California, Los Angeles from 1986 to 2010. Multivariable Cox proportional hazards models were used to analyze unique associations of clinical severity, pre-referral brain MRI, and sociodemographic characteristics with time to surgery. Results: Shorter time to surgery was associated with active (hazard ratio [HR] 5.67, 95% confidence interval [CI] 3.74-8.70) and successfully treated infantile spasms (HR 2.20, 95% CI 1.63-2.96); daily or more seizures (HR 2.09, 95% CI 1.58-2.76); MRI before referral regardless of imaging findings (HR 1.95, 95% CI 1.47-2.58); private insurance (HR 1.54, 95% CI 1.14-2.09); and Hispanic ethnicity (HR 1.38, 95% CI 1.01-1.87). There were race/ethnicity by insurance interactions (log-rank p = 0.049) with shortest time to surgery for Hispanic children with private insurance. Conclusions: Shorter intervals to surgical treatment were associated with greater epilepsy severity and insurance type, consistent with existing literature. However, associations of shorter times to treatment with having a brain MRI before referral and Hispanic ethnicity were unexpected and warrant further investigation. More knowledgeable referring providers and parents with greater help-seeking capability may explain obtaining an MRI before referral. Shorter intervals to surgery among Hispanic children may relate to the same factors yielding an increased volume of Hispanic children receiving surgery at the University of California, Los Angeles since 2000. Neurology (R) 2013;80:1231-1239 C1 [Baca, Christine B.; Vickrey, Barbara G.; Vassar, Stefanie; Vinters, Harry V.; Sankar, Raman] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Dept Neurol, Los Angeles, CA 90095 USA. [Hauptman, Jason S.; Dadour, Andrew; Oh, Taemin; Mathern, Gary W.] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Dept Neurosurg, Los Angeles, CA 90095 USA. [Sankar, Raman] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Dept Pediat, Los Angeles, CA 90095 USA. [Mathern, Gary W.] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Dept Psychiat & Biobehav Med, Los Angeles, CA 90095 USA. [Sankar, Raman] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Div Pediat Neurol, Los Angeles, CA 90095 USA. [Salamon, Noriko] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Div Neuroradiol, Los Angeles, CA 90095 USA. [Vinters, Harry V.] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Sect Neuropathol, Los Angeles, CA 90095 USA. [Baca, Christine B.; Vickrey, Barbara G.; Vassar, Stefanie] VA Greater Los Angeles Hlth Care Syst, Dept Neurol, Los Angeles, CA USA. RP Baca, CB (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Dept Neurol, Los Angeles, CA 90095 USA. EM cbower@mednet.ucla.edu FU Epilepsy Foundation [213971]; NIH [R01 NS38992, NIA: RC4AG038804, P50 AG16570, P01 AG12435, NS 044378]; NIH/National Institute of Neurological Disorders and Stroke [R37-NS031146-11]; NIH (National Institute of Neurological Disorders and Stroke) [R37-NS031146-11, 1U54 NS081764]; US Veterans Administration Health Services Research and Development Service [NRI-11-126, VA QUERI PRP]; American Heart Association [AHA/PRT 0875133N]; Food and Drug Administration [R01 FD003923]; UCB Pharma; Sunovion; Upsher-Smith; Lundbeck Pharma; Pfizer; [NIH-MH079933] FX This study was supported by Epilepsy Foundation grant 213971 (PI: Dr. Baca) and NIH grant R01 NS38992 (PI: Dr. Mathern).; C. Baca receives salary support from Epilepsy Foundation grant 213971 for this project and also receives research support from the NIH/National Institute of Neurological Disorders and Stroke (R37-NS031146-11). B. Vickrey serves on scientific advisory boards for the Sports Concussion Institute, American Heart Association, and the NIH; receives research support from the NIH (NIA: RC4AG038804; National Institute of Neurological Disorders and Stroke: R37-NS031146-11 and 1U54 NS081764), the US Veterans Administration Health Services Research and Development Service (NRI-11-126 and VA QUERI PRP), the American Heart Association (AHA/PRT 0875133N), and the Food and Drug Administration (R01 FD003923); and is a consultant to EMD Serono Canada. S. Vassar, J. Hauptman, A. Dadour, T. Oh, and N. Salamon report no disclosures relevant to the manuscript. H. Vinters: the H. V. Vinters trust owns shares in and receives dividends from the following makers of drugs and medical equipment: GE, 3M, Pfizer, Teva Pharma, Becton Dickinson, and GlaxoSmithKline PLC. The Vinters laboratory has received research funding in the past from Neuropace, Inc., and currently receives NIH funds for research on stroke and dementia (P50 AG16570, P01 AG12435, NS 044378). R. Sankar serves on scientific advisory boards for and has received honoraria and funding for travel from UCB Pharma, Sunovion, Upsher-Smith, and Lundbeck Pharma; serves on speakers' bureaus for and has received speaker honoraria from UCB, GlaxoSmithKline, and Lundbeck. He receives funding from NIH-MH079933 (coinvestigator) and from Pfizer (Lyrica pediatric partial seizures trial). G. Mathern received research funding from NIH grant R01 NS38992, which partially supported this study and he serves on the Data Management Committee for NeuroPace, Inc. Go to Neurology.org for full disclosures. NR 36 TC 21 Z9 22 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD MAR PY 2013 VL 80 IS 13 BP 1231 EP 1239 DI 10.1212/WNL.0b013e3182897082 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 113OF UT WOS:000316676700020 PM 23468549 ER PT J AU McKenna, BS Brown, GG Drummond, SPA Turner, TH Mano, QR AF McKenna, Benjamin S. Brown, Gregory G. Drummond, Sean P. A. Turner, Travis H. Mano, Quintino R. TI Linking Mathematical Modeling With Human Neuroimaging to Segregate Verbal Working Memory Maintenance Processes From Stimulus Encoding SO NEUROPSYCHOLOGY LA English DT Article DE verbal working memory; functional MRI; mathematical modeling; stimulus degradation; pseudoword length ID SHORT-TERM-MEMORY; LATERAL FRONTAL-CORTEX; PRIMARY VISUAL-CORTEX; PARIETAL CORTEX; WORD-LENGTH; ACTIVATION; FMRI; DORSAL; DISSOCIATION; ORGANIZATION AB Objective: A fundamental dissociation for most working memory (WM) theories involves the separation of sensory-perceptual encoding of stimulus information from the maintenance of this information. The present paper reports tests of this separability hypothesis for visually presented pseudowords at both mathematical and neuroimaging levels of analysis. Method: Levels of analysis were linked by two experimental manipulations-visual degradation and pseudoword length variation-that coupled findings from a mathematical modeling study of WM performed in a separate sample to findings from an event-related functional MRI (fMRI) study reported in the present paper. Results from the mathematical modeling study generated parametric signatures of stimulus encoding and WM rehearsal and displacement. These signatures led to specific predictions about neurophysiological responses to study manipulations in a priori regions of interest (ROI). Results: Results demonstrated predicted dissociations of activation signatures in several ROIs. Significant patterns of brain response mirroring the encode signature were observed only during the task encode interval and only in the visual cortex and posterior fusiform gyrus. In contrast, significant brain response mirroring the rehearsal/displacement signature was observed only in the dorsolateral prefrontal cortex, inferior frontal gyrus, and supramarginal gyro. Conclusions: Present findings support the separability hypothesis insofar as brain regions that underlie sensory-perceptual processes demonstrated encode signatures whereas brain regions that support WM maintenance demonstrated the rehearsal/displacement signature. These results also provide evidence for the utility of combining mathematical modeling with fMRI to integrate information across cognitive and neural levels of analysis. C1 [McKenna, Benjamin S.; Brown, Gregory G.; Drummond, Sean P. A.; Mano, Quintino R.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [McKenna, Benjamin S.; Brown, Gregory G.; Mano, Quintino R.] Vet Affairs San Diego Healthcare Syst, Mental Illness Res Educ & Clin Ctr, San Diego, CA USA. [Drummond, Sean P. A.] Vet Affairs San Diego Healthcare Syst, Psychol Serv, San Diego, CA USA. [Turner, Travis H.] Ralph H Johnson Vet Affairs Med Ctr, Psychol Serv, Charleston, SC USA. RP Brown, GG (reprint author), 3350 La Jolla Village Dr,Mail Code 116A, La Jolla, CA 92161 USA. EM gbrown@ucsd.edu FU VA Mental Illness Research, Education, and Clinical Center; National Science Foundation [NSF-0729021] FX This research was supported by a VA Mental Illness Research, Education, and Clinical Center grant to the VA Desert Pacific Health care System; by a National Science Foundation Grant NSF-0729021; and by the VA San Diego Center of Excellence for Stress and Mental Health for infrastructure support. NR 56 TC 6 Z9 6 U1 2 U2 9 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0894-4105 J9 NEUROPSYCHOLOGY JI Neuropsychology PD MAR PY 2013 VL 27 IS 2 BP 243 EP 255 DI 10.1037/a0031515 PG 13 WC Psychology, Clinical; Neurosciences; Psychology SC Psychology; Neurosciences & Neurology GA 111NT UT WOS:000316528700011 PM 23527652 ER PT J AU Mechanick, JI Youdim, A Jones, DB Garvey, WT Hurley, DL McMahon, MM Heinberg, LJ Kushner, R Adams, TD Shikora, S Dixon, JB Brethauer, S AF Mechanick, Jeffrey I. Youdim, Adrienne Jones, Daniel B. Garvey, W. Timothy Hurley, Daniel L. McMahon, M. Molly Heinberg, Leslie J. Kushner, Robert Adams, Ted D. Shikora, Scott Dixon, John B. Brethauer, Stacy TI Clinical Practice Guidelines for the Perioperative Nutritional, Metabolic, and Nonsurgical Support of the Bariatric Surgery Patient-2013 Update: Cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery SO SURGERY FOR OBESITY AND RELATED DISEASES LA English DT Article DE Bariatric surgery; Obesity; Metabolic surgery; Diabetes surgery; Metabolic syndrome; Clinical practice guidelines; Best practice guidelines; Weight loss surgery ID Y-GASTRIC-BYPASS; LAPAROSCOPIC-SLEEVE-GASTRECTOMY; TYPE-2 DIABETES-MELLITUS; WEIGHT-LOSS SURGERY; PROSPECTIVE-RANDOMIZED-TRIAL; OF-THE-LITERATURE; BODY-MASS INDEX; OUTCOMES LONGITUDINAL DATABASE; HELICOBACTER-PYLORI INFECTION; CARDIOVASCULAR RISK-FACTORS AB The development of these updated guidelines was commissioned by the AACE, TOS, and ASMBS Board of Directors and adheres to the AACE 2010 protocol for standardized production of clinical practice guidelines (CPG). Each recommendation was re-evaluated and updated based on the evidence and subjective factors per protocol. Examples of expanded topics in this update include: the roles of sleeve gastrectomy, bariatric surgery in patients with type-2 diabetes, bariatric surgery for patients with mild obesity, copper deficiency, informed consent, and behavioral issues. There are 74 recommendations (of which 56 are revised and 2 are new) in this 2013 update, compared with 164 original recommendations in 2008. There are 403 citations, of which 33 (8.2%) are EL 1, 131 (32.5%) are EL 2, 170 (42.2%) are EL 3, and 69 (17.1%) are EL 4. There is a relatively high proportion (40.4%) of strong (EL 1 and 2) studies, compared with only 16.5% in the 2008 AACE-TOS-ASMBS CPG. These updated guidelines reflect recent additions to the evidence base. Bariatric surgery remains a safe and effective intervention for select patients with obesity. A team approach to perioperative care is mandatory with special attention to nutritional and metabolic issues. (Surg Obes Relat Dis 2013;9:159-191.) (C) 2013 American Society for Metabolic and Bariatric Surgery. All rights reserved. C1 [Mechanick, Jeffrey I.] Icahn Sch Med Mt Sinai, New York, NY 10128 USA. [Youdim, Adrienne] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Jones, Daniel B.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. [Garvey, W. Timothy] Univ Alabama Birmingham, AACE, Birmingham VA Med Ctr, Birmingham, AL USA. [Hurley, Daniel L.; McMahon, M. Molly] Mayo Clin, Div Endocrinol Diabet Metab & Nutr, AACE, Rochester, MN USA. [Heinberg, Leslie J.] Cleveland Clin, Lerner Coll Med, TOS, BMI Director Behav Serv, Cleveland, OH 44106 USA. [Kushner, Robert] Northwestern Univ, TOS, Feinberg Sch Med, Chicago, IL 60611 USA. [Adams, Ted D.] Univ Utah, Sch Med, Hlth & Fitness Inst, TOS,Intermt Healthcare & Cardiovasc Genet Div, Salt Lake City, UT USA. [Shikora, Scott] Harvard Univ, Brigham & Womens Hosp, ASMBS, Med Sch,Ctr Metab Hlth & Bariatr Surg, Boston, MA 02115 USA. [Dixon, John B.] Baker IDI Heart & Diabet Inst, Melbourne, Vic, Australia. [Brethauer, Stacy] Cleveland Clin, Lerner Coll Med, Bariatr & Metab Inst, ASMBS, Cleveland, OH 44106 USA. RP Mechanick, JI (reprint author), Icahn Sch Med Mt Sinai, 1192 Pk Ave, New York, NY 10128 USA. EM jeffreymechanick@gmail.com NR 395 TC 151 Z9 160 U1 2 U2 28 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1550-7289 J9 SURG OBES RELAT DIS JI Surg. Obes. Relat. Dis. PD MAR-APR PY 2013 VL 9 IS 2 BP 159 EP 191 DI 10.1016/j.soard.2012.12.010 PG 33 WC Surgery SC Surgery GA 117BA UT WOS:000316925900001 PM 23537696 ER PT J AU Udayasankar, J Zraika, S Aston-Mourney, K Subramanian, SL Brooks-Worrell, BM Taborsky, GJ Hull, RL AF Udayasankar, J. Zraika, S. Aston-Mourney, K. Subramanian, S. L. Brooks-Worrell, B. M. Taborsky, G. J. Hull, R. L. TI Rosiglitazone Treatment Does Not Decrease Amyloid Deposition in Transplanted Islets From Transgenic Mice Expressing Human Islet Amyloid Polypeptide SO TRANSPLANTATION PROCEEDINGS LA English DT Article ID DIABETES-MELLITUS; MOUSE ISLETS; HYPERGLYCEMIA; DYSFUNCTION; ACTIVATION; PREVENTS; LANGERHANS; SECRETION; METFORMIN; PANCREAS AB In human islet transplantation, insulin independence decreases over time. We previously showed that amyloid deposition following transplantation of islets from human islet amyloid polypeptide (hIAPP) transgenic mice resulted in B-cell loss and that rosiglitazone treatment decreased islet amyloid deposition and preserved B-cell area in the endogenous pancreas of hIAPP transgenic mice. Thus, we sought to determine if rosiglitazone treatment decreases islet amyloid deposition and the associated B-cell loss after islet transplantation. Streptozocin-diabetic mice were transplanted with 100 islets from hIAPP transgenic (T) mice or nontransgenic (NT) littermates under the kidney capsule and received either rosiglitazone (R) in drinking water or plain drinking water (C). The resultant groups (NTC [n = 11], NTR [n = 9], TC [n = 14], and TR [n = 10]) were followed for 12 weeks after which the graft was removed and processed for histology. Amyloid was detected in nearly all T islet grafts (TC = 13/14, TR = 10/10) but not in NT grafts. Rosiglitazone did not alter amyloid deposition (% graft area occupied by amyloid; TC: 2.15 +/- 0.7, TR: 1.72 +/- 0.66; P = .86). % beta-celligraft area was decreased in the TC grafts compared to NTC (56.2 +/- 3.1 vs 73.8 +/- 1.4; P < .0001) but was not different between TC and TR groups (56.2 +/- 3.1 vs 61.0 +/- 2.9; P = .34). Plasma glucose levels before and after transplantation did not differ between NTC and TC groups and rosiglitazone did not affect plasma glucose levels post islet transplantation. Rosiglitazone did not decrease amyloid deposition in hIAPP transgenic islet grafts. Therefore, rosiglitazone treatment of recipients of amyloid forming islets may not improve transplantation outcomes. C1 VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. RP Hull, RL (reprint author), VA Puget Sound Hlth Care Syst 151, 1660 S Columbian Way, Seattle, WA 98108 USA. EM rhull@u.washington.edu OI Aston-Mourney, Kathryn/0000-0003-1412-6715; Hull, Rebecca/0000-0001-9690-4087 FU Department of Veterans Affairs; VA Puget Sound Health Care System (Seattle, WA, USA); GlaxoSmithKline [DK74404, DK80945, DK017047]; Juvenile Diabetes Research Foundation Postdoctoral Fellowship; American Diabetes Association Mentor-Based Fellowship; University of Washington McAbee Fellowship; NIH [DK007247] FX This work was supported by the Department of Veterans Affairs, VA Puget Sound Health Care System (Seattle, WA, USA), an investigator-initiated research grant from GlaxoSmithKline (GJT), DK74404 (RLH), DK80945 (SZ), DK017047 (University of Washington Diabetes Research Center, Cellular and Molecular Imaging Core), Juvenile Diabetes Research Foundation Postdoctoral Fellowship (JU), American Diabetes Association Mentor-Based Fellowship (KAM), University of Washington McAbee Fellowship (KAM) and NIH-training grant DK007247 (SLS). NR 37 TC 1 Z9 1 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0041-1345 J9 TRANSPL P JI Transplant. Proc. PD MAR PY 2013 VL 45 IS 2 BP 574 EP 579 DI 10.1016/j.transproceed.2012.05.079 PG 6 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA 114WA UT WOS:000316772500019 PM 23267797 ER PT J AU Bhargava, P Lackey, AE Dhand, S Moshiri, M Jambhekar, K Pandey, T AF Bhargava, Puneet Lackey, Amanda E. Dhand, Sabeen Moshiri, Mariam Jambhekar, Kedar Pandey, Tarun TI Radiology Education 2.0-On the Cusp of Change: Part 1. Tablet Computers, Online Curriculums, Remote Meeting Tools and Audience Response Systems SO ACADEMIC RADIOLOGY LA English DT Article DE Radiology education; tablet computers; portable devices ID RESOURCES; RETENTION; INTERNET; FUTURE AB We are in the midst of an evolving educational revolution. Use of digital devices such as smart phones and tablet computers is rapidly increasing among radiologists who now regularly use them for medical, technical, and administrative tasks. These electronic tools provide a wide array of new tools to the radiologists allowing for faster, more simplified, and widespread distribution of educational material. The utility, future potential, and limitations of some these powerful tools are discussed in this article. C1 [Bhargava, Puneet] Univ Washington, Dept Radiol, Seattle, WA 98108 USA. [Bhargava, Puneet] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Lackey, Amanda E.; Jambhekar, Kedar; Pandey, Tarun] Univ Arkansas Med Sci, Dept Radiol, Little Rock, AR 72205 USA. [Dhand, Sabeen] Northwestern Univ, Dept Radiol, Chicago, IL 60611 USA. [Moshiri, Mariam] Univ Washington, Med Ctr, Seattle, WA 98108 USA. RP Bhargava, P (reprint author), Univ Washington, Dept Radiol, Mail Box 358280,1660 S Columbian Way, Seattle, WA 98108 USA. EM bhargp@uw.edu OI Bhargava, Puneet/0000-0002-3849-9666 NR 21 TC 14 Z9 14 U1 0 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1076-6332 J9 ACAD RADIOL JI Acad. Radiol. PD MAR PY 2013 VL 20 IS 3 BP 364 EP 372 DI 10.1016/j.acra.2012.11.002 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 109LE UT WOS:000316369200015 PM 23452483 ER PT J AU Bhargava, P Dhand, S Lackey, AE Pandey, T Moshiri, M Jambhekar, K AF Bhargava, Puneet Dhand, Sabeen Lackey, Amanda E. Pandey, Tarun Moshiri, Mariam Jambhekar, Kedar TI Radiology Education 2.0-On the Cusp of Change: Part 2. eBooks; File Sharing and Synchronization Tools; Websites/Teaching Files; Reference Management Tools and Note Taking Applications SO ACADEMIC RADIOLOGY LA English DT Article ID INTERNET AB Increasing use of smartphones and handheld computers is accompanied by a rapid growth in the other related industries. Electronic books have revolutionized the centuries-old conventional books and magazines markets and have simplified publishing by reducing the cost and processing time required to create and distribute any given book. We are now able to read, review, store, and share various types of documents via several electronic tools, many of which are available free of charge. Additionally, this electronic revolution has resulted in an explosion of readily available Internet-based educational resources for the residents and has paved the path for educators to reach out to a larger and more diverse student population. (C)AUR, 2013 C1 [Bhargava, Puneet] Univ Washington, Dept Radiol, Seattle, WA 98108 USA. [Bhargava, Puneet] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Dhand, Sabeen] Northwestern Univ, Dept Radiol, Chicago, IL 60611 USA. [Moshiri, Mariam] Univ Washington, Med Ctr, Seattle, WA 98108 USA. [Lackey, Amanda E.; Pandey, Tarun; Jambhekar, Kedar] Univ Arkansas Med Sci, Dept Radiol, Little Rock, AR 72205 USA. RP Bhargava, P (reprint author), Univ Washington, Dept Radiol, Mail Box 358280,1660 S Columbian Way, Seattle, WA 98108 USA. EM bhargp@uw.edu OI Bhargava, Puneet/0000-0002-3849-9666 NR 8 TC 13 Z9 13 U1 1 U2 28 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1076-6332 J9 ACAD RADIOL JI Acad. Radiol. PD MAR PY 2013 VL 20 IS 3 BP 373 EP 381 DI 10.1016/j.acra.2012.11.001 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 109LE UT WOS:000316369200016 PM 23452484 ER PT J AU Huang, JV Lu, L Ye, SY Bergman, BC Sparagna, GC Sarraf, M Reusch, JEB Greyson, CR Schwartz, GG AF Huang, Janice V. Lu, Li Ye, Shuyu Bergman, Bryan C. Sparagna, Genevieve C. Sarraf, Mohammad Reusch, Jane E. B. Greyson, Clifford R. Schwartz, Gregory G. TI Impaired contractile recovery after low-flow myocardial ischemia in a porcine model of metabolic syndrome SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE metabolic syndrome; heart; ischemia; reperfusion; contractility; fatty acids; Akt; cardiolipin ID PYRUVATE-DEHYDROGENASE COMPLEX; CORONARY-ARTERY-DISEASE; DIET-INDUCED OBESITY; HIGH-FAT DIET; INSULIN-RESISTANCE; ISCHEMIA/REPERFUSION INJURY; NONDIABETIC PATIENTS; CARDIOVASCULAR RISK; GLUCOSE-METABOLISM; REPERFUSION INJURY AB Huang JV, Lu L, Ye S, Bergman BC, Sparagna GC, Sarraf M, Reusch JE, Greyson CR, Schwartz GG. Impaired contractile recovery after low-flow myocardial ischemia in a porcine model of metabolic syndrome. Am J Physiol Heart Circ Physiol 304: H861-H873, 2013. First published January 18, 2013; doi:10.1152/ajpheart.00535.2012.Clinical metabolic syndrome conveys a poor prognosis in patients with acute coronary syndrome, not fully accounted for by the extent of coronary atherosclerosis. To explain this observation, we determined whether postischemic myocardial contractile and metabolic function are impaired in a porcine dietary model of metabolic syndrome without atherosclerosis. Micropigs (n = 28) were assigned to a control diet (low fat, no added sugars) or an intervention diet (high saturated fat and simple sugars, no added cholesterol) for 7 mo. The intervention diet produced obesity, hypertension, dyslipidemia, and impaired glucose tolerance, but not atherosclerosis. Under open-chest, anesthetized conditions, pigs underwent 45 min of low-flow myocardial ischemia and 120 min of reperfusion. In both diet groups, contractile function was similar at baseline and declined similarly during ischemia. However, after 120 min of reperfusion, regional work recovered to 21 +/- 12% of baseline in metabolic syndrome pigs compared with 61 +/- 13% in control pigs (P = 0.01). Ischemiareperfusion caused a progressive decline in mechanical/metabolic efficiency (regional work/O-2 consumption) in metabolic syndrome hearts, but not in control hearts. Metabolic syndrome hearts demonstrated altered fatty acyl composition of cardiolipin and increased Akt phosphorylation in both ischemic and nonischemic regions, suggesting tonic activation. Metabolic syndrome hearts used more fatty acid than control hearts (P = 0.03). When fatty acid availability was restricted by prior insulin exposure, differences between groups in postischemic contractile recovery and mechanical/metabolic efficiency were eliminated. In conclusion, pigs with characteristics of metabolic syndrome demonstrate impaired contractile and metabolic recovery after low-flow myocardial ischemia. Contributory mechanisms may include remodeling of cardiolipin, abnormal activation of Akt, and excessive utilization of fatty acid substrates. C1 [Huang, Janice V.; Lu, Li; Ye, Shuyu; Sparagna, Genevieve C.; Sarraf, Mohammad; Greyson, Clifford R.; Schwartz, Gregory G.] Vet Affairs Med Ctr, Cardiol Sect, Denver, CO USA. [Huang, Janice V.; Lu, Li; Ye, Shuyu; Sarraf, Mohammad; Greyson, Clifford R.; Schwartz, Gregory G.] Univ Colorado, Sch Med, Div Cardiol, Aurora, CO USA. [Bergman, Bryan C.; Reusch, Jane E. B.] Univ Colorado, Sch Med, Div Endocrinol & Metab, Aurora, CO USA. [Sparagna, Genevieve C.] Univ Colorado, Dept Integrat Physiol, Boulder, CO 80309 USA. [Reusch, Jane E. B.] Vet Affairs Med Ctr, Endocrinol & Metab Sect, Denver, CO USA. RP Schwartz, GG (reprint author), Denver Vet Affairs Med Ctr, Cardiol Sect 111B, 1055 Clermont St, Denver, CO 80220 USA. EM Gregory.Schwartz@va.gov FU National Heart, Lung, and Blood Institute [HL-049944]; Medical Research Service of the Department of Veterans Affairs FX This work was supported by National Heart, Lung, and Blood Institute Grant HL-049944 (to G. G. Schwartz) and the Medical Research Service of the Department of Veterans Affairs. NR 63 TC 3 Z9 3 U1 0 U2 6 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD MAR PY 2013 VL 304 IS 6 BP H861 EP H873 DI 10.1152/ajpheart.00535.2012 PG 13 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 107HM UT WOS:000316206400010 PM 23335793 ER PT J AU Singh, NM Husain, S AF Singh, N. M. Husain, S. CA AST Infect Dis Community Practice TI Aspergillosis in Solid Organ Transplantation SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article DE Antifungal; aspergillosis; invasive fungal infections; opportunistic infection; pulmonary infection ID INVASIVE FUNGAL-INFECTIONS; COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM-CELL; B LIPID COMPLEX; CHRONIC GRANULOMATOUS-DISEASE; SURVEILLANCE NETWORK TRANSNET; BRONCHOALVEOLAR LAVAGE FLUID; POLYMERASE-CHAIN-REACTION; AMPHOTERICIN-B; LUNG TRANSPLANTATION C1 [Singh, N. M.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Singh, N. M.] Univ Pittsburgh, Pittsburgh, PA USA. [Husain, S.] Univ Toronto, Univ Hlth Network Multiorgan Transplant, Toronto, ON, Canada. RP Singh, NM (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. EM nis5@pitt.edu FU Pfizer; Astellas FX The authors of this manuscript have conflicts of interest to disclose as described by the American Journal of Transplantation. Dr. Singh has received investigator initiated grant support from Pfizer and Astellas. Dr. Husain receives grant support from Pfizer and Astellas and is a consultant for Merck. NR 139 TC 52 Z9 52 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD MAR PY 2013 VL 13 SU 4 SI SI BP 228 EP 241 DI 10.1111/ajt.12115 PG 14 WC Surgery; Transplantation SC Surgery; Transplantation GA 103HY UT WOS:000315907900025 PM 23465016 ER PT J AU Baddley, JW Forrest, GN AF Baddley, J. W. Forrest, G. N. CA AST Infect Dis Community Practice TI Cryptococcosis in Solid Organ Transplantation SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article DE Antifungal; cryptococcus; fungal infection; fungal meningitis; meningitis; pulmonary infection ID RECONSTITUTION INFLAMMATORY SYNDROME; INVASIVE FUNGAL-INFECTIONS; CALCINEURIN-INHIBITOR AGENTS; HEMATOPOIETIC STEM-CELL; B LIPID COMPLEX; AMPHOTERICIN-B; PULMONARY CRYPTOCOCCOSIS; NEOFORMANS INFECTION; PACIFIC-NORTHWEST; BRITISH-COLUMBIA C1 [Baddley, J. W.] Univ Alabama Birmingham, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA. [Baddley, J. W.] Birmingham Vet Affairs, Birmingham, AL USA. [Forrest, G. N.] Portland VA Med Ctr, Portland, OR USA. RP Baddley, JW (reprint author), Univ Alabama Birmingham, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA. EM jbaddley@uab.edu NR 86 TC 19 Z9 19 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD MAR PY 2013 VL 13 SU 4 SI SI BP 242 EP 249 DI 10.1111/ajt.12116 PG 8 WC Surgery; Transplantation SC Surgery; Transplantation GA 103HY UT WOS:000315907900026 PM 23465017 ER PT J AU Doran, KM Colucci, AC Hessler, RA Ngai, CK Williams, ND Wallach, AB Tanner, M Allen, MH Goldfrank, LR Wall, SP AF Doran, Kelly M. Colucci, Ashley C. Hessler, Robert A. Ngai, Calvin K. Williams, Nicholas D. Wallach, Andrew B. Tanner, Michael Allen, Machelle H. Goldfrank, Lewis R. Wall, Stephen P. TI An Intervention Connecting Low-Acuity Emergency Department Patients With Primary Care: Effect on Future Primary Care Linkage SO ANNALS OF EMERGENCY MEDICINE LA English DT Article ID FOLLOW-UP COMPLIANCE; PREVENTIVE CARE; MISSING DATA; UNINSURED EMERGENCY; PEDIATRIC EMERGENCY; ADVANCED STATISTICS; CLINICAL-RESEARCH; CONTROLLED-TRIAL; ACUTE ASTHMA; IMPROVE AB Study objective: Our objective is to determine whether a point-of-care intervention that navigates willing, low-acuity patients from the emergency department (ED) to a Primary Care Clinic will increase future primary care follow-up. Methods: We conducted a quasi-experimental trial at an urban safety net hospital. Adults presenting to the ED for select low-acuity problems were eligible. Patients were excluded if arriving by emergency medical services, if febrile, or if the triage nurse believed they required ED care. We enrolled 965 patients. Navigators escorted a subset of willing participants to the Primary Care Clinic (in the same hospital complex), where they were assigned a personal physician, were given an overview of clinic services, and received same-day clinic care. The primary outcome was Primary Care Clinic follow-up within 1 year of the index ED visit among patients having no previous primary care provider. Results: In the bivariate intention-to-treat analysis, 50.3% of intervention group patients versus 36.9% of control group patients with no previous primary care provider had at least 1 Primary Care Clinic follow-up visit in the year after the intervention. In the multivariable analysis, the absolute difference in having at least 1 Primary Care Clinic follow-up for the intervention group compared with the control group was 9.3% (95% confidence interval 2.2% to 16.3%). There was no significant difference in the number of future ED visits. Conclusion: A point-of-care intervention offering low-acuity ED patients the opportunity to alternatively be treated at the hospital's Primary Care Clinic resulted in increased future primary care follow-up compared with standard ED referral practices. [Ann Emerg Med. 2013;61:312-321.] C1 [Doran, Kelly M.] Yale Univ, Sch Med, Robert Wood Johnson Fdn, Clin Scholars Program, New Haven, CT USA. [Doran, Kelly M.] US Dept Vet Affairs, New Haven, CT USA. [Colucci, Ashley C.; Hessler, Robert A.; Ngai, Calvin K.; Williams, Nicholas D.; Goldfrank, Lewis R.; Wall, Stephen P.] Bellevue Hosp Ctr, Dept Emergency Med, New York, NY 10016 USA. [Wallach, Andrew B.; Tanner, Michael] Bellevue Hosp Ctr, Div Gen Internal Med, New York, NY 10016 USA. [Allen, Machelle H.] Bellevue Hosp Ctr, Dept Obstet & Gynecol, New York, NY 10016 USA. NYU, Sch Med, New York, NY USA. RP Wall, SP (reprint author), Bellevue Hosp Ctr, Dept Emergency Med, New York, NY 10016 USA. EM stephen.wall@nyumc.org OI Wall, Stephen/0000-0003-3965-5074; Wallach, Andrew/0000-0003-4791-2376; Tanner, Michael/0000-0002-3012-8641 FU Commonwealth Fund FX By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The authors have stated that no such relationships exist. The Primary Care Access Project was supported by a grant from The Commonwealth Fund. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and the preparation, review, or approval of the article. NR 55 TC 12 Z9 12 U1 3 U2 15 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-0644 J9 ANN EMERG MED JI Ann. Emerg. Med. PD MAR PY 2013 VL 61 IS 3 BP 312 EP 321 DI 10.1016/j.annemergmed.2012.10.021 PG 10 WC Emergency Medicine SC Emergency Medicine GA 106TL UT WOS:000316167500013 PM 23261312 ER PT J AU Zhu, X Walton, RG Tian, L Luo, N Ho, SR Fu, Y Garvey, WT AF Zhu, X. Walton, R. G. Tian, L. Luo, N. Ho, S-R. Fu, Y. Garvey, W. T. TI Prostaglandin A(2) Enhances Cellular Insulin Sensitivity via a Mechanism that Involves the Orphan Nuclear Receptor NR4A3 SO HORMONE AND METABOLIC RESEARCH LA English DT Article DE NR4A3; MINOR; insulin sensitivity; prostaglandin A(2); glucose transport; skeletal muscle; C2C12 cells ID 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); GLUCOSE-METABOLISM; ENDOTHELIAL-CELLS; GENE-EXPRESSION; INDUCTION; PRODUCTS; NUR77; IDENTIFICATION; TRANSCRIPTION; SUPERFAMILY AB We have previously reported that members of the NR4A family of orphan nuclear receptors can augment insulin's ability to stimulate glucose transport in adipocytes. In the current study, we endeavored to test for an insulin-sensitizing effect in muscle cells and to identify a potential transactivator. Lentiviral constructs were used to engineer both hyperexpression and shRNA silencing of NR4A3 in C2C12 myocytes. The NR4A3 hyper-expression construct led to a significant increase in glucose transport rates in the presence of maximal insulin while the NR4A3 knock-down exhibited a significant reduction in insulin-stimulated glucose transport rates. Consistently, insulin-mediated AKT phosphorylation was increased by NR4A3 hyperexpression and decreased following shRNA NR4A3 suppression. Then, we examined effects of prostaglandin A(2)(PGA(2)) on insulin action and NR4A3 transactivation. PGA(2) augmented insulin-stimulated glucose uptake in C2C12 myocytes and AKT phosphorylation after 12-h treatment, without significant effects on basal transport or basal AKT phosphorylation. More importantly, we demonstrated that PGA(2) led to a greater improvement in insulin-stimulated glucose rates in NR4A3 over-expressing C2C12 myocytes, when compared with Lac-Z controls stimulated with insulin and PGA(2). Moreover, the sensitizing effect of PGA(2) was significantly diminished in NR4A3 knockdown myocytes compared to scramble controls. These results show for the first time that: (i) PGA(2) augments insulin action in myocytes as manifested by enhanced stimulation of glucose transport and AKT phosphorylation; and (ii) the insulin sensitizing effect is dependent upon the orphan nuclear receptor NR4A3. C1 [Zhu, X.; Tian, L.; Ho, S-R.] Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA. [Walton, R. G.; Luo, N.; Fu, Y.; Garvey, W. T.] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Garvey, W. T.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Zhu, X (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, 1675 Univ Blvd, Birmingham, AL 35294 USA. EM xiaolin@uab.edu FU National Institutes of Health [DK-083562, DK-038764, HL-055782]; Merit Review program of the Department of Veterans Affairs; American Diabetes Association; UAB Diabetes Research and Training Center [P60-DK079626]; UAB Nutrition and Obesity Research Center [P30-DK56336] FX This work was supported from grants from the National Institutes of Health ( DK-083562, DK-038764, HL-055782 to W.T.G.), the Merit Review program of the Department of Veterans Affairs (W.T.G.), and the American Diabetes Association (Y.F.). We gratefully acknowledge the support of the research core facilities of the UAB Diabetes Research and Training Center (P60-DK079626) and the UAB Nutrition and Obesity Research Center (P30-DK56336). NR 29 TC 5 Z9 5 U1 0 U2 8 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0018-5043 J9 HORM METAB RES JI Horm. Metab. Res. PD MAR PY 2013 VL 45 IS 3 BP 213 EP 220 DI 10.1055/s-0032-1327619 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 106ZZ UT WOS:000316185700005 PM 23104421 ER PT J AU Sibila, O Restrepo, MI Anzueto, A AF Sibila, Oriol Restrepo, Marcos I. Anzueto, Antonio TI What is the Best Antimicrobial Treatment for Severe Community-Acquired Pneumonia (Including the Role of Steroids and Statins and Other Immunomodulatory Agents) SO INFECTIOUS DISEASE CLINICS OF NORTH AMERICA LA English DT Article DE Community-acquired infections; Pneumonia; Therapeutics; Intensive care unit ID RESISTANT STAPHYLOCOCCUS-AUREUS; BACTEREMIC PNEUMOCOCCAL PNEUMONIA; INTENSIVE-CARE-UNIT; CONVERTING-ENZYME-INHIBITOR; POPULATION-BASED COHORT; RESPIRATORY-TRACT INFECTIONS; RANDOMIZED CONTROLLED-TRIALS; SEVERE SEPSIS; PSEUDOMONAS-AERUGINOSA; CYTOKINE EXPRESSION AB Community-acquired pneumonia (CAP) is the leading cause of death from infectious diseases in the United States. The mortality rate due to severe CAP has shown little improvement over the past few years, with a rate as high as 50% mainly in patients admitted to intensive care units. Death and adverse outcomes from CAP result from a complex interplay between the pathogen and the host. Several therapies have been tested in patients with severe CAP in recent years. This article reviews recent data regarding different treatments including antimicrobials and adjunctive therapies in patients with severe CAP. C1 [Sibila, Oriol; Restrepo, Marcos I.; Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Sibila, Oriol] Hosp Santa Creu & Sant Pau, Serv Pneumol, Barcelona, Spain. [Restrepo, Marcos I.; Anzueto, Antonio] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Anzueto, A (reprint author), South Texas Vet Hlth Care Syst, Audie L Murphy Div San Antonio, 7400 Merton Minter Blvd,11C6, San Antonio, TX 78229 USA. EM anzueto@uthscsa.edu RI Restrepo, Marcos/H-4442-2014 FU Instituto de Salud Carlos III [BAE11/00102]; Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR); Societat Catalana de Pneumologia (SOCAP); Fundacio Catalana de Pneumologia (FUCAP); National Heart, Lung, and Blood Institute [K23HL096054] FX Financial Support: Dr Sibila is supported by Instituto de Salud Carlos III (BAE11/00102), Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR), Societat Catalana de Pneumologia (SOCAP) and Fundacio Catalana de Pneumologia (FUCAP). Dr Restrepo's time is partially protected by Award Number K23HL096054 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health. The funding agencies had no role in the preparation, review, or approval of the article. The views expressed in this article are those of the author and do not necessarily represent the views of the Department of Veterans Affairs. Conflicts of Interest: Dr Marcos I. Restrepo participated as a consultant in the data safety monitoring board for clinical trials run by Theravance, Trius, and Pfizer (Wyeth). Dr Antonio Anzueto has served in the speaker's bureaus of Pfizer, Boehringer Ingelheim, GlaxoSmithKline, Astra-Zeneca; and in the advisory board of Glaxo SmithKline, Boehringer Ingelheim, Bayer-Healthcare, and Pfizer. NR 110 TC 11 Z9 12 U1 0 U2 9 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0891-5520 EI 1557-9824 J9 INFECT DIS CLIN N AM JI Infect. Dis. Clin. North Am. PD MAR PY 2013 VL 27 IS 1 BP 133 EP + DI 10.1016/j.idc.2012.11.014 PG 16 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 104YH UT WOS:000316032200011 PM 23398870 ER PT J AU Melmed, GY Siegel, CA Spiegel, BM Allen, JI Cima, R Colombel, JF Dassopoulos, T Denson, LA Dudley-Brown, S Garb, A Hanauer, SB Kappelman, MD Lewis, JD Lynch, I Moynihan, A Rubin, DT Sartor, RB Schwartz, RM Wolf, DC Ullman, TA AF Melmed, Gil Y. Siegel, Corey Allan Spiegel, Brennan M. Allen, John I. Cima, Robert Colombel, Jean-Frederic Dassopoulos, Themistocles Denson, Lee A. Dudley-Brown, Sharon Garb, Andrew Hanauer, Stephen B. Kappelman, Michael D. Lewis, James D. Lynch, Isabelle Moynihan, Amy Rubin, David T. Sartor, R. Balfour Schwartz, Ronald M. Wolf, Douglas C. Ullman, Thomas A. TI Quality Indicators for Inflammatory Bowel Disease: Development of Process and Outcome Measures SO INFLAMMATORY BOWEL DISEASES LA English DT Article DE inflammatory bowel disease; Crohn's disease; ulcerative colitis; quality; quality indicators; quality of care; quality measures ID ULCERATIVE-COLITIS; CROHNS-DISEASE; ARTHRITIS CARE; OF-CARE; SET; MANAGEMENT; ADULTS; GUIDELINES; CHILDREN; EXPERTS AB Introduction: Variation in adherence to management guidelines for inflammatory bowel disease (IBD) suggests variable quality of care. Quality indicators (QIs) can be developed to measure the structure, processes, and outcomes of health care delivery. The RAND/UCLA appropriateness method was used to develop a set of process and outcome QIs to define quality of care for IBD. Methods: Guidelines and position papers for IBD published from 2006 to 2011 were reviewed for potential QIs, which were rated by a multidisciplinary panel. Potential process and outcome QIs were discussed at 3 moderated in-person meetings, with pre-meeting and post-meeting confidential electronic voting. Panelists rated the validity and feasibility of QIs on a 1 through 9 scale; disagreement was assessed using a validated index. QIs rated above 8 were selected for the final set. Results: More than 500 potential process QIs were extracted from guidelines. Following ratings and discussion by the first panel, 35 process QIs were selected for literature review. After the second panel, 10 process QIs were included in the final set. Candidate outcome QIs were then derived from physician, nurse, and patient input and ratings, in addition to outcomes associated with candidate process QIs. None of the top QIs exhibited disagreement. Conclusions: A set of QIs for IBD was developed with expert interpretation of the literature and multidisciplinary input. Outcome QIs focused largely on remission and quality of life, whereas process QIs were aimed at therapeutic optimization and patient safety. Evaluation of these QIs in clinical practice is needed to assess the correlation of performance on process QIs with performance on outcome QIs. (Inflamm Bowel Dis 2013;19:662-668) C1 [Melmed, Gil Y.] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA. [Melmed, Gil Y.; Spiegel, Brennan M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Siegel, Corey Allan; Moynihan, Amy] Dartmouth Hitchcock Med Ctr, Dept Gastroenterol, Lebanon, NH 03766 USA. [Siegel, Corey Allan; Moynihan, Amy] New Hampshire & Dartmouth Inst Hlth Policy & Clin, Hanover, NH USA. [Spiegel, Brennan M.] VA Greater Angeles Healthcare Syst, Dept Gastroenterol, Los Angeles, CA USA. [Spiegel, Brennan M.] CURE Digest Dis Res Ctr, Los Angeles, CA USA. [Spiegel, Brennan M.] UCLA VA Ctr Outcomes Res & Educ, Los Angeles, CA USA. [Allen, John I.] Minnesota Gastroenterol, Dept Gastroenterol, Minneapolis, MN USA. [Cima, Robert] Mayo Clin, Dept Surg, Rochester, MN USA. [Colombel, Jean-Frederic] Icahn Sch Med Mt Sinai, New York, NY USA. [Dassopoulos, Themistocles] Washington Univ Sch Med, Dept Gastroenterol, St Louis, MO USA. [Denson, Lee A.] Cincinnati Childrens Hosp, Dept Pediat, Cincinnati, OH USA. [Dudley-Brown, Sharon] Johns Hopkins Univ, JSch Med & Nursing, Baltimore, MD USA. [Garb, Andrew] Loeb & Loeb, Los Angeles, CA USA. [Hanauer, Stephen B.; Rubin, David T.] Univ Chicago, Dept Med & Gastroenterol, Chicago, IL 60637 USA. [Kappelman, Michael D.] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA. [Sartor, R. Balfour] Univ N Carolina, Dept Med, Chapel Hill, NC USA. [Sartor, R. Balfour] Univ N Carolina, Dept Microbiol, Chapel Hill, NC USA. [Sartor, R. Balfour] Univ N Carolina, Dept Immunol, Chapel Hill, NC USA. [Lewis, James D.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Lynch, Isabelle] VA San Francisco, Dept Gastroenterol, San Francisco, CA USA. [Schwartz, Ronald M.] Minnesota Gastroenterol, Minneapolis, MN USA. [Wolf, Douglas C.] Atlanta Gastroenterol Associates, Atlanta, GA USA. [Ullman, Thomas A.] Mt Sinai Sch Med, Dept Med, Dr Henry Janowitz Div Gastroenterol, New York, NY USA. RP Melmed, GY (reprint author), 8730 Alden Dr,203B, Los Angeles, CA 90048 USA. EM melmedg@cshs.org FU Crohn's and Colitis Foundation of America; Pfizer; Abbott Laboratories; Janssen Pharmaceuticals; Salix; UCB; Warner-Chilcott; National Institute of Diabetes and Digestive and Kidney Diseases [K23DK078678, DK088957]; Shire; Centocor; Takeda; Janssen; Abbott Laboratories, Abbott Park, Illinois; Abbott Laboratories, Abbott Park, Paris; Abbott Laboratories, Abbott Park, France; Centocor, Malvern, PA; Falk Pharma, Freiburg, Germany; Given Imaging, Hamburg, Germany; Merck Co., Inc., NJ; Schering Plough Corporation, Kenilworth, NJ; Shire Pharmaceuticals, Wayne, PA; UCB Pharma; Abbott/Abvie; Prometheus FX Supported by the Crohn's and Colitis Foundation of America.; G. Y. Melmed: consultant (Janssen, Celgene, Amgen, Given Imaging), non-CME speaker (Abbott Laboratories, Prometheus Labs), and research support (Pfizer); co-chairs the Quality of Care committee of the CCFA.; C. A. Siegel serves as a consultant to Abbott Laboratories, Elan, Given Imaging, Janssen Pharmaceuticals, Millenium, Salix and UCB; received research support from Abbott Laboratories, Janssen Pharmaceuticals, Salix, UCB and Warner-Chilcott, and has delivered CME talks for Abbott Laboratories and Janssen Pharmaceuticals. Supported by Grant Number K23DK078678 from the National Institute of Diabetes and Digestive and Kidney Diseases. Dr. Siegel is the Chair of the Quality of Care committee of the CCFA.; J. D. Lewis: served as a consultant for Amgen, Millennium Pharmaceuticals, and Abbott. He has served on a Data and Safety Monitoring Board for clinical trials sponsored by Pfizer. He has received research support from Shire, Centocor, and Takeda. He has provided expert opinion related to legal matters on behalf of Roche. Dr. Lewis is Chair of the Crohn's and Colitis Foundation of America's National Scientific Advisory Committee.; M. D. Kappelman: serves as a consultant to GlaxoSmithKline and Cubist, and has received research support from Janssen. Dr. Kappelman is supported by Grant Number DK088957 from the National Institute of Diabetes and Digestive and Kidney Diseases. Dr. Kappelman is the Chair of the Professional Education Committee and a member of the Quality of Care committee of the CCFA.; J.-F. Colombel: Consultant: Abbott Laboratories, Abbott Park, Illinois; Amgen, Thousand Oaks, CA; Biogen Idec Inc, Cambridge, M; Boehringer-Ingelheim, Inc., Ridgefield, CT; Bristol Meyers Squibb, Princeton, NJ; Cellerix SL, Madrid, Spain; Chemocentryx, Inc., Mountain View, CA; Centocor, Malvern, PA; Cosmo Technologies, Ltd, Milan, Italy; Elan Pharmaceuticals, Inc., San Francisco, CA; Genentech, San Francisco, CA; Giuliani SPA, Milano, It; Given Imaging, Hamburg, Ge; Glaxo Smith Kline, Research Triangle Park, NC; Immune Pharmaceuticals Ltd., ISR; Merck & Co., Inc., NJ; Millenium Pharmaceuticals Inc., Cambridge, MA; Neovacs SA, Paris, F; Ocerra Therapeutics, Inc. (previously named Renovia, Inc.), San Diego, CA; Pfizer Inc., New York, NY; Prometheus, San Diego, CA; Sanofi, USA; Schering Plough Corporation, Kenilworth, NJ; Shire Pharmaceuticals, Wayne, PA; Synta Pharmaceutical Corporation, Lexington, MA; Takeda, Philadelphia, PE; Teva Pharmaceuticals, North Wales, PA and Petah Tikva, Israel; Therakos, Exton, PA; TXcell, Valbonne, France; UCB Pharma (previously named Celltech Therapeutics, Ltd), Atlanta, GA and Brussels, Belgium; Wyeth Pharmaceuticals, Collegeville, PA. Speakers fees: Abbott Laboratories, Abbott Park, Illinois and Paris, France; Centocor, Malvern, PA; Falk Pharma, Freiburg, Germany; Ferring, Denmark and Paris, France; Given Imaging, Hamburg, Germany; Merck & Co., Inc., NJ; Schering Plough Corporation, Kenilworth, NJ and Paris, France; Shire Pharmaceuticals, Wayne, PA; UCB Pharma, Atlanta GA and Brussels, Belgium and Paris, France.; D. T. Rubin: Consultant: Abbott/Abbvie, UCB, Janssen, Prometheus. Grant support: Abbott/Abvie, UCB, Prometheus, Salix. CCFA: Professional Education Committee member, Chair, Professional Membership Task Force. NR 29 TC 42 Z9 47 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD MAR PY 2013 VL 19 IS 3 BP 662 EP 668 DI 10.1097/mib.0b013e31828278a2 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 110NG UT WOS:000316450200038 PM 23388547 ER PT J AU Adappa, ND Howland, TJ Palmer, JN Kennedy, DW Doghramji, L Lysenko, A Reed, DR Lee, RJ Cohen, NA AF Adappa, Nithin D. Howland, Timothy J. Palmer, James N. Kennedy, David W. Doghramji, Laurel Lysenko, Anna Reed, Danielle R. Lee, Robert J. Cohen, Noam A. TI Genetics of the taste receptor T2R38 correlates with chronic rhinosinusitis necessitating surgical intervention SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY LA English DT Article DE innate immunity; antimicrobial; nitric oxide; mucociliary clearance; endoscopic sinus surgery ID SOLITARY CHEMOSENSORY CELLS; ENDOSCOPIC SINUS SURGERY; PHENYLTHIOCARBAMIDE; BIOFILMS; IMPACT; LONG AB Background We recently demonstrated the bitter taste receptor T2R38 upregulates sinonasal mucosal innate defense in response to gram-negative quorum-sensing molecules through increased nitric oxide production and mucociliary clearance. T2R38 was initially identified in the quest to understand the variability in bitter taste perception to the compound phenylthiocarbamide (PTC) and demonstrated to have polymorphisms generating diplotypes dividing people into PTC supertasters, heterozygotes (with variable PTC detection), and nontasters. We have further demonstrated that sinonasal epithelial cultures derived from supertasters significantly increase innate defenses in response to gram-negative quorum-sensing molecules compared with sinonasal cultures derived from heterozygotes and nontaster individuals. Based on this data, we hypothesize that supertasters are less likely to require sinus surgery compared with heterozygous or nontasters and that supertasters have improved surgical outcomes. Methods Banked sinonasal tissue samples from patients who had undergone primary functional endoscopic sinus surgery at the University of Pennsylvania or the Philadelphia Veterans Affairs Medical Center were genotyped for T2R38 and compared to the expected population distribution. Necessity for additional antibiotic therapy following the postoperative healing time frame was evaluated. Results A total of 28 patients were included in the study. Only 1 supertaster was identified (expected 5.6, p < 0.043). Additionally, 14 heterozygous and 13 nontaster patients were identified. Conclusion This pilot study investigating the genetics of the bitter taste receptor T2R38 in the context of primary sinonasal surgery demonstrates supertaster patients are less likely to need surgical intervention for chronic rhinosinusitis. Additional study is necessary to ascertain postsurgical outcomes. C1 [Adappa, Nithin D.; Howland, Timothy J.; Palmer, James N.; Kennedy, David W.; Doghramji, Laurel; Lee, Robert J.; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA. [Lysenko, Anna; Reed, Danielle R.] Monell Chem Senses Ctr, Philadelphia, PA 19104 USA. [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Surg Serv, Philadelphia, PA USA. RP Cohen, NA (reprint author), Hosp Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Ravdin Bldg 5th Floor,3400 Spruce St, Philadelphia, PA 19104 USA. EM noam.cohen@uphs.upenn.edu OI Cohen, Noam/0000-0002-9462-3932; Reed, Danielle/0000-0002-4374-6107; Lee, Robert/0000-0001-5826-6686 NR 16 TC 31 Z9 31 U1 1 U2 15 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2042-6976 J9 INT FORUM ALLERGY RH JI Int. Forum Allergy Rhinol. PD MAR PY 2013 VL 3 IS 3 BP 184 EP 187 DI 10.1002/alr.21140 PG 4 WC Otorhinolaryngology SC Otorhinolaryngology GA 108BE UT WOS:000316265000004 PM 23322450 ER PT J AU Thomas, ML Brown, GG Gur, RC Hansen, JA Nock, MK Heeringa, S Ursano, RJ Stein, MB AF Thomas, Michael L. Brown, Gregory G. Gur, Ruben C. Hansen, John A. Nock, Matthew K. Heeringa, Steven Ursano, Robert J. Stein, Murray B. TI Parallel psychometric and cognitive modeling analyses of the Penn Face Memory Test in the Army Study to Assess Risk and Resilience in Servicemembers SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Article DE Psychometric modeling; Item response theory; Cognitive modeling; Penn Face Memory Test; Army Study to Assess Risk and Resilience in Servicemembers ID MEDIAL TEMPORAL-LOBE; ITEM RESPONSE THEORY; CEREBRAL BLOOD-FLOW; RECOGNITION MEMORY; CONSTRUCT-VALIDITY; SIGNAL-DETECTION; INDIVIDUAL-DIFFERENCES; VALIDATION; RECOLLECTION; PSYCHOLOGY AB Objective: The psychometric properties of the Penn Face Memory Test (PFMT) were investigated in a large sample (4,236 participants) of U.S. Army Soldiers undergoing computerized neurocognitive testing. Data were drawn from the initial phase of the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS), a large-scale study directed towards identifying risk and resilience factors for suicidal behavior and other stress-related disorders in Army Soldiers. In this paper, we report parallel psychometric and cognitive modeling analyses of the PFMT to determine whether ability estimates derived from the measure are precise and valid indicators of memory in the Army STARRS sample. Method: Single-sample cross-validation methodology combined with exploratory factor and multidimensional item response theory techniques were used to explore the latent structure of the PFMT. To help resolve rotational indeterminacy of the exploratory solution, latent constructs were aligned with parameter estimates derived from an unequal-variance signal detection model. Results: Analyses suggest that the PFMT measures two distinct latent constructs, one associated with memory strength and one associated with response bias, and that test scores are generally precise indicators of ability for the majority of Army STARRS participants. Conclusions: These findings support the use of the PFMT as a measure of major constructs related to recognition memory and have implications for further cognitivepsychometric model development. C1 [Thomas, Michael L.; Brown, Gregory G.; Stein, Murray B.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Brown, Gregory G.] VA San Diego Healthcare Syst, San Diego, CA USA. [Gur, Ruben C.; Hansen, John A.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Gur, Ruben C.; Hansen, John A.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Nock, Matthew K.] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA. [Heeringa, Steven] Univ Michigan, Inst Social Res, Ann Arbor, MI USA. [Ursano, Robert J.] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Bethesda, MD 20814 USA. RP Brown, GG (reprint author), San Diego VA Med Ctr, Psychol Serv 116B, 3350 La Jolla Village Dr, San Diego, CA 92161 USA. EM gbrown@ucsd.edu FU Department of the Army; U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Mental Health (NIH/NIMH) [U01MH087981] FX Army STARRS was sponsored by the Department of the Army and funded under cooperative agreement U01MH087981 with the U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Mental Health (NIH/NIMH). The contents are solely the responsibility of the authors and do not necessarily represent the views of the Department of Health and Human Services, NIMH, the Department of the Army, or the Department of Defense. NR 70 TC 10 Z9 10 U1 14 U2 28 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1380-3395 EI 1744-411X J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PD MAR 1 PY 2013 VL 35 IS 3 BP 225 EP 245 DI 10.1080/13803395.2012.762974 PG 21 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 104IM UT WOS:000315985900001 PM 23383967 ER PT J AU Melrose, RJ Harwood, D Khoo, T Mandelkern, M Sultzer, DL AF Melrose, Rebecca J. Harwood, Dylan Khoo, Theresa Mandelkern, Mark Sultzer, David L. TI Association between cerebral metabolism and Rey-Osterrieth Complex Figure Test performance in Alzheimer's disease SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Article DE Alzheimer's disease; ReyOsterrieth Complex Figure; Fluorodeoxyglucose positron emission tomography; Visuospatial; Construction ID CLOCK DRAWING TEST; PREDICT INSTRUMENTAL ACTIVITIES; MILD COGNITIVE IMPAIRMENT; FUNCTIONAL ABILITIES; BLOOD-FLOW; BRAIN; DEMENTIA; DISTURBANCES; OBJECT; DIAGNOSIS AB The copy condition of the ReyOsterrieth Complex Figure (ROCF) is sensitive to Alzheimer's disease (AD) pathology, but its neural correlates remain unclear. We used fluorodeoxyglucose positron emission tomography (FDGPET) to elucidate this association in 77 patients with probable AD. We observed a correlation between ROCF and metabolic rate of bilateral temporalparietal cortex and occipital lobe, and right frontal lobe. Global and local elements of the ROCF correlated with metabolic rate of these same regions. The copy approach correlated with right lateral temporal cortex. The ROCF appears reflective of posterior temporalparietal cortex functioning, highlighting the role of visuospatial processing in constructional abilities in AD. C1 [Melrose, Rebecca J.; Harwood, Dylan; Khoo, Theresa; Sultzer, David L.] VA Greater Los Angeles Healthcare Syst, Brain Behav & Aging Res Ctr, Los Angeles, CA USA. [Melrose, Rebecca J.; Harwood, Dylan; Sultzer, David L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Mandelkern, Mark] VA Greater Los Angeles Healthcare Syst, Nucl Med Serv, Los Angeles, CA USA. [Mandelkern, Mark] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA. RP Melrose, RJ (reprint author), West Los Angeles VA Healthcare Syst, Bldg 401,Room A209,11301 Wilshire Blvd,116AE, Los Angeles, CA 90073 USA. EM rjmelrose@ucla.edu FU Department of Veterans Affairs; National Institutes of Health (NIH) [R01 MH56031]; Forest Research Institute FX Support was provided by the Department of Veterans Affairs (Merit Review to D. Sultzer and Career Development Award to R. Melrose) and National Institutes of Health (NIH; R01 MH56031). David Sultzer has received research grant support from Forest Research Institute. Potential conflicts to study participants were disclosed. NR 61 TC 6 Z9 6 U1 3 U2 11 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1380-3395 J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PD MAR 1 PY 2013 VL 35 IS 3 BP 246 EP 258 DI 10.1080/13803395.2012.763113 PG 13 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 104IM UT WOS:000315985900002 PM 23387510 ER PT J AU Christophi, CA Resnick, HE Ratner, RE Temprosa, M Fowler, S Knowler, WC Shamoon, H Barrett-Connor, E Kahn, SE AF Christophi, C. A. Resnick, H. E. Ratner, R. E. Temprosa, M. Fowler, S. Knowler, W. C. Shamoon, H. Barrett-Connor, E. Kahn, S. E. CA Diabet Prevention Program Res Grp TI Confirming Glycemic Status in the Diabetes Prevention Program: Implications for Diagnosing Diabetes in High Risk Adults SO JOURNAL OF DIABETES AND ITS COMPLICATIONS LA English DT Article DE Diabetes mellitus; Screening; Epidemiology ID IMPAIRED GLUCOSE-TOLERANCE; NUTRITION EXAMINATION SURVEY; CAUCASIAN POPULATION; FASTING GLUCOSE; PREVALENCE; HEALTH; HOORN AB Aims: To examine the ability of fasting plasma glucose (FPG) and/or 2-h glucose to confirm diabetes and to determine the proportion of participants with HbA1c >= 6.5%. Methods: Diabetes confirmation rates were calculated after a single elevated FPG and/or 2-h glucose on an oral glucose tolerance test (OGTT) using a confirmatory OGTT performed within 6 weeks. Results: 772 (24%) participants had elevated FPG or 2-h glucose on an OGTT that triggered a confirmation visit. There were 101 triggers on FPG alone, 574 on 2-h glucose alone, and 97 on both. Only 47% of participants who triggered had confirmed diabetes. While the confirmation rate for FPG was higher than that for 2-h glucose, the larger number of 2-h glucose triggers resulted in 87% of confirmed cases triggering on 2-h glucose. Confirmation rates increased to 75% among persons with FPG >= 126 mg/dl and HbA1c >= 6.5%. Conclusions: Only half of the persons with elevated FPG and IGT were subsequently confirmed to have diabetes. At current diagnostic levels, more persons trigger on 2-h glucose than on FPG, but fewer of these persons have their diagnoses confirmed. In individuals with FPG >= 126 mg/dl and HbA1c >= 6.5%, the confirmation rate was increased. (C) 2013 Elsevier Inc. All rights reserved. C1 [Christophi, C. A.; Temprosa, M.; Fowler, S.] George Washington Univ, Ctr Biostat, Rockville, MD 20852 USA. [Resnick, H. E.] Amer Assoc Homes & Serv Aging, Inst Future Aging Serv, Washington, DC USA. [Resnick, H. E.] Georgetown Univ, Washington, DC USA. [Ratner, R. E.] MedStar Res Inst, Hyattsville, MD USA. [Knowler, W. C.] NIDDKD, Phoenix, AZ USA. [Shamoon, H.] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Barrett-Connor, E.] Univ Calif San Diego, San Diego, CA 92103 USA. [Kahn, S. E.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Kahn, S. E.] Univ Washington, Seattle, WA 98195 USA. RP Christophi, CA (reprint author), George Washington Univ, Ctr Biostat, Diabet Prevent Program Coordinating Ctr, Rockville, MD 20852 USA. EM dppmail@bsc.gwu.edu RI Altshuler, David/A-4476-2009; de Bakker, Paul/B-8730-2009; Uwaifo, Gabriel/M-2361-2016 OI Altshuler, David/0000-0002-7250-4107; de Bakker, Paul/0000-0001-7735-7858; Uwaifo, Gabriel/0000-0002-6962-9304; Shamoon, Harry/0000-0002-5014-5211; Franks, Paul/0000-0002-0520-7604; Kahn, Steven/0000-0001-7307-9002 FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health; NIDDK; Indian Health Service; Office of Research on Minority Health; National Institute of Child Health and Human Development; National Institute on Aging; Centers for Disease Control and Prevention; Department of Veterans Affairs; American Diabetes Association; intramural research program of the NIDDK; McKesson BioServices Corp.; Matthews Media Group, Inc.; Henry M. Jackson Foundation; Coordinating Center FX The Investigators gratefully acknowledge the commitment and dedication of the participants of the DPP. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health provided funding to the clinical centers and the Coordinating Center for the design and conduct of the study; collection, management, analysis, and interpretation of the data. The Southwestern American Indian Centers were supported directly by the NIDDK and the Indian Health Service. The General Clinical Research Center Program, National Center for Research Resources and Department of Veteran Affairs supported data collection at many of the clinical centers. Funding for data collection and participant support was also provided by the Office of Research on Minority Health, the National Institute of Child Health and Human Development, the National Institute on Aging, the Centers for Disease Control and Prevention, The Department of Veterans Affairs and the American Diabetes Association. Bristol-Myers Squibb and Parke-Davis provided medication. This research was also supported, in part, by the intramural research program of the NIDDK. LifeScan Inc., Health O Meter, Hoechst Marion Roussel, Inc., Merck-Medco Managed Care, Inc., Merck and Co., Nike Sports Marketing, Slim Fast Foods Co., and Quaker Oats Co. donated materials, equipment, or medicines for concomitant conditions. McKesson BioServices Corp., Matthews Media Group, Inc., and the Henry M. Jackson Foundation provided support services under subcontract with the Coordinating Center. The opinions expressed are those of the investigators and do not necessarily reflect the views of the Indian Health Service or other funding agencies. A complete list of Centers, investigators, and staff can be found in Appendix 1. NR 20 TC 5 Z9 5 U1 0 U2 21 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1056-8727 J9 J DIABETES COMPLICAT JI J. Diabetes Complications PD MAR-APR PY 2013 VL 27 IS 2 BP 150 EP 157 DI 10.1016/j.jdiacomp.2012.09.012 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 109NG UT WOS:000316374700008 PM 23140912 ER PT J AU Faulenbach, MV Wright, LA Lorenzo, C Utzschneider, KM Goedecke, JH Fujimoto, WY Boyko, EJ McNeely, MJ Leonetti, DL Haffner, SM Kahn, SE AF Faulenbach, Mirjam V. Wright, Lorena A. Lorenzo, Carlos Utzschneider, Kristina M. Goedecke, Julia H. Fujimoto, Wilfred Y. Boyko, Edward J. McNeely, Marguerite J. Leonetti, Donna L. Haffner, Steven M. Kahn, Steven E. CA Amer Diabet Assoc GENNID Study Grp TI Impact of differences in glucose tolerance on the prevalence of a negative insulinogenic index SO JOURNAL OF DIABETES AND ITS COMPLICATIONS LA English DT Article DE Oral glucose tolerance test; Glucose; Insulin; Insulinogenic index; Impaired glucose tolerance; Diabetes ID BETA-CELL FUNCTION; DIABETES-MELLITUS; MEXICAN-AMERICANS; HIGH-RISK; SECRETION; HYPERINSULINEMIA; SENSITIVITY; RESISTANCE; OBESITY; NIDDM AB Objective: To determine the prevalence of a negative insulinogenic index (change in plasma insulin/change in plasma glucose from 0 to 30 mm) from an oral glucose tolerance test according to glucose tolerance category. Materials and Methods: Data from the San Antonio Heart Study (n = 2494), Japanese American Community Diabetes Study (JACDS; n=594) and Genetics of NIDDM Study (n=1519) were examined. Glucose tolerance was defined by ADA criteria. Results: In the combined cohort, the prevalence of a negative insulinogenic index was significantly higher in diabetes 20/616 (3.2%) compared to normal glucose tolerance 43/2667 (1.6%) (p<0.05). Longitudinally, in the JACDS cohort, the prevalence did not change from baseline (3/594; 0.5%) to 5 (4/505; 0.7%) and 10 years (8/426; 1.9%) (p=0.9) and no subject had a repeat negative insulinogenic index. Conclusions: A negative insulinogenic index occurs at a low prevalence across glucose tolerance categories although more often in diabetes, but without recurrence over time. (C) 2013 Published by Elsevier Inc. C1 [Faulenbach, Mirjam V.; Wright, Lorena A.; Utzschneider, Kristina M.; Fujimoto, Wilfred Y.; Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Faulenbach, Mirjam V.; Wright, Lorena A.; Utzschneider, Kristina M.; Fujimoto, Wilfred Y.; Boyko, Edward J.; Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. [Lorenzo, Carlos; Haffner, Steven M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Clin Epidemiol, San Antonio, TX 78229 USA. [Goedecke, Julia H.; McNeely, Marguerite J.] Univ Cape Town, Dept Human Biol, South African Med Res Council, ZA-7700 Rondebosch, South Africa. [Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Dept Med, Div Gen Internal Med, Seattle, WA USA. [Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA. [Leonetti, Donna L.] Univ Washington, Dept Anthropol, Seattle, WA 98195 USA. RP Kahn, SE (reprint author), VA Puget Sound Hlth Care Syst 151, Seattle, WA 98108 USA. EM skahn@u.washington.edu RI Goedecke, Julia/J-8628-2013; Goedecke, Julia/E-1820-2016 OI Goedecke, Julia/0000-0001-6795-4771; Goedecke, Julia/0000-0001-6795-4771; Kahn, Steven/0000-0001-7307-9002; Boyko, Edward/0000-0002-3695-192X FU Department of Veterans Affairs; NIH in Seattle [DK-002654, DK-007247, DK-017047, DK-031170, DK-035816, HL-049293, RR-000037]; NIH in San Antonio [HL-24799, HL-36820]; American Diabetes Association; Swiss National Foundation [PBZHB-116877] FX We thank the study participants who made this analysis possible. The study was supported in part by the Department of Veterans Affairs, NIH grants, DK-002654, DK-007247, DK-017047, DK-031170, DK-035816, HL-049293 and RR-000037 in Seattle, HL-24799 and HL-36820 in San Antonio, and the American Diabetes Association. MVF was supported by the Swiss National Foundation grant PBZHB-116877. NR 15 TC 3 Z9 3 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1056-8727 J9 J DIABETES COMPLICAT JI J. Diabetes Complications PD MAR-APR PY 2013 VL 27 IS 2 BP 158 EP 161 DI 10.1016/j.jdiacomp.2012.09.011 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 109NG UT WOS:000316374700009 PM 23140910 ER PT J AU Zhu, CW Sano, M Ferris, SH Whitehouse, PJ Patterson, MB Aisen, PS AF Zhu, Carolyn W. Sano, Mary Ferris, Steven H. Whitehouse, Peter J. Patterson, Marian B. Aisen, Paul S. TI Health-Related Resource Use and Costs in Elderly Adults with and without Mild Cognitive Impairment SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE mild cognitive impairment; casecontrol study; medical care; resource use; cost; informal care ID ALZHEIMERS-DISEASE; CLINICAL-TRIALS; CARE UTILIZATION; RATING-SCALE; SELF-REPORTS; DEMENTIA AB Objectives To assess differences in resource use and cost between older adults with and without mild cognitive impairment (MCI) over time. Design Multicenter, longitudinal study. Setting Sixty-eight Alzheimer's Disease Cooperative Study (ADCS) sites in the United States. Participants Two hundred fifty-nine individuals diagnosed with MCI and 107 cognitively normal elderly adults followed annually for 3years. Measurements The Resource Use Instrument (RUI) was used to capture medical and nonmedical care use. Generalized linear latent and mixed models were used to estimate differences in resource use and costs in older adults with and without MCI after controlling for clinical and demographic characteristics. Results At baseline, average annual direct medical cost per person was substantially higher for participants with MCI ($6,499) than for those without ($2,969) P<.001). Informal care use was also substantially higher (33% vs 8.4%, P<.001). Results from multivariate analyses of longitudinal data show that, after controlling for participant and informant characteristics, direct medical costs were 44% higher for participants with MCI than for those without. Participants with MCI were almost five times as likely to use informal care as those without. Number of medical conditions and older age were associated with higher medical cost. Worse functional and cognitive status, older age, being married, and being female were associated with higher likelihood of informal care use. Having an adult child informant was associated with higher likelihood of using informal care. Conclusion The RUI captured differences in resource use and costs between individuals with and without MCI. Clinicians who care for individuals with MCI should address informal care needs early in the disease course. C1 [Zhu, Carolyn W.] Alzheimer Dis Res Ctr, Dept Geriatr & Palliat Med, Bronx, NY USA. [Sano, Mary] Alzheimer Dis Res Ctr, Mt Sinai Sch Med, Dept Psychiat, Bronx, NY USA. [Sano, Mary] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Ferris, Steven H.] NYU, Langone Med Ctr, Alzheimers Dis Ctr, New York, NY USA. [Whitehouse, Peter J.; Patterson, Marian B.] Case Western Reserve Univ, Dept Neurol, Cleveland, OH 44106 USA. [Aisen, Paul S.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. RP Zhu, CW (reprint author), Mt Sinai Sch Med, Dept Geriatr & Palliat Med, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM carolyn.zhu@mssm.edu OI Ferris, Steven/0000-0001-8641-6223 FU National Institute on Aging [U01AG10483]; National Institute on Aging (NIA), National Center for Research Resources, National Institutes of Health (NIH); Baxter; Bristol Myers Squibb; Janssen Alzheimer Immunotherapy; Eisai; Eli Lilly; Medivation; Pfizer; NIA, NIH; Pfizer Inc.; Baxter International Inc.; NIH [NIA U01-AG10483, NIA U01-AG024904, NIA R01-AG030048, R01-AG16381] FX The work was supported by National Institute on Aging Grant U01AG10483. Dr. Sano serves on a scientific advisory board for Medivation, Inc. and as a consultant for Bayer Schering Pharma, Bristol-Meyers Squibb, Elan Corporation, Genentech, Inc., Medivation, Inc., Medpace Inc., Pfizer Inc, Janssen, Takeda Pharmaceutical Company Limited, and United Biosource Corporation and receives research support from the National Institute on Aging (NIA), National Center for Research Resources, National Institutes of Health (NIH).; Dr. Ferris serves as a consultant or advisory board member for Accera, Baxter, Bristol Myers Squibb, Eisai, Intellect Neurosciences, Janssen Alzheimer Immunotherapy, Elan, Eli Lilly, MedAvante, Merck, Merz, Neuronix, Pfizer, and United Biosource and receives research support from Baxter, Bristol Myers Squibb, Janssen Alzheimer Immunotherapy, Eisai, Eli Lilly, Medivation, Pfizer, and the NIA, NIH.; D. Aisen serves on a scientific advisory board for NeuroPhage and as a consultant to Elan Corporation, Wyeth, Eisai Inc., Bristol-Myers Squibb, Eli Lilly and Company, NeuroPhage, Merck & Co., Roche, Amgen, Abbott, Pfizer Inc, Novartis, Bayer, Astellas, Dainippon, Biomarin, Solvay, Otsuka, Daiichi, AstraZeneca, Janssen, Medivation, Inc., Theravance, Cardeus, and Anavex and receives research support from Pfizer Inc., Baxter International Inc., and the NIH (NIA U01-AG10483 (PI), NIA U01-AG024904 (Coordinating Center Director), NIA R01-AG030048 (PI), and R01-AG16381 (Co-I)). NR 29 TC 14 Z9 14 U1 1 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2013 VL 61 IS 3 BP 396 EP 402 DI 10.1111/jgs.12132 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 108ZM UT WOS:000316334900011 PM 23414481 ER PT J AU Buehring, B Hind, J Fidler, E Krueger, D Binkley, N Robbins, J AF Buehring, Bjoern Hind, Jacqueline Fidler, Ellen Krueger, Diane Binkley, Neil Robbins, JoAnne TI Tongue Strength Is Associated with Jumping Mechanography Performance and Handgrip Strength but Not with Classic Functional Tests in Older Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE sarcopenia; swallowing; jumping mechanography; muscle function; tongue strength ID LOWER-EXTREMITY FUNCTION; PHYSICAL PERFORMANCE; LINGUAL EXERCISE; HIP FRACTURE; MUSCLE MASS; SARCOPENIA; AGE; DISABILITY; POWER; HOSPITALIZATION AB Objectives To determine whether classic muscle function tests and jumping mechanography (JM) are related to tongue strength. Design Cross-sectional. Setting Community. Participants Ninety-seven community-dwelling individuals aged 70 and older (49 female, 48 male, mean age 80.7, range 7095) with and without identified sarcopenia. Measurements Participants performed muscle function tests including the Short Physical Performance Battery (SPPB), grip strength, and JM. Isometric tongue strength was evaluated using the Iowa Oral Performance Instrument (IOPI). JM consisted of maximal countermovement jumps performed on a force plate to calculate weight-corrected peak power and jump height. Total body dual-energy X-ray absorptiometry was used to assess appendicular lean mass (ALM) to define sarcopenia based on commonly used ALM/height2 cutoffs. Associations between IOPI measures and other muscle function tests were evaluated. Results Sarcopenia was present in 23.7% (23/97) of this cohort. Anterior isometric tongue pressure was positively correlated with grip strength (P=.003), jump height (P=.01), and power (P=.04). Individuals in the lowest tertile of tongue pressure had lower scores on these muscle function tests than individuals in the other tertiles. Classic functional tests and ALM/height2 were unrelated to tongue strength. Conclusion In older adults with and without sarcopenia, isometric tongue pressure is positively correlated with grip strength and jump height and power. These data support consideration of oropharyngeal functional decline as part of the sarcopenia syndrome. C1 [Buehring, Bjoern; Fidler, Ellen; Krueger, Diane; Binkley, Neil] Univ Wisconsin, Osteoporosis Clin Res Program, Madison, WI 53705 USA. [Buehring, Bjoern; Hind, Jacqueline; Binkley, Neil; Robbins, JoAnne] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53705 USA. [Buehring, Bjoern; Hind, Jacqueline; Binkley, Neil; Robbins, JoAnne] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI USA. RP Buehring, B (reprint author), Univ Wisconsin, Osteoporosis Clin Res Program, 2870 Univ Ave,Suite 100, Madison, WI 53705 USA. EM bbuehring@medicine.wisc.edu RI Buehring, Bjoern/L-5581-2013 OI Buehring, Bjoern/0000-0003-3841-624X FU Merck Co., Inc. FX Sponsored by an investigator initiated research grant from Merck & Co., Inc. Jacqueline Hind was a consultant for Swallow Solutions, LLC, during data collection and analysis for this manuscript. Dr. Binkley is participating in a multicenter trial with Lilly in functional outcomes in older adults. He also consults on the same project. Dr. Robbins serves as the Chief Clinical Research Officer for Swallow Solutions, LLC. All other authors have no conflicts of interest. NR 29 TC 17 Z9 17 U1 3 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2013 VL 61 IS 3 BP 418 EP 422 DI 10.1111/jgs.12124 PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 108ZM UT WOS:000316334900015 PM 23379330 ER PT J AU Neuman, MD Ibrahim, SA Barg, FA Osigwe, C Karlawish, JH AF Neuman, Mark D. Ibrahim, Said A. Barg, Frances A. Osigwe, Chidimma Karlawish, Jason H. TI Race and Patient Preferences for Hip Fracture Care SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Letter C1 [Neuman, Mark D.] Univ Penn, Leonard Davis Inst Hlth Econ, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA. [Ibrahim, Said A.] Vet Affairs Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Ibrahim, Said A.; Karlawish, Jason H.] Univ Penn, Leonard Davis Inst Hlth Econ, Dept Med, Philadelphia, PA 19104 USA. [Barg, Frances A.] Univ Penn, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA. [Osigwe, Chidimma] Louisiana State Univ, Sch Med, New Orleans, LA USA. RP Neuman, MD (reprint author), Univ Penn, Leonard Davis Inst Hlth Econ, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA. FU NIA NIH HHS [P30AG031043] NR 10 TC 1 Z9 1 U1 2 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2013 VL 61 IS 3 BP 468 EP 470 DI 10.1111/jgs.12082 PG 3 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 108ZM UT WOS:000316334900031 PM 23496189 ER PT J AU Deffebach, ME Fuss, C AF Deffebach, Mark E. Fuss, Cristina TI Ground Glass Nodules: Just the Beginning SO JOURNAL OF THORACIC ONCOLOGY LA English DT Editorial Material ID FLEISCHNER-SOCIETY; GUIDELINES; MANAGEMENT C1 [Deffebach, Mark E.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. [Fuss, Cristina] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Deffebach, ME (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, 3710 SW US Vet Hosp Rd,P3PULM, Portland, OR 97201 USA. EM deffebac@ohsu.edu NR 4 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD MAR PY 2013 VL 8 IS 3 BP 257 EP 258 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA 107HG UT WOS:000316205600008 PM 23407555 ER PT J AU Wong, ML Clarke, CA Yang, J Hwang, J Hiatt, RA Wang, S AF Wong, Melisa L. Clarke, Christina A. Yang, Juan Hwang, Jimmy Hiatt, Robert A. Wang, Sunny TI Incidence of Non-Small-Cell Lung Cancer among California Hispanics According to Neighborhood Socioeconomic Status SO JOURNAL OF THORACIC ONCOLOGY LA English DT Article DE Non-small-cell lung cancer; Incidence; Socioeconomic status; Hispanic Americans; Race and ethnicity ID CIGARETTE-SMOKING BEHAVIOR; ENGLISH-LANGUAGE USE; UNITED-STATES; EDUCATION; PATTERNS; MORTALITY; WOMEN; ACCULTURATION; BELIEFS; GENDER AB Introduction: Lung cancer incidence is associated with markers of lower socioeconomic status (SES) in whites, blacks, and Asians but with markers of higher SES in Hispanics. The magnitude and etiology of this positive gradient in Hispanics remain undefined. We examined non-small-cell lung cancer (NSCLC) incidence and eversmoking rates among California Hispanics according to measures of SES. Methods: We computed neighborhood (n) SES-specific incidence rates by sex and race or ethnicity for 74,179 NSCLC cases in the California Cancer Registry, 1998-2002. Associations between nSES and NSCLC incidence were examined, using incidence rate ratios and linear trend tests, and stratified by age, stage, and histology. Ever-smoking rates among Hispanics were obtained from California Health Interview Survey 2001 data, and odds ratios for ever-smoking were calculated for measures of SES and acculturation. Results: Compared with the lowest nSES quintile, the NSCLC incidence in the highest quintile was 1.86 and 1.18 times higher for Hispanic women and men, respectively. The positive nSES gradients remained significant for all ages, stages, and nonsquamous histologies in women, and only for older age, local or regional stages, and adenocarcinoma histology in men. Ever-smoking rates were associated with English-speaking households and U.S.-born status for Hispanic women and low education and U.S.-born status for Hispanic men. Conclusions: For California Hispanics, higher nSES was strongly associated with increased NSCLC incidence in women, but weakly associated in men, and ever-smoking rates were strongly correlated with increased acculturation. This finding may portend an increasing burden of NSCLC in Hispanic women, given future trends in acculturation and SES. C1 [Wong, Melisa L.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Clarke, Christina A.; Yang, Juan] Canc Prevent Inst Calif, Fremont, CA USA. [Clarke, Christina A.] Stanford Canc Ctr, Dept Med, Stanford, CA USA. [Hwang, Jimmy; Hiatt, Robert A.; Wang, Sunny] Univ Calif San Francisco, Dept Med, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA. [Hiatt, Robert A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Wang, Sunny] San Francisco VA Med Ctr, Dept Med, Div Hematol & Oncol, San Francisco, CA 94121 USA. RP Wang, S (reprint author), San Francisco VA Med Ctr, 4150 Clement St 111H1, San Francisco, CA 94121 USA. EM sunny.wang@ucsf.edu FU California Department of Public Health; National Cancer Institute's Surveillance, Epidemiology and End Results Program [HHSN261201000036C, HHSN261201000035C, HHSN261201000034C, HHSN261201000040C]; Centers for Disease Control and Prevention's National Program of Cancer Registries [1U58 DP000807-01]; University of California, San Francisco Pathways Funding Agency, Philip R. Lee Program; Northern California Institute for Research and Education (NCIRE), San Francisco VA Medical Center; University of California, San Francisco Pathways Funding Agency, Philip R. Lee Program, University of California, San Francisco, Department of Medicine; University of California, San Francisco Helen Diller Comprehensive Cancer Center FX Drs. Clarke and Yang's efforts on this project and the collection of cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute's Surveillance, Epidemiology and End Results Program under contract HHSN261201000036C awarded to the Northern California Cancer Center, contract HHSN261201000035C awarded to the University of Southern California, and contract HHSN261201000034C awarded to the Public Health Institute; and the Centers for Disease Control and Prevention's National Program of Cancer Registries, under agreement #1U58 DP000807-01 awarded to the Public Health Institute.; This work is supported by the National Cancer Institute's Surveillance, Epidemiology and End Results program under contract HHSN261201000040C awarded to the Cancer Prevention Institute of California; the University of California, San Francisco Pathways Funding Agency, Philip R. Lee Program; and the Northern California Institute for Research and Education (NCIRE), San Francisco VA Medical Center.; Dr. Wong's efforts on this project were supported by the University of California, San Francisco Pathways Funding Agency, Philip R. Lee Program, University of California, San Francisco, Department of Medicine. Dr. Wang's efforts on this project were supported by the Northern California Institute for Research and Education, San Francisco VA Medical Center, and the University of California, San Francisco Helen Diller Comprehensive Cancer Center. All the other authors declare no conflict of interest. NR 36 TC 2 Z9 2 U1 1 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD MAR PY 2013 VL 8 IS 3 BP 287 EP 294 DI 10.1097/JTO.0b013e31827bd7f5 PG 8 WC Oncology; Respiratory System SC Oncology; Respiratory System GA 107HG UT WOS:000316205600012 PM 23399956 ER PT J AU Huckans, M Hutson, L Twamley, E Jak, A Kaye, J Storzbach, D AF Huckans, Marilyn Hutson, Lee Twamley, Elizabeth Jak, Amy Kaye, Jeffrey Storzbach, Daniel TI Efficacy of Cognitive Rehabilitation Therapies for Mild Cognitive Impairment (MCI) in Older Adults: Working Toward a Theoretical Model and Evidence-Based Interventions SO NEUROPSYCHOLOGY REVIEW LA English DT Review DE Mild cognitive impairment; Cognitive rehabilitation therapy; Cognitive training; Systematic review; Neuropsychological; Dementia ID RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; ALZHEIMERS-DISEASE; RISK-FACTORS; PREDICT CONVERSION; PHARMACOLOGICAL-TREATMENT; CARDIOVASCULAR HEALTH; DEPRESSIVE SYMPTOMS; MEDITERRANEAN DIET; PHYSICAL-ACTIVITY AB To evaluate the efficacy of cognitive rehabilitation therapies (CRTs) for mild cognitive impairment (MCI). Our review revealed a need for evidence-based treatments for MCI and a lack of a theoretical rehabilitation model to guide the development and evaluation of these interventions. We have thus proposed a theoretical rehabilitation model of MCI that yields key intervention targets-cognitive compromise, functional compromise, neuropsychiatric symptoms, and modifiable risk and protective factors known to be associated with MCI and dementia. Our model additionally defines specific cognitive rehabilitation approaches that may directly or indirectly target key outcomes-restorative cognitive training, compensatory cognitive training, lifestyle interventions, and psychotherapeutic techniques. Fourteen randomized controlled trials met inclusion criteria and were reviewed. Studies markedly varied in terms of intervention approaches and selected outcome measures and were frequently hampered by design limitations. The bulk of the evidence suggested that CRTs can change targeted behaviors in individuals with MCI and that CRTs are associated with improvements in objective cognitive performance, but the pattern of effects on specific cognitive domains was inconsistent across studies. Other important outcomes (i.e., daily functioning, quality of life, neuropsychiatric symptom severity) were infrequently assessed across studies. Few studies evaluated long-term outcomes or the impact of CRTs on conversion rates from MCI to dementia or normal cognition. Overall, results from trials are promising but inconclusive. Additional well-designed and adequately powered trials are warranted and required before CRTs for MCI can be considered evidence-based. C1 [Huckans, Marilyn; Storzbach, Daniel] Portland VA Med Ctr, Res & Dev Serv, Portland, OR 97239 USA. [Huckans, Marilyn; Hutson, Lee; Storzbach, Daniel] Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR 97239 USA. [Huckans, Marilyn; Storzbach, Daniel] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA. [Twamley, Elizabeth] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92093 USA. [Twamley, Elizabeth] Univ Calif San Diego, Stein Inst Res Aging, San Diego, CA 92093 USA. [Twamley, Elizabeth] VA San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, San Diego, CA 92161 USA. [Jak, Amy] VA San Diego Healthcare Syst, Dept Psychol Serv, San Diego, CA 92161 USA. [Kaye, Jeffrey] Portland VA Med Ctr, Dept Neurol, Portland, OR 97239 USA. [Kaye, Jeffrey] Oregon Hlth & Sci Univ, Layton Aging & Alzheimers Dis Ctr, Portland, OR 97239 USA. [Kaye, Jeffrey] Oregon Hlth & Sci Univ, Oregon Ctr Aging & Technol ORATECH, Portland, OR 97239 USA. [Huckans, Marilyn] Portland VA Med Ctr MHN, Portland, OR 97239 USA. RP Huckans, M (reprint author), Portland VA Med Ctr MHN, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM marilyn.huckans@va.gov OI Kaye, Jeffrey/0000-0002-9971-3478 FU VA Merit Review awards; National Institute on Drug Abuse [2P50DA018165-06A1]; National Institute on Aging [P30AG08017, P30AG024978] FX This material is the result of work supported with resources and the use of facilities at the Portland Veterans Affairs Medical Center, Portland, Oregon and Oregon Health & Science University, Portland Oregon. This work is in part supported by VA Merit Review awards to DS and JK, a grant from the National Institute on Drug Abuse to MH (2P50DA018165-06A1), and grants from the National Institute on Aging to JK (P30AG08017; P30AG024978). All authors read and approved the final contents of the manuscript. NR 84 TC 41 Z9 41 U1 4 U2 57 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1040-7308 J9 NEUROPSYCHOL REV JI Neuropsychol. Rev. PD MAR PY 2013 VL 23 IS 1 SI SI BP 63 EP 80 DI 10.1007/s11065-013-9230-9 PG 18 WC Psychology, Clinical; Neurosciences SC Psychology; Neurosciences & Neurology GA 107MR UT WOS:000316222200005 PM 23471631 ER PT J AU Westbrook, SD Kirkpatrick, WR Wiederhold, NP Freytes, CO Toro, JJ Patterson, TF Redding, SW AF Westbrook, Steven D. Kirkpatrick, William R. Wiederhold, Nathan P. Freytes, Cesar O. Toro, Juan J. Patterson, Thomas F. Redding, Spencer W. TI Microbiology and epidemiology of oral yeast colonization in hemopoietic progenitor cell transplant recipients SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY LA English DT Article ID BONE-MARROW-TRANSPLANTATION; FUNGAL-INFECTIONS; SEPSIS SECONDARY; FLUCONAZOLE; MUCOSITIS; CHEMOTHERAPY; PREVENTION; TRIAL AB Objective. We monitored the epidemiology and microbiology of oral yeast colonization in patients undergoing hemopoietic progenitor cell transplantation (HPCT) to examine associations between yeast colonization and oral mucositis. Study Design. One hundred twenty-one consecutive HPCT patients were sampled for oral yeasts prior to fluconazole (FLC) prophylaxis, at transplantation, and weekly until discharge. Clinical oral mucositis screenings were performed triweekly. Results. Yeast colonization was evident at 216 of 510 total visits. Candida albicans and Candida glabrata were the predominant organisms. Eight patients showed elevated minimal inhibitory concentrations to FLC. One patient developed fungal septicemia. Patients with oral mucositis assessment scale scores <20 had higher colonization rates than those with higher scores. Conclusions. FLC is effective in controlling a variety of oral yeasts in HPCT recipients. FLC-resistant yeasts do emerge and can be the source of fungal sepsis. A positive association was not shown between yeast colonization and the presence or severity of oral mucositis. (Oral Surg Oral Med Oral Pathol Oral Radiol 2013;115:354-358) C1 [Westbrook, Steven D.; Redding, Spencer W.] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, San Antonio, TX 78229 USA. [Kirkpatrick, William R.; Wiederhold, Nathan P.; Freytes, Cesar O.; Toro, Juan J.; Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Austin, TX USA. [Wiederhold, Nathan P.] Univ Texas Austin, Coll Pharm, Div Pharmacotherapy, Austin, TX 78712 USA. RP Westbrook, SD (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, 7703 Floyd Curl Dr,MSC 7914, San Antonio, TX 78229 USA. EM westbrooks@uthscsa.edu OI Wiederhold, Nathan/0000-0002-2225-5122 FU Public Health Service from the National Institute of Dental and Craniofacial Research [DE-18096] FX The authors thank Marcos Olivo for his technical assistance with yeast identification and isolation. We are grateful to the Fungus Testing Laboratory of the University of Texas Health Science Center at San Antonio for their assistance in determining the MICs of the yeast isolates. This work was supported in part by Public Health Service Grant DE-18096 from the National Institute of Dental and Craniofacial Research. NR 20 TC 3 Z9 3 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2212-4403 J9 OR SURG OR MED OR PA JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol. PD MAR PY 2013 VL 115 IS 3 BP 354 EP 358 DI 10.1016/j.oooo.2012.10.012 PG 5 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 109DJ UT WOS:000316345500022 PM 23312542 ER PT J AU Murinson, BB Gordin, V Flynn, S Driver, LC Gallagher, RM Grabois, M AF Murinson, Beth B. Gordin, Vitaly Flynn, Susie Driver, Larry C. Gallagher, Rollin M. Grabois, Martin CA Amer Acad Pain Med TI Recommendations for a New Curriculum in Pain Medicine for Medical Students: Toward a Career Distinguished by Competence and Compassion SO PAIN MEDICINE LA English DT Article DE Medical Education; Curriculum; AAPM; Medical Student; Learning Objectives ID PHYSICIANS; EDUCATION; EMPATHY; SCHOOLS AB Objective The education of physicians is a fundamental obligation within medicine that must remain closely aligned with clinical care. And although medical education in pain care is essential, the current state of medical education does not meet the needs of physicians, patients, or society. To address this, we convened a committee of pain specialist medical student educators. Methods Tasked with creating systematically developed and valid recommendations for clinical education, we conducted a survey of pain medicine leadership within the American Academy of Pain Medicine (AAPM). The survey was conducted in two waves. We asked AAPM board members to rate 194 previously published pain medicine learning objectives for medical students; 79% of those eligible for participation responded. Results The Top 5 list included the awareness of acute and chronic pain, skillfulness in clinical appraisal, promotion of compassionate practices, displaying empathy toward the patient, and knowledge of terms and definitions for substance abuse. The Top 10 list included the major pharmacological classes as well as skills in examination, communication, prescribing, and interviewing. The Top 20 list included the pain care of cognitively impaired populations, those with comorbid illness, and older adults. With the survey results in consideration, the committee produced a new recommended topic list for curricula in pain medicine. We strongly recommend that adequate resources are devoted to fully integrated medical curricula in pain so that students will learn not only the necessary clinical knowledge but also be prepared to address the professional, personal, and ethical challenges that arise in caring for those with pain. Conclusions We conclude that improved medical education in pain is essential to prepare providers who manifest both competence and compassion toward their patients. C1 [Murinson, Beth B.] Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD 21287 USA. [Gordin, Vitaly] Penn State Coll Med, Dept Anesthesia, Hershey, PA USA. [Flynn, Susie] Amer Acad Pain Med, Chicago, IL USA. [Driver, Larry C.] UT MD Anderson Canc Ctr, Dept Anesthesiol & Pain Med, Houston, TX USA. [Gallagher, Rollin M.] Philadelphia VA Med Ctr, Dept Pain Med, Philadelphia, PA USA. [Gallagher, Rollin M.] Univ Penn, Ctr Pain Med Res & Policy, Philadelphia, PA 19104 USA. [Grabois, Martin] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA. RP Murinson, BB (reprint author), Johns Hopkins Sch Med, Dept Neurol, Ctr Excellence Pain Educ, Meyer 5-119,600 North Wolfe St, Baltimore, MD 21287 USA. EM bb@jhmi.edu OI Murinson, Beth/0000-0003-1543-4322 FU Mayday Fund; Milbank Foundation for Rehabilitation Research; National Institute of Health Pain Consortium; National Institutes of Health FX This work was supported in part by philanthropic funding from the Mayday Fund and the Milbank Foundation for Rehabilitation Research. Dr. Murinson was the recipient of a National Institutes of Health career development award and the director of the Johns Hopkins University Center of Excellence in Pain Education funded by the National Institute of Health Pain Consortium. NR 20 TC 14 Z9 14 U1 0 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-2375 J9 PAIN MED JI Pain Med. PD MAR PY 2013 VL 14 IS 3 BP 345 EP 350 DI 10.1111/pme.12051 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 107IV UT WOS:000316210600011 PM 23387441 ER PT J AU Fu, Y Cheetham, T Bourn, D Orwoll, E Cohen, DM AF Fu, Yi Cheetham, Tim Bourn, David Orwoll, Eric Cohen, David M. TI Functional polymorphisms affecting the clinically important arginine-137 residue of AVPR2 do not influence serum sodium concentration at the population level SO PHYSIOLOGICAL GENOMICS LA English DT Article DE osmoregulation; arginine vasopressin; hyponatremia; hypernatremia ID NEPHROGENIC DIABETES-INSIPIDUS; CORONARY-HEART-DISEASE; V2 RECEPTOR MUTANTS; VASOPRESSIN RECEPTOR; INAPPROPRIATE ANTIDIURESIS; OSTEOPOROTIC FRACTURES; HYPONATREMIA; RESCUE; MEN; HOPEWELL AB Fu Y, Cheetham T, Bourn D, Orwoll E, Cohen DM. Functional polymorphisms affecting the clinically important arginine-137 residue of AVPR2 do not influence serum sodium concentration at the population level. Physiol Genomics 45: 210-216, 2013. First published January 29, 2013; doi:10.1152/physiolgenomics.00161.2012.-The protein product of the AVPR2 gene, coding for the arginine vasopressin receptor type 2, is essential for vasopressin-dependent concentration of the urine. The arginine residue at position 137 in the protein product of this gene is uniquely pivotal for function. The R137H mutant inactivates the receptor conferring congenital nephrogenic diabetes insipidus, whereas activating mutations at this same residue (i.e., R137C and R137L) confer pathological water retention in the nephrogenic syndrome of inappropriate antidiuresis. These mutations were discovered in human subjects with conspicuous phenotypes in clinical water balance. Prevalence of these polymorphisms among asymptomatic individuals has not been assessed, nor has their contribution to broad interindividual variation in serum sodium concentration; no data addressing minor allele frequency are available. We genotyped two large cohorts using a validated high-throughput Pyrosequencing-based assay that we designed to capture the totality of pathological variation at this important residue. In the Osteoporotic Fractures in Men (MrOS) Study, all participants were male (i.e., hemizygous for AVPR2 gene on the X-chromosome), and participants were oversampled at the extremes of the population distribution for serum sodium concentration. In the Offspring Cohort of the Framingham Heart Study, male and female participants were genotyped. No pathological variants affecting R137 were detected among the 5,142 AVPR2 alleles successfully genotyped. Even at the population extremes of serum sodium distribution, we estimate minor allele frequency < 0.06%. We conclude that these disease-associated variants are exceedingly uncommon and do not contribute broadly to interindividual variability in serum sodium concentration or to its heritability. C1 [Fu, Yi; Cohen, David M.] Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Portland, OR 97239 USA. [Orwoll, Eric] Oregon Hlth & Sci Univ, Dept Med, Div Endocrinol & Metab, Portland, OR 97239 USA. [Fu, Yi; Cohen, David M.] Portland VA Med Ctr, Portland, OR USA. [Cheetham, Tim] Royal Victoria Infirm, Dept Paediat Endocrinol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England. [Bourn, David] Inst Genet, Mol Genet Lab, Newcastle Upon Tyne, Tyne & Wear, England. RP Cohen, DM (reprint author), Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Mailcode PP262, Portland, OR 97239 USA. EM cohend@ohsu.edu OI Orwoll, Eric/0000-0002-8520-7355 FU National Institutes of Health (NIH); Department of Veterans Affairs; American Heart Association; NIH; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Institute on Aging (NIA); National Center for Research Resources; NIH Roadmap for Medical Research [U01 AR-45580, U01 AR-45614, U01 AR-45632, U01 AR-45647, U01 AR-45654, U01 AR-45583, U01 AG-18197, U01-AG-027810, UL1 RR-024140]; American Diabetes Association [1-04-JF-46]; NIAMS [R01-AR-051124]; National Heart, Lung, and Blood Institute's (NHLBI's) Framingham Heart Study [N01-HC-25195]; NHLBI; Boston University FX This work is supported by grants from the National Institutes of Health (NIH), the Department of Veterans Affairs, and the American Heart Association. The MrOS Study is supported by NIH funding. The following institutes provide support: the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute on Aging (NIA), the National Center for Research Resources, and NIH Roadmap for Medical Research under the following grant numbers: U01 AR-45580, U01 AR-45614, U01 AR-45632, U01 AR-45647, U01 AR-45654, U01 AR-45583, U01 AG-18197, U01-AG-027810, and UL1 RR-024140. Support for MrOS was also provided by the American Diabetes Association (1-04-JF-46). The NIAMS provides funding for the MrOS ancillary study "Replication of candidate gene associations and bone strength phenotype in MrOS" under the grant number R01-AR-051124.; A portion of this work was supported by the National Heart, Lung, and Blood Institute's (NHLBI's) Framingham Heart Study (contract no. N01-HC-25195). The Framingham Heart Study is conducted and supported by the NHLBI in collaboration with Boston University. This manuscript was not prepared in collaboration with investigators of the Framingham Heart Study and does not necessarily reflect the opinions or views of the Framingham Heart Study, Boston University, or NHLBI. NR 36 TC 4 Z9 4 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1094-8341 J9 PHYSIOL GENOMICS JI Physiol. Genomics PD MAR PY 2013 VL 45 IS 6 BP 210 EP 216 DI 10.1152/physiolgenomics.00161.2012 PG 7 WC Cell Biology; Genetics & Heredity; Physiology SC Cell Biology; Genetics & Heredity; Physiology GA 109EF UT WOS:000316348100002 PM 23362144 ER PT J AU Kim, W Charchian, B Chang, EY Liang, LJ Dumas, AJ Perez, M Siebens, HC Kim, HS AF Kim, Woojae Charchian, Beny Chang, Eric Y. Liang, Li-Jung Dumas, Armen J. Perez, Mario Siebens, Hilary C. Kim, Hyung S. TI Strengthening Information Capture in Rehabilitation Discharge Summaries: An Application of the Siebens Domain Management Model SO PM&R LA English DT Article ID BIOPSYCHOSOCIAL MODEL; MEDICAL RECORDS; CARE; PATTERNS; PATIENT; TEACH; GUIDE AB Objective: To increase relevant information capture in inpatient rehabilitation discharge summaries. Design: In July 2008, the Siebens Domain Management Model (SDMM) was incorporated into discharge summaries. This model organizes patients' health-related issues into 4 domains: I. Medical/Surgical Issues, II. Mental Status/Emotions/Coping, III. Physical Function, and IV. Living Environment ((c) Hilary C. Siebens MD 2005). Discharge summary content was measured through retrospective chart review. Setting: An inpatient rehabilitation unit affiliated with a physical medicine and rehabilitation residency program. Participants: Forty cases with discharge summaries: 20 traditional reports (historic controls) and 20 SDMM reports after model introduction randomly chosen from residents' final inpatient rotation week. Methods: A documentation review form included 36 items that covered the 4 SDMM domains and assessed item presence in reports. The Global score and 4 Domain scores per each patient report were calculated to reflect the percentage of items present in the entire report and each domain, respectively. Descriptive statistics for these scores were generated and compared between traditional and SDMM reports by using a 2-group t-test. Main Outcome Measurements: Global scores and Domain scores. Results: Global scores increased from 34% to 53% of items present in traditional versus SDMM reports respectively (P < .001); Domain Scores also increased in domains 1(81% to 92%, P = .047), II (9% to 47%, P < .001), III (25% to 34%, P = .062), and IV (11% to 33%, P < .001). Conclusion: Traditional rehabilitation discharge summaries lacked information relevant to rehabilitation care. Information capture and total relevant report content increased significantly after SDMM integration into reports. PM R 2013;5:182-188 C1 [Kim, Woojae] Valley Orthoped Inst, Palmdale, CA USA. [Charchian, Beny] Orthohealing Ctr, Los Angeles, CA USA. [Chang, Eric Y.] Univ Calif Irvine, Sch Med, Div Pain Med, Dept Anesthesiol & Perioperat Care, Irvine, CA 92717 USA. [Chang, Eric Y.] Univ Calif Irvine, Sch Med, Dept Phys Med & Rehabil, Irvine, CA 92717 USA. [Liang, Li-Jung; Dumas, Armen J.; Perez, Mario; Kim, Hyung S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Dumas, Armen J.; Perez, Mario; Kim, Hyung S.] VA Greater Los Angeles Healthcare Syst, Phys Med & Rehabil Serv, Los Angeles, CA USA. [Siebens, Hilary C.] Siebens Patient Care Commun, Seal Beach, CA USA. RP Kim, HS (reprint author), 11301 Wilshire Blvd MC117, Los Angeles, CA 90073 USA. EM Hyung.Kim@va.gov FU Department of Veterans Affairs, Greater Los Angeles FX We thank Harriet U. Aronow, PhD, Carol Stein, MA, OTR/L, Crystal Barker, MSN, RN-BC, PHN, CRRN, Milena Zirovich, MD, Stephen Figoni, PhD, and Antonia E. Scremin, MD, for their contributions to this project, and the Department of Veterans Affairs, Greater Los Angeles for funding statistical support. NR 38 TC 5 Z9 5 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1934-1482 J9 PM&R JI PM&R PD MAR PY 2013 VL 5 IS 3 BP 182 EP 188 DI 10.1016/j.pmrj.2013.01.003 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 110HN UT WOS:000316433300004 PM 23481328 ER PT J AU Evans, CT St Andre, JR Pape, TLB Steiner, ML Stroupe, KT Hogan, TP Weaver, FM Smith, BM AF Evans, Charlesnika T. St Andre, Justin R. Pape, Theresa L. -B. Steiner, Monica L. Stroupe, Kevin T. Hogan, Timothy P. Weaver, Frances M. Smith, Bridget M. TI An Evaluation of the Veterans Affairs Traumatic Brain Injury Screening Process Among Operation Enduring Freedom and/or Operation Iraqi Freedom Veterans SO PM&R LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; AFGHANISTAN; SYMPTOMS; HEALTH; CARE AB Objective: To describe the early results of the U.S. Department of Veterans Affairs (VA) screening program for traumatic brain injury (TBI) and to identify patient and facility characteristics associated with receiving a TBI screen and results of the screening. Design: National retrdspective cohort study. Setting: VA Medical facilities. Patients: A total of 170,681 Operation Enduring Freedom and/or Operation Iraqi Freedom (OEF/OIF) Veterans who sought care at VA medical facilities from April 2007 to September 30, 2008. Methods: Data were abstracted from VA administrative and operational databases, including patient demographics, facility characteristics, and outcomes. Main Outcome Measurements: The main outcomes were receipt of and results of the TBI screen. Results: The majority of veterans eligible received the TBI screen (91.6%). Screening rates varied by patient and facility characteristics. In all, 25% of screened veterans had probable TBI exposure, in which the majority. of the exposures were blasts (85.0%). The rate of a positive TBI screen was 20.5% for the screened cohort. Male gender, service in the army, multiple deployments, and mental health diagnoses in the previous year were associated with a positive screen. Conclusions: TBI screening rates are high in VA; concomitant mental health diagnoses were highly prevalent in individuals with positive TBI screens. These data indicate that there will be a significant need for long-term health care services for veterans with TBI symptomatology. PM R 2013;5:210-220 C1 [Evans, Charlesnika T.] Edward Hines Jr Vet Affairs VA Hosp, Dept VA, Ctr Management Complex Chron Care, Hines, IL 60141 USA. [Evans, Charlesnika T.] Spinal Cord Injury Qual Enhancement Res Initiat S, Dept VA, Hines, IL USA. [Evans, Charlesnika T.] Northwestern Univ, Feinberg Sch Med, Ctr Healthcare Studies, Chicago, IL 60611 USA. [St Andre, Justin R.; Pape, Theresa L. -B.; Stroupe, Kevin T.; Hogan, Timothy P.; Weaver, Frances M.; Smith, Bridget M.] Hines VA Hosp, Ctr Management Complex Chron Care, Dept VA, Hines, IL USA. [St Andre, Justin R.; Hogan, Timothy P.; Weaver, Frances M.; Smith, Bridget M.] SCI QUERI, Dept VA, Hines, IL USA. [St Andre, Justin R.] Hlth Res & Educ Trust, Chicago, IL USA. [Pape, Theresa L. -B.; Steiner, Monica L.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Dept VA, Hines, IL 60141 USA. [Pape, Theresa L. -B.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Stroupe, Kevin T.; Weaver, Frances M.; Smith, Bridget M.] Loyola Univ Chicago, Stritch Sch Med, Program Hlth Serv Res, Maywood, IL USA. [Hogan, Timothy P.] Edith Nourse Rogers Mem Vet Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Hogan, Timothy P.] Edith Nourse Rogers Mem Vet Hosp, eHlth QUERI, Natl eHlth QUERI Coordinating Ctr, Bedford, MA USA. [Hogan, Timothy P.] Univ Massachusetts, Sch Med, Div Hlth Informat & Implementat Sci, Worcester, MA USA. RP Evans, CT (reprint author), Edward Hines Jr Vet Affairs VA Hosp, Dept VA, Ctr Management Complex Chron Care, 5000 S 5th Ave, Hines, IL 60141 USA. EM Charlesnika.Evans@va.gov OI Pape, Theresa/0000-0001-7738-5963 NR 21 TC 12 Z9 12 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1934-1482 J9 PM&R JI PM&R PD MAR PY 2013 VL 5 IS 3 BP 210 EP 220 DI 10.1016/j.pmrj.2012.12.004 PG 11 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 110HN UT WOS:000316433300008 PM 23375630 ER PT J AU Weinstein, S Osei-Bonsu, S Aslam, R Yee, J AF Weinstein, Stefanie Osei-Bonsu, Samuel Aslam, Rizwan Yee, Judy TI Multidetector CT of the Postoperative Colon: Review of Normal Appearances and Common Complications SO RADIOGRAPHICS LA English DT Article ID POUCH-ANAL ANASTOMOSIS; COMPUTED-TOMOGRAPHY; ANTERIOR RESECTION; RECTAL-CANCER; ABDOMINOPERINEAL RESECTION; ABDOMINAL COMPLICATIONS; DIVERSION COLITIS; COLORECTAL-CANCER; HARTMANNS POUCH; BARIUM ENEMA AB If not properly recognized, the normal postoperative appearance of the pelvis following colorectal surgery can be misinterpreted as disease, including infection or recurrent tumor. However, multidetector computed tomography (CT) with the supplemental use of multiplanar reformation clearly demonstrates the expected postoperative anatomic changes in this setting. The high-resolution images achievable with multidetector CT enable the radiologist to play an important role in the postoperative assessment of patients following colon surgery. Whenever possible, the radiologist should be aware of the specific indication for the study, the type of surgery that was performed (ranging from segmental bowel excision to more extensive radical resection), and what anastomoses were created. This knowledge, as well as familiarity with the normal multidetector CT appearances of various postoperative complications, is critical for prompt diagnosis and appropriate management of these complications and for better differentiation of complications from normal findings. (C)RSNA, 2013 center dot radiographics.rsna.org C1 [Weinstein, Stefanie; Osei-Bonsu, Samuel; Aslam, Rizwan; Yee, Judy] UCSF Med Ctr, Dept Radiol, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Weinstein, S (reprint author), UCSF Med Ctr, Dept Radiol, San Francisco VA Med Ctr, 4150 Clement St 114, San Francisco, CA 94121 USA. EM Stefanie.Weinstein@ucsf.edu NR 54 TC 7 Z9 7 U1 0 U2 4 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0271-5333 J9 RADIOGRAPHICS JI Radiographics PD MAR-APR PY 2013 VL 33 IS 2 BP 515 EP 532 DI 10.1148/rg.332125723 PG 18 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 104MU UT WOS:000315998700016 PM 23479710 ER PT J AU Maynard, C Bradley, SM Bryson, CL AF Maynard, Charles Bradley, Steven M. Bryson, Chris L. TI The practice of transradial percutaneous coronary intervention in the Washington State Clinical Outcomes Assessment Program SO AMERICAN HEART JOURNAL LA English DT Article ID CARDIOVASCULAR DATA REGISTRY; TRANSFEMORAL APPROACH; FEMORAL ACCESS; ANGIOGRAPHY AB Background Transradial percutaneous coronary intervention (tPCI) as opposed to the femoral approach (fPCI) is associated with lower rates of bleeding. The purposes of this study were to describe the use of tPCI in the Washington State Clinical Outcomes Assessment Program, identify the predictors of bleeding, and determine whether tPCI was associated with less bleeding in women vs men, age <75 years vs >= 75 years, and baseline creatinine <2.0 mg/dL vs >= 2.0 mg/dL. Methods This study included 23,599 individuals who had a first tPCI or fPCI performed in 30 centers in Washington State in 2010 and 2011. Data were collected according to specifications from the American College of Cardiology National Cardiovascular Data Registry Cath-PCI version 4.3. The American College of Cardiology National Cardiovascular Data Registry bleeding model was used to calculate adjusted rates. Results Transradial percutaneous coronary intervention was used in only 5% of procedures, and in just 3 centers, tPCI was used in >10% of cases. Patient demographics and medical histories were similar in tPCI and fPCI, although the percent of acute cases was higher in fPCI (68% vs 45%, P < .0001). The overall bleeding rate was 2.2%, and the 3 most important predictors of bleeding were acute procedure, women, and age >= 75 years. For women, unadjusted rates of bleeding were 1.4% for tPCI and 4.0% for fPCI (P = .013). Among women, adjusted rates were almost 20% lower for tPCI (3.3% vs 4.1%). Conclusion In Washington State, tPCI was used infrequently, although it was associated with lower bleeding rates in high-risk groups including women. (Am Heart J 2013;165:332-7.) C1 [Maynard, Charles; Bryson, Chris L.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Northwest Ctr Excellence, Seattle, WA USA. [Maynard, Charles; Bryson, Chris L.] Univ Washington, Seattle, WA 98195 USA. [Maynard, Charles; Bryson, Chris L.] Fdn Hlth Care Qual, Clin Outcomes Assessment Program, Seattle, WA USA. [Bradley, Steven M.] VA Eastern Colorado Hlth Care Syst, Denver, CO USA. [Bradley, Steven M.] Univ Colorado, Denver, CO 80202 USA. RP Maynard, C (reprint author), Hlth Serv Res & Dev, 1100 Olive Way 1400, Seattle, WA 98101 USA. EM cmaynard@u.washington.edu RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 NR 12 TC 3 Z9 3 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD MAR PY 2013 VL 165 IS 3 BP 332 EP 337 DI 10.1016/j.ahj.2012.11.011 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 100OL UT WOS:000315710500016 PM 23453101 ER PT J AU Hess, CN Rao, SV Kong, DF Miller, JM Anstrom, KJ Bertrand, OF Collet, JP Effron, MB Eloff, BC Fadiran, EO Farb, A Gilchrist, IC Holmes, DR Jacobs, AK Kaul, P Newby, LK Rutledge, DR Tavris, DR Tsai, TT White, RM Peterson, ED Krucoff, MW AF Hess, Connie N. Rao, Sunil V. Kong, David F. Miller, Julie M. Anstrom, Kevin J. Bertrand, Olivier F. Collet, Jean-Philippe Effron, Mark B. Eloff, Benjamin C. Fadiran, Emmanuel O. Farb, Andrew Gilchrist, Ian C. Holmes, David R. Jacobs, Alice K. Kaul, Prashant Newby, L. Kristin Rutledge, David R. Tavris, Dale R. Tsai, Thomas T. White, Roseann M. Peterson, Eric D. Krucoff, Mitchell W. TI TransRadial Education And Therapeutics (TREAT): Shifting the balance of safety and efficacy of antithrombotic agents in percutaneous coronary intervention. A report from the Cardiac Safety Research Consortium SO AMERICAN HEART JOURNAL LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; CLINICAL-OUTCOMES; FEMORAL APPROACH; VASCULAR COMPLICATIONS; ANTIPLATELET THERAPY; GENDER-DIFFERENCES; RANDOMIZED-TRIALS; HEART-ASSOCIATION; BLOOD-TRANSFUSION; ADVERSE OUTCOMES AB Percutaneous coronary intervention (PCI) is an integral part of the treatment of coronary artery disease. The most common complication of PCI, bleeding, typically occurs at the vascular access site and is associated with short-term and long-term morbidity and mortality. Periprocedural bleeding also represents the primary safety concern of concomitant antithrombotic therapies essential for PCI success. Use of radial access for PCI reduces procedural bleeding and hence may change the risk profile and net clinical benefit of these drugs. This new drug-device safety interaction creates opportunities to advance the safe and effective use of antithrombotic agents during PCI. In June 2010 and March 2011, leaders from government, academia, professional societies, device manufacturing, and pharmaceutical industries convened for 2 think tank meetings. Titled TREAT I and II, these forums examined approaches to improve the overall safety of PCI by optimizing strategies for antithrombotic drug use and radial artery access. This article summarizes the content and proceedings of these sessions. (Am Heart J 2013;165:344-353.e1.) C1 [Hess, Connie N.; Rao, Sunil V.; Kong, David F.; Anstrom, Kevin J.; Newby, L. Kristin; Peterson, Eric D.; Krucoff, Mitchell W.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. [Miller, Julie M.] Johns Hopkins Univ, Baltimore, MD USA. [Bertrand, Olivier F.] Quebec Heart Lung Inst, Quebec City, PQ, Canada. [Collet, Jean-Philippe] Inst Cardiol, Paris, France. [Effron, Mark B.] Lilly USA LLC, Indianapolis, IN USA. [Eloff, Benjamin C.; Fadiran, Emmanuel O.; Farb, Andrew; Tavris, Dale R.] US FDA, Silver Spring, MD USA. [Gilchrist, Ian C.] Penn State Heart & Vasc Inst, Hershey, PA USA. [Holmes, David R.] Mayo Clin, Rochester, MN USA. [Jacobs, Alice K.] Boston Med Ctr, Boston, MA USA. [Kaul, Prashant] Univ N Carolina, Chapel Hill, NC USA. [Rutledge, David R.; White, Roseann M.] Abbott Vasc, San Francisco, CA USA. [Tsai, Thomas T.] Denver VA Med Ctr, Denver, CO USA. RP Krucoff, MW (reprint author), Duke Clin Res Inst, 508 Fulton, Durham, NC 27705 USA. EM kruco001@mc.duke.edu RI Effron, Mark/P-9300-2015 OI Gilchrist, Ian/0000-0001-8525-8454 FU NIH [5T32HL069749-09] FX We thank Drs Morton J. Kern, Venugopal Menon, Tejas Patel, Jon R. Resar, Tara A. Ryan, Jeffrey E. Shuren, Norman Stockbridge, and Jean-Francois Tanguay for their reviews of this manuscript. C.N.H. was funded by NIH grant 5T32HL069749-09. NR 47 TC 3 Z9 3 U1 0 U2 6 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD MAR PY 2013 VL 165 IS 3 BP 344 EP + DI 10.1016/j.ahj.2012.09.008 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 100OL UT WOS:000315710500018 PM 23453103 ER PT J AU Goldsmith, EC Bradshaw, AD Spinale, FG AF Goldsmith, Edie C. Bradshaw, Amy D. Spinale, Francis G. TI Cellular Mechanisms of Tissue Fibrosis. 2. Contributory pathways leading to myocardial fibrosis: moving beyond collagen expression SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY LA English DT Article DE fibrosis; collagen; myocardium; extracellular matrix ID PROCOLLAGEN C-PROTEINASE; VENTRICULAR PRESSURE-OVERLOAD; BONE MORPHOGENETIC PROTEIN-1; MARROW-DERIVED CELLS; FRIZZLED-RELATED PROTEIN-2; NEWLY SYNTHESIZED COLLAGEN; EHLERS-DANLOS-SYNDROME; CARDIAC FIBROBLASTS; MYOFIBROBLAST DIFFERENTIATION; MATRIX METALLOPROTEINASES AB Goldsmith EC, Bradshaw AD, Spinale FG. Cellular Mechanisms of Tissue Fibrosis. 2. Contributory pathways leading to myocardial fibrosis: moving beyond collagen expression. Am J Physiol Cell Physiol 304: C393-C402, 2013. First published November 21, 2012; doi: 10.1152/ajpcell.00347.2012.-While the term "fibrosis" can be misleading in terms of the complex patterns and processes of myocardial extracellular matrix (ECM) remodeling, fibrillar collagen accumulation is a common consequence of relevant pathophysiological stimuli, such as pressure overload (PO) and myocardial infarction (MI). Fibrillar collagen accumulation in both PO and MI is predicated on a number of diverse cellular and extracellular events, which include changes in fibroblast phenotype (transdifferentiation), post-translational processing and assembly, and finally, degradation. The expansion of a population of transformed fibroblasts/myofibroblasts is a significant cellular event with respect to ECM remodeling in both PO and MI. The concept that this cellular expansion within the myocardial ECM may be due, at least in part, to endothelial-mesenchymal transformation and thereby not dissimilar to events observed in cancer progression holds intriguing future possibilities. Studies regarding determinants of procollagen processing, such as procollagen C-endopeptidase enhancer (PCOLCE), and collagen assembly, such as the secreted protein acidic and rich in cysteine (SPARC), have identified potential new targets for modifying the fibrotic response in both PO and MI. Finally, the transmembrane matrix metalloproteinases, such as MMP-14, underscore the diversity and complexity of this ECM proteolytic family as this protease can degrade the ECM as well as induce a profibrotic response. The growing recognition that the myocardial ECM is a dynamic entity containing a diversity of matri-cellular and nonstructural proteins as well as proteases and that the fibrillar collagens can change in structure and content in a rapid temporal fashion has opened up new avenues for modulating what was once considered an irreversible event - myocardial fibrosis. C1 [Goldsmith, Edie C.; Spinale, Francis G.] Univ S Carolina, Sch Med, Dept Cell Biol & Anat, Columbia, SC 29208 USA. [Spinale, Francis G.] Univ S Carolina, Sch Med, Cardiovasc Translat Res Ctr, Columbia, SC 29208 USA. [Spinale, Francis G.] WJB Dorn Vet Affairs Med Ctr, Columbia, SC USA. [Bradshaw, Amy D.] Med Univ S Carolina, Div Cardiol, Columbia, SC USA. [Bradshaw, Amy D.] Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA. RP Spinale, FG (reprint author), Univ S Carolina, Sch Med, CBA, Cardiovasc Translat Res Ctr, 6439 Garners Ferry Rd, Columbia, SC 29208 USA. EM cvctrc@uscmed.sc.edu FU National Institutes of Health [HL-057952, HL-089944, HL-095608, HL-111090, HL-097214, HL-094517]; Veterans' Affairs Health Administration [5I01BX000168, 1I01BX001385] FX This work was supported by National Institutes of Health Grants HL-057952, HL-089944, HL-095608, HL-111090, HL-097214, and HL-094517 and by Merit Awards (5I01BX000168 and 1I01BX001385) from the Veterans' Affairs Health Administration. NR 98 TC 45 Z9 47 U1 0 U2 15 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6143 J9 AM J PHYSIOL-CELL PH JI Am. J. Physiol.-Cell Physiol. PD MAR PY 2013 VL 304 IS 5 BP C393 EP C402 DI 10.1152/ajpcell.00347.2012 PG 10 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 100EX UT WOS:000315680300001 PM 23174564 ER PT J AU Lohavanichbutr, P Mendez, E Holsinger, FC Rue, TC Zhang, YZ Houck, J Upton, MP Futran, N Schwartz, SM Wang, P Chen, C AF Lohavanichbutr, Pawadee Mendez, Eduardo Holsinger, F. Christopher Rue, Tessa C. Zhang, Yuzheng Houck, John Upton, Melissa P. Futran, Neal Schwartz, Stephen M. Wang, Pei Chen, Chu TI A 13-Gene Signature Prognostic of HPV-Negative OSCC: Discovery and External Validation SO CLINICAL CANCER RESEARCH LA English DT Article ID SQUAMOUS-CELL CARCINOMA; PLASMINOGEN-ACTIVATOR INHIBITOR; HUMAN-PAPILLOMAVIRUS; GENE-EXPRESSION; OROPHARYNGEAL CANCER; LUNG-CANCER; ORAL-CANCER; HIGH-RISK; RECEPTOR; SURVIVAL AB Purpose: To identify a prognostic gene signature for patients with human papilloma virus (HPV)negative oral squamous cell carcinomas (OSCC). Experimental Design: Two gene expression datasets were used: a training dataset from the Fred Hutchinson Cancer Research Center (FHCRC, Seattle, WA; n = 97) and a validation dataset from the MD Anderson Cancer Center (MDACC, Houston, TX; n = 71). We applied L1/L2-penalized Cox regression models to the FHCRC data on the 131-gene signature previously identified to be prognostic in patients with OSCCs to identify a prognostic model specific for patients with high-risk HPV-negative OSCCs. The models were tested with the MDACC dataset using a receiver operating characteristic (ROC) analysis. Results: A 13-gene model was identified as the best predictor of HPV-negative OSCC-specific survival in the training dataset. The risk score for each patient in the validation dataset was calculated from this model and dichotomized at the median. The estimated 2-year mortality (+/- SE) of patients with high-risk scores was 47.1% (+/- 9.24%) compared with 6.35% (+/- 4.42) for patients with low-risk scores. ROC analyses showed that the areas under the curve for the age, gender, and treatment modality-adjusted models with risk score [0.78; 95% confidence interval (CI), 0.74-0.86] and risk score plus tumor stage (0.79; 95% CI, 0.75-0.87) were substantially higher than for the model with tumor stage (0.54; 95% CI, 0.48-0.62). Conclusions: We identified and validated a 13-gene signature that is considerably better than tumor stage in predicting survival of patients with HPV-negative OSCCs. Further evaluation of this gene signature as a prognostic marker in other populations of patients with HPV-negative OSCC is warranted. Clin Cancer Res; 19(5); 1197-203. (C) 2012 AACR. C1 [Lohavanichbutr, Pawadee; Houck, John; Schwartz, Stephen M.; Chen, Chu] Fred Hutchinson Canc Res Ctr, Program Epidemiol, Seattle, WA 98109 USA. [Mendez, Eduardo] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA. [Zhang, Yuzheng; Wang, Pei] Fred Hutchinson Canc Res Ctr, Program Biostat & Biomath, Seattle, WA 98109 USA. [Mendez, Eduardo; Futran, Neal; Chen, Chu] Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. [Rue, Tessa C.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Upton, Melissa P.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Schwartz, Stephen M.; Chen, Chu] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Mendez, Eduardo] VA Puget Sound Hlth Care Syst, Surg & Perioperat Care Serv, Seattle, WA USA. [Holsinger, F. Christopher] Univ Texas Houston, MD Anderson Canc Ctr, Dept Otolaryngol Head & Neck Surg, Houston, TX 77030 USA. RP Chen, C (reprint author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Avenue North,M5-C800,POB 19024, Seattle, WA 98109 USA. EM cchen@fhcrc.org OI Schwartz, Stephen/0000-0001-7499-8502 FU NIH, National Cancer Institute [NIH NCI R01CA095419]; National Center for Research Resources grant [1KL2RR025015-01]; Amos Medical Faculty Development Program Award from the Robert Wood Johnson Foundation; Fred Hutchinson Cancer Research Center; Specialized Program of Research Excellence in Head and Neck Cancer Grant from the National Cancer Institute [P50CA97007]; Clinician Investigator Program in Translational Research [K12CA088084]; Clinical Research Program [2 L30CA117652-02A1]; THANC Foundation Young Investigator Award FX The study at FHCRC was supported by grants from the NIH, National Cancer Institute (NIH NCI R01CA095419), National Center for Research Resources grant 1KL2RR025015-01, Amos Medical Faculty Development Program Award from the Robert Wood Johnson Foundation, and by institutional funds from the Fred Hutchinson Cancer Research Center. The study at the MD Anderson Cancer Center was supported by Specialized Program of Research Excellence in Head and Neck Cancer Grant P50CA97007 from the National Cancer Institute, "Clinician Investigator Program in Translational Research" K12CA088084, Clinical Research Program 2 L30CA117652-02A1, and THANC Foundation Young Investigator Award in Head and Neck Cancer. NR 37 TC 20 Z9 20 U1 0 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD MAR 1 PY 2013 VL 19 IS 5 BP 1197 EP 1203 DI 10.1158/1078-0432.CCR-12-2647 PG 7 WC Oncology SC Oncology GA 100YB UT WOS:000315740200027 PM 23319825 ER PT J AU Goldstein, SL Jaber, BL Faubel, S Chawla, LS AF Goldstein, Stuart L. Jaber, Bertrand L. Faubel, Sarah Chawla, Lakhmir S. CA Amer Soc Nephrology TI AKI Transition of Care: A Potential Opportunity to Detect and Prevent CKD SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID ACUTE KIDNEY INJURY; ACUTE-RENAL-FAILURE; GELATINASE-ASSOCIATED LIPOCALIN; STEM-CELL TRANSPLANTATION; CRITICALLY-ILL CHILDREN; LONG-TERM RISK; CARDIAC-SURGERY; CARDIOVASCULAR-DISEASE; HOSPITALIZED-PATIENTS; PROSPECTIVE COHORT AB The incidence rate of AKI is increasing across the spectrum of hospitalized children and adults. Given the increased morbidity and mortality associated with AKI, significant research effort has been appropriately focused on standardizing AKI definitions, identifying risk factors, and discovering and validating novel, earlier structural biomarkers of kidney injury. In addition, a growing body of evidence demonstrates that AKI is a risk factor for the future development or accelerated progression of CKD. Unfortunately, prospective observational studies have not consistently followed survivors of episodes of AKI for longitudinal outcomes after hospital discharge, which could lead to ascertainment bias in terms of over- or underestimation of CKD development. Furthermore, data show that clinical follow-up of AKI survivors is low. This lack of systematic study and clinical follow-up represents a potential missed opportunity to prevent chronic disease after an acute illness and improve outcomes. Therefore, prospective study of transitions of care after episodes of AKI is needed to identify which patients are at risk for CKD development and to optimally target therapeutic interventions. Clin J Am Soc Nephrol 8: 476-483, 2013. doi: 10.2215/CJN.12101112 C1 [Goldstein, Stuart L.] Cincinnati Childrens Hosp Med Ctr, Ctr Acute Care Nephrol, Cincinnati, OH 45229 USA. [Jaber, Bertrand L.] Tufts Univ, Sch Med, Dept Med, St Elizabeths Med Ctr,Div Nephrol, Boston, MA 02111 USA. [Faubel, Sarah] Univ Colorado, Div Nephrol, Denver, CO 80202 USA. [Faubel, Sarah] Denver Vet Affairs Med Ctr, Denver, CO USA. [Chawla, Lakhmir S.] George Washington Univ, Med Ctr, Dept Anesthesiol & Crit Care Med, Washington, DC 20037 USA. RP Goldstein, SL (reprint author), Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave,MLC 7022,RILF 2, Cincinnati, OH 45229 USA. EM stuart.goldstein@cchmc.org FU NIDDK NIH HHS [R01 DK075976, R01 DK088923] NR 75 TC 54 Z9 55 U1 0 U2 7 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD MAR PY 2013 VL 8 IS 3 BP 476 EP 483 DI 10.2215/CJN.12101112 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 102GP UT WOS:000315833200020 PM 23471414 ER PT J AU Falvey, CM Rosano, C Simonsick, EM Harris, T Strotmeyer, ES Satterfield, S Yaffe, K AF Falvey, Cherie M. Rosano, Caterina Simonsick, Eleanor M. Harris, Tamara Strotmeyer, Elsa S. Satterfield, Suzanne Yaffe, Kristine CA Hlth ABC Study TI Macro- and Microstructural Magnetic Resonance Imaging Indices Associated With Diabetes Among Community-Dwelling Older Adults SO DIABETES CARE LA English DT Article ID DIFFUSION TENSOR MRI; WHITE-MATTER; COGNITIVE DECLINE; SPATIAL STATISTICS; ALZHEIMERS-DISEASE; HUMAN BRAIN; TYPE-2; MELLITUS; ATROPHY; ABNORMALITIES AB OBJECTIVE-To better understand the association between diabetes and cognitive impairment, we evaluated macro- and microstructural brain MRI measures for the total brain and regions of interest (RO1s) in a group of community-dwelling elders with and without diabetes. RESEARCH DESIGN AND METHODS-MRI measures were obtained on 308 elders (mean age 83.3 years; n = 85 with diabetes) from the Health ABC Healthy Brain Substudy. We performed a series of linear regressions and used standardized beta values to estimate the cross-sectional association between diabetes and macrostructural (gray matter volume [GMV] and white matter hyperintensities [WMHs]) and microstructural (mean diffusivity [MD] and fractional anisotropy [FA]) measures for the total brain and ROIs. Models were adjusted for age, race, and sex; GMV values for ROIs were also adjusted for total brain volume (TBV). RESULTS-In multivariate-adjusted models, diabetes was associated with lower total GMV (P = 0.0006), GMV in the putamen (P = 0.02 for left and right), and TBV (P = 0.04) and greater cerebral atrophy (P = 0.02). There was no association with WMHs. On microstructural measures, diabetes was associated with reduced FA for total white matter (P = 0.006) and greater MD for the hippocampus (P = 0.006 left; P = 0.01 right), dorsolateral prefrontal cortex (P = 0.0007, left; P = 0.002, right), left posterior cingulate (P = 0.02), and right putamen (P = 0.02). Further adjustment for stroke, hypertension, and myocardial infarction produced similar results. CONCLUSIONS-In this cross-sectional study, elders with diabetes compared with those without had greater brain atrophy and early signs of neurodegeneration. Further studies are needed to determine whether these structural changes associated with diabetes predict risk of cognitive decline. Diabetes Care 36:677-682,2013 C1 [Falvey, Cherie M.; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Falvey, Cherie M.; Yaffe, Kristine] San Francisco Vet Adm Med Ctr, San Francisco, CA USA. [Rosano, Caterina; Strotmeyer, Elsa S.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Simonsick, Eleanor M.] NIA, Clin Res Branch, Baltimore, MD 21224 USA. [Harris, Tamara] NIA, Lab Epidemiol Demog & Biometry, Intramural Res Program, Bethesda, MD 20892 USA. [Satterfield, Suzanne] Univ Tennessee, Hlth Sci Ctr, Dept Prevent Med, Memphis, TN USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Falvey, CM (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. EM cherie.falvey@ucsf.edu RI Strotmeyer, Elsa/F-3015-2014 OI Rosano, Caterina/0000-0002-0909-1506; Strotmeyer, Elsa/0000-0002-4093-6036; Rosano, Caterina/0000-0002-4271-6010 FU National Institute on Aging (NIA) [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, R01-AG028050]; National Institute of Nursing Research [R01-NR012459]; National Institutes of Health (NIH), NIA; American Health Assistance Foundation [A201-0029]; NIA [K24AG031155]; NIH (NIA, National Institute of Diabetes and Digestive and Kidney Diseases, and NIMH); Department of Defense; American Health Assistance Foundation; Anonymous Foundation; Alzheimer's Association; NIH/NIA; NIH FX This work was supported by National Institute on Aging (NIA) grants N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, and R01-AG028050 and National Institute of Nursing Research Grant R01-NR012459. This research was supported in part by the Intramural Research Program of the National Institutes of Health (NIH), NIA, and American Health Assistance Foundation Grant A201-0029. K.Y. is supported in part by NIA Grant K24AG031155. K.Y. has served on data safety-monitoring boards for the NIH (National Institute of Mental Health [NIMH] and NIA trials) and has received research support from the NIH (NIA, National Institute of Diabetes and Digestive and Kidney Diseases, and NIMH), Department of Defense, American Health Assistance Foundation, Anonymous Foundation, and Alzheimer's Association. S.S. receives research support from the NIH/NIA. T.H. receives research support from the NIH. NR 40 TC 34 Z9 39 U1 2 U2 10 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD MAR PY 2013 VL 36 IS 3 BP 677 EP 682 DI 10.2337/dc12-0814 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 103OU UT WOS:000315928700040 PM 23160721 ER PT J AU Jain, A Singh, JA AF Jain, Archana Singh, Jasvinder A. TI Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature SO IMMUNOTHERAPY LA English DT Review DE adverse effect; biologic; harm; rheumatic disease; rheumatoid arthritis; TNF biologic; TNF inhibitor ID TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA ANTAGONISTS; SERIOUS BACTERIAL-INFECTIONS; MODIFYING ANTIRHEUMATIC DRUGS; RANDOMIZED CONTROLLED-TRIALS; DAILY CLINICAL-PRACTICE; FACTOR THERAPY; BIOLOGICS-REGISTER; BRITISH-SOCIETY; HEART-FAILURE AB A focused review of the risk of harms of anti-TNF inhibitors in adult rheumatic diseases was performed. An increased risk of serious infections, tuberculosis and other opportunistic infections has been reported across various studies, with etanercept appearing to have a modestly better safety profile in terms of tuberculosis and opportunistic infections, and infliximab posing a higher risk of serious infections. Evidence suggests no increase in risk of cancer with anti-TNF biologics, but there is an increased risk of non-melanoma skin cancer. Elderly patients appear to be at increased risk of incident or worsening heart failure with anti-TNF biologic use. C1 [Jain, Archana; Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit, Birmingham, AL USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA. EM jasvinder.md@gmail.com OI singh, jasvinder/0000-0003-3485-0006 FU Takeda; Savient; URL pharmaceuticals; Ardea; Novartis; Allergan FX JA Singh has received research and travel grants from Takeda and Savient; and consultant fees from URL pharmaceuticals, Savient, Takeda, Ardea, Novartis and Allergan. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 81 TC 28 Z9 29 U1 0 U2 15 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1750-743X J9 IMMUNOTHERAPY-UK JI Immunotherapy PD MAR PY 2013 VL 5 IS 3 BP 265 EP 299 DI 10.2217/IMT.13.10 PG 35 WC Immunology SC Immunology GA 100LU UT WOS:000315703500012 PM 23444956 ER PT J AU Zou, CB Chen, Y Smith, RM Snavely, C Li, J Coon, TA Chen, BB Zhao, YT Mallampalli, RK AF Zou, Chunbin Chen, Yan Smith, Rebecca M. Snavely, Courtney Li, Jin Coon, Tiffany A. Chen, Bill B. Zhao, Yutong Mallampalli, Rama K. TI SCFFbxw15 Mediates Histone Acetyltransferase Binding to Origin Recognition Complex (HBO1) Ubiquitin-Proteasomal Degradation to Regulate Cell Proliferation SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID NF-KAPPA-B; F-BOX; EPITHELIAL-CELLS; BETA-TRCP; PROTEIN; PHOSPHORYLATION; LIPOPOLYSACCHARIDE; ACTIVATION; LIGASES; ACETYLATION AB Histone acetyltransferase binding to origin recognition complex (HBO1) plays a crucial role in DNA replication licensing and cell proliferation, yet its molecular regulation in cells is relatively unknown. Here an uncharacterized protein, Fbxw15, directly interacts with HBO1, a labile protein (t(1/2) = similar to 3 h), to mediate its ubiquitination (Lys(338)) and degradation in the cytoplasm. Fbxw15-mediated HBO1 depletion required mitogen-activated protein kinase 1 (Mek1), which was sufficient to trigger HBO1 phosphorylation and degradation in cells. Mek1 ability to produce HBO1 degradation was blocked by Fbxw15 silencing. Lipopolysaccharide induced HBO1 degradation, an effect abrogated by Fbxw15 or Mek1 cellular depletion. Modulation of Fbxw15 levels was able to differentially regulate histone H3K14 acetylation and cellular proliferation by altering HBO1 levels. These studies authenticate Fbxw15 as a ubiquitin E3 ligase subunit that mediates endotoxin-induced HBO1 depletion in cells, thereby controlling cell replicative capacity. C1 [Zou, Chunbin; Chen, Yan; Smith, Rebecca M.; Snavely, Courtney; Li, Jin; Coon, Tiffany A.; Chen, Bill B.; Zhao, Yutong; Mallampalli, Rama K.] Univ Pittsburgh, Acute Lung Injury Ctr Excellence, Dept Med, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15240 USA. [Mallampalli, Rama K.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15260 USA. [Chen, Yan] Cent S Univ, Xiangya Hosp 2, Dept Internal Med, Div Resp Dis, Changsha 410011, Hunan, Peoples R China. RP Mallampalli, RK (reprint author), Dept Med, Div Pulm Allergy & Crit Care Med, 628 NW Montefiore,3459 5th Ave, Pittsburgh, PA 15213 USA. EM mallampallirk@upmc.edu FU National Institutes of Health [HL096376, HL097376, HL098174, HL116472, HL01916]; United States Department of Veterans Affairs; Veterans Health Administration; Office of Research and Development; Biomedical Laboratory Research and Development; American Heart Association [12SDG12040330] FX This work was supported, in whole or in part, by National Institutes of Health Grants HL096376, HL097376, and HL098174 (to R. K. M.), HL116472 (to B. B. C.), and HL01916 (to Y. Z.). This work was also supported in part by the United States Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development, a Merit Review Award from the United States Department of Veterans Affairs, and American Heart Association Award 12SDG12040330 (to C. Z.). NR 46 TC 13 Z9 13 U1 0 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD MAR 1 PY 2013 VL 288 IS 9 BP 6306 EP 6316 DI 10.1074/jbc.M112.426882 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 102CJ UT WOS:000315820700025 PM 23319590 ER PT J AU Salsman, JM Butt, Z Pilkonis, PA Cyranowski, JM Zill, N Hendrie, HC Kupst, MJ Kelly, MAR Bode, RK Choi, SW Lai, JS Griffith, JW Stoney, CM Brouwers, P Knox, SS Cella, D AF Salsman, John M. Butt, Zeeshan Pilkonis, Paul A. Cyranowski, Jill M. Zill, Nicholas Hendrie, Hugh C. Kupst, Mary Jo Kelly, Morgen A. R. Bode, Rita K. Choi, Seung W. Lai, Jin-Shei Griffith, James W. Stoney, Catherine M. Brouwers, Pim Knox, Sarah S. Cella, David TI Emotion assessment using the NIH Toolbox SO NEUROLOGY LA English DT Article ID POSITIVE EMOTIONS; PSYCHOLOGICAL STRESS; DEPRESSIVE SYMPTOMS; HEALTH; LIFE; WELL; LONELINESS; RECOVERY; PURPOSE; RISK AB One of the goals of the NIH Toolbox for Assessment of Neurological and Behavioral Function was to identify or develop brief measures of emotion for use in prospective epidemiologic and clinical research. Emotional health has significant links to physical health and exerts a powerful effect on perceptions of life quality. Based on an extensive literature reviewand expert input, the Emotion team identified 4 central subdomains: Negative Affect, Psychological Well-Being, Stress and Self-Efficacy, and Social Relationships. A subsequent psychometric review identified several existing self-report and proxy measures of these subdomains with measurement characteristics that met the NIH Toolbox criteria. In cases where adequate measures did not exist, robust item banks were developed to assess concepts of interest. A population-weighted sample was recruited by an online survey panel to provide initial item calibration andmeasure validation data. Participants aged 8 to 85 years completed self-report measures whereas parents/guardians responded for children aged 3 to 12 years. Data were analyzed using a combination of classic test theory and item response theory methods, yielding efficient measures of emotional health concepts. An overview of the development of the NIH Toolbox Emotion battery is presented along with preliminary results. Norming activities led to further refinement of the battery, thus enhancing the robustness of emotional health measurement for researchers using the NIH Toolbox. Neurology (R) 2013; 80 (Suppl3):S76-S86 C1 [Salsman, John M.; Butt, Zeeshan; Choi, Seung W.; Lai, Jin-Shei; Griffith, James W.; Cella, David] Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, Chicago, IL 60611 USA. [Bode, Rita K.] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA. [Salsman, John M.; Lai, Jin-Shei; Cella, David] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. [Butt, Zeeshan] Northwestern Univ, Comprehens Transplant Ctr, Chicago, IL 60611 USA. [Salsman, John M.; Butt, Zeeshan; Lai, Jin-Shei; Griffith, James W.; Cella, David] Northwestern Univ, Ctr Patient Centered Outcomes, Chicago, IL 60611 USA. [Pilkonis, Paul A.; Cyranowski, Jill M.; Kelly, Morgen A. R.] Univ Pittsburgh, Dept Psychiat, Med Ctr, Pittsburgh, PA USA. [Zill, Nicholas] Westat Corp, Rockville, MD USA. [Hendrie, Hugh C.] Indiana Univ Sch Med, Ctr Aging Res, Indianapolis, IN USA. [Kupst, Mary Jo] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA. [Kelly, Morgen A. R.] Family Serv Western Pennsylvania, Pittsburgh, PA USA. [Kelly, Morgen A. R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Stoney, Catherine M.] NHLBI, NIH, Bethesda, MD 20892 USA. [Brouwers, Pim] NIH, Div AIDS Res, Bethesda, MD 20892 USA. [Knox, Sarah S.] W Virginia Univ, Sch Med, Dept Community Med, Morgantown, WV 26506 USA. RP Salsman, JM (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, Chicago, IL 60611 USA. EM j-salsman@northwestern.edu RI Griffith, James/O-2551-2016 OI Griffith, James/0000-0002-4840-8692 FU Office of Behavioral and Social Sciences Research, NIH [HHS-N-260-2006-00007-C]; Blueprint for Neuroscience Research; NIH [HHSN265200423601C, U01 AR052177-05, KL2RR0254740, HD067440, DK091786, DK062467-10, DK06246708S1, AR052155, AT006453, MH056888, MH066302, MH090333, HL076852, AR52155, MH37896, MH085874, MH083647, AG012546, AR052186, MH086637, U01 DK082342]; GlaxoSmithKline; American Cancer SocietyIllinois Division [PSB-08-15]; National Cancer Institute [5K07CA158008-01A1]; Boehringer Ingelheim; Pfizer; Patient-Centered Outcomes Research Institute (PCORI); Daiichi Sankyo, Inc.; Frankel Foundation; Pittsburgh Foundation; National Council for Adoption; Brookings Institution; Marriage and Religion Research Institute; NorthShore University HealthSystem; Cleveland Clinic Foundation/Teva Neurosciences, Inc.; Ironwood Pharmaceuticals, Inc.; Forest Laboratories, Inc.; Department of Defense (DOD)-United States Army; FWO FX This study is funded in whole or in part with Federal funds from the Blueprint for Neuroscience Research and the Office of Behavioral and Social Sciences Research, NIH, under contract no. HHS-N-260-2006-00007-C.; J. Salsman served as an independent contractor for the RTOG (Study no. 0841) and has received research support from the NIH (Contract no. HHSN265200423601C), GlaxoSmithKline, the American Cancer SocietyIllinois Division (PSB-08-15), and the NIH (U01 AR052177-05). He currently receives research support from the National Cancer Institute (5K07CA158008-01A1). Z. Butt served as a consultant for Johnson & Johnson and the American Society of Transplant Surgeons. He received support from Boehringer Ingelheim, Pfizer, the Patient-Centered Outcomes Research Institute (PCORI), and NIH grant KL2RR0254740. He currently receives research support from Daiichi Sankyo, Inc., the Frankel Foundation, and NIH grants HD067440, DK091786, DK062467-10, and DK06246708S1. P. Pilkonis served as a consultant for Lundbeck Pharmaceuticals. He currently receives support from NIH grants AR052155, AT006453, MH056888, MH066302, and MH090333. J. Cyranowski has received research funding from the Pittsburgh Foundation and from NIH grants HL076852, AR52155, and MH37896; she currently receives research support from NIH grants MH085874, MH083647, AG012546, AR052186, and MH086637. N. Zill received research support from the National Council for Adoption, the Brookings Institution, and the Marriage and Religion Research Institute. He served as a reviewer for an NIH SBIR Review Panel. He holds a TIAA-CREF Retirement Annuity Contract that invests in US Treasury Bonds and an International Stock Index Fund. He received consulting income and income from selling stock and exercising stock options from Westat, an employee-owned S Corporation. He holds an IRA and brokerage account with Vanguard that includes holdings in the Vanguard Health Care, Precious Metals and Mining, High-Yield Corporate Bond, High-Yield Tax Exempt Bond, and Long-Term Corporate Bond mutual funds, as well as the Vanguard Consumer Discretionary, Consumer Staples, FTSE International Small Cap, and Corporate Long-Term Bond Exchange Traded Funds. He has holdings in a number of closed-ended mutual funds, including the Aberdeen Asia Pacific Income Fund, Templeton Global High Income Fund, Templeton Dragon Fund, Alliance-Bernstein Global High Income Fund, Alliance-Bernstein Corporate Income Fund, Blackrock Income Opportunity Trust, Putnam Master Intermediate Income Trust, Nuveen Floating Rate Income Opportunity Fund, India Fund, Morgan Stanley India Investment Fund, Latin American Discovery Fund, Aberdeen Latin American Equity Fund, Singapore Fund, and Turkish Investment Fund. He has stock holdings in AT& T, Boardwalk Pipeline Partners, Banco de Columbia, Consolidated Edison, Exxon, Frontier Communications, GlaxoSmithKline, Honeywell, Huntington Ingalls Industries, IBM, Intel, 3M, MeadWestvaco, Newell Rubbermaid, Northrop Grumman, Occidental Petroleum, SCANA, Sherwin-Williams, Siemens, Southern, Verizon, Johnson Controls, American Superconductor, Ocean Power Technology, and Maxwell Technology. Dr. Zill's wife, Karen, prepared discussion guides for the Independent Lens program on PBS. She holds a TIAA Retirement Annuity Contract that invests in US Treasury Bonds. H. Hendrie currently receives research funding from NIH/NIA grant R01AG009956, R24MH080827, 5R01AG026096-05, UF20303/U01AG022376, R01AG031222, R01AG019181, and R01AG029884. M. Kupst reports no disclosures. M. Kelly has been employed by the University of Pittsburgh School of Medicine and Family Services of Western Pennsylvania. Dr.; Kelly is the coprincipal investigator on a study sponsored by Ortho McNeil Janssen for which Family Services of Western Pennsylvania receives remuneration. Dr. Kelly does not receive direct remuneration for her role in that study. R. Bode reports no disclosures. S. Choi has received research support from Boehringer-Ingelheim, Novartis, and the NIH. J.-S. Lai has received research support from the NIH, Agency for Healthcare Research and Quality, and Pfizer, Inc. J. Griffith has received financial support from NorthShore University HealthSystem, the Cleveland Clinic Foundation/Teva Neurosciences, Inc., Ironwood Pharmaceuticals, Inc., and Forest Laboratories, Inc., the NIH, the Department of Defense (DOD)-United States Army, and the FWO, Belgium. In addition to NIH Toolbox funding, he receives funding from the NIH for other research (grant U01 DK082342). He has also been a paid consultant to Dr. Kathryn Grant of DePaul University, and maintains a clinical psychology practice for which he bills for his services. C. Stoney reports no disclosures. P. Brouwers and S. Knox report no disclosures. D. Cella serves on the editorial board of the Journal of Supportive Oncology, has received travel support from Pfizer, honoraria from Virginia Commonwealth University and Moffit Cancer Center for speaking engagements, and research support from Boehringer-Ingelheim, Novartis, and the NIH. He also receives royalties from Up to Date. Go to Neurology. org for full disclosures. NR 33 TC 10 Z9 10 U1 4 U2 16 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD MAR PY 2013 VL 80 SU 3 BP S76 EP S86 DI 10.1212/WNL.0b013e3182872e11 PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA 104LS UT WOS:000315995100014 PM 23479549 ER PT J AU D'Alonzo, KT DeMarco, RF DeSanto-Madeya, S Horowitz, JA Moriarty, HJ Shepard, M AF D'Alonzo, Karen T. DeMarco, Rosanna F. DeSanto-Madeya, Susan Horowitz, June Andrews Moriarty, Helene J. Shepard, Margaret TI Effective use of Critique and Dialog at Academic Conferences- Building a Community of Scholars SO NURSING RESEARCH LA English DT Meeting Abstract C1 [D'Alonzo, Karen T.] Rutgers State Univ, Piscataway, NJ 08855 USA. [DeMarco, Rosanna F.; Horowitz, June Andrews] Boston Coll, Chestnut Hill, MA 02167 USA. [DeSanto-Madeya, Susan] Univ Massachusetts Boston, Boston, MA USA. [Moriarty, Helene J.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Shepard, Margaret] UMDNJ, Newark, NJ 07107 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-6562 J9 NURS RES JI Nurs. Res. PD MAR-APR PY 2013 VL 62 IS 2 BP E7 EP E8 PG 2 WC Nursing SC Nursing GA 103WX UT WOS:000315951300020 ER PT J AU Horowitz, JA DuBois, N Hayes, M Moriarty, HJ Zirkle, D AF Horowitz, June Andrews DuBois, Nancy Hayes, Margaret Moriarty, Helene J. Zirkle, Dorothy TI Challenges and Strategies When Context, Culture, and Time Affect Measurement in Family Research SO NURSING RESEARCH LA English DT Meeting Abstract C1 [Horowitz, June Andrews; Hayes, Margaret; Zirkle, Dorothy] Boston Coll, Chestnut Hill, MA 02167 USA. [DuBois, Nancy] Thomas Jefferson Univ, Philadelphia, PA USA. [Moriarty, Helene J.] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-6562 J9 NURS RES JI Nurs. Res. PD MAR-APR PY 2013 VL 62 IS 2 BP E41 EP E41 PG 1 WC Nursing SC Nursing GA 103WX UT WOS:000315951300116 ER PT J AU Jackson-Malik, P McLaughlin, M AF Jackson-Malik, Pamela McLaughlin, Mary TI Rapid Oral Fluid Testing for HIV in Veterans with Mental Health Diagnoses and Living in Community Assisted Living Residences SO NURSING RESEARCH LA English DT Meeting Abstract C1 [Jackson-Malik, Pamela; McLaughlin, Mary] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-6562 J9 NURS RES JI Nurs. Res. PD MAR-APR PY 2013 VL 62 IS 2 BP E106 EP E106 PG 1 WC Nursing SC Nursing GA 103WX UT WOS:000315951300302 ER PT J AU Moriarty, HJ DeMarco, RF Horowitz, JA True, G Winter, L AF Moriarty, Helene J. DeMarco, Rosanna F. Horowitz, June Andrews True, Gala Winter, Laraine TI Using Qualitative Data to Understand and Inform Quantitative Data in Intervention Studies with Families SO NURSING RESEARCH LA English DT Meeting Abstract C1 [Moriarty, Helene J.; Winter, Laraine] Philadelphia VA Med Ctr, Philadelphia, PA USA. [True, Gala] Philadelphia VA Med Ctr, CHERP, Philadelphia, PA USA. [DeMarco, Rosanna F.; Horowitz, June Andrews] Boston Coll, Chestnut Hill, MA 02167 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-6562 J9 NURS RES JI Nurs. Res. PD MAR-APR PY 2013 VL 62 IS 2 BP E42 EP E42 PG 1 WC Nursing SC Nursing GA 103WX UT WOS:000315951300118 ER PT J AU Shepard, M DeSanto-Madeya, S Horowitz, JA Moriarty, HJ AF Shepard, Margaret DeSanto-Madeya, Susan Horowitz, June Andrews Moriarty, Helene J. TI Emerging Research Methods That Are Responsive To Families And Communities SO NURSING RESEARCH LA English DT Meeting Abstract C1 [Shepard, Margaret] UMDNJ, Newark, NJ USA. [DeSanto-Madeya, Susan] Univ Massachusetts Boston, Boston, MA USA. [Horowitz, June Andrews] Boston Coll, Chestnut Hill, MA 02167 USA. [Moriarty, Helene J.] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-6562 J9 NURS RES JI Nurs. Res. PD MAR-APR PY 2013 VL 62 IS 2 BP E41 EP E41 PG 1 WC Nursing SC Nursing GA 103WX UT WOS:000315951300115 ER PT J AU Royer, HR Falk, EC Heidrich, SM AF Royer, Heather R. Falk, Elizabeth C. Heidrich, Susan M. TI Sexually Transmitted Disease Testing Misconceptions Threaten the Validity of Self-Reported Testing History SO PUBLIC HEALTH NURSING LA English DT Article DE beliefs; screening; sexually transmitted diseases; women's health ID UNITED-STATES; YOUNG-WOMEN; CHLAMYDIA; STIGMA; ADOLESCENTS; INFECTIONS; PREVALENCE; KNOWLEDGE; GONORRHEA; HEALTH AB Objective Sexually transmitted disease (STD) testing is fundamental to STD prevention and control. We sought to comprehensively examine young women's beliefs about the STD testing process. Design and Sample Descriptive, cross-sectional, survey investigation. Women aged 1824 (n=302) drawn from four women's health clinics and one university classroom. Measures Participants completed the RoTEST, which measures five domains of women's STD testing beliefs and a demographic survey. Results Many women believed they would be screened for all STDs when they receive STD testing (40%) and that visual inspection by a provider was a valid method of STD screening for gonorrhea (35%), chlamydia (32%) and HSV (77%). More than a quarter believed that a Pap test screens for gonorrhea (23%) and chlamydia (26%). Twenty-one percent reported that discussing STD testing with a provider is difficult and most reported feeling more comfortable seeking STD testing from an STD specialist rather than a family doctor (79%). Conclusions Young women have numerous misconceptions about the STD testing process that may interfere with the validity of their self-reported STD testing history and subsequently undermine public health efforts to improve STD prevention and control. Innovative approaches to educating women about the testing process are needed. C1 [Royer, Heather R.] Univ Wisconsin Milwaukee, Coll Nursing, Milwaukee, WI USA. [Falk, Elizabeth C.] Univ Wisconsin Whitewater, Univ Hlth & Counseling Serv, Whitewater, WI USA. [Heidrich, Susan M.] Univ Wisconsin Madison, Sch Nursing, Madison, WI USA. [Heidrich, Susan M.] Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, Madison, WI 53792 USA. RP Royer, HR (reprint author), 1921 E Hartford Ave, Milwaukee, WI 53211 USA. EM hrroyer@uwm.edu NR 23 TC 3 Z9 3 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0737-1209 J9 PUBLIC HEALTH NURS JI Public Health Nurs. PD MAR-APR PY 2013 VL 30 IS 2 BP 117 EP 127 DI 10.1111/phn.12013 PG 11 WC Public, Environmental & Occupational Health; Nursing SC Public, Environmental & Occupational Health; Nursing GA 100BK UT WOS:000315669500004 PM 23452106 ER PT J AU Wiener, H Klei, L Calkins, M Wood, J Nimgaonkar, V Gur, R Bradford, LD Richard, J Edwards, N Savage, R Kwentus, J Allen, T McEvoy, J Santos, A Gur, R Devlin, B Go, R AF Wiener, Howard Klei, Lambertus Calkins, Monica Wood, Joel Nimgaonkar, Vishwajit Gur, Ruben Bradford, L. DiAnne Richard, Jan Edwards, Neil Savage, Robert Kwentus, Joseph Allen, Trina McEvoy, Joseph Santos, Alberto Gur, Raquel Devlin, Bernie Go, Rodney TI Principal Components of Heritability From Neurocognitive Domains Differ Between Families With Schizophrenia and Control Subjects SO SCHIZOPHRENIA BULLETIN LA English DT Article DE schizophrenia; cognition; heritability; principal components; linkage ID RECURRENT MICRODELETIONS; AFRICAN-AMERICANS; PSYCHOSIS VARIANT; LINKAGE ANALYSIS; EXPLORE RISKS; CHILDHOOD; ZNF804A; MEMORY; IMPAIRMENT; PROJECT AB Objective: Various measures of neurocognitive function show mean differences among individuals with schizophrenia (SZ), their relatives, and population controls. We use eigenvector transformations that maximize heritability of multiple neurocognitive measures, namely principal components of heritability (PCH), and evaluate how they distribute in SZ families and controls. Methods: African-Americans with SZ or schizoaffective disorder (SZA) (n = 514), their relatives (n = 1092), and adult controls (n = 300) completed diagnostic interviews and computerized neurocognitive tests. PCH were estimated from 9 neurocognitive domains. Three Pd, PCH1-PCH3, were modeled to determine if status (SZ, relative, and control), other psychiatric covariates, and education were significant predictors of mean values. A small-scale linkage analysis was also conducted in a subset of the sample. Results: PCH1, PCH2, and PCH3 account for 72% of the genetic variance. PCH1 represents 8 of 9 neurocognitive domains, is most highly correlated with spatial processing and emotion recognition, and has unadjusted heritability of 68%. The means for PCH1 differ significantly among SZ, their relatives, and controls. PCH2, orthogonal to PCH1, is most closely correlated with working memory and has an unadjusted heritability of 45%. Mean PCH2 is different only between SZ families and controls. PCH3 apparently represents a heritable component of neurocognition similar across the 3 diagnostic groups. No significant linkage evidence to PCH1-PCH3 or individual neurocognitive measures was discovered. Conclusions: PCH1 is highly heritable and genetically correlated with SZ. It should prove useful in future genetic analyses. Mean PCH2 differentiates SZ families and controls but not SZ and unaffected family members. C1 [Wiener, Howard; Go, Rodney] Univ Alabama Birmingham, Dept Epidemiol & Int Hlth, Birmingham, AL USA. [Klei, Lambertus; Wood, Joel; Nimgaonkar, Vishwajit; Devlin, Bernie] Univ Pittsburgh Sch Med, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA USA. [Calkins, Monica; Gur, Ruben; Richard, Jan; Gur, Raquel] Univ Penn, Dept Psychiat, Neuropsychiat Sect, Philadelphia, PA 19104 USA. [Nimgaonkar, Vishwajit; Devlin, Bernie] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA. [Gur, Ruben] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Bradford, L. DiAnne] Morehouse Sch Med, Dept Psychiat, Atlanta, GA 30310 USA. [Edwards, Neil] Univ Tennessee, Coll Med, Dept Psychiat, Memphis, TN USA. [Savage, Robert] Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, Birmingham, AL USA. [Kwentus, Joseph] Univ Mississippi Med Ctr, Dept Psychiat & Human Behav, Jackson, MS USA. [Allen, Trina; McEvoy, Joseph] Duke Univ Med Ctr, John Umstead Hosp, Butner, NC USA. [Santos, Alberto] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. RP Devlin, B (reprint author), Western Psychiat Inst & Clin, Computat Genet Program, Room 430,Oxford Bldg,3501 Forbes Ave, Pittsburgh, PA 15213 USA. EM devlinbj@upmc.edu FU National Institute of Mental Health [MH066006, MH066278, MH066049, MH066181, MH066121, MH066005, MH066050, MH066263, MH066004, K08MH79364]; National Institute of Mental Health; federal contract from the National Institutes of Health [HHSN268200782096C]; University of Pennsylvania; AstraZeneca; Pfizer; Merck; University of Mississippi; Eli Lilly; Bristol Meyers; Johnson Johnson; Takeda FX This work was supported by the National Institute of Mental Health (MH066006, MH066278, MH066049, MH066181, MH066121, MH066005, MH066050, MH066263, MH066004, and K08MH79364). The National Institute of Mental Health also provided funding to pay for Open Access. Genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, contract number HHSN268200782096C. University of Pennsylvania with AstraZeneca, Pfizer, and Merck (to Ru.G.). University of Mississippi with Eli Lilly, AstraZeneca, Pfizer, Bristol Meyers, Johnson & Johnson and Takeda (to J.K.). University of Pennsylvania with AstraZeneca and Pfizer. (Dr Ra.G.) Drs Ru.G. and Ra.G. and Ms J.R. may receive royalties from future commercial use of the Penn Computerized Neurocognitive Battery. NR 40 TC 5 Z9 5 U1 2 U2 12 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2013 VL 39 IS 2 BP 464 EP 471 DI 10.1093/schbul/sbr161 PG 8 WC Psychiatry SC Psychiatry GA 098NV UT WOS:000315556900029 PM 22234486 ER PT J AU Lawson, EH Ko, CY Louie, R Han, L Rapp, M Zingmond, DS AF Lawson, Elise H. Ko, Clifford Y. Louie, Rachel Han, Lein Rapp, Michael Zingmond, David S. TI Linkage of a clinical surgical registry with Medicare inpatient claims data using indirect identifiers SO SURGERY LA English DT Article ID SURGERY; LINKING; NSQIP AB Background. A variety of data sources are available for measuring the quality of health care. Linking records from different sources can create unique and powerful databases that can be used to evaluate clinically relevant questions and direct health care policy. The objective of this study was to develop and validate a deterministic linkage algorithm that uses indirect patient identifiers to reliably match records from a surgical clinical registry with Medicare inpatient claims data. Methods. Patient records from the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP), years 2005-2008, were linked to claims data in the Medicare Provider Analysis and Review file (MedPAR) by the use of a deterministic linkage algorithm and the following indirect patient identifiers: hospital, age, sex, diagnosis, procedure and dates of admission, discharge, and procedure. We validated the linkage procedure by systematically reviewing subsets of matched and unmatched records and by determining agreement on patient-level coding of inpatient mortality. Results. Of the 150,454 records in ACS-NSQIP eligible for matching, 80.5% were linked to a MedPAR record. This percentage is within the expected match range given the estimated percentage of ACS-NSQIP patients likely to be Medicare beneficiaries. Systematic checks revealed no evidence of bias in the linkage procedure and there was excellent agreement on patient-level coding of mortality (kappa 0.969). The final linked database contained 121,070 patient records from 217 hospitals. Conclusion. This study demonstrates the feasibility and validity of a method for linking 2 data sources without direct personal identifiers. As clinical registries and other data sources continue to proliferate, linkage algorithms such as described here will be critical for quality measurement purposes. (Surgery 2013;153:423-30.) C1 [Lawson, Elise H.; Ko, Clifford Y.; Louie, Rachel; Zingmond, David S.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Lawson, Elise H.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA. [Lawson, Elise H.; Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Han, Lein; Rapp, Michael] Ctr Medicare & Medicaid Serv, Baltimore, MD USA. RP Lawson, EH (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 Le Conte Ave 72-215 CHS, Los Angeles, CA 90095 USA. EM elawson@mednet.ucla.edu FU Centers for Medicare & Medicaid Services (CMS); VA Health Services Research and Development program [RWJ 65-020]; American College of Surgeons through the Robert Wood Johnson Foundation Clinical Scholars Program FX Supported by a contract from the Centers for Medicare & Medicaid Services (CMS). In addition, Dr Lawson's time was supported by the VA Health Services Research and Development program (RWJ 65-020) and the American College of Surgeons through the Robert Wood Johnson Foundation Clinical Scholars Program. Dr Ko is an employee of the American College. of Surgeons. Dr Han and Dr Rapp are employees of CMS. NR 5 TC 24 Z9 24 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0039-6060 J9 SURGERY JI Surgery PD MAR PY 2013 VL 153 IS 3 BP 423 EP 430 DI 10.1016/j.surg.2012.08.065 PG 8 WC Surgery SC Surgery GA 101AQ UT WOS:000315748000019 PM 23122901 ER PT J AU Stickrath, C Aagaard, E Anderson, M AF Stickrath, Chad Aagaard, Eva Anderson, Mel TI MiPLAN: A Learner-Centered Model for Bedside Teaching in Today's Academic Medical Centers SO ACADEMIC MEDICINE LA English DT Article ID DUTY-HOUR REGULATIONS; INTERNAL-MEDICINE; CASE PRESENTATIONS; ATTENDING ROUNDS; EXAMINATION ROOM; EDUCATION; STUDENTS; STRATEGIES; RESIDENT; FACULTY AB Clinician educators and medical trainees face intense pressure to complete numerous patient care and teaching activities in a limited amount of time. To address the need for effective and efficient teaching methods for use in the inpatient setting, the authors used constructivist learning theory, the principles of adult learning, and their expertise as clinician educators to develop the MiPLAN model for bedside teaching. This three-part model is designed to enable clinical teachers to simultaneously provide care to patients while assessing learners, determining high-yield teaching topics, and providing feedback to learners. The "M" refers to a preparatory meeting between teacher and learners before engaging in patient care or educational activities. During this meeting, team members should become acquainted and the teacher should set goals and clarify expectations. The "i" refers to five behaviors for the teacher to adopt during learners' bedside presentations: introduction, in the moment, inspection, interruptions, and independent thought. "PLAN" is an algorithm to establish priorities for teaching subsequent to a learner's presentation: patient care, learners' questions, attending's agenda, and next steps. The authors suggest that the MiPLAN model can help clinical teachers gain more confidence in their ability to teach at the bedside and increase the frequency and quality of bedside teaching. They propose further research to assess the generalizability of this model to other institutions, settings, and specialties and to evaluate educational and patient outcomes. C1 [Stickrath, Chad; Aagaard, Eva; Anderson, Mel] Univ Colorado, Sch Med, Aurora, CO USA. [Stickrath, Chad; Anderson, Mel] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. RP Stickrath, C (reprint author), Denver Vet Affairs Med Ctr, 1055 Clermont St 111, Denver, CO 80220 USA. EM Chad.Stickrath@va.gov NR 38 TC 10 Z9 10 U1 1 U2 22 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 J9 ACAD MED JI Acad. Med. PD MAR PY 2013 VL 88 IS 3 BP 322 EP 327 DI 10.1097/ACM.0b013e318280d8f7 PG 6 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 098CJ UT WOS:000315522600016 PM 23348088 ER PT J AU Durazzo, TC Mon, A Gazdzinski, S Meyerhoff, DJ AF Durazzo, Timothy C. Mon, Anderson Gazdzinski, Stefan Meyerhoff, Dieter J. TI Chronic cigarette smoking in alcohol dependence: associations with cortical thickness and N-acetylaspartate levels in the extended brain reward system SO ADDICTION BIOLOGY LA English DT Review DE Alcohol dependence; brain reward system; cigarette smoking; cortical thickness; N-acetylaspartate; nicotine ID MAGNETIC-RESONANCE-SPECTROSCOPY; FRONTAL-SUBCORTICAL CIRCUITS; NATIONAL EPIDEMIOLOGIC SURVEY; ANTERIOR CINGULATE CORTEX; PROTON MR SPECTROSCOPY; SURFACE-BASED ANALYSIS; HUMAN CEREBRAL-CORTEX; SHORT-TERM RECOVERY; DSM-IV ALCOHOL; ORBITOFRONTAL CORTEX AB Chronic smoking in alcohol dependence is associated with abnormalities in brain morphology and metabolite levels in large lobar regions (e.g. frontal lobe). Here, we evaluated if these abnormalities are specifically apparent in several cortical and select subcortical components of the extended brain reward system (BRS), a network that is critically involved in the development and maintenance of all forms of addictive disorders. We studied 33 non-smoking and 43 smoking alcohol-dependent individuals (ALC) with 1 week of abstinence and 42 non-smoking Controls. At 1.5 Tesla, we obtained regional measures of cortical thickness and N-acetylaspartate (NAA; a surrogate marker of neuronal integrity) concentration in major components of the BRS as well as the corresponding measures throughout the cortex. Smoking ALC and non-smoking ALC demonstrated decreased thickness compared with Controls in the dorsolateral prefrontal cortex (DLPFC), insula, orbitofrontal cortex (OFC), the total BRS, total frontal cortex and global cortex. Smoking ALC had significantly decreased thickness compared to non-smoking ALC in the ACC, insula, the total BRS and total frontal cortex. Smoking ALC had also lower NAA concentrations than both non-smoking ALC and Controls in the DLPFC, insula, superior corona radiata and the total BRS. Alcohol consumption and common medical and psychiatric co-morbidities did not mediate differences between smoking and non-smoking ALC. This dual modality magnetic resonance (MR) study indicated that chronic smoking in ALC was associated with significant cortical thinning and NAA abnormalities in anterior brain regions that are implicated in the development and maintenance of addictive disorders. C1 [Durazzo, Timothy C.; Mon, Anderson; Gazdzinski, Stefan; Meyerhoff, Dieter J.] San Francisco VA Med Ctr, CIND, San Francisco, CA 94121 USA. [Durazzo, Timothy C.; Mon, Anderson; Meyerhoff, Dieter J.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. RP Durazzo, TC (reprint author), San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis 114M, 4150 Clement St, San Francisco, CA 94121 USA. EM timothy.durazzo@ucsf.edu FU National Institutes of Health [AA10788, DA24136] FX This work was supported by the National Institutes of Health [AA10788 to D.J.M.; DA24136 to T. C. D.] and by the use of resources and facilities at the San Francisco Veterans Administration Medical Center. The authors have no disclosures or conflicts of interest to report. We thank Mary Rebecca Young, Bill Clift, and Drs. Peter Banys and Ellen Herbst of the Veterans Administration Substance Abuse Day Hospital, which routinely offers smoking cessation with substance abuse treatment, and Dr. David Pating, Karen Moise and their colleagues at the Kaiser Permanente Chemical Dependency Recovery Program in San Francisco for their valuable assistance in recruiting participants. We also wish to extend our gratitude to the study participants, who made this research possible. NR 112 TC 18 Z9 18 U1 1 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1355-6215 J9 ADDICT BIOL JI Addict. Biol. PD MAR PY 2013 VL 18 IS 2 BP 379 EP 391 DI 10.1111/j.1369-1600.2011.00407.x PG 13 WC Biochemistry & Molecular Biology; Substance Abuse SC Biochemistry & Molecular Biology; Substance Abuse GA 097VB UT WOS:000315500500017 PM 22070867 ER PT J AU McGinnis, KA Justice, AC Kraemer, KL Saitz, R Bryant, KJ Fiellin, DA AF McGinnis, Kathleen A. Justice, Amy C. Kraemer, Kevin L. Saitz, Richard Bryant, Kendall J. Fiellin, David A. TI Comparing Alcohol Screening Measures Among HIV-Infected and -Uninfected Men SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE AUDIT; HIV; Veterans; Alcohol-Related Disorders; Mass Screening ID IDENTIFICATION TEST AUDIT; USE DISORDERS; PRIMARY-CARE; CONSUMPTION QUESTIONS; DISEASE PROGRESSION; FOLLOW-UP; DRINKING; RELIABILITY; DRINKERS; RISK AB Background Brief measures of unhealthy alcohol use have not been well validated among people with HIV. We compared the Alcohol Use Disorders Identification Test (AUDIT) to reference standards for unhealthy alcohol use based on 30-day Timeline Follow Back (TLFB) and Composite International Diagnostic InterviewSubstance Abuse Module (CIDI-SAM), among 837 male HIV-infected and -uninfected patients in the Veterans Aging Cohort Study. Methods Three reference standards were (i) Risky drinkingbased on TLFB >14 drinks over 7 consecutive days or >4 drinks on 1day; (ii) Alcohol dependencebased on a CIDI-SAM diagnosis; and (iii) Unhealthy alcohol userisky drinking or a CIDI-SAM diagnosis of abuse or dependence. Various cutoffs for the AUDIT, AUDIT-C, and heavy episodic drinking were compared with the reference standards. Results Mean age of patients was 52years, 53% (444) were HIV-infected, and 53% (444) were African American. Among HIV-infected and -uninfected patients, the prevalence of risky drinking (14 vs. 12%, respectively), alcohol dependence (8 vs. 7%), and unhealthy alcohol use (22 vs. 20%) was similar. For risky drinking and alcohol dependence, multiple cutoffs of AUDIT, AUDIT-C, and heavy episodic drinking provided good sensitivity (80%) and specificity (90%). For unhealthy alcohol use, few cutoffs provided sensitivity 80%; however, many cutoffs provided good specificity. For all 3 alcohol screening measures, sensitivity improved when heavy episodic drinking was included with the cutoff. Sensitivity of measures for risky drinking and unhealthy alcohol use was lower in HIV-infected than in uninfected patients. Conclusions For identifying risky drinking, alcohol dependence, and unhealthy alcohol use, AUDIT-C performs as well as AUDIT and similarly in HIV-infected and -uninfected patients. Cutoffs should be based on the importance of specific operating characteristics for the intended research or clinical use. Incorporating heavy episodic drinking increased sensitivity for detecting alcohol dependence and unhealthy alcohol use. C1 [McGinnis, Kathleen A.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA. [Justice, Amy C.; Fiellin, David A.] Yale Univ, Sch Med, Div Gen Internal Med, New Haven, CT USA. [Justice, Amy C.; Fiellin, David A.] West Haven VA Healthcare Syst, Vet Aging Cohort Study Coordinating Ctr, West Haven, CT USA. [Justice, Amy C.; Fiellin, David A.] Yale Univ, Sch Publ Hlth, Ctr Interdisciplinary Res AIDS, New Haven, CT USA. [Kraemer, Kevin L.] Univ Pittsburgh, Dept Med, Ctr Res Hlth Care, Div Gen Internal Med, Pittsburgh, PA USA. [Saitz, Richard] Boston Med Ctr, Dept Med, Clin Addict Res & Educ CARE Unit, Gen Internal Med Sect, Boston, MA USA. Boston Univ, Sch Med, Boston, MA 02118 USA. [Saitz, Richard] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Bryant, Kendall J.] NIAAA, Bethesda, MD USA. RP McGinnis, KA (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr,151C-H, Pittsburgh, PA 15206 USA. EM kathleen.mcginnis3@va.gov OI Fiellin, David/0000-0002-4006-010X; /0000-0002-2535-1427 FU National Institute on Alcohol Abuse and Alcoholism [U10 AA 13566] FX The Veterans Aging Cohort Study is funded by the National Institute on Alcohol Abuse and Alcoholism (U10 AA 13566). NR 34 TC 16 Z9 16 U1 3 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD MAR PY 2013 VL 37 IS 3 BP 435 EP 442 DI 10.1111/j.1530-0277.2012.01937.x PG 8 WC Substance Abuse SC Substance Abuse GA 097VC UT WOS:000315500600009 PM 23050632 ER PT J AU Shi, Y Pulliam, DA Liu, YH Hamilton, RT Jernigan, AL Bhattacharya, A Sloane, LB Qi, WB Chaudhuri, A Buffenstein, R Ungvari, Z Austad, SN Van Remmen, H AF Shi, Yun Pulliam, Daniel A. Liu, Yuhong Hamilton, Ryan T. Jernigan, Amanda L. Bhattacharya, Arunabh Sloane, Lauren B. Qi, Wenbo Chaudhuri, Asish Buffenstein, Rochelle Ungvari, Zoltan Austad, Steven N. Van Remmen, Holly TI Reduced mitochondrial ROS, enhanced antioxidant defense, and distinct age-related changes in oxidative damage in muscles of long-lived Peromyscus leucopus SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE Peromyscus leucopus; mitochondria; reactive oxygen species; skeletal muscle; oxidative damage; comparative biology of aging ID HYDROGEN-PEROXIDE PRODUCTION; SKELETAL-MUSCLE; UNCOUPLING PROTEIN-3; SUPEROXIDE-DISMUTASE; ELECTRON-TRANSPORT; STRESS RESISTANCE; MOUSE HINDLIMB; FIBER TYPES; LONGEVITY; MICE AB Shi Y, Pulliam DA, Liu Y, Hamilton RT, Jernigan AL, Bhattacharya A, Sloane LB, Qi W, Chaudhuri A, Buffenstein R, Ungvari Z, Austad SN, Van Remmen H. Reduced mitochondrial ROS, enhanced antioxidant defense, and distinct age-related changes in oxidative damage in muscles of long-lived Peromyscus leucopus. Am J Physiol Regul Integr Comp Physiol 304: R343-R355, 2013. First published January 16, 2013; doi:10.1152/ajpregu.00139.2012.-Comparing biological processes in closely related species with divergent life spans is a powerful approach to study mechanisms of aging. The oxidative stress hypothesis of aging predicts that longer-lived species would have lower reactive oxygen species (ROS) generation and/or an increased antioxidant capacity, resulting in reduced oxidative damage with age than in shorter-lived species. In this study, we measured ROS generation in the young adult animals of the long-lived white-footed mouse, Peromyscus leucopus (maximal life span potential, MLSP = 8 yr) and the common laboratory mouse, Mus musculus (C57BL/6J strain; MLSP = 3.5 yr). Consistent with the hypothesis, our results show that skeletal muscle mitochondria from adult P. leucopus produce less ROS (superoxide and hydrogen peroxide) compared with M. musculus. Additionally, P. leucopus has an increase in the activity of antioxidant enzymes superoxide dismutase 1, catalase, and glutathione peroxidase 1 at young age. P. leucopus compared with M. musculus display low levels of lipid peroxidation (isoprostanes) throughout life; however, P. leucopus although having elevated protein carbonyls at a young age, the accrual of protein oxidation with age is minimal in contrast to the linear increase in M. musculus. Altogether, the results from young animals are in agreement with the predictions of the oxidative stress hypothesis of aging with the exception of protein carbonyls. Nonetheless, the age-dependent increase in protein carbonyls is more pronounced in short-lived M. musculus, which supports enhanced protein homeostasis in long-lived P. leucopus. C1 [Shi, Yun; Pulliam, Daniel A.; Liu, Yuhong; Hamilton, Ryan T.; Jernigan, Amanda L.; Bhattacharya, Arunabh; Sloane, Lauren B.; Qi, Wenbo; Chaudhuri, Asish; Buffenstein, Rochelle; Austad, Steven N.; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. [Shi, Yun; Pulliam, Daniel A.; Liu, Yuhong; Hamilton, Ryan T.; Jernigan, Amanda L.; Bhattacharya, Arunabh; Qi, Wenbo; Austad, Steven N.; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cell & Struct Biol, San Antonio, TX 78245 USA. [Chaudhuri, Asish] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78245 USA. [Buffenstein, Rochelle; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78245 USA. [Chaudhuri, Asish; Van Remmen, Holly] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Ungvari, Zoltan] Univ Oklahoma, Hlth Sci Ctr, Dept Geriatr Med, Reynolds Oklahoma Ctr Aging, Oklahoma City, OK USA. RP Van Remmen, H (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, 15355 Lambda Dr, San Antonio, TX 78245 USA. EM vanremmen@uthscsa.edu FU NCCIH NIH HHS [R01 AT006526]; NIA NIH HHS [R01 AG022891]; NINDS NIH HHS [R01 NS056218] NR 71 TC 16 Z9 17 U1 0 U2 32 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD MAR PY 2013 VL 304 IS 5 BP R343 EP R355 DI 10.1152/ajpregu.00139.2012 PG 13 WC Physiology SC Physiology GA 100DY UT WOS:000315677200003 PM 23325454 ER PT J AU Odden, MC Tager, IB Gansevoort, RT Bakker, SJL Fried, LF Newman, AB Katz, R Satterfield, S Harris, TB Sarnak, MJ Siscovick, D Shlipak, MG AF Odden, Michelle C. Tager, Ira B. Gansevoort, Ron T. Bakker, Stephan J. L. Fried, Linda F. Newman, Anne B. Katz, Ronit Satterfield, Suzanne Harris, Tamara B. Sarnak, Mark J. Siscovick, David Shlipak, Michael G. TI Hypertension and low HDL cholesterol were associated with reduced kidney function across the age spectrum: a collaborative study SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE Chronic kidney insufficiency; Aged; Hypertension; Cholesterol; Obesity; Smoking ID SERUM CYSTATIN-C; URINARY ALBUMIN EXCRETION; CORONARY HEART-DISEASE; CARDIOVASCULAR-DISEASE; RENAL DYSFUNCTION; BLOOD-PRESSURE; POPULATION; RISK; ATHEROSCLEROSIS; PREDICTORS AB Purpose: To determine if the associations among established risk factors and reduced kidney function vary by age. Methods: We pooled cross-sectional data from 14,788 nondiabetics aged 40 to 100 years in 4 studies: Cardiovascular Health Study, Health, Aging, and Body Composition Study, Multi-Ethnic Study of Atherosclerosis, and Prevention of Renal and Vascular End-Stage Disease cohort. Results: Hypertension and low high-density lipoprotein (HDL) cholesterol were associated with reduced cystatin C-based estimated glomerular filtration rate (eGFR) across the age spectrum. In adjusted analyses, hypertension was associated with a 23 (95% confidence interval [CI], 0.1, 4.4), 5.1 (95% Cl, 4.1, 6.1), and 6.9 (95% CI, 3.0, 10.4) mL/min/1.73 m(2) lower eGFR in participants 40 to 59, 60 to 79, and at least 80 years, respectively (P for interaction < .001). The association of low HDL cholesterol with reduced kidney function was also greater in the older age groups: 4.9 (95% CI, 3.5, 6.3), 7.1 (95% CI, 6.0, 83), 8.9 (95% CI, 5.4,11.9) mL/min/1.73 m(2) (P for interaction < .001). Smoking and obesity were associated with reduced kidney function in participants under 80 years. All estimates of the potential population impact of the risk factors were modest. Conclusions: Hypertension, obesity, smoking, and low HDL cholesterol are modestly associated with reduced kidney function in nondiabetics. The associations of hypertension and HDL cholesterol with reduced kidney function seem to be stronger in older adults. (C) 2013 Elsevier Inc. All rights reserved. C1 [Odden, Michelle C.] Oregon State Univ, Sch Biol & Populat Hlth Sci, Corvallis, OR 97331 USA. [Tager, Ira B.] Univ Calif Berkeley, Dept Epidemiol, Berkeley, CA 94720 USA. [Gansevoort, Ron T.; Bakker, Stephan J. L.] Univ Groningen, Univ Med Ctr Groningen, Div Nephrol, Dept Internal Med, Groningen, Netherlands. [Fried, Linda F.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Newman, Anne B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Katz, Ronit] Univ Washington, Collaborat Hlth Studies Coordinating Ctr, Seattle, WA 98195 USA. [Satterfield, Suzanne] Univ Tennessee, Dept Med, Hlth Sci Ctr, Memphis, TN 38104 USA. [Harris, Tamara B.] NIA, Lab Epidemiol Demog & Biometry Program, NIH, Bethesda, MD 20892 USA. [Sarnak, Mark J.] Tufts Med Ctr, Div Nephrol, Dept Med, Boston, MA USA. [Siscovick, David] Univ Washington, Dept Med, Seattle, WA USA. [Siscovick, David] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, Dept Gen Internal Med, San Francisco, CA USA. RP Odden, MC (reprint author), Oregon State Univ, 321 Milam Hall, Corvallis, OR 97331 USA. EM Michelle.Odden@oregonstate.edu RI Newman, Anne/C-6408-2013; Bakker, Stephan/J-4023-2015 OI Newman, Anne/0000-0002-0106-1150; Bakker, Stephan/0000-0003-3356-6791 FU National Heart, Lung, and Blood Institute (NHLBI) [N01-HC-85239, N01-HC-85079, N01-HC-85080, N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC-85084, N01-HC-85085, N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133]; NHLBI [HL080295, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95169]; NIA [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, R01-AG028050, R01AG027002]; National Institute of Nursing Research [R01-NR012459]; NIH, NIA; Dutch Kidney Foundation, Bussum, The Netherlands [E013]; National Institute of Diabetes and Digestive, and Kidney Diseases [T32DK07791, DK52866]; American Heart Association Western States Affiliate Clinical Research Program; National Institute on Aging [K01AG039387]; [R01-HL-63963-01A1] FX The Cardiovascular Health Study was supported by National Heart, Lung, and Blood Institute (NHLBI) contracts N01-HC-85239, N01-HC-85079 through N01-HC-85086; N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133 and NHLBI grant HL080295, with additional contribution from National Institute of Neurological Disorders and Stroke. Additional support was provided through AG-023629, AG-15928, AG-20098, and AG-027058 from the National Institute on Aging (NIA). See also http://www.chs-nhlbi.org/pi.htm. Health ABC was supported through the NIA contracts N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106; NIA grant R01-AG028050, and National Institute of Nursing Research grant R01-NR012459. In addition, this research was supported in part by the Intramural Research Program of the NIH, NIA. MESA was supported by grant R01-HL-63963-01A1 and by contracts N01-HC-95159 through N01-HC-95165 and N01-HC-95169 from the NHLBI. PREVEND is supported by grant E013 of the Dutch Kidney Foundation, Bussum, The Netherlands, and grants T32DK07791 and DK52866 from the National Institute of Diabetes and Digestive, and Kidney Diseases.; This project was also supported by grant R01AG027002 from the NIA. Dr. Odden is supported by a the American Heart Association Western States Affiliate Clinical Research Program and the National Institute on Aging (K01AG039387). NR 34 TC 8 Z9 8 U1 1 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD MAR PY 2013 VL 23 IS 3 BP 106 EP 111 DI 10.1016/j.annepidem.2012.12.004 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 095XI UT WOS:000315367900002 PM 23313266 ER PT J AU Zatzick, D Jurkovich, G Rivara, FP Russo, J Wagner, A Wang, J Dunn, C Lord, SP Petrie, M O'Connor, SS Katon, W AF Zatzick, Douglas Jurkovich, Gregory Rivara, Frederick P. Russo, Joan Wagner, Amy Wang, Jin Dunn, Chris Lord, Sarah Peregrine Petrie, Megan O'Connor, Stephen S. Katon, Wayne TI A Randomized Stepped Care Intervention Trial Targeting Posttraumatic Stress Disorder for Surgically Hospitalized Injury Survivors SO ANNALS OF SURGERY LA English DT Article DE injury; physical function; PTSD; stepped care; surgical hospitalization; traumatic brain injury ID COGNITIVE-BEHAVIORAL THERAPY; NATIONAL COMORBIDITY SURVEY; TRAUMATIC BRAIN-INJURY; COLLABORATIVE CARE; PREVENTIVE INTERVENTIONS; FUNCTIONAL OUTCOMES; POPULATION-IMPACT; ANXIETY DISORDERS; MAJOR TRAUMA; DEPRESSION AB Objective: To test the effectiveness of a stepped care intervention model targeting posttraumatic stress disorder (PTSD) symptoms after injury. Background: Few investigations have evaluated interventions for injured patients with PTSD and related impairments that can be feasibly implemented in trauma surgical settings. Methods: The investigation was a pragmatic effectiveness trial in which 207 acutely injured hospitalized trauma survivors were screened for high PTSD symptom levels and then randomized to a stepped combined care management, psychopharmacology, and cognitive behavioral psychotherapy intervention (n = 104) or usual care control (n = 103) conditions. The symptoms of PTSD and functional limitations were reassessed at 1, 3, 6, 9, and 12 months after the index injury admission. Results: Regression analyses demonstrated that over the course of the year after injury, intervention patients had significantly reduced PTSD symptoms when compared with controls [group by time effect, CAPS (Clinician-Administered PTSD Scale): F(2, 185) = 5.50, P < 0.01; PCL-C (PTSD Checklist Civilian Version): F(4, 185) = 5.45, P < 0.001]. Clinically and statistically significant PTSD treatment effects were observed at the 6-, 9-, and 12-month postinjury assessments. Over the course of the year after injury, intervention patients also demonstrated significant improvements in physical function [MOS SF-36 PCS (Medical Outcomes Study Short Form 36 Physical Component Summary) main effect: F(1, 172) = 9.87, P < 0.01]. Conclusions: Stepped care interventions can reduce PTSD symptoms and improve functioning over the course of the year after surgical injury hospitalization. Orchestrated investigative and policy efforts could systematically introduce and evaluate screening and intervention procedures for PTSD at US trauma centers. (Trial Registration: clinicaltrials.gov identifier: NCT00270959) C1 [Zatzick, Douglas; Russo, Joan; Wagner, Amy; Wang, Jin; Dunn, Chris; Lord, Sarah Peregrine; Petrie, Megan; O'Connor, Stephen S.; Katon, Wayne] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA. [Zatzick, Douglas; Jurkovich, Gregory; Rivara, Frederick P.; Wang, Jin; O'Connor, Stephen S.] Univ Washington, Sch Med, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA. [Jurkovich, Gregory] Univ Washington, Sch Med, Dept Surg, Seattle, WA 98104 USA. [Rivara, Frederick P.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98104 USA. [Wagner, Amy] Portland VA Med Ctr, Portland, OR USA. RP Zatzick, D (reprint author), Univ Washington, Sch Med, Harborview Injury Prevent & Res Ctr, 325 9th Ave,Box 359911, Seattle, WA 98104 USA. EM dzatzick@u.washington.edu FU National Institute of Mental Health [R01/MH073613, K24/MH086814] FX This work was supported by the National Institute of Mental Health grants R01/MH073613 and K24/MH086814 (Dr Zatzick). NR 55 TC 53 Z9 53 U1 5 U2 20 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 J9 ANN SURG JI Ann. Surg. PD MAR PY 2013 VL 257 IS 3 BP 390 EP 399 DI 10.1097/SLA.0b013e31826bc313 PG 10 WC Surgery SC Surgery GA 088BN UT WOS:000314808900004 PM 23222034 ER PT J AU Merkow, RP Hall, BL Cohen, ME Wang, X Adams, JL Chow, WB Lawson, EH Bilimoria, KY Richards, K Ko, CY AF Merkow, Ryan P. Hall, Bruce L. Cohen, Mark E. Wang, Xue Adams, John L. Chow, Warren B. Lawson, Elise H. Bilimoria, Karl Y. Richards, Karen Ko, Clifford Y. TI Validity and Feasibility of the American College of Surgeons Colectomy Composite Outcome Quality Measure SO ANNALS OF SURGERY LA English DT Article DE ACS NSQIP; colon surgery; outcomes; quality improvement; quality measure; surgery ID IMPROVEMENT PROGRAM; RISK-ADJUSTMENT; CARE; ASSOCIATION AB Objective: To develop a reliable, robust, parsimonious, risk-adjusted 30-day composite colectomy outcome measure. Background: A fundamental aspect in the pursuit of high-quality care is the development of valid and reliable performance measures in surgery. Colon resection is associated with appreciable morbidity and mortality and therefore is an ideal quality improvement target. Methods: From 2010 American College of Surgeons National Surgical Quality Improvement Program data, patients were identified who underwent colon resection for any indication. A composite outcome of death or any serious morbidity within 30 days of the index operation was established. A 6-predictor, parsimonious model was developed and compared with a more complex model with more variables. National caseload requirements were calculated on the basis of increasing reliability thresholds. Results: From 255 hospitals, 22,346 patients were accrued who underwent a colon resection in 2010, most commonly for neoplasm (46.7%). A mortality or serious morbidity event occurred in 4461 patients (20.0%). At the hospital level, the median composite event rate was 20.7% (interquartile range: 15.8%-26.3%). The parsimonious model performed similarly to the full model (Akaike information criterion: 19,411 vs 18,988), and hospital-level performance comparisons were highly correlated (R = 0.97). At a reliability threshold of 0.4, 56 annual colon resections would be required and achievable at an estimated 42% of US and 69% of American College of Surgeons National Surgical Quality Improvement Program hospitals. This 42% of US hospitals performed approximately 84% of all colon resections in the country in 2008. Conclusions: It is feasible to design a measure with a composite outcome of death or serious morbidity after colon surgery that has a low burden for data collection, has substantial clinical importance, and has acceptable reliability. C1 [Merkow, Ryan P.; Hall, Bruce L.; Cohen, Mark E.; Wang, Xue; Chow, Warren B.; Bilimoria, Karl Y.; Richards, Karen; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA. [Merkow, Ryan P.; Bilimoria, Karl Y.] Northwestern Univ, Dept Surg, Feinberg Sch Med, Chicago, IL 60611 USA. [Merkow, Ryan P.] Univ Colorado Denver, Dept Surg, Aurora, CO USA. [Hall, Bruce L.] Washington Univ, Dept Surg, St Louis, MO 63130 USA. [Hall, Bruce L.] Barnes Jewish Hosp, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, Ctr Hlth Policy, St Louis, MO 63130 USA. [Hall, Bruce L.] Washington Univ, John M Olin Sch Business, St Louis, MO 63130 USA. [Hall, Bruce L.] John Cochran Vet Affairs Med Ctr, Dept Surg, St Louis, MO USA. [Adams, John L.] RAND Corp, Santa Monica, CA USA. [Chow, Warren B.; Lawson, Elise H.; Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Chow, Warren B.; Lawson, Elise H.; Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Merkow, RP (reprint author), Amer Coll Surg, 633 N St Clair St,22nd Floor, Chicago, IL 60611 USA. EM RMerkow@facs.org FU American College of Surgeons Clinical Scholars in Residence Program, Chicago, IL FX RPM and WBC are supported by the American College of Surgeons Clinical Scholars in Residence Program, Chicago, IL. BLH, JLA, and KYB are consultants to the ACS NSQIP. The authors declare no conflicts of interest. NR 23 TC 18 Z9 18 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 J9 ANN SURG JI Ann. Surg. PD MAR PY 2013 VL 257 IS 3 BP 483 EP 489 DI 10.1097/SLA.0b013e318273bf17 PG 7 WC Surgery SC Surgery GA 088BN UT WOS:000314808900017 PM 23299518 ER PT J AU Agassandian, M Mallampalli, RK AF Agassandian, Marianna Mallampalli, Rama K. TI Surfactant phospholipid metabolism SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS LA English DT Review DE Surfactant; Apoprotein; Phospholipid ID CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; RESPIRATORY-DISTRESS-SYNDROME; FATTY-ACID SYNTHASE; HUMAN CARDIOLIPIN SYNTHASE; HUMAN-FETAL LUNG; ADULT-RAT LUNG; LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASE 1; EARLY EMBRYONIC LETHALITY; CHOLINE-KINASE-ALPHA; II CELLS AB Pulmonary surfactant is essential for life and is composed of a complex lipoprotein-like mixture that lines the inner surface of the lung to prevent alveolar collapse at the end of expiration. The molecular composition of surfactant depends on highly integrated and regulated processes involving its biosynthesis, remodeling, degradation, and intracellular trafficking. Despite its multicomponent composition, the study of surfactant phospholipid metabolism has focused on two predominant components, disaturated phosphatidylcholine that confers surface-tension lowering activities, and phosphatidylglycerol, recently implicated in innate immune defense. Future studies providing a better understanding of the molecular control and physiological relevance of minor surfactant lipid components are needed. This article is part of a Special Issue entitled Phospholipids and Phospholipid Metabolism. (C) 2012 Elsevier B.V. All rights reserved. C1 [Agassandian, Marianna; Mallampalli, Rama K.] Univ Pittsburgh, Acute Lung Injury Ctr Excellence, Dept Med, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA. RP Mallampalli, RK (reprint author), Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, UPMC Montefiore, Dept Med, NW 628, Pittsburgh, PA 15213 USA. EM mallampallirk@upmc.edu FU US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; US Department of Veterans Affairs; National Institutes of Health [HL096376, HL097376, HL098174] FX The authors wish to thank Leah Kaercher for editorial assistance with the manuscript and preparation of the figures. This material is based upon work supported, in part, by the US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. This work was supported by a Merit Review Award from the US Department of Veterans Affairs and National Institutes of Health RO1 grants HL096376, HL097376 and HL098174 (to R.K.M.). NR 272 TC 38 Z9 38 U1 3 U2 48 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1388-1981 EI 0006-3002 J9 BBA-MOL CELL BIOL L JI Biochim. Biophys. Acta Mol. Cell Biol. Lipids PD MAR PY 2013 VL 1831 IS 3 SI SI BP 612 EP 625 DI 10.1016/j.bbalip.2012.09.010 PG 14 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA 099IB UT WOS:000315613600015 PM 23026158 ER PT J AU Beardsley, RM Suhler, EB Rosenbaum, JT Lin, P AF Beardsley, Robert M. Suhler, Eric B. Rosenbaum, James T. Lin, Phoebe TI Pharmacotherapy of scleritis: current paradigms and future directions SO EXPERT OPINION ON PHARMACOTHERAPY LA English DT Review DE alkylating agent; antimetabolite; biologic response modifier; noninfectious; scleritis; therapy ID JUVENILE IDIOPATHIC ARTHRITIS; INFLAMMATORY EYE DISEASE; NONNECROTIZING ANTERIOR SCLERITIS; SYSTEMIC AUTOIMMUNE-DISEASE; PRIMARY SJOGRENS-SYNDROME; TERM-FOLLOW-UP; RHEUMATOID-ARTHRITIS; WEGENERS-GRANULOMATOSIS; BEHCETS-DISEASE; LONG-TERM AB Introduction: Scleritis is an inflammatory condition affecting the eye wall that may be associated with a number of systemic inflammatory diseases. Because scleritis can be refractory to standard treatment, knowledge of the body of available and emerging therapies is paramount and is reviewed here. Areas covered: This review focuses on both traditional and emerging therapies for noninfectious scleritis. The authors cover the mechanisms of action and potential adverse effects of each of the treatment modalities. In addition, a summary of the significant MEDLINE indexed literature under the subject heading 'scleritis', 'treatment', 'immunomodulator' will be provided on each therapy, including commentary on appropriate use and relative contra-indications. Novel treatments and potential drug candidates that are currently being evaluated in clinical trials with therapeutic potential will also be reviewed. Expert opinion: While oral nonsteroidal anti-inflammatory drugs and oral corticosteroids are widely used, effective, first-line agents for inflammatory scleritis, refractory cases require antimetabolites, T-cell inhibitors, or biologic response modifiers. In particular, there is emerging evidence for the use of targeted biologic response modifiers, and potentially, for local drug delivery. C1 [Beardsley, Robert M.; Suhler, Eric B.; Rosenbaum, James T.; Lin, Phoebe] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA. [Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA. [Rosenbaum, James T.] Devers Eye Inst, Portland, OR USA. RP Lin, P (reprint author), Oregon Hlth & Sci Univ, Casey Eye Inst, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA. EM linp@ohsu.edu FU Department of Veterans Affairs; RPB (research to prevent blindness); Aquinox; Mitotech; [IK08EY022948-01] FX P Lin has received IK08EY022948-01 grant support. Eric B Suhler runs clinical trials for BMS, Genentech, Eyegate, Novartis and Abbott. He is supported by the Department of Veterans Affairs and by an RPB (research to prevent blindness) grant. James T Rosenbaum runs clinical trials for BMS, Eyegate, Genentech, Novartis and Abbott. He also consults for Teva, Regeneron, Santen, Allergan, Novartis, UCB, Amgen, Elan. He also has research grants from Aquinox and Mitotech. NR 141 TC 8 Z9 8 U1 0 U2 4 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1465-6566 J9 EXPERT OPIN PHARMACO JI Expert Opin. Pharmacother. PD MAR PY 2013 VL 14 IS 4 BP 411 EP 424 DI 10.1517/14656566.2013.772982 PG 14 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 096OT UT WOS:000315414800005 PM 23425055 ER PT J AU Chiesa-Fuxench, ZC Kim, EJ Schaffer, A Fett, N AF Chiesa-Fuxench, Zelma C. Kim, Ellen J. Schaffer, Andras Fett, Nicole TI Linear lupus panniculitis of the scalp presenting as alopecia along Blaschko's lines: A variant of lupus panniculitis not unique to East Asians SO JOURNAL OF DERMATOLOGY LA English DT Letter C1 [Chiesa-Fuxench, Zelma C.] Univ Puerto Rico, Sch Med, Dept Dermatol, San Juan, PR 00936 USA. [Kim, Ellen J.; Schaffer, Andras; Fett, Nicole] Univ Penn, Dept Dermatol, Sch Med, Philadelphia, PA 19104 USA. [Fett, Nicole] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Fett, N (reprint author), Univ Penn, Dept Dermatol, Perelman Ctr Adv Med, Suite 1-330A,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM nicole.fett@uphs.upenn.edu NR 4 TC 3 Z9 4 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0385-2407 J9 J DERMATOL JI J. Dermatol. PD MAR PY 2013 VL 40 IS 3 BP 231 EP 232 DI 10.1111/1346-8138.12041 PG 2 WC Dermatology SC Dermatology GA 097JE UT WOS:000315469000023 PM 23252454 ER PT J AU Barnes, DE Boscardin, WJ Landefeld, CS AF Barnes, Deborah E. Boscardin, W. John Landefeld, C. Seth TI Recovery, Dependence or Death After Discharge SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Letter C1 [Barnes, Deborah E.; Boscardin, W. John] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Landefeld, C. Seth] Univ Alabama Birmingham, Birmingham, AL USA. [Barnes, Deborah E.; Boscardin, W. John] San Francisco VA Med Ctr, San Francisco, CA USA. RP Barnes, DE (reprint author), Univ Calif San Francisco, San Francisco, CA 94143 USA. EM Deborah.barnes@ucsf.edu NR 4 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2013 VL 28 IS 3 BP 343 EP 343 DI 10.1007/s11606-012-2310-3 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 096WA UT WOS:000315434200006 PM 23435831 ER PT J AU Chang, ET Rose, DE Yano, EM Wells, KB Metzger, ME Post, EP Lee, ML Rubenstein, LV AF Chang, Evelyn T. Rose, Danielle E. Yano, Elizabeth M. Wells, Kenneth B. Metzger, Maureen E. Post, Edward P. Lee, Martin L. Rubenstein, Lisa V. TI Determinants of Readiness for Primary Care-Mental Health Integration (PC-MHI) in the VA Health Care System SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE primary care; mental health; depression; collaborative care; implementation; readiness ID COMORBIDITY SURVEY REPLICATION; RANDOMIZED CONTROLLED-TRIAL; LATE-LIFE DEPRESSION; COLLABORATIVE CARE; QUALITY-IMPROVEMENT; COST-EFFECTIVENESS; ORGANIZATIONAL READINESS; TRANSLATING EVIDENCE; UNITED-STATES; MEDICAL HOME AB Depression management can be challenging for primary care (PC) settings. While several evidence-based models exist for depression care, little is known about the relationships between PC practice characteristics, model characteristics, and the practice's choices regarding model adoption. We examined three Veterans Affairs (VA)-endorsed depression care models and tested the relationships between theoretically-anchored measures of organizational readiness and implementation of the models in VA PC clinics. 1) Qualitative assessment of the three VA-endorsed depression care models, 2) Cross-sectional survey of leaders from 225 VA medium-to-large PC practices, both in 2007. We assessed PC readiness factors related to resource adequacy, motivation for change, staff attributes, and organizational climate. As outcomes, we measured implementation of one of the VA-endorsed models: collocation, Translating Initiatives in Depression into Effective Solutions (TIDES), and Behavioral Health Lab (BHL). We performed bivariate and, when possible, multivariate analyses of readiness factors for each model. Collocation is a relatively simple arrangement with a mental health specialist physically located in PC. TIDES and BHL are more complex; they use standardized assessments and care management based on evidence-based collaborative care principles, but with different organizational requirements. By 2007, 107 (47.5 %) clinics had implemented collocation, 39 (17.3 %) TIDES, and 17 (7.6 %) BHL. Having established quality improvement processes (OR 2.30, [1.36, 3.87], p = 0.002) or a depression clinician champion (OR 2.36, [1.14, 4.88], p = 0.02) was associated with collocation. Being located in a VA regional network that endorsed TIDES (OR 8.42, [3.69, 19.26], p < 0.001) was associated with TIDES implementation. The presence of psychologists or psychiatrists on PC staff, greater financial sufficiency, or greater spatial sufficiency was associated with BHL implementation. Both readiness factors and characteristics of depression care models influence model adoption. Greater model simplicity may make collocation attractive within local quality improvement efforts. Dissemination through regional networks may be effective for more complex models such as TIDES. C1 [Chang, Evelyn T.] VA Greater Los Angeles, Los Angeles, CA 90073 USA. [Rose, Danielle E.; Yano, Elizabeth M.; Lee, Martin L.; Rubenstein, Lisa V.] VA HSR&D Ctr Excellence Study Healthcare Provider, Sepulveda, CA USA. [Yano, Elizabeth M.; Wells, Kenneth B.; Lee, Martin L.] UCLA Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA USA. [Wells, Kenneth B.] UCLA Psychiat & Biobehav Sci, Los Angeles, CA USA. [Wells, Kenneth B.; Rubenstein, Lisa V.] RAND, Santa Monica, CA USA. [Metzger, Maureen E.; Post, Edward P.] VA Ctr Clin Management Res, Ann Arbor, MI USA. [Metzger, Maureen E.; Post, Edward P.] Serious Mental Illness Treatment Resource & Evalu, Ann Arbor, MI USA. [Post, Edward P.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA. RP Chang, ET (reprint author), VA Greater Los Angeles, Los Angeles, CA 90073 USA. EM evelyn.chang@va.gov OI Post, Edward/0000-0002-5782-8736 FU VA Office of Academic Affiliations, Health Services Research and Development through the Health Services Fellowship Training Program [TMP 65-020]; VA HSR&D Service through a Research Career Scientist Award [RCS 05-195]; VA HSRD Project [09-082] FX Funding support provided by VA Office of Academic Affiliations, Health Services Research and Development through the Health Services Fellowship Training Program (TMP 65-020). Dr. Yano's time was funded by the VA HSR&D Service through a Research Career Scientist Award (Project # RCS 05-195). The project was also supported by VA HSR&D Project # 09-082 (Yano, PI). NR 59 TC 18 Z9 18 U1 1 U2 22 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2013 VL 28 IS 3 BP 353 EP 362 DI 10.1007/s11606-012-2217-z PG 10 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 096WA UT WOS:000315434200010 PM 23054917 ER PT J AU Anderson, WG Horton, JR Johnson, K Goldstein, NE AF Anderson, Wendy G. Horton, Jay R. Johnson, Kimberly Goldstein, Nathan E. TI Update in Hospice and Palliative Care SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Review ID DEMENTIA; TRIAL; PAIN; COMMUNICATION; EFFICACY; LIFE; END C1 [Anderson, Wendy G.] Univ Calif San Francisco, Div Hosp Med, San Francisco, CA 94143 USA. [Anderson, Wendy G.] Univ Calif San Francisco, Palliat Care Program, San Francisco, CA 94143 USA. [Horton, Jay R.; Goldstein, Nathan E.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA. [Johnson, Kimberly] Duke Univ, Med Ctr, Ctr Geriatr Res Educ & Clin, VA Med Ctr,Div Geriatr, Durham, NC USA. [Johnson, Kimberly] Duke Univ, Med Ctr, Ctr Geriatr Res Educ & Clin, VA Med Ctr,Ctr Palliat Care, Durham, NC USA. [Goldstein, Nathan E.] James J Peters VA Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA. RP Anderson, WG (reprint author), Univ Calif San Francisco, 521 Parnassus Ave,Box 0903, San Francisco, CA 94143 USA. EM Wendy.Anderson@ucsf.edu FU University of California San Francisco Clinical and Translational Science Institute Career Development Program; NIH [5KL2 RR024130-06] FX Dr. Anderson was funded by the University of California San Francisco Clinical and Translational Science Institute Career Development Program, which is supported by NIH grant number 5KL2 RR024130-06. The authors presented these articles for the State of the Science Plenary Session at the Annual Assembly of the American Academy of Hospice and Palliative Medicine and the Hospice and Palliative Nurses Association on March 10, 2012, in Denver, Colorado. NR 18 TC 0 Z9 0 U1 1 U2 12 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD MAR PY 2013 VL 16 IS 3 BP 314 EP 319 DI 10.1089/jpm.2012.0481 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 097GO UT WOS:000315462200021 ER PT J AU Bouldin, ELD Andresen, EM Dunton, NE Simon, M Waters, TM Liu, MZ Daniels, MJ Mion, LC Shorr, RI AF Bouldin, Erin L. D. Andresen, Elena M. Dunton, Nancy E. Simon, Michael Waters, Teresa M. Liu, Minzhao Daniels, Michael J. Mion, Lorraine C. Shorr, Ronald I. TI Falls Among Adult Patients Hospitalized in the United States: Prevalence and Trends SO JOURNAL OF PATIENT SAFETY LA English DT Article DE accidental falls; epidemiology; hospital units; injuries/epidemiology; databases ID PREVENTING FALLS; INPATIENT FALLS; ACUTE-CARE; INJURIES; CIRCUMSTANCES; SYSTEM AB Objectives: The purpose of this study was to provide normative data on fall prevalence in U. S. hospitals by unit type and to determine the 27-month secular trend in falls before the implementation of the Centers for Medicare and Medicaid Service (CMS) rule, which does not reimburse hospitals for care related to injury resulting from hospital falls. Methods: We used data from the National Database of Nursing Quality Indicators (NDNQI) collected between July 1, 2006, and September 30, 2008, to estimate prevalence and secular trends of falls occurring in adult medical, medical-surgical, and surgical nursing units. More than 88 million patient days (pd) of observation were contributed from 6100 medical, surgical, and medical-surgical nursing units in 1263 hospitals across the United States. Results: A total of 315,817 falls occurred (rate = 3.56 falls/1000 pd) during the study period, of which, 82,332 (26.1%) resulted in an injury (rate = 0.93/1000 pd). Both total fall and injurious fall rates were highest in medical units (fall rate = 4.03/1000 pd; injurious fall rate = 1.08/1000 pd) and lowest in surgery units (fall rate = 2.76/1000 pd; injurious fall rate = 0.67/1000 pd). Falls (0.4% decrease per quarter, P < 0.0001) and injurious falls (1% decrease per quarter, P G 0.0001) both decreased over the 27-month study. Conclusions: In this large sample, fall and injurious fall prevalence varied by nursing unit type in U.S. hospitals. Over the 27-month study, there was a small, but statistically significant, decrease in falls (P G 0.0001) and injurious falls (P < 0.0001). C1 [Bouldin, Erin L. D.] VA Puget Sound Hlth Care Syst, Northwest Ctr Outcomes Res Older Adults, Seattle, WA USA. [Bouldin, Erin L. D.; Andresen, Elena M.] Univ Florida, Coll Med, Dept Epidemiol, Gainesville, FL USA. [Bouldin, Erin L. D.; Andresen, Elena M.] Univ Florida, Coll Publ Hlth & Hlth Profess, Dept Epidemiol, Gainesville, FL USA. [Andresen, Elena M.] Oregon Hlth & Sci Univ, Inst Dev & Disabil, Portland, OR 97201 USA. [Dunton, Nancy E.] Univ Kansas, Med Ctr, Sch Nursing, Dept Hlth Policy & Management, Kansas City, KS 66103 USA. [Simon, Michael] Univ Southampton, Fac Hlth Sci, Southampton SO9 5NH, Hants, England. [Waters, Teresa M.] Univ Tennessee, Hlth Sci Ctr, Dept Prevent Med, Knoxville, TN 37996 USA. [Liu, Minzhao; Daniels, Michael J.] Univ Florida, Dept Stat, Coll Liberal Arts & Sci, Gainesville, FL 32611 USA. [Mion, Lorraine C.] Vanderbilt Univ, Sch Nursing, Nashville, TN 37240 USA. [Shorr, Ronald I.] Malcom Randall VAMC, GRECC, Gainesville, FL 32608 USA. [Shorr, Ronald I.] Univ Florida, Dept Aging & Geriatr Res, Gainesville, FL USA. RP Shorr, RI (reprint author), Malcom Randall VAMC, GRECC 182, 1601 SW Archer Rd, Gainesville, FL 32608 USA. EM rshorr@ufl.edu RI Simon, Michael/C-5601-2008 OI Simon, Michael/0000-0003-2349-7219 FU NIH/NIA [R01-AG025285, R01-AG033005] FX Grant Support: NIH/NIA R01-AG025285, NIH/NIA R01-AG033005 NR 22 TC 25 Z9 27 U1 0 U2 19 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1549-8417 J9 J PATIENT SAF JI J. Patient Saf. PD MAR PY 2013 VL 9 IS 1 BP 13 EP 17 DI 10.1097/PTS.0b013e3182699b64 PG 5 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 096MO UT WOS:000315408600003 PM 23143749 ER PT J AU Dionne, KR Zhuang, YH Leser, JS Tyler, KL Clarke, P AF Dionne, Kalen R. Zhuang, Yonghua Leser, J. Smith Tyler, Kenneth L. Clarke, Penny TI Daxx Upregulation within the Cytoplasm of Reovirus-Infected Cells Is Mediated by Interferon and Contributes to Apoptosis SO JOURNAL OF VIROLOGY LA English DT Article ID CENTRAL-NERVOUS-SYSTEM; DEATH-ASSOCIATED PROTEIN; TRAIL-INDUCED APOPTOSIS; PML ONCOGENIC DOMAINS; N-TERMINAL KINASE; GENE-EXPRESSION; JNK ACTIVATION; KAPPA-B; INTERACTING PROTEIN; SIGNALING PATHWAYS AB Reovirus infection is a well-characterized experimental system for the study of viral pathogenesis and antiviral immunity within the central nervous system (CNS). We have previously shown that c-Jun N-terminal kinase (JNK) and the Fas death receptor each play a role in neuronal apoptosis occurring in reovirus-infected brains. Death-associated protein 6 (Daxx) is a cellular protein that mechanistically links Fas signaling to JNK signaling in several models of apoptosis. In the present study, we demonstrate that Daxx is upregulated in reovirus-infected brain tissue through a type I interferon-mediated mechanism. Daxx upregulation is limited to brain regions that undergo reovirus-induced apoptosis and occurs in the cytoplasm and nucleus of neurons. Cytoplasmic Daxx is present in Fas-expressing cells during reovirus encephalitis, suggesting a role for Daxx in Fas-mediated apoptosis following reovirus infection. Further, in vitro expression of a dominant negative form of Daxx (DN-Daxx), which binds to Fas but which does not transmit downstream signaling, inhibits apoptosis of reovirus-infected cells. In contrast, in vitro depletion of Daxx results in increased expression of caspase 3 and apoptosis, suggesting that Daxx plays an antiapoptotic role in the nucleus. Overall, these data imply a regulatory role for Daxx in reovirus-induced apoptosis, depending on its location in the nucleus or cytoplasm. C1 [Dionne, Kalen R.; Tyler, Kenneth L.] Univ Colorado, Med Scientist Training Program, Aurora, CO USA. [Dionne, Kalen R.; Tyler, Kenneth L.] Univ Colorado, Neurosci Program, Denver, CO 80202 USA. [Dionne, Kalen R.; Zhuang, Yonghua; Leser, J. Smith; Tyler, Kenneth L.; Clarke, Penny] Univ Colorado, Dept Neurol, Denver, CO 80202 USA. [Tyler, Kenneth L.] Univ Colorado, Dept Med, Denver, CO USA. [Tyler, Kenneth L.] Univ Colorado, Dept Microbiol, Denver, CO 80202 USA. [Tyler, Kenneth L.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Clarke, P (reprint author), Univ Colorado, Dept Neurol, Denver, CO 80202 USA. EM Penny.Clarke@UCDenver.edu RI Zhuang, Yonghua/A-2946-2013 OI Zhuang, Yonghua/0000-0002-1822-2395; Tyler, Kenneth/0000-0003-3294-5888 FU VA Merit Grant [1/01BX000963]; institutional Medical Scientist Training Program training grant [T32GM008497]; National Research Service Award for Individual Predoctoral MD/PhD Fellows [F30NS071630]; [RO1NS076512] FX This work was supported by RO1NS076512 (K.L.T) and VA Merit Grant 1/01BX000963 (K.L.T). K.R.D. was supported by an institutional Medical Scientist Training Program training grant (T32GM008497) and a National Research Service Award for Individual Predoctoral MD/PhD Fellows (F30NS071630). NR 75 TC 11 Z9 11 U1 1 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD MAR PY 2013 VL 87 IS 6 BP 3447 EP 3460 DI 10.1128/JVI.02324-12 PG 14 WC Virology SC Virology GA 095QD UT WOS:000315348500043 PM 23302889 ER PT J AU Bloecker, K Guermazi, A Wirth, W Benichou, O Kwoh, CK Hunter, DJ Englund, M Resch, H Eckstein, F AF Bloecker, K. Guermazi, A. Wirth, W. Benichou, O. Kwoh, C. K. Hunter, D. J. Englund, M. Resch, H. Eckstein, F. CA OAI Investigators TI Tibial coverage, meniscus position, size and damage in knees discordant for joint space narrowing - data from the Osteoarthritis Initiative SO OSTEOARTHRITIS AND CARTILAGE LA English DT Article DE Meniscus; Joint space narrowing; Radiographic osteoarthritis; Magnetic resonance imaging; Tibial coverage ID CARTILAGE LOSS; LATERAL MENISCUS; RADIOGRAPHIC FEATURES; ARTICULAR-CARTILAGE; MRI; ASSOCIATION; EXTRUSION; VOLUME; OAI; SEGMENTATION AB Introduction: Meniscal extrusion is thought to be associated with less meniscus coverage of the tibial surface, but the association of radiographic disease stage with quantitative measures of tibial plateau coverage is unknown. We therefore compared quantitative and semi-quantitative measures of meniscus position and morphology in individuals with bilateral painful knees discordant on medial joint space narrowing (mJSN). Methods: A sample of 60 participants from the first half (2,678 cases) of the Osteoarthritis Initiative cohort fulfilled the inclusion criteria: bilateral frequent pain, Osteoarthritis Research Society International (OARSI) mJSN grades 1-3 in one, no-JSN in the contra-lateral (CL), and no lateral JSN in either knee (43 unilateral mJSN1; 17 mJSN2/3; 22 men, 38 women, body mass index (BMI) 31.3 +/- 3.9 kg/m(2)). Segmentation and three-dimensional quantitative analysis of the tibial plateau and meniscus, and semiquantitative evaluation of meniscus damage (magnetic resonance imaging (MRI) osteoarthritis knee score = MOAKS) was performed using coronal 3T MR images (MPR DESSwe and intermediate-weighted turbo spin echo (IW-TSE) images). CL knees were compared using paired t-tests (between-knee, within-person design). Results: Medial tibial plateau coverage was 36 +/- 9% in mJSN1 vs 45 +/- 8% in CL no-JSN knees, and was 31 +/- 9% in mJSN2/3 vs 46 +/- 6% in no-JSN knees (both P < 0.001). mJSN knees showed greater meniscus extrusion and damage (MOAKS), but no significant difference in meniscus volume. No significant differences in lateral tibial coverage, lateral meniscus morphology or position were observed. Conclusions: Knees with medial JSN showed substantially less medial tibial plateau coverage by the meniscus. We suggest that the less meniscal coverage, i.e., less mechanical protection may be a reason for greater rates of cartilage loss observed in JSN knees. (C) 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved. C1 [Bloecker, K.; Wirth, W.; Eckstein, F.] Paracelsus Med Univ, Inst Anat & Musculoskeletal Res, A-5020 Salzburg, Austria. [Bloecker, K.; Resch, H.] Paracelsus Med Univ, Dept Traumatol & Sports Injuries, A-5020 Salzburg, Austria. [Guermazi, A.] Boston Univ, Sch Med, Dept Radiol, Quantitat Imaging Ctr, Boston, MA 02118 USA. [Guermazi, A.] BICL LLC, Boston, MA USA. [Wirth, W.; Eckstein, F.] Chondrometrics GmbH, Ainring, Germany. [Benichou, O.] Eli Lilly & Co, Indianapolis, IN 46285 USA. [Kwoh, C. K.] Univ Pittsburgh, Div Rheumatol & Clin Immunol, Pittsburgh, PA USA. [Kwoh, C. K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Hunter, D. J.] Univ Sydney, Royal N Shore Hosp, Dept Rheumatol, Sydney, NSW 2006, Australia. [Hunter, D. J.] Univ Sydney, Kolling Inst, Sydney, NSW 2006, Australia. [Englund, M.] Lund Univ, Dept Orthoped, Lund, Sweden. [Englund, M.] Boston Univ, Sch Med, Clin Epidemiol Res &Training Unit, Boston, MA 02118 USA. RP Bloecker, K (reprint author), Paracelsus Med Univ, Inst Anat & Musculoskeletal Res, Strubergasse 21, A-5020 Salzburg, Austria. EM katja.bloecker@pmu.ac.at RI Wirth, Wolfgang/C-8724-2011; Englund, Martin/J-7245-2012 OI Wirth, Wolfgang/0000-0002-2297-8283; Englund, Martin/0000-0003-3320-2437 FU OAI [N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, N01-AR-2-2262]; National Institutes of Health, a branch of the Department of Health and Human Services; Pfizer, Inc.; Novartis Pharmaceuticals Corporation; Merck Research Laboratories; GlaxoSmithKline; Foundation for the National Institutes of Health; Paracelsus Medical University (PMU) Forschungsfond [PMU FFF R-12702/036/BLO]; Australian Research Council Future Fellowship; Swedish Research Council; Royal Physiographic Society in Lund and Koch Foundations FX We would like to thank the OAI participants, OAI investigators and OAI Clinical Center's staff for generating this publicly available image data set. The study and image acquisition were supported by the Osteoarthritis Initiative (OAI). The OAI is a public-private partnership comprised of five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Pfizer, Inc.; Novartis Pharmaceuticals Corporation; Merck Research Laboratories; and GlaxoSmithKline. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript has received the approval of the OAI Publications Committee based on a review of its scientific content and data interpretation. The image analysis was supported by the Paracelsus Medical University (PMU) Forschungsfond (PMU FFF R-12702/036/BLO).; David Hunter is funded by an Australian Research Council Future Fellowship. Martin Englund is funded by Swedish Research Council, the Royal Physiographic Society in Lund, King Gustav 80-Year Birthday Fund and Koch Foundations. NR 44 TC 25 Z9 25 U1 0 U2 10 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1063-4584 J9 OSTEOARTHR CARTILAGE JI Osteoarthritis Cartilage PD MAR PY 2013 VL 21 IS 3 BP 419 EP 427 DI 10.1016/j.joca.2012.11.015 PG 9 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA 098MA UT WOS:000315552200003 PM 23220556 ER PT J AU Reusch, JEB Bridenstine, M Regensteiner, JG AF Reusch, Jane E. B. Bridenstine, Mark Regensteiner, Judith G. TI Type 2 diabetes mellitus and exercise impairment SO REVIEWS IN ENDOCRINE & METABOLIC DISORDERS LA English DT Article DE Diabetes; Exercise capacity; Vascular; Endothelial function; Diastolic dysfunction ID ALL-CAUSE MORTALITY; LOW CARDIORESPIRATORY FITNESS; UPTAKE KINETIC RESPONSES; LIFE-STYLE INTERVENTION; INSULIN-RESISTANCE; PHYSICAL-ACTIVITY; SKELETAL-MUSCLE; MITOCHONDRIAL BIOGENESIS; DIASTOLIC DYSFUNCTION; OXYGEN-UPTAKE AB Limitations in physical fitness, a consistent finding in individuals with both type I and type 2 diabetes mellitus, correlate strongly with cardiovascular and all-cause mortality. These limitations may significantly contribute to the persistent excess cardiovascular mortality affecting this group. Exercise impairments in VO2 peak and VO2 kinetics manifest early on in diabetes, even with good glycemic control and in the absence of clinically apparent complications. Subclinical cardiac dysfunction is often present but does not fully explain the observed defect in exercise capacity in persons with diabetes. In part, the cardiac limitations are secondary to decreased perfusion with exercise challenge. This is a reversible defect. Similarly, in the skeletal muscle, impairments in nutritive blood flow correlate with slowed (or inefficient) exercise kinetics and decreased exercise capacity. Several correlations highlight the likelihood of endothelial-specific impairments as mediators of exercise dysfunction in diabetes, including insulin resistance, endothelial dysfunction, decreased myocardial perfusion, slowed tissue hemoglobin oxygen saturation, and impairment in mitochondrial function. Both exercise training and therapies targeted at improving insulin sensitivity and endothelial function improve physical fitness in subjects with type 2 diabetes. Optimization of exercise functions in people with diabetes has implications for diabetes prevention and reductions in mortality risk. Understanding the molecular details of endothelial dysfunction in diabetes may provide specific therapeutic targets for the remediation of this defect. Rat models to test this hypothesis are under study. C1 [Reusch, Jane E. B.] Denver VA Med Ctr, Denver, CO 80220 USA. [Reusch, Jane E. B.; Bridenstine, Mark] Univ Colorado, Sch Med, Div Endocrinol, Aurora, CO 80045 USA. [Regensteiner, Judith G.] Univ Colorado, Sch Med, Div Gen Internal Med & Cardiol, Aurora, CO 80045 USA. [Reusch, Jane E. B.; Regensteiner, Judith G.] Univ Colorado, Sch Med, Dept Med, Ctr Womens Hlth Res, Aurora, CO 80045 USA. RP Reusch, JEB (reprint author), Denver VA Med Ctr, Clermont St, Denver, CO 80220 USA. EM Jane.Reusch@ucdenver.edu FU NCATS NIH HHS [UL1 TR000154]; NHLBI NIH HHS [P01 HL014985, T32 HL007171]; NICHD NIH HHS [K12 HD057022]; NIDDK NIH HHS [R01 DK064741] NR 87 TC 26 Z9 27 U1 0 U2 31 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1389-9155 EI 1573-2606 J9 REV ENDOCR METAB DIS JI Rev. Endocr. Metab. Disord. PD MAR PY 2013 VL 14 IS 1 BP 77 EP 86 DI 10.1007/s11154-012-9234-4 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 098SC UT WOS:000315568000010 PM 23299658 ER PT J AU Hartwell, KJ LeMatty, T McRae-Clark, AL Gray, KM George, MS Brady, KT AF Hartwell, Karen J. LeMatty, Todd McRae-Clark, Aimee L. Gray, Kevin M. George, Mark S. Brady, Kathleen T. TI Resisting the Urge to Smoke and Craving during a Smoking Quit Attempt on Varenicline: Results from a Pilot fMRI Study SO AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE LA English DT Article ID NICOTINE DEPENDENCE; LABORATORY MODEL; CUE-REACTIVITY; ABSTINENCE; CESSATION; ACTIVATION; BUPROPION; RESPONSES; COGNITION; MOOD AB Background: Varenicline has been shown to reduce cigarette craving during a quit attempt. Objectives: Use BOLD fMRI to explore differences in smoking cue reactivity at baseline and after five weeks of varenicline smoking cessation treatment. Methods: Treatment-seeking nicotine-dependent adult smokers underwent BOLD fMRI scans with block presentation of visual smoking, neutral, and rest cues under two conditions: craving or resisting the urge to smoke at baseline and following 5 weeks of standard varenicline therapy. Data were analyzed using FMRI Expert Analysis Tool, version 5.98 of Functional Magnetic Imaging of the Brain Software Library focused on the smoking vs. neutral cue contrast at the individual and group level, Z>2.3 with cluster threshold p=0.05. Results: Twenty-one participants were scanned at baseline and 16 completed the study; 10 were abstinent at the 2nd session, confirmed with urinary cotinine. In the Crave Condition no significant differences were found between the abstinent and non-abstinent groups at either time point. During the baseline Resist Condition, the abstinent group compared to the non-abstinent group demonstrated activation in a distributed network involved in alertness, learning and memory. Additionally, within the abstinent group, increased activation of the superior frontal gyrus was found at baseline compared to week 5. Conclusion: Successful smoking cessation with varenicline is associated with increased activation, prior to a quit attempt, in brain areas related to attentiveness and memory while resisting the urge to smoke Scientific Significance: Varenicline may exert effects by both reducing craving and enhancing resistance to smoking urges during cue-elicited craving. C1 [Hartwell, Karen J.; LeMatty, Todd; McRae-Clark, Aimee L.; Gray, Kevin M.; George, Mark S.; Brady, Kathleen T.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Hartwell, Karen J.; George, Mark S.; Brady, Kathleen T.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Hartwell, KJ (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 67 President St,MSC 861, Charleston, SC 29425 USA. EM hartwelk@musc.edu RI McRae-Clark, Aimee/I-3341-2013 OI McRae-Clark, Aimee/0000-0002-9774-318X FU NCRR NIH HHS [UL1 RR029882]; NICHD NIH HHS [K12 HD055885, K12HD055885]; NIDA NIH HHS [R21 DA026085, 5R21DA026085-02] NR 33 TC 5 Z9 5 U1 3 U2 23 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0095-2990 J9 AM J DRUG ALCOHOL AB JI Am. J. Drug Alcohol Abuse PD MAR PY 2013 VL 39 IS 2 BP 92 EP 98 DI 10.3109/00952990.2012.750665 PG 7 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 093IH UT WOS:000315184600005 PM 23421569 ER PT J AU Oliva, EM Trafton, JA Harris, AHS Gordon, AJ AF Oliva, Elizabeth M. Trafton, Jodie A. Harris, Alex H. S. Gordon, Adam J. TI Trends in Opioid Agonist Therapy in the Veterans Health Administration: Is Supply Keeping up with Demand? SO AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE LA English DT Article DE opioid agonist therapy; buprenorphine; veterans; office-based treatment; VA; VHA; methadone ID SUBSTANCE-ABUSE TREATMENT; BUPRENORPHINE; METHADONE; DEPENDENCE; ADDICTION; ADOPTION; COSTS AB Background: Opioid agonist therapy (OAT) through addiction specialty clinic settings (clinic-based OAT) using methadone or buprenorphine or office-based settings using buprenorphine (office-based OAT) is an evidence-based treatment for opioid dependence. The low number of clinic-based OATs available to veterans (N = 53) presents a barrier to OAT access; thus, the expansion in office-based OAT has been encouraged. Objectives: To examine trends in office-based OAT utilization over time and whether availability of office-based OAT improved the proportion of veterans with opioid use disorders treated with OAT. Methods: We examined Veterans Health Administration (VHA) administrative data for evidence of buprenorphine prescribing and clinic-based OAT clinic stops from October 2003 through September 2010 [fiscal years (FY) 2004-2010]. Results: The number of patients receiving buprenorphine increased from 300 at 27 facilities in FY2004 to 6147 at 118 facilities in FY2010. During this time, the number of patients diagnosed with an opioid use disorder increased by 45%; however, the proportion of opioid use disorder patients receiving OAT remained relatively stable, ranging from 25% to 27%, Conclusions: Office-based OAT utilization and the number of opioid use disorder veterans treated with OAT are increasing at the same rate over time, suggesting that office-based OAT is being used to meet the growing need for OAT care. Although office-based OAT is increasingly being used within the VHA and may be one way the VHA is keeping up with the demand for OAT, more research is needed to understand how to engage a greater proportion of opioid use disorder patients in treatment. C1 [Oliva, Elizabeth M.; Trafton, Jodie A.; Harris, Alex H. S.] VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA 94025 USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Mental Hlth Res Educ & Clin Ctr, Pittsburgh, PA USA. [Gordon, Adam J.] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA USA. RP Oliva, EM (reprint author), VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, 795 Willow Rd,MPD 152, Menlo Pk, CA 94025 USA. EM elizabeth.oliva@va.gov NR 21 TC 9 Z9 9 U1 3 U2 9 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0095-2990 J9 AM J DRUG ALCOHOL AB JI Am. J. Drug Alcohol Abuse PD MAR PY 2013 VL 39 IS 2 BP 103 EP 107 DI 10.3109/00952990.2012.741167 PG 5 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 093IH UT WOS:000315184600007 PM 23421571 ER PT J AU Tanner, RM Gutierrez, OM Judd, S McClellan, W Bowling, CB Bradbury, BD Safford, MM Cushman, M Warnock, D Muntner, P AF Tanner, Rikki M. Gutierrez, Orlando M. Judd, Suzanne McClellan, William Bowling, C. Barrett Bradbury, Brian D. Safford, Monika M. Cushman, Mary Warnock, David Muntner, Paul TI Geographic Variation in CKD Prevalence and ESRD Incidence in the United States: Results From the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Chronic kidney disease; geography; end-stage renal disease ID CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; GLOMERULAR-FILTRATION-RATE; RISK; POPULATION; JAPAN; DEATH; CARE AB Background: It is not known whether geographic differences in the prevalence of chronic kidney disease exist and are associated with end-stage renal disease (ESRD) incidence rates across the United States. Study Design: Cross-sectional and ecologic. Setting & Participants: White (n = 16,410) and black (n = 11,109) participants from across the continental United States in the population-based Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Predictor: Geographic region, defined by the 18 networks of the US ESRD Network Program. Outcomes & Measurements: Albuminuria, defined as albumin-creatinine ratio >= 30 mg/g, and decreased estimated glomerular filtration rate (eGFR), defined as <60 mL/min/1.73 m(2), were measured in the REGARDS Study. ESRD incidence rates were obtained from the US Renal Data System. Results: For whites, the network-specific prevalence of albuminuria ranged from 8.4% (95% CI, 3.3%-13.5%) in Network 15 to 14.8% (95% CI, 8.0%-21.6%) in Network 3, and decreased eGFR ranged from 4.3% (95% CI, 2.0%-6.6%) in Network 4 to 16.7% (95% CI, 12.7%-20.7%) in Network 7. For blacks, the prevalence of albuminuria ranged from 12.1% (95% CI, 8.7%-15.5%) in Network 5 to 26.5% (95% CI, 16.7%-36.3%) in Network 4, and decreased eGFR ranged from 6.7% (95% CI, 5.0%-8.4%) in Network 17/18 to 13.4% (95% CI, 7.8%-19.1%) in Network 12. Spearman correlation coefficients for the prevalence of albuminuria and decreased eGFR with network-specific ESRD incidence rates were 0.49 and 0.24, respectively, for whites and 0.29 and 0.25, respectively, for blacks. Limitations: There were few cases of albuminuria and decreased eGFR in some geographic regions. Conclusions: In the United States, substantial geographic variations in the prevalence of albuminuria and decreased eGFR exist, but were correlated only modestly with ESRD incidence, suggesting the chronic kidney disease burden may not explain the geographic variation in ESRD incidence. Am J Kidney Dis. 61(3):395-403. (C) 2013 by the National Kidney Foundation, Inc. C1 [Tanner, Rikki M.; Gutierrez, Orlando M.; Judd, Suzanne; Bowling, C. Barrett; Safford, Monika M.; Warnock, David; Muntner, Paul] Univ Alabama Birmingham, Birmingham, AL 35294 USA. [McClellan, William] Emory Univ, Atlanta, GA 30322 USA. [Bowling, C. Barrett] Birmingham VA Med Ctr, Birmingham, AL USA. [Bradbury, Brian D.] Amgen Inc, Ctr Observat Res, Thousand Oaks, CA 91320 USA. [Bradbury, Brian D.] Univ Calif Los Angeles, Dept Epidemiol, Los Angeles, CA USA. [Cushman, Mary] Univ Vermont, Burlington, VT USA. RP Muntner, P (reprint author), Univ Alabama Birmingham, Dept Epidemiol, 1665 Univ Blvd,Ste 230J, Birmingham, AL 35294 USA. EM pmuntner@uab.edu FU National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Department of Health and Human Services [U01 NS041588]; Amgen Corp FX Support: This research project is supported by cooperative agreement U01 NS041588 from the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Department of Health and Human Services. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NINDS or NIH. Representatives of the funding agency were involved in the review of the manuscript but not directly involved in the collection, management, analysis, or interpretation of the data. Additional funding was provided by an investigator-initiated grant-in-aid from Amgen Corp to Dr Warnock. NR 31 TC 10 Z9 11 U1 0 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAR PY 2013 VL 61 IS 3 BP 395 EP 403 DI 10.1053/j.ajkd.2012.10.018 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 090GF UT WOS:000314966600009 PM 23228944 ER PT J AU Zhao, W Marchani, EE Cheung, CYK Steinbart, EJ Schellenberg, GD Bird, TD Wijsman, EM AF Zhao, Wei Marchani, Elizabeth E. Cheung, Charles Y. K. Steinbart, Ellen J. Schellenberg, Gerard D. Bird, Thomas D. Wijsman, Ellen M. TI Genome scan in familial late-onset Alzheimer's disease: A locus on chromosome 6 contributes to age-at-onset SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Article DE linkage analysis; MCMC; oligogenic; dementia; age-censored ID NEUROTROPHIC FACTOR BDNF; MONTE-CARLO SEGREGATION; LINKAGE ANALYSIS; APOLIPOPROTEIN-E; GENETIC ASSOCIATION; MULTIPLE IMPUTATION; QUANTITATIVE TRAIT; OF-ONSET; SYSTEMATIC METAANALYSES; OLIGOGENIC SEGREGATION AB Alzheimer's disease (AD) is a common, genetically complex, fatal neurodegenerative disorder of late life. Although several genes are known to play a role in early-onset AD, identification of the genetic basis of late onset AD (LOAD) has been challenging, with only the APOE gene known to have a high contribution to both AD risk and age-at-onset. Here, we present the first genome-scan analysis of the complete, well-characterized University of Washington LOAD sample of 119 pedigrees, using age-at-onset as the trait of interest. The analysis approach used allows for a multilocus trait model while at the same time accommodating age censoring, effects of APOE as a known genetic covariate, and full pedigree and marker information. The results provide strong evidence for linkage of loci contributing to age-at-onset to genomic regions on chromosome 6q16.3, and to 19q13.42 in the region of the APOE locus. There was evidence for interaction between APOE and the locus on chromosome 6q and suggestive evidence for linkage to chromosomes 11p13, 15q12-14, and 19p13.12. These results provide the first independent confirmation of an AD age-at-onset locus on chromosome 6 and suggest that further efforts towards identifying the underlying causal locus or loci are warranted. (c) 2013 Wiley Periodicals, Inc. C1 [Zhao, Wei; Cheung, Charles Y. K.; Wijsman, Ellen M.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Marchani, Elizabeth E.; Bird, Thomas D.; Wijsman, Ellen M.] Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98195 USA. [Steinbart, Ellen J.; Bird, Thomas D.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Steinbart, Ellen J.; Bird, Thomas D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Schellenberg, Gerard D.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA. [Wijsman, Ellen M.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA. RP Wijsman, EM (reprint author), Univ Washington, Dept Med, Div Med Genet, Box 357720, Seattle, WA 98195 USA. EM wijsman@u.washington.edu OI Wijsman, Ellen/0000-0002-2725-6669 FU National Institutes of Health (NIH) [P50 AG005136, T32 AG000258, K99 AG040184]; Veterans Affairs Research Funds; Metropolitan Life Foundation; [NIH U24 AG021886] FX We thank the patients and their families, whose help and participation made this work possible. We thank Leslie Leong and Hiep Nguyen for technical assistance; Adele Sadovnick, Leonard Heston, and Haydeh Payami for family material; and David Cook for discussions. Supported by National Institutes of Health (NIH) grants P50 AG005136, T32 AG000258, and K99 AG040184; Veterans Affairs Research Funds; and The Metropolitan Life Foundation. Some samples used in this study were obtained from the National Cell Repository for Alzheimer's Disease (NCRAD), supported by NIH U24 AG021886. NR 92 TC 1 Z9 1 U1 2 U2 16 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4841 EI 1552-485X J9 AM J MED GENET B JI Am. J. Med. Genet. B PD MAR PY 2013 VL 162B IS 2 BP 201 EP 212 DI 10.1002/ajmg.b.32133 PG 12 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA 095JP UT WOS:000315330800012 PM 23355194 ER PT J AU Fallows, RR Hilsabeck, RC AF Fallows, Robert R. Hilsabeck, Robin C. TI Comparing Two Methods of Delivering Neuropsychological Feedback SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Article DE Feedback; Written information; Neuropsychology ID WRITTEN INFORMATION; CONTROLLED-TRIAL; NATIONAL-SURVEY; MIXED METHODS; PERCEPTIONS; INTERVENTION; ADOLESCENT; SERVICE AB Feedback methods have been studied in medical and psychotherapy settings, but limited research is available in neuropsychology. The purpose of this study was to examine whether supplementing oral feedback with written information would lead to greater retention of information and improved adherence to recommendations. Seventy-two veterans were enrolled in the study and randomized to receive oral feedback only or oral feedback with written information. The participants were then interviewed immediately after feedback and 1 month later by phone. Univariate analyses revealed that the written group freely recalled more recommendations at the phone interview; however, there were no differences in recall of diagnostic information or the number of recommendations attempted. Findings indicate that receiving supplemental written information improves recall of recommendations and that patients prefer to receive written information in addition to oral feedback. Recommendations to improve the retention of feedback information are discussed. C1 [Fallows, Robert R.; Hilsabeck, Robin C.] S Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX USA. [Hilsabeck, Robin C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. RP Hilsabeck, RC (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, MS 7792, San Antonio, TX 78229 USA. EM hilsabeck@uthscsa.edu NR 38 TC 4 Z9 4 U1 0 U2 9 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0887-6177 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD MAR PY 2013 VL 28 IS 2 BP 180 EP 188 DI 10.1093/arclin/acs142 PG 9 WC Psychology, Clinical; Psychology SC Psychology GA 092YS UT WOS:000315159500010 PM 23315402 ER PT J AU Dowty, JG Win, AK Buchanan, DD Lindor, NM Macrae, FA Clendenning, M Antill, YC Thibodeau, SN Casey, G Gallinger, S Le Marchand, L Newcomb, PA Haile, RW Young, GP James, PA Giles, GG Gunawardena, SR Leggett, BA Gattas, M Boussioutas, A Ahnen, DJ Baron, JA Parry, S Goldblatt, J Young, JP Hopper, JL Jenkins, MA AF Dowty, James G. Win, Aung K. Buchanan, Daniel D. Lindor, Noralane M. Macrae, Finlay A. Clendenning, Mark Antill, Yoland C. Thibodeau, Stephen N. Casey, Graham Gallinger, Steve Le Marchand, Loic Newcomb, Polly A. Haile, Robert W. Young, Graeme P. James, Paul A. Giles, Graham G. Gunawardena, Shanaka R. Leggett, Barbara A. Gattas, Michael Boussioutas, Alex Ahnen, Dennis J. Baron, John A. Parry, Susan Goldblatt, Jack Young, Joanne P. Hopper, John L. Jenkins, Mark A. TI Cancer Risks for MLH1 and MSH2 Mutation Carriers SO HUMAN MUTATION LA English DT Article DE Lynch syndrome; MLH1; MSH2; risk; penetrance; cancer; colorectal cancer; endometrial cancer; segregation analysis; Colon CFR ID NONPOLYPOSIS COLORECTAL-CANCER; MISMATCH-REPAIR GENES; BODY-MASS INDEX; LYNCH-SYNDROME; COLON-CANCER; FAMILY REGISTRY; BREAST-CANCER; ENDOMETRIAL CANCER; GERMLINE MUTATIONS; PROSTATE-CANCER AB We studied 17,576 members of 166 MLH1 and 224 MSH2 mutation-carrying families from the Colon Cancer Family Registry. Average cumulative risks of colorectal cancer (CRC), endometrial cancer (EC), and other cancers for carriers were estimated using modified segregation analysis conditioned on ascertainment criteria. Heterogeneity in risks was investigated using a polygenic risk modifier. Average CRC cumulative risks at the age of 70 years (95% confidence intervals) for MLH1 and MSH2 mutation carriers, respectively, were estimated to be 34% (25%50%) and 47% (36%60%) for male carriers and 36% (25%51%) and 37% (27%50%) for female carriers. Corresponding EC risks were 18% (9.1%34%) and 30% (18%45%). A high level of CRC risk heterogeneity was observed (P<0.001), with cumulative risks at the age of 70 years estimated to follow U-shaped distributions. For example, 17% of male MSH2 mutation carriers have estimated lifetime risks of 0%10% and 18% have risks of 90%100%. Therefore, average risks are similar for the two genes but there is so much individual variation about the average that large proportions of carriers have either very low or very high lifetime cancer risks. Our estimates of CRC and EC cumulative risks for MLH1 and MSH2 mutation carriers are the most precise currently available. C1 [Dowty, James G.; Win, Aung K.; Hopper, John L.; Jenkins, Mark A.] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Parkville, Vic 3010, Australia. [Buchanan, Daniel D.; Clendenning, Mark; Young, Joanne P.] Queensland Inst Med Res, Familial Canc Lab, Brisbane, Qld 4006, Australia. [Lindor, Noralane M.] Mayo Clin, Dept Med Genet, Rochester, MN USA. [Macrae, Finlay A.] Royal Melbourne Hosp, Dept Colorectal Med & Genet, Parkville, Vic 3050, Australia. [Antill, Yoland C.] Cabrini Hlth, Familial Canc Ctr, Melbourne, Vic, Australia. [Antill, Yoland C.] So Hlth, Familial Canc Ctr, Clayton, Vic, Australia. [Thibodeau, Stephen N.; Gunawardena, Shanaka R.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA. [Casey, Graham; Haile, Robert W.] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA. [Gallinger, Steve] Univ Toronto, Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada. [Le Marchand, Loic] Univ Hawaii, Canc Res Ctr, Honolulu, HI 96813 USA. [Newcomb, Polly A.] Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA 98104 USA. [Young, Graeme P.] Flinders Univ S Australia, Ctr Canc Prevent & Control, Bedford Pk, SA, Australia. [James, Paul A.; Boussioutas, Alex] Peter MacCallum Canc Ctr, Familial Canc Ctr, Melbourne, Vic, Australia. [Giles, Graham G.] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia. [Leggett, Barbara A.] Royal Brisbane & Womens Hosp Res Fdn, Conjoint Gastroenterol Lab, Clin Res Ctr, Brisbane, Qld, Australia. [Leggett, Barbara A.] Queensland Inst Med Res, Brisbane, Qld 4006, Australia. [Gattas, Michael] Royal Childrens Hosp, Queensland Clin Genet Serv, Herston, Qld, Australia. [Boussioutas, Alex] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3010, Australia. [Ahnen, Dennis J.] Univ Colorado, Sch Med, Dept Med, Denver, CO USA. [Ahnen, Dennis J.] Denver VA Med Ctr, Denver, CO USA. [Baron, John A.] Univ N Carolina, Dept Med, Chapel Hill, NC USA. [Parry, Susan] Auckland City Hosp, New Zealand Familial Gastrointestinal Canc Regist, Auckland, New Zealand. [Goldblatt, Jack] Univ Western Australia, Genet Serv & Familial Canc Program Western Austra, Sch Paediat & Child Hlth, Perth, WA 6009, Australia. RP Dowty, JG (reprint author), Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Parkville, Vic 3010, Australia. EM jdowty@unimelb.edu.au RI Gallinger, Steven/E-4575-2013; James, Paul/G-2943-2014; Jenkins, Mark/P-7803-2015; Leggett, Barbara/D-3579-2011 OI Jenkins, Mark/0000-0002-8964-6160; Dowty, James/0000-0003-2383-0886; Giles, Graham/0000-0003-4946-9099; Boussioutas, Alex/0000-0002-8109-6897; Win, Aung Ko/0000-0002-2794-5261; Buchanan, Daniel/0000-0003-2225-6675 FU NCI NIH HHS [U24 CA074806, CA-95-011, K05 CA152715, K22 CA095011, P50 CA116201, R01 CA122340, R01 CA128978, U01 CA069398, U01 CA069631, U01 CA074783, U01 CA074794, U01 CA074799, U01 CA074800, U01 CA074806, U01 CA097735, U24 CA074783, U24 CA074794, U24 CA074799, U24 CA074800, U24 CA097735] NR 43 TC 44 Z9 44 U1 1 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1059-7794 J9 HUM MUTAT JI Hum. Mutat. PD MAR PY 2013 VL 34 IS 3 BP 490 EP 497 DI 10.1002/humu.22262 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA 093IX UT WOS:000315186400011 PM 23255516 ER PT J AU Hong, O Chin, DL Ronis, DL AF Hong, OiSaeng Chin, Dal Lae Ronis, David L. TI Predictors of Hearing Protection Behavior Among Firefighters in the United States SO INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE LA English DT Article DE Hearing protection; Firefighter; Predictors; Noise-induced hearing loss ID HEALTH-PROMOTION MODEL; CONSTRUCTION WORKERS USE; NOISE EXPOSURE; INTERVENTION; EFFICACY AB Noise-induced hearing loss (NIHL) is a major occupational health problem that can be prevented through the use of hearing protection devices (HPDs). The purpose of this study is to identify significant factors related to firefighters' use of HPDs. A total of 404 firefighters from 35 fire departments in multiple states in the United States participated in an Internet-based survey from March 2010 to May 2011. Pearson correlations and multiple regression analysis suggested that several modifying and cognitive-perceptual factors were significantly related to HPD use, including noise exposure, interpersonal influences, organizational support, perceived barriers to HPD use, and perceived susceptibility to hearing loss. The multiple regression model explained 56% (R (2) = .56, adjusted R (2) = .54) of the variance in firefighters' use of HPDs (F (13, 372) = 35.65, p < .001). Future research should focus on incorporating these significant predictors into effective behavioral interventions designed to promote the use of HPDs in this population. C1 [Hong, OiSaeng; Chin, Dal Lae] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA. [Ronis, David L.] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA. [Ronis, David L.] US Dept Vet Affairs, Ctr Clin Management Res, Ann Arbor, MI USA. [Hong, OiSaeng] Univ Calif San Francisco, Sch Nursing, Occupat & Environm Hlth Nursing Program, San Francisco, CA 94143 USA. RP Hong, O (reprint author), Univ Calif San Francisco, Sch Nursing, Occupat & Environm Hlth Nursing Program, 2 Koret Way,Room N 531D, San Francisco, CA 94143 USA. EM oisaeng.hong@nursing.ucsf.edu NR 37 TC 4 Z9 4 U1 1 U2 13 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1070-5503 J9 INT J BEHAV MED JI Int. J. Behav. Med. PD MAR PY 2013 VL 20 IS 1 BP 121 EP 130 DI 10.1007/s12529-011-9207-0 PG 10 WC Psychology, Clinical SC Psychology GA 094NQ UT WOS:000315271400017 PM 22161219 ER PT J AU Hauptman, JS Dadour, A Oh, T Baca, CB Vickrey, BG Vassar, SD Sankar, R Salamon, N Vinters, HV Mathern, GW AF Hauptman, Jason S. Dadour, Andrew Oh, Taemin Baca, Christine B. Vickrey, Barbara G. Vassar, Stefanie D. Sankar, Raman Salamon, Noriko Vinters, Harry V. Mathern, Gary W. TI Sociodemographic changes over 25 years of pediatric epilepsy surgery at UCLA SO JOURNAL OF NEUROSURGERY-PEDIATRICS LA English DT Article DE socioeconomic disparity; seizure; craniotomy; health inequity; epilepsy ID TEMPORAL-LOBE EPILEPSY; UNITED-STATES; DISPARITIES; OUTCOMES; RACE/ETHNICITY; CHILDREN; SEIZURE; ACCESS; CARE AB Object. Low income, government insurance, and minority status are associated with delayed treatment for neurosurgery patients. Less is known about the influence of referral location and how socioeconomic factors and referral patterns evolve over time. For pediatric epilepsy surgery patients at the University of California, Los Angeles (UCLA), this study determined how referral location and sociodemographic features have evolved over 25 years. Methods. Children undergoing epilepsy neurosurgery at UCLA (453 patients) were classified by location of residence and compared with clinical epilepsy and sociodemographic factors. Results. From 1986 to 2010, referrals from Southern California increased (+33%) and referrals from outside of California decreased (-19%). Over the same period, the number of patients with preferred provider organization (PPO) and health maintenance organization (HMO) insurance increased (+148% and +69%, respectively) and indemnity insurance decreased (-96%). Likewise, the number of Hispanics (+117%) and Asians (100%) increased and Caucasians/whites decreased (-24%). The number of insurance companies decreased from 52 carriers per 100 surgical patients in 1986-1990 to 19 per 100 in 2006-2010. Patients living in the Eastern US had a younger age at surgery (-46%), shorter intervals from seizure onset to referral for evaluation (-28%) and from presurgical evaluation to surgery (-61%) compared with patients from Southern California. The interval from seizure onset to evaluation was shorter (-33%) for patients from Los Angeles County compared with those living in non-California Western US states. Conclusions. Referral locations evolved over 25 years at UCLA, with more cases coming from local regions; the percentage of minority patients also increased. The interval from seizures onset to surgery was shortest for patients living farthest from UCLA but still within the US. Geographic location and race/ethnicity was not associated with differences in becoming seizure free after epilepsy surgery in children. (http://thejns.org/doi/abs/10.3171/2012.11.PEDS12359) C1 [Hauptman, Jason S.; Dadour, Andrew; Oh, Taemin; Mathern, Gary W.] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Dept Neurosurg, Los Angeles, CA 90095 USA. [Baca, Christine B.; Vickrey, Barbara G.; Vassar, Stefanie D.; Sankar, Raman; Vinters, Harry V.] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Dept Neurol, Los Angeles, CA 90095 USA. [Sankar, Raman] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Dept Pediat, Los Angeles, CA 90095 USA. [Mathern, Gary W.] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Dept Psychiat & BioBehav Med, Los Angeles, CA 90095 USA. [Sankar, Raman] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Div Pediat Neurol, Los Angeles, CA 90095 USA. [Salamon, Noriko] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Div Neuroradiol, Los Angeles, CA 90095 USA. [Vinters, Harry V.] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Sect Neuropathol, Los Angeles, CA 90095 USA. [Baca, Christine B.; Vickrey, Barbara G.] VA Greater Los Angeles Hlth Care Syst, Dept Neurol, Los Angeles, CA USA. RP Mathern, GW (reprint author), 710 Westwood Plaza,Room 2123, Los Angeles, CA 90095 USA. EM gmathern@ucla.edu FU Epilepsy Foundation [213971]; NIH (National Institute on Aging, National Institute of Neurological Disorders and Stroke); US Veterans Administration Health Services Research and Development Service; American Heart Association; SCAN Foundation; Kansas City Area Life Sciences Institute; UCB Pharma; Sunovion; Upsher-Smith; Supernus; Lundbeck Pharma; Pfizer; University of California Pediatric Neuropathology Consortium; NeuroPace, Inc.; NIH [R01 NS38992]; [NIH-M11079933] FX Dr. Baca receives salary support from the Epilepsy Foundation Grant 213971. Dr. Vickrey serves on scientific advisory boards for the Sports Concussion Institute, National Multiple Sclerosis Society, and the NIH; serves on the editorial boards of Neurorehabilitation and Neural Repair and Circulation, Cardiovascular Quality and Outcomes, and is a section editor for Stroke; receives research support from the NIH (National Institute on Aging, National Institute of Neurological Disorders and Stroke), the US Veterans Administration Health Services Research and Development Service, the American Heart Association, and SCAN Foundation; and received funding for travel and a speaker honorarium from the Kansas City Area Life Sciences Institute. Dr. Sankar serves on scientific advisory boards for and has received honoraria and funding for travel from UCB Pharma, Sunovion, Upsher-Smith, Supernus, and Lundbeck Pharma; receives royalties from the publication of Pediatric Neurology, 3rd ed. (Demos Publishing, 2008) and Epilepsy: Mechanisms, Models, and Translational Perspectives (CRC Press, 2011); serves on speakers' bureaus for and has received speaker honoraria from UCB, GlaxoSmithKline, and Lundbeck. He receives funding from NIH-M11079933 (co-primary investigator) and from Pfizer (Lyrica pediatric partial seizures trial). He serves on the editorial board for Epilepsy & Behavior. Dr. Vinters is on the editorial boards of Neuropathology and Applied Neurobiology, Neuropathology, Journal of Neuroscience Research, and the Korean Journal of Pathology. The Harry V. Vinters laboratory was supported in part by the University of California Pediatric Neuropathology Consortium, and Harry V. Vinters trust owns shares in and receives dividends from the following makers of drugs and medical equipment: GE, 3M, Pfizer, Teva Pharma, and GlaxoSmithKline. The Vinters laboratory has received research funding in the past from NeuroPace, Inc. Dr. Mathern received research funding from NIH grant R01 NS38992, which partially supported this paper. He is also on the editorial boards for Neurology, Epilepsy Research, Epileptic Disorders, and Epilepsy & Seizures. He serves on the Data Management Committee for NeuroPace, Inc. NR 16 TC 4 Z9 5 U1 0 U2 3 PU AMER ASSOC NEUROLOGICAL SURGEONS PI ROLLING MEADOWS PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA SN 1933-0707 J9 J NEUROSURG-PEDIATR JI J. Neurosurg.-Pediatr. PD MAR PY 2013 VL 11 IS 3 BP 250 EP 255 DI 10.3171/2012.11.PEDS12359 PG 6 WC Clinical Neurology; Pediatrics; Surgery SC Neurosciences & Neurology; Pediatrics; Surgery GA 094DV UT WOS:000315244100004 PM 23331214 ER PT J AU Shah, GN Price, TO Banks, WA Morofuji, Y Kovac, A Ercal, N Sorenson, CM Shin, ES Sheibani, N AF Shah, Gul N. Price, Tulin O. Banks, William A. Morofuji, Yoichi Kovac, Andrej Ercal, Nuran Sorenson, Christine M. Shin, Eui S. Sheibani, Nader TI Pharmacological Inhibition of Mitochondrial Carbonic Anhydrases Protects Mouse Cerebral Pericytes from High Glucose-Induced Oxidative Stress and Apoptosis SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS LA English DT Article ID BLOOD-BRAIN-BARRIER; MICROVASCULAR PERICYTES; ENDOTHELIAL-CELLS; NITRIC-OXIDE; HYPERGLYCEMIA; EXPRESSION; COMPLICATIONS; PLURIPOTENT; DAMAGE; MODEL AB Diabetes-associated complications in the microvasculature of the brain are caused by oxidative stress, generated by overproduction of reactive oxygen species from hyperglycemia-induced accelerated oxidative metabolism of glucose. Pericytes, essential for the viability of the microvasculature, are especially susceptible to oxidative stress. Mitochondrial carbonic anhydrases, regulators of the oxidative metabolism of glucose, determine the rate of reactive oxygen species production and inhibition of mitochondrial carbonic anhydrases rescues glucose-induced pericyte loss in the diabetic mouse brain. We hypothesized that high glucose induces intracellular oxidative stress and pericyte apoptosis and that inhibition of mitochondrial carbonic anhydrases protects pericytes from oxidative stress-induced apoptosis. To validate our hypothesis, conditionally immortalized cerebral pericyte (IPC) cultures were established from Immortomice to investigate the effect of high glucose on oxidative stress and pericyte apoptosis. The IPCs expressed pericyte markers and induced high transendothelial electrical resistance and low permeability in brain endothelial cell monolayers comparable with pericytes in primary cultures. The IPCs also secreted cytokines constitutively and in response to lipopolysaccharide similar to pericytes. High glucose caused oxidative stress and apoptosis of these cells, with both oxidative stress and apoptosis significantly reduced after mitochondrial carbonic anhydrase inhibition. These results provide the first evidence that pharmacological inhibition of mitochondrial carbonic anhydrases attenuates pericyte apoptosis caused by high glucose-induced oxidative stress. Carbonic anhydrase inhibitors have a long history of safe clinical use and can be immediately evaluated for this new indication in translational research. Thus, mitochondrial carbonic anhydrases may provide a new therapeutic target for oxidative stress-related illnesses of the brain. C1 [Shah, Gul N.; Price, Tulin O.] St Louis Univ, Dept Internal Med, Edward A Doisy Res Ctr, Div Endocrinol, St Louis, MO 63104 USA. [Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Banks, William A.; Morofuji, Yoichi; Kovac, Andrej] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA USA. [Ercal, Nuran] Missouri Univ Sci & Technol, Dept Chem, Rolla, MO USA. [Sorenson, Christine M.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI USA. [Shin, Eui S.; Sheibani, Nader] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA. RP Shah, GN (reprint author), St Louis Univ, Dept Internal Med, Edward A Doisy Res Ctr, Div Endocrinol, 1100 S Grand Blvd,DRC 315, St Louis, MO 63104 USA. EM shahgn@slu.edu FU National Institutes of Health [R01-DK083485, RC4-EY021357, EY016695, P30-EY016665, P30-CA014520] FX This study was supported by the National Institutes of Health [Grants R01-DK083485, RC4-EY021357, EY016695, P30-EY016665, and P30-CA014520]. NR 40 TC 14 Z9 15 U1 0 U2 5 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0022-3565 J9 J PHARMACOL EXP THER JI J. Pharmacol. Exp. Ther. PD MAR PY 2013 VL 344 IS 3 BP 637 EP 645 DI 10.1124/jpet.112.201400 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 093LD UT WOS:000315192500010 PM 23249625 ER PT J AU Robinson-Cohen, C Littman, AJ Duncan, GE Roshanravan, B Ikizler, TA Himmelfarb, J Kestenbaum, BR AF Robinson-Cohen, Cassianne Littman, Alyson J. Duncan, Glen E. Roshanravan, Baback Ikizler, T. Alp Himmelfarb, Jonathan Kestenbaum, Bryan R. TI Assessment of Physical Activity in Chronic Kidney Disease SO JOURNAL OF RENAL NUTRITION LA English DT Article ID OLDER-ADULTS; ACTIVITY QUESTIONNAIRE; ACTIVITY SCALE; UNITED-STATES; ELDERLY PASE; EXERCISE; ACCELEROMETER; HEALTH; HEMODIALYSIS; INFLAMMATION AB Background: Physical inactivity plays an important role in the development of kidney disease and its complications; however, the validity of standard tools for measuring physical activity (PA) is not well understood. Study Design: We investigated the performance of several readily available and widely used PA and physical function questionnaires, individually and in combination, against accelerometry among a cohort of chronic kidney disease (CKD) participants. Setting and Participants: Forty-six participants from the Seattle Kidney Study, an observational cohort study of persons with CKD, completed the Physical Activity Scale for the Elderly, Human Activity Profile (HAP), Medical Outcomes Study SF-36 questionnaire, and the Four-week Physical Activity History questionnaires. We simultaneously measured PA using an Actigraph GT3X accelerometer during a 14-day period. We estimated the validity of each instrument by testing its associations with log-transformed accelerometry counts. We used the Akaike information criterion to investigate the performance of combinations of questionnaires. Results: All questionnaire scores were significantly associated with log-transformed accelerometry counts. The HAP correlated best with accelerometry counts (r(2) = 0.32) followed by SF-36 (r(2) = 0.23). Forty-three percent of the variability in accelerometry counts data was explained by a model that combined the HAP, SF-36, and Four-week Physical Activity History questionnaires. Conclusion: A combination of measurement tools can account for a modest component of PA in patients with CKD; however, a substantial proportion of PA is not captured by standard assessments. (c) 2013 by the National Kidney Foundation, Inc. All rights reserved. C1 [Robinson-Cohen, Cassianne; Littman, Alyson J.; Duncan, Glen E.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Robinson-Cohen, Cassianne; Roshanravan, Baback; Himmelfarb, Jonathan; Kestenbaum, Bryan R.] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA. [Littman, Alyson J.] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Duncan, Glen E.] Univ Washington, Nutr Sci Program, Seattle, WA 98195 USA. [Roshanravan, Baback; Himmelfarb, Jonathan; Kestenbaum, Bryan R.] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA. [Ikizler, T. Alp] Vet Adm Tennessee Valley Healthcare Syst, Nashville, TN USA. [Ikizler, T. Alp] Vanderbilt Univ, Div Nephrol, Nashville, TN USA. RP Robinson-Cohen, C (reprint author), Univ Washington, Harborview Med Ctr, Kidney Res Inst, Box 359606,325 9th Ave, Seattle, WA 98104 USA. EM cassyrc@u.washington.edu RI Duncan, Glen/A-3771-2008 OI Duncan, Glen/0000-0001-6909-1869; Robinson-Cohen, Cassianne/0000-0003-4783-7046 FU Office of Research and Development Cooperative Studies Program, Department of Veterans Affairs; Seattle Epidemiologic Research and Information Center of the Department of Veterans Affairs; VA Rehabilitation Career Development Award [6982] FX This material is based on work supported in part by the Office of Research and Development Cooperative Studies Program, Department of Veterans Affairs. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. The Seattle Epidemiologic Research and Information Center of the Department of Veterans Affairs supported the involvement of all of the authors in this research. A.J.L. was supported by VA Rehabilitation Career Development Award (#6982). NR 40 TC 12 Z9 12 U1 1 U2 16 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1051-2276 J9 J RENAL NUTR JI J. Renal Nutr. PD MAR PY 2013 VL 23 IS 2 BP 123 EP 131 DI 10.1053/j.jrn.2012.04.008 PG 9 WC Nutrition & Dietetics; Urology & Nephrology SC Nutrition & Dietetics; Urology & Nephrology GA 093NN UT WOS:000315198700014 PM 22739659 ER PT J AU Muir, ER Zhang, Y Nateras, OSE Peng, Q Duong, TQ AF Muir, Eric R. Zhang, Yi Nateras, Oscar San Emeterio Peng, Qi Duong, Timothy Q. TI Human Vitreous: MR Imaging of Oxygen Partial Pressure SO RADIOLOGY LA English DT Article ID PROLIFERATIVE DIABETIC-RETINOPATHY; NUCLEAR CATARACT; RETINAL OXYGENATION; TEMPERATURE; VITRECTOMY; EYE; BODY; TENSION; LENS; AGE AB Purpose: To develop a magnetic resonance (MR) imaging approach to noninvasively image quantitative Po-2 in the human vitreous. Materials and Methods: Human studies were approved by the institutional review board with informed consent obtained from all subjects and were HIPAA compliant. Animal studies were performed with animal care committee approval. An MR imaging method to measure the longitudinal relaxation rate, or R1, of water was implemented with a 3.0-T MR imager. R1 was calibrated in water phantoms at multiple Po-2 and temperature conditions (n = 10) and in ex vivo animal vitreous (n = 2). Vitreous Po-2 was imaged in three human volunteers (age range, 26-28 years) in multiple sessions on separate days to evaluate reproducibility. The effects of temperature and ambient air were evaluated by acquiring data with the eye open and closed. Statistical analysis consisted of t tests, with P less than .05 indicating significant difference. Results: Calibrations of phantoms and ex vivo vitreous yielded an R1 association with oxygen of 0.209 sec(-1) + Po-2 . 2.07 X 10(-4) sec(-1)/mm Hg at 37 degrees C, and an association with temperature (Delta[1/R1]/Delta Temperature) of 0.106 sec/degrees C +/- 0.009 (standard deviation). A difference in R1 was found between the phantoms and vitreous. If uncorrected, vitreal Po2 would be significantly overestimated (P,.001). In vivo human vitreous Po-2 maps were spatially heterogeneous, with a whole vitreous Po 2 of 16.7 mm Hg 6 6.5 (eye closed). Measurements between open and closed eyes showed spatially dependent R1 differences, which translated to temperature differences of 0.34-0.83 C across the eye. Conclusion: This study established an MR imaging protocol to image quantitative vitreous Po-2 noninvasively and evaluated effects from vitreal macromolecules, temperature gradients, and ambient air on vitreal Po-2 values. Measurement of vitreous Po-2 with MR imaging has the potential to be used to study eye diseases noninvasively. (C) RSNA, 2012 C1 [Muir, Eric R.; Zhang, Yi; Nateras, Oscar San Emeterio; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA. [Zhang, Yi; Nateras, Oscar San Emeterio; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Duong, Timothy Q.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Duong, Timothy Q.] SW Natl Primate Res Ctr, San Antonio, TX USA. [Peng, Qi] Albert Einstein Coll Med, Dept Radiol, New York, NY USA. [Peng, Qi] Montefiore Med Ctr, New York, NY USA. RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. EM duongt@uthscsa.edu RI Duong, Timothy/B-8525-2008; Muir, Eric/H-8830-2013 FU NEI NIH HHS [EY018855, R01 EY018855, R01 EY014211]; NHLBI NIH HHS [T32 HL007446, T32HL007446]; NIH HHS [P51 OD011133] NR 29 TC 5 Z9 5 U1 0 U2 8 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD MAR PY 2013 VL 266 IS 3 BP 905 EP 911 DI 10.1148/radiol.12120777 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 094YC UT WOS:000315300400023 PM 23220896 ER PT J AU Nargiso, JE Friend, KB Egan, C Florin, P Stevenson, J Amodei, B Barovier, L AF Nargiso, Jessica E. Friend, Karen B. Egan, Crystelle Florin, Paul Stevenson, John Amodei, Brenda Barovier, Linda TI Coalitional Capacities and Environmental Strategies to Prevent Underage Drinking SO AMERICAN JOURNAL OF COMMUNITY PSYCHOLOGY LA English DT Article DE Coalitions; Prevention; Capacity; Measurement; Training and technical assistance ID COMMUNITY-BASED PREVENTION; HEALTH PROMOTION; DRUG-ABUSE; ALCOHOL; SYSTEMS; TRIAL; INTERVENTIONS; PENNSYLVANIA; PARTNERSHIPS; PREVALENCE AB Coalitions are the most common platform for implementing community-level environmental strategies (ES), such as media, policy, or enforcement for substance use prevention. The current study examines the associations between two types of coalition capacity (general and innovation-specific) and ES implementation efforts and outputs within 14 intervention communities over a three-year period. Efforts refer to the amount of energy exerted to implement an ES while outputs refer to the materials produced through these efforts. Quantitative measures of capacity were provided by coalition key informants and expert-raters. Additionally, Training and Technical Assistance (TTA) provided proactively to improve the implementation of ES was also examined. Greater general capacity, as rated by a coalition informant, was associated with more ES policy effort. Both expert-rated general and innovation-specific capacity, however, were associated with greater ES outputs. Study results also found that community coalitions that endorsed weaker mobilization, structure and task leadership, (measures of general capacity), utilized more TTA compared to those who perceived their coalition as having greater capacity. Moreover, communities that utilized more TTA resources reported a greater number of successful policy changes. The study supports the need to consider both general and innovation-specific capacity for ES implementation and offers promising preliminary findings regarding the role of TTA for improving coalitions' capacity to facilitate policy change. C1 [Nargiso, Jessica E.; Friend, Karen B.] Brown Univ, Ctr Alcohol & Addict Studies, Warren Alpert Med Sch, Providence, RI 02912 USA. [Friend, Karen B.] Pacific Inst Res & Evaluat, Decis Sci Inst, Pawtucket, RI 02860 USA. [Egan, Crystelle] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Florin, Paul; Stevenson, John] Univ Rhode Isl, Dept Psychol, Kingston, RI 02881 USA. [Amodei, Brenda] Dev Disabil & Hosp, Dept Behav Healthcare, Cranston, RI 02920 USA. [Barovier, Linda] Educ Dev Ctr Inc, Waltham, MA 02453 USA. RP Nargiso, JE (reprint author), Brown Univ, Ctr Alcohol & Addict Studies, Warren Alpert Med Sch, Box G-S121-4, Providence, RI 02912 USA. EM Jessica_Nargiso@brown.edu FU NIDA NIH HHS [T32 DA016184] NR 33 TC 9 Z9 9 U1 0 U2 15 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0091-0562 J9 AM J COMMUN PSYCHOL JI Am. J. Community Psychol. PD MAR PY 2013 VL 51 IS 1-2 BP 222 EP 231 DI 10.1007/s10464-012-9536-4 PG 10 WC Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Social Work SC Public, Environmental & Occupational Health; Psychology; Social Work GA 088KV UT WOS:000314834100019 PM 22752558 ER PT J AU Levine, DJ Riley, DJ Jorgensen, JH McClain, WD Tio, F Visvesvara, GS Abboud-Werner, SL AF Levine, Deborah J. Riley, Daniel J. Jorgensen, James H. McClain, William D. Tio, Fermin Visvesvara, Govinda S. Abboud-Werner, Sherry L. TI Key Diagnostic Features of Granulomatous Interstitial Nephritis Due to Encephalitozoon cuniculi in a Lung Transplant Recipient SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY LA English DT Article DE microsporidia; lung; kidney; transplant; albendazole ID BONE-MARROW-TRANSPLANTATION; ENTEROCYTOZOON-BIENEUSI; MICROSPORIDIOSIS; AIDS; INFECTION; MYOSITIS; PATIENT; GENOTYPES AB Microsporidia are increasingly recognized as opportunistic pathogens in immunocompromised organ transplant recipients (OTR). Disseminated infection due to Encephalitozoon sp. is reported mainly in human immunodeficiency virus (HIV)-positive patients and rarely in HIV-negative OTR. The clinical spectrum ranges from keratoconjunctivitis, to pneumonitis, to acute kidney injury. The kidney is a common site for disseminated infection; however, specialized techniques are required for definitive diagnosis. We report the first case of disseminated Encephalitozoon cuniculi infection in an HIV-negative lung transplant recipient diagnosed on renal biopsy. Five months after transplant, he presented with fever and a lung infiltrate and developed acute kidney injury. Renal biopsy showed granulomatous interstitial nephritis with gram-positive rod-shaped organisms with a "belt-like stripe" in tubular epithelial cells. Electron microscopy, polymerase chain reaction, and mammalian cell cultures of the urine sediment confirmed E. cuniculi infection. Retrospective review of a previous lung biopsy showed similar organisms. On the basis of electron microscopy findings, the patient was treated with albendazole, and immunosuppressive therapy was reduced. However, the patient expired due to Aspergillus pneumonia and disseminated E. cuniculi infection. Microsporidia should be considered in cases of fever of unknown origin and/or multiorgan infection in HIV-negative OTR when other causes have been excluded, as successful treatment requires early detection. C1 [Levine, Deborah J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Pulm Dis, San Antonio, TX 78229 USA. [Riley, Daniel J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Jorgensen, James H.; McClain, William D.; Tio, Fermin; Abboud-Werner, Sherry L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Jorgensen, James H.; McClain, William D.; Tio, Fermin; Abboud-Werner, Sherry L.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Visvesvara, Govinda S.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. RP Abboud-Werner, SL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM abboudwerner@uthscsa.edu NR 33 TC 4 Z9 4 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0147-5185 J9 AM J SURG PATHOL JI Am. J. Surg. Pathol. PD MAR PY 2013 VL 37 IS 3 BP 447 EP 452 DI 10.1097/PAS.0b013e31827e1968 PG 6 WC Pathology; Surgery SC Pathology; Surgery GA 092BY UT WOS:000315095000017 PM 23388129 ER PT J AU Lawson, KM Back, SE Hartwell, KJ Maria, MMS Brady, KT AF Lawson, Katie M. Back, Sudie E. Hartwell, Karen J. Maria, Megan Moran-Santa Brady, Kathleen T. TI A Comparison of Trauma Profiles among Individuals with Prescription Opioid, Nicotine, or Cocaine Dependence SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; SEXUAL ABUSE; DSM-IV; ASSOCIATION; POPULATION; PREVALENCE; SMOKING; PTSD AB Background and Objectives Exposure to traumatic events is common among individuals with substance use disorders. Little is known, however, about the trauma histories among individuals with various types of addiction. Methods The present study compared the trauma histories (general, sexual, physical and emotional) of non-treatment seeking outpatients dependent on prescription opioids (n=41), nicotine (n=87) or cocaine (n=73). The Life Stressor ChecklistRevised (LSC-R) was completed by participants to assess childhood and adult trauma. Results The findings revealed that all three groups endorsed high levels of trauma exposure, with 96.5% of the entire sample experiencing at least one traumatic event in their lifetime. The prescription opiate group experienced a greater number of general and total traumas than the nicotine group. However, no group differences in the number of emotional, physical, or sexual traumas were revealed. The prescription opiate group reported a younger age of first traumatic event than the cocaine group, and was significantly more likely to report childhood traumatic events than both the cocaine and nicotine groups. Conclusions and Scientific Significance The findings provide clinically relevant information that may help improve screening, interventions, and preventative efforts. (Am J Addict 2013;22:127-131) C1 [Back, Sudie E.; Hartwell, Karen J.; Maria, Megan Moran-Santa; Brady, Kathleen T.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Hartwell, Karen J.; Brady, Kathleen T.] Ralph H Johnson VAMC, Charleston, SC USA. RP Lawson, KM (reprint author), 430 Biobehav Hlth Bldg, University Pk, PA 16802 USA. EM kml5509@psu.edu FU NCRR NIH HHS [UL1 RR029882]; NICHD NIH HHS [5 K12 HD055885‐02, K12 HD055885]; NIDA NIH HHS [K24 DA00435, K23 DA021228, K24 DA000435, R33 DA036085‐03] NR 22 TC 7 Z9 7 U1 2 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 J9 AM J ADDICTION JI Am. J. Addict. PD MAR-APR PY 2013 VL 22 IS 2 BP 127 EP 131 DI 10.1111/j.1521-0391.2013.00319.x PG 5 WC Substance Abuse SC Substance Abuse GA 092AK UT WOS:000315091000007 PM 23414497 ER PT J AU Lozano, BE LaRowe, SD Smith, JP Tuerk, P Roitzsch, J AF Lozano, Brian E. LaRowe, Steven D. Smith, Joshua P. Tuerk, Peter Roitzsch, John TI Brief Motivational Feedback May Enhance Treatment Entry in Veterans with Comorbid Substance Use and Psychiatric Disorders SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID INTERVENTION; DRINKING AB Background and Objectives There are limited investigations of brief interventions to facilitate treatment entry among individuals with substance use disorders. This study investigated the effectiveness of brief motivational feedback (BMF) for increasing entry into intensive substance abuse treatment in veteran patients. Methods Veteran patients (N=84) with substance use disorders referred for an intake assessment in a substance abuse specialty clinic received either (i) intake assessment plus BMF or (ii) intake assessment as usual (AAU). BMF consisted of brief motivational enhancement feedback pertaining to estimates of alcohol and drug consumption, money spent on drugs and alcohol, and self-reported problems due to substance abuse. Primary outcome was entry in treatment groups in an intensive outpatient program for substance abuse. Results Patients in BMF and AAU conditions did not significantly differ on indices of treatment entry. However, among patients with comorbid substance dependence and psychiatric disorders, those who received BMF were significantly more likely to enter outpatient treatment groups. Conclusions and Scientific Significance The addition of motivational feedback to a standard intake assessment enhanced substance abuse treatment entry among veteran patients with comorbid substance use disorders and psychiatric disorders. These preliminary findings extend the use of motivational feedback to facilitate entry into substance abuse treatment among veteran patients with comorbid substance use and psychiatric disorders. Furthermore, they suggest opportunity for more effective patient-treatment matching based on initial motivation and other individual factors such as psychiatric comorbidity. (Am J Addict 2013;22:132-135) C1 [Lozano, Brian E.; LaRowe, Steven D.; Tuerk, Peter] Ralph H Johnson VAMC, Charleston, SC 29401 USA. [Lozano, Brian E.; LaRowe, Steven D.; Smith, Joshua P.; Tuerk, Peter; Roitzsch, John] Med Univ S Carolina, Charleston, SC 29425 USA. RP Lozano, BE (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM brian.lozano@va.gov OI LaRowe, Steven/0000-0002-7664-2451 NR 11 TC 1 Z9 1 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 J9 AM J ADDICTION JI Am. J. Addict. PD MAR-APR PY 2013 VL 22 IS 2 BP 132 EP 135 DI 10.1111/j.1521-0391.2013.00315.x PG 4 WC Substance Abuse SC Substance Abuse GA 092AK UT WOS:000315091000008 PM 23414498 ER PT J AU Kaufman, KM Zhao, J Kelly, JA Hughes, T Adler, A Sanchez, E Ojwang, JO Langefeld, CD Ziegler, JT Williams, AH Comeau, ME Marion, MC Glenn, SB Cantor, RM Grossman, JM Hahn, BH Song, YW Yu, CY James, JA Guthridge, JM Brown, EE Alarcon, GS Kimberly, RP Edberg, JC Ramsey-Goldman, R Petri, MA Reveille, JD Vila, LM Anaya, JM Boackle, SA Stevens, AM Freedman, BI Criswell, LA Pons-Estel, BA Lee, JH Lee, JS Chang, DM Scofield, RHA Gilkeson, GS Merrill, JT Niewold, TB Vyse, TJ Bae, SC Alarcon-Riquelme, ME Jacob, CO Sivils, KM Gaffney, PM Harley, JB Sawalha, AH Tsao, BP AF Kaufman, Kenneth M. Zhao, Jian Kelly, Jennifer A. Hughes, Travis Adler, Adam Sanchez, Elena Ojwang, Joshua O. Langefeld, Carl D. Ziegler, Julie T. Williams, Adrienne H. Comeau, Mary E. Marion, Miranda C. Glenn, Stuart B. Cantor, Rita M. Grossman, Jennifer M. Hahn, Bevra H. Song, Yeong Wook Yu, Chack-Yung James, Judith A. Guthridge, Joel M. Brown, Elizabeth E. Alarcon, Graciela S. Kimberly, Robert P. Edberg, Jeffrey C. Ramsey-Goldman, Rosalind Petri, Michelle A. Reveille, John D. Vila, Luis M. Anaya, Juan-Manuel Boackle, Susan A. Stevens, Anne M. Freedman, Barry I. Criswell, Lindsey A. Pons-Estel, Bernardo A. Lee, Joo-Hyun Lee, Ji-Seon Chang, Deh-Ming Scofield, R. Hal A. Gilkeson, Gary S. Merrill, Joan T. Niewold, Timothy B. Vyse, Timothy James Bae, Sang-Cheol Alarcon-Riquelme, Marta E. Jacob, Chaim O. Sivils, Kathy Moser Gaffney, Patrick M. Harley, John B. Sawalha, Amr H. Tsao, Betty P. CA Argentine Collaborat Grp Biolupus Network TI Fine mapping of Xq28: both MECP2 and IRAK1 contribute to risk for systemic lupus erythematosus in multiple ancestral groups SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Article ID GENOME-WIDE ASSOCIATION; KAPPA-B ACTIVATION; ACETYLTRANSFERASE ARD1; GENETIC SUSCEPTIBILITY; BINDING-PROTEIN; IDENTIFICATION; HAPLOTYPE; REPLICATION; VARIANTS; INSIGHTS AB Objectives The Xq28 region containing IRAK1 and MECP2 has been identified as a risk locus for systemic lupus erythematosus (SLE) in previous genetic association studies. However, due to the strong linkage disequilibrium between IRAK1 and MECP2, it remains unclear which gene is affected by the underlying causal variant(s) conferring risk of SLE. Methods We fine-mapped >= 136 SNPs in a similar to 227 kb region on Xq28, containing IRAK1, MECP2 and seven adjacent genes (L1CAM, AVPR2, ARHGAP4, NAA10, RENBP, HCFC1 and TMEM187), for association with SLE in 15 783 case-control subjects derived from four different ancestral groups. Results Multiple SNPs showed strong association with SLE in European Americans, Asians and Hispanics at p < 5 x 10(-8) with consistent association in subjects with African ancestry. Of these, six SNPs located in the TMEM187-IRAK1-MECP2 region captured the underlying causal variant(s) residing in a common risk haplotype shared by all four ancestral groups. Among them, rs1059702 best explained the Xq28 association signals in conditional testings and exhibited the strongest p value in transancestral meta-analysis (p(meta) = 1.3 x 10(-27), OR = 1.43), and thus was considered to be the most likely causal variant. The risk allele of rs1059702 results in the amino acid substitution S196F in IRAK1 and had previously been shown to increase NF-kappa B activity in vitro. We also found that the homozygous risk genotype of rs1059702 was associated with lower mRNA levels of MECP2, but not IRAK1, in SLE patients (p = 0.0012) and healthy controls (p = 0.0064). Conclusions These data suggest contributions of both IRAK1 and MECP2 to SLE susceptibility. C1 [Kaufman, Kenneth M.; Harley, John B.] Cincinnati Childrens Hosp, Med Ctr, Div Rheumatol, Cincinnati, OH USA. [Kaufman, Kenneth M.; Harley, John B.] Cincinnati Childrens Hosp, Med Ctr, Ctr Autoimmune Genom & Etiol, Cincinnati, OH USA. [Kaufman, Kenneth M.; Merrill, Joan T.; Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. [Zhao, Jian; Grossman, Jennifer M.; Hahn, Bevra H.; Tsao, Betty P.] Univ Calif Los Angeles, Div Rheumatol, Los Angeles, CA USA. [Kelly, Jennifer A.; Hughes, Travis; Adler, Adam; Sanchez, Elena; Glenn, Stuart B.; James, Judith A.; Guthridge, Joel M.; Scofield, R. Hal A.; Alarcon-Riquelme, Marta E.; Sivils, Kathy Moser; Gaffney, Patrick M.; Sawalha, Amr H.] Oklahoma Med Res Fdn, Arthritis & Clin Immunol Program, Oklahoma City, OK 73104 USA. [Ojwang, Joshua O.] Brevard Coll, Dept Chem, Palm Bay, FL USA. [Langefeld, Carl D.; Ziegler, Julie T.; Williams, Adrienne H.; Comeau, Mary E.; Marion, Miranda C.] Wake Forest Sch Med, Dept Biostat, Winston Salem, NC USA. [Cantor, Rita M.] Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA USA. [Song, Yeong Wook] Seoul Natl Univ, Div Rheumatol, Seoul, South Korea. [Yu, Chack-Yung] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA. [James, Judith A.; Scofield, R. Hal A.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. [Brown, Elizabeth E.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA. [Brown, Elizabeth E.; Alarcon, Graciela S.; Kimberly, Robert P.; Edberg, Jeffrey C.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Ramsey-Goldman, Rosalind] Northwestern Univ, Feinberg Sch Med, Div Rheumatol, Chicago, IL 60611 USA. [Petri, Michelle A.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Reveille, John D.] Univ Texas Houston, Hlth Sci Ctr, Dept Internal Med, Houston, TX 77225 USA. [Vila, Luis M.] Univ Puerto Rico, Dept Med, San Juan, PR 00936 USA. [Anaya, Juan-Manuel] Univ Rosario, Ctr Autoimmune Dis Res, Bogota, Colombia. [Boackle, Susan A.] Univ Colorado Denver, Div Rheumatol, Aurora, CO USA. [Stevens, Anne M.] Univ Washington, Dept Pediat, Div Rheumatol, Seattle, WA 98195 USA. [Stevens, Anne M.] Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, Seattle, WA USA. [Freedman, Barry I.] Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC USA. [Criswell, Lindsey A.] Univ Calif San Francisco, Dept Med, Rosalind Russell Med Res Ctr Arthrit, San Francisco, CA USA. [Pons-Estel, Bernardo A.; Argentine Collaborat Grp] Dept Med, Rosario, Santa Fe, Argentina. [Lee, Joo-Hyun] Inje Univ, Coll Med, Ilsan Paik Hosp, Dept Rheumatol, Gimhae, South Korea. [Lee, Ji-Seon; Bae, Sang-Cheol] Hanyang Univ, Hosp Rheumat Dis, Dept Rheumatol, Seoul 133791, South Korea. [Chang, Deh-Ming] Natl Def Med Ctr, Taipei, Taiwan. [Scofield, R. Hal A.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. [Gilkeson, Gary S.] Med Univ S Carolina, Dept Med, Div Rheumatol, Charleston, SC 29425 USA. [Merrill, Joan T.] Oklahoma Med Res Fdn, Clin Pharmacol Program, Oklahoma City, OK 73104 USA. [Niewold, Timothy B.] Univ Chicago, Rheumatol Sect, Chicago, IL 60637 USA. [Niewold, Timothy B.] Univ Chicago, Gwen Knapp Ctr Lupus & Immunol Res, Chicago, IL 60637 USA. [Vyse, Timothy James] Kings Coll London, Div Genet & Mol Med, London WC2R 2LS, England. [Vyse, Timothy James] Kings Coll London, Div Immunol, London WC2R 2LS, England. [Alarcon-Riquelme, Marta E.; Biolupus Network] Pfizer Univ Granada Junta Andalucia, Ctr Genom Invest Oncol GENYO, Granada, Spain. [Jacob, Chaim O.] Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90033 USA. RP Kaufman, KM (reprint author), MLC 15012,3333 Burnet Ave, Cincinnati, OH 45229 USA. EM kaufman.kenneth@cchmc.org RI Sanchez, Elena/B-4140-2017; Zhao, Jian/E-6292-2012; Yu, Chack-Yung/E-4360-2011; Anaya, Juan-Manuel/J-1960-2016 OI Sanchez, Elena/0000-0002-7041-5485; Universidad del Rosario, Biblioteca/0000-0003-3491-9392; Kimberly, Robert/0000-0002-5330-3086; Alarcon Riquelme, Marta Eugenia/0000-0002-7632-4154; Niewold, Timothy/0000-0003-3532-6660; Anaya, Juan-Manuel/0000-0002-6444-1249 FU US National Institutes of Health [R01AR43814, R01AR043274, R01AI063274, N01AR62277, R3724717, AR042460, P01AI083194, P20RR020143, R01AR33062, P30AR055385, 5UL1RR025777, P30048311, K08AI083790, LRPAI071651, R01CA141700]; Lupus Research Institute; Merit Award from the US Department of Veterans Affairs; Alliance for Lupus Research; Arthritis National Research Foundation Eng Tan Scholar Award; Arthritis Foundation; Korea Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea [A111218-11-GM01]; Korean R&D Programme of MKE/KEIT [10035615]; Swedish Research Council; Swedish Association Against Rheumatism; King Gustaf Vth 80th Jubilee Foundation; Fundacion Instituto de Salud Carlos III [PS0900129]; European FEDER funds; Consejeria de Salud de Andalucia [PI-0012]; Wenner Gren Foundation; Wellcome Trust; Arthritis Research UK; CTSA Grant from the National Center for Research Resources, Kirkland Scholar Award [I ULI RR025014-02]; Wake Forest University Health Sciences Center for Public Health Genomics; Federico Wilhelm Agricola Foundation Research; US National Institutes of Health. [RC1AR058621, UL1RR024999, K24AR002138, P602AR30692, P01AR49084, UL1RR025741, R01AR051545-01A2, P30AR053483, P30GM103510, U19AI082714, R21AI070304, 1U54RR23417-01, P60AR053308, M01RR-00079, P60AR049459, UL1RR029882] FX Support for this work was obtained from the US National Institutes of Health grants: R01AR43814 (BPT), R01AR043274 (KLM), R01AI063274 (PMG), N01AR62277 (JBH), R3724717 (JBH), AR042460 (JBH), P01AI083194 (JBH), P20RR020143 (JBH), P01AR49084 (RPK and EEB), R01AR33062 (RPK), P30AR055385 (EEB), 5UL1RR025777 (RPK and JCE), R01AR33062 (RPK), P01AR49084 (RPK, JCE, EEB, GSA, JDR, RRG, LMB and MAP), P30048311 (EEB), K08AI083790 (TBN), LRPAI071651 (TBN), R01CA141700 (MEAR), RC1AR058621 (MEAR) and UL1RR024999 (TBN), K24AR002138 (RRG), P602AR30692 (RRG), P01AR49084 (RRG), UL1RR025741 (RRG), R01AR051545-01A2 (AMS), P30AR053483 (JAJ and JMG), P30GM103510 (JAJ), U19AI082714 (JAJ and JMG), R21AI070304 (SAB), 1U54RR23417-01 (JDR), P60AR053308 (LAC), M01RR-00079 (LAC), P60AR049459 (DLK) and UL1RR029882 (DLK). This study was also supported by a grant from Lupus Research Institute (BPT, TBN), the Merit Award from the US Department of Veterans Affairs (JBH and GSG), The Alliance for Lupus Research (KLM, TBN, LAC and COJ), the Arthritis National Research Foundation Eng Tan Scholar Award (TBN), the Arthritis Foundation (AMS and PMG), the Korea Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea (A111218-11-GM01; SCB) and Korean R&D Programme of MKE/KEIT (10035615; YWS). Additional funding awarded from the Swedish Research Council, Swedish Association Against Rheumatism and the King Gustaf Vth 80th Jubilee Foundation and the Fundacion Instituto de Salud Carlos III PS0900129 partially funded through European FEDER funds and the Consejeria de Salud de Andalucia PI-0012, the Wenner Gren Foundation for support (CG), the Wellcome Trust (TJV), Arthritis Research UK (TJV), CTSA Grant Number I ULI RR025014-02 (AMS) from the National Center for Research Resources, Kirkland Scholar Award (LAC), Wake Forest University Health Sciences Center for Public Health Genomics (CDL, MCC, MCM, and PSR) and the Federico Wilhelm Agricola Foundation Research grant (BAPE). NR 40 TC 30 Z9 31 U1 2 U2 14 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD MAR PY 2013 VL 72 IS 3 BP 437 EP 444 DI 10.1136/annrheumdis-2012-201851 PG 8 WC Rheumatology SC Rheumatology GA 088BQ UT WOS:000314809200021 PM 22904263 ER PT J AU Zhan, HC Cardozo, C Yu, WN Wang, AT Moliterno, AR Dang, CV Spivak, JL AF Zhan, Huichun Cardozo, Christopher Yu, Wayne Wang, Antai Moliterno, Alison R. Dang, Chi V. Spivak, Jerry L. TI MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients SO BLOOD CELLS MOLECULES AND DISEASES LA English DT Article DE MicroRNA; Myeloproliferative neoplasm; Polycythemia vera; Essential thrombocythemia; Hematopoiesis ID HEMATOPOIETIC STEM-CELLS; TYROSINE KINASE JAK2; MYELOPROLIFERATIVE DISORDERS; ERYTHROID-DIFFERENTIATION; SECONDARY MYELOFIBROSIS; MYELOID METAPLASIA; EXPRESSION; MUTATION; ERYTHROPOIESIS; JAK2V617F AB Polycythemia vera (PV) and essential thrombocythemia (ET) are the two most common myeloproliferative neoplasms. The same JAK2(V617F) mutation can be found in both disorders and is able to recapitulate many of the phenotypic abnormalities of these diseases in the murine models. The disease phenotype is also influenced by other unknown genetic or epigenetic factors. MicroRNAs (miRNA) are 18-24 nucleotides single-stranded non-protein-coding RNAs that function primarily as gene repressors by binding to their target messenger RNAs. We performed miRNA expression profiling by oligonucleotide microarray analysis in purified peripheral blood CD34+ cells from eight JAK2(V617F)-positive PV patients and six healthy donors. A quantitative reverse-transcription polymerase chain reaction assay was used to verify differential miRNA expression. Since erythrocytosis is the only feature that distinguishes PV from ET, we also compared specific miRNA expression in the nucleated erythroid cells directly descended from the early erythroid progenitor cells of PV and ET patients. Our data indicate that significant miRNA deregulation occurs in PV CD34+ cells and confirm a genetic basis for the gender-specific differences that characterize PV with respect to miRNA. The results of our study also suggest that deregulated miRNAs may represent an important mechanism by which the PV erythrocytosis and ET thrombocytosis phenotypes are determined. Published by Elsevier Inc. C1 [Zhan, Huichun; Cardozo, Christopher] James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Zhan, Huichun; Wang, Antai] Columbia Univ, Med Ctr, New York, NY USA. [Cardozo, Christopher] Mt Sinai Sch Med, New York, NY USA. [Yu, Wayne; Moliterno, Alison R.; Spivak, Jerry L.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Dang, Chi V.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. RP Zhan, HC (reprint author), James J Peters VA Med Ctr, Room 3F-12,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Huichun.Zhan@va.gov FU Veterans Affairs Career Development Award [10959632]; Veterans Affairs Rehabilitation Research and Development Service grant [B9212-C] FX Huichun Zhan is currently supported by the Veterans Affairs Career Development Award (grant 10959632) and Veterans Affairs Rehabilitation Research and Development Service grant B9212-C. We would like to thank Drs. Katia Basso, David Dominguez, and Riccardo Dalla-Favera from Columbia University for their assistance in microRNA analysis. We thank Drs. Min Lu and Ronald Hoffman from Mount Sinai School of Medicine for their assistance in the colony formation assay. We thank Drs. Yan Makeyev and Imitiaz Patel for providing precious patient samples. We thank Hai Xu from Johns Hopkins University for his assistance in microRNA microarray experiments. We thank Drs. Azra Raza and Naomi Galili from Columbia University Medical Center, Drs. Erik Langhoff, Mary Sano, and Elisa Sanchez-Valencia from James J. Peters VA Medical Center, and Dr. Robert Brodsky from Johns Hopkins University for their continuing support throughout this work. NR 50 TC 9 Z9 9 U1 0 U2 13 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1079-9796 J9 BLOOD CELL MOL DIS JI Blood Cells Mol. Dis. PD MAR PY 2013 VL 50 IS 3 BP 190 EP 195 DI 10.1016/j.bcmd.2012.11.009 PG 6 WC Hematology SC Hematology GA 091UE UT WOS:000315074500010 PM 23265742 ER PT J AU Smucny, J Rojas, DC Eichman, LC Tregellas, JR AF Smucny, Jason Rojas, Donald C. Eichman, Lindsay C. Tregellas, Jason R. TI Neuronal effects of auditory distraction on visual attention SO BRAIN AND COGNITION LA English DT Article DE Attention; Dorsolateral prefrontal cortex; Fusiform gyrus; Pre-supplementary motor area; Posterior cingulate; Distraction ID ANTERIOR CINGULATE CORTEX; PREFRONTAL CORTEX; SUSTAINED ATTENTION; HEMODYNAMIC-RESPONSE; SELECTIVE ATTENTION; FUNCTIONAL-ANATOMY; PERFORMANCE; BRAIN; TASK; FMRI AB Selective attention in the presence of distraction is a key aspect of healthy cognition. The underlying neurobiological processes, have not, however, been functionally well characterized. In the present study, we used functional magnetic resonance imaging to determine how ecologically relevant distracting noise affects cortical activity in 27 healthy adults during two versions of the visual Sustained Attention To Response Task (SARI) that differ in difficulty (and thus attentional load). A significant condition (noise or silence) by task (easy or difficult) interaction was observed in several areas, including dorsolateral prefrontal cortex (DLPFC), fusiform gyrus (FG), posterior cingulate (PCC), and pre-supplementary motor area (PreSMA). Post hoc analyses of interaction effects revealed deactivation of DLPFC, PCC, and PreSMA during distracting noise under conditions of low attentional load, and activation of FG and PCC during distracting noise under conditions of high attentional load. These results suggest that distracting noise may help alert subjects to task goals and reduce demands on cortical resources during tasks of low difficulty and attentional load. Under conditions of higher load, however, additional cognitive resources may be required in the presence of noise. (C) 2012 Elsevier Inc. All rights reserved. C1 [Smucny, Jason; Rojas, Donald C.; Tregellas, Jason R.] Univ Colorado, Neurosci Program, Aurora, CO 80045 USA. [Smucny, Jason; Rojas, Donald C.; Eichman, Lindsay C.; Tregellas, Jason R.] Denver VA Med Ctr, Res Serv, Denver, CO USA. [Rojas, Donald C.; Eichman, Lindsay C.; Tregellas, Jason R.] Univ Colorado, Dept Psychiat, Aurora, CO 80045 USA. RP Tregellas, JR (reprint author), Univ Colorado, Dept Psychiat, Anschutz Med Campus,Bldg 500,4th Floor, Aurora, CO 80045 USA. EM Jason.Smucny@ucdenver.edu; Don.Rojas@ucden-ver.edu; Lindsay.Eichman@ucdenver.edu; Jason.Tregel-las@ucdenver.edu RI Tregellas, Jason/J-3637-2015 OI Rojas, Don/0000-0001-6560-9616; Smucny, Jason/0000-0001-5656-7987 FU VA Biomedical Laboratory and Clinical Science Research and Development Service; National Association for Research in Schizophrenia and Affective Disorders (NARSAD); Blowitz-Ridgeway Foundation FX The authors thank Debra Singel for help with fMRI data acquisition. The research was supported by the VA Biomedical Laboratory and Clinical Science Research and Development Service, the National Association for Research in Schizophrenia and Affective Disorders (NARSAD) and the Blowitz-Ridgeway Foundation. NR 49 TC 8 Z9 8 U1 2 U2 38 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0278-2626 J9 BRAIN COGNITION JI Brain Cogn. PD MAR PY 2013 VL 81 IS 2 BP 263 EP 270 DI 10.1016/j.bandc.2012.11.008 PG 8 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 091RN UT WOS:000315067600012 PM 23291265 ER PT J AU Atherton, S Holmquist, J AF Atherton, S. Holmquist, J. TI Transitions in Care: Clinical Nurse Specialist Developed Patient Safety Measures for Prevention of Healthcare-Associated Infections SO CLINICAL NURSE SPECIALIST LA English DT Meeting Abstract C1 [Atherton, S.; Holmquist, J.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0887-6274 J9 CLIN NURSE SPEC JI Clin. Nurse Spec. PD MAR-APR PY 2013 VL 27 IS 2 BP E60 EP E60 PG 1 WC Nursing SC Nursing GA 088YK UT WOS:000314873600154 ER PT J AU David, CM Shaffer, B Zellars, R AF David, C. M. Shaffer, B. Zellars, R. TI Clinical Nurse Specialist Led Fall Program: Improving Performance Through Environment Sweeps SO CLINICAL NURSE SPECIALIST LA English DT Meeting Abstract C1 [David, C. M.; Shaffer, B.; Zellars, R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0887-6274 J9 CLIN NURSE SPEC JI Clin. Nurse Spec. PD MAR-APR PY 2013 VL 27 IS 2 BP E12 EP E13 PG 2 WC Nursing SC Nursing GA 088YK UT WOS:000314873600031 ER PT J AU Loudon, T AF Loudon, T. TI Identification of Clinical Deterioration: Clinical Nurse Specialist Implementation of Modified Early Warning System (MEWS) to Support Transition to Higher Level of Care in the Acute Care Setting SO CLINICAL NURSE SPECIALIST LA English DT Meeting Abstract C1 [Loudon, T.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0887-6274 J9 CLIN NURSE SPEC JI Clin. Nurse Spec. PD MAR-APR PY 2013 VL 27 IS 2 BP E61 EP E61 PG 1 WC Nursing SC Nursing GA 088YK UT WOS:000314873600156 ER PT J AU Richardson, J AF Richardson, J. TI The Inpatient to Outpatient Transition: Clinical Nurse Specialist Facilitating Evidence-Based Practice in Primary Care SO CLINICAL NURSE SPECIALIST LA English DT Meeting Abstract C1 [Richardson, J.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0887-6274 J9 CLIN NURSE SPEC JI Clin. Nurse Spec. PD MAR-APR PY 2013 VL 27 IS 2 BP E60 EP E61 PG 2 WC Nursing SC Nursing GA 088YK UT WOS:000314873600155 ER PT J AU Richardson, J Atherton, S Holmquist, J Loudon, T AF Richardson, J. Atherton, S. Holmquist, J. Loudon, T. TI The Value of the Clinical Nurse Specialist: Improving Patient Outcomes Across Transitions in Care SO CLINICAL NURSE SPECIALIST LA English DT Meeting Abstract C1 [Richardson, J.; Atherton, S.; Holmquist, J.; Loudon, T.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0887-6274 J9 CLIN NURSE SPEC JI Clin. Nurse Spec. PD MAR-APR PY 2013 VL 27 IS 2 BP E60 EP E60 PG 1 WC Nursing SC Nursing GA 088YK UT WOS:000314873600153 ER PT J AU Moatamed, NA Apple, SK Bennett, CJ Aronson, WJ Klisak, I Shirley, BJ Moatamed, F AF Moatamed, Neda A. Apple, Sophia K. Bennett, Carol J. Aronson, William J. Klisak, Ivana Shirley, Bobbi-Jo Moatamed, Farhad TI Exclusion of the uniform tetraploid cells significantly improves specificity of the urine fish assay SO DIAGNOSTIC CYTOPATHOLOGY LA English DT Article DE voided urine; bladder wash; FISH; sensitivity; specificity ID IN-SITU HYBRIDIZATION; SUPERFICIAL BLADDER-CANCER; BTA TRAK ASSAY; VOIDED URINE; UROTHELIAL CARCINOMA; FLOW-CYTOMETRY; FOLLOW-UP; PAPANICOLAOU EXAMINATION; INTERPHASE CYTOGENETICS; DNA-PLOIDY AB The urine fluorescence in situ hybridization (FISH) assay (UroVysion), with the current scoring criteria, has a higher sensitivity than routine cytopathology but a lower specificity. Among 215 urine FISH tests we performed, 45 had associated histopathology and clinical follow up. In this study, a cell with four signals for each probe was classified as a uniform tetraploid cell (UTC); a presumed reparative cell which is currently classified as an abnormal cell in the FDA approved assay. By using the existing criteria, the tests were scored as positive or negative before and after exclusion of the UTCs. Before the exclusion, 24 positive, 13 negative, seven false positive, and one false negative result were obtained with 96% sensitivity and 65% specificity. After the exclusion, the results changed to 22 positive, 19 negative, one false positive, and three false negatives resulting in a 88% sensitivity of 88% and a 95% specificity; a significant improvement in the specificity. We conclude that exclusion of the UTCs as abnormal cells would result in a more solid performance of the FISH assay. Diagn. Cytopathol. 2013. (c) 2011 Wiley Periodicals, Inc. C1 [Moatamed, Neda A.; Apple, Sophia K.; Moatamed, Farhad] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Klisak, Ivana; Shirley, Bobbi-Jo; Moatamed, Farhad] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Bennett, Carol J.] VA Greater Los Angeles Healthcare Syst, Dept Surg, Urol Sect, Los Angeles, CA USA. RP Moatamed, NA (reprint author), Dept Pathol & Lab Med, 10833 Le Conte Ave,BOX 951732,1P-241 CHS, Los Angeles, CA 90095 USA. EM nmoatamed@mednet.ucla.edu FU Department of Veterans Affairs, as part of the Laboratory Quality Assurance program FX Contract grant sponsor: Department of Veterans Affairs, as part of the Laboratory Quality Assurance program. NR 49 TC 5 Z9 5 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 8755-1039 J9 DIAGN CYTOPATHOL JI Diagn. Cytopathol. PD MAR PY 2013 VL 41 IS 3 BP 218 EP 225 DI 10.1002/dc.21831 PG 8 WC Medical Laboratory Technology; Pathology SC Medical Laboratory Technology; Pathology GA 092EH UT WOS:000315101500006 PM 21987521 ER PT J AU Moussa, I Hermann, A Messenger, JC Dehmer, GJ Weaver, WD Rumsfeld, JS Masoudi, FA AF Moussa, Issam Hermann, Anthony Messenger, John C. Dehmer, Gregory J. Weaver, W. Douglas Rumsfeld, John S. Masoudi, Frederick A. TI The NCDR CathPCI Registry: a US national perspective on care and outcomes for percutaneous coronary intervention SO HEART LA English DT Article ID CARDIOVASCULAR DATA REGISTRY; MORTALITY RISK PREDICTION; STRATEGIES AB Aims: The NCDR CathPCI Registry collects detailed clinical, process-of-care and outcomes data for patients undergoing coronary angiography and percutaneous coronary intervention (PCI) in the USA. The registry contributes to quality of care by providing data feedback on a wide range of performance metrics to participating centres and by facilitating local and national quality improvement efforts. Interventions: No treatments are mandated, participating centres receive routine quality-of-care and outcomes performance feedback reports and access to a quality dashboard for personalized performance reports. Population: Patients undergoing cardiac catheterization and PCI are retrospectively identified. No informed consent is required, as data are anonymised. From inception in 1998, more than 12 million records have been submitted from 1577 participating US centres. Baseline data: Approximately 250 fields encompassing patient demographics, medical history and risk factors, hospital presentation, initial cardiac status, procedural details, medications, laboratory values, and in-hospital outcomes. Linkages with outside sources of data have permitted longitudinal outcomes assessment in some cases. Centre personnel enter the data into the registry, in some cases facilitated by software vendors. There are non-financial incentives for centre participation. Data completeness is noteworthy with most fields missing at rates less than 5%. A comprehensive data quality program is employed to enhance data validity. Endpoints: Main outcome measures include quality process metrics and in-hospital patient outcomes. Data are available for research by application to: http://www.ncdr.com C1 [Moussa, Issam] Mayo Clin, Div Cardiol, Jacksonville, FL 32224 USA. [Hermann, Anthony] Amer Coll Cardiol Fdn, Washington, DC USA. [Messenger, John C.; Masoudi, Frederick A.] Univ Colorado, Div Cardiol, Cardiac & Vasc Ctr, Aurora, CO 80045 USA. [Dehmer, Gregory J.] Scott & White Healthcare, Div Cardiol, Coll Med, Texas A&M Hlth Sci Ctr, Temple, TX USA. [Weaver, W. Douglas] Henry Ford Hosp, Div Cardiol, Detroit, MI 48202 USA. [Rumsfeld, John S.] Denver VA Med Ctr, Cardiol Sect, Denver, CO USA. RP Masoudi, FA (reprint author), Univ Colorado, Div Cardiol, Anschutz Med Campus,Box B132,12401 17th Ave, Aurora, CO 80045 USA. EM fred.masoudi@ucdenver.edu NR 12 TC 27 Z9 27 U1 0 U2 3 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1355-6037 J9 HEART JI Heart PD MAR PY 2013 VL 99 IS 5 BP 297 EP 303 DI 10.1136/heartjnl-2012-303379 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 091EX UT WOS:000315033300004 PM 23322530 ER PT J AU Schwacke, JH Spainhour, JCG Ierardi, JL Chaves, JM Arthur, JM Janech, MG Velez, JCQ AF Schwacke, John H. Spainhour, John Christian G. Ierardi, Jessalyn L. Chaves, Jose M. Arthur, John M. Janech, Michael G. Velez, Juan Carlos Q. TI Network Modeling Reveals Steps in Angiotensin Peptide Processing SO HYPERTENSION LA English DT Article DE mass spectrometry; proteomics; renin-angiotensin system; systems biology ID CONVERTING ENZYME-INHIBITION; AMINOPEPTIDASE-A; DIABETIC-NEPHROPATHY; BAYESIAN NETWORKS; PARTIAL ESCAPE; RAT; RECEPTOR; SYSTEM; KIDNEY; ACE AB New insights into the intrarenal renin-angiotensin (Ang) system have modified our traditional view of the system. However, many finer details of this network of peptides and associated peptidases remain unclear. We hypothesized that a computational systems biology approach, applied to peptidomic data, could help to unravel the network of enzymatic conversions. We built and refined a Bayesian network model and a dynamic systems model starting from a skeleton created with established elements of the renin-Ang system and further developed it with archived matrix-assisted laser desorption ionization-time of flight mass spectra from experiments conducted in mouse podocytes exposed to exogenous Ang substrates. The model-building process suggested previously unrecognized steps, 3 of which were confirmed in vitro, including the conversion of Ang(2-10) to Ang(2-7) by neprilysin, Ang(1-9) to Ang(2-9), and Ang(1-7) to Ang(2-7) by aminopeptidase A. These data suggest a wider role of neprilysin and aminopeptidase A in glomerular formation of bioactive Ang peptides and shunting their formation. Other steps were also suggested by the model, and supporting evidence for those steps was evaluated using model-comparison methods. Our results demonstrate that systems biology methods applied to peptidomic data are effective in identifying novel steps in the Ang peptide processing network, and these findings improve our understanding of the glomerular renin-Ang system. (Hypertension. 2013;61:690-700.). circle Online Data Supplement C1 [Schwacke, John H.; Spainhour, John Christian G.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Ierardi, Jessalyn L.; Chaves, Jose M.; Arthur, John M.; Janech, Michael G.; Velez, Juan Carlos Q.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. [Arthur, John M.; Janech, Michael G.; Velez, Juan Carlos Q.] Ralph H Johnson Vet Affairs Med Ctr, Med Serv, Charleston, SC USA. [Arthur, John M.; Janech, Michael G.; Velez, Juan Carlos Q.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA. RP Velez, JCQ (reprint author), Med Univ S Carolina, Div Nephrol, Clin Sci Bldg,829 96 Jonathan Lucas St, Charleston, SC 29425 USA. EM velezj@musc.edu RI Velez, Juan Carlos/N-3782-2016 OI Janech, Michael/0000-0002-3202-4811 FU National Institute of General Medicine [5T32GM74934-8]; Department of Veterans' Affairs [CDA-2]; Nephcure Foundation; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) [DK080944-04]; Dialysis Clinics Incorporated; NIDDK of the NIH [1R01DK080234] FX J.C.G. Spainhour was supported under a training grant from the National Institute of General Medicine (5T32GM74934-8). M. G. Janech was supported by Career Development Awards (CDA) through the Department of Veterans' Affairs (CDA-2) and the Nephcure Foundation. J.C.Q. Velez is supported by a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) (DK080944-04) and Dialysis Clinics Incorporated. J.H. Schwacke was supported, in part, by a grant from NIDDK of the NIH (1R01DK080234). NR 69 TC 12 Z9 12 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0194-911X J9 HYPERTENSION JI Hypertension PD MAR PY 2013 VL 61 IS 3 BP 690 EP + DI 10.1161/HYPERTENSIONAHA.111.00318 PG 18 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 089DC UT WOS:000314888600023 PM 23283355 ER PT J AU Hernandez, R Prohaska, TR Wang, PC Sarkisian, CA AF Hernandez, Rosalba Prohaska, Thomas R. Wang, Pin-Chieh Sarkisian, Catherine A. TI The Longitudinal Relationship Between Depression and Walking Behavior in Older Latinos: The "(sic)Caminemos!" Study SO JOURNAL OF AGING AND HEALTH LA English DT Article DE older adults; Hispanics; Latinos; depressive symptomatology; physical activity; longitudinal analyses ID NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; PHYSICAL-ACTIVITY; MEXICAN-AMERICANS; SOCIAL SUPPORT; DOSE-RESPONSE; SELF-EFFICACY; ADULTS; EXERCISE; PARTICIPATION AB Objectives: This study sought to evaluate the relationship between baseline depression and prospective engagement in walking and exercise behavior after enrollment in an exercise intervention. Methods: The study used baseline, 1-month, 12-month, and 24-month in-person interview and pedometer data collected from Latinos aged > 60 years participating in an exercise intervention (AiCaminemos!) at 27 senior centers (n = 572). Results: After joining an exercise intervention, and when using continuous pedometer data and scores from the Yale Physical Activity Survey (YPAS) as the outcomes of interest, older adults with baseline depression exhibited comparable levels of physical activity across time when compared to their nondepressed counterparts. Significant difference in physical activity levels between the depressed and nondepressed subgroups no longer existed within one month of initiating the exercise intervention. Discussion: Among sedentary older Latino adults, having depression may not delay exercise initiation nor does it appear to prevent achievement or maintenance of an exercise program. C1 [Hernandez, Rosalba] NW Feinberg Sch Med, Dept Prevent Med, Chicago, IL USA. [Hernandez, Rosalba; Prohaska, Thomas R.] Univ Illinois, Sch Publ Hlth, Chicago, IL USA. [Prohaska, Thomas R.] George Mason Univ, Coll Hlth & Human Serv, Fairfax, VA 22030 USA. [Wang, Pin-Chieh; Sarkisian, Catherine A.] Vet Adm Greater Los Angeles Healthcare Syst, Geriatr Res Educ Clin Ctr, Los Angeles, CA USA. [Wang, Pin-Chieh; Sarkisian, Catherine A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Geriatr, Los Angeles, CA 90095 USA. RP Hernandez, R (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, 680 N Lake Shore Dr,Suite 1400, Chicago, IL 60611 USA. EM rosalba.hernandez@northwestern.edu FU NHLBI NIH HHS [5T32 HL069771-10, T32 HL069771]; NIA NIH HHS [P30 AG028748, P30AG028748, R01 AG024460, R01 AG024460-05] NR 57 TC 5 Z9 5 U1 3 U2 17 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0898-2643 J9 J AGING HEALTH JI J. Aging Health PD MAR PY 2013 VL 25 IS 2 BP 319 EP 341 DI 10.1177/0898264312468488 PG 23 WC Gerontology; Health Policy & Services SC Geriatrics & Gerontology; Health Care Sciences & Services GA 087NV UT WOS:000314769500006 PM 23264440 ER PT J AU Rosenfeld, A Christensen, V Daya, M AF Rosenfeld, Anne Christensen, Vivian Daya, Mohamud TI Long Enough to Act? Symptom and Behavior Patterns Prior to Out-of-Hospital Sudden Cardiac Death SO JOURNAL OF CARDIOVASCULAR NURSING LA English DT Article DE myocardial infarction; narrative analysis; out-of-hospital death; sudden cardiac death; symptoms ID ACUTE MYOCARDIAL-INFARCTION; ACUTE CORONARY SYNDROMES; TREATMENT-SEEKING DELAY; HEART-DISEASE; UNITED-STATES; FAMILY REPORTS; REDUCE DELAY; WOMEN; ARREST; CARE AB Background: Sudden cardiac death is a major cause of death in the United States. Most cases occur outside the hospital, yet little is known about the symptoms and actions of individuals who die before reaching the hospital. Objective: The purpose of this study was to describe the symptoms, symptom management, and care-seeking patterns in sudden cardiac death victims. Methods: This cross-sectional study used qualitative and quantitative data collection methods to obtain descriptions of symptoms and treatment-seeking delay from family members and bystanders (respondents) in 140 cases of sudden cardiac death due to presumed myocardial infarction. Decedents were identified from death certificate data from the state of Oregon in the United States. Respondents completed a survey of demographics and myocardial infarction symptoms and an in-depth interview. Narrative analysis was used to analyze qualitative data. Results: Three behavior patterns or trajectory types were developed focusing on key characteristics of the symptom patterns, the meanings attributed to those symptoms, the actions taken by the decedents and their family members or bystanders, and the time course of events. Each case was categorized as 1 trajectory type. The trajectory types are Normal Day (n = 49), Something Not Right (n = 62), and Thought It Was Something Else (n = 29). The key distinction across the trajectory types is the perception and interpretation of symptoms and the resulting actions between symptom perception and death. Conclusions: This study is 1 of the first to describe what victims of sudden cardiac death are doing and thinking during the period between symptom onset and collapse. The trajectory types identified in this study suggest that misinterpretation of symptoms (the Something Not Right and Thought It Was Something Else groups) is common among victims and bystanders. C1 [Rosenfeld, Anne] Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97201 USA. [Christensen, Vivian] Portland VA Med Ctr, Evidence Based Synth Program, Coordinating Ctr, Portland, OR USA. [Daya, Mohamud] Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR 97201 USA. RP Rosenfeld, A (reprint author), Univ Arizona, Coll Nursing, POB 210203, Tucson, AZ 85721 USA. EM arosenfeld@nursing.arizona.edu FU American Heart Association Pacific Mountain Affiliate [0450040Z] FX This study was funded by American Heart Association Pacific Mountain Affiliate Grant in Aid 0450040Z. NR 45 TC 0 Z9 0 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0889-4655 J9 J CARDIOVASC NURS JI J. Cardiovasc. Nurs. PD MAR-APR PY 2013 VL 28 IS 2 BP 166 EP 175 DI 10.1097/JCN.0b013e3182452410 PG 10 WC Cardiac & Cardiovascular Systems; Nursing SC Cardiovascular System & Cardiology; Nursing GA 091AR UT WOS:000315021600015 PM 22343214 ER PT J AU Schuster, MG Meibohm, A Lloyd, L Strom, B AF Schuster, Mindy G. Meibohm, Anne Lloyd, Lisa Strom, Brian TI Risk factors and outcomes of Candida krusei bloodstream infection: A matched, case-control study SO JOURNAL OF INFECTION LA English DT Article DE Candida krusei; Candidemia; Risk factors; Case-control ID INTENSIVE-CARE-UNIT; ANTIMICROBIAL SURVEILLANCE PROGRAM; BONE-MARROW-TRANSPLANTATION; IN-VITRO SUSCEPTIBILITIES; IMMUNOCOMPROMISED PATIENTS; ANTIFUNGAL SUSCEPTIBILITY; ATTRIBUTABLE MORTALITY; NOSOCOMIAL CANDIDEMIA; CHANGING EPIDEMIOLOGY; SPECIES DISTRIBUTION AB Objectives: To investigate the risk factors and outcomes associated with Candida krusei bloodstream. Methods: We performed a case control study of patients with C. krusei bloodstream infection at the University of Pennsylvania from 1982 to 2010. Controls were without candidemia, and matched to cases on duration of hospitalization and underlying disease. Results: We enrolled 34 cases and 114 matched controls. Most subjects (62%) had hematologic malignancies. In the multivariate model, including a priori the duration of fluconazole use (OR 1.06; 95% CI 1.00, 1.11) and days of neutropenia (OR 1.01; 95% CI 0.98, 1.13), risk factors associated with C. krusei bloodstream infection were splenectomy (OR 11.66; 95% CI 1.04, 130.64), and exposure to antimicrobials with anaerobic activity (OR 5.74; 95% CI 1.76, 18.67). Outcomes of infected patients were poor. Only 32% of case patients survived to hospital discharge, compared to 89% of controls. For 48% death was attributed to C. krusei infection. Conclusions: C. krusei bloodstream infection occurs most commonly in neutropenic patients with hematologic malignancy. The association with prior fluconazole exposure is less marked than previously described. Splenectomy and the receipt of antimicrobials with anaerobic activity are significant risk factors. The outcome of infected patients remains poor, despite appropriate antifungal therapy. (C) 2012 Published by Elsevier Ltd on behalf of The British Infection Association. C1 [Schuster, Mindy G.; Strom, Brian] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Lloyd, Lisa] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Schuster, MG (reprint author), Univ Penn, 3 Silverstein,Suite E,3400 Spruce St, Philadelphia, PA 19104 USA. EM Mindy.Schuster2@uphs.upenn.edu NR 37 TC 7 Z9 7 U1 0 U2 9 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0163-4453 J9 J INFECTION JI J. Infect. PD MAR PY 2013 VL 66 IS 3 BP 278 EP 284 DI 10.1016/j.jinf.2012.11.002 PG 7 WC Infectious Diseases SC Infectious Diseases GA 087ZP UT WOS:000314803900008 PM 23174708 ER PT J AU Bhatia, N Xiao, TZ Rosenthal, KA Siddiqui, IA Thiyagarajan, S Smart, B Meng, Q Zuleger, CL Mukhtar, H Kenney, SC Albertini, MR Longley, BJ AF Bhatia, Neehar Xiao, Tony Z. Rosenthal, Kimberly A. Siddiqui, Imtiaz A. Thiyagarajan, Saravanan Smart, Brendan Meng, Qiao Zuleger, Cindy L. Mukhtar, Hasan Kenney, Shannon C. Albertini, Mark R. Longley, B. Jack TI MAGE-C2 Promotes Growth and Tumorigenicity of Melanoma Cells, Phosphorylation of KAP1, and DNA Damage Repair SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Article ID DOUBLE-STRAND BREAKS; METASTATIC MELANOMA; ANTIGEN-EXPRESSION; MULTIPLE-MYELOMA; GENE-EXPRESSION; GERM-CELLS; CANCER; TESTIS; APOPTOSIS; PROGRESSION AB Melanoma-associated antigen-encoding (MAGE) genes are expressed in melanoma and other cancers but not in normal somatic cells. MAGE expression is associated with aggressive tumor growth, poor clinical outcome, and resistance to chemotherapy, but the mechanisms have not been completely elucidated. In this study, we show that downregulation of MAGE-C2 in A375 melanoma cells and low-passage cultures from human metastatic melanomas (MRA cells) results in increased apoptosis and decreased growth of tumor xenografts in athymic nude mice. Previously, we showed that MAGE-C2 binds KAP1, a scaffolding protein that regulates DNA repair. Phosphorylation of KAP1-Serine 824 (Ser824) by ataxia-telangiectasia mutated (ATM) kinase is necessary for repair of DNA double-strand breaks (DSBs); now we show that MAGE-C2 knockdown reduces, whereas MAGE-C2 overexpression increases, ATM kinase dependent phosphorylation of KAP1-Ser824. We demonstrate that MAGE-C2 increases co-precipitation of KAP1 with ATM and that binding of MAGE-C2 to KAP1 is necessary for increased KAP1-Ser824 phosphorylation. Furthermore, ectopic expression of MAGE-C2 enhances repair of I-Scel endonuclease induced DSBs in U-2OS cells. As phosphorylation of KAP1-Ser824 facilitates relaxation of heterochromatin, which is necessary for DNA repair and cellular proliferation, our results suggest that MAGE-C2 can promote tumor growth by phosphorylation of KAP1-Ser824 and by enhancement of DNA damage repair. Journal of Investigative Dermatology (2013) 133, 759-767; doi:10.1038/jid.2012.355; published online 25 October 2012 C1 [Bhatia, Neehar; Zuleger, Cindy L.; Albertini, Mark R.] Univ Wisconsin, Carbone Canc Ctr, Dept Med, Madison, WI 53705 USA. [Xiao, Tony Z.; Rosenthal, Kimberly A.; Siddiqui, Imtiaz A.; Smart, Brendan; Mukhtar, Hasan; Longley, B. Jack] Univ Wisconsin, Dept Dermatol, Madison, WI 53705 USA. [Thiyagarajan, Saravanan] Mazumdar Shaw Canc Ctr, Bangalore, Karnataka, India. [Meng, Qiao; Kenney, Shannon C.] Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA. [Albertini, Mark R.] William S Middleton Mem Vet Adm Med Ctr, Med Serv, Madison, WI USA. RP Bhatia, N (reprint author), Univ Wisconsin, Carbone Canc Ctr, Dept Med, WI Inst Med Res 4040, 1111 Highland Ave, Madison, WI 53705 USA. EM bneehar@medicine.wisc.edu; bjlongley@dermatology.wisc.edu FU University of Wisconsin Carbone Cancer Center, the Office of Research and Development, Biomedical Laboratory Research and Development Service, Department of Veterans Affairs; National Cancer Institute [P30 CA014520]; Gretchen and Andrew Dawes Melanoma Research Fund; Ann's Hope Foundation; Jay Van Sloan Memorial from the Steve Leuthold Family; Tim Eagle Memorial FX We acknowledge Dr Maria Jasin for providing us modified U2-OS cells for DNA repair assay, and Dr Andrew Simpson and Dr Otavia Caballero for reagents. We also thank Dr V.S. Setaluri for critical suggestions and support. We are grateful to Tisha Kawahara for support with the IRB protocol. This work was supported by the University of Wisconsin Carbone Cancer Center, the Office of Research and Development, Biomedical Laboratory Research and Development Service, Department of Veterans Affairs; by Grant P30 CA014520 from the National Cancer Institute; the Gretchen and Andrew Dawes Melanoma Research Fund; Ann's Hope Foundation; the Jay Van Sloan Memorial from the Steve Leuthold Family; and the Tim Eagle Memorial. The contents do not represent the views of the Department of Veterans Affairs or of the United States Government. Melanoma patient samples were used under UW-Madison Health Sciences IRB protocol number M-2009-1157. NR 38 TC 17 Z9 18 U1 0 U2 6 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAR PY 2013 VL 133 IS 3 BP 759 EP 767 DI 10.1038/jid.2012.355 PG 9 WC Dermatology SC Dermatology GA 090VQ UT WOS:000315008500024 PM 23096706 ER PT J AU Kougias, P Tiwari, V Barshes, NR Bechara, CF Lowery, B Pisimisis, G Berger, DH AF Kougias, Panagiotis Tiwari, Vikram Barshes, Neal R. Bechara, Carlos F. Lowery, Briauna Pisimisis, George Berger, David H. TI Modeling anesthetic times. Predictors and implications for short-term outcomes SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE Modeling; Regression; Anesthetic length; Precision ID SURGERY; EXPENDITURES; VARIABILITY; DURATION; THEATER AB Background: Little is known about the predictors of anesthetic times and impact of anesthetic and operative times on patient outcomes. Methods: We documented operative case length, anesthetic induction time length, and anesthetic recovery time length in 1713 consecutive patients who underwent elective vascular surgical interventions. We recorded patient and procedure-related characteristics that might influence the anesthetic time length, including a variable for possible July effect. Multivariate linear regression was used to model the length of anesthetic times. Multivariate logistic regression was used to model the impact of anesthetic and operative time lengths on a composite outcome of perioperative (30-d postoperative) death, myocardial infarction, cardiac arrhythmias, stroke, and congestive heart failure. Results: Statistically significant predictors of anesthetic induction time included body mass index, anesthesia type, and procedure type. Statistically significant predictors of anesthetic recovery time included operative case length, procedure type, and anesthesia type. After adjusting for the statistically significant covariates of total blood transfusion, history of coronary artery disease, and procedure type, there was a trend for increased likelihood of the composite end point as a function of operative time (odds ratio, 1.14; 95% confidence interval, 0.97-1.33; P = 0.09), which did not reach statistical significance. Multivariate analysis showed no association between the anesthetic time and composite end point. Conclusions: Modeling individually anesthetic induction and recovery time on the basis of operative and anesthetic procedure characteristics is feasible. Anesthetic and operative times do not impact perioperative morbidity and mortality. Published by Elsevier Inc. C1 [Kougias, Panagiotis; Barshes, Neal R.; Bechara, Carlos F.; Lowery, Briauna; Pisimisis, George; Berger, David H.] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA. [Tiwari, Vikram] Vanderbilt Univ, Med Ctr, Director Perioperat Serv, Nashville, TN USA. RP Kougias, P (reprint author), Houston VAMC, Michael E DeBakey Dept Surg, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA. EM pkougias@bcm.edu NR 14 TC 5 Z9 5 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 J9 J SURG RES JI J. Surg. Res. PD MAR PY 2013 VL 180 IS 1 BP 1 EP 7 DI 10.1016/j.jss.2012.10.007 PG 7 WC Surgery SC Surgery GA 089LQ UT WOS:000314912400008 PM 23158406 ER PT J AU Trimarchi, S Tolenaar, JL Jonker, FHW Murray, B Tsai, TT Eagle, KA Rampoldi, V Verhagen, HJM van Herwaarden, JA Moll, FL Muhs, BE Elefteriades, JA AF Trimarchi, Santi Tolenaar, Jip L. Jonker, Frederik H. W. Murray, Brian Tsai, Thomas T. Eagle, Kim A. Rampoldi, Vincenzo Verhagen, Hence J. M. van Herwaarden, Joost A. Moll, Frans L. Muhs, Bart E. Elefteriades, John A. TI Importance of false lumen thrombosis in type B aortic dissection prognosis SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article ID INTERNATIONAL REGISTRY; ECHOCARDIOGRAPHY; PATENCY; REPAIR AB Background: Partial thrombosis of the false lumen has been reported as a significant predictor of mortality during follow-up in patients with acute type B aortic dissection. The purpose of this study was to investigate the correlation of false lumen thrombosis and aortic expansion during follow-up in patients with acute type B aortic dissection. Methods: All medically treated patients with acute type B aortic dissection observed in 4 cardiovascular referral centers between 1998 and 2011, with admission and follow-up computed tomography or magnetic resonance imaging scans, were included. Aortic diameters of the dissected aortas were measured at 4 levels on the baseline and follow-up scans, and annual growth rates were calculated. Univariate and multivariate regression analyses were used to investigate the effect of false lumen thrombosis on aortic growth rate. Results: A total of 84 patients were included, of whom 40 (47.6%) had a partially thrombosed false lumen, 7 (8.3%) had a completely thrombosed false lumen, and 37 (44.0%) had a patent false lumen. A total of 273 of the 336 (81.3%) evaluated aortic levels were dissected segments. Overall, the mean aortic diameter increased significantly at all evaluated levels (P <. 001). Univariate analysis showed that annual aortic growth rates were significantly higher in those segments having a false lumen with partial thrombosis (mean, 4.25 +/- 10.2) when compared with the patent group (mean, 2.10 +/- 5.56; P = .035). In multivariate analysis, partial lumen thrombosis was an independent predictor of higher aortic growth (adjusted mean difference, 2.05 mm/year; 95% confidence interval, 0.10-4.01; P = .040). Conclusions: In patients with acute type B aortic dissection, aortic segments with a partially thrombosed false lumen have a significantly higher annual aortic growth rate when compared with those presenting with patent or complete thrombosis of the false lumen. Therefore, patients with partial thrombosis require more intensive follow-up and may benefit from prophylactic intervention. (J Thorac Cardiovasc Surg 2013;145:S208-12) C1 [Trimarchi, Santi; Tolenaar, Jip L.; Rampoldi, Vincenzo] Policlin San Donato IRCCS, Thorac Aort Res Ctr, Milan, Italy. [Jonker, Frederik H. W.] Maasstad Hosp, Dept Surg, Rotterdam, Netherlands. [Murray, Brian; Elefteriades, John A.] Yale Univ, Sch Med, Sect Cardiac Surg, New Haven, CT USA. [Tsai, Thomas T.] Denver VA Med Ctr, Div Cardiol & Intervent Cardiol, Denver, CO USA. [Eagle, Kim A.] Univ Michigan Hlth Syst, Ctr Cardiovasc, Ann Arbor, MI USA. [Verhagen, Hence J. M.] Erasmus MC, Dept Vasc Surg, Rotterdam, Netherlands. [van Herwaarden, Joost A.; Moll, Frans L.] Univ Med Ctr Utrecht, Dept Vasc Surg, Utrecht, Netherlands. [Muhs, Bart E.] Yale Univ, Sch Med, Vasc Surg Sect, New Haven, CT USA. RP Trimarchi, S (reprint author), Univ Milan, Thorac Aort Res Ctr, Policlin San Donato IRCCS, Piazza Malan 2, I-20097 San Donato Milanese, MI, Italy. EM santi.trimarchi@unimi.it RI Trimarchi, Santi/J-7361-2016 OI Trimarchi, Santi/0000-0001-5996-3264 NR 15 TC 36 Z9 36 U1 0 U2 9 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD MAR PY 2013 VL 145 IS 3 SU S BP S208 EP S212 DI 10.1016/j.jtcvs.2012.11.048 PG 5 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 089BQ UT WOS:000314884000039 PM 23260434 ER PT J AU Csiszar, A Sosnowska, D Tucsek, Z Gautam, T Toth, P Losonczy, G Colman, RJ Weindruch, R Anderson, RM Sonntag, WE Ungvari, Z AF Csiszar, Anna Sosnowska, Danuta Tucsek, Zsuzsanna Gautam, Tripti Toth, Peter Losonczy, Gyorgy Colman, Ricki J. Weindruch, Richard Anderson, Rozalyn M. Sonntag, William E. Ungvari, Zoltan TI Circulating Factors Induced by Caloric Restriction in the Nonhuman Primate Macaca Mulatta Activate Angiogenic Processes in Endothelial Cells SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Dietary restriction; Vascular aging; Angiogenesis; Microcirculation; Cardiovascular system ID VASCULAR OXIDATIVE STRESS; LEWIS DWARF RATS; MEMBRANE REDOX SYSTEM; SMOOTH-MUSCLE-CELLS; KAPPA-B ACTIVATION; RHESUS-MONKEYS; DIETARY RESTRICTION; LIFE-SPAN; MITOCHONDRIAL BIOGENESIS; BODY-COMPOSITION AB Moderate caloric restriction (CR) without malnutrition increases healthspan in virtually every species studied, including nonhuman primates. In mice, CR exerts significant microvascular protective effects resulting in increased microvascular density in the heart and the brain, which likely contribute to enhanced tolerance to ischemia and improved cardiac performance and cognitive function. Yet, the underlying mechanisms by which CR confer microvascular protection remain elusive. To test the hypothesis that circulating factors triggered by CR regulate endothelial angiogenic capacity, we treated cultured human endothelial cells with sera derived from Macaca mulatta on long-term (over 10 years) CR. Cells treated with sera derived from ad-libitum-fed control monkeys served as controls. We found that factors present in CR sera upregulate vascular endothelial growth factor (VEGF) signaling and stimulate angiogenic processes, including endothelial cell proliferation and formation of capillary-like structures. Treatment with CR sera also tended to increase cellular migration (measured by a wound-healing assay using electric cellsubstrate impedance sensing [ECIS] technology) and adhesion to collagen. Collectively, we find that circulating factors induced by CR promote endothelial angiogenic processes, suggesting that increased angiogenesis may be a potential mechanism by which CR improves cardiac function and prevents vascular cognitive impairment. C1 [Csiszar, Anna; Sosnowska, Danuta; Tucsek, Zsuzsanna; Gautam, Tripti; Toth, Peter; Sonntag, William E.; Ungvari, Zoltan] Univ Oklahoma, Hlth Sci Ctr, Dept Geriatr Med, Reynolds Oklahoma Ctr Aging, Norman, OK 73019 USA. [Csiszar, Anna; Sonntag, William E.; Ungvari, Zoltan] Univ Oklahoma, Hlth Sci Ctr, Peggy & Charles Stephenson Canc Ctr, Norman, OK 73019 USA. [Losonczy, Gyorgy] Semmelweis Univ, Dept Pulmonol, H-1085 Budapest, Hungary. [Colman, Ricki J.] Univ Wisconsin, William S Middleton Mem Vet Hosp, Wisconsin Natl Primate Res Center, Madison, WI 53706 USA. [Weindruch, Richard; Anderson, Rozalyn M.] Univ Wisconsin, William S Middleton Mem Vet Hosp, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA. [Weindruch, Richard; Anderson, Rozalyn M.] Univ Wisconsin, William S Middleton Mem Vet Hosp, Geriatr Res Educ & Clin Ctr, Madison, WI 53706 USA. RP Csiszar, A (reprint author), Univ Oklahoma HSC, Reynolds Oklahoma Ctr Aging, Dept Geriatr Med, 975 NE 10th St,BRC 1303, Oklahoma City, OK 73104 USA. EM anna-csiszar@ouhsc.edu; zoltan-ungvari@ouhsc.edu FU American Federation for Aging Research; Oklahoma Center for the Advancement of Science and Technology; University of Oklahoma College of Medicine Alumni Association; American Heart Association; National Institutes of Health (NIH) [AG031085, AT006526, P01 AG011915, P51 RR000167, AG038747, NS056218, P01 AG11370]; Ellison Medical Foundation; Arkansas Claude Pepper Older Americans Independence Center at University of Arkansas Medical Center; NCRR [RR15459-01, RR020141-01]; Donald W. Reynolds Foundation FX This work was supported by grants from the American Federation for Aging Research (to A. C.), the Oklahoma Center for the Advancement of Science and Technology (to A. C., Z.U., and W. E. S.), the University of Oklahoma College of Medicine Alumni Association (to A. C.), the American Heart Association (to A. C., P. T., and Z.U.), the National Institutes of Health (NIH) (AG031085 to A. C., AT006526 to Z.U., P01 AG011915 to R. W., P51 RR000167 to W.N.P.R.C., and AG038747, NS056218, and P01 AG11370 to W. E. S.), the Ellison Medical Foundation (to W. E. S.), and the Arkansas Claude Pepper Older Americans Independence Center at University of Arkansas Medical Center (to A. C.). This research was conducted in part at a facility constructed with support from Research Facilities Improvement Program grant numbers RR15459-01 and RR020141-01 from NCRR.; The authors would like to express their gratitude for the support of the Donald W. Reynolds Foundation, which funds aging research at the University of Oklahoma Health Sciences Center under its Aging and Quality of Life Program. NR 124 TC 19 Z9 20 U1 3 U2 15 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD MAR PY 2013 VL 68 IS 3 BP 235 EP 249 DI 10.1093/gerona/gls158 PG 15 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 088PM UT WOS:000314847600003 PM 22904098 ER PT J AU Duong, VH Jaglal, MV Zhang, L Kale, V Lancet, JE Komrokji, RS List, AF AF Duong, Vu H. Jaglal, Michael V. Zhang, Ling Kale, Vishakha Lancet, Jeffrey E. Komrokji, Rami S. List, Alan F. TI Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy SO LEUKEMIA RESEARCH LA English DT Article DE Myelodysplastic syndromes; Myelodysplastic-myeloproliferative diseases; Dasatinib; Azacitidine; Decitabine ID ACUTE MYELOID-LEUKEMIA; SRC FAMILY KINASES; SCORING SYSTEM; ONCOLOGY-GROUP; TRISOMY-8; EXPRESSION; INHIBITOR; SURVIVAL; IMPACT; LYN AB Given evidence for the role of Src family kinases, especially Lyn kinase, in myeloblast proliferation and the in vitro inhibitory activity of dasatinib on Src and Lyn, we conducted a phase II study to assess overall response to 100 mg/day dasatinib in patients with higher-risk myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia, or acute myeloid leukemia arising from MDS and who had failed prior treatment with azanucleoside analogs. Among 18 patients treated, 3 responded, 4 had stable disease, and 10 experienced disease progression. Toxicities were limited and consistent with previous reports. Dasatinib appears to be safe but with limited efficacy. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Duong, Vu H.] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA. [Jaglal, Michael V.; Zhang, Ling; Lancet, Jeffrey E.; Komrokji, Rami S.; List, Alan F.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [Kale, Vishakha] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Komrokji, RS (reprint author), H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr,FOB 3,Room 3117, Tampa, FL 33612 USA. EM rami.komrokji@moffitt.org OI Jaglal, Michael/0000-0002-4305-2535 FU Bristol-Myers Squibb FX We thank Rasa Hamilton (Moffitt Cancer Center) for editorial assistance. This study was funded by Bristol-Myers Squibb. NR 26 TC 8 Z9 8 U1 0 U2 7 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0145-2126 J9 LEUKEMIA RES JI Leuk. Res. PD MAR PY 2013 VL 37 IS 3 BP 300 EP 304 DI 10.1016/j.leukres.2012.11.001 PG 5 WC Oncology; Hematology SC Oncology; Hematology GA 088XP UT WOS:000314871500014 PM 23273539 ER PT J AU Goulet, JL Brandt, C Crystal, S Fiellin, DA Gibert, C Gordon, AJ Kerns, RD Maisto, S Justice, AC AF Goulet, Joseph L. Brandt, Cynthia Crystal, Stephen Fiellin, David A. Gibert, Cynthia Gordon, Adam J. Kerns, Robert D. Maisto, Stephen Justice, Amy C. TI Agreement Between Electronic Medical Record-based and Self-administered Pain Numeric Rating Scale Clinical and Research Implications SO MEDICAL CARE LA English DT Article DE veterans; pain screening; electronic medical records ID 5TH VITAL SIGN; COGNITIVE IMPAIRMENT; DIABETES PATIENTS; VETERANS; MANAGEMENT; DEPRESSION; PREVALENCE; QUALITY; SYSTEM; CARE AB Background: Pain screening may improve the quality of care by identifying patients in need of further assessment and management. Many health care systems use the numeric rating scale (NRS) for pain screening, and record the score in the patients' electronic medical record (EMR). Objective: Determine the level of agreement between EMR and patient survey NRS, and whether discrepancies vary by demographic and clinical characteristics. Methods: We linked survey data from a sample of veterans receiving care in 8 Veterans Affairs medical facilities, to EMR data including an NRS collected on the day of the survey to compare responses to the NRS question from these 2 sources. We assessed correlation, agreement on clinical cut-points (eg, severe), and, using the survey as the gold standard, whether patient characteristics were associated with a discrepancy on moderate-severe pain. Results: A total of 1643 participants had a survey and EMR NRS score on the same day. The correlation was 0.56 (95% confidence interval, 0.52-0.59), but the mean EMR score was significantly lower than the survey score (1.72 vs. 2.79; P < 0.0001). Agreement was moderate (kappa = 0.35). Characteristics associated with an increased odds of a discrepancy included: diabetes [adjusted odds ratio (AOR) = 1.48], posttraumatic stress disorder (AOR = 1.59), major depressive disorder (AOR = 1.81), other race versus white (AOR = 2.29), and facility in which care was received. Conclusions: The underestimation of pain using EMR data, especially clinically actionable levels of pain, has important clinical and research implications. Improving the quality of pain care may require better screening. C1 [Goulet, Joseph L.; Brandt, Cynthia; Kerns, Robert D.; Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT 06516 USA. [Goulet, Joseph L.; Kerns, Robert D.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Brandt, Cynthia] Yale Univ, Sch Med, Dept Anesthesiol, New Haven, CT 06510 USA. [Crystal, Stephen] Rutgers State Univ, Inst Hlth, Ctr Hlth Serv Res Pharmacotherapy Chron Dis Manag, New Brunswick, NJ 08903 USA. [Fiellin, David A.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. [Gibert, Cynthia] VA Med Ctr, Washington, DC USA. [Gibert, Cynthia] George Washington Univ, Med Ctr, Washington, DC 20037 USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Gordon, Adam J.] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA USA. [Kerns, Robert D.] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA. [Kerns, Robert D.] Yale Univ, Sch Med, Dept Psychol, New Haven, CT 06510 USA. [Maisto, Stephen] VA Syracuse, Syracuse, NY USA. [Maisto, Stephen] Syracuse Univ, Dept Psychol, Syracuse, NY USA. [Justice, Amy C.] Yale Univ, Sch Med, Sch Med & Publ Hlth, New Haven, CT USA. RP Goulet, JL (reprint author), VA Connecticut Healthcare Syst, 950 Campbell Ave,Bldg 35A,Room 2-207, West Haven, CT 06516 USA. EM joseph.goulet@va.gov OI Fiellin, David/0000-0002-4006-010X; Goulet, Joseph/0000-0002-0842-804X FU National Institute on Alcohol and Alcohol Abuse [U01 AA 13566, U10 AA 13566]; VA HSR&D Research Enhancement Award Program [REAP 08-266]; AHRQ [U18-HS016097] FX Supported by National Institute on Alcohol and Alcohol Abuse (U01 AA 13566 and U10 AA 13566), and VA HSR&D Research Enhancement Award Program (REAP 08-266). S. C.'s work is supported in part by AHRQ U18-HS016097. NR 41 TC 18 Z9 19 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD MAR PY 2013 VL 51 IS 3 BP 245 EP 250 DI 10.1097/MLR.0b013e318277f1ad PG 6 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 090NE UT WOS:000314985100007 PM 23222528 ER PT J AU Chen, MC Go, VLW Wu, SV AF Chen, Monica C. Go, Vay Liang W. Wu, S. Vincent TI Identification and Characterization of Corticotropin Releasing Hormone (CRH) Type 1 System in Human Pancreatic Neuroendocrine Tumors SO PANCREAS LA English DT Meeting Abstract C1 [Chen, Monica C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Go, Vay Liang W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Wu, S. Vincent] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 J9 PANCREAS JI Pancreas PD MAR PY 2013 VL 42 IS 2 BP 371 EP 371 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 090JL UT WOS:000314975200045 ER PT J AU Chen, MC Go, VLW Pham, H Mulugeta, M Solorzano, S Martin, MG Tache, Y Wu, SV AF Chen, Monica C. Go, Vay Liang W. Hung Pham Mulugeta, Million Solorzano, Sergio Martin, Martin G. Tache, Yvette Wu, S. Vincent TI Regulation of Corticotropin Releasing Hormone (CRH) and Urocortin Family Peptide Expression in Human Carcinoid BON Cells SO PANCREAS LA English DT Meeting Abstract C1 [Chen, Monica C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Go, Vay Liang W.; Hung Pham; Mulugeta, Million; Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Solorzano, Sergio; Martin, Martin G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. [Tache, Yvette; Wu, S. Vincent] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 J9 PANCREAS JI Pancreas PD MAR PY 2013 VL 42 IS 2 BP 371 EP 372 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 090JL UT WOS:000314975200046 ER PT J AU Gandy, S Haroutunian, V DeKosky, ST Sano, M Schadt, EE AF Gandy, Sam Haroutunian, Vahram DeKosky, Steven T. Sano, Mary Schadt, Eric E. TI CR1 and the "Vanishing Amyloid" Hypothesis of Alzheimer's Disease SO BIOLOGICAL PSYCHIATRY LA English DT Editorial Material ID OLDEST-OLD; DEMENTIA; GENE C1 [Gandy, Sam; Haroutunian, Vahram; Sano, Mary] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Gandy, Sam; Haroutunian, Vahram; Sano, Mary] Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, New York, NY 10029 USA. [Gandy, Sam] Icahn Sch Med Mt Sinai, Ctr Cognit Hlth, New York, NY 10029 USA. [Gandy, Sam] Icahn Sch Med Mt Sinai, NFL Neurol Ctr, New York, NY 10029 USA. [Schadt, Eric E.] Icahn Sch Med Mt Sinai, Inst Genom & Multiscale Biol, New York, NY 10029 USA. [Schadt, Eric E.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA. [Gandy, Sam; Haroutunian, Vahram; Sano, Mary] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [DeKosky, Steven T.] Univ Virginia, Charlottesville, VA USA. RP Gandy, S (reprint author), Icahn Sch Med Mt Sinai, 1 Gustave L Levy Pl,Box 1137, New York, NY 10029 USA. EM samuel.gandy@mssm.edu FU BLRD VA [I01 BX000348]; NIA NIH HHS [P01 AG025204, AG02219, AG025204, AG042965, AG05133, AG05138, AG14449, P01 AG002219, P01 AG014449, P50 AG005133, P50 AG005138, RF1 AG042965]; NINDS NIH HHS [NS075685, R01 NS075685] NR 15 TC 8 Z9 9 U1 2 U2 25 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAR 1 PY 2013 VL 73 IS 5 BP 393 EP 395 DI 10.1016/j.biopsych.2013.01.013 PG 3 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 085SP UT WOS:000314634900002 PM 23399469 ER PT J AU McCormick, AV Wheeler, JM Guthrie, CR Liachko, NF Kraemer, BC AF McCormick, Allyson V. Wheeler, Jeanna M. Guthrie, Chris R. Liachko, Nicole F. Kraemer, Brian C. TI Dopamine D2 Receptor Antagonism Suppresses Tau Aggregation and Neurotoxicity SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Alzheimer's disease; antipsychotics; dopamine; drug screen; protein aggregation; tau ID PLACEBO-CONTROLLED TRIALS; CAENORHABDITIS-ELEGANS; ALZHEIMERS-DISEASE; C-ELEGANS; TAUOPATHY; DEMENTIA; METAANALYSIS; PLAQUES; TANGLES; PROTEIN AB Background: Tauopathies, including Alzheimer's disease and frontotemporal dementia, are diseases characterized by the formation of pathological tau protein aggregates in the brain and progressive neurodegeneration. Presently no effective disease-modifying treatments exist for tauopathies. Methods: To identify drugs targeting tau neurotoxicity, we have used a Caenorhabditis elegans model of tauopathy to screen a drug library containing 1120 compounds approved for human use for the ability to suppress tau-induced behavioral effects. Results: One compound, the typical antipsychotic azaperone, improved the motility of tau transgenic worms, reduced levels of insoluble tau, and was protective against neurodegeneration. We found that azaperone reduces insoluble tau in a human cell culture model of tau aggregation and that other antipsychotic drugs (flupenthixol, perphenazine, and zotepine) also ameliorate the effects of tau expression in both models. Conclusions: Reduction of dopamine signaling through the dopamine D2 receptor with the use of gene knockouts in Caenorhabditis elegans or RNA interference knockdown in human cell culture has similar protective effects against tau toxicity. These results suggest dopamine D2 receptor antagonism holds promise as a potential neuroprotective strategy for targeting tau aggregation and neurotoxicity. C1 [McCormick, Allyson V.; Wheeler, Jeanna M.; Guthrie, Chris R.; Liachko, Nicole F.; Kraemer, Brian C.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Kraemer, Brian C.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA USA. RP Kraemer, BC (reprint author), Univ Washington Med, Seattle Vet Affairs Puget Sound Hlth Care Syst, Div Gerontol, 1660 S Columbian Way, Seattle, WA 98108 USA. EM kraemerb@u.washington.edu FU Alzheimer's Association [IIRG-08-90627]; Department of Veterans Affairs; National Institutes of Health [R01NS064131] FX This work was supported by a grant from the Alzheimer's Association (IIRG-08-90627, made possible in part by a generous gift from Sherrill Miller). Support was also provided by the Department of Veterans Affairs and a National Institutes of Health grant [R01NS064131] to BK. NR 24 TC 14 Z9 17 U1 0 U2 21 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAR 1 PY 2013 VL 73 IS 5 BP 464 EP 471 DI 10.1016/j.biopsych.2012.08.027 PG 8 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 085SP UT WOS:000314634900012 PM 23140663 ER PT J AU Holt, CL Wang, MQ Clark, EM Williams, BR Schulz, E AF Holt, Cheryl L. Wang, Min Qi Clark, Eddie M. Williams, Beverly Rosa Schulz, Emily TI Religious involvement and physical and emotional functioning among African Americans: The mediating role of religious support SO PSYCHOLOGY & HEALTH LA English DT Article DE religion; religious support; African Americans; functioning; depression ID SOCIAL SUPPORT; HEALTH CONNECTION; DEPRESSION; MODEL; SPIRITUALITY; PERCEPTIONS; MORTALITY; SAMPLE; ADULTS; SCALES AB Objectives: Religious social support may in part account for the relationship between religious involvement and health-related outcomes. African Americans, on average, tend to have relatively high levels of religious involvement, and suffer a higher burden of health conditions than other groups. This study aimed to examine whether religious social support played a mediating role between religious involvement and physical and emotional functioning, and depressive symptoms. Design: The study used a cross sectional telephone survey among a national probability sample of African Americans (n=803). Study participants completed telephone interviews and data were analysed using structural equation modelling. Main outcome measures: Physical and emotional functioning and depressive symptoms served as study outcomes. Results: In both the emotional functioning and depressive symptoms models, the indirect effect test from religious behaviours to emotional religious support indicated evidence for mediation. There was no mediation for the physical functioning model. Conclusion: Implications for faith-based health promotion interventions are discussed. C1 [Holt, Cheryl L.; Wang, Min Qi] Univ Maryland, Sch Publ Hlth, Dept Behav & Community Hlth, College Pk, MD 20742 USA. [Clark, Eddie M.] St Louis Univ, Dept Psychol, St Louis, MO 63103 USA. [Williams, Beverly Rosa] Birmingham VA Med Ctr, Div Gerontol Geriatr Palliat Care, Dept Med, Birmingham, AL USA. [Williams, Beverly Rosa] Univ Alabama Birmingham, Birmingham, AL USA. [Schulz, Emily] Arizona Sch Hlth Sci, Dept Occupat Therapy, Mesa, AZ USA. RP Holt, CL (reprint author), Univ Maryland, Sch Publ Hlth, Dept Behav & Community Hlth, College Pk, MD 20742 USA. EM cholt14@umd.edu NR 45 TC 12 Z9 12 U1 2 U2 18 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0887-0446 J9 PSYCHOL HEALTH JI Psychol. Health PD MAR 1 PY 2013 VL 28 IS 3 BP 267 EP 283 DI 10.1080/08870446.2012.717624 PG 17 WC Public, Environmental & Occupational Health; Psychology, Multidisciplinary SC Public, Environmental & Occupational Health; Psychology GA 089LH UT WOS:000314911500003 PM 22928653 ER PT J AU McClure, MM Harvey, PD Bowie, CR Iacoviello, B Siever, LJ AF McClure, Margaret M. Harvey, Philip D. Bowie, Christopher R. Iacoviello, Brian Siever, Larry J. TI Functional outcomes, functional capacity, and cognitive impairment in schizotypal personality disorder SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Schizophrenia spectrum; Cognition; Functional outcome; Performance-based assessments; Schizotypal personality disorder ID WORKING-MEMORY; NEUROPSYCHOLOGICAL DYSFUNCTION; SKILLS ASSESSMENT; SCHIZOPHRENIA; PERFORMANCE; SPECIFICITY; SENSITIVITY; DISABILITY; DETERMINANTS; RELIABILITY AB Background: Individuals with schizotypal personality disorder (SPD) exhibit impaired cognitive functioning in a pattern similar to that found in schizophrenia; less clear is the extent to which these individuals also share schizophrenia patients' impairments in functional capacity and real-world functioning. Method: We evaluated 46 SPD patients, as well as 38 individuals with avoidant personality disorder (AvPD) and 55 healthy controls (HC) on: cognitive functioning, real-world functioning (employment and residential status), and functional capacity (indexed by the UPSA, a performance-based skills assessment). Results: We found that individuals with SPD exhibited worse performance on both the cognitive battery and the UPSA than the other groups; they were also less likely to be employed and to be living independently. Additionally, cognitive and UPSA performance in the SPD group was intercorrelated to a degree comparable to what has been found in schizophrenia, and this relationship was not present in the AvPD group. Finally, real-world functioning was related to UPSA performance for both patient groups. Conclusions: SPD patients exhibit impaired real-world functioning suggesting that these deficits extend across the schizophrenia spectrum. In addition, there is supportive evidence for the validity and importance of performance-based measures such as the UPSA to predict everyday outcomes across the schizophrenia spectrum. Published by Elsevier B.V. C1 [McClure, Margaret M.; Iacoviello, Brian; Siever, Larry J.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [McClure, Margaret M.; Siever, Larry J.] VA VISN3 Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. [McClure, Margaret M.] Fairfield Univ, Dept Psychol, Fairfield, CT 06430 USA. [Harvey, Philip D.] Univ Miami, Miller Sch Med, Dept Psychiat, Miami, FL 33136 USA. [Harvey, Philip D.] Miami VA Med Ctr, Res Serv, Miami, FL USA. [Bowie, Christopher R.] Queens Univ, Kingston, ON, Canada. RP McClure, MM (reprint author), James J Peters VAMC, VA VISN MIRECC 3, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Margaret.McNamara@mssm.edu FU NIMH [MH 56140, MH 78775]; VA VISN-3 MIRECC; National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [MO1-RR-00071] FX This research was supported by NIMH Grant Number MH 56140 to Dr. Siever, NIMH Grant Number MH 78775 to Dr. Harvey, and by the VA VISN-3 MIRECC. This research was also supported by Grant Number MO1-RR-00071 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NCRR or NIH. NR 38 TC 14 Z9 14 U1 2 U2 12 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD MAR PY 2013 VL 144 IS 1-3 BP 146 EP 150 DI 10.1016/j.schres.2012.12.012 PG 5 WC Psychiatry SC Psychiatry GA 088GI UT WOS:000314821400022 PM 23375943 ER PT J AU Samagh, SP Kramer, EJ Melkus, G Laron, D Bodendorfer, BM Natsuhara, K Kim, HT Liu, XH Feeley, BT AF Samagh, Sanjum P. Kramer, Erik J. Melkus, Gerd Laron, Dominique Bodendorfer, Blake M. Natsuhara, Kyle Kim, Hubert T. Liu, Xuhui Feeley, Brian T. TI MRI quantification of fatty infiltration and muscle atrophy in a mouse model of rotator cuff tears SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article DE rotator cuff; muscle atrophy; fatty infiltration; MRI; mouse ID SUPRASCAPULAR NEUROPATHY; REPAIR; SHEEP; SUPRASPINATUS; DEGENERATION; VOLUME; WATER AB Rotator cuff pathology is the most common shoulder problem seen by orthopedic surgeons. Rotator cuff muscle fatty infiltration and muscle atrophy are common in larger tears and are considered predicting factors for the prognosis of cuff repair. Clinically, MRI is the gold standard in determining fatty infiltration and muscle atrophy; however, analysis for MRI imaging is primarily qualitative in nature with the results lacking further validation. We have recently developed a mouse model of rotator cuff tears. The goal of this study is to quantify and verify rotator cuff muscle atrophy and fatty infiltration using high-resolution MRI in our mouse model. The rotator cuff muscles were analyzed for fat using a triglyceride quantification assay (TQA), muscle volume was measured through water displacement (WD), and histology. The study revealed that MRI had a high correlation with fat as measured with histology and TQA (R2?=?098). MRI also correlated well with atrophy measured with WD and wet weight. This suggests that MRI is a reliable modality in evaluating the progression of fatty infiltration and muscle atrophy following rotator cuff tears in a small animal model. (C) 2012 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 31: 421426, 2013 C1 [Samagh, Sanjum P.; Kramer, Erik J.; Natsuhara, Kyle; Kim, Hubert T.; Liu, Xuhui] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA. [Samagh, Sanjum P.; Laron, Dominique; Bodendorfer, Blake M.; Kim, Hubert T.; Liu, Xuhui; Feeley, Brian T.] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA USA. [Melkus, Gerd] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA. RP Feeley, BT (reprint author), Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA USA. EM feeleyb@orthosurg.ucsf.edu OI Melkus, Gerd/0000-0001-5387-8958 FU Orthopaedic Research Education Foundation (OREF) FX Grant sponsor: Orthopaedic Research Education Foundation (OREF). NR 33 TC 15 Z9 15 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0736-0266 J9 J ORTHOP RES JI J. Orthop. Res. PD MAR PY 2013 VL 31 IS 3 BP 421 EP 426 DI 10.1002/jor.22233 PG 6 WC Orthopedics SC Orthopedics GA 076TJ UT WOS:000313980600012 PM 22991068 ER PT J AU Abern, MR Aronson, WJ Terris, MK Kane, CJ Presti, JC Amling, CL Freedland, SJ AF Abern, Michael R. Aronson, William J. Terris, Martha K. Kane, Christopher J. Presti, Joseph C., Jr. Amling, Christopher L. Freedland, Stephen J. TI Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: Possible implications for active surveillance from the SEARCH database SO PROSTATE LA English DT Article DE prostatic neoplasms; prostatectomy; retropubic; treatment outcome; active surveillance ID DISEASE RECURRENCE; MEN; BIOPSY; DEATH; DIAGNOSIS; MORTALITY; OUTCOMES; THERAPY; IMPACT; TIME AB INTRODUCTION Active surveillance (AS) is increasingly accepted as appropriate management for low-risk prostate cancer (PC) patients. It is unknown whether delaying radical prostatectomy (RP) is associated with increased risk of biochemical recurrence (BCR) for men with intermediate-risk PC. METHODS We performed a retrospective analysis of 1,561 low and intermediate-risk men from the Shared Equal Access Regional Cancer Hospital (SEARCH) database treated with RP between 1988 and 2011. Patients were stratified by interval between diagnosis and RP (=3, 36, 69, or >9 months) and by risk using the D'Amico classification. Cox proportional hazard models were used to analyze BCR. Logistic regression was used to analyze positive surgical margins (PSM), extracapsular extension (ECE), and pathologic upgrading. RESULTS Overall, 813 (52%) men were low-risk, and 748 (48%) intermediate-risk. Median follow-up among men without recurrence was 52.9 months, during which 437 men (38.9%) recurred. For low-risk men, RP delays were unrelated to BCR, ECE, PSM, or upgrading (all P?>?0.05). For intermediate-risk men, however, delays >9 months were significantly related to BCR (HR: 2.10, P?=?0.01) and PSM (OR: 4.08, P?9 months were associated with BCR in subsets of intermediate-risk men with biopsy Gleason score =3?+?4 (HR: 2.51, P?9 months predicted greater BCR and PSM risk. If confirmed in future studies, this suggests delayed RP for intermediate-risk PC may compromise outcomes. Prostate 73: 409417, 2013. (c) 2012 Wiley Periodicals, Inc. C1 [Abern, Michael R.; Freedland, Stephen J.] Duke Univ, Sch Med, Dept Surg, Div Urol Surg, Durham, NC 27705 USA. [Aronson, William J.] VA Greater Los Angeles Healthcare Syst, Dept Surg, Urol Sect, Los Angeles, CA USA. [Aronson, William J.] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA. [Terris, Martha K.] VAMC, Urol Sect, Augusta, GA USA. [Terris, Martha K.] Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA. [Kane, Christopher J.] Univ Calif San Diego, Div Urol, San Diego, CA USA. [Presti, Joseph C., Jr.] Stanford Univ, Sch Med, Dept Urol, Palo Alto, CA 94304 USA. [Presti, Joseph C., Jr.] VAMC, Urol Sect, Palo Alto, CA USA. [Amling, Christopher L.] Oregon Hlth & Sci Univ, Dept Urol, Portland, OR USA. [Freedland, Stephen J.] VAMC, Urol Sect, Durham, NC USA. RP Abern, MR (reprint author), Duke Univ, Sch Med, Dept Surg, Div Urol Surg, 200 Trent Dr,DUMC Box 2804, Durham, NC 27705 USA. EM michael.abern@duke.edu OI Terris, Martha/0000-0002-3843-7270 NR 33 TC 27 Z9 27 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-4137 J9 PROSTATE JI Prostate PD MAR PY 2013 VL 73 IS 4 BP 409 EP 417 DI 10.1002/pros.22582 PG 9 WC Endocrinology & Metabolism; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA 076WZ UT WOS:000313991200009 PM 22996686 ER PT J AU Hooker, SA Ross, K Masters, KS Park, C Allen, LA Bekelman, DB Grigsby, M AF Hooker, Stephanie A. Ross, Kaile Masters, Kevin S. Park, Crystal Allen, Larry A. Bekelman, David B. Grigsby, Megan TI EFFECTS OF A SPIRITUAL INTERVENTION FOR HEART FAILURE PATIENTS: THE DENVER SPIRITED HEART PILOT STUDY SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Hooker, Stephanie A.; Ross, Kaile; Masters, Kevin S.; Grigsby, Megan] Univ Colorado, Denver, CO 80220 USA. [Park, Crystal] Univ Connecticut, Storrs, CT USA. [Allen, Larry A.; Bekelman, David B.] Univ Colorado, Sch Med, Aurora, CO USA. [Hooker, Stephanie A.; Bekelman, David B.] Denver Vet Affairs Med Ctr, Denver, CO USA. EM stephanie.hooker@ucdenver.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD MAR PY 2013 VL 45 SU 2 MA C-039 BP S201 EP S201 PG 1 WC Psychology, Multidisciplinary SC Psychology GA V47BT UT WOS:000209928001358 ER PT J AU Hooker, SA Ross, K Masters, KS Park, C Allen, LA Bekelman, DB Grigsby, M AF Hooker, Stephanie A. Ross, Kaile Masters, Kevin S. Park, Crystal Allen, Larry A. Bekelman, David B. Grigsby, Megan TI QUALITATIVE EVALUATION OF A PSYCHOSPIRITUAL INTERVENTION FOR CHRONIC HEART FAILURE (HF) PATIENTS: THE DENVER SPIRITED HEART PILOT STUDY SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Hooker, Stephanie A.; Ross, Kaile; Masters, Kevin S.; Grigsby, Megan] Univ Colorado, Denver, CO 80220 USA. [Allen, Larry A.; Bekelman, David B.] Univ Colorado, Sch Med, Aurora, CO USA. [Hooker, Stephanie A.; Bekelman, David B.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Park, Crystal] Univ Connecticut, Storrs, CT USA. EM stephanie.hooker@ucdenver.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD MAR PY 2013 VL 45 SU 2 MA 2037 BP S64 EP S64 PG 1 WC Psychology, Multidisciplinary SC Psychology GA V47BT UT WOS:000209928000250 ER PT J AU Lewis, M Bann, C Sterba, K Thorpe, CT Carpenter, D DeVellis, R AF Lewis, Megan Bann, Carla Sterba, Katherine Thorpe, Carolyn T. Carpenter, Delesha DeVellis, Robert TI ADHERENCE MEDIATES THE LINK BETWEEN DYADIC EFFICACY AND WELL-BEING AMONG COUPLES MANAGING CHRONIC ILLNESS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Lewis, Megan; Bann, Carla] Res Triangle Inst, Res Triangle Pk, NC 27709 USA. [Sterba, Katherine] Med Univ South Carolina, Charleston, SC USA. [Thorpe, Carolyn T.] Univ Pittsburgh, Pittsburgh, PA USA. [Thorpe, Carolyn T.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Carpenter, Delesha; DeVellis, Robert] Univ North Carolina Chapel Hill, Chapel Hill, NC USA. EM melewis@rti.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD MAR PY 2013 VL 45 SU 2 MA C-125 BP S220 EP S220 PG 1 WC Psychology, Multidisciplinary SC Psychology GA V47BT UT WOS:000209928001435 ER PT J AU Littman, AJ Boyko, EJ Arterburn, DE Haselkorn, JK Sangeorzan, BJ AF Littman, Alyson J. Boyko, Edward J. Arterburn, David E. Haselkorn, Jodie K. Sangeorzan, Bruce J. TI PHYSICAL ACTIVITIES, BARRIERS, AND FACILITATORS IN VETERANS WITH AMPUTATIONS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Littman, Alyson J.; Boyko, Edward J.] VA Puget Sound, Epidemiol, Seattle, WA USA. [Littman, Alyson J.] UW, Epidemiol, Seattle, WA USA. [Arterburn, David E.] Grp Hlth Res Inst, Seattle, WA USA. [Arterburn, David E.; Haselkorn, Jodie K.] VA Puget Sound, Multiple Sclerosis Ctr Excellence West, Seattle, WA USA. [Haselkorn, Jodie K.] UW, Rehabil Med, Seattle, WA USA. [Sangeorzan, Bruce J.] VA Puget Sound, Rehabil R&D Ctr Excellence Limb Loss Prevent & Pr, Seattle, WA USA. EM alyson@u.washington.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD MAR PY 2013 VL 45 SU 2 MA B-166 BP S136 EP S136 PG 1 WC Psychology, Multidisciplinary SC Psychology GA V47BT UT WOS:000209928001106 ER PT J AU Lovejoy, TI AF Lovejoy, Travis I. TI GENDER AND SEXUAL ORIENTATION MODERATE THE EFFECTS OF MOTIVATIONAL INTERVIEWING IN REDUCING SEXUAL RISK BEHAVIOR IN HIV plus OLDER ADULTS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Lovejoy, Travis I.] Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR 97239 USA. EM travis.lovejoy@va.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD MAR PY 2013 VL 45 SU 2 MA D-066 BP S273 EP S273 PG 1 WC Psychology, Multidisciplinary SC Psychology GA V47BT UT WOS:000209928002047 ER PT J AU Michalek, AK Prochaska, J Kan, D Banys, P Batki, S Clift, W Lane, P Young, R AF Michalek, Anne K. Prochaska, Judith Kan, David Banys, Peter Batki, Steven Clift, William Lane, Patricia Young, Rebecca TI EFFECTIVE INTERVENTION RECRUITMENT & RETENTION STRATEGIES: WE BUILT IT AND THEY CAME ... AND RETURNED! SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Michalek, Anne K.; Prochaska, Judith; Kan, David; Banys, Peter; Batki, Steven] Univ Calif San Francisco, San Francisco, CA 94109 USA. [Kan, David; Banys, Peter; Batki, Steven; Clift, William; Lane, Patricia; Young, Rebecca] San Francisco VA Med Ctr, San Francisco, CA USA. [Prochaska, Judith] Stanford Univ, Stanford, CA 94305 USA. EM anne.michalek@ucsf.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD MAR PY 2013 VL 45 SU 2 MA A-220 BP S54 EP S54 PG 1 WC Psychology, Multidisciplinary SC Psychology GA V47BT UT WOS:000209928000212 ER PT J AU Trivedi, R Beaver, K Zeliadt, SB Nelson, K Eugenio, E Rosland, AM Grimesey, J Bouldin, E Piette, JD AF Trivedi, Ranak Beaver, Kristine Zeliadt, Steven B. Nelson, Karin Eugenio, Evercita Rosland, Ann-Marie Grimesey, Jackie Bouldin, Erin Piette, John D. TI WHO ARE INFORMAL CAREGIVERS? RESULTS FROM A NATIONALLY-REPRESENTATIVE US SURVEY SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Trivedi, Ranak; Zeliadt, Steven B.; Nelson, Karin] Univ Washington, VA Puget Sound, Seattle, WA 98101 USA. [Beaver, Kristine; Eugenio, Evercita; Grimesey, Jackie; Bouldin, Erin] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Rosland, Ann-Marie; Piette, John D.] Univ Michigan, VA Ann Arbor Hlth Care Syst, Ann Arbor, MI 48109 USA. EM ranak.trivedi@va.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD MAR PY 2013 VL 45 SU 2 MA B-124 BP S126 EP S126 PG 1 WC Psychology, Multidisciplinary SC Psychology GA V47BT UT WOS:000209928001066 ER PT J AU Light-McGroary, K Goodlin, SJ AF Light-McGroary, KellyAnn Goodlin, Sarah J. TI The challenges of understanding and managing pain in the heart failure patient SO CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE LA English DT Review DE heart failure; opioids; pain AB Purpose of review Heart failure is a leading cause of significant disability and death throughout the world. The assessment and management of pain syndromes in heart failure require specialized knowledge of the pathophysiology of pain and of heart failure. Effective treatment entails an understanding of the physical, psychological, spiritual and social aspects of the pain experience and how pharmacological interventions need to be carefully tailored in this patient population. As we intensify technology to manage the challenges of heart failure it is critical that we review as a profession this critical issue. Recent findings We will review the various aspects of the pain experience for the heart failure patient, disease-specific treatment modalities and ways to incorporate existing expertise in pain management in to the care of these complex patients. Most recently the Pain Assessment, Incidence & Nature in Heart Failure trial has been completed and is currently in publication. This study was the first attempt at trying to understand the complexity of pain in the heart failure patients and will be the foundation for future work. Summary In closing, as palliative care and hospice move further in to the care of patients with complex, chronic illnesses, it is essential that we take this foundational work and expand upon it. Recognizing that pain and suffering in the heart failure patient is multidimensional and that the physical experience of pain is multifactorial is the beginning of developing expertise and improving the quality of care delivered to these patients. C1 [Light-McGroary, KellyAnn] Univ Iowa Hosp & Clin, Dept Med, Iowa City, IA 52242 USA. [Goodlin, Sarah J.] Portland VA Med Ctr, Portland, OR USA. RP Light-McGroary, K (reprint author), Univ Iowa Hosp & Clin, 200 Hawkins Dr,T402-GH, Iowa City, IA 52242 USA. EM Kellyann-light-mcgroary@uiowa.edu NR 12 TC 5 Z9 5 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1751-4258 EI 1751-4266 J9 CURR OPIN SUPPORT PA JI Curr. Opin Support Palliat. Car. PD MAR PY 2013 VL 7 IS 1 BP 14 EP 20 DI 10.1097/SPC.0b013e32835c1f2f PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA AJ2IC UT WOS:000337478100004 PM 23254859 ER PT J AU Lesselroth, BJ Adams, K Tallett, S Wood, SD Keeling, A Cheng, K Church, VL Felder, R Tran, H AF Lesselroth, Blake J. Adams, Kathleen Tallett, Stephanie Wood, Scott D. Keeling, Amy Cheng, Karen Church, Victoria L. Felder, Robert Hanna Tran TI Design of Admission Medication Reconciliation Technology: A Human Factors Approach to Requirements and Prototyping SO HERD-HEALTH ENVIRONMENTS RESEARCH & DESIGN JOURNAL LA English DT Article DE Evidence-based design; human factors; patient-centered care; safety; technology ID CARE INFORMATION-SYSTEMS; ADVERSE DRUG EVENTS; HEALTH-CARE; HOSPITAL ADMISSION; PATIENT SAFETY; TIME; PHARMACISTS; PHYSICIANS; EFFICIENCY; IMPLEMENTATION AB OBJECTIVE: Our objectives were to (1) develop an in-depth understanding of the workflow and information flow in medication reconciliation, and (2) design medication reconciliation support technology using a combination of rapid-cycle prototyping and human-centered design. BACKGROUND: Although medication reconciliation is a national patient safety goal, limitations both of physical environment and in workflow can make it challenging to implement durable systems. We used several human factors techniques to gather requirements and develop a new process to collect a medication history at hospital admission. METHODS: We completed an ethnography and time and motion analysis of pharmacists in order to illustrate the processes used to reconcile medications. We then used the requirements to design prototype multimedia software for collecting a bedside medication history. We observed how pharmacists incorporated the technology into their physical environment and documented usability issues. RESULTS: Admissions occurred in three phases: (1) list compilation, (2) order processing, and (3) team coordination. Current medication reconciliation processes at the hospital average 19 minutes to complete and do not include a bedside interview. Use of our technology during a bedside interview required an average of 29 minutes. The software represents a viable proof-of-concept to automate parts of history collection and enhance patient communication. However, we discovered several usability issues that require attention. CONCLUSIONS: We designed a patient-centered technology to enhance how clinicians collect a patient's medication history. By using multiple human factors methods, our research team identified system themes and design constraints that influence the quality of the medication reconciliation process and implementation effectiveness of new technology. C1 [Lesselroth, Blake J.; Church, Victoria L.] Portland VA Med Ctr, Portland Patient Safety Ctr Inquiry, Portland, OR USA. [Lesselroth, Blake J.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA. [Adams, Kathleen; Tallett, Stephanie; Felder, Robert; Hanna Tran] Portland VA Med Ctr, Portland, OR USA. [Wood, Scott D.] VHA Off Informat & Analyt Informat Patient Safety, Ann Arbor, MI USA. [Keeling, Amy] Univ Washington, Sch Art, Div Design, Seattle, WA 98195 USA. [Cheng, Karen] Univ Washington, Sch Art, Div Design, Visual Commun Design Program, Seattle, WA 98195 USA. RP Lesselroth, BJ (reprint author), Portland VA Med Ctr, Portland Patient Safety Ctr Inquiry, Dept Med, Mail Code P3 MED,3720 SW US Vet Hosp Dr, Portland, OR 97239 USA. EM blake.lesselroth@va.gov NR 62 TC 0 Z9 0 U1 1 U2 4 PU VENDOME GROUP LLC PI NEW YORK PA 6 EAST 32 ST, 8 FLOOR, NEW YORK, NY 10016 USA SN 1937-5867 EI 2167-5112 J9 HERD-HEALTH ENV RES JI Herd-Health Env. Res. Des. J. PD SPR PY 2013 VL 6 IS 3 BP 30 EP 48 PG 19 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AN9LY UT WOS:000340929500004 PM 23817905 ER PT J AU Friedlander, AH AF Friedlander, Arthur H. TI Carotid Artery Calcifications are a Risk Indicator for Both Stroke and Myocardial Infarction SO JOURNAL OF EVIDENCE-BASED DENTAL PRACTICE LA English DT Letter C1 [Friedlander, Arthur H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Friedlander, Arthur H.] Ronald Reagan UCLA Med Ctr, Hosp Dent Serv, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. RP Friedlander, AH (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM arthur.friedlander@va.gov NR 5 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER INC PI SAN DIEGO PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1532-3382 J9 J EVID-BASED DENT PR JI J. Evid.-Based Dent. Pract. PD MAR PY 2013 VL 13 IS 1 BP 37 EP 37 DI 10.1016/j.jebdp.2012.12.002 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA V37RW UT WOS:000209293900015 PM 23481018 ER PT J AU Zappaterra, MW LaMantia, AS Walsh, CA Lehtinen, MK AF Zappaterra, Mauro W. LaMantia, Anthony S. Walsh, Christopher A. Lehtinen, Maria K. TI Isolation of Cerebrospinal Fluid from Rodent Embryos for use with Dissected Cerebral Cortical Explants SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS LA English DT Article DE Neuroscience; Issue 73; Neurobiology; Developmental Biology; Anatomy; Physiology; Stem Cell Biology; Cellular Biology; Biomedical Engineering; Medicine; Surgery; Neural Stem Cells (NSCs); stem cells; Cerebral Cortex; Cerebrospinal Fluid; CSF; ventricular embryonic CSF; Isolation; Brain; Cerebral Cortical Explant; tissue; culture; mouse; animal model AB The CSF is a complex fluid with a dynamically varying proteome throughout development and in adulthood. During embryonic development, the nascent CSF differentiates from the amniotic fluid upon closure of the anterior neural tube. CSF volume then increases over subsequent days as the neuroepithelial progenitor cells lining the ventricles and the choroid plexus generate CSF. The embryonic CSF contacts the apical, ventricular surface of the neural stem cells of the developing brain and spinal cord. CSF provides crucial fluid pressure for the expansion of the developing brain and distributes important growth promoting factors to neural progenitor cells in a temporally-specific manner. To investigate the function of the CSF, it is important to isolate pure samples of embryonic CSF without contamination from blood or the developing telencephalic tissue. Here, we describe a technique to isolate relatively pure samples of ventricular embryonic CSF that can be used for a wide range of experimental assays including mass spectrometry, protein electrophoresis, and cell and primary explant culture. We demonstrate how to dissect and culture cortical explants on porous polycarbonate membranes in order to grow developing cortical tissue with reduced volumes of media or CSF. With this method, experiments can be performed using CSF from varying ages or conditions to investigate the biological activity of the CSF proteome on target cells. C1 [Zappaterra, Mauro W.] VA Greater Los Angeles Healthcare Syst, Dept Phys Med & Rehabil, Los Angeles, CA USA. [LaMantia, Anthony S.] George Washington Univ, Sch Med & Hlth Sci, Inst Neurosci, Dept Pharmacol & Physiol, Washington, DC 20052 USA. [Walsh, Christopher A.] Boston Childrens Hosp, Div Genet, Dept Med, Boston, MA USA. [Walsh, Christopher A.] Boston Childrens Hosp, Howard Hughes Med Inst, Boston, MA USA. [Lehtinen, Maria K.] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Pathol, Cambridge, MA 02138 USA. RP Lehtinen, MK (reprint author), Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Pathol, Cambridge, MA 02138 USA. EM Maria.Lehtinen@childrens.harvard.edu FU NIH [R00 NS072192, HD029178, 2 RO1NS032457]; Children's Hospital Boston Career Development Fellowship/Harvard Medical School Shore Fellowship; Alfred P. Sloan Foundation FX We are grateful for support from the NIH (Award numbers R00 NS072192 to M.K.L., HD029178 to A-S.L., and 2 RO1NS032457 to C.A.W.). M.K.L. is the recipient of the Children's Hospital Boston Career Development Fellowship/Harvard Medical School Shore Fellowship and a Fellow of the Alfred P. Sloan Foundation. C.A.W. is an Investigator of the Howard Hughes Medical Institute. NR 12 TC 0 Z9 0 U1 0 U2 1 PU JOURNAL OF VISUALIZED EXPERIMENTS PI CAMBRIDGE PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA SN 1940-087X J9 JOVE-J VIS EXP JI J. Vis. Exp. PD MAR PY 2013 IS 73 AR UNSP e50333 DI 10.3791/50333 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA V36QW UT WOS:000209226900050 PM 23524481 ER PT J AU Cohen, AN Chinman, MJ Hamilton, AB Whelan, F Young, AS AF Cohen, Amy N. Chinman, Matthew J. Hamilton, Alison B. Whelan, Fiona Young, Alexander S. TI Using Patient-facing Kiosks to Support Quality Improvement at Mental Health Clinics SO MEDICAL CARE LA English DT Article DE health information technology; quality improvement; mental health ID RANDOMIZED CONTROLLED-TRIAL; PRIMARY-CARE; SELF-ASSESSMENT; SCHIZOPHRENIA; ILLNESS; IMPLEMENTATION; DEPRESSION; OUTCOMES; PROGRAM; INTERVENTION AB Objectives: Evidence-based services improve outcomes in schizophrenia, but most patients at mental health clinics do not receive such services. This gap in care has been perpetuated by a lack of routinely collected data on patients' clinical status and the treatments they receive. However, routine data collection can be completed by patients themselves, especially when aided by health information technology. It is not known whether these data can be used to improve care quality. Methods: In a controlled trial, 8 medical centers of the Veterans Health Administration were assigned to implementation or usual care. A total of 571 patients with schizophrenia were overweight and had not used evidence-based weight services. The implementation strategy included data from patient-facing kiosks, continuous data feedback, clinical champions, education, social marketing, and evidence-based quality improvement teams. Mixed methods evaluated the impact of the kiosks on utilization of and retention in weight services. Results: Compared with usual care, implementation resulted in individuals being more likely to use weight services, availing services >5 weeks sooner, and continuing to use the services 3 times more. When compared with the year before implementation, patients at implementation sites saw a 3-fold increase in treatment visits. Usual care resulted in no change. Conclusions: Mental health clinics have been slow to adopt health information technology. This study is among the first to implement and evaluate automated collection of data from patients at these clinics. Patient-facing kiosks are feasible in routine care and provide data that can be used to substantially improve the quality of care. C1 [Cohen, Amy N.; Hamilton, Alison B.; Young, Alexander S.] VA Desert Pacific Mental Illness Res Educ & Clin, Los Angeles, CA USA. [Cohen, Amy N.; Hamilton, Alison B.; Young, Alexander S.] VA Hlth Serv Res & Dev Ctr Excellence Study Healt, Palo Alto, CA USA. [Cohen, Amy N.; Hamilton, Alison B.; Whelan, Fiona; Young, Alexander S.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Chinman, Matthew J.] VA VISN 4 Mental Illness Res Educ & Clin Ctr MIRE, Philadelphia, PA USA. [Chinman, Matthew J.] RAND, Pittsburgh, PA USA. RP Cohen, AN (reprint author), Greater Los Angeles VA Healthcare Ctr, 11301 Wilshire Blvd 210A, Los Angeles, CA 90073 USA. EM amy.cohen@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service Quality Enhancement Research Initiative (QUERI) [MNT 03-213]; VA Desert Pacific Mental Illness Research, Education and Clinical Center (MIRECC); UCLA-RAND NIMH Partnered Research Center for Quality Care [P30 MH082760] FX Supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service Quality Enhancement Research Initiative (QUERI; MNT 03-213), and VA Desert Pacific Mental Illness Research, Education and Clinical Center (MIRECC) and by the UCLA-RAND NIMH Partnered Research Center for Quality Care (P30 MH082760). The views expressed in this article are those of the authors and do not necessarily represent the views of the affiliated institutions. NR 40 TC 7 Z9 7 U1 2 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD MAR PY 2013 VL 51 IS 3 SU 1 BP S13 EP S20 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA AJ7YH UT WOS:000337917300004 PM 23407006 ER PT J AU Gabrielian, S Yuan, A Andersen, RM McGuire, J Rubenstein, L Sapir, N Gelberg, L AF Gabrielian, Sonya Yuan, Anita Andersen, Ronald M. McGuire, James Rubenstein, Lisa Sapir, Negar Gelberg, Lillian TI Chronic Disease Management for Recently Homeless Veterans A Clinical Practice Improvement Program to Apply Home Telehealth Technology to a Vulnerable Population SO MEDICAL CARE LA English DT Article DE homeless; disease management; peer support ID MENTALLY-ILL; PEER SUPPORT; HEALTH-CARE; SYSTEMS; ACCESS AB Background: Although vulnerable populations may benefit from in-home health information technologies (HIT) that promote disease self-management, there is a "digital divide" in which these groups are often unlikely to use such programs. We describe the early phases of applying and testing an existing Veterans Affairs (VA) HIT-care management program, Care Coordination Home Telehealth (CCHT), to recently homeless Veterans in the US Department of Housing and Urban Development-VA Supportive Housing (HUD-VASH) program. Peers were used to support patient participation. Methods: CCHT uses in-home messaging devices to provide health education and daily questions about clinical indicators from chronic illness care guidelines, with patient responses reviewed by VHA nurses. Patients could also receive adjunctive peer support. We used medical record review, Veteran interviews, and staff surveys to "diagnose" barriers to CCHT use, assess program acceptability, explore the role of peer support, and inform future quality improvement. Subjects: Fourteen eligible Veterans in HUD-VASH agreed to CCHT participation. Ten of these Veterans opted to have adjunctive peer support and the other 4 enrolled in CCHT usual care. Results: Although barriers to enrollment/engagement must be addressed, this subset of Veterans in HUD-VASH was satisfied with CCHT. Most Veterans did not require support from peers to engage in CCHT but valued peer social assistance amidst the isolation felt in their scattered-site homes. Conclusions: HIT tools hold promise for in-home care management for recently housed Veterans. Patient-level barriers to enrollment must be addressed in the next steps of quality improvement, testing and evaluating peer-driven CCHT recruitment. C1 [Gabrielian, Sonya] Vet Adm Greater Los Angeles, Mental Illness Res Educ & Clin Ctr, Los Angeles, CA 90073 USA. [Yuan, Anita; Gelberg, Lillian] Vet Adm Greater Los Angeles, Dept Primary Care, Los Angeles, CA 90073 USA. [Andersen, Ronald M.; Gelberg, Lillian] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. [McGuire, James] Vet Hlth Adm Justice Programs, Washington, DC USA. [Rubenstein, Lisa; Sapir, Negar] Vet Adm Greater Los Angeles, Hlth Serv Res & Dev Ctr Excellence Study Healthca, Los Angeles, CA USA. [Rubenstein, Lisa] RAND Corp, Santa Monica, CA USA. [Gelberg, Lillian] Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA USA. RP Gabrielian, S (reprint author), Vet Adm Greater Los Angeles, Mental Illness Res Educ & Clin Ctr, VA Healthcare Ctr, 11301 Wilshire Blvd,210A Los Angeles, Los Angeles, CA 90073 USA. EM sonya.gabrielian@va.gov FU PACT Demonstration Laboratory initiative is provided by the VA Office of Patient Care Services; VISN 22 VA Assessment and Improvement Lab for Patient Centered Care (VAIL-PCC) [XVA 65-018]; Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs; Office of Academic Affiliations, Advanced Fellowship Program in Health Services Research, Department of Veterans Affairs [TPP 65-013]; NIDA [DA 022445]; UCLA/DREW Project EXPORT, National Center on Minority Health and Health Disparities [P20MD000148/P20MD000182]; VAIL-PCC [XVA 650-18] FX This work was undertaken as part of the Veterans Administration's PACT Demonstration Laboratory initiative, supporting and evaluating VA's transition to a patient-centered medical home. Funding for the PACT Demonstration Laboratory initiative is provided by the VA Office of Patient Care Services. In particular, this project was supported by the VISN 22 VA Assessment and Improvement Lab for Patient Centered Care (VAIL-PCC) (XVA 65-018; PI: Rubenstein). S. G. was supported by the Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs. A.Y. was supported by the Office of Academic Affiliations, Advanced Fellowship Program in Health Services Research, Department of Veterans Affairs (TPP 65-013). L. G. and R. M. A. were supported in part by NIDA DA 022445. R. M. A. received additional support from the UCLA/DREW Project EXPORT, National Center on Minority Health and Health Disparities, P20MD000148/P20MD000182. L. R. and N.S. were supported in part by VAIL-PCC (XVA 650-18). NR 21 TC 6 Z9 6 U1 2 U2 17 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD MAR PY 2013 VL 51 IS 3 SU 1 BP S44 EP S51 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA AJ7YH UT WOS:000337917300008 PM 23407011 ER PT J AU Hynes, DM Whittier, ER Owens, A AF Hynes, Denise M. Whittier, Erika R. Owens, Arika TI Health Information Technology and Implementation Science Partners in Progress in the VHA INTRODUCTION SO MEDICAL CARE LA English DT Editorial Material DE Veterans; health information technology; electronic health record; quality improvement; implementation research; qualitative analysis ID SELF-ASSESSMENT; QUERI; CARE; SCHIZOPHRENIA; QUALITY; ILLNESS AB Background: The Veterans Health Administration (VHA) Quality Enhancement Research Initiative (QUERI) has demonstrated how implementation science can enhance the quality of health care. During this time an increasing number of implementation research projects have developed or utilized health information technology (HIT) innovations to leverage the VHA's electronic health record and information systems. Objective: To describe the HIT approaches used and to characterize the facilitators and barriers to progress within implementation research projects in the VHA QUERI program. Participants: Nine case studies were selected from among 88 projects and represented 8 of 14 HIT categories identified. Each case study included key informants whose roles on the project were principal investigator, implementation science and informatics development. Approach: We conducted documentation analysis and semi-structured in-person interviews with key informants for each of the 9 case studies. We used qualitative analysis software to identify and thematically code information and interview responses. Results: Thematic analyses revealed 3 domains or pathways critical to progression through the QUERI steps. These pathways addressed: (1) compliance and collaboration with information technology policies and procedures; (2) operating within organizational policies and building collaborations with end users, clinicians, and administrators; and (3) obtaining and maintaining research resources and approvals. Conclusion: Sustained efforts in HIT innovation and in implementation science in the Veterans Health Administration demonstrates the interdependencies of these initiatives and the critical pathways that can contribute to progress. Other health care quality improvement efforts that rely on HIT can learn from the Veterans Health Administration experience. C1 [Hynes, Denise M.; Whittier, Erika R.; Owens, Arika] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, VA Informat Resource Ctr, Hines, IL 60141 USA. [Hynes, Denise M.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, CMC3, Hines, IL 60141 USA. [Hynes, Denise M.] Univ Illinois, Dept Med, Chicago, IL USA. [Hynes, Denise M.] Univ Illinois, Ctr Clin & Translat Sci, Chicago, IL USA. RP Hynes, DM (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, VA Informat Resource Ctr, 5th & Roosevelt Rd,Bldg 18,Room 206 151-V, Hines, IL 60141 USA. EM denise.hynes@va.gov NR 23 TC 3 Z9 3 U1 3 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD MAR PY 2013 VL 51 IS 3 SU 1 BP S6 EP S12 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA AJ7YH UT WOS:000337917300003 PM 23407014 ER PT J AU Hynes, DM AF Hynes, Denise M. TI Health Information Technology in VHA Quality Improvement Research Overview INTRODUCTION SO MEDICAL CARE LA English DT Editorial Material DE administrative data; database; health information technology; personal health record; electronic health record; health services research; quality improvement; telehealth; Veterans; secure messaging C1 [Hynes, Denise M.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, VA Informat Resource Ctr VIReC, Hines, IL 60141 USA. [Hynes, Denise M.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, CMC3, Hines, IL 60141 USA. [Hynes, Denise M.] Univ Illinois, Dept Med, Chicago, IL USA. [Hynes, Denise M.] Univ Illinois, Ctr Clin & Translat Sci, Chicago, IL USA. RP Hynes, DM (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Informat Resource Ctr, 5th & Roosevelt Rd,Bldg 18,Room 206 151-V, Hines, IL 60141 USA. EM denise.hynes@va.gov NR 10 TC 0 Z9 0 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD MAR PY 2013 VL 51 IS 3 SU 1 BP S4 EP S5 PG 2 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA AJ7YH UT WOS:000337917300002 PM 23407010 ER PT J AU McInnes, DK Solomon, JL Shimada, SL Petrakis, BA Bokhour, BG Asch, SM Nazi, KM Houston, TK Gifford, AL AF McInnes, D. Keith Solomon, Jeffrey L. Shimada, Stephanie L. Petrakis, Beth A. Bokhour, Barbara G. Asch, Steven M. Nazi, Kim M. Houston, Thomas K. Gifford, Allen L. TI Development and Evaluation of an Internet and Personal Health Record Training Program for Low-income Patients With HIV or Hepatitis C SO MEDICAL CARE LA English DT Article DE vulnerable populations; health informatics; HIV; hepatitis C; veterans ID BEHAVIORAL SKILLS MODEL; ANTIRETROVIRAL THERAPY; CARE UTILIZATION; DIGITAL DIVIDE; DEEP SOUTH; INFORMATION; ACTIVATION; ADHERENCE; INTERVENTION; MOTIVATION AB Background: Vulnerable populations face difficulties accessing and using the internet and personal health record (PHR) systems for health-related purposes. Populations disconnected from the internet also tend to be disconnected from health care services. Objectives: To develop and evaluate an intervention to increase skills in health-related internet and PHR use for vulnerable populations with limited computer and internet experience. Research Design: Preevaluation and postevaluation using quantitative surveys, semistructured interviews, focus groups, and ethnographic observation. Subjects: Fourteen low-income Veterans receiving care at Veterans Affairs medical centers for human immunodeficiency virus or hepatitis C. Measures: Internet and PHR use, self-efficacy, patient activation, disease knowledge, predictors of medication adherence. Results: At follow-up one (FU1), mean number of internet for health features used increased from 1.57 to 4.07 (P < 0.001) as did number of PHR features, from 0.36 to 2.00 (P < 0.001). Mean self-efficacy increased at FU1, from 7.12 to 8.60, (P = 0.009) and was maintained at follow-up two (FU2). Patient activation increased only at FU2, from 3.42 to 3.61 (P = 0.03). Disease specific knowledge showed borderline increase at FU1, from 67.9% to 72.2% (P = 0.05), whereas there were no changes in predictors of medication adherence. Qualitative findings underscored the interest in using internet and PHRs and their contribution to increased engagement in care. Training cost per participant was $287. Conclusions: Group training of vulnerable patients represents a cost-effective method to increase internet and PHR skills, and improve patient confidence in finding health-related information, making online health-related transactions, and interacting with health care providers. C1 [McInnes, D. Keith; Solomon, Jeffrey L.; Shimada, Stephanie L.; Petrakis, Beth A.; Bokhour, Barbara G.; Houston, Thomas K.; Gifford, Allen L.] ENRM VA Med Ctr, VA QUERI Program, Bedford, MA 01730 USA. [McInnes, D. Keith; Solomon, Jeffrey L.; Shimada, Stephanie L.; Petrakis, Beth A.; Bokhour, Barbara G.; Houston, Thomas K.; Gifford, Allen L.] ENRM VA Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA. [McInnes, D. Keith; Shimada, Stephanie L.; Bokhour, Barbara G.; Gifford, Allen L.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. [Asch, Steven M.] VA Palo Alto Healthcare Syst, VA QUERI Program, Palo Alto, CA USA. [Asch, Steven M.] VA Palo Alto Healthcare Syst, Ctr Hlth Care Evaluat, Palo Alto, CA USA. [Asch, Steven M.] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA. [Nazi, Kim M.] US Dept Vet Affairs, Vet & Consumers Hlth Informat Off, Off Informat & Analyt, Vet Hlth Adm, Washington, DC USA. [Houston, Thomas K.] Univ Massachusetts, Dept Quantitat Hlth Sci, Sch Med, Worcester, MA 01605 USA. [Gifford, Allen L.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. RP McInnes, DK (reprint author), ENRM VA Med Ctr, VA QUERI Program, Bldg 70,200 Springs Rd, Bedford, MA 01730 USA. EM keith.mcinnes@va.gov FU Department of Veterans Affairs (VA) Quality Enhancement Research Initiatives (QUERI) HIV/Hepatitis and eHealth (RRP) [09-192]; VA Health Services Research and Development Career Development Award (CDA) [09-016] FX Supported by the Department of Veterans Affairs (VA) Quality Enhancement Research Initiatives (QUERI) HIV/Hepatitis and eHealth (RRP#09-192). In addition, D. K. M. was supported by a VA Health Services Research and Development Career Development Award (CDA#09-016). NR 41 TC 12 Z9 12 U1 3 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD MAR PY 2013 VL 51 IS 3 SU 1 BP S62 EP S66 PG 5 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA AJ7YH UT WOS:000337917300011 PM 23407015 ER PT J AU Nazi, KM Hogan, TP McInnes, DK Woods, SS Graham, G AF Nazi, Kim M. Hogan, Timothy P. McInnes, D. Keith Woods, Susan S. Graham, Gail TI Evaluating Patient Access to Electronic Health Records Results From a Survey of Veterans SO MEDICAL CARE LA English DT Article DE PHR; personal health record; EHR; eHealth; access; portal ID MEDICAL-RECORDS; MEANINGFUL USE; TECHNOLOGIES; CARE AB Objective: Personal Health Records (PHRs) tethered to an Electronic Health Record (EHR) offer patients unprecedented access to their personal health information. At the Department of Veteran Affairs (VA), the My HealtheVet Pilot Program was an early PHR prototype enabling patients to import 18 types of information, including clinical notes and laboratory test results, from the VA EHR into a secure PHR portal. The goal of this study was to explore Veteran perceptions about this access to their medical records, including perceived value and effect on satisfaction, self-care, and communication. Methods: Patients enrolled in the pilot program were invited to participate in a web-based survey. Results: Among 688 Veteran respondents, there was a high degree of satisfaction with the pilot program, with 84% agreeing that the information and services were helpful. The most highly ranked feature was access to personal health information from the VA EHR. The majority of respondents (72%) indicated that the pilot Web site made it easy for them to locate relevant information. Most participants (66%) agreed that the pilot program helped improve their care, with 90% indicating that they would recommend it to another Veteran. Conclusions: Veterans' primary motivation for use of the pilot Web site was the ability to access their own personal health information from the EHR. With patients viewing such access as beneficial to their health and care, PHRs with access to EHR data are positioned to improve health care quality. Making additional information accessible to patients is crucial to meet their needs and preferences. C1 [Nazi, Kim M.] US Dept Vet Affairs, Vet & Consumers Hlth Informat Off, Off Informat & Analyt, Vet Hlth Adm, Washington, DC USA. [Hogan, Timothy P.; McInnes, D. Keith] Edith Nourse Rogers Mem Vet Hosp, Ctr Hlth Qual Outcomes & Econ Res, Natl eHlth QUERI Coordinating Ctr, Bedford, MA USA. [Hogan, Timothy P.] Edith Nourse Rogers Mem Vet Hosp, eHlth Qual Enhancement Res Initiat QUERI, Natl eHlth QUERI Coordinating Ctr, Bedford, MA USA. [Hogan, Timothy P.] Univ Massachusetts, Sch Med, Div Hlth Informat & Implementat Sci, Worcester, MA USA. [McInnes, D. Keith] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. [Woods, Susan S.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. [Woods, Susan S.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Woods, Susan S.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA. [Graham, Gail] US Dept Vet Affairs, Off Informat & Analyt, Vet Hlth Adm, Washington, DC USA. RP Nazi, KM (reprint author), Stratton VA Med Ctr, 113 Holland Ave, Albany, NY 12208 USA. EM kim.nazi@va.gov NR 28 TC 22 Z9 22 U1 1 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD MAR PY 2013 VL 51 IS 3 SU 1 BP S52 EP S56 PG 5 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA AJ7YH UT WOS:000337917300009 PM 23407012 ER PT J AU Shimada, SL Hogan, TP Rao, SR Allison, JJ Quill, AL Feng, H Phillips, BD Nazi, KM Haidary, ST Houston, TK AF Shimada, Stephanie L. Hogan, Timothy P. Rao, Sowmya R. Allison, Jeroan J. Quill, Ann L. Feng, Hua Phillips, Barrett D. Nazi, Kim M. Haidary, Susan T. Houston, Thomas K. TI Patient-Provider Secure Messaging in VA Variations in Adoption and Association With Urgent Care Utilization SO MEDICAL CARE LA English DT Article DE veterans; urgent care; ambulatory care; continuity; implementation; secure messaging; Internet ID KAISER PERMANENTE; MEDICAL HOME; IMPLEMENTATION; FRAMEWORK; QUALITY; ACCESS; IMPACT AB Background: The Veterans Health Administration has implemented patient to clinical team electronic asynchronous secure messaging (SM). This disruptive technology has the potential to support continuous, coordinated quality care, but limited evidence supports this connection. Objectives: The objective of this paper is to (1) measure SM implementation and identify facility characteristics associated with higher rates of adoption and (2) understand the association of SM use and noncontinuity care [ie, urgent care (UC)] utilization rates. Measures: We conducted a retrospective cohort study of 132 VA facilities implementing SM in primary care. We used a combination of cross-sectional survey data on predictors of SM implementation and longitudinal data (July 2010-June 2012) on use of SM and UC. Results: Human resources (coordinator and staff/volunteer availability to directly assist Veterans), computer resources (computers and computer rooms for Veterans), and leadership support for coordinators were associated with increased SM adoption rates. Higher SM use was associated with lower UC rates; early adopters of SM achieved a greater decrease in UC utilization over time than later adopters. Conclusions: In this exploratory analysis of early SM implementation in VA, we found a path of associations linking SM and reductions in UC utilization. These results suggest a need for further examination of the relationship between SM and its effects on health care utilization patterns. C1 [Shimada, Stephanie L.; Hogan, Timothy P.; Rao, Sowmya R.; Allison, Jeroan J.; Quill, Ann L.; Feng, Hua; Phillips, Barrett D.; Houston, Thomas K.] Edith Nourse Rogers Mem Vet Hosp, CHQOER, Bedford, MA 01730 USA. [Shimada, Stephanie L.; Hogan, Timothy P.; Rao, Sowmya R.; Allison, Jeroan J.; Quill, Ann L.; Feng, Hua; Phillips, Barrett D.; Houston, Thomas K.] eHlth Qual Enhancement Res Initiat QUERI, Amherst, MA USA. [Shimada, Stephanie L.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. [Hogan, Timothy P.; Rao, Sowmya R.; Allison, Jeroan J.; Feng, Hua; Phillips, Barrett D.; Houston, Thomas K.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA. [Nazi, Kim M.; Haidary, Susan T.] US Dept Vet Affairs, Vet & Consumers Hlth Informat Off, Off Informat & Analyt, Vet Hlth Adm, Washington, DC USA. RP Shimada, SL (reprint author), Edith Nourse Rogers Mem Vet Hosp, 200 Springs Rd 152, Bedford, MA 01730 USA. EM stephanie.shimada@va.gov FU eHealth Quality Enhancement Research Initiative [EHQ 10-190]; VA Career Development Award [CDA 10-210]; University of Massachusetts Center for Clinical and Translational Research; NIH Clinical and Translational Sciences Award [1UL1RR031982-01] FX The authors acknowledge the eHealth Quality Enhancement Research Initiative (EHQ 10-190) for funding to support this paper. Dr Shimada's efforts were covered by a VA Career Development Award (CDA 10-210). Drs Allison and Houston were supported by the University of Massachusetts Center for Clinical and Translational Research, funding by NIH Clinical and Translational Sciences Award (1UL1RR031982-01). Theresa Hancock and Alex Hersh of the Veterans/Consumers Health Informatics Office, D. Keith McInnes and Beth Ann Petrakis of the eHealth QUERI, Tracey Martin and other My HealtheVet coordinators were also instrumental to data collection. NR 20 TC 12 Z9 12 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD MAR PY 2013 VL 51 IS 3 SU 1 BP S21 EP S28 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA AJ7YH UT WOS:000337917300005 PM 23407007 ER PT J AU Spears, GV Roth, CP Miake-Lye, IM Saliba, D Shekelle, PG Ganz, DA AF Spears, Gwendolyn V. Roth, Carol P. Miake-Lye, Isomi M. Saliba, Debra Shekelle, Paul G. Ganz, David A. TI Redesign of an Electronic Clinical Reminder to Prevent Falls in Older Adults SO MEDICAL CARE LA English DT Article DE quality improvement; fall prevention; primary care; clinical reminder ID PRIMARY-CARE PRACTICES; URINARY-INCONTINENCE; GERIATRIC SYNDROMES; QUALITY INDICATORS; MOBILITY PROBLEMS; INTERVENTION; FACILITATORS; PERCEPTIONS; MANAGEMENT; PHYSICIANS AB Background: Falls are the leading cause of unintentional injury among US older adults. Guidelines recommend screening patients for fall risk, and providing exercise for patients with gait and balance problems. We redesigned an electronic clinical reminder to improve identification and management of Veterans at high risk for falls, and piloted the reminder in 3 Veterans Health Administration community-based outpatient clinics. Methods: This project had 5 key elements: (1) case finding, (2) efficient collection of condition-specific clinical data, (3) clinical reminders to prompt appropriate care, (4) patient and family education materials, and (5) primary care provider (PCP) decision support/PCP and staff education. We reviewed clinical reminder reports, interviewed nurses and PCPs, directly observed clinic operations, and watched nurses and PCPs use the clinical reminder with a dummy patient record to determine areas in need of improvement. Results: Over a 1-year period, 2943 Veterans aged 75 years and older visited the 3 clinics, with 2264 screened for fall risk by the intake nurse, yielding 472 positive screens. PCPs completed gait, balance, and strength evaluations on 231 screen-positive Veterans. Among the 162 Veterans who had a gait, balance, or strength problem on evaluation and were free of advanced dementia or poor prognosis, 39 were offered physical therapy or exercise. PCPs and nurses held divergent opinions about the clinical reminder and the project, with PCPs more negative and nurses more positive. Conclusions: A fall prevention clinical reminder can be incorporated into routine care, but low referral rates to exercise programs suggest that further quality improvement cycles are needed. C1 [Spears, Gwendolyn V.; Miake-Lye, Isomi M.; Saliba, Debra; Shekelle, Paul G.; Ganz, David A.] VA Greater Los Angeles HSR&D Ctr Excellence, Sepulveda, CA USA. [Roth, Carol P.] RAND Corp, Santa Monica, CA USA. [Saliba, Debra; Ganz, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Saliba, Debra; Shekelle, Paul G.; Ganz, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Saliba, Debra] Univ Calif Los Angeles, Borun Ctr Gerontol Res, Los Angeles, CA USA. [Saliba, Debra] Los Angeles Jewish Home, Los Angeles, CA USA. RP Ganz, DA (reprint author), VA Greater Los Angeles Healthcare Syst 11G, 11301 Wilshire Blvd,Bldg 220,Room 313, Los Angeles, CA 90073 USA. EM dganz@mednet.ucla.edu FU US Department of Veterans Affairs, Veterans Health Administration Quality Enhancement Research Initiative [RRP 09-202]; VA Career Development Award from the VA Health Services Research & Development (HSR&D) Service through the VA Greater Los Angeles HSR&D Center of Excellence [VA CD2 08-012-1]; John A. Hartford Foundation; American Federation for Aging Research through the UCLA Geriatrics Center of Excellence; VA Greater Los Angeles HSR&D Center of Excellence [LIP 65-127]; Robert Wood Johnson Foundation Physician Faculty Scholars Program FX Supported by the US Department of Veterans Affairs, Veterans Health Administration Quality Enhancement Research Initiative (Project # RRP 09-202). David Ganz was supported by a VA Career Development Award from the VA Health Services Research & Development (HSR&D) Service (Project # VA CD2 08-012-1) through the VA Greater Los Angeles HSR&D Center of Excellence. Additional support was provided by the John A. Hartford Foundation and the American Federation for Aging Research through the UCLA Geriatrics Center of Excellence, a locally initiated project through the VA Greater Los Angeles HSR&D Center of Excellence (LIP 65-127), and the Robert Wood Johnson Foundation Physician Faculty Scholars Program. NR 19 TC 3 Z9 3 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD MAR PY 2013 VL 51 IS 3 SU 1 BP S37 EP S43 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA AJ7YH UT WOS:000337917300007 PM 23407009 ER PT J AU Tsai, TT Box, TL Gethoffer, H Noonan, G Varosy, PD Maddox, TM Fihn, SD Gross, TP Jesse, RL Rumsfeld, JS AF Tsai, Thomas T. Box, Tamara L. Gethoffer, Hans Noonan, Gregory Varosy, Paul D. Maddox, Thomas M. Fihn, Stephan D. Gross, Thomas P. Jesse, Robert L. Rumsfeld, John S. TI Feasibility of Proactive Medical Device Surveillance The VA Clinical Assessment Reporting and Tracking (CART) Program SO MEDICAL CARE LA English DT Article DE patient safety; device safety; cardiovascular ID COMPREHENSIVE APPROACH; SAFETY NET; STENTS; HOLES AB Background: Timely identification and reporting of medical device problems is critical to postmarket device surveillance programs to maximize patient safety. Cardiac catheterization laboratories are high-device utilization areas well suited for device surveillance. Objective: To demonstrate the feasibility of the national VA Clinical Assessment, Reporting, and Tracking (CART) system, embedded in the electronic health record of all 76 VA cardiac catheterization laboratories, to document unexpected problems with medical devices at the point of care. Methods: We evaluated 260,258 consecutive cardiac catheterization and/or percutaneous coronary intervention procedures on 175,098 Veterans between August 2006 and February 2012. Unexpected device problems (UDPs) encountered for any equipment used during a procedure were entered by clinicians at the point of care as part of regular care documentation. All UDPs were reviewed in collaboration with the FDA to ascertain the likelihood of a device defect (eg, in manufacture or design) and/or contributing to a procedural complication (level I, unlikely; level II, possibly; level III, likely). Results: Of the 260,258 procedure reports, 974 (0.37%) UDP's were reported by 71 (92.2%) of the 76 VA hospitals. After triage, 739 (75.9%) were deemed level I, 196 (20.1%) level II, and 39 (4.0%) level III. Of the 39 level III reports, 12 (30.7%) are in the submission phase as a FDA MedWatch report. The number of monthly UDP reports increased significantly from 2006 to 2012 (P < 0.001). Conclusions: Leveraging a clinical application embedded in the electronic health record and in collaboration with FDA, a proactive national cardiac device surveillance program has been successfully implemented in the VA. C1 [Tsai, Thomas T.; Box, Tamara L.; Gethoffer, Hans; Noonan, Gregory; Varosy, Paul D.; Maddox, Thomas M.; Rumsfeld, John S.] Univ Colorado, VA Eastern Colorado Hlth Care Syst, Dept Med, CART Coordinating Ctr, Denver, CO 80220 USA. [Fihn, Stephan D.] VA Hlth Serv R&D, Off Analyt & Business Intelligence, Seattle, WA USA. [Fihn, Stephan D.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Gross, Thomas P.] US FDA, Ctr Devices & Radiol Hlth, Silver Spring, MD USA. [Jesse, Robert L.; Rumsfeld, John S.] VA Cent Off, Washington, DC USA. [Jesse, Robert L.] Richmond VA Med Ctr, Richmond, VA USA. RP Tsai, TT (reprint author), Univ Colorado, VA Eastern Colorado Hlth Care Syst, Dept Med, CART Coordinating Ctr,Cardiol Sect 111B, 1055 Clermont St, Denver, CO 80220 USA. EM thomas.tsai@va.gov NR 18 TC 11 Z9 11 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD MAR PY 2013 VL 51 IS 3 SU 1 BP S57 EP S61 PG 5 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA AJ7YH UT WOS:000337917300010 PM 23407013 ER PT J AU Baruch, L AF Baruch, Lawrence TI Laboratory Monitoring of Anticoagulant Medications: Focus on Novel Oral Anticoagulants SO POSTGRADUATE MEDICINE LA English DT Article DE apixaban; coagulation assays; dabigatran; edoxaban; rivaroxaban ID INDUCED CLOTTING TIME; FACTOR-XA INHIBITOR; DIRECT THROMBIN INHIBITORS; PATHOLOGISTS CONFERENCE XXXI; ECARIN CHROMOGENIC ASSAY; NONVALVULAR ATRIAL-FIBRILLATION; PARTIAL THROMBOPLASTIN TIME; DIRECT FXA-INHIBITORS; HEALTHY MALE-SUBJECTS; DABIGATRAN ETEXILATE AB Novel oral anticoagulants, direct thrombin inhibitors, and factor Xa inhibitors are being introduced into clinical practice. In contrast to vitamin K antagonists, such as warfarin, these novel agents, because of their relatively wide therapeutic range and predictable pharmacokinetics, have been evaluated in clinical trials and approved for clinical use without the need for routine coagulation monitoring. On occasion, it will be important to assess the anticoagulant status of patients treated with these agents. As a result of their targeted mechanisms of action, they affect standard coagulation assays differently than vitamin K antagonists and heparins, and such assay results may not provide clinically useful information. Thus, less commonly used coagulation assays (eg, chromogenic anti-factor Xa activity assays, diluted thrombin time, and ecarin-based clotting tests) may be introduced into clinical practice. These assays are currently limited by the absence of validated therapeutic targets and lack of standardization across laboratories, vendors, and medication classes. This article provides an overview of the coagulation assays and their potential role in determining the anticoagulant status of patients treated with the emerging anticoagulants. C1 James J Peters VA Med Ctr, Program Med, Bronx, NY 10468 USA. RP Baruch, L (reprint author), James J Peters VA Med Ctr, Program Med, Bronx, NY 10468 USA. FU Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) FX This work was supported by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI). Editorial assistance was provided by Annie Rowe, PhD, CMPP, of UBC-Envision Group, which was contracted by BIPI for these services. The author meets criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE), was fully responsible for all content and editorial decisions, and was involved at all stages of manuscript development. The author received no compensation related to the development of the manuscript. NR 70 TC 2 Z9 2 U1 0 U2 4 PU JTE MULTIMEDIA PI WEST CONSHOHOCKEN PA 18 ELIZABETH ST, STE 110, WEST CONSHOHOCKEN, PA 19428 USA SN 0032-5481 EI 1941-9260 J9 POSTGRAD MED JI Postgrad. Med. PD MAR PY 2013 VL 125 IS 2 DI 10.3810/pgm.2013.03.2647 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA AX2SJ UT WOS:000346794200013 PM 23816779 ER PT J AU Schunemann, HJ Tugwell, P Reeves, BC Akl, EA Santesso, N Spencer, FA Shea, B Wells, G Helfand, M AF Schuenemann, Holger J. Tugwell, Peter Reeves, Barnaby C. Akl, Elie A. Santesso, Nancy Spencer, Frederick A. Shea, Beverley Wells, George Helfand, Mark TI Non-randomized studies as a source of complementary, sequential or replacement evidence for randomized controlled trials in systematic reviews on the effects of interventions SO RESEARCH SYNTHESIS METHODS LA English DT Review DE GRADE; observational studies; non randomized studies; decision making; systematic reviews AB The terms applicability, generalizability, external validity and transferability are related, sometimes used interchangeably and have in common that they lack a clear and consistent definition in the classic epidemiological literature. However, all of these terms generally describe one overarching theme: whether or not available research evidence can be directly utilized to answer the healthcare questions at hand, ideally supported by a judgment about the degree of confidence for this utilization. This concept has been called directness. The objectives of this paper were to delineate how non-randomized studies (NRS) inform judgments in relation to directness and the concepts that it encompasses in the context of systematic reviews. We will briefly review what is known and describe the theoretical and practical issues as well as offer guidance to those tackling the challenges of judging directness and using research evidence to answer healthcare questions with evidence from NRS. In particular, we suggest a framework in which authors can use NRS as a complement, sequence or replacement for randomized controlled trials (RCTs) by focusing on judgments about the population, intervention, comparison and outcomes. Authors of systematic reviews will use NRS to complement judgments about the inconsistencies, the rationale and credibility of subgroup analysis, the baseline risk estimates for the determination of absolute benefits and downsides, and the directness of surrogate outcomes. This evidence includes contextual or supplementary evidence. Authors of systematic review and other summaries of the evidence use NRS as sequential evidence to provide evidence when insufficient evidence is available for an outcome from RCTs, but NRS evidence is available (e.g., long-term harms). Use of evidence from NRS may also serve to replace RCT evidence when NRS provide equivalent (or potentially higher) confidence in the evidence (i.e. quality) compared to indirect evidence from RCTs. These judgments will be made in the context of other domains that influence the overall quality of the body of evidence, including the risk of bias, publication bias (i.e. limitations in the detailed study design and execution), inconsistency, imprecision and factors that increase our confidence in effects. This article will support systematic reviewers in their interaction with decision makers, that is, those who use the systematic review to develop guidelines, address health policy makers, and make clinical decisions, by making these judgments transparent. Copyright (C) 2013 John Wiley & Sons, Ltd. C1 [Schuenemann, Holger J.; Akl, Elie A.; Santesso, Nancy] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8S 4K1, Canada. [Schuenemann, Holger J.; Spencer, Frederick A.] McMaster Univ, Dept Med, Hamilton, ON L8S 4K1, Canada. [Tugwell, Peter; Shea, Beverley; Wells, George] Ottawa Hosp, Res Inst, Clin Epidemiol Unit, Ottawa, ON, Canada. [Reeves, Barnaby C.] Univ Bristol, Bristol Royal Infirm, Bristol Heart Inst, Bristol, Avon, England. [Akl, Elie A.] Amer Univ Beirut, Dept Internal Med, Beirut, Lebanon. [Helfand, Mark] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. [Helfand, Mark] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. RP Schunemann, HJ (reprint author), McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol & Biostat, Room 2C10B,1280 Main St W, Hamilton, ON L8S 4K1, Canada. EM schuneh@mcmaster.ca FU Agency for Healthcare Quality and Research (through the Ottawa Collaborating Centre of the Agency for Healthcare Quality and Research); Cochrane Collaboration Discretionary Fund; UK National Institute for Health Research Bristol Cardiovascular Biomedical Research Unit FX The Workshop was supported financially by the Agency for Healthcare Quality and Research (through the Ottawa Collaborating Centre of the Agency for Healthcare Quality and Research) and by a grant from the Cochrane Collaboration Discretionary Fund. BCR is supported in part by the UK National Institute for Health Research Bristol Cardiovascular Biomedical Research Unit. The views expressed in this article are those of the authors and not necessarily those of the funding bodies, The Cochrane Collaboration or its registered entities, committees or working groups, The Campbell Collaboration or the Patient Centered Outcomes Research Institute. NR 20 TC 23 Z9 23 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1759-2879 EI 1759-2887 J9 RES SYNTH METHODS JI Res. Synth. Methods PD MAR PY 2013 VL 4 IS 1 SI SI BP 49 EP 62 DI 10.1002/jrsm.1078 PG 14 WC Mathematical & Computational Biology; Multidisciplinary Sciences SC Mathematical & Computational Biology; Science & Technology - Other Topics GA V38ZN UT WOS:000209381400006 PM 26053539 ER PT J AU Sweeney, AC Weitlauf, JC Manning, EA Sze, JA Waldrop, AE Hasser, C AF Sweeney, Alison C. Weitlauf, Julie C. Manning, Elizabeth A. Sze, Jocelyn A. Waldrop, Angela E. Hasser, Caitlin TI Intimate Partner Violence: Perspectives on Universal Screening for Women in VHA Primary Care SO WOMENS HEALTH ISSUES LA English DT Editorial Material ID POSTTRAUMATIC-STRESS-DISORDER; MILITARY SEXUAL TRAUMA; MENTAL-HEALTH; UNINTENDED PREGNANCY; DOMESTIC VIOLENCE; FEMALE-PATIENTS; VETERANS; PREVALENCE; DEPRESSION; SYMPTOMS C1 [Sweeney, Alison C.] Michael E DeBakey VA Med Ctr, Dept Vet Affairs, Houston, TX 77030 USA. [Weitlauf, Julie C.; Manning, Elizabeth A.] VA Palo Alto Hlth Care Syst, Dept Vet Affairs, Palo Alto, CA USA. [Weitlauf, Julie C.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Sze, Jocelyn A.] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA. [Waldrop, Angela E.; Hasser, Caitlin] Univ Calif San Francisco, Dept Psychiat, San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA. RP Sweeney, AC (reprint author), Michael E DeBakey VA Med Ctr, Dept Vet Affairs, 2002 Holcombe Blvd 116B, Houston, TX 77030 USA. EM alison.sweeney@va.gov NR 61 TC 6 Z9 6 U1 3 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 EI 1878-4321 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD MAR-APR PY 2013 VL 23 IS 2 BP E73 EP E76 DI 10.1016/j.whi.2012.12.004 PG 4 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA AO1WD UT WOS:000341105300002 PM 23415320 ER PT J AU Yuen, EK Herbert, JD Forman, EM Goetter, EM Comer, R Bradley, JC AF Yuen, Erica K. Herbert, James D. Forman, Evan M. Goetter, Elizabeth M. Comer, Ronald Bradley, Jean-Claude TI Treatment of Social Anxiety Disorder Using Online Virtual Environments in Second Life SO BEHAVIOR THERAPY LA English DT Article DE social anxiety; virtual reality; Second Life; telehealth; telepsychology ID COGNITIVE-BEHAVIORAL THERAPY; CONTROLLED EFFECTIVENESS TRIAL; NEGATIVE EVALUATION SCALE; SHEEHAN DISABILITY SCALE; REALITY EXPOSURE THERAPY; DEPRESSION INVENTORY-II; COMMITMENT THERAPY; UNITED-STATES; CONCURRENT VALIDITY; PANIC DISORDER AB Over 80% of people with social anxiety disorder (SAD) do not receive any type of treatment, despite the existence of effective evidence-based treatments. Barriers to treatment include lack of trained therapists (particularly in non-metropolitan areas), logistical difficulties (e.g., cost, time, transportation), concerns regarding social stigma, and fear of negative evaluation from health care providers. Interventions conducted through electronic communication media, such as the Internet, have the potential to reach individuals who otherwise would not have access to evidence-based treatments. Second Life is an online virtual world that holds great promise in the widespread delivery of evidence-based treatments. We assessed the feasibility, acceptability, and initial efficacy of an acceptance-based behavior therapy in Second Life to treat adults with generalized SAD. Participants (n=14) received 12 sessions of weekly therapy and were assessed at pretreatment, midtreatment, post-treatment, and follow-up. Participants and therapists rated the treatment program as acceptable and feasible, despite frequently encountered technical difficulties. Analyses showed significant pretreatment to follow-up improvements in social anxiety symptoms, depression, disability, and quality of life, with effect sizes comparable to previously published results of studies delivering in-person cognitive behavior therapy for SAD. Implications and future directions are discussed. C1 [Yuen, Erica K.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. [Herbert, James D.] Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA. RP Herbert, JD (reprint author), Univ Penn, Dept Psychol, 119 Stratton,1341 Chestnut St, Philadelphia, PA 19104 USA. EM james.herbert@drexel.edu RI Forman, Evan/I-1042-2012 OI Bradley, Jean-Claude/0000-0001-7144-4846 NR 68 TC 20 Z9 20 U1 7 U2 85 PU ASSOC ADV BEHAVIOR THERAPY PI NEW YORK PA 305 7TH AVE #16A, NEW YORK, NY 10001-6008 USA SN 0005-7894 J9 BEHAV THER JI Behav. Therapy PD MAR PY 2013 VL 44 IS 1 BP 51 EP 61 PG 11 WC Psychology, Clinical SC Psychology GA 074XW UT WOS:000313849400005 PM 23312426 ER PT J AU Halfond, R Corona, R Moon, A AF Halfond, Raquel Corona, Rosalie Moon, Anya TI Latino Parent and Adolescent Perceptions of Hoped-for and Feared Possible Selves for Adolescents SO JOURNAL OF ADOLESCENT RESEARCH LA English DT Article DE possible selves; Latino; adolescents; parents; school achievement; teen pregnancy ID SEXUAL RISK; INTERVENTION; COMMUNICATION; MOTHERS; AMERICAN; ACHIEVEMENT; PSYCHOLOGY; ETHNICITY; IDENTITY; BEHAVIOR AB The authors examined Latino parent and adolescent reports of hoped-for and feared possible selves for adolescents. Twenty-nine Latino parents (18 mothers, 11 fathers) and their 18 adolescents participated in semistructured individual interviews. Interviews were digitally recorded, transcribed, and coded for themes via content analysis. Themes that emerged included achievement, interpersonal, personal characteristics, financial-material, cultural roots, and risk behaviors. More parents than adolescents mentioned feared interpersonal selves such as being a teenage parent. Findings suggest that Latino parents and adolescents express hopes and fears for future outcomes that are not consistent with the high rates of school dropout and teen pregnancy among Latino adolescents. Results shed light on strategies for program and policy prevention efforts. C1 [Halfond, Raquel] Harbor UCLA Med Ctr, Child & Adolescent Psychiat Div, Torrance, CA 90509 USA. [Halfond, Raquel; Corona, Rosalie; Moon, Anya] Virginia Commonwealth Univ, Richmond, VA USA. [Moon, Anya] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Halfond, R (reprint author), Harbor UCLA Med Ctr, Child & Adolescent Psychiat Div, 1000 W Carson St,Box 498, Torrance, CA 90509 USA. EM halfondrw@vcu.edu NR 66 TC 1 Z9 1 U1 4 U2 24 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0743-5584 J9 J ADOLESCENT RES JI J. Adolesc. Res. PD MAR PY 2013 VL 28 IS 2 BP 209 EP 240 DI 10.1177/0743558412457818 PG 32 WC Psychology, Developmental SC Psychology GA 077YM UT WOS:000314065300004 ER PT J AU Loftis, JM Wilhelm, CJ Vandenbark, AA Huckans, M AF Loftis, Jennifer M. Wilhelm, Clare J. Vandenbark, Arthur A. Huckans, Marilyn TI Partial MHC/Neuroantigen Peptide Constructs: A Potential Neuroimmune-Based Treatment for Methamphetamine Addiction SO PLOS ONE LA English DT Article ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; BLOOD-BRAIN-BARRIER; MIGRATION INHIBITORY FACTOR; CELL-RECEPTOR LIGAND; WHITE-MATTER; DEPENDENT INDIVIDUALS; MICROGLIAL ACTIVATION; COGNITIVE ENHANCEMENT; PSYCHIATRIC-SYMPTOMS; STIMULANT ADDICTION AB Relapse rates following current methamphetamine abuse treatments are very high (similar to 40-60%), and the neuropsychiatric impairments (e. g., cognitive deficits, mood disorders) that arise and persist during remission from methamphetamine addiction likely contribute to these high relapse rates. Pharmacotherapeutic development of medications to treat addiction has focused on neurotransmitter systems with only limited success, and there are no Food and Drug Administration approved pharmacotherapies for methamphetamine addiction. A growing literature shows that methamphetamine alters peripheral and central immune functions and that immune factors such as cytokines, chemokines, and adhesion molecules play a role in the development and persistence of methamphetamine induced neuronal injury and neuropsychiatric impairments. The objective of this study was to evaluate the efficacy of a new immunotherapy, partial MHC/neuroantigen peptide construct (RTL551; pI-A(b)/mMOG-35-55), in treating learning and memory impairments induced by repeated methamphetamine exposure. C57BL/6J mice were exposed to two different methamphetamine treatment regimens (using repeated doses of 4 mg/kg or 10 mg/kg, s.c.). Cognitive performance was assessed using the Morris water maze and CNS cytokine levels were measured by multiplex assay. Immunotherapy with RTL551 improved the memory impairments induced by repeated methamphetamine exposure in both mouse models of chronic methamphetamine addiction. Treatment with RTL551 also attenuated the methamphetamine induced increases in hypothalamic interleukin-2 (IL-2) levels. Collectively, these initial results indicate that neuroimmune targeted therapies, and specifically RTL551, may have potential as treatments for methamphetamine-induced neuropsychiatric impairments. C1 [Loftis, Jennifer M.; Wilhelm, Clare J.; Vandenbark, Arthur A.; Huckans, Marilyn] Portland VA Med Ctr, Portland, OR USA. [Huckans, Marilyn] Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR USA. [Loftis, Jennifer M.; Wilhelm, Clare J.; Huckans, Marilyn] Oregon Hlth & Sci Univ, Dept Psychiat, Sch Med, Portland, OR 97201 USA. [Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Sch Med, Dept Neurol, Portland, OR 97201 USA. [Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Sch Med, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. RP Loftis, JM (reprint author), Portland VA Med Ctr, Portland, OR USA. EM loftisj@ohsu.edu FU National Institutes of Health [RC1DA028537, R41DA029345]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development; Methamphetamine Abuse Research Center, Portland, OR [NIDA P50DA018165] FX This work was supported by National Institutes of Health grants RC1DA028537 and R41DA029345 to JML and MH. JML (Research Scientist) and MH (Staff Psychologist and Neuropsychologist) are supported by career development awards from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development. This research was supported, in part, by the Methamphetamine Abuse Research Center, Portland, OR (NIDA P50DA018165). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 61 TC 5 Z9 5 U1 1 U2 10 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 27 PY 2013 VL 8 IS 2 AR e56306 DI 10.1371/journal.pone.0056306 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 098BN UT WOS:000315519000021 PM 23460798 ER PT J AU Tao, WC Higgs, MH Spain, WJ Ransom, CB AF Tao, Wucheng Higgs, Matthew H. Spain, William J. Ransom, Christopher B. TI Postsynaptic GABA(B) Receptors Enhance Extrasynaptic GABA(A) Receptor Function in Dentate Gyrus Granule Cells SO JOURNAL OF NEUROSCIENCE LA English DT Article ID LONG-TERM POTENTIATION; TONIC INHIBITION; RAT HIPPOCAMPUS; MOLECULAR-BASIS; B RECEPTORS; ACTIVATION; NEURONS; MODULATION; LOCALIZATION; EXCITABILITY AB Ambient GABA in the brain tonically activates extrasynaptic GABA(A) receptors, and activity-dependent changes in ambient GABA concentration can also activate GABA(B) receptors. To investigate an interaction between postsynaptic GABA(B) and GABA(A) receptors, we recorded GABA(A) currents elicited by exogenous GABA (10 mu M) from dentate gyrus granule cells (DGGCs) in adult rat hippocampal slices. The GABA(B) receptor agonist baclofen (20 mu M) enhanced GABA(A) currents. This enhancement was blocked by the GABA(B) receptor antagonist CGP 55845 and intracellular solutions containing the GTP analog GDP-beta-s, indicating that baclofen was acting on postsynaptic GABA(B) receptors. Modulation of GABA(A) currents by postsynaptic GABA(B) receptors was not observed in CA1 pyramidal cells or layer 2/3 cortical pyramidal neurons. Baclofen reduced the frequency of spontaneous inhibitory postsynaptic currents (sIPSCs) but did not alter sIPSC amplitude or kinetics. Thus, GABA(A) receptors activated at synapses were not modulated by postsynaptic GABA(B) receptors. In contrast, tonic GAB(A) currents and currents activated by the GABA(A) receptor delta subunit-selective agonist THIP (10 mu M) were potentiated by baclofen. Our data indicate that postsynaptic GABA(B) receptors enhance the function of extrasynaptic GABA(A) receptors, including delta subunit-containing receptors that mediate tonic inhibition in DGGCs. The modulation of GABA(A) receptor function by postsynaptic GABA(B) receptors is a newly identified mechanism that will influence the inhibitory tone of DGGCs when GABA(B) and GABA(A) receptors are both activated. C1 [Higgs, Matthew H.; Spain, William J.; Ransom, Christopher B.] Vet Affairs Puget Sound Hlth Care Syst, Epilepsy Ctr Excellence, Seattle, WA 98108 USA. [Tao, Wucheng; Higgs, Matthew H.; Spain, William J.] Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA. [Spain, William J.; Ransom, Christopher B.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. RP Ransom, CB (reprint author), Univ Washington, Dept Neurol, Epilepsy Ctr Excellence, VA Puget Sound, 1600 South Columbian Way, Seattle, WA 98108 USA. EM cbr5@uw.edu FU Veterans Affairs (VA) Merit Review Award; VA Career Development Award; VA Epilepsy Centers of Excellence FX This work was supported by a Veterans Affairs (VA) Merit Review Award (W.J.S.), a VA Career Development Award (C.B.R.), and the VA Epilepsy Centers of Excellence (C.B.R., W.J.S., M.H.H.). The authors appreciate the expert technical assistance of Sue Usher and discussions with Professor Bertil Hille during the course of experiments. NR 36 TC 28 Z9 31 U1 0 U2 9 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD FEB 27 PY 2013 VL 33 IS 9 BP 3738 EP 3743 DI 10.1523/JNEUROSCI.4829-12.2013 PG 6 WC Neurosciences SC Neurosciences & Neurology GA 098ZO UT WOS:000315588000002 PM 23447585 ER PT J AU Cruz, RJ Dew, MA Myaskovsky, L Goodpaster, B Fox, K Fontes, P DiMartini, A AF Cruz, Ruy J., Jr. Dew, Mary Amanda Myaskovsky, Larissa Goodpaster, Bret Fox, Kristen Fontes, Paulo DiMartini, Andrea TI Objective Radiologic Assessment of Body Composition in Patients with End-Stage Liver Disease: Going Beyond the BMI SO TRANSPLANTATION LA English DT Article DE Radiologic assessment; Assessment liver transplant candidates; Body composition; Cachexia ID COMPUTED-TOMOGRAPHY; MASS INDEX; INSULIN SENSITIVITY; SARCOPENIC OBESITY; ADIPOSE-TISSUE; MUSCLE MASS; MORTALITY; CIRRHOSIS; HEMODIALYSIS; SURVIVAL AB Background. Body mass index (BMI) is a commonly used but likely inexact measure of body composition for patients with end-stage liver disease. For this reason, we examined whether body composition measurements from direct visualization on computed tomography (CT) scans provide new insights in both the degree of malnutrition and the discordant combinations such as obesity with muscle mass loss. This technology is widely used in other medically ill populations but not yet in liver transplantation. Methods. We examined actual body composition using abdominal CT scan data and software designed to measure fat and muscle compartments. Results. In 234 liver transplant candidates, we found that BMI was highly and significantly correlated to subcutaneous and visceral fat. However, we additionally found that, even among obese patients, cachexia, as defined by muscle mass, was common, with 56% of those with BMI above 30 being cachexic. We also found that patients with nonalcoholic steatohepatitis, compared with other types of liver diseases, were significantly more likely to have larger amounts of visceral fat while also having less muscle. In an exploratory analysis, muscle mass corrected for height was a significant predictor of posttransplantation survival. Conclusions. Body composition by CT scan data provides a specific method to identify obesity and muscle wasting for end-stage liver disease patients. Whether these data can aid in the prognostication of outcomes and survival requires further investigation. C1 [Cruz, Ruy J., Jr.; Fontes, Paulo; DiMartini, Andrea] Univ Pittsburgh, Dept Transplantat Surg, Med Ctr, Pittsburgh, PA USA. [Dew, Mary Amanda; Myaskovsky, Larissa; Fox, Kristen; DiMartini, Andrea] Univ Pittsburgh, Dept Psychiat, Med Ctr, Pittsburgh, PA USA. [Dew, Mary Amanda] Univ Pittsburgh, Dept Psychol, Med Ctr, Pittsburgh, PA 15260 USA. [Dew, Mary Amanda] Univ Pittsburgh, Dept Epidemiol, Med Ctr, Pittsburgh, PA 15261 USA. [Myaskovsky, Larissa; Goodpaster, Bret] Univ Pittsburgh, Dept Med, Med Ctr, Pittsburgh, PA USA. [Goodpaster, Bret] Univ Pittsburgh, Med Ctr, Dept Hlth & Phys Educ, Pittsburgh, PA USA. [Dew, Mary Amanda] Univ Pittsburgh, Dept Biostat, Med Ctr, Pittsburgh, PA 15261 USA. [Fontes, Paulo; DiMartini, Andrea] Univ Pittsburgh, Starzl Transplant Inst, Med Ctr, Pittsburgh, PA USA. [Myaskovsky, Larissa] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [DiMartini, Andrea] Western Psychiat Inst & Clin, Pittsburgh, PA 15213 USA. RP DiMartini, A (reprint author), Western Psychiat Inst & Clin, 3811 OHara St, Pittsburgh, PA 15213 USA. EM dimartiniaf@upmc.edu FU National Institute of Digestive Disorders and Kidney Diseases (Rockville, MD) [R01 DK066266]; National Center for Research Resources, a component of the National Institutes of Health [5UL1 RR024153-04]; National Institutes of Health Roadmap for Medical Research; Starzl Transplant Institute Junior Investigator Award FX R.J.C.J. received the Starzl Transplant Institute Junior Investigator Award to conduct this research. This research is also funded by grant R01 DK066266 from the National Institute of Digestive Disorders and Kidney Diseases (Rockville, MD) and grant 5UL1 RR024153-04 from the National Center for Research Resources, a component of the National Institutes of Health, and National Institutes of Health Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the National Institute of Digestive Disorders and Kidney Diseases, National Center for Research Resources or National Institutes of Health. Information on National Center for Research Resources is available at http://www.ncrr.nih.gov/. NR 24 TC 21 Z9 21 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0041-1337 J9 TRANSPLANTATION JI Transplantation PD FEB 27 PY 2013 VL 95 IS 4 BP 617 EP 622 DI 10.1097/TP.0b013e31827a0f27 PG 6 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA 093NS UT WOS:000315199200017 PM 23348896 ER PT J AU Walling, AM Asch, SM Lorenz, KA Wenger, NS AF Walling, Anne M. Asch, Steven M. Lorenz, Karl A. Wenger, Neil S. TI Impact of Consideration of Transplantation on End-of-Life Care for Patients During a Terminal Hospitalization SO TRANSPLANTATION LA English DT Article DE Transplant; End-of-life care; Palliative care; Quality of care ID LIVER-TRANSPLANTATION; SUSTAINING TREATMENTS; PALLIATIVE CARE; ADVANCED CANCER; PREFERENCES; OUTCOMES AB Background. Many patients considered for transplantation die before receiving the organ, underlining the importance of providing high-quality symptomatic relief and communication for all transplant patients. Methods. To study how consideration of transplantation affects the end-of-life care received by patients, care was evaluated by abstracting medical records for 496 adults who died in one high-volume transplant medical center between April 2005 and April 2006. Sixteen quality indicators from the Assessing Care of Vulnerable Elders set that focused on communication and symptom management were measured to calculate an overall patient-level quality score. We evaluated the predictors of quality of end-of-life care, with the main independent variable being whether the patient was being considered for transplantation. Restricting to patients who died an "expected death," we also evaluated the end-of-life treatments received. Results. Twenty-five percent of decedent patients were considered for transplantation. In adjusted models, patients considered for transplantation received lower-quality end-of-life care, had longer hospital stays before death, and were more likely to receive aggressive life-sustaining treatments. Conclusions. Care models should incorporate an emphasis on symptom relief and communication along with transplant preparation. C1 [Walling, Anne M.; Wenger, Neil S.] Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Wenger, Neil S.] Univ Calif Los Angeles, Hlth Syst Eth Ctr, Los Angeles, CA 90024 USA. [Lorenz, Karl A.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. [Walling, Anne M.; Wenger, Neil S.] RAND Hlth, Santa Monica, CA USA. [Asch, Steven M.] VA Palo Alto Healthcare Syst, Menlo Pk, CA USA. [Asch, Steven M.] Stanford Sch Med, Palo Alto, CA USA. [Walling, Anne M.] Univ Calif Los Angeles, Div Gen Internal Med, Los Angeles, CA 90024 USA. RP Walling, AM (reprint author), Univ Calif Los Angeles, Div Gen Internal Med, 911 Broxton Plaza, Los Angeles, CA 90024 USA. EM awalling@mednet.ucla.edu FU National Palliative Care Research Center Career Development Award FX This project was supported by a donation from Mary Kay Farley to RAND Health. A.M.W. was supported by a National Palliative Care Research Center Career Development Award. NR 20 TC 4 Z9 4 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0041-1337 J9 TRANSPLANTATION JI Transplantation PD FEB 27 PY 2013 VL 95 IS 4 BP 641 EP 646 DI 10.1097/TP.0b013e318277f238 PG 6 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA 093NS UT WOS:000315199200021 PM 23197177 ER PT J AU Smith, AK AF Smith, Alexander K. TI Palliative Care An Approach for All Internists SO JAMA INTERNAL MEDICINE LA English DT Editorial Material ID CONTROLLED-TRIAL; CANCER; OUTCOMES C1 [Smith, Alexander K.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94941 USA. [Smith, Alexander K.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Smith, AK (reprint author), Univ Calif San Francisco, Dept Med, 4150 Clement St,181G, San Francisco, CA 94941 USA. EM aksmith@ucsf.edu FU NIA NIH HHS [K23 AG040772] NR 7 TC 1 Z9 1 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 J9 JAMA INTERN MED JI JAMA Intern. Med. PD FEB 25 PY 2013 VL 173 IS 4 BP 291 EP 292 DI 10.1001/jamainternmed.2013.1888 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 153NZ UT WOS:000319610400008 PM 23358724 ER PT J AU Gross, R Bellamy, SL Chapman, J Han, XY O'Duor, J Palmer, SC Houts, PS Coyne, JC Strom, BL AF Gross, Robert Bellamy, Scarlett L. Chapman, Jennifer Han, Xiaoyan O'Duor, Jacqueline Palmer, Steven C. Houts, Peter S. Coyne, James C. Strom, Brian L. TI Managed Problem Solving for Antiretroviral Therapy Adherence A Randomized Trial SO JAMA INTERNAL MEDICINE LA English DT Article ID SELF-ADMINISTERED THERAPY; HIV-INFECTED PATIENTS; MEDICATION ADHERENCE; HEALTH LITERACY; VIRAL LOAD; PROTEASE; FAILURE; INTERVENTIONS; SUPPRESSION; RESISTANCE AB Background: Adherence to antiretroviral therapy is critical to successful treatment of human immunodeficiency virus (HIV). Few interventions have been demonstrated to improve both adherence and virologic outcomes. We sought to determine whether an intervention derived from problem solving theory, Managed Problem Solving (MAPS), would improve antiretroviral outcomes. Methods: We conducted a randomized investigator blind trial of MAPS compared with usual care in HIV-1 infected individuals at 3 HIV clinics in Philadelphia, Pennsylvania. Eligible patients had plasma HIV-1 viral loads greater than 1000 copies/mL and were initiating or changing therapy. Managed Problem Solving consists of 4 in-person and 12 telephone-based meetings with a trained interventionist, then monthly follow-up calls for a year. Primary outcome was medication adherence measured using electronic monitors, summarized as fraction of doses taken quarterly over 1 year. Secondary outcome was undetectable HIV viral load over 1 year. We assessed 218 for eligibility, with 190 eligible and 180 enrolled, 91 randomized to MAPS and 89 to usual care. Fifty-six participants were lost to follow-up: 33 in the MAPS group and 23 in usual care group. Results: In primary intention-to-treat analyses, the odds of being in a higher adherence category was 1.78 (95% CI, 1.07-2.96) times greater for MAPS than usual care. In secondary analyses, the odds of an undetectable viral load was 1.48 (95% CI, 0.94-2.31) times greater for MAPS than usual care. In as-treated analyses, the effect of MAPS was stronger for both outcomes. There was neither a difference by prior treatment status nor change in effect over time. Conclusions: Managed Problem Solving is an effective antiretroviral adherence intervention over the first year with a new regimen. It was equally effective at improving adherence in treatment experienced and naive patients and did not lose effect over time. Implementation of MAPS should be strongly considered where resources are available. Trial Registration: clinicaltrials.gov Identifier: NCT00130273 C1 [Gross, Robert; Bellamy, Scarlett L.; Chapman, Jennifer; Han, Xiaoyan; Strom, Brian L.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Palmer, Steven C.; Coyne, James C.] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Gross, Robert; O'Duor, Jacqueline] Univ Penn, Perelman Sch Med, Div Infect Dis, Philadelphia, PA 19104 USA. [Gross, Robert; Bellamy, Scarlett L.; Chapman, Jennifer; Han, Xiaoyan; Strom, Brian L.] Univ Penn, Perelman Sch Med, Dept Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Gross, Robert; O'Duor, Jacqueline] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Gross, Robert] Vet Affairs Med Ctr, Philadelphia, PA USA. [Houts, Peter S.] Penn State Univ, Coll Med, Hershey, PA USA. [Coyne, James C.] Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci, Hlth Psychol Sect, Groningen, Netherlands. RP Gross, R (reprint author), Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Div Infect Dis,Dept Med, 804 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM grossr@mail.med.upenn.edu FU National Institute of Mental Health [R01 MH067498]; National Center for Research Resources [UL1 RR024134]; Penn Center for AIDS Research [P30 AI 045008] FX The study was supported by R01 MH067498 from the National Institute of Mental Health, UL1 RR024134 from the National Center for Research Resources, core services and support from the Penn Center for AIDS Research (P30 AI 045008), and career support from the Philadelphia Veterans Affairs Medical Center (Dr Gross). NR 40 TC 23 Z9 23 U1 0 U2 8 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 J9 JAMA INTERN MED JI JAMA Intern. Med. PD FEB 25 PY 2013 VL 173 IS 4 BP 300 EP 306 DI 10.1001/jamainternmed.2013.2152 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 153NZ UT WOS:000319610400011 PM 23358784 ER PT J AU Odden, MC Peralta, CA Covinsky, KE AF Odden, Michelle C. Peralta, Carmen A. Covinsky, Kenneth E. TI Walking Speed Is a Useful Marker of Frailty in Older Persons Reply SO JAMA INTERNAL MEDICINE LA English DT Letter C1 [Odden, Michelle C.] Oregon State Univ, Sch Biol & Populat Hlth Sci, Corvallis, OR 97330 USA. [Peralta, Carmen A.; Covinsky, Kenneth E.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Peralta, Carmen A.; Covinsky, Kenneth E.] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA. RP Odden, MC (reprint author), Oregon State Univ, Sch Biol & Populat Hlth Sci, 321 Milam Hall, Corvallis, OR 97330 USA. EM Michelle.Odden@oregonstate.edu NR 2 TC 1 Z9 1 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 J9 JAMA INTERN MED JI JAMA Intern. Med. PD FEB 25 PY 2013 VL 173 IS 4 BP 326 EP 326 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 153NZ UT WOS:000319610400029 ER PT J AU Yang, YF Cao, ZH Tian, L Garvey, WT Cheng, GJ AF Yang, Youfeng Cao, Zehong Tian, Ling Garvey, W. Timothy Cheng, Guangjie TI VPO1 Mediates ApoE Oxidation and Impairs the Clearance of Plasma Lipids SO PLOS ONE LA English DT Article ID LOW-DENSITY-LIPOPROTEIN; VASCULAR PEROXIDASE 1; HEME-CONTAINING PEROXIDASE; APOLIPOPROTEIN-E; DEFICIENT MICE; CHOLESTEROL TRANSPORT; TNF-ALPHA; OX-LDL; ATHEROSCLEROSIS; MYELOPEROXIDASE AB Objective: ApoE is an abundant component of chylomicron, VLDL, IDL, and HDL. It binds to multiple types of lipids and is implicated in cholesterol and triglyceride homeostasis. Oxidation of ApoE plays a crucial role in the genesis of atherosclerosis. It is proposed that heme-containing peroxidases (hPx) are major mediators of lipoprotein oxidization. Vascular peroxidase 1 (VPO1) is a recently-discovered hPx, which is expressed in cardiovascular system, lung, liver etc. and secreted into plasma. Its plasma concentration is three orders of magnitude of that of myeloperoxidase. If VPO1 mediates ApoE oxidation and affects the lipid metabolism remains to be elucidated. Methods: Recombinant ApoE and VPO1 were expressed and purified from stably-expressing cell lines deriving from HEK293 cells. ApoE oxidation was carried out by VPO1 in the presence of H2O2 and chloride. ApoE oxidation was verified by a variety of approaches including immunoblot and amino acid analyses. To evaluate the functional changes in VPO1-oxidized ApoE, lipid emulsion particle binding assays were employed. Results: Oxidized ApoE binds weaker to lipid emulsion particles, which mimic the large lipid complexes in vivo. In lipid efflux assay, oxidized ApoE showed reduced capability in efflux of lipids from foam cells. Mice administrated with oxidized ApoE via blood exhibited weaker clearance ability of plasma lipids. Conclusions: Our data suggest that VPO1 is a new mediator regulating lipid homeostasis, implying a role in genesis and development of atherosclerosis. C1 [Yang, Youfeng; Cao, Zehong; Cheng, Guangjie] Univ Alabama Birmingham, Dept Med, Div Pulm Allergy & Crit Care Med, Birmingham, AL USA. [Tian, Ling; Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL USA. [Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL USA. RP Cheng, GJ (reprint author), Univ Alabama Birmingham, Dept Med, Div Pulm Allergy & Crit Care Med, Birmingham, AL USA. EM gjcheng@uab.edu OI Cheng, Guangjie/0000-0002-9368-379X FU National Heart, Blood, and Lung Institute; National Institute of Allergy and Infectious Diseases, National Institutes of Health [R01 HL086836, R21AI101642]; National Institutes of Health [DK-083562, DK-038764]; Merit Review program of the Department of Veterans Affairs; UAB Diabetes Research and Training Center [P60-DK079626] FX This work was supported by the National Heart, Blood, and Lung Institute, and National Institute of Allergy and Infectious Diseases, National Institutes of Health under Award Number R01 HL086836 and R21AI101642 (to GC). WTG was supported by the National Institutes of Health (Award Number DK-083562 and DK-038764), the Merit Review program of the Department of Veterans Affairs, and the UAB Diabetes Research and Training Center (P60-DK079626). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 55 TC 6 Z9 6 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 25 PY 2013 VL 8 IS 2 AR e57571 DI 10.1371/journal.pone.0057571 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 115ZB UT WOS:000316849500115 PM 23451244 ER PT J AU Jordaan, G Liao, W Sharma, S AF Jordaan, Gwen Liao, Wei Sharma, Sanjai TI E-cadherin gene re-expression in chronic lymphocytic leukemia cells by HDAC inhibitors SO BMC CANCER LA English DT Article DE CLL; E-cadherin; Aberrant splicing; Nonsense mediated decay; Chromatin modeling; HDAC inhibitors; Wnt pathway ID WNT SIGNALING PATHWAY; BETA-CATENIN; HISTONE DEACETYLASE; CANCER; EXPRESSION; EPIGENETICS; ACTIVATION; CHROMATIN; TRANSACTIVATION; IDENTIFICATION AB Background: The tumor suppressor gene E-cadherin gene is frequently silenced in chronic lymphocytic leukemia (CLL) cells and results in wnt-pathway activation. We analyzed the role of histone epigenetic modifications in E-cadherin gene silencing. Methods: CLL specimens were treated with histone deacetylase inhibitor (HDACi) MS-275 and analyzed for E-cadherin expression with western blot and RT-PCR analysis. The downstream effects of HDACi treated leukemic cells were studied by analyzing the effect on wnt-pathway signaling. HDACi induced alterations in E-cadherin splicing were investigated by transcript specific real time PCR analysis. Results: Treatment of CLL specimens with histone deacetylase inhibitors (HDACi) treatment resulted in an increase of the E-cadherin RNA transcript (5 to 119 fold increase, n=10) in eight out of ten CLL specimens indicating that this gene is down regulated by histone hypoacetylation in a majority of CLL specimens. The E-cadherin re-expression in CLL specimens was noted by western blot analysis as well. Besides epigenetic silencing another mechanism of E-cadherin inactivation is aberrant exon 11 splicing resulting in an alternatively spliced transcript that lacks exon 11 and is degraded by the non-sense mediated decay (NMD) pathway. Our chromatin immunoprecipitation experiments show that HDACi increased the acetylation of histones H3 and H4 in the E-cadherin promoter region. This also affected the E-cadherin exon 11 splicing pattern as HDACi treated CLL specimens preferentially expressed the correctly spliced transcript and not the exon 11 skipped aberrant transcript. The re-expressed E-cadherin binds to beta-catenin with inhibition of the active wnt-beta-catenin pathway in these cells. This resulted in a down regulation of two wnt target genes, LEF and cyclinD1 and the wnt pathway reporter. Conclusion: The E-cadherin gene is epigenetically modified and hypoacetylated in CLL leukemic cells. Treatment of CLL specimens with HDACi MS-275 activates transcription from this silent gene with expression of more correctly spliced E-cadherin transcripts as compared to the aberrant exon11 skipped transcripts that in turn inhibits the wnt signaling pathway. The data highlights the role of epigenetic modifications in altering gene splicing patterns. C1 [Jordaan, Gwen; Liao, Wei; Sharma, Sanjai] Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA 90073 USA. RP Sharma, S (reprint author), Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Greater Los Angeles VA Healthcare Ctr, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM sasharma@mednet.ucla.edu FU Flight Attendant Medical Research Institute Fund (FAMRI); Veterans Administration Merit Review Grant FX The authors thank Dr. Alan Lichtenstein for clinical samples and useful discussions. This work was supported by a grant from Flight Attendant Medical Research Institute Fund (FAMRI) and Veterans Administration Merit Review Grant to SS. NR 55 TC 10 Z9 12 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2407 J9 BMC CANCER JI BMC Cancer PD FEB 25 PY 2013 VL 13 AR 88 DI 10.1186/1471-2407-13-88 PG 11 WC Oncology SC Oncology GA 099RD UT WOS:000315638000001 PM 23432814 ER PT J AU Biju, KC Santacruz, RA Chen, C Zhou, Q Yao, JM Rohrabaugh, SL Clark, RA Roberts, JL Phillips, KA Imam, SZ Li, SL AF Biju, K. C. Santacruz, Rene A. Chen, Cang Zhou, Qing Yao, Jiemin Rohrabaugh, Sara L. Clark, Robert A. Roberts, James L. Phillips, Kimberley A. Imam, Syed Z. Li, Senlin TI Bone marrow-derived microglia-based neurturin delivery protects against dopaminergic neurodegeneration in a mouse model of Parkinson's disease SO NEUROSCIENCE LETTERS LA English DT Article DE Parkinson's disease; Gene therapy; Neurodegenerative disease; Neurotrophic factors; Dopamine ID GENE-THERAPY; NEUROTROPHIC FACTOR; TRANSPLANTATION; GDNF; CNS AB Although neurotrophic factors have long been recognized as potent agents for protecting against neuronal degeneration, clinical success in treating Parkinson's disease and other neurodegenerative disorders has been hindered by difficulties in delivery of trophic factors across the blood brain barrier (BBB). Bone marrow hematopoietic stem cell-based gene therapy is emerging as a promising tool for overcoming drug delivery problems, as myeloid cells can cross the BBB and are recruited in large numbers to sites of neurodegeneration, where they become activated microglia that can secrete trophic factors. We tested the efficacy of bone marrow-derived microglial delivery of neurturin (NTN) in protecting dopaminergic neurons against neurotoxin-induced death in mice. Bone marrow cells were transduced ex vivo with lentivirus expressing the NTN gene driven by a synthetic macrophage-specific promoter. Infected bone marrow cells were then collected and transplanted into recipient animals. Eight weeks after transplantation, the mice were injected with the neurotoxin1-methyl-4-phenyl-1,2,3,6-tetrahydropuridine (MPTP) for seven days to induce dopaminergic neurodegeneration. Microglia-mediated NTN delivery dramatically ameliorated MPTP-induced degeneration of tyrosine hydroxylase (TH)-positive neurons of the substantia nigra and their terminals in the striatum. Microglia-mediated NTN delivery also induced significant recovery of synaptic marker staining in the striatum of MPTP-treated animals. Functionally, NTN treatment restored MPTP-induced decline in general activity, rearing behavior, and food intake. Thus, bone marrow-derived microglia can serve as cellular vehicles for sustained delivery of neurotrophic factors capable of mitigating dopaminergic injury. Published by Elsevier Ireland Ltd. C1 [Biju, K. C.; Santacruz, Rene A.; Chen, Cang; Zhou, Qing; Yao, Jiemin; Rohrabaugh, Sara L.; Clark, Robert A.; Li, Senlin] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Santacruz, Rene A.; Li, Senlin] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Roberts, James L.; Li, Senlin] Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. [Clark, Robert A.; Roberts, James L.; Li, Senlin] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Roberts, James L.] Trinity Univ, Dept Biol, San Antonio, TX 78212 USA. [Phillips, Kimberley A.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA. [Imam, Syed Z.] US FDA, Div Neurotoxicol, NCTR, Jefferson, AR USA. RP Li, SL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM lis1@uthscsa.edu OI Phillips, Kimberley/0000-0002-5517-3596 FU NIH [NS046004, AG024579]; Veterans Health Administration; NIH Clinical and Translational Science Award [UL1 TR0000149] FX This work was supported by NIH grants (NS046004 and AG024579), a Merit Review Grant from the Veterans Health Administration, and a NIH Clinical and Translational Science Award (UL1 TR0000149) Pilot Project grant awarded to S.L. NR 23 TC 11 Z9 11 U1 1 U2 14 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD FEB 22 PY 2013 VL 535 BP 24 EP 29 DI 10.1016/j.neulet.2012.12.034 PG 6 WC Neurosciences SC Neurosciences & Neurology GA 095XK UT WOS:000315368100005 PM 23295906 ER PT J AU Switzer, GE Bruce, JG Myaskovsky, L DiMartini, A Shellmer, D Confer, DL Abress, LK King, RJ Harnaha, AG Ohngemach, S Dew, MA AF Switzer, Galen E. Bruce, Jessica G. Myaskovsky, Larissa DiMartini, Andrea Shellmer, Diana Confer, Dennis L. Abress, Linda K. King, Roberta J. Harnaha, Allyson G. Ohngemach, Sibylle Dew, Mary Amanda TI Race and ethnicity in decisions about unrelated hematopoietic stem cell donation SO BLOOD LA English DT Article ID BONE-MARROW DONATION; AFRICAN-AMERICANS; ORGAN DONATION; UNITED-STATES; DONORS; REGISTRY; TRANSPLANTATION; WILLINGNESS; KNOWLEDGE; ATTITUDES AB Large international registries of potential unrelated hematopoietic stem cell (HSC) donors, including the National Marrow Donor program (NMDP), continue to face difficulties finding matched donors for racial/ethnic minorities. One reason, in addition to the generally less common HLA types among minority patients, is the much higher registry attrition rate of racial/ethnic minorities compared with whites. Reasons for the higher attrition among minority potential donors remain unexplained. The goal of our cross-sectional telephone interview study was to generate a diverse sample of potential HSC donors who have preliminarily matched a patient and to identify factors associated with race/ethnicity and with the decision to continue toward potential donation or to opt out of the registry. Multiple culturally related, psychosocial, and donation-related factors were associated both with race/ethnic group membership and attrition from the registry. The most consistent factor associated with opting out of the registry across all race/ethnic groups was ambivalence about donation: doubts and worries, feeling unsure about donation, wishing someone else would donate in one's place. Our findings suggest that universal donor recruitment and management approaches based on reducing donation-related ambivalence and tailored messages and strategies for each of the individual race/ethnic groups are important. (Blood. 2013;121(8):1469-1476) C1 [Switzer, Galen E.; Myaskovsky, Larissa] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Switzer, Galen E.; Myaskovsky, Larissa] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Switzer, Galen E.; Bruce, Jessica G.; Myaskovsky, Larissa; DiMartini, Andrea; Harnaha, Allyson G.; Ohngemach, Sibylle; Dew, Mary Amanda] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Switzer, Galen E.] Univ Pittsburgh, Dept Clin & Translat Sci, Pittsburgh, PA USA. [DiMartini, Andrea; Shellmer, Diana] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA. [Confer, Dennis L.; Abress, Linda K.; King, Roberta J.] Natl Marrow Donor Program, Minneapolis, MN USA. [Dew, Mary Amanda] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA. [Dew, Mary Amanda] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. [Dew, Mary Amanda] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. RP Switzer, GE (reprint author), Div Gen Internal Med, Iroquois Bldg,Ste 502,3600 Forbes Ave, Pittsburgh, PA 15213 USA. EM switzerge@upmc.edu FU National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD [R01 HL081405] FX This project was supported by a grant from the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (R01 HL081405). NR 37 TC 22 Z9 23 U1 5 U2 9 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD FEB 21 PY 2013 VL 121 IS 8 BP 1469 EP 1476 DI 10.1182/blood-2012-06-437343 PG 8 WC Hematology SC Hematology GA 182NK UT WOS:000321750000033 PM 23258921 ER PT J AU Olson, APJ Tierney, LM AF Olson, Andrew P. J. Tierney, Lawrence M., Jr. TI Remarkably Wise SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material C1 [Olson, Andrew P. J.] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA. [Tierney, Lawrence M., Jr.] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA. [Tierney, Lawrence M., Jr.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Olson, APJ (reprint author), Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA. EM olso5714@umn.edu NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 20 PY 2013 VL 309 IS 7 BP 669 EP 670 DI 10.1001/jama.2013.196 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 091EK UT WOS:000315032000021 PM 23423412 ER PT J AU Barnett, CM Heinrich, MC Nelson, DA Lim, JY Beadling, C Warrick, A Neff, T Thomas, G Garzotto, M Higano, CS Beer, TM Qian, DZ AF Barnett, Christine M. Heinrich, Michael C. Nelson, Dylan A. Lim, Jeong Youn Beadling, Carol Warrick, Andrea Neff, Tanaya Thomas, George Garzotto, Mark Higano, Celestia S. Beer, Tomasz M. Qian, David Z. TI Genomic analysis of prostate cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of American-Society-of-Clinical-Oncology (ASCO) CY FEB 14-16, 2013 CL Orlando, FL SP Amer Soc Clin Oncol, Conquer Canc Fdn C1 Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Knight Diagnost Labs, Portland, OR 97201 USA. Univ Washington, Seattle Canc Care Alliance, Puget Sound Oncol Consortium, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD FEB 20 PY 2013 VL 31 IS 6 SU S MA 80 PG 1 WC Oncology SC Oncology GA AE0TR UT WOS:000333679600081 ER PT J AU Shelton, JB Skolarus, TA Ryoo, JJ Malin, J Antonio, ALM He, R Saigal, C AF Shelton, Jeremy B. Skolarus, Ted A. Ryoo, Joan Joonsun Malin, Jennifer Antonio, Anna Liza M. He, Ren Saigal, Christopher TI Specification and validation of prostate cancer quality-of-care e-measures in the Veterans Health Administration (VHA) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of American-Society-of-Clinical-Oncology (ASCO) CY FEB 14-16, 2013 CL Orlando, FL SP Amer Soc Clin Oncol, Conquer Canc Fdn C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA. Univ Michigan, Ann Arbor, MI 48109 USA. Kaiser Permanente, Los Angeles Med Ctr, Los Angeles, CA USA. WellPoint Inc, Indianapolis, IN USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD FEB 20 PY 2013 VL 31 IS 6 SU S MA 178 PG 1 WC Oncology SC Oncology GA AE0TR UT WOS:000333679600179 ER PT J AU Schiros, CG Gladden, JD Clark, D Gupta, H Lloyd, SG McGiffin, DC Ahmed, MI Aban, I Dell'Italia, LJ Perry, G Denney, TS AF Schiros, Chun G. Gladden, James D. Clark, Donald, III Gupta, Himanshu Lloyd, Steven G. McGiffin, David C. Ahmed, Mustafa I. Aban, Inmaculada Dell'Italia, Louis J. Perry, Gilbert Denney, Thomas S., Jr. TI Response to Letter Regarding Article, "Magnetic Resonance Imaging With 3-Dimensional Analysis of Left Ventricular Remodeling in Isolated Mitral Regurgitation: Implications Beyond Dimensions" SO CIRCULATION LA English DT Letter C1 [Schiros, Chun G.; Gladden, James D.; Clark, Donald, III; Gupta, Himanshu; Lloyd, Steven G.; McGiffin, David C.; Ahmed, Mustafa I.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Aban, Inmaculada] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA. [Dell'Italia, Louis J.; Perry, Gilbert] Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Denney, Thomas S., Jr.] Auburn Univ, Dept Elect & Comp Engn, Samuel Ginn Coll Engn, Auburn, AL 36849 USA. RP Schiros, CG (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD FEB 19 PY 2013 VL 127 IS 7 BP E462 EP E462 DI 10.1161/CIRCULATIONAHA.112.134858 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 094YS UT WOS:000315302200011 PM 23550297 ER PT J AU Crawford, F Anandan, C Chappell, FM Murray, GD Price, JF Sheikh, A Simpson, CR Maxwell, M Stansby, GP Young, MJ Abbott, CA Boulton, AJ Boyko, EJ Kastenbauer, T Leese, GP Monami, M Monteiro-Soares, M Rith-Najarian, SJ Veves, A Coates, N Jeffcoate, WJ Leech, N Fahey, T Tierney, J AF Crawford, Fay Anandan, Chantelle Chappell, Francesca M. Murray, Gordon D. Price, Jacqueline F. Sheikh, Aziz Simpson, Colin R. Maxwell, Martin Stansby, Gerard P. Young, Matthew J. Abbott, Caroline A. Boulton, Andrew J. M. Boyko, Edward J. Kastenbauer, Thomas Leese, Graham P. Monami, Matteo Monteiro-Soares, Matilde Rith-Najarian, Stephen J. Veves, Aristidis Coates, Nikki Jeffcoate, William J. Leech, Nicola Fahey, Tom Tierney, Jayne TI Protocol for a systematic review and individual patient data meta-analysis of prognostic factors of foot ulceration in people with diabetes: the international research collaboration for the prediction of diabetic foot ulcerations (PODUS) SO BMC MEDICAL RESEARCH METHODOLOGY LA English DT Review ID METHODOLOGICAL STANDARDS; MULTIPLE IMPUTATION; EPIDEMIOLOGY STROBE; GUIDELINES; STATEMENT; RULES AB Background: Diabetes-related lower limb amputations are associated with considerable morbidity and mortality and are usually preceded by foot ulceration. The available systematic reviews of aggregate data are compromised because the primary studies report both adjusted and unadjusted estimates. As adjusted meta-analyses of aggregate data can be challenging, the best way to standardise the analytical approach is to conduct a meta-analysis based on individual patient data (IPD). There are however many challenges and fundamental methodological omissions are common; protocols are rare and the assessment of the risk of bias arising from the conduct of individual studies is frequently not performed, largely because of the absence of widely agreed criteria for assessing the risk of bias in this type of review. In this protocol we propose key methodological approaches to underpin our IPD systematic review of prognostic factors of foot ulceration in diabetes. Review questions; 1. What are the most highly prognostic factors for foot ulceration (i.e. symptoms, signs, diagnostic tests) in people with diabetes? 2. Can the data from each study be adjusted for a consistent set of adjustment factors? 3. Does the model accuracy change when patient populations are stratified according to demographic and/or clinical characteristics? Methods: MEDLINE and EMBASE databases from their inception until early 2012 were searched and the corresponding authors of all eligible primary studies invited to contribute their raw data. We developed relevant quality assurance items likely to identify occasions when study validity may have been compromised from several sources. A confidentiality agreement, arrangements for communication and reporting as well as ethical and governance considerations are explained. We have agreement from the corresponding authors of all studies which meet the eligibility criteria and they collectively possess data from more than 17000 patients. We propose, as a provisional analysis plan, to use a multi-level mixed model, using "study" as one of the levels. Such a model can also allow for the within-patient clustering that occurs if a patient contributes data from both feet, although to aid interpretation, we prefer to use patients rather than feet as the unit of analysis. We intend to only attempt this analysis if the results of the investigation of heterogeneity do not rule it out and the model diagnostics are acceptable. Discussion: This review is central to the development of a global evidence-based strategy for the risk assessment of the foot in patients with diabetes, ensuring future recommendations are valid and can reliably inform international clinical guidelines. C1 [Crawford, Fay] Newcastle Upon Tyne Hosp NHS Fdn Trust, Freeman Rd Hosp, Dept Vasc Surg, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England. [Anandan, Chantelle; Chappell, Francesca M.; Murray, Gordon D.; Price, Jacqueline F.; Sheikh, Aziz; Simpson, Colin R.; Maxwell, Martin] Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland. [Stansby, Gerard P.] Fac Med Sci, Sch Surg & Reprod Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England. [Young, Matthew J.] Royal Infirm Edinburgh NHS Trust, Dept Diabet, Edinburgh EH16 4SA, Midlothian, Scotland. [Abbott, Caroline A.] Univ Manchester, Ctr Endocrinol & Diabet, Inst Human Dev, Core Technol Facil, Manchester M13 9NT, Lancs, England. [Boulton, Andrew J. M.] Manchester Royal Infirm, Div Med, Manchester M13 9WL, Lancs, England. [Boyko, Edward J.] Univ Washington, Epidemiol Res & Informat Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA 98101 USA. [Kastenbauer, Thomas] Sci Consulting & Clin Monitoring SCCM, A-1220 Vienna, Austria. [Leese, Graham P.] Univ Dundee, Ninewells Hosp & Med Sch, Dept Diabet & Endocrinol, Dundee DD1 9SY, Scotland. [Monami, Matteo] AOU Careggi, Sez Diabetol, Florence, Italy. [Monteiro-Soares, Matilde] Ctr Hosp Vila Nova de Gaia Espinho EPE, Unidade 1, Serv Endocrinol Pe Diabet, P-4434502 Vila Nova De Gaia, Portugal. [Rith-Najarian, Stephen J.] Cass Lake Indian Hlth Serv Hosp, Cass Lake, MN 56633 USA. [Veves, Aristidis] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Coates, Nikki] Newcastle Hosp Community Hlth, Podiatry Dept, Geoffrey Rhodes Clin, Newcastle Upon Tyne NE6 2UZ, Tyne & Wear, England. [Jeffcoate, William J.] City Hosp Nottingham, Dept Diabet & Endocrinol, Nottingham NG5 1PB, England. [Leech, Nicola] Royal Victoria Infirm, Ward 31, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England. [Fahey, Tom] Royal Coll Surgeons Ireland, Dublin 2, Ireland. [Tierney, Jayne] MRC, Clin Trials Unit, London WC2B 6NH, England. RP Crawford, F (reprint author), Newcastle Upon Tyne Hosp NHS Fdn Trust, Freeman Rd Hosp, Dept Vasc Surg, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England. EM Fay.crawford@ed.ac.uk RI ; Fahey, Tom/C-9367-2012; FMUP, CINTESIS/C-6631-2014; Sheikh, Aziz /D-2818-2009; Simpson, Colin/L-7180-2014; Monteiro-Soares, Matilde/F-7192-2013 OI Murray, Gordon/0000-0001-9866-4734; Fahey, Tom/0000-0002-5896-5783; Boyko, Edward/0000-0002-3695-192X; FMUP, CINTESIS/0000-0001-7248-2086; Sheikh, Aziz /0000-0001-7022-3056; Simpson, Colin/0000-0002-5194-8083; Monteiro-Soares, Matilde/0000-0002-4586-2910 FU National Institute for Health Research Health Technology Assessment (NIHR HTA) Programme [10/57/08] FX This project was funded by the National Institute for Health Research Health Technology Assessment (NIHR HTA) Programme (project number 10/57/08) and will be published in full in Health Technology Assessment. NR 33 TC 8 Z9 9 U1 1 U2 17 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2288 J9 BMC MED RES METHODOL JI BMC Med. Res. Methodol. PD FEB 15 PY 2013 VL 13 AR 22 DI 10.1186/1471-2288-13-22 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 107OW UT WOS:000316228700001 PM 23414550 ER PT J AU Mathewkutty, S Sethi, SS Aneja, A Shah, K Iyengar, RL Hermann, L Khakimov, S Razzouk, L Esquitin, R Vedanthan, R Benjamin, TA Grace, M Nisenbaum, R Ramanathan, K Ramanathan, L Chesebro, J Farkouh, ME AF Mathewkutty, Shiny Sethi, Sanjum S. Aneja, Ashish Shah, Kshitij Iyengar, Rupa L. Hermann, Luke Khakimov, Sayyar Razzouk, Louai Esquitin, Ricardo Vedanthan, Rajesh Benjamin, Terrie-Ann Grace, Marie Nisenbaum, Rosane Ramanathan, Krishnan Ramanathan, Lakshmi Chesebro, James Farkouh, Michael E. TI Biomarkers After Risk Stratification in Acute Chest Pain (from the BRIC Study) SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID ACUTE CORONARY SYNDROMES; NATRIURETIC PEPTIDE; EMERGENCY-DEPARTMENT; ST-ELEVATION; MYOCARDIAL-INFARCTION; CT ANGIOGRAPHY; CYSTATIN-C; OUTCOMES; DIAGNOSIS; ISCHEMIA AB Current models incompletely risk-stratify patients with acute chest pain. In this study, N-terminal pro-B-type natriuretic peptide and cystatin C were incorporated into a contemporary chest pain triage algorithm in a clinically stratified population to improve acute coronary syndrome discrimination. Adult patients with chest pain presenting without myocardial infarction (n = 382) were prospectively enrolled from 2008 to 2009. After clinical risk stratification, N-terminal pro-B-type natriuretic peptide and cystatin C were measured and standard care was performed. The primary end point was the result of a clinical stress test. The secondary end point was any major adverse cardiac event at 6 months. Associations were determined through multivariate stratified analyses. In the low-risk group, 76 of 78 patients with normal levels of the 2 biomarkers had normal stress test results (negative predictive value 97%). Normal biomarkers predicted normal stress test results with an odds ratio of 10.56 (p = 0.006). In contrast, 26 of 33 intermediate-risk patients with normal levels of the 2 biomarkers had normal stress test results (negative predictive value 79%). Biomarkers and stress test results were not associated in the intermediate-risk group (odds ratio 2.48, p = 0.09). There were 42 major adverse cardiac events in the overall cohort. No major adverse cardiac events occurred at 6 months in the low-risk subgroup that underwent stress testing. In conclusion, N-terminal pro-B-type natriuretic peptide and cystatin C levels predict the results of stress tests in low-risk patients with chest pain but should not be substituted for stress testing in intermediate-risk patients. There is potential for their use in the early discharge of low-risk patients after clinical risk stratification. (C) 2013 Elsevier Inc. All rights reserved. (Am J Cardiol 2013;111:493-498) C1 [Mathewkutty, Shiny; Sethi, Sanjum S.; Iyengar, Rupa L.; Khakimov, Sayyar; Vedanthan, Rajesh; Farkouh, Michael E.] Mt Sinai Sch Med, Zena & Michael Wiener Cardiovasc Inst, New York, NY 10029 USA. [Hermann, Luke] Mt Sinai Sch Med, Dept Emergency Med, New York, NY USA. [Grace, Marie; Ramanathan, Lakshmi] Mt Sinai Sch Med, Dept Pathol, New York, NY USA. [Aneja, Ashish] Case Western Reserve Univ, Metrohlth Campus, Heart & Vasc Ctr, Cleveland, OH 44106 USA. [Shah, Kshitij] James J Peters VA Med Ctr, Dept Med, Bronx, NY USA. [Razzouk, Louai] NYU, Div Cardiol, New York, NY USA. [Esquitin, Ricardo] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Cardiol, Boston, MA 02215 USA. [Benjamin, Terrie-Ann] Cleveland Clin, Dept Med, Cleveland, OH 44106 USA. [Nisenbaum, Rosane] Univ Toronto, Ctr Res Inner City Hlth, Toronto, ON, Canada. [Nisenbaum, Rosane] Univ Toronto, Appl Hlth Res Ctr, Toronto, ON, Canada. [Nisenbaum, Rosane] Univ Toronto, Keenan Res Ctr, Li Ka Shing Knowledge Inst, St Michaels Hosp, Toronto, ON, Canada. [Nisenbaum, Rosane] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada. [Ramanathan, Krishnan] Univ British Columbia, St Pauls Hosp, Div Cardiol, Vancouver, BC V5Z 1M9, Canada. [Chesebro, James] Univ Massachusetts, Sch Med, Div Cardiovasc Med, Worcester, MA USA. [Farkouh, Michael E.] Univ Toronto, Peter Munk Cardiac Ctr, Toronto, ON, Canada. [Farkouh, Michael E.] Univ Toronto, Li Ka Shing Knowledge Inst, Toronto, ON, Canada. RP Farkouh, ME (reprint author), Mt Sinai Sch Med, Zena & Michael Wiener Cardiovasc Inst, New York, NY 10029 USA. EM michael.farkouh@mssm.edu OI Esquitin, Ricardo/0000-0002-3475-3671; Razzouk, Louai/0000-0002-0306-6182 FU Radiometer (Bronshoj, Denmark); Ontario Ministry of Health and Long-Term Care, Toronto, Ontario, Canada FX This study was sponsored partly by Radiometer (Bronshoj, Denmark).; Dr. Nisenbaum gratefully acknowledges the support of the Ontario Ministry of Health and Long-Term Care, Toronto, Ontario, Canada. The views expressed in this publication are the views of the investigators and do not necessarily reflect the views of the Ontario Ministry of Health and Long-Term Care. NR 30 TC 4 Z9 6 U1 0 U2 5 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD FEB 15 PY 2013 VL 111 IS 4 BP 493 EP 498 DI 10.1016/j.amjcard.2012.10.032 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 095GN UT WOS:000315322800006 PM 23218997 ER PT J AU Alessi, C Vitiello, MV AF Alessi, Cathy Vitiello, Michael V. TI Primary Insomnia in Older Persons SO AMERICAN FAMILY PHYSICIAN LA English DT Editorial Material C1 [Alessi, Cathy] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Vitiello, Michael V.] Univ Washington, Seattle, WA 98195 USA. RP Alessi, C (reprint author), Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 5 PU AMER ACAD FAMILY PHYSICIANS PI KANSAS CITY PA 8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA SN 0002-838X J9 AM FAM PHYSICIAN JI Am. Fam. Physician PD FEB 15 PY 2013 VL 87 IS 4 BP 280 EP 281 PG 2 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 090UX UT WOS:000315006600008 ER PT J AU An, JB Liu, HR Magyar, CE Guo, YC Veena, MS Srivatsan, ES Huang, JT Rettig, MB AF An, Jiabin Liu, Huiren Magyar, Clara E. Guo, Yanchuan Veena, Mysore S. Srivatsan, Eri S. Huang, Jiaoti Rettig, Matthew B. TI Hyperactivated JNK Is a Therapeutic Target in pVHL-Deficient Renal Cell Carcinoma SO CANCER RESEARCH LA English DT Article ID HIPPEL-LINDAU PROTEIN; HYPOXIA-INDUCIBLE FACTOR; EMBRYONIC STEM-CELLS; C-JUN; E-CADHERIN; TUMOR SUPPRESSION; KINASE SAPK/JNK; VHL; PHOSPHORYLATION; GENE AB Clear cell renal cell carcinomas (RCC), the major histologic subtype of RCC accounting for more than 80% of cases, are typified by biallelic inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene. Although accumulation of hypoxia-inducible factor alpha (HIF-alpha) is the most well-studied effect of VHL inactivation, direct inhibition of HIF alpha or restoration of wild-type pVHL protein expression has not proved readily feasible, given the limitations associated with pharmacologic targeting of transcription factors (i.e., HIF-a) and gene replacement therapy of tumor suppressor genes (i.e., VHL). Here, we have established that phosphorylated c-Jun, a substrate of the c-Jun-NH2-kinase (JNK), is selectively activated in clear cell RCC patient specimens. Using multiple isogenic cell lines, we show that HIF-alpha-independent JNK hyperactivation is unique to the pVHL-deficient state. Importantly, pVHL-deficient RCCs are dependent upon JNK activity for in vitro and in vivo growth. A multistep signaling pathway that links pVHL loss to JNK activation involves the formation of a CARD9/BCL10/TRAF6 complex as a proximal signal to sequentially stimulate TAK1 (MAPKKK), MKK4 (MAPKK), and JNK (MAPK). JNK stimulates c-Jun phosphorylation, activation, and dimerization with c-Fos to form a transcriptionally competent AP1 complex that drives transcription of the Twist gene and induces epithelial-mesenchymal transition. Thus, JNK represents a novel molecular target that is selectively activated in and drives the growth of pVHL-deficient clear cell RCCs. These findings can serve as the preclinical foundation for directed efforts to characterize potent pharmacologic inhibitors of the JNK pathway for clinical translation. Cancer Res; 73(4); 1374-85. (C) 2012 AACR. C1 [An, Jiabin; Liu, Huiren; Rettig, Matthew B.] VA Greater Los Angeles Healthcare Syst, Dept Med, Div Hematol Oncol, Los Angeles, CA USA. [Veena, Mysore S.; Srivatsan, Eri S.] VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. [An, Jiabin; Liu, Huiren; Rettig, Matthew B.] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Dept Urol, Los Angeles, CA 90095 USA. [Magyar, Clara E.; Huang, Jiaoti] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Veena, Mysore S.; Srivatsan, Eri S.] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Dept Surg, Los Angeles, CA 90095 USA. [Rettig, Matthew B.] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Dept Med, Los Angeles, CA 90095 USA. [Guo, Yanchuan] Chinese Acad Sci, Tech Inst Phys & Chem, Beijing, Peoples R China. RP Rettig, MB (reprint author), UCLA VAGLAHS, 11301 Wilshire Blvd,Bldg 500,Room 4237, Los Angeles, CA 90073 USA. EM mrettig@mednet.ucla.edu FU Department of Veterans Affairs; NIH [2P30DK041301] FX The authors thank G. Thomas (Institute of Cancer Research, United Kingdom) for the isogenic pairs of ACHN and SN12C cell lines, W. Kaelin (Dana Farber Cancer Institute) for the 786-0 lines and the CARD9 plasmids, and B. Zbar (National Cancer Institute) for the UMRC6 and UOK121 pairs. The Vector Core (NIH grant 2P30DK041301) at the David Geffen School of Medicine prepared and titered lentiviral particles.; This work was supported by a Merit Review grant (M.B. Rettig) from the Department of Veterans Affairs. NR 36 TC 15 Z9 20 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD FEB 15 PY 2013 VL 73 IS 4 BP 1374 EP 1385 DI 10.1158/0008-5472.CAN-12-2362 PG 12 WC Oncology SC Oncology GA 091DR UT WOS:000315029800012 PM 23393199 ER PT J AU Mallampalli, RK Glasser, JR Coon, TA Chen, BB AF Mallampalli, Rama K. Glasser, Jennifer R. Coon, Tiffany A. Chen, Bill B. TI Calmodulin protects Aurora B on the midbody to regulate the fidelity of cytokinesis SO CELL CYCLE LA English DT Article DE Aurora B; FBXL2; calmodulin; mitosis; midbody ID SPINDLE POLE BODY; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; SCF UBIQUITIN LIGASE; KINASE INHIBITOR; F-BOX; CHROMOSOME SEGREGATION; MITOTIC PROGRESSION; CELLS; DEGRADATION; COMPLETION AB Aurora B kinase is an integral regulator of cytokinesis as it stabilizes the intercellular canal within the midbody to ensure proper chromosomal segregation during cell division. Here we identified an E3 ligase subunit, F-box protein FBXL2, that by recognizing a calmodulin binding signature within Aurora B, ubiquitinates and removes the kinase from the midbody. Calmodulin, by competing with the F-box protein for access to the calmodulin binding signature, protected Aurora B from FBXL2. Calmodulin co-localized with Aurora B on the midbody, preserved Aurora B levels in cells, and stabilized intercellular canals during delayed abscission. Genetic or pharmaceutical depletion of endogenous calmodulin significantly reduced Aurora B protein levels at the midbody resulting in tetraploidy and multi-spindle formation. The calmodulin inhibitor, calmidazolium, reduced Aurora B protein levels resulting in tetraploidy, mitotic arrest, and apoptosis of tumorigenic cells and profoundly inhibited tumor formation in athymic nude mice. These observations indicate molecular interplay between Aurora B and calmodulin in telophase and suggest that calmodulin acts as a checkpoint sensor for chromosomal segregation errors during mitosis. C1 [Mallampalli, Rama K.; Glasser, Jennifer R.; Coon, Tiffany A.; Chen, Bill B.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA. [Chen, Bill B.] Univ Pittsburgh, Acute Lung Injury Ctr Excellence, Pittsburgh, PA USA. [Mallampalli, Rama K.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA. RP Chen, BB (reprint author), Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA. EM chenb@upmc.edu FU US Department of Veterans Affairs; National Institutes of Health [HL116472, HL096376, HL097376, HL098174] FX We thank D. W. Gerlich for providing pH2B-mCherry-IRES-puro2 and pMyrPalm-mEGFP plasmids. This material is based upon work supported, in part, by the US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. This work was supported by a Merit Review Award from the US Department of Veterans Affairs and National Institutes of Health R01 grants HL116472 (to B. B. C.), HL096376, HL097376 and HL098174 (to R.K.M.). NR 65 TC 5 Z9 5 U1 0 U2 4 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1538-4101 J9 CELL CYCLE JI Cell Cycle PD FEB 15 PY 2013 VL 12 IS 4 BP 663 EP 673 DI 10.4161/cc.23586 PG 11 WC Cell Biology SC Cell Biology GA 089PR UT WOS:000314923000022 PM 23370391 ER PT J AU Stein, DJ Koenen, KC Friedman, MJ Hill, E McLaughlin, KA Petukhova, M Ruscio, AM Shahly, V Spiegel, D Borges, G Bunting, B Caldas-de-Almeida, JM de Girolamo, G Demyttenaere, K Florescu, S Haro, JM Karam, EG Kovess-Masfety, V Lee, S Matschinger, H Mladenova, M Posada-Villa, J Tachimori, H Viana, MC Kessler, RC AF Stein, Dan J. Koenen, Karestan C. Friedman, Matthew J. Hill, Eric McLaughlin, Katie A. Petukhova, Maria Ruscio, Ayelet Meron Shahly, Victoria Spiegel, David Borges, Guilherme Bunting, Brendan Caldas-de-Almeida, Jose Miguel de Girolamo, Giovanni Demyttenaere, Koen Florescu, Silvia Maria Haro, Josep Karam, Elie G. Kovess-Masfety, Viviane Lee, Sing Matschinger, Herbert Mladenova, Maya Posada-Villa, Jose Tachimori, Hisateru Viana, Maria Carmen Kessler, Ronald C. TI Dissociation in Posttraumatic Stress Disorder: Evidence from the World Mental Health Surveys SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Dissociation; dissociative subtype; DSM-5; epidemiology; nosology; posttraumatic stress disorder; World Mental Health Surveys ID NATIONAL COMORBIDITY SURVEY; ADULT PSYCHIATRIC-DISORDERS; CHILDHOOD ADVERSITIES; LATENT STRUCTURE; COMBAT VETERANS; PTSD; TRAUMA; EXPERIENCES; DSM-5; ABUSE AB Background: Although the proposal for a dissociative subtype of posttraumatic stress disorder (PTSD) in DSM-5 is supported by considerable clinical and neurobiological evidence, this evidence comes mostly from referred samples in Western countries. Cross-national population epidemiologic surveys were analyzed to evaluate generalizability of the subtype in more diverse samples. Methods: Interviews were administered to 25,018 respondents in 16 countries in the World Health Organization World Mental Health Surveys. The Composite International Diagnostic Interview was used to assess 12-month DSM-IV PTSD and other common DSM-IV disorders. Items from a checklist of past-month nonspecific psychological distress were used to assess dissociative symptoms of depersonalization and derealization. Differences between PTSD with and without these dissociative symptoms were examined across a variety of domains, including index trauma characteristics, prior trauma history, childhood adversity, sociodemographic characteristics, psychiatric comorbidity, functional impairment, and treatment seeking. Results: Dissociative symptoms were present in 14.4% of respondents with 12-month DSM-IV/Composite International Diagnostic Interview PTSD and did not differ between high and low/middle income countries. Symptoms of dissociation in PTSD were associated with high counts of re-experiencing symptoms and net of these symptom counts with male sex, childhood onset of PTSD, high exposure to prior (to the onset of PTSD) traumatic events and childhood adversities, prior histories of separation anxiety disorder and specific phobia, severe role impairment, and suicidality. Conclusion: These results provide community epidemiologic data documenting the value of the dissociative subtype in distinguishing a meaningful proportion of severe and impairing cases of PTSD that have distinct correlates across a diverse set of countries. C1 [Stein, Dan J.] Univ Cape Town, Dept Psychiat & Mental Hlth, ZA-7925 Cape Town, South Africa. [Koenen, Karestan C.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA. [Friedman, Matthew J.] US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, Hanover, NH USA. Geisel Sch Med Dartmouth, Hanover, NH USA. [Hill, Eric; Petukhova, Maria; Shahly, Victoria; Kessler, Ronald C.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. [McLaughlin, Katie A.] Harvard Univ, Sch Med, Div Gen Pediat, Childrens Hosp Boston, Boston, MA 02115 USA. [Ruscio, Ayelet Meron] Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA. [Spiegel, David] Stanford Univ, Dept Psychiat & Behav Sci, Sch Med, Stanford, CA 94305 USA. [Borges, Guilherme] Natl Inst Psychiat Mexico, Div Epidemiol & Psychosocial Res, Dept Epidemiol Res, Mexico City, DF, Mexico. Metropolitan Autonomous Univ, Mexico City, DF, Mexico. [Bunting, Brendan] Univ Ulster, Psychol Res Inst, Coleraine BT52 1SA, Londonderry, North Ireland. [Caldas-de-Almeida, Jose Miguel] Univ Nova Lisboa, Fac Ciencias Med, Chron Dis Res Ctr, P-1200 Lisbon, Portugal. [Caldas-de-Almeida, Jose Miguel] Univ Nova Lisboa, Fac Ciencias Med, Dept Mental Hlth, P-1200 Lisbon, Portugal. [de Girolamo, Giovanni] Ctr S Giovanni Dio Fatebenefratelli, Ist Ricovero & Cura Carattere Sci, Brescia, Italy. [Demyttenaere, Koen] Univ Hosp Gasthuisberg, Dept Psychiat, B-3000 Louvain, Belgium. [Florescu, Silvia] Natl Sch Publ Hlth Management & Profess Dev, Hlth Serv Res & Evaluat Ctr, Bucharest, Romania. [Maria Haro, Josep] Ctr Invest Biomed Red Salud Mental, Barcelona, Spain. [Karam, Elie G.] Balamand Univ, Fac Med, Inst Dev Res Advocacy & Appl Care, Med Inst Neuropsychol Disorders,St George Hosp Un, Beirut, Lebanon. [Kovess-Masfety, Viviane] Univ Paris 05, Equipes Accueil 4069, Paris, France. [Kovess-Masfety, Viviane] Ecole Hautes Etud Sante Publ, Sch Publ Hlth, Dept Epidemiol, Paris, France. [Lee, Sing] Chinese Univ Hong Kong, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China. [Matschinger, Herbert] Univ Leipzig, Inst Social Med Occupat Hlth & Publ Hlth, Publ Hlth Res Unit, D-04109 Leipzig, Germany. [Mladenova, Maya] New Bulgarian Univ, Sofia, Bulgaria. [Posada-Villa, Jose] Pontificia Univ Javeriana, Inst Colombiano Sistema Nervioso, Bogota, Colombia. [Tachimori, Hisateru] Natl Ctr Neurol & Psychiat, Natl Inst Mental Hlth, Tokyo, Japan. [Viana, Maria Carmen] Univ Fed Espirito Santo, Dept Social Med, Vitoria, Brazil. RP Kessler, RC (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA. EM Kessler@hcp.med.harvard.edu RI Lee, Sing/O-2136-2015; Haro, Josep Maria/D-1423-2011; Stein, Dan/A-1752-2008; Faculdade de Ciencias Medicas, Nova Medical School/K-6209-2013 OI Haro, Josep Maria/0000-0002-3984-277X; Stein, Dan/0000-0001-7218-7810; Viana, Maria Carmen/0000-0002-0464-4845; caldas de almeida, jose miguel/0000-0003-1902-6772; Borges, Guilherme/0000-0002-3269-0507; McLaughlin, Katie/0000-0002-1362-2410 FU United States National Institute of Mental Health [R01MH070884]; John D. and Catherine T. MacArthur Foundation; Pfizer Foundation; US Public Health Service [R13-MH066849, R01-MH069864, R01-MH092526, R01-DA016558]; Fogarty International Center [FIRCA R03-TW006481]; Pan American Health Organization; Eli Lilly & Company Foundation; Ortho-McNeil Pharmaceutical, Inc.; GlaxoSmithKline; Bristol-Myers Squibb; Shire Pharmaceuticals; State of Sao Paulo Research Foundation [03/00204-3]; Ministry of Health; National Center for Public Health Protection; Ministry of Social Protection; European Commission [QLG5-1999-01042, SANCO 2004123]; Piedmont Region (Italy); Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III, Spain [FIS 00/0028]; Ministerio de Ciencia y Tecnologia, Spain [SAF 2000-158-CE]; Departament de Salut, Generalitat de Catalunya, Spain, Instituto de Salud Carlos III [CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP]; Japan Ministry of Health, Labour and Welfare [H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013]; Lebanese Ministry of Public Health; World Health Organization (Lebanon), National Institute of Health/Fogarty International Center [R03 TW006481-01]; Astra Zeneca; Eli Lilly; Hikma Pharm; Janssen Cilag; MSD; Novartis; Pfizer; Sanofi Aventis; Servier; National Institute of Psychiatry Ramon de la Fuente [INPRFMDIES 4280]; National Council on Science and Technology [CONACyT-G30544-H]; PanAmerican Health Organization; Health & Social Care Research & Development Division of the Public Health Agency; Champalimaud Foundation; Gulbenkian Foundation; Foundation for Science and Technology; National Institute of Statistics-National Centre for Training in Statistics, Statistics [70]; Ministry of Public Health; Eli Lilly Romania Societate cu Responsabilitate Limitata; National Institute of Mental Health [U01-MH60220]; National Institute of Drug Abuse; Substance Abuse and Mental Health Services Administration; Robert Wood Johnson Foundation [044708]; John W. Alden Trust; Abbott; Eli-Lilly; Jazz Pharmaceuticals; Johnson Johnson; Lundbeck; Orion; Pharmacia; Roche; Solvay; Sumitomo; Takeda; Tikvah; Wyeth; AstraZeneca; EliLilly; Analysis Group Inc.; Eli Lilly Company; EPI-Q; Johnson & Johnson Pharmaceuticals; Ortho-McNeil Janssen Scientific Affairs.; Pfizer Inc.; Sanofi-Aventis Groupe; Shire US, Inc. FX The research reported here was carried out in conjunction with the World Health Organization World Mental Health (WMH) Survey Initiative. These activities were supported by the United States National Institute of Mental Health (R01MH070884), the John D. and Catherine T. MacArthur Foundation, the Pfizer Foundation, the US Public Health Service (R13-MH066849, R01-MH069864, R01-MH092526, and R01-DA016558), the Fogarty International Center (FIRCA R03-TW006481), the Pan American Health Organization, the Eli Lilly & Company Foundation, Ortho-McNeil Pharmaceutical, Inc., GlaxoSmithKline, Bristol-Myers Squibb, and Shire Pharmaceuticals. The Sao Paulo Megacity Mental Health Survey is supported by the State of Sao Paulo Research Foundation Thematic Project Grant 03/00204-3. The Bulgarian Epidemiological Study of common mental disorders is supported by the Ministry of Health and the National Center for Public Health Protection. The Beijing, Peoples Republic of China World Mental Health Survey Initiative is supported by the Pfizer Foundation. The Colombian National Study of Mental Health is supported by the Ministry of Social Protection. The European Study of the Epidemiology of Mental Disorders project is funded by the European Commission (Contracts QLG5-1999-01042; SANCO 2004123), the Piedmont Region (Italy), Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III, Spain (FIS 00/0028), Ministerio de Ciencia y Tecnologia, Spain (SAF 2000-158-CE), Departament de Salut, Generalitat de Catalunya, Spain, Instituto de Salud Carlos III (CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP), and other local agencies and by an unrestricted educational grant from GlaxoSmithKline. The World Mental Health Japan Survey is supported by the Grant for Research on Psychiatric and Neurological Diseases and Mental Health (H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013) from the Japan Ministry of Health, Labour and Welfare. The Lebanese National Mental Health Survey (Lebanese Evaluation of the Burden of Ailments and Needs Of the Nation) is supported by the Lebanese Ministry of Public Health, the World Health Organization (Lebanon), National Institute of Health/Fogarty International Center (R03 TW006481-01), anonymous private donations to the Institute for Development, Research, Advocacy & Applied Care, Lebanon, and unrestricted Grants from Astra Zeneca, Eli Lilly, GlaxoSmithKline, Hikma Pharm, Janssen Cilag, MSD, Novartis, Pfizer, Sanofi Aventis, and Servier. The Mexican National Comorbidity Survey is supported by The National Institute of Psychiatry Ramon de la Fuente (INPRFMDIES 4280) and by the National Council on Science and Technology (CONACyT-G30544-H), with supplemental support from the PanAmerican Health Organization. The Northern Ireland Study of Mental Health was funded by the Health & Social Care Research & Development Division of the Public Health Agency. The Portuguese Mental Health Study was carried out by the Department of Mental Health, Faculty of Medical Sciences, NOVA University of Lisbon, with collaboration of the Portuguese Catholic University, and was funded by Champalimaud Foundation, Gulbenkian Foundation, Foundation for Science and Technology and Ministry of Health.; The Romania WMH study projects ''Policies in Mental Health Area'' and ''National Study regarding Mental Health and Services Use'' were carried out by National School of Public Health & Health Services Management (former National Institute for Research & Development in Health), with technical support of Metro Media Transilvania, the National Institute of Statistics-National Centre for Training in Statistics, Statistics Contract 70, Cheyenne Services Societate cu Responsabilitate Limitata, Statistics Netherlands and were funded by Ministry of Public Health (former Ministry of Health) with supplemental support of Eli Lilly Romania Societate cu Responsabilitate Limitata. The US National Comorbidity Survey Replication is supported by the National Institute of Mental Health (U01-MH60220) with supplemental support from the National Institute of Drug Abuse, the Substance Abuse and Mental Health Services Administration, the Robert Wood Johnson Foundation (Grant 044708), and the John W. Alden Trust.; Dr. Stein has received research grants and/or consultancy honoraria from Abbott, Astra Zeneca, Eli-Lilly, GlaxoSmithKline, Jazz Pharmaceuticals, Johnson & Johnson, Lundbeck, Orion, Pfizer, Pharmacia, Roche, Servier, Solvay, Sumitomo, Takeda, Tikvah, and Wyeth. Dr. Demyttenaere has served on advisory boards and speaker bureaus for and has research grants from AstraZeneca, EliLilly, GlaxoSmithKline, Lundbeck, Takeda, and Servier. Dr. Haro has been a consultant for AstraZeneca, Eli Lilly and Co., and Lundbeck. Dr. Kessler has been a consultant for AstraZeneca, Analysis Group, Bristol-Myers Squibb, Cerner-Galt Associates, Eli Lilly & Company, GlaxoSmithKline Inc., HealthCore Inc., Health Dialog, Integrated Benefits Institute, John Snow Inc., Kaiser Permanente, Matria Inc., Mensante, Merck & Co Inc., Ortho-McNeil Janssen Scientific Affairs, Pfizer Inc., Primary Care Network, Research Triangle Institute, Sanofi-Aventis Groupe, Shire US Inc., SRA International Inc., Takeda Global Research & Development, Transcept Pharmaceuticals Inc., and Wyeth-Ayerst; has served on advisory boards for Appliance Computing II, Eli Lilly & Company, Mindsite, Ortho-McNeil Janssen Scientific Affairs, Plus One Health Management, and Wyeth-Ayerst; and has had research support for his epidemiological studies from Analysis Group Inc., Bristol-Myers Squibb, Eli Lilly & Company, EPI-Q, GlaxoSmithKline, Johnson & Johnson Pharmaceuticals, Ortho-McNeil Janssen Scientific Affairs., Pfizer Inc., Sanofi-Aventis Groupe, and Shire US, Inc. Drs. Koenen and Friedman, Mr. Hill, and Drs. McLaughlin, Petukhova, Ruscio, Shahly, Spiegel, Borges, Bunting, Caldas-de-Almeida, de Girolamo, Florescu, Karam, Kovess-Masfety, Lee, Matschinger, Mladenova, Posada-Villa, Tachimori, and Viana report no biomedical financial interests or potential conflicts of interest. NR 60 TC 68 Z9 68 U1 3 U2 60 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD FEB 15 PY 2013 VL 73 IS 4 BP 302 EP 312 DI 10.1016/j.biopsych.2012.08.022 PG 11 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 085SG UT WOS:000314634000004 PM 23059051 ER PT J AU Ahearn, EP Chen, P Hertzberg, M Cornette, M Suvalsky, L Cooley-Olson, D Swanlund, J Eickhoff, J Becker, T Krahn, D AF Ahearn, Eileen P. Chen, Peijun Hertzberg, Michael Cornette, Michelle Suvalsky, Lori Cooley-Olson, Deanna Swanlund, Jamie Eickhoff, Jens Becker, Tara Krahn, Dean TI Suicide attempts in veterans with bipolar disorder during treatment with lithium, divalproex, and atypical antipsychotics SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Bipolar; Suicide; Atypical antipsychotics ID SCHIZOPHRENIA-PATIENTS; CLOZAPINE TREATMENT; BEHAVIOR; TRIAL; RISK; PHARMACOTHERAPY; HALOPERIDOL; RISPERIDONE; AGGRESSION; PREVENTION AB Suicide attempt rates were assessed in 1306 subjects in this 6 year retrospective study of Bipolar disorder. Participants were Veterans from 5 different Veterans Administration Hospitals who met criteria for bipolar type 1 or 2 and who had at least one prescription for lithium or divalproex or both during the study period. This study focused on the impact of atypical antipsychotics on the suicide attempt rate when used in addition to or in place of lithium or divalproex. Medication exposure was calculated using computerized pharmacy records. Suicide attempts were established through chart review including emergency room records, inpatient records, and outpatient records. There were a total of 117 suicide attempts and 2 suicide completions during the study period. Most attempts (59%) occurred when patients were on no medications. Nearly 90% of subjects spent an average of 45 months during the 6 year period on none of the aforementioned medications. The lowest percentage of suicide attempts (15%) occurred while on lithium, 21% while on divalproex and 24% while on atypical antipsychotics. When total months of exposure were taken into account, the lowest attempt rate occurred on lithium plus divalproex (6.3 attempts per 10,000 months of exposure), followed by divalproex alone (7.0 attempts/10,000 months of exposure), and lithium alone (7.7 attempts per 10,000 months of exposure). Patients on atypical antipsychotics alone had an attempt rate of 26.1 attempts per 10,000 months of exposure. In this study, lithium and divalproex provided protection against suicide attempts. Results need to be replicated in future prospective studies and clearly strategies for improving medication compliance among veterans are warranted. Published by Elsevier B.V. C1 [Ahearn, Eileen P.; Cooley-Olson, Deanna; Swanlund, Jamie; Krahn, Dean] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. [Ahearn, Eileen P.; Eickhoff, Jens; Becker, Tara; Krahn, Dean] Univ Wisconsin, Madison, WI USA. [Chen, Peijun] Louis Stokes Cleveland VA Med Ctr, Cleveland, OH USA. [Chen, Peijun] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Hertzberg, Michael] Durham VA Med Ctr, Durham, NC USA. [Hertzberg, Michael] Duke Univ, Med Ctr, Durham, NC 27706 USA. [Cornette, Michelle] Med Coll Wisconsin, Milwaukee, WI USA. [Suvalsky, Lori] Minneapolis VA Med Ctr, Minneapolis, MN USA. RP Ahearn, EP (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA. EM Eileen.Ahearn@va.gov FU American Foundation for Suicide Prevention FX This work was supported by a grant from the American Foundation for Suicide Prevention. The Foundation had no direct involvement in the study other than to provide funding. NR 30 TC 9 Z9 11 U1 1 U2 21 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD FEB 15 PY 2013 VL 145 IS 1 BP 77 EP 82 DI 10.1016/j.jad.2012.07.015 PG 6 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 078IK UT WOS:000314091800011 PM 22871534 ER PT J AU Harkness, JH Hitzemann, RJ Edmunds, S Phillips, TJ AF Harkness, John H. Hitzemann, Robert J. Edmunds, Stephanie Phillips, Tamara J. TI Effects of sodium butyrate on methamphetamine-sensitized locomotor activity SO BEHAVIOURAL BRAIN RESEARCH LA English DT Article DE Sensitization; Psychostimulant; Histone acetylation; Epigenetics; Addiction ID INDUCED BEHAVIORAL SENSITIZATION; HISTONE DEACETYLASE INHIBITORS; INCENTIVE-SENSITIZATION; GENE-EXPRESSION; INBRED MICE; DELTA-FOSB; ADDICTION; COCAINE; MECHANISMS; STIMULATION AB Neuroadaptations associated with behavioral sensitization induced by repeated exposure to methamphetamine (MA) appear to be involved in compulsive drug pursuit and use. Increased histone acetylation, an epigenetic effect resulting in altered gene expression, may promote sensitized responses to psychostimulants. The role of histone acetylation in the expression and acquisition of MA-induced locomotor sensitization was examined by measuring the effect of histone deacetylase inhibition by sodium butyrate (NaB). For the effect on expression, mice were treated repeatedly with MA (10 days of 2 mg/kg MA) or saline (10 days), and then vehicle or NaB (630 mg/kg, intraperitoneally) was administered 30 min prior to MA challenge and locomotor response was measured. NaB treatment increased the locomotor response to MA in both acutely MA treated and sensitized animals. For acquisition, NaB was administered 30 min prior to each MA exposure (10 days of 1 or 2 mg/kg), but not prior to the MA challenge test. Treatment with NaB during the sensitization acquisition period significantly increased locomotor activation by MA in sensitized mice only. NaB alone did not significantly alter locomotor activity. Acute NaB or MA, but not the combination, increased striatal acetylation at histone H4. Repeated treatment with MA, but not NaB or MA plus NaB, increased striatal acetylation at histone H3. Although increased histone acetylation may alter the expression of genes involved in acute locomotor response to MA and in the acquisition of MA-induced sensitization, results for acetylation at H3 and H4 showed little correspondence with behavior. Published by Elsevier B.V. C1 [Harkness, John H.; Hitzemann, Robert J.; Edmunds, Stephanie; Phillips, Tamara J.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. [Harkness, John H.; Hitzemann, Robert J.; Phillips, Tamara J.] Oregon Hlth & Sci Univ, Methamphetamine Abuse Res Ctr, Portland, OR 97239 USA. [Hitzemann, Robert J.; Edmunds, Stephanie; Phillips, Tamara J.] Portland VA Med Ctr, Portland, OR 97239 USA. RP Phillips, TJ (reprint author), VA Med Ctr, R&D32,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM harknesj@ohsu.edu; hitzeman@ohsu.edu; edmundss@ohsu.edu; phillipt@ohsu.edu FU Department of Veterans Affairs, and NIDA/NIH [T32DA07262, P50DA018165] FX This work was supported by the Department of Veterans Affairs, and NIDA/NIH grants T32DA07262 and P50DA018165. Thank you to James Stafford for helpful discussions regarding the IHC procedure and interpretation. NR 43 TC 6 Z9 6 U1 0 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-4328 EI 1872-7549 J9 BEHAV BRAIN RES JI Behav. Brain Res. PD FEB 15 PY 2013 VL 239 BP 139 EP 147 DI 10.1016/j.bbr.2012.10.046 PG 9 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA 079CA UT WOS:000314146600017 PM 23137698 ER PT J AU Levine, AJ Miller, JA Shapshak, P Gelman, B Singer, EJ Hinkin, CH Commins, D Morgello, S Grant, I Horvath, S AF Levine, Andrew J. Miller, Jeremy A. Shapshak, Paul Gelman, Benjamin Singer, Elyse J. Hinkin, Charles H. Commins, Deborah Morgello, Susan Grant, Igor Horvath, Steve TI Systems analysis of human brain gene expression: mechanisms for HIV-associated neurocognitive impairment and common pathways with Alzheimer's disease SO BMC MEDICAL GENOMICS LA English DT Article DE HIV encephalitis; HIV-associated dementia; HIV-associated neurocognitive disorder; Weighted gene coexpression network analysis; WGCNA; CNS penetration effectiveness; National neuroAIDS tissue consortium; Coexpression module ID COEXPRESSION NETWORK ANALYSIS; HUMAN-IMMUNODEFICIENCY-VIRUS; NEUROAIDS TISSUE CONSORTIUM; CENTRAL-NERVOUS-SYSTEM; ANTIRETROVIRAL THERAPY; AIDS DEMENTIA; CNS PENETRATION; BASAL GANGLIA; WHITE-MATTER; TRANSCRIPTOME AB Background: Human Immunodeficiency Virus-1 (HIV) infection frequently results in neurocognitive impairment. While the cause remains unclear, recent gene expression studies have identified genes whose transcription is dysregulated in individuals with HIV-association neurocognitive disorder (HAND). However, the methods for interpretation of such data have lagged behind the technical advances allowing the decoding genetic material. Here, we employ systems biology methods novel to the field of NeuroAIDS to further interrogate extant transcriptome data derived from brains of HIV + patients in order to further elucidate the neuropathogenesis of HAND. Additionally, we compare these data to those derived from brains of individuals with Alzheimer's disease (AD) in order to identify common pathways of neuropathogenesis. Methods: In Study 1, using data from three brain regions in 6 HIV-seronegative and 15 HIV + cases, we first employed weighted gene co-expression network analysis (WGCNA) to further explore transcriptome networks specific to HAND with HIV-encephalitis (HIVE) and HAND without HIVE. We then used a symptomatic approach, employing standard expression analysis and WGCNA to identify networks associated with neurocognitive impairment (NCI), regardless of HIVE or HAND diagnosis. Finally, we examined the association between the CNS penetration effectiveness (CPE) of antiretroviral regimens and brain transcriptome. In Study 2, we identified common gene networks associated with NCI in both HIV and AD by correlating gene expression with pre-mortem neurocognitive functioning. Results: Study 1: WGCNA largely corroborated findings from standard differential gene expression analyses, but also identified possible meta-networks composed of multiple gene ontology categories and oligodendrocyte dysfunction. Differential expression analysis identified hub genes highly correlated with NCI, including genes implicated in gliosis, inflammation, and dopaminergic tone. Enrichment analysis identified gene ontology categories that varied across the three brain regions, the most notable being downregulation of genes involved in mitochondrial functioning. Finally, WGCNA identified dysregulated networks associated with NCI, including oligodendrocyte and mitochondrial functioning. Study 2: Common gene networks dysregulated in relation to NCI in AD and HIV included mitochondrial genes, whereas upregulation of various cancer-related genes was found. Conclusions: While under-powered, this study identified possible biologically-relevant networks correlated with NCI in HIV, and common networks shared with AD, opening new avenues for inquiry in the investigation of HAND neuropathogenesis. These results suggest that further interrogation of existing transcriptome data using systems biology methods can yield important information. C1 [Levine, Andrew J.; Singer, Elyse J.] Univ Calif Los Angeles, David Geffen Sch Med, Natl Neurol AIDS Bank, Dept Neurol, Los Angeles, CA 90095 USA. [Miller, Jeremy A.; Horvath, Steve] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Shapshak, Paul] Univ S Florida, Morsani Coll Med, Dept Med, Div Infect Dis & Int Med, Tampa, FL USA. [Shapshak, Paul] Univ S Florida, Morsani Coll Med, Dept Psychiat & Behav Med, Tampa, FL USA. [Gelman, Benjamin] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA. [Gelman, Benjamin] Univ Texas Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA. [Hinkin, Charles H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Hinkin, Charles H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Commins, Deborah] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA. [Morgello, Susan] Mt Sinai Sch Med, Manhattan HIV Brain Bank, Dept Neurol, New York, NY USA. [Morgello, Susan] Mt Sinai Sch Med, Manhattan HIV Brain Bank, Dept Neurosci, New York, NY USA. [Morgello, Susan] Mt Sinai Sch Med, Manhattan HIV Brain Bank, Dept Pathol, New York, NY USA. [Grant, Igor] Univ Calif San Diego, Dept Psychiat, Calif NeuroAIDS Tissue Network, San Diego, CA 92103 USA. [Horvath, Steve] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA USA. RP Levine, AJ (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Natl Neurol AIDS Bank, Dept Neurol, Los Angeles, CA 90095 USA. EM ajlevine@mednet.ucla.edu FU National NeuroAIDS Tissue Consortium; National Neurological AIDS Bank [U01-MH08021, R24-NS38841]; Texas NeuroAIDS Research Center [U01-MH083507, R24-NS45491]; Manhattan HIV Brain Bank [U01-MH083501, R24-MH59724]; California NeuroAIDS Tissue Network [U01-MH083506, R24-MH59745]; National Institute for Drug Abuse [R01DA030913] FX This study was funded in through the National NeuroAIDS Tissue Consortium, which consists of National Neurological AIDS Bank (U01-MH08021 and R24-NS38841 - Singer), Texas NeuroAIDS Research Center (U01-MH083507 and R24-NS45491 - Gelman), Manhattan HIV Brain Bank (U01-MH083501 and R24-MH59724 - Morgello), and California NeuroAIDS Tissue Network (U01-MH083506 and R24-MH59745 - Grant). Funding was also provided by the National Institute for Drug Abuse grant R01DA030913 (Levine & Horvath). NR 91 TC 13 Z9 14 U1 2 U2 16 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1755-8794 J9 BMC MED GENOMICS JI BMC Med. Genomics PD FEB 13 PY 2013 VL 6 AR 4 DI 10.1186/1755-8794-6-4 PG 20 WC Genetics & Heredity SC Genetics & Heredity GA 124MF UT WOS:000317467800001 PM 23406646 ER PT J AU Kullgren, JT Volpp, KG Polsky, D AF Kullgren, Jeffrey T. Volpp, Kevin G. Polsky, Daniel TI Are the Healthy Behaviors of US High-Deductible Health Plan Enrollees Driven by People Who Chose These Plans? Smoking as a Case Study SO PLOS ONE LA English DT Article ID ANTE MORAL HAZARD; EMPLOYEE CHOICE; POPULATION; ENROLLMENT; INSURANCE; BENEFITS AB Purpose: To determine whether negative associations between enrollment in a high-deductible health plan (HDHP) and one exemplar unhealthy behavior - daily smoking - are found only among people who chose these plans. Design: Cross-sectional analysis of nationally-representative data. Setting: United States from 2007 to 2008. Subjects: 6,941 privately insured non-elderly adult participants in the 2007 Health Tracking Household Survey. Measures: Self-reported smoking status. Analysis: We classified subjects as HDHP or traditional health plan enrollees with employer-sponsored insurance (ESI) and no choice of plans, ESI with a choice of plans, or coverage through the non-group market. We used multivariate logistic regression to measure associations between HDHP enrollment and daily smoking within each of the 3 coverage source groups while controlling for potential confounders. Results: HDHP enrollment was associated with lower odds of smoking among individuals with ESI and a choice of plans (AOR 0.55, 95% CI 0.33-0.90) and those with non-group coverage (AOR 0.64, 95% CI 0.34-1.22), though the latter association was not statistically significant. HDHP enrollment was not associated with lower odds of smoking among individuals with ESI and no choice of plans (AOR 1.04, 95% CI 0.69-1.56). Conclusions: HDHP enrollment is associated with lower odds of smoking only among individuals who chose to enroll in an HDHP. Lower rates of unhealthy behaviors among HDHP enrollees may be a reflection of individuals who choose these plans. C1 [Kullgren, Jeffrey T.] Vet Affairs Ann Arbor Healthcare Syst, Vet Affairs Ctr Clin Management Res, Ann Arbor, MI USA. [Kullgren, Jeffrey T.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA. [Kullgren, Jeffrey T.] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA. [Volpp, Kevin G.; Polsky, Daniel] Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA. [Volpp, Kevin G.; Polsky, Daniel] Penn Carnegie Mellon Univ, Roybal Ctr Behav Econ & Hlth P30, Philadelphia, PA USA. [Volpp, Kevin G.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. [Volpp, Kevin G.; Polsky, Daniel] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Volpp, Kevin G.; Polsky, Daniel] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA. RP Kullgren, JT (reprint author), Vet Affairs Ann Arbor Healthcare Syst, Vet Affairs Ctr Clin Management Res, Ann Arbor, MI USA. EM jkullgre@med.umich.edu FU US Department of Veterans Affairs; Robert Wood Johnson Foundation FX The US Department of Veterans Affairs and the Robert Wood Johnson Foundation funded the study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. These contents do not represent the views of the Department of Veterans Affairs, the United States Government, or the Robert Wood Johnson Foundation. NR 32 TC 1 Z9 1 U1 1 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 13 PY 2013 VL 8 IS 2 AR e56154 DI 10.1371/journal.pone.0056154 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 104DM UT WOS:000315970300120 PM 23418528 ER PT J AU Foreman, P Van Cott, A Pugh, MJ AF Foreman, Perry Van Cott, Anne Pugh, Mary Jo TI Increased Mortality in Elderly Veterans Diagnosed with Epilepsy SO NEUROLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN) CY MAR 16-23, 2013 CL San Diego, CA SP Amer Acad Neurol C1 [Foreman, Perry] Sinai Hosp, Berman Brain & Spine Inst, Baltimore, MD 21215 USA. [Van Cott, Anne] Univ Pittsburgh, Pittsburgh, PA USA. [Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Pugh, Mary Jo] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD FEB 12 PY 2013 VL 80 SU S MA P03117 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA AB8VR UT WOS:000332068602086 ER PT J AU Goetz, C Stebbins, G Chung, K Hauser, R Miyasaki, J Nicholas, A Poewe, W Seppi, K Rascol, O Stacy, M Nutt, J Tanner, C Urkowitz, A Jaglin, J Ge, S AF Goetz, Christopher Stebbins, Glenn Chung, Kathryn Hauser, Robert Miyasaki, Janis Nicholas, Anthony Poewe, Werner Seppi, Klaus Rascol, Olivier Stacy, Mark Nutt, John Tanner, Caroline Urkowitz, Alison Jaglin, Jean Ge, Song TI No PD Dyskinesia Scale Protects Against Placebo Responses: A Comparison of Multiple Scales SO NEUROLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN) CY MAR 16-23, 2013 CL San Diego, CA SP Amer Acad Neurol C1 [Goetz, Christopher] Rush Univ, Med Ctr, Neurol Sci Movement Disorder Sect, Chicago, IL 60612 USA. [Stebbins, Glenn; Jaglin, Jean; Ge, Song] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Chung, Kathryn] Oregon Hlth & Sci Univ, Lake Oswego, OR USA. [Chung, Kathryn] Portland VA Med Ctr, Lake Oswego, OR USA. [Hauser, Robert] Univ S Florida, Tampa, FL USA. [Miyasaki, Janis] Univ Toronto, Edmond J Safra Program Parkinsons Dis, Toronto, ON, Canada. [Nicholas, Anthony] Univ Alabama Birmingham, Birmingham, AL USA. [Nicholas, Anthony] Birmingham VA Med Ctr, Birmingham, AL USA. [Poewe, Werner; Seppi, Klaus] Med Univ Innsbruck, A-6020 Innsbruck, Austria. [Rascol, Olivier] Univ Hosp Toulouse, Clin Invest Ctr CIC9302, Toulouse, France. [Rascol, Olivier] Univ Hosp Toulouse, Dept Clin Pharmacol, INSERM, Toulouse, France. [Rascol, Olivier] Univ Hosp Toulouse, Dept Neurosci, INSERM, Toulouse, France. [Rascol, Olivier] Univ Toulouse 3, F-31062 Toulouse, France. [Stacy, Mark] Duke Univ, Durham, NC USA. [Nutt, John] Oregon Hlth & Sci Univ, Portland, OR USA. [Nutt, John] Portland VA Med Ctr, Portland, OR USA. [Tanner, Caroline] Parkinsons Inst & Clin Ctr, Sunnyvale, CA USA. [Urkowitz, Alison] Michael J Fox Fdn Parkinsons Res, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD FEB 12 PY 2013 VL 80 SU S MA P04187 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA AB8VR UT WOS:000332068603076 ER PT J AU Hellman, A Duda, J Morley, J AF Hellman, Amy Duda, John Morley, James TI Continuous Non-Invasive Arterial Pressure Monitoring To Detect Autonomic Dysfunction in Parkinson's Disease SO NEUROLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN) CY MAR 16-23, 2013 CL San Diego, CA SP Amer Acad Neurol C1 [Hellman, Amy; Duda, John; Morley, James] Univ Penn, Sch Med, Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA 19104 USA. [Hellman, Amy; Duda, John; Morley, James] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD FEB 12 PY 2013 VL 80 SU S MA P06101 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA AB8VR UT WOS:000332068604169 ER PT J AU Hsiao, J Lee, G Lu, P Teng, E AF Hsiao, Julia Lee, Grace Lu, Po Teng, Edmond TI Longitudinal Declines in Instrumental Activities of Daily Living in Stable and Progressive Mild Cognitive Impairment SO NEUROLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN) CY MAR 16-23, 2013 CL San Diego, CA SP Amer Acad Neurol C1 [Hsiao, Julia] VA Greater Los Angeles Healthcare Syst, Neurol, Los Angeles, CA USA. [Lee, Grace; Teng, Edmond] Univ Calif Los Angeles, Los Angeles, CA USA. [Lu, Po] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Teng, Edmond] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD FEB 12 PY 2013 VL 80 SU S MA P07154 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA AB8VR UT WOS:000332068605136 ER PT J AU Joshi, A Teng, E Tassniyom, K Shapira, J Mendez, M AF Joshi, Aditi Teng, Edmond Tassniyom, Kanida Shapira, Jill Mendez, Mario TI Hippocampal and Medial Temporal Sclerosis in Behavioral Variant Frontotemporal Dementia SO NEUROLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN) CY MAR 16-23, 2013 CL San Diego, CA SP Amer Acad Neurol C1 [Joshi, Aditi; Shapira, Jill; Mendez, Mario] Univ Calif Los Angeles, Los Angeles, CA USA. [Teng, Edmond] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Tassniyom, Kanida] Khon Kaen Univ, Khon Kaen, Thailand. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD FEB 12 PY 2013 VL 80 SU S MA S44007 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA AB8VR UT WOS:000332068606222 ER PT J AU Joshi, A Shapiro, D Jimenez, E Mather, M Shapira, J Kaiser, N Mendez, M AF Joshi, Aditi Shapiro, David Jimenez, Elvira Mather, Michelle Shapira, Jill Kaiser, Natalie Mendez, Mario TI Auditory Startle in Behavioral Variant Frontotemporal Dementia Compared to Alzheimer's Disease and Healthy Controls SO NEUROLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN) CY MAR 16-23, 2013 CL San Diego, CA SP Amer Acad Neurol C1 [Joshi, Aditi; Mather, Michelle] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Jimenez, Elvira; Shapira, Jill; Mendez, Mario] Univ Calif Los Angeles, Los Angeles, CA USA. [Kaiser, Natalie] VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD FEB 12 PY 2013 VL 80 SU S MA P07167 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA AB8VR UT WOS:000332068605149 ER PT J AU Kraakevik, J Heath, S AF Kraakevik, Jeff Heath, Susan TI My Parkinson's Story: A Novel Format For a Patient Education Video Series SO NEUROLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN) CY MAR 16-23, 2013 CL San Diego, CA SP Amer Acad Neurol C1 [Kraakevik, Jeff] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Heath, Susan] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD FEB 12 PY 2013 VL 80 SU S MA P04257 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA AB8VR UT WOS:000332068603146 ER PT J AU Kremen, S Tassniyom, K Mendez, M Teng, E AF Kremen, Sarah Tassniyom, Kanida Mendez, Mario Teng, Edmond TI Extrapyramidal Signs in Primary Progressive Aphasia: Analyses of the NACC UDS Cohort SO NEUROLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN) CY MAR 16-23, 2013 CL San Diego, CA SP Amer Acad Neurol C1 [Kremen, Sarah] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Kremen, Sarah] Univ Calif Los Angeles, Easton Alzheimers Dis Res Ctr, Los Angeles, CA USA. [Tassniyom, Kanida] Khon Kaen Univ, Fac Med, Dept Psychiat, Khon Kaen, Thailand. [Mendez, Mario; Teng, Edmond] Greater Los Angeles VA Med Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD FEB 12 PY 2013 VL 80 SU S MA P06071 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA AB8VR UT WOS:000332068604139 ER PT J AU Pantelyat, A Freedman, R Pawlowski, S Kesari, A Duda, J Morley, J AF Pantelyat, Alexander Freedman, Rebecca Pawlowski, Stephanie Kesari, Adhithi Duda, John Morley, James TI Quantitative Assessment of Bradykinesia in Parkinson's Disease (PD) SO NEUROLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN) CY MAR 16-23, 2013 CL San Diego, CA SP Amer Acad Neurol C1 [Pantelyat, Alexander; Duda, John; Morley, James] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Freedman, Rebecca; Kesari, Adhithi] Univ Penn, Philadelphia, PA USA. [Pawlowski, Stephanie] Philadelphia VA Med Ctr PADRECC, Philadelphia, PA USA. [Morley, James] Hosp Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD FEB 12 PY 2013 VL 80 SU S MA P04192 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA AB8VR UT WOS:000332068603081 ER PT J AU Peterson, A Murchison, C Zabetian, C Leverenz, J Watson, G Montine, T Carney, N Bowman, G Quinn, J AF Peterson, Amie Murchison, Charles Zabetian, Cyrus Leverenz, James Watson, G. Montine, Thomas Carney, Natasha Bowman, Gene Quinn, Joseph TI The Relationship between Vitamin D and Cognitive Performance in Persons with Parkinson's SO NEUROLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN) CY MAR 16-23, 2013 CL San Diego, CA SP Amer Acad Neurol C1 [Peterson, Amie] Portland VA OHSU, Portland, OR USA. [Murchison, Charles] OHSU, Portland, OR USA. [Zabetian, Cyrus] Univ Washington, Seattle, WA 98195 USA. [Leverenz, James] Univ Washington, Seattle, WA 98195 USA. [Watson, G.] Univ Washington, VA Puget Sound, Seattle, WA 98195 USA. [Montine, Thomas] Univ Washington, Bellevue, WA USA. [Carney, Natasha] Portland VA, Portland, OR USA. [Bowman, Gene; Quinn, Joseph] OHSU, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD FEB 12 PY 2013 VL 80 SU S MA P04170 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA AB8VR UT WOS:000332068603059 ER PT J AU Corrales-Medina, VF Musher, DM Shachkina, S Chirinos, JA AF Corrales-Medina, Vicente F. Musher, Daniel M. Shachkina, Svetlana Chirinos, Julio A. TI Acute pneumonia and the cardiovascular system SO LANCET LA English DT Review ID COMMUNITY-ACQUIRED PNEUMONIA; ANGIOTENSIN-CONVERTING ENZYME; ACUTE CORONARY SYNDROMES; THROMBOSIS-INDUCING ACTIVITY; SHORT-TERM MORTALITY; ACUTE KIDNEY INJURY; RISK-FACTORS; BACTERIAL PNEUMONIA; NATRIURETIC PEPTIDE; PNEUMOCOCCAL PNEUMONIA AB Although traditionally regarded as a disease confined to the lungs, acute pneumonia has important effects on the cardiovascular system at all severities of infection. Pneumonia tends to affect individuals who are also at high cardiovascular risk. Results of recent studies show that about a quarter of adults admitted to hospital with pneumonia develop a major acute cardiac complication during their hospital stay, which is associated with a 60% increase in short-term mortality. These findings suggest that outcomes of patients with pneumonia can be improved by prevention of the development and progression of associated cardiac complications. Before this hypothesis can be tested, however, an adequate mechanistic understanding of the cardiovascular changes that occur during pneumonia, and their role in the trigger of various cardiac complications, is needed. In this Review, we summarise knowledge about the burden of cardiac complications in adults with acute pneumonia, the cardiovascular response to this infection, the potential effects of commonly used cardiovascular and anti-infective drugs on these associations, and possible directions for future research. C1 [Corrales-Medina, Vicente F.; Shachkina, Svetlana] Univ Ottawa, Dept Med, Ottawa, ON K1Y 4E9, Canada. [Corrales-Medina, Vicente F.; Shachkina, Svetlana] Ottawa Hosp, Res Inst, Ottawa, ON, Canada. [Musher, Daniel M.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Musher, Daniel M.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. [Musher, Daniel M.] Michael E DeBakey VA Med Ctr, Infect Dis Sect, Houston, TX USA. [Chirinos, Julio A.] Univ Penn, Div Cardiol, Philadelphia, PA 19104 USA. [Chirinos, Julio A.] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Corrales-Medina, VF (reprint author), Univ Ottawa, Dept Med, 1053 Carling Ave,CPC 470, Ottawa, ON K1Y 4E9, Canada. EM vcorrales@toh.on.ca OI Corrales-Medina, Vicente/0000-0002-9691-491X FU Research Priority Grant from the Department of Medicine of The Ottawa Hospital; Junior Investigator Award of the Ottawa Hospital Research Institute FX We thank Alexandra Davis, librarian at The Ottawa Hospital, for her assistance in the design of our search strategies and the retrieval of selected articles. We also acknowledge Yoko S Schreiber and Bing Wang, from the Division of Infectious Diseases at the University of Ottawa, for their assistance with the translation of articles in French, German, and Chinese; and Waheed Raja and Zubair A Khan, from the Divisions of Internal Medicine at Texas Tech University Health Sciences Center and Cooper University Hospital, respectively, for their helpful assistance during the literature search process. VFC-M is supported by a Research Priority Grant from the Department of Medicine of The Ottawa Hospital, and a Junior Investigator Award of the Ottawa Hospital Research Institute. NR 100 TC 59 Z9 61 U1 3 U2 19 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD FEB 9 PY 2013 VL 381 IS 9865 BP 496 EP 505 DI 10.1016/S0140-6736(12)61266-5 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 088CH UT WOS:000314810900035 PM 23332146 ER PT J AU Paintlia, MK Paintlia, AS Singh, AK Singh, I AF Paintlia, Manjeet K. Paintlia, Ajaib S. Singh, Avtar K. Singh, Inderjit TI S-Nitrosoglutathione Induces Ciliary Neurotrophic Factor Expression in Astrocytes, Which Has Implications to Protect the Central Nervous System under Pathological Conditions SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID FIBRILLARY ACIDIC PROTEIN; ACTIVATED-RECEPTOR-GAMMA; TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE ACTIVATION; IN-VITRO; SIGNALING PATHWAY; GLIAL-CELLS; CYCLOOXYGENASE-2 EXPRESSION; OLIGODENDROCYTE PROGENITORS; DEMYELINATING DISEASES AB Accumulating evidence suggests that reactive astrogliosis has beneficial and detrimental outcomes in various CNS disorders, but the mechanism behind this dichotomy is unclear. Recent advances in this direction suggested that NO signaling is critical to regulate the outcomes of reactive astrogliosis in vivo. Using biochemical and genetic approaches, we here investigated the effect of S-nitrosoglutathione (GSNO; a physiological NO donor) in astrocytes in vitro settings. GSNO enhanced the expressions of glial fibrillary acidic protein and neurotrophic factors including ciliary neurotrophic factor (CNTF) in astrocytes in a dose-dependent manner. The enhanced CNTF expression in GSNO-treated astrocytes was ascribed to NO-mediated sGC/cGMP/PKG signaling. It was associated with p38 MAPK-dependent increased peroxisome proliferator-activated receptor-gamma transactivation. In addition, the chromatin accessibility of peroxisome proliferator-activated receptor-gamma accompanied with ATF2 and CREB (cAMP-response element-binding protein) was enhanced across the CNTF gene promoter in GSNO treated astrocytes. Interestingly, secreted CNTF was responsible for increased expression of glial fibrillary acidic protein in GSNO-treated astrocytes in an autocrine manner via a JAK2- and STAT3-dependent mechanism. In addition, CNTF secreted by GSNO-treated astrocytes enhanced the differentiation of immature oligodendrocytes in vitro. These effects of GSNO were consistent with an endogenously produced NO in astrocytes stimulated with proinflammatory cytokines in vitro. We conclude that NO signaling induces CNTF expression in astrocytes that favors the beneficial outcomes of reactive astrogliosis in vivo. Our data suggest that the endogenously produced NO or its exogenous source has potential to modulate the outcomes of reactive astrogliosis to protect CNS under pathological conditions. C1 [Paintlia, Manjeet K.; Paintlia, Ajaib S.; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Darby Childrens Res Inst, Charleston, SC 29425 USA. [Singh, Avtar K.] Ralph H Johnson Vet Affairs Med Ctr, Dept Pathol & Lab Med, Charleston, SC 29425 USA. RP Singh, I (reprint author), Med Univ S Carolina, Dept Pediat, 173 Ashley Ave, Charleston, SC 29425 USA. EM singhi@musc.edu FU National Institutes of Health [NS-22576, NS-37766, VA-1BX001072, VA-BX001999, C06 RR018823, C06 RR015455] FX This work was supported, in whole or in part, by National Institutes of Health Grants NS-22576, NS-37766, VA-1BX001072, VA-BX001999, C06 RR018823, and C06 RR015455. NR 69 TC 12 Z9 12 U1 0 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD FEB 8 PY 2013 VL 288 IS 6 BP 3831 EP 3843 DI 10.1074/jbc.M112.405654 PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 088OP UT WOS:000314845000015 PM 23264628 ER PT J AU Zeliadt, SB Hannon, PA Trivedi, RB Bonner, LM Vu, TT Simons, C Kimmie, CA Hu, EY Zipperer, C Lin, DW AF Zeliadt, Steven B. Hannon, Peggy A. Trivedi, Ranak B. Bonner, Laura M. Vu, Thuy T. Simons, Carol Kimmie, Crystal A. Hu, Elaine Y. Zipperer, Chris Lin, Daniel W. TI A preliminary exploration of the feasibility of offering men information about potential prostate cancer treatment options before they know their biopsy results SO BMC MEDICAL INFORMATICS AND DECISION MAKING LA English DT Article DE Prostate cancer; Biopsy; Decision aid; Prostate biopsy; Treatment decision making ID DECISION-MAKING; AIDS AB Background: A small pre-test study was conducted to ascertain potential harm and anxiety associated with distributing information about possible cancer treatment options at the time of biopsy, prior to knowledge about a definitive cancer diagnosis. Priming men about the availability of multiple options before they have a confirmed diagnosis may be an opportunity to engage patients in more informed decision-making. Methods: Men with an elevated PSA test or suspicious Digital Rectal Examination (DRE) who were referred to a urology clinic for a biopsy were randomized to receive either the clinic's usual care (UC) biopsy instruction sheet (n = 11) or a pre-biopsy educational (ED) packet containing the biopsy instruction sheet along with a booklet about the biopsy procedure and a prostate cancer treatment decision aid originally written for newly diagnosed men that described in detail possible treatment options (n = 18). Results: A total of 62% of men who were approached agreed to be randomized, and 83% of the ED group confirmed they used the materials. Anxiety scores were similar for both groups while awaiting the biopsy procedure, with anxiety scores trending lower in the ED group: 41.2 on a prostate-specific anxiety instrument compared to 51.7 in the UC group (p = 0.13). ED participants reported better overall quality of life while awaiting biopsy compared to the UC group (76.4 vs. 48.5, p = 0.01). The small number of men in the ED group who went on to be diagnosed with cancer reported being better informed about the risks and side effects of each option compared to men diagnosed with cancer in the UC group (p = 0.07). In qualitative discussions, men generally reported they found the pre-biopsy materials to be helpful and indicated having information about possible treatment options reduced their anxiety. However, 2 of 18 men reported they did not want to think about treatment options until after they knew their biopsy results. Conclusions: In this small sample offering pre-biopsy education about potential treatment options was generally well received by patients, appeared to be beneficial to men who went on to be diagnosed, and did not appear to increase anxiety unnecessarily among those who had a negative biopsy. C1 [Zeliadt, Steven B.; Trivedi, Ranak B.; Bonner, Laura M.; Simons, Carol; Hu, Elaine Y.] VA Puget Sound Hlth Care Syst, Northwest HSR&D Ctr Excellence, Seattle, WA 98101 USA. [Zeliadt, Steven B.; Hannon, Peggy A.; Trivedi, Ranak B.; Vu, Thuy T.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Kimmie, Crystal A.] Seattle Inst Biomed & Clin Res, Seattle, WA USA. [Zipperer, Chris] Washington State Dept Hlth, Canc Prevent & Control Unit, Olympia, WA USA. [Kimmie, Crystal A.; Lin, Daniel W.] Dept Vet Affairs Med Ctr, Urol Serv, Seattle, WA USA. [Lin, Daniel W.] Univ Washington, Sch Med, Dept Urol, Seattle, WA 98195 USA. RP Zeliadt, SB (reprint author), VA Puget Sound Hlth Care Syst, Northwest HSR&D Ctr Excellence, Metropolitan Pk West,1100 Olive Way 1400, Seattle, WA 98101 USA. EM szeliadt@uw.edu FU Washington State Department of Health [N17493]; Centers for Disease Control and Prevention; National Cancer Institute through the Cancer Prevention and Control Research Network [1-U48-DP-000050]; Department of Veterans Affairs [HFP 83-027] FX This work was conducted at the VA Puget Sound Healthcare System. Financial support for this study was provided in part by a contract with the Washington State Department of Health (Contract Number N17493; CK), the Centers for Disease Control and Prevention and the National Cancer Institute through the Cancer Prevention and Control Research Network (Grant 1-U48-DP-000050; PAH; TV), and by the Department of Veterans Affairs (HFP 83-027; SBZ). The funding agreement ensured the authors' independence in designing the study, interpreting the data, writing, and publishing the report. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or of the United States government. NR 29 TC 3 Z9 3 U1 0 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6947 J9 BMC MED INFORM DECIS JI BMC Med. Inform. Decis. Mak. PD FEB 6 PY 2013 VL 13 AR 19 DI 10.1186/1472-6947-13-19 PG 9 WC Medical Informatics SC Medical Informatics GA 107NL UT WOS:000316224400001 PM 23388205 ER PT J AU Sano, M AF Sano, Mary TI Never Too Fit for Body and Mind SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material ID PHYSICAL-ACTIVITY; CARDIORESPIRATORY FITNESS; MORTALITY; MEN; IMPAIRMENT; EXERCISE; ADULTS; WOMEN; RISK C1 [Sano, Mary] Mt Sinai Sch Med, New York, NY USA. [Sano, Mary] James J Peters Vet Affairs Med Ctr, New York, NY USA. [Sano, Mary] Mt Sinai Sch Med, Bronx, NY USA. [Sano, Mary] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. RP Sano, M (reprint author), James J Peters Vet Affairs Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM mary.sano@mssm.edu FU NIA NIH HHS [P50 AG005138] NR 11 TC 0 Z9 0 U1 0 U2 1 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 5 PY 2013 VL 158 IS 3 BP 213 EP 214 DI 10.7326/0003-4819-158-3-201302050-00013 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 087JP UT WOS:000314757900010 PM 23381042 ER PT J AU Wynn, JK Mathis, KI Ford, J Breitmeyer, BG Green, MF AF Wynn, Jonathan K. Mathis, Kristopher I. Ford, Judith Breitmeyer, Bruno G. Green, Michael F. TI Object substitution masking in schizophrenia: an event-related potential analysis SO FRONTIERS IN PSYCHOLOGY LA English DT Article DE visual processing; schizophrenia; ERP; visual backward masking; reentrant processing ID PSYCHIATRIC RATING-SCALE; BACKWARD VISUAL MASKING; PROCESSING DEFICITS; SENSORY CONTRIBUTIONS; RECOGNITION AREAS; QUALITY-ASSURANCE; AWARENESS; PERCEPTION; ATTENTION; ERP AB Schizophrenia patients exhibit deficits on visual processing tasks, including visual backward masking, and these impairments are related to deficits in higher-level processes. In the current study we used electroencephalography techniques to examine successive stages and pathways of visual processing in a specialized masking paradigm, four-dot masking, which involves masking by object substitution. Seventy-six schizophrenia patients and 66 healthy controls had event-related potentials (ERPs) recorded during four-dot masking. Target visibility was manipulated by changing stimulus onset asynchrony (SOA) between the target and mask, such that performance decreased with increasing SOA. Three SOAs were used: 0, 50, and 100 ms. The P100 and N100 perceptual ERPs were examined. Additionally, the visual awareness negativity (VAN) to correct vs. incorrect responses, an index of reentrant processing, was examined for SOAs 50 and 100 ms. Results showed that patients performed worse than controls on the behavioral task across all SOAs. The ERP results revealed that patients had significantly smaller P100 and N100 amplitudes, though there was no effect of SOA on either component in either group. In healthy controls, but not patients, N100 amplitude correlated significantly with behavioral performance at SOAs where masking occurred, such that higher accuracy correlated with a larger N100. Healthy controls, but not patients, exhibited a larger VAN to correct vs. incorrect responses. The results indicate that the N100 appears to be related to attentional effort in the task in controls, but not patients. Considering that the VAN is thought to reflect reentrant processing, one interpretation of the findings is that patients' lack of VAN response and poorer performance may be related to dysfunctional reentrant processing. C1 [Wynn, Jonathan K.; Mathis, Kristopher I.; Green, Michael F.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Wynn, Jonathan K.; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA. [Ford, Judith] San Francisco VA Med Ctr, San Francisco, CA USA. [Ford, Judith] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Breitmeyer, Bruno G.] Univ Houston, Dept Psychol, Houston, TX USA. RP Wynn, JK (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jkwynn@ucla.edu RI Wynn, Jonathan/H-3749-2014 OI Wynn, Jonathan/0000-0002-1763-8540 FU NIMH NIH HHS [R29 MH043292, R01 MH043292, R01 MH065707] NR 64 TC 2 Z9 2 U1 0 U2 5 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1664-1078 J9 FRONT PSYCHOL JI Front. Psychol. PD FEB 4 PY 2013 VL 4 AR 30 DI 10.3389/fpsyg.2013.00030 PG 9 WC Psychology, Multidisciplinary SC Psychology GA AA0KW UT WOS:000330785000001 PM 23382723 ER PT J AU Singh, JA AF Singh, Jasvinder A. TI Racial and Gender Disparities Among Patients with Gout SO CURRENT RHEUMATOLOGY REPORTS LA English DT Article DE Gout; Hyperuricemia; Race; Ethnicity; Gender; Disparity; Epidemiology; Prevalence; Genetic risk factors; Adverse effects ID IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS; ACUTE MYOCARDIAL-INFARCTION; QUALITY-OF-LIFE; UNITED-STATES; URIC-ACID; AFRICAN-AMERICAN; SEX-DIFFERENCES; HEALTH-CARE; PHYSICIAN COMMUNICATION; RACE/ETHNIC DISPARITY AB Gout affects 8.3 million Americans according to NHANES 2007-2008, approximately 3.9 % of the US population. Gout has substantial effect on physical function, productivity, health-related quality of life (HRQOL), and health care costs. Uncontrolled gout is also associated with significant use of emergency care services. Women are less likely to have gout than men, but in the postmenopausal years the gender difference in disease incidence decreases. Compared with whites, racial and/or ethnic minorities, especially blacks, have higher prevalence of gout. Blacks are also less likely to receive quality gout care, leading to disproportionate morbidity. Women are less likely than men to receive allopurinol, and less likely to undergo joint aspirations for crystal analysis to establish diagnosis, but those on urate-lowering therapy are as likely as, or more likely than, men to undergo serum urate check within six months of initiation. Although a few studies provide the knowledge related to gender and race and/or ethnicity disparities for gout, several knowledge gaps exist in gout epidemiology and outcomes differences by gender and race and/or ethnicity. These should be investigated in future studies. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Dept Med, Div Rheumatol, Sch Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL 35294 USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com OI singh, jasvinder/0000-0003-3485-0006 FU National Institute of Aging; National Cancer Institute; National Institute of Arthritis and Musculoskeletal Diseases; Agency for Health Quality; Research Center for Education and Research on Therapeutics FX Dr Singh is supported by research grants from the National Institute of Aging, the National Cancer Institute, the National Institute of Arthritis and Musculoskeletal Diseases, the Agency for Health Quality, and the Research Center for Education and Research on Therapeutics, and by the resources and facilities at the Birmingham VA Medical Center, Alabama, USA. The views expressed in this article are those of the author and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 79 TC 22 Z9 22 U1 2 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3774 J9 CURR RHEUMATOL REP JI Curr. Rheumatol. Rep. PD FEB PY 2013 VL 15 IS 2 AR 307 DI 10.1007/s11926-012-0307-x PG 9 WC Rheumatology SC Rheumatology GA 225VT UT WOS:000324993800004 PM 23315156 ER PT J AU Price, M Davidson, TM Andrews, JO Ruggiero, KJ AF Price, Matthew Davidson, Tatiana M. Andrews, Jeannette O. Ruggiero, Kenneth J. TI Access, use and completion of a brief disaster mental health intervention among Hispanics, African-Americans and Whites affected by Hurricane Ike SO JOURNAL OF TELEMEDICINE AND TELECARE LA English DT Article ID RECRUITMENT AB African-Americans and Hispanics are disproportionally affected by disasters. We evaluated differences in the use and completion of a web-based mental health intervention, Disaster Recovery Web (DRW), by White, African-American and Hispanic adults in the aftermath of Hurricane Ike. Approximately one year after the hurricane, a telephone survey was carried out with adults from Galveston and Chambers counties. A total of 1249 adults participated in the survey (80% White, 14% African-American and 6% Hispanic). Mental health and mental health service utilization were assessed. Whites were more likely to have previously used the Internet to obtain general health information than African-Americans or Hispanics (P < 0.001). A logistic regression was used to identify differences in the use of the Internet intervention after controlling for covariates. There were no differences in rates of non-use and dropout attrition between Whites, African-Americans and Hispanics. Thus the findings suggest that web-based mental health interventions can be used to reach African-American, Hispanic and White adults at similar rates after a disaster. C1 [Price, Matthew; Davidson, Tatiana M.; Andrews, Jeannette O.; Ruggiero, Kenneth J.] Med Univ S Carolina, Charleston, SC 29425 USA. [Ruggiero, Kenneth J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Price, M (reprint author), Natl Crime Victims Res & Treatment Ctr, 67 President St,2 South MSC 861, Charleston, SC 29425 USA. EM prima@musc.edu FU National Institute of Mental Health [R34 MH77149, R01 MH081056-03S2]; South Carolina Clinical and Translational Research Institute [NCRR/NIH UL1 RR029882]; [T32 MH018869]; [P60 MH082598] FX The study was supported by National Institute of Mental Health grant R34 MH77149. Dr Price was supported by T32 MH018869. Dr Davidson was supported by National Institute of Mental Health grant R01 MH081056-03S2. Dr Ruggiero was supported by P60 MH082598. Dr Andrews was supported by the South Carolina Clinical and Translational Research Institute (NCRR/NIH UL1 RR029882). NR 17 TC 8 Z9 8 U1 1 U2 6 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 1357-633X J9 J TELEMED TELECARE JI J. Telemed. Telecare PD FEB PY 2013 VL 19 IS 2 BP 70 EP 74 DI 10.1177/1357633X13476230 PG 5 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 184OO UT WOS:000321901300002 PM 23514936 ER PT J AU Kraybill, ML Thorgusen, SR Suchy, Y AF Kraybill, Matthew L. Thorgusen, Sommer R. Suchy, Yana TI The Push-Turn-Taptap Task Outperforms Measures of Executive Functioning in Predicting Declines in Functionality: Evidence-Based Approach to Test Validation SO CLINICAL NEUROPSYCHOLOGIST LA English DT Article DE Executive functioning; Motor programming; Functional independence; Geriatrics; Evidence-based practice ID BEHAVIORAL DYSCONTROL SCALE; MILD COGNITIVE IMPAIRMENT; LOWER-EXTREMITY FUNCTION; DEMENTIA RATING-SCALE; ADULT AGE-DIFFERENCES; INSTRUMENTAL ACTIVITIES; OLDER-ADULTS; ECOLOGICAL VALIDITY; ELECTRONIC VERSION; ALZHEIMERS-DISEASE AB Performance on the Push-Turn-Taptap (PTT) task has been shown to be a strong predictor of concurrent everyday functioning. This study utilized a prospective, longitudinal design to evaluate the PTT task for predicting future performance on a behavioral assessment of everyday functioning. The PTT task was compared to other measures of executive functioning as well as general cognition in terms of administration time and ability to identify participants who evidenced functional decline. A total of 50 community-dwelling older adults (ages 5887) completed the PTT task, Mattis Dementia Rating Scale, Geriatric Depression Scale, Behavioral Dyscontrol Scale, Delis-Kaplan Executive Function System, and Timed Instrumental Activities of Daily Living. Baseline PTT performance (a) was highly correlated with an objective measure of everyday functioning after approximately one year (r=.497, p<.001), (b) was associated with changes in follow-up functioning, F(3, 46)=3.15, p=.03, (c) was a better predictor of future functional status than a longer battery of EF, and (d) reliably identified individuals with the greatest magnitude of functional decline. The PTT tasks may provide a particularly advantageous method of predicting future changes in everyday functioning in older adults. C1 [Kraybill, Matthew L.; Thorgusen, Sommer R.; Suchy, Yana] Univ Utah, Dept Psychol, Salt Lake City, UT 84112 USA. RP Kraybill, ML (reprint author), San Francisco VA Med Ctr, 4150 Clement St,S-116, San Francisco, CA 94121 USA. EM mkraybill@gmail.com OI Suchy, Yana/0000-0001-6513-565X NR 73 TC 9 Z9 9 U1 1 U2 5 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1385-4046 J9 CLIN NEUROPSYCHOL JI Clin. Neuropsychol. PD FEB 1 PY 2013 VL 27 IS 2 BP 238 EP 255 DI 10.1080/13854046.2012.735702 PG 18 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 146MH UT WOS:000319094700004 PM 23116212 ER PT J AU Falchook, GS Trent, JC Heinrich, MC Beadling, C Patterson, J Bastida, CC Blackman, SC Kurzrock, R AF Falchook, G. S. Trent, J. C. Heinrich, M. C. Beadling, C. Patterson, J. Bastida, C. C. Blackman, S. C. Kurzrock, R. TI BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance SO ONCOTARGET LA English DT Article DE Gastrointestinal stromal tumor; Dabrafenib; GSK2118436; BRAF mutation; BRAF inhibition; V600E ID IMATINIB MESYLATE; PHASE-II; MUTATIONS; MELANOMA; GENE; CANCER; PDGFRA; GIST AB Activating oncogenic mutations of BRAF have been described in patients with gastrointestinal stromal tumor (GIST), but treatment of GIST with BRAF inhibitors and mechanisms of mediating the emergence of resistance in GIST have not been reported. Dabrafenib is a potent ATP-competitive inhibitor of BRAF kinase and is highly selective for mutant BRAF in kinase panel screening, cell lines, and xenografts. We report prolonged antitumor activity in the first patient with V600E BRAF-mutated GIST who was treated with a BRAF inhibitor. Whole exome sequencing performed in tumor tissue obtained at the time of progressive disease demonstrated a somatic gain-of-function PIK3CA mutation (H1047R) as well as a CDKN2A aberration, which may have contributed to eventual resistance to treatment. C1 [Falchook, G. S.; Bastida, C. C.] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USA. [Trent, J. C.] Univ Miami, Sarcoma Med Oncol Program, Sylvester Comprehens Canc Ctr, Miami, FL USA. [Heinrich, M. C.; Beadling, C.; Patterson, J.] Portland VA Med Ctr, Portland, OR USA. [Heinrich, M. C.; Beadling, C.; Patterson, J.] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Oncol, Portland, OR 97201 USA. [Blackman, S. C.] GlaxoSmithKline, Collegeville, PA USA. [Kurzrock, R.] Univ Calif San Diego, Dept Med, Hematol Oncol Div, Moores Canc Ctr, San Diego, CA 92103 USA. RP Falchook, GS (reprint author), Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USA. EM gfalchoo@mdanderson.org FU Center for Clinical and Translational Sciences; National Institutes of Health Clinical and Translational Science Award [UL1 RR024148]; National Institutes of Health Cancer Center Support Grant (CCSG) [CA016672]; GIST Cancer Research Fund; Life Raft Group; VA Merit Review Grant; GlaxoSmithKline; Novartis; Pfizer FX This work was performed in the U.T. MD Anderson Cancer Center Clinical and Translational Research Center (CTRC) and was supported by the Center for Clinical and Translational Sciences, which is funded by National Institutes of Health Clinical and Translational Science Award UL1 RR024148 and by the National Institutes of Health Cancer Center Support Grant (CCSG) award CA016672 to MD Anderson Cancer Center. Short read sequencing assays were performed by the Oregon Health & Science University Massively Parallel Sequencing Shared Resource. Funded in part by philanthropic donations from the GIST Cancer Research Fund and the Life Raft Group (MCH) and a VA Merit Review Grant (MCH). We would like to thank Dr. Vicki Goodman of GlaxoSmithKline for her comments on this manuscript.; Gerald Falchook received research funding and travel reimbursement for conference attendance from GlaxoSmithKline. Razelle Kurzrock received research funding from GlaxoSmithKline, Novartis, and Pfizer. Samuel Blackman was an employee of GlaxoSmithKline at the time of the study. The other coauthors report no conflicts of interest. NR 25 TC 43 Z9 44 U1 0 U2 5 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD FEB PY 2013 VL 4 IS 2 BP 310 EP 315 PG 6 WC Oncology; Cell Biology SC Oncology; Cell Biology GA 142FO UT WOS:000318782500017 PM 23470635 ER PT J AU Kwon, S Mann, GN Wu, P Drake, F Gow, K AF Kwon, S. Mann, G. N. Wu, P. Drake, F. Gow, K. TI General Surgery Resident Operative Experience in Surgical Oncology Over Two Decades SO ANNALS OF SURGICAL ONCOLOGY LA English DT Meeting Abstract CT 66th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO) CY MAR 06-09, 2013 CL National Harbor, MD SP Soc Surg Oncol (SSO) C1 [Kwon, S.; Mann, G. N.; Drake, F.] Univ Washington, Seattle, WA 98195 USA. [Wu, P.] Vet Affairs Puget Sound, Seattle, WA USA. [Gow, K.] Seattle Childrens Hosp, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2013 VL 20 SU 1 BP S113 EP S114 PG 2 WC Oncology; Surgery SC Oncology; Surgery GA 133XR UT WOS:000318174700333 ER PT J AU Merkow, RP Bilimoria, KY Tomlinson, JS Paruch, JL Stewart, A Winchester, D Ko, CY Bentrem, DJ AF Merkow, R. P. Bilimoria, K. Y. Tomlinson, J. S. Paruch, J. L. Stewart, A. Winchester, D. Ko, C. Y. Bentrem, D. J. TI Postoperative Complications Reduce Adjuvant Chemotherapy Use in Resectable Pancreatic Cancer SO ANNALS OF SURGICAL ONCOLOGY LA English DT Meeting Abstract CT 66th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO) CY MAR 06-09, 2013 CL National Harbor, MD SP Soc Surg Oncol (SSO) C1 [Merkow, R. P.; Bilimoria, K. Y.; Paruch, J. L.; Stewart, A.; Winchester, D.; Ko, C. Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA. [Bentrem, D. J.] Northwestern Univ, Dept Surg, Surg Outcomes & Qual Improvement Ctr, Chicago, IL 60611 USA. [Bentrem, D. J.] Northwestern Univ, Northwestern Inst Comparat Effectiveness Res NICE, Chicago, IL 60611 USA. [Tomlinson, J. S.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Tomlinson, J. S.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2013 VL 20 SU 1 BP S27 EP S28 PG 2 WC Oncology; Surgery SC Oncology; Surgery GA 133XR UT WOS:000318174700063 ER PT J AU Hausauer, AK Maurer, T Leslie, KS Parvataneni, R Stuart, SE Chren, MM AF Hausauer, Amelia K. Maurer, Toby Leslie, Kieron S. Parvataneni, Rupa Stuart, Sarah E. Chren, Mary-Margaret TI Recurrence After Treatment of Cutaneous Basal Cell and Squamous Cell Carcinomas in Patients Infected With Human Immunodeficiency Virus SO JAMA DERMATOLOGY LA English DT Letter ID MALIGNANCIES C1 [Hausauer, Amelia K.; Maurer, Toby; Leslie, Kieron S.; Parvataneni, Rupa; Stuart, Sarah E.; Chren, Mary-Margaret] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. [Maurer, Toby; Leslie, Kieron S.] San Francisco Gen Hosp, Dept Dermatol, San Francisco, CA 94110 USA. [Chren, Mary-Margaret] San Francisco VA Med Ctr, San Francisco, CA USA. RP Chren, MM (reprint author), Mt Zion Canc Res Bldg,2340 Sutter St,Room N412,Ma, San Francisco, CA 94143 USA. EM chrenm@derm.ucsf.edu FU NIAMS NIH HHS [K24 AR052667, R01 AR054983] NR 5 TC 3 Z9 3 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6068 J9 JAMA DERMATOL JI JAMA Dermatol. PD FEB PY 2013 VL 149 IS 2 BP 239 EP 241 DI 10.1001/2013.jamadermatol.245 PG 4 WC Dermatology SC Dermatology GA 127CH UT WOS:000317672300029 PM 23426494 ER PT J AU Bosley, JC Zhao, NW Hill, S Shofer, FS Asch, DA Becker, LB Merchant, RM AF Bosley, Justin C. Zhao, Nina W. Hill, Shawndra Shofer, Frances S. Asch, David A. Becker, Lance B. Merchant, Raina M. TI Decoding twitter: Surveillance and trends for cardiac arrest and resuscitation communication SO RESUSCITATION LA English DT Article DE Cardiopulmonary resuscitation; Heart arrest; Defibrillation; Resuscitation; Social media ID AMERICAN-HEART-ASSOCIATION; EMERGENCY CARDIOVASCULAR CARE; CARDIOPULMONARY-RESUSCITATION; SOCIAL MEDIA; SURVIVAL AB Aim of the study: Twitter has over 500 million subscribers but little is known about how it is used to communicate health information. We sought to characterize how Twitter users seek and share information related to cardiac arrest, a time-sensitive cardiovascular condition where initial treatment often relies on public knowledge and response. Methods: Tweets published April-May 2011 with keywords cardiac arrest, CPR, AED, resuscitation, heart arrest, sudden death and defib were identified. Tweets were characterized by content, dissemination, and temporal trends. Tweet authors were further characterized by: self-identified background, tweet volume, and followers. Results: Of 62,163 tweets (15,324, 25%) included resuscitation/cardiac arrest-specific information. These tweets referenced specific cardiac arrest events (1130, 7%), CPR performance or AED use (6896, 44%), resuscitation-related education, research, or news media (7449, 48%), or specific questions about cardiac arrest/resuscitation (270, 2%). Regarding dissemination (1980, 13%) of messages were retweeted. Resuscitation specific tweets primarily occurred on weekdays. Most users (10,282, 93%) contributed three or fewer tweets during the study time frame. Users with more than 15 resuscitation-specific tweets in the study time frame had a mean 1787 followers and most self-identified as having a healthcare affiliation. Conclusion: Despite a large volume of tweets, Twitter can be filtered to identify public knowledge and information seeking and sharing about cardiac arrest. To better engage via social media, healthcare providers can distil tweets by user, content, temporal trends, and message dissemination. Further understanding of information shared by the public in this forum could suggest new approaches for improving resuscitation related education. (C) 2012 Elsevier Ireland Ltd. All rights reserved. C1 [Bosley, Justin C.; Zhao, Nina W.; Shofer, Frances S.; Becker, Lance B.; Merchant, Raina M.] Univ Penn, Dept Emergency Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Hill, Shawndra] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [Asch, David A.; Merchant, Raina M.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Merchant, RM (reprint author), Univ Penn, 423 Guardian St,Blockley Hall, Philadelphia, PA 19104 USA. EM raina.merchant@uphs.upenn.edu OI Asch, David/0000-0002-7970-286X FU NIH [10714038]; Physio-Control Seattle, Washington; Zoll Medical, Boston MA; Cardiac Science, Bothell, Washington; Philips Medical Seattle, Washington; Philips Healthcare, Seattle, WA; Laerdal Medical, Stavanger, Norway; NIH, Bethesda, MD FX Merchant: Grant/research support: NIH, K23 grant 10714038, Pilot funding: Physio-Control Seattle, Washington; Zoll Medical, Boston MA; Cardiac Science, Bothell, Washington; Philips Medical Seattle, Washington.; Becker: Speaker honoraria/consultant fees: Philips Healthcare, Seattle, WA. Institutional grant/research support: Philips Healthcare, Seattle, WA; Laerdal Medical, Stavanger, Norway; NIH, Bethesda, MD; Cardiac Science, Bothell, Washington. NR 28 TC 22 Z9 23 U1 2 U2 24 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0300-9572 J9 RESUSCITATION JI Resuscitation PD FEB PY 2013 VL 84 IS 2 BP 206 EP 212 DI 10.1016/j.resuscitation.2012.10.017 PG 7 WC Critical Care Medicine; Emergency Medicine SC General & Internal Medicine; Emergency Medicine GA 123UH UT WOS:000317416100029 PM 23108239 ER PT J AU Reis, JP Loria, CM Launer, LJ Sidney, S Liu, K Jacobs, DR Zhu, N Lloyd-Jones, DM He, K Yaffe, K AF Reis, Jared P. Loria, Catherine M. Launer, Lenore J. Sidney, Stephen Liu, Kiang Jacobs, David R., Jr. Zhu, Na Lloyd-Jones, Donald M. He, Ka Yaffe, Kristine TI Cardiovascular health through young adulthood and cognitive functioning in midlife SO ANNALS OF NEUROLOGY LA English DT Article ID RISK-FACTORS; METABOLIC SYNDROME; INCIDENT DEMENTIA; BLOOD-PRESSURE; US ADULTS; IMPAIRMENT; LIFE; DECLINE; CARDIA; ASSOCIATION AB Objective A study was undertaken to examine the association between overall cardiovascular health as recently defined by the American Heart Association in young adulthood to middle age and cognitive function in midlife. Overall ideal cardiovascular health incorporates 7 metrics, including the avoidance of overweight or obesity, a healthful diet, nonsmoking, and physical activity, total cholesterol, blood pressure, and fasting glucose at goal levels. Methods This analysis of the Coronary Artery Risk Development in Young Adults study, a multicenter community-based study with 25 years of follow-up, included 2,932 participants aged 18 to 30 years at baseline (year 0) who attended follow-up examinations at years 7 and 25. Cardiovascular health metrics were measured at each examination. The Digit Symbol Substitution Test (DSST), modified Stroop test, and Rey Auditory Verbal Learning Test (RAVLT) were completed at year 25. Results A greater number of ideal cardiovascular metrics in young adulthood and middle age were independently associated with better cognitive function in midlife (p for trend < 0.01, for all). Specifically, each additional ideal metric was associated with 1.32 more symbols on the DSST (95% confidence interval [CI] = 0.93 1.71), a 0.77-point lower interference score on the Stroop test (95% CI=1.03 to 0.45), and 0.12 more words on the RAVLT (95% CI = 0.04 to 0.20). Participants who had 5 ideal metrics at a greater number of the 3 examinations over the 25-year period exhibited better performance on each cognitive test in middle age (p for trend < 0.01, for all). Interpretation Ideal cardiovascular health in young adulthood and its maintenance to middle age is associated with better psychomotor speed, executive function, and verbal memory in midlife. ANN NEUROL 2013;73:170179 C1 [Reis, Jared P.; Loria, Catherine M.] NHLBI, Div Cardiovasc Sci, Bethesda, MD 20892 USA. [Launer, Lenore J.] NIA, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA. [Sidney, Stephen] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA. [Liu, Kiang; Lloyd-Jones, Donald M.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA. [Jacobs, David R., Jr.; Zhu, Na] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Jacobs, David R., Jr.] Univ Oslo, Dept Nutr, Oslo, Norway. [He, Ka] Univ N Carolina, Dept Nutr, Chapel Hill, NC USA. [He, Ka] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. RP Reis, JP (reprint author), NHLBI, Div Cardiovasc Sci, 6701 Rockledge Dr,Suite 10197, Bethesda, MD 20892 USA. EM reisjp@mail.nih.gov FU National Heart, Lung, and Blood Institute; University of Alabama at Birmingham [N01-HC95095, N01-HC48047]; Kaiser Foundation Research Institute [N01-HC48050]; Northwestern University [N01-HC48049]; University of Minnesota [N01-HC48048] FX CARDIA is conducted and supported by the National Heart, Lung, and Blood Institute in collaboration with the University of Alabama at Birmingham (N01-HC95095, N01-HC48047), Kaiser Foundation Research Institute (N01-HC48050), Northwestern University (N01-HC48049), and University of Minnesota (N01-HC48048). NR 38 TC 42 Z9 43 U1 0 U2 18 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD FEB PY 2013 VL 73 IS 2 BP 170 EP 179 DI 10.1002/ana.23836 PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 113UA UT WOS:000316693200006 PM 23443990 ER PT J AU Littman, AJ Jacobson, IG Boyko, EJ Powell, TM Smith, TC AF Littman, A. J. Jacobson, I. G. Boyko, E. J. Powell, T. M. Smith, T. C. CA Millennium Cohort Study Team TI Weight change following US military service SO INTERNATIONAL JOURNAL OF OBESITY LA English DT Article DE military veterans; weight gain; prospective; cohort; posttraumatic stress disorder; military deployment ID VETERANS; OBESITY; COHORT; OVERWEIGHT; VALIDITY; BURDEN AB BACKGROUND: Although overweight and obesity are less prevalent among active-duty military personnel compared with similar persons not serving in the military, no such differences have been observed between veterans and non-veterans. OBJECTIVES: To assess the magnitude of weight changes before, concurrent with and following discharge from the military, relative to weight during service, and to determine the demographic, service-related and psychological characteristics associated with clinically important weight gain among those who were discharged from military service during follow-up. METHODS: Eligible Millennium Cohort Study participants (n = 38 686) completed the questionnaires approximately every 3 years (2001, 2004 and 2007) that were used to estimate annual weight changes, as well as the percentage experiencing clinically important weight gain, defined as >= 10%. Analyses were stratified by sex. RESULTS: Weight gain was greatest around the time of discharge from service and in the 3 years before discharge (1.0-1.3 kg per year), while it was nearly half as much during service (0.6-0.7 kg per year) and >= 3 years after service ended (0.7 kg per year). Consequently, 6-year weight gain was over 2 kg greater in those who were discharged compared with those who remained in the military during follow-up (5.7 vs 3.5 kg in men; 6.3 vs 4.0 kg in women). In those who were discharged, younger age, less education, being overweight at baseline, being in the active-duty component (vs Reserve/National Guard) and having experienced deployment with combat exposures (vs non-deployment) were associated with increased risks of clinically important weight gain. CONCLUSIONS: This study provides the first prospectively collected evidence for an increased rate of weight gain around the time of military discharge that may explain previously reported higher rates of obesity in veterans, and identifies characteristics of higher-risk groups. Discharge from military service presents a window of risk and opportunity to prevent unhealthy weight gain in military personnel and veterans. International Journal of Obesity (2013) 37, 244-253; doi:10.1038/ijo.2012.46; published online 10 April 2012 C1 [Littman, A. J.; Boyko, E. J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Littman, A. J.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Jacobson, I. G.; Powell, T. M.; Smith, T. C.] USN, Dept Deployment Hlth Res, Hlth Res Ctr, San Diego, CA 92152 USA. RP Littman, AJ (reprint author), Vet Affairs Puget Sound Hlth Care Syst 152E, Seattle Epidemiol Res & Informat Ctr, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM alyson@u.washington.edu OI Boyko, Edward/0000-0002-3695-192X FU Henry M Jackson Foundation for the Advancement of Military Medicine, Rockville, MD; VA Rehabilitation Research and Development Career Development Award [6982]; Cooperative Studies Program, Department of Veterans; Puget Sound VA Medical Center; Department of Defense [60002] FX We are indebted to the Millennium Cohort Study participants, without whom these analyses would not be possible. In addition to the authors, the Millennium Cohort Study Team includes Paul J Amoroso, MD; Gary D Gackstetter, MD, from the Analytic Services, Inc., Arlington, VA; Gregory C Gray, MD, MPH, from the College of Public Health and Health Professions, University of Florida, Gainesville, FL; Tomoko Hooper, MD, from the Departments of Preventive Medicine and Biometrics, Uniformed Services University of Health Sciences, Bethesda, MD; James R Riddle, DVM, MPH, from the Air Force Research Laboratory, Wright-Patterson Air Force Base, OH; Margaret AK Ryan, MD, MPH, from Naval Hospital Camp Pendleton, Occupational Health Department; Melissa Bagnell, MPH; Nancy Crum-Cianflone, MD, MPH; Gia Gumbs, MPH; Nisara Granado, MPH, PhD; Jaime Horton; Kelly Jones, MPH; Cynthia LeardMann, MPH; William Lee; Travis Leleu; Michelle Linfesty; Gordon Lynch; Jamie McGrew; Hope McMaster, PhD; Sheila Medina-Torne, MPH; Amanda Pietrucha, MPH; Donald Sandweiss, MD; Amber Seelig, MPH; Beverly Sheppard; Katherine Snell; Steven Speigle; Kari Sausedo, MA; Donald Slymen, PhD; Besa Smith, MPH, PhD; Jennifer Walstrom; Timothy S Wells, DVM, MPH, PhD; Martin White, MPH; James Whitmer; and Charlene Wong, MPH; from the Department of Deployment Health Research, Naval Health Research Center, San Diego, CA. We thank Scott L Seggerman and Greg D Boyd from the Management Information Division, Defense Manpower Data Center, Monterey, CA. Additionally, we thank Michelle LeWark from the Naval Health Research Center. We also thank all the professionals from the US Army Medical Research and Materiel Command, especially those from the Military Operational Medicine Research Program, Fort Detrick, MD. We appreciate the support of the Henry M Jackson Foundation for the Advancement of Military Medicine, Rockville, MD. Dr Littman was supported by a VA Rehabilitation Research and Development Career Development Award (#6982).; The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Navy, Department of the Army, Department of the Air Force, Department of Defense, Department of Veterans Affairs or the US Government. This material is the result of work partly supported with resources and the use of facilities from the Cooperative Studies Program, Department of Veterans and the Puget Sound VA Medical Center. This work represents report 0934, supported by the Department of Defense, under work unit no. 60002. This research has been conducted in compliance with all applicable federal regulations governing the protection of human subjects in research (Protocol NHRC.2000.007). NR 21 TC 11 Z9 11 U1 1 U2 7 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0307-0565 J9 INT J OBESITY JI Int. J. Obes. PD FEB PY 2013 VL 37 IS 2 BP 244 EP 253 DI 10.1038/ijo.2012.46 PG 10 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 117DK UT WOS:000316932100014 PM 22491091 ER PT J AU Tsuang, D Leverenz, JB Lopez, OL Hamilton, RL Bennett, DA Schneider, JA Buchman, AS Larson, EB Crane, PK Kaye, JA Kramer, P Woltjer, R Trojanowski, JQ Weintraub, D Chen-Plotkin, AS Irwin, DJ Rick, J Schellenberg, GD Watson, GS Kukull, W Nelson, PT Jicha, GA Neltner, JH Galasko, D Masliah, E Quinn, JF Chung, KA Yearout, D Mata, IF Wan, JY Edwards, KL Montine, TJ Zabetian, CP AF Tsuang, Debby Leverenz, James B. Lopez, Oscar L. Hamilton, Ronald L. Bennett, David A. Schneider, Julie A. Buchman, Aron S. Larson, Eric B. Crane, Paul K. Kaye, Jeffrey A. Kramer, Patricia Woltjer, Randy Trojanowski, John Q. Weintraub, Daniel Chen-Plotkin, Alice S. Irwin, David J. Rick, Jacqueline Schellenberg, Gerard D. Watson, G. Stennis Kukull, Walter Nelson, Peter T. Jicha, Gregory A. Neltner, Janna H. Galasko, Doug Masliah, Eliezer Quinn, Joseph F. Chung, Kathryn A. Yearout, Dora Mata, Ignacio F. Wan, Jia Y. Edwards, Karen L. Montine, Thomas J. Zabetian, Cyrus P. TI APOE epsilon 4 Increases Risk for Dementia in Pure Synucleinopathies SO JAMA NEUROLOGY LA English DT Article ID APOLIPOPROTEIN-E GENOTYPE; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; LEWY BODIES; COGNITIVE DECLINE; BODY; ALLELE; ASSOCIATION; METAANALYSIS; CONSORTIUM AB Objective: To test for an association between the apolipoprotein E (APOE) epsilon 4 allele and dementias with synucleinopathy. Design: Genetic case-control association study. Setting: Academic research. Patients: Autopsied subjects were classified into 5 categories: dementia with high-level Alzheimer disease (AD) neuropathologic changes (NCs) but without Lewy body disease (LBD) NCs (AD group; n = 244), dementia with LBDNCs and high-level ADNCs (LBD-AD group; n = 224), dementia with LBDNCs and no or low levels of ADNCs (pure DLB [pDLB] group; n = 91), Parkinson disease dementia (PDD) with no or low levels of ADNCs (n = 81), and control group (n = 269). Main Outcome Measure: The APOE allele frequencies. Results: The APOE e4 allele frequency was significantly higher in the AD (38.1%), LBD-AD (40.6%), pDLB (31.9%), and PDD (19.1%) groups compared with the control group (7.2%; overall chi(2)(4) = 185.25; P = 5.56 X 10(-39)), and it was higher in the pDLB group than the PDD group (P = . 01). In an age-adjusted and sex-adjusted dominant model, epsilon 4 was strongly associated with AD (odds ratio, 9.9; 95% CI, 6.4-15.3), LBD-AD (odds ratio, 12.6; 95% CI, 8.1-19.8), pDLB (odds ratio, 6.1; 95% CI, 3.5-10.5), and PDD (odds ratio, 3.1; 95% CI, 1.7-5.6). Conclusions: The APOE epsilon 4 allele is a strong risk factor across the LBD spectrum and occurs at an increased frequency in pDLB relative to PDD. This suggests that epsilon 4 increases the likelihood of presenting with dementia in the context of a pure synucleinopathy. The elevated epsilon 4 frequency in the pDLB and PDD groups, in which the overall brain neuritic plaque burden was low, indicates that apoE might contribute to neurodegeneration through mechanisms unrelated to amyloid processing. JAMA Neurol. 2013;70(2):223-228. Published online November 19, 2012. doi:10.1001/jamaneurol.2013.600 C1 [Tsuang, Debby; Leverenz, James B.; Watson, G. Stennis; Yearout, Dora; Mata, Ignacio F.; Zabetian, Cyrus P.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Tsuang, Debby; Leverenz, James B.; Watson, G. Stennis] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Leverenz, James B.; Yearout, Dora; Mata, Ignacio F.; Zabetian, Cyrus P.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Larson, Eric B.; Crane, Paul K.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Kukull, Walter; Wan, Jia Y.; Edwards, Karen L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Montine, Thomas J.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Larson, Eric B.] Grp Hlth Cooperat Puget Sound, Seattle, WA USA. [Lopez, Oscar L.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Hamilton, Ronald L.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15260 USA. [Trojanowski, John Q.; Irwin, David J.; Schellenberg, Gerard D.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA. [Weintraub, Daniel; Chen-Plotkin, Alice S.; Irwin, David J.; Rick, Jacqueline] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Trojanowski, John Q.] Univ Penn, Inst Aging, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Bennett, David A.; Buchman, Aron S.] Rush Univ, Dept Neurol Sci, Chicago, IL 60612 USA. [Schneider, Julie A.] Rush Univ, Dept Pathol, Chicago, IL 60612 USA. [Kaye, Jeffrey A.; Kramer, Patricia; Quinn, Joseph F.; Chung, Kathryn A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Woltjer, Randy] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA. [Quinn, Joseph F.; Chung, Kathryn A.] Portland VA Med Ctr, Portland, OR USA. [Nelson, Peter T.; Neltner, Janna H.] Univ Kentucky, Dept Pathol, Lexington, KY 40506 USA. [Jicha, Gregory A.] Univ Kentucky, Dept Neurol, Lexington, KY 40506 USA. [Galasko, Doug] Univ Calif San Diego, Dept Neurol, San Diego, CA 92103 USA. [Masliah, Eliezer] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA. RP Zabetian, CP (reprint author), VA Puget Sound Hlth Care Syst, GRECC S-182,1660 S Columbian Way, Seattle, WA 98108 USA. EM zabetian@u.washington.edu RI Crane, Paul/C-8623-2014; Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894 FU National Institutes of Health [P30 AG008017, P30 AG028383, P30 AG010124, P30 AG010161, P50 NS053488, P50 AG005131, P50 NS062684, P50 AG005136, P50 AG005133, R01 NS048595, R01 NS065070, R01 AG010845, U01 AG006781]; Department of Veterans Affairs [1I01BX000531] FX Dr Schneider's work was funded by grants from the National Institutes of Health.; This work was supported by grant 1I01BX000531 from the Department of Veterans Affairs and grants P30 AG008017, P30 AG028383, P30 AG010124, P30 AG010161, P50 NS053488, P50 AG005131, P50 NS062684, P50 AG005136, P50 AG005133, R01 NS048595, R01 NS065070, R01 AG010845, and U01 AG006781 from the National Institutes of Health. NR 37 TC 62 Z9 63 U1 0 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6149 J9 JAMA NEUROL JI JAMA Neurol. PD FEB PY 2013 VL 70 IS 2 BP 223 EP 228 DI 10.1001/jamaneurol.2013.600 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 115GT UT WOS:000316801300010 PM 23407718 ER PT J AU Gabrielian, A MacCumber, MM Kukuyev, A Mitsuyasu, R Holland, GN Sarraf, D AF Gabrielian, Anna MacCumber, Mathew M. Kukuyev, Alla Mitsuyasu, Ronald Holland, Gary N. Sarraf, David TI Didanosine-Associated Retinal Toxicity in Adults Infected With Human Immunodeficiency Virus SO JAMA OPHTHALMOLOGY LA English DT Editorial Material ID ZIDOVUDINE; THERAPY C1 [Gabrielian, Anna; MacCumber, Mathew M.] Rush Univ, Med Ctr, Dept Ophthalmol, Chicago, IL 60612 USA. [Kukuyev, Alla; Holland, Gary N.] Univ Calif Los Angeles, Jules Stein Eye Inst, Ocular Inflammatory Dis Ctr, Los Angeles, CA 90095 USA. [Sarraf, David] Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA 90095 USA. [Kukuyev, Alla; Holland, Gary N.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA. [Mitsuyasu, Ronald] Univ Calif Los Angeles, Ctr Clin AIDS Res & Educ, Los Angeles, CA 90095 USA. [Sarraf, David] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. RP Sarraf, D (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, 100 Stein Plaza, Los Angeles, CA 90095 USA. EM dsarraf@ucla.edu OI Kukuyev, Alla/0000-0003-3472-6523 NR 8 TC 3 Z9 3 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6165 J9 JAMA OPHTHALMOL JI JAMA Ophthalmol. PD FEB PY 2013 VL 131 IS 2 BP 255 EP 259 PG 6 WC Ophthalmology SC Ophthalmology GA 113RB UT WOS:000316684400029 PM 23411900 ER PT J AU Thompson, CF Nabili, V Wang, MB AF Thompson, Christopher F. Nabili, Vishad Wang, Marilene B. TI Pathology Quiz Case 2 Diagnosis SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Editorial Material ID SOLITARY EXTRAMEDULLARY PLASMACYTOMA; NECK REGION; HEAD C1 [Thompson, Christopher F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Thompson, CF (reprint author), VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 9 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6181 J9 JAMA OTOLARYNGOL JI JAMA Otolaryngol-Head Neck Surg. PD FEB PY 2013 VL 139 IS 2 BP 197 EP 198 DI 10.1001/jamaoto.2013.1280a PG 2 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 114HS UT WOS:000316732300016 PM 23429957 ER PT J AU Wen, Y Feng, J Sachs, G AF Wen, Yi Feng, Jing Sachs, George TI Helicobacter pylori 5 ' ureB-sRNA, a cis-Encoded Antisense Small RNA, Negatively Regulates ureAB Expression by Transcription Termination SO JOURNAL OF BACTERIOLOGY LA English DT Article ID 2-COMPONENT SYSTEM; ALLELIC EXCHANGE; ACID ADAPTATION; PEPTIC-ULCER; PH; COLONIZATION; ATTENUATION; MECHANISMS; LEVEL; GENE AB Urease is an essential component of gastric acid acclimation by Helicobacter pylori. The increased level of urease in gastric acidity is due, in part, to acid activation of the two-component system consisting of the membrane sensor HP0165 (ArsS) and its response regulator HP0166 (ArsR), which regulates transcription of the seven genes in two separate operons (ureAB and ureIEFGH) of the urease gene cluster. Recently, we identified a novel cis-encoded antisense small RNA, 5' ureB-sRNA, targeted at the 5' end of ureB, which downregulates ureAB expression by truncation of the ureAB transcript at neutral pH. It is not known whether the truncated transcript is due to transcription termination or processing of the full-length mRNA by codegradation of a ureAB mRNA-sRNA hybrid complex. S1 nuclease mapping assays show that the truncated transcript is due to transcription termination. Further studies using an in vitro transcription assay found that 5' ureB-sRNA promotes premature termination of transcription of ureAB mRNA. These results suggest that the antisense small RNA 5' ureB-sRNA downregulates ureAB expression by enhancing transcription termination 5' of ureB. With this mechanism, a limited amount of 5' ureB-sRNA is sufficient to regulate the relatively high level of ureAB transcript. C1 [Wen, Yi] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Membrane Biol Lab, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Wen, Y (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Membrane Biol Lab, Los Angeles, CA 90095 USA. EM ywen@ucla.edu FU U.S. Veterans Administration; NIH [DK46917, 53462, 58333] FX This work was supported by U.S. Veterans Administration and NIH grants DK46917, 53462, and 58333. NR 44 TC 8 Z9 9 U1 1 U2 10 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0021-9193 J9 J BACTERIOL JI J. Bacteriol. PD FEB PY 2013 VL 195 IS 3 BP 444 EP 452 DI 10.1128/JB.01022-12 PG 9 WC Microbiology SC Microbiology GA 117NS UT WOS:000316960800006 PM 23104809 ER PT J AU Yen, YT Cameron, TA Bensing, BA Seepersaud, R Zambryski, PC Sullam, PM AF Yen, Yihfen T. Cameron, Todd A. Bensing, Barbara A. Seepersaud, Ravin Zambryski, Patricia C. Sullam, Paul M. TI Differential Localization of the Streptococcal Accessory Sec Components and Implications for Substrate Export SO JOURNAL OF BACTERIOLOGY LA English DT Article ID BINDING PROTEIN-GSPB; SURFACE GLYCOPROTEIN GSPB; RICH REPEAT GLYCOPROTEIN; SIGNAL PEPTIDE; STAPHYLOCOCCUS-AUREUS; ESCHERICHIA-COLI; HUMAN PLATELETS; GORDONII; SYSTEM; BIOGENESIS AB The accessory Sec system of Streptococcus gordonii is comprised of SecY2, SecA2, and five proteins (Asp1 through -5) that are required for the export of a serine-rich glycoprotein, GspB. We have previously shown that a number of the Asps interact with GspB, SecA2, or each other. To further define the roles of these Asps in export, we examined their subcellular localization in S. gordonii and in Escherichia coli expressing the streptococcal accessory Sec system. In particular, we assessed how the locations of these accessory Sec proteins were altered by the presence of other components. Using fluorescence microscopy, we found in E. coli that SecA2 localized within multiple foci at the cell membrane, regardless of whether other accessory Sec proteins were expressed. Asp2 alone localized to the cell poles but formed a similar punctate pattern at the membrane when SecA2 was present. Asp1 and Asp3 localized diffusely in the cytosol when expressed alone or with SecA2. However, these proteins redistributed to the membrane in a punctate arrangement when all of the accessory Sec components were present. Cell fractionation studies with S. gordonii further corroborated these microscopy results. Collectively, these findings indicate that Asp1 to -3 are not integral membrane proteins that form structural parts of the translocation channel. Instead, SecA2 serves as a docking site for Asp2, which in turn attracts a complex of Asp1 and Asp3 to the membrane. These protein interactions may be important for the trafficking of GspB to the cell membrane and its subsequent translocation. C1 [Yen, Yihfen T.; Bensing, Barbara A.; Seepersaud, Ravin; Sullam, Paul M.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Yen, Yihfen T.; Bensing, Barbara A.; Seepersaud, Ravin; Sullam, Paul M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Cameron, Todd A.; Zambryski, Patricia C.] Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA. RP Sullam, PM (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA. EM paul.sullam@ucsf.edu OI Cameron, Todd/0000-0002-6608-6551 FU Department of Veterans Affairs; VA Merit Review program; Northern California Institute for Research and Education; American Heart Association [10POST3010018, 12POST11040013]; National Institutes of Health [R01 AI41513, R01 AI057433]; National Science Foundation [MCB-0343566] FX This work was supported by the Department of Veterans Affairs, the VA Merit Review program, the Northern California Institute for Research and Education, grants 10POST3010018 and 12POST11040013 (to Y.T.Y.) from the American Heart Association, grants R01 AI41513 and R01 AI057433 (to P.M.S.) from the National Institutes of Health, and grant MCB-0343566 (to P.C.Z.) from the National Science Foundation. NR 44 TC 6 Z9 6 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0021-9193 J9 J BACTERIOL JI J. Bacteriol. PD FEB PY 2013 VL 195 IS 4 BP 682 EP 695 DI 10.1128/JB.01742-12 PG 14 WC Microbiology SC Microbiology GA 117NW UT WOS:000316961200006 PM 23204472 ER PT J AU Spindler, MA Galifianakis, NB Wilkinson, JR Duda, JE AF Spindler, Meredith A. Galifianakis, Nicholas B. Wilkinson, Jayne R. Duda, John E. TI Globus pallidus interna deep brain stimulation for tardive dyskinesia: Case report and review of the literature SO PARKINSONISM & RELATED DISORDERS LA English DT Review DE Tardive dyskinesia; Tardive dystonia; Deep brain stimulation; Pallidal stimulation; Globus pallidus ID SECONDARY DYSTONIA; PARKINSONS-DISEASE; PATHOPHYSIOLOGY; MECHANISMS; NEURONS; HYPOTHESIS; OUTCOMES; PATIENT; MOOD AB Tardive dyskinesia (TD) can be a disabling condition and is frequently refractory to medical therapy. Over the past decade there have been many reports of TD patients experiencing significant benefit with deep brain stimulation (DBS) of the globus pallidus interna (GPi). The growing literature on this treatment option for TD consists predominantly of case reports and series. The reported benefit ranges widely, but the majority of cases experienced at least a 50% improvement in symptoms. The anatomical distribution of dyskinesias has not clearly influenced outcome, though fixed postures appear less likely to improve than phasic movements. Onset of benefit can be immediate or take months, and benefit is sustained in most cases, for at least 6 months and up to several years. A wide variety of voltages, frequencies, and pulse widths have demonstrated efficacy. A small number of reports which examined psychiatric symptoms before and after surgery did not find any decline, and in some cases revealed improvement in mood. However, these overall positive results should be interpreted with caution, as the majority of reports lacked blinded assessments, control groups, or standardized therapy parameters. Finally, we present an illustrative case of refractory tardive dyskinesia treated with GPi-DBS with 5 years of follow-up and 4 accompanying video segments. Published by Elsevier Ltd. C1 [Spindler, Meredith A.; Wilkinson, Jayne R.; Duda, John E.] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr PADRECC, Philadelphia, PA 19104 USA. [Spindler, Meredith A.; Wilkinson, Jayne R.; Duda, John E.] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Galifianakis, Nicholas B.] Univ Calif San Francisco, Sch Med, Dept Neurol, San Francisco, CA USA. RP Duda, JE (reprint author), Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr PADRECC, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM John.duda@va.gov NR 45 TC 10 Z9 10 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8020 J9 PARKINSONISM RELAT D JI Parkinsonism Relat. Disord. PD FEB PY 2013 VL 19 IS 2 BP 141 EP 147 DI 10.1016/j.parkreldis.2012.09.016 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 115RG UT WOS:000316829000001 PM 23099106 ER PT J AU Levitt, JM Jian, WG Lerner, SP Sonpavde, G AF Levitt, Jonathan M. Jian, Weiguo Lerner, Seth P. Sonpavde, Guru TI A conventional preclinical schedule of cisplatin is more effective than a metronomic frequent bolus schedule for urothelial carcinoma SO UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS LA English DT Article DE Cisplatin; Transitional cell carcinoma; Standard; Metronomic ID TRANSITIONAL-CELL CARCINOMA; PHASE-II TRIAL; GEMCITABINE PLUS CISPLATIN; COOPERATIVE-ONCOLOGY-GROUP; METASTATIC BLADDER-CANCER; 5-DAY CONTINUOUS-INFUSION; LONG-TERM-SURVIVAL; RANDOMIZED-TRIAL; BREAST-CANCER; CHEMOTHERAPY AB Objectives: Given the frequent inability to administer a conventional 3-weekly schedule of cisplatin to human subjects with urothelial carcinoma, we evaluated a frequent bolus metronomic schedule in a preclinical system of transitional cell carcinoma (TCC) of the urothelium. We hypothesized that the anti-angiogenic and anti-cell-migratory activity of lower concentrations of cisplatin may confer similar anti-tumor activity and demonstrate less nephrotoxicity than conventional cytotoxic concentrations. Materials and methods: We evaluated the activity of cisplatin in vitro against human urothelial carcinoma (5637) and endothelial cells (human umbilical vein endothelial cells, HUVECs). The MIT assay was employed to assess viability, and flow cytometry with Annexin-FITC labeling was employed to assess apoptosis. Cell migration in monolayer culture was assessed by scratch assay. Murine xenografts (n = 12 per group) bearing measurable subcutaneous tumors of 5637 cells were administered either no therapy, cisplatin 2 mg/kg/3 days a week (metronomic) or 6 mg/kg/ once a week (standard) intraperitoneal (i.p.) for 4 weeks. Blood was collected from 5 mice per group at baseline and at the end of therapy to measure changes in serum creatinine. Results: Significant antiproliferative activity, but poor pro-apoptotic activity, was observed against 5637 urothelial carcinoma cells in vitro by MIT assay with cisplatin at concentrations lower than those attainable in vivo. Anti-proliferative activity against HUVECs required higher concentrations than attainable in vivo. Anti-migratory activity was observed against 5637 and HUVECs at earlier time points and with concentrations lower than anti-proliferative concentrations. In murine 5637 xenografts, standard cisplatin was significantly better at inhibiting tumor growth than the no treatment control (P = 0.005), while metronomic therapy was not better than control (P = 0.22). Standard cisplatin was also significantly nephrotoxic (P = 0.016), while metronomic cisplatin (P = 0.374) or no therapy (P = 0.178) did not demonstrate significant nephrotoxicity compared with baseline. Conclusions: Cisplatin exhibited anti-cell-migratory activity against urothelial carcinoma and endothelial cells at lower than cytotoxic concentrations. However, a standard preclinical schedule was better than control in vivo for inhibiting tumor growth, while a metronomic schedule was not better. Despite the lower nephrotoxicity of the metronomic schedule, its lower anti-tumor activity suggests that a standard clinical schedule of cisplatin should not be routinely substituted by a split schedule without definitive clinical data. (C) 2013 Elsevier Inc. All rights reserved. C1 [Levitt, Jonathan M.; Jian, Weiguo; Lerner, Seth P.; Sonpavde, Guru] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA. [Levitt, Jonathan M.] Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA. [Sonpavde, Guru] Texas Oncol Canc Ctr, Webster, TX 77598 USA. [Sonpavde, Guru] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Sect Med Oncol, Dept Med, Houston, TX 77030 USA. RP Sonpavde, G (reprint author), Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA. EM gurus@bcm.edu NR 32 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1078-1439 J9 UROL ONCOL-SEMIN ORI JI Urol. Oncol.-Semin. Orig. Investig. PD FEB PY 2013 VL 31 IS 2 BP 234 EP 240 DI 10.1016/j.urolonc.2010.11.004 PG 7 WC Oncology; Urology & Nephrology SC Oncology; Urology & Nephrology GA 114XY UT WOS:000316777500016 PM 21723160 ER PT J AU Sonnenberg, A Boardman, CR AF Sonnenberg, Amnon Boardman, Charles R. TI Costs of Fear SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Editorial Material ID AMERICAN-SURGEONS; PRACTICE PATTERNS C1 [Sonnenberg, Amnon; Boardman, Charles R.] Portland VA Med Ctr, Portland, OR USA. [Sonnenberg, Amnon; Boardman, Charles R.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr P3 GI, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 13 TC 2 Z9 2 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD FEB PY 2013 VL 108 IS 2 BP 173 EP 175 DI 10.1038/ajg.2012.192 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 112NZ UT WOS:000316600300003 PM 23381065 ER PT J AU Sonnenberg, A Genta, RM AF Sonnenberg, Amnon Genta, Robert M. TI Helicobacter pylori is a Risk Factor for Colonic Neoplasms SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID COLORECTAL-CANCER RISK; INTESTINAL METAPLASIA; GASTROINTESTINAL-TRACT; GASTRITIS; INFECTION; DISEASE; IMMUNOHISTOCHEMISTRY; CLASSIFICATION; METAANALYSIS; PATHOLOGY AB OBJECTIVES: It has been suggested that Helicobacter pylori (H. pylori) constitutes a risk for the development of adenomatous polyps and adenocarcinoma of the colon. Our aim was to study the association between H. pylori-positive gastritis and the occurrence of any colonic neoplasm. METHODS: From a computerized database of surgical pathology reports, we selected 156,000 subjects who underwent colonoscopy and esophago-gastro-duodenoscopy with biopsy results from both procedures. RESULTS: Compared with normal gastric mucosa, H. pylori gastritis occurred more frequently among patients with hyperplastic polyps (OR = 1.24, 95 % CI: 1.18-1.30), adenomatous polyps (1.52, 1.46-1.57), advanced adenomas (1.80, 1.69-1.92), villous adenomas or adenomas with high-grade dysplasia (1.97, 1.82-2.14), and adenocarcinomas (2.35, 1.98-2.80). Similarly, the strength of the association between H. pylori-positive gastritis and colonic neoplasm increased with size and number of the adenomas. The association between H. pylori gastritis and the occurrence of colonic neoplasm was similar for different locations of the large bowel. Other gastric conditions etiologically associated with H. pylori, such as intestinal metaplasia, adenoma, lymphoma, and adenocarcinoma, were also significantly associated with an increased risk of colonic neoplasm. CONCLUSIONS: Various forms of gastritis related to H. pylori infection confer an increased risk for colonic neoplasm. In the past, when H. pylori infection was more prevalent, its attributable risk to the occurrence of colorectal neoplasm may have been quite substantial. Am J Gastroenterol 2013; 108: 208-215; doi: 10.1038/ajg.2012.407; published online 4 December 2012 C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Genta, Robert M.] Miraca Life Sci, Irving, TX USA. [Genta, Robert M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Genta, Robert M.] Dallas VA Med Ctr, Dallas, TX USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr P3 GI, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu FU Takeda Pharmaceuticals FX Amnon Sonnenberg is supported by a grant from Takeda Pharmaceuticals. Robert M. Genta is employed by Miraca Life Sciences, Irving, TX. NR 32 TC 52 Z9 58 U1 1 U2 14 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD FEB PY 2013 VL 108 IS 2 BP 208 EP 215 DI 10.1038/ajg.2012.407 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 112NZ UT WOS:000316600300009 PM 23208272 ER PT J AU Harper, N Castiblanco, J Rather, C Andrews, C Ramirez, D Jacobs, RL He, WJ Ahuja, S AF Harper, Nathan Castiblanco, John Rather, Cynthia Andrews, Charles Ramirez, Daniel Jacobs, Robert L. He, Weijing Ahuja, Sunil TI RNA-Seq-Derived Whole Genome Transcriptomic Profiling Following Challenge to Mt. Cedar in a Pollen Challenge Chamber Uncover Novel Insights Into Allergic Rhinoconjunctivitis Pathogenesis SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) CY FEB 22-26, 2013 CL San Antonio, TX SP Amer Acad Allergy, Asthma & Immunol (AAAAI) C1 [Harper, Nathan; Castiblanco, John; He, Weijing; Ahuja, Sunil] South Texas Vet Hlth Care Syst, Vet Adm Ctr Personalized Med, San Antonio, TX USA. [Harper, Nathan; Castiblanco, John; He, Weijing; Ahuja, Sunil] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Rather, Cynthia; Andrews, Charles; Ramirez, Daniel; Jacobs, Robert L.] Biogen Res Chamber, San Antonio, TX USA. RI CASTIBLANCO, JOHN/B-6599-2009 OI CASTIBLANCO, JOHN/0000-0002-7965-9822 NR 0 TC 0 Z9 0 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2013 VL 131 IS 2 SU S BP AB40 EP AB40 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 111WC UT WOS:000316550800147 ER PT J AU He, WJ Carrillo, A Harper, N Jimenez, F Martinez, H Ahuja, S Rather, C Ramirez, D Andrews, C Jacobs, RL Ahuja, S AF He, Weijing Carrillo, Andrew Harper, Nathan Jimenez, Fabio Martinez, Hernan Ahuja, Seema Rather, Cynthia Ramirez, Daniel Andrews, Charles Jacobs, Robert L. Ahuja, Sunil TI Exposure to Juniperus Ashei (Mt. Cedar) Pollen in a Pollen Challenge Chamber Elicits Changes in White Blood Cell Counts and Cytokines in Mountain Cedar Positive and Negative Subjects SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) CY FEB 22-26, 2013 CL San Antonio, TX SP Amer Acad Allergy, Asthma & Immunol (AAAAI) C1 [He, Weijing; Carrillo, Andrew; Harper, Nathan; Jimenez, Fabio; Martinez, Hernan; Ahuja, Seema; Ahuja, Sunil] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [He, Weijing; Carrillo, Andrew; Harper, Nathan; Jimenez, Fabio; Martinez, Hernan; Ahuja, Seema; Ahuja, Sunil] South Texas Vet Hlth Care Syst, Vet Adm Ctr Personalized Med, San Antonio, TX USA. [Rather, Cynthia; Ramirez, Daniel; Andrews, Charles; Jacobs, Robert L.] Biogen Res Chamber, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2013 VL 131 IS 2 SU S BP AB45 EP AB45 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 111WC UT WOS:000316550800165 ER PT J AU Ramirez, D Rather, C Harper, N Carrillo, A He, WJ Andrews, C Ahuja, S Jacobs, RL AF Ramirez, Daniel Rather, Cynthia Harper, Nathan Carrillo, Andrew He, Weijing Andrews, Charles Ahuja, Sunil Jacobs, Robert L. TI Exposure to Juniperus Ashei (Mt. Cedar) and Virginia Live Oak Pollen in a Pollen Challenge Chamber Elicits Similar Symptomology When Compared to Natural Season SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) CY FEB 22-26, 2013 CL San Antonio, TX SP Amer Acad Allergy, Asthma & Immunol (AAAAI) C1 [Ramirez, Daniel; Rather, Cynthia; Andrews, Charles; Jacobs, Robert L.] Biogen Res Chamber, San Antonio, TX USA. [Harper, Nathan; Carrillo, Andrew; He, Weijing; Ahuja, Sunil] South Texas Vet Hlth Care Syst, Vet Adm Ctr Personalized Med, San Antonio, TX USA. [Harper, Nathan; Carrillo, Andrew; He, Weijing; Ahuja, Sunil] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2013 VL 131 IS 2 SU S BP AB49 EP AB49 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 111WC UT WOS:000316550800178 ER PT J AU Viswanathan, RK Mathur, SK AF Viswanathan, Ravi K. Mathur, Sameer K. TI Autoimmune Phenotype in Refractory Chronic Urticaria Does Not Affect Response to Omalizumab SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) CY FEB 22-26, 2013 CL San Antonio, TX SP Amer Acad Allergy, Asthma & Immunol (AAAAI) C1 [Viswanathan, Ravi K.; Mathur, Sameer K.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. [Viswanathan, Ravi K.; Mathur, Sameer K.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2013 VL 131 IS 2 SU S BP AB30 EP AB30 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 111WC UT WOS:000316550800109 ER PT J AU Schult, TM Awosika, ER Schmunk, SK Hodgson, MJ Heymach, BL Parker, CD AF Schult, Tamara M. Awosika, Ebi R. Schmunk, Sandra K. Hodgson, Michael J. Heymach, Bria L. Parker, Celestine Dent TI Sitting on Stability Balls: Biomechanics Evaluation in a Workplace Setting SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Article DE intervention effectiveness; office ergonomics; seating; stability ball ID LOW-BACK-PAIN; SEDENTARY TIME; EXERCISE BALL; OFFICE CHAIR; WORK; PERFORMANCE; DISCOMFORT; COMFORT; DISEASE; HEALTH AB Use of a stability ball alone and stability ball chair were evaluated in the Veterans Health Administration as possible alternatives to incorporate with regular office chair use. The evaluation of stability ball use was conducted under the auspices of a work site health promotion program as a cross-over trial with participants rotating through use of the stability ball, stability ball chair, and regular office chair on a monthly basis for a total duration of 3 months. Rotations on regular office chairs served as the control. Three medical facilities participated. A total of 193 employees completed a baseline questionnaire; 159 completed at least one post-rotation questionnaire. Self-reported measures included perceived posture when sitting, perceptions of overall balance, energy levels, job performance, safety, and pain. Use was associated with improvements in perceived posture (p < 0.0001) and energy levels (p = 0.007) for stability ball users compared with the office chair control, and improvements in perceived posture (p < 0.0001) and overall balance (p = 0.05) for stability ball chair users compared with the control. Use of stability balls at work decreases the likelihood of reporting pain from regular office chair use from approximately 45% to 21%. Alternatively, a high number of participants reported pain with use of the stability ball alone and stability ball chair, 42% and 45%, respectively. The perceived risks and benefits of stability ball use should be weighed when incorporating use. [Supplementary materials are available for this article. Go to the publisher's online edition of Journal of Occupational and Environmental Hygiene for the following free supplementary resource: Post-Active Sitting Device Questionnaire] C1 [Schult, Tamara M.; Awosika, Ebi R.; Schmunk, Sandra K.] Vet Hlth Adm, Off Publ Hlth, Minneapolis, MN 55417 USA. [Hodgson, Michael J.] Vet Hlth Adm, Off Publ Hlth, Washington, DC USA. [Heymach, Bria L.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Parker, Celestine Dent] Birmingham VA Med Ctr, Birmingham, AL USA. RP Schult, TM (reprint author), Vet Hlth Adm, Off Publ Hlth, 1 Vet Dr V68, Minneapolis, MN 55417 USA. EM tamara.schult@va.gov NR 25 TC 6 Z9 6 U1 3 U2 49 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1545-9624 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PD FEB 1 PY 2013 VL 10 IS 2 BP 55 EP 63 DI 10.1080/15459624.2012.748324 PG 9 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 108XG UT WOS:000316329000004 PM 23252582 ER PT J AU Malinoski, D Ewing, T Bhakta, A Schutz, R Imayanagita, B Casas, T Woo, N Margulies, D Barrios, C Lekawa, M Chung, R Bukur, M Kong, A AF Malinoski, Darren Ewing, Tyler Bhakta, Akash Schutz, Randi Imayanagita, Bryan Casas, Tamara Woo, Noah Margulies, Daniel Barrios, Cristobal Lekawa, Michael Chung, Rex Bukur, Marko Kong, Allen TI Which central venous catheters have the highest rate of catheter-associated deep venous thrombosis: A prospective analysis of 2,128 catheter days in the surgical intensive care unit SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY LA English DT Article DE Catheter-associated deep venous thrombosis; risk factors; central venous catheter; critical care ID UPPER-EXTREMITY; VEIN THROMBOSIS; NATURAL-HISTORY; TRAUMA PATIENTS; RISK-FACTORS; ANTICOAGULATION; COMPLICATIONS; TRIAL AB BACKGROUND: Catheter-associated deep venous thromboses (CADVTs) are a common occurrence in the surgical intensive care unit (SICU), necessitating central venous catheter (CVC) removal and replacement. Previous studies evaluating risk factors for CADVT in SICU patients are limited, and most lack a true denominator of all CVC days. We sought to determine the true incidence of and risk factors for CADVT based on patient characteristics as well as CVC site, type, and duration of insertion. METHODS: The following data from all SICU patients in two urban Level I trauma centerswere prospectively collected from 2009 to 2012: demographics, risk factors for DVT, CVC site/type/duration, and duplex results. Sites included the subclavian (SC), internal jugular (IJ), arm (for peripherally inserted central catheter [PICC] lines), and femoral. Types included multilumen (ML), introducer/hemodialysis (I/HD), and PICC. High-risk patients received weekly screening duplex examinations and a CADVT was defined as a DVT being detected on duplex with a CVC in place or within 7 days of removal. Rates of CADVT were normalized per 1,000 CVC days, and independent predictors of CADVT were determined using logistic regression. RESULTS: Data were complete for 184 patients, 354 CVCs, and 2,128 CVC days. Fifty-nine CADVTs were diagnosed in 28% of patients. Rates of CADVT were 9 per 1,000 catheter days for SC, 61 for IJ (p < 0.01 vs. SC), 27 for arm (p < 0.01), 36 for femoral (p < 0.01), 22 for ML, 57 for I/HD (p < 0.01 vs. ML), and 27 for PICC (p = 0.24). After adjusting for patient risk factors, predictors of CADVT included the IJ and arm sites (odds ratio, 6.0 and 3.0 compared with SC) and the I/HD type (odds ratio, 2.6 compared with ML, all p < 0.05). CONCLUSION: The IJ and arm sites and I/HD type are associated with increased CADVT. These data may be used to determine the optimal site and type of CVC for insertion. (J Trauma Acute Care Surg. 2013; 74: 454-462. Copyright (C) 2013 by Lippincott Williams & Wilkins) C1 [Malinoski, Darren] Portland VA Med Ctr, Sect Surg Crit Care, Portland, OR USA. [Ewing, Tyler] Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA. [Schutz, Randi; Imayanagita, Bryan; Woo, Noah; Barrios, Cristobal; Lekawa, Michael; Kong, Allen] Univ Calif Irvine, Div Trauma & Crit Care, Irvine, CA USA. [Malinoski, Darren; Casas, Tamara; Chung, Rex; Bukur, Marko] Cedars Sinai Med Ctr, Dept Surg, Los Angeles, CA 90048 USA. [Bhakta, Akash] Midwestern Univ, Downers Grove, IL 60515 USA. RP Malinoski, D (reprint author), Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Sect Surg Crit Care, POB 1034 P3ANES, Portland, OR 97207 USA. EM malinosk@ohsu.edu NR 21 TC 7 Z9 8 U1 0 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 2163-0755 J9 J TRAUMA ACUTE CARE JI J. Trauma Acute Care Surg. PD FEB PY 2013 VL 74 IS 2 BP 454 EP 460 PG 7 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA 108UH UT WOS:000316321200029 PM 23354238 ER PT J AU Katon, J Reiber, G Williams, MA Yanez, D Miller, E AF Katon, Jodie Reiber, Gayle Williams, Michelle A. Yanez, David Miller, Edith TI Weight Loss After Diagnosis with Gestational Diabetes and Birth Weight Among Overweight and Obese Women SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Gestational weight gain; Weight loss; Gestational diabetes; Birth weight; Obesity ID ANTEPARTUM MATERNAL METABOLISM; PREGNANCY OUTCOMES; GAIN; MELLITUS; RISK; ASSOCIATIONS; VALIDITY; TRENDS AB To determine if, among overweight or obese women with gestational diabetes (GDM), weight loss after GDM diagnosis is associated with lower infant birth weight within levels of overweight or obesity class. Overweight and obese women with singleton pregnancies managed for GDM at a large diabetes and pregnancy program located in Charlotte, NC between November 2000 and April 2010, were eligible for this retrospective cohort study. All were managed using a rigorous standardized clinical protocol. Clinical information including maternal pre-pregnancy body mass index, gestational weight gain, treatment, and medical and obstetric history was abstracted from medical records. The association of weight loss after GDM diagnosis and birth weight was analyzed using linear regression stratified by maternal pre-pregnancy overweight or obesity class (I, II/III). Of the 322 women in this study 19 % lost weight between diagnosis of GDM and delivery. After adjustment for maternal age, parity, race/ethnicity, gestational week at first hemoglobin A1c (A1C), A1C at diagnosis, weight gain prior to GDM, treatment with insulin or oral hypoglycemic agents, gestational age at delivery, and infant sex, weight loss was associated with 238.3 g lower mean infant birth weight among overweight women (95 % CI -393.72, -82.95 g), but was not associated with lower mean infant birth weight among obese class II/III women (95 % CI -275.61, 315.38 g). Weight loss, after diagnosis of GDM, is associated with lower infant birth weight among overweight women, but not among obese class II/III women. C1 [Katon, Jodie; Reiber, Gayle; Williams, Michelle A.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. [Reiber, Gayle] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Reiber, Gayle] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Yanez, David] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA. [Miller, Edith] Carolinas Med Ctr, Diabet & Pregnancy Program, Charlotte, NC 28203 USA. RP Katon, J (reprint author), Univ Washington, Sch Publ Hlth, Dept Epidemiol, POB 357236, Seattle, WA 98195 USA. EM jkaton@u.washington.edu FU NICHD NIH HHS [T32 HD052462] NR 29 TC 3 Z9 3 U1 2 U2 7 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD FEB PY 2013 VL 17 IS 2 BP 374 EP 383 DI 10.1007/s10995-012-1044-5 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 104PC UT WOS:000316005600021 PM 22692470 ER PT J AU Livi, CB Hardman, RL Christy, BA Dodds, SG Jones, D Williams, C Strong, R Bokov, A Javors, MA Ikeno, Y Hubbard, G Hasty, P Sharp, ZD AF Livi, Carolina B. Hardman, Rulon L. Christy, Barbara A. Dodds, Sherry G. Jones, Diane Williams, Charnae Strong, Randy Bokov, Alex Javors, Martin A. Ikeno, Yuji Hubbard, Gene Hasty, Paul Sharp, Zelton Dave TI Rapamycin extends life span of Rb1(+/-) mice by inhibiting neuroendocrine tumors SO AGING-US LA English DT Article DE mTOR; rapamycin; Rb1; neuroendocrine tumors ID GENETICALLY HETEROGENEOUS MICE; FATAL NEOPLASTIC DISEASES; RETINOBLASTOMA GENE; CALORIC RESTRICTION; DELAYED OCCURRENCE; GROWTH-HORMONE; CANCER; CARCINOGENESIS; RB; LONGEVITY AB Chronic treatment of mice with an enterically released formulation of rapamycin (eRapa) extends median and maximum life span, partly by attenuating cancer. The mechanistic basis of this response is not known. To gain a better understanding of these in vivo effects, we used a defined preclinical model of neuroendocrine cancer, Rb1(+/-) mice. Previous results showed that diet restriction (DR) had minimal or no effect on the lifespan of Rb1(+/-) mice, suggesting that the beneficial response to DR is dependent on pRb1. Since long-term eRapa treatment may at least partially mimic chronic DR in lifespan extension, we predicted that it would have a minimal effect in Rb1(+/-) mice. Beginning at 9 weeks of age until death, we fed Rb1(+/-) mice a diet without or with eRapa at 14 mg/kg food, which results in an approximate dose of 2.24 mg/kg body weight per day, and yielded rapamycin blood levels of about 4 ng/ml. Surprisingly, we found that eRapa dramatically extended life span of both female and male Rb1(+/-) mice, and slowed the appearance and growth of pituitary and decreased the incidence of thyroid tumors commonly observed in these mice. In this model, eRapa appears to act differently than DR, suggesting diverse mechanisms of action on survival and anti-tumor effects. In particular the beneficial effects of rapamycin did not depend on the dose of Rb1. C1 [Livi, Carolina B.; Christy, Barbara A.; Dodds, Sherry G.; Jones, Diane; Williams, Charnae; Hasty, Paul; Sharp, Zelton Dave] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA. [Livi, Carolina B.; Christy, Barbara A.; Dodds, Sherry G.; Jones, Diane; Williams, Charnae; Hasty, Paul; Sharp, Zelton Dave] Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, San Antonio, TX 78229 USA. [Hardman, Rulon L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. [Javors, Martin A.; Ikeno, Yuji; Hubbard, Gene] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Bokov, Alex] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Livi, Carolina B.; Christy, Barbara A.; Strong, Randy; Javors, Martin A.; Ikeno, Yuji; Hubbard, Gene; Hasty, Paul; Sharp, Zelton Dave] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. [Livi, Carolina B.; Christy, Barbara A.; Strong, Randy; Hasty, Paul; Sharp, Zelton Dave] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA. [Strong, Randy; Ikeno, Yuji] South Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Res Serv, San Antonio, TX 78229 USA. RP Sharp, ZD (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA. EM sharp@uthscsa.edu FU NIH [ISG 1RC2AG036613-01, 2P01AG017242-12, AG13319, UL1RR025767]; The Glenn Foundation for Medical Research; Department of Veteran Affairs (VA Merit Review Grant); Cancer Therapy Research Center [CA054174]; NCRR [UL 1RR025767]; RCMI [G12MD007591]; NIH (CTSA, Technology Transfer Resource); NIH (CBL) FX The authors gratefully acknowledge Gregory Friesenhahn for rapamycin blood level measurements, Jesse Usrey and Dr. Michael Duff Davis for technical assistance with MRI imaging. Viviane Diaz and the Nathan Shock Animal Core staff provided expert care for our mice. This work was supported by the following funding agencies: NIH (ISG 1RC2AG036613-01, Project 1, ZDS and PH; 2P01AG017242-12, PH; AG13319, YI; UL1RR025767, CTSA, Technology Transfer Resource to ZDS and CBL supported MRI imaging costs associated with this study), The Glenn Foundation for Medical Research (ZDS and YI), Department of Veteran Affairs (VA Merit Review Grant, YI). We would also like to thank the Cancer Therapy Research Center (CA054174), the NCRR (UL 1RR025767) and the RCMI (G12MD007591) for additional support. NR 42 TC 38 Z9 38 U1 1 U2 5 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1945-4589 J9 AGING-US JI Aging-US PD FEB PY 2013 VL 5 IS 2 BP 100 EP 110 PG 11 WC Cell Biology SC Cell Biology GA 104HL UT WOS:000315982700004 PM 23454836 ER PT J AU Fiedler, SE Dudiki, T Vijayaraghavan, S Carr, DW AF Fiedler, Sarah E. Dudiki, Tejasvi Vijayaraghavan, Srinivasan Carr, Daniel W. TI Loss of R2D2 Proteins ROPN1 and ROPN1L Causes Defects in Murine Sperm Motility, Phosphorylation, and Fibrous Sheath Integrity SO BIOLOGY OF REPRODUCTION LA English DT Article DE AKAP; fibrous sheath; OmniBank; PKA; ROPN1; sperm ID ZONA-PELLUCIDA BINDING; TYROSINE PHOSPHORYLATION; KINASE-A; EPIDIDYMAL MATURATION; REGULATORY SUBUNIT; MOUSE SPERMATOZOA; ANCHORING PROTEIN; MAMMALIAN SPERMATOZOA; ACROSOME REACTION; LATE STEPS AB The fibrous sheath (FS) is a flagellar cytoskeletal structure unique to sperm that surrounds the outer dense fibers and axoneme. Its primary components are A-kinase anchoring proteins (AKAPs) 3 and 4, which suggests that the FS affects flagellar beating via the scaffolding of signaling pathways necessary for motility. Sperm proteins ROPN1 and ROPN1L bind AKAP3. To determine the role of ROPN1 and ROPN1L in sperm function, we created mice deficient in ROPN1 (RKO), mice deficient in ROPN1L (RLKO), and double knockout mice (DKO). All three strains of mice had normal testicular morphology and spermatogenesis. Only the DKOs had obvious defects in sperm morphology (thinning and shredding of the principal piece), which was accompanied by a reduction in AKAP3 levels. RLKO mice had slightly reduced sperm motility and increased levels of ROPN1. RKO mice had moderately impaired motility and increased levels of ROPN1L. DKO sperm were immotile. We have previously determined that RKO male mice are subfertile, and DKO males are infertile. Together these data indicate that ROPN1L and ROPN1 compensate for each other in the absence of the opposing protein, possibly to maintain AKAP3 incorporation in the FS. Sperm from mice lacking ROPN1L exhibited reductions in both cAMP-dependent protein kinase (PKA) phosphorylation of a 270-kDa protein (perhaps FSCB), and in capacitation-induced tyrosine phosphorylation. Sperm from mice lacking ROPN1 had reduced levels of FSCB and increased tyrosine phosphorylation of noncapacitated sperm. These data demonstrate that mutations in ROPN1 and ROPN1L can cause defects in FS integrity, sperm motility, and PKA-dependent signaling processes, leading to male infertility. C1 [Fiedler, Sarah E.; Carr, Daniel W.] Portland VA Med Ctr, Portland, OR USA. [Fiedler, Sarah E.; Carr, Daniel W.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Dudiki, Tejasvi; Vijayaraghavan, Srinivasan] Kent State Univ, Dept Biol Sci, Kent, OH 44242 USA. RP Carr, DW (reprint author), Vet Affairs Med Ctr, Mail Code R&D8,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM carrd@ohsu.edu FU Department of Veterans' Affairs Biomedical Laboratory Research and Development Service; Eunice Kennedy Shriver National Institute of Child Health & Human Development [R03HD068668, HD38520] FX Supported by the Department of Veterans' Affairs Biomedical Laboratory Research and Development Service (D. W. C.) and by grants R03HD068668 and HD38520 to D. W. C. and S. V., respectively, from the Eunice Kennedy Shriver National Institute of Child Health & Human Development. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Eunice Kennedy Shriver National Institute of Child Health & Human Development or the National Institutes of Health. NR 51 TC 16 Z9 16 U1 0 U2 6 PU SOC STUDY REPRODUCTION PI MADISON PA 1691 MONROE ST,SUITE # 3, MADISON, WI 53711-2021 USA SN 0006-3363 EI 1529-7268 J9 BIOL REPROD JI Biol. Reprod. PD FEB PY 2013 VL 88 IS 2 AR 41 DI 10.1095/biolreprod.112.105262 PG 10 WC Reproductive Biology SC Reproductive Biology GA 103ZP UT WOS:000315958600001 PM 23303679 ER PT J AU Lindenberger, E Lugassy, M Clark, E Bixby, K Sutcliffe, N Shah, R AF Lindenberger, Elizabeth Lugassy, Mara Clark, Elizabeth Bixby, Kathleen Sutcliffe, Natalie Shah, Ruchir TI Neurodegenerative Diseases: Palliative Care From Day One SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 13-16, 2013 CL New Orleans, LA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Lindenberger, Elizabeth] Mt Sinai Sch Med, New York, NY USA. [Lugassy, Mara] Metropolitan Jewish Hosp, New York, NY USA. [Clark, Elizabeth] James J Peters VA Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA. [Bixby, Kathleen] Dept Vet Affairs, Washington, DC USA. [Sutcliffe, Natalie] James J Peters VA Med Ctr, Bronx, NY USA. [Shah, Ruchir] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2013 VL 45 IS 2 BP 318 EP 319 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 100GE UT WOS:000315684600018 ER PT J AU Bailey, A Leigh, A Redman, A Kennemer, D AF Bailey, Amos Leigh, Alexandra Redman, Amanda Kennemer, Darren TI Disease Update: More Deadly than AIDS, Dying of Hepatitis C Infection in the US SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 13-16, 2013 CL New Orleans, LA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Bailey, Amos; Kennemer, Darren] Birmingham VA Med Ctr, Birmingham, AL USA. [Leigh, Alexandra] Univ Alabama Birmingham, Birmingham Hosp, Birmingham VA Med Ctr, Birmingham, AL USA. [Redman, Amanda] Birmingham VA Med Ctr Birmingham, Birmingham, AL USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2013 VL 45 IS 2 BP 333 EP 333 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 100GE UT WOS:000315684600044 ER PT J AU Schell, J Arnold, R Weisbord, S Moss, A AF Schell, Jane Arnold, Robert Weisbord, Steven Moss, Alvin (Woody) TI The ABCs of Renal Palliative Care: Tools for Decision-Making and Symptom Management in Kidney Disease SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 13-16, 2013 CL New Orleans, LA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Schell, Jane] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Arnold, Robert] Univ Pittsburgh, Pittsburgh, PA USA. [Weisbord, Steven] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Moss, Alvin (Woody)] W Virginia Univ, Sch Med, Morgantown, WV USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2013 VL 45 IS 2 BP 339 EP 340 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 100GE UT WOS:000315684600054 ER PT J AU McMichael, B Stewart, T Villars, P AF McMichael, Brian Stewart, Tanya Villars, Patrice TI "We Took a Sexual History, Now What Do We Do with the Answers?!" SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 13-16, 2013 CL New Orleans, LA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [McMichael, Brian] Sect Palliat Care & Med Eth, Pittsburgh, PA USA. [Stewart, Tanya] Evercare Oregon, Lake Oswego, OR USA. [Villars, Patrice] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2013 VL 45 IS 2 BP 341 EP 342 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 100GE UT WOS:000315684600057 ER PT J AU Aziz, W Getter, B Ross, J Sanchez-Reilly, S Lee, S AF Aziz, Wesam Getter, Benjamin Ross, Jeanette Sanchez-Reilly, Sandra Lee, Shuko TI YouTube as a Palliative Care Source of Information to "The World" SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 13-16, 2013 CL New Orleans, LA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Aziz, Wesam; Getter, Benjamin; Ross, Jeanette; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Aziz, Wesam; Getter, Benjamin; Ross, Jeanette; Sanchez-Reilly, Sandra; Lee, Shuko] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2013 VL 45 IS 2 BP 360 EP 361 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 100GE UT WOS:000315684600086 ER PT J AU Nash, R Bailey, A Bishop, J AF Nash, Ryan Bailey, Amos Bishop, Jeffrey TI A Palliative Response to the Anticipatory Corpse SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 13-16, 2013 CL New Orleans, LA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Nash, Ryan] Univ Alabama Birmingham, Ctr Palliat Care, Birmingham, AL USA. [Bailey, Amos] Birmingham VA Med Ctr, Birmingham, AL USA. [Bishop, Jeffrey] St Louis Univ, St Louis, MO 63103 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2013 VL 45 IS 2 BP 363 EP 364 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 100GE UT WOS:000315684600091 ER PT J AU Patel, C Abel, J Ross, J Lee, S Wiesenthal, A Sanchez-Reilly, S AF Patel, Chikal Abel, Jordan Ross, Jeanette Lee, Shuko Wiesenthal, Alison Sanchez-Reilly, Sandra TI Changing Practice by Changing Hearts: Medical Students Reflecting on Their Hands-on Palliative Care Experience SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 13-16, 2013 CL New Orleans, LA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Patel, Chikal; Abel, Jordan; Ross, Jeanette; Wiesenthal, Alison; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Patel, Chikal; Abel, Jordan; Ross, Jeanette; Lee, Shuko; Sanchez-Reilly, Sandra] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2013 VL 45 IS 2 BP 366 EP 367 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 100GE UT WOS:000315684600096 ER PT J AU Kaiser, R Balish, M Bixby, K Tillman, D AF Kaiser, Robert Balish, Marshall Bixby, Kathleen Tillman, Douglas TI The Promise and Perils of BiPAP: Devising Effective Clinical Practice Guidelines for ALS Patients SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 13-16, 2013 CL New Orleans, LA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Kaiser, Robert] George Washington Univ, Sch Med, DC VA Med Ctr, Washington, DC 20052 USA. [Balish, Marshall; Tillman, Douglas] DC VA Med Ctr, Washington, DC USA. [Bixby, Kathleen] US Dept Vet Affairs, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2013 VL 45 IS 2 BP 377 EP 378 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 100GE UT WOS:000315684600113 ER PT J AU Ahluwalia, S Luhrs, C Cortez, T Bailey, A Shreve, S Baum, H Zuccaro, M AF Ahluwalia, Sangeeta Luhrs, Carol Cortez, Therese Bailey, Amos Shreve, Scott Baum, Hannah Zuccaro, Mary TI The Use of Toolkits for Palliative Care Quality Improvement: The VA's "Strive for 65 Implementation Package'' SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 13-16, 2013 CL New Orleans, LA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Ahluwalia, Sangeeta; Baum, Hannah] Vet Adm, Los Angeles, CA USA. [Luhrs, Carol] VA New York Harbor Hlth Care Syst, Brooklyn, NY USA. [Cortez, Therese] VA Vet Integrated Serv Network 3, New York, NY USA. [Bailey, Amos] Birmingham VA Med Ctr, Birmingham, AL USA. [Shreve, Scott; Zuccaro, Mary] US Dept Vet Affairs, Lebanon, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2013 VL 45 IS 2 BP 391 EP 391 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 100GE UT WOS:000315684600133 ER PT J AU Bearden, D Patel, K Tucker, R Wozencraft, C Allman, R Ahmed, A AF Bearden, Donna Patel, Kanan Tucker, Rodney Wozencraft, Colin Allman, Richard Ahmed, Ali TI Six-Month Natural History of Hospitalized Medicare Beneficiaries With Heart Failure Referred for Hospice Care SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 13-16, 2013 CL New Orleans, LA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Bearden, Donna; Patel, Kanan; Wozencraft, Colin; Allman, Richard; Ahmed, Ali] Univ Alabama Birmingham, Birmingham, AL USA. [Tucker, Rodney] Univ Alabama Birmingham, Ctr Palliat & Support Care, Birmingham, AL USA. [Allman, Richard] Birmingham VA Med Ctr, Birmingham, AL USA. [Ahmed, Ali] VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2013 VL 45 IS 2 BP 421 EP 422 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 100GE UT WOS:000315684600179 ER PT J AU Ersek, M Smith, D Richardson, D Cannuscio, C Moore, D AF Ersek, Mary Smith, Dawn Richardson, Diane Cannuscio, Carolyn Moore, Denise TI A National Study Comparing End-of-life Care for Men and Women Veterans SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 13-16, 2013 CL New Orleans, LA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Ersek, Mary; Richardson, Diane; Moore, Denise] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Smith, Dawn] Univ Penn, Dept Vet Affairs, Philadelphia, PA 19104 USA. [Cannuscio, Carolyn] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2013 VL 45 IS 2 BP 429 EP 430 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 100GE UT WOS:000315684600191 ER PT J AU Jesus, OTV Qiu, A Carretero, E Oliver, DC Sanchez-Reilly, S AF Jesus, Ortiz Ter-Veen Qiu, Ann Carretero, Edgar Oliver, Dulce Cruz Sanchez-Reilly, Sandra TI Barriers to Quality End of Life Care for Latinos: Hospice Healthcare Professionals' Perspective SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 13-16, 2013 CL New Orleans, LA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Jesus, Ortiz Ter-Veen; Qiu, Ann; Carretero, Edgar; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Jesus, Ortiz Ter-Veen; Sanchez-Reilly, Sandra] South Texas Vet Hlth Care Syst, GEC GRECC, San Antonio, TX USA. [Oliver, Dulce Cruz] St Louis Univ, St Louis, MO 63103 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2013 VL 45 IS 2 BP 436 EP 437 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 100GE UT WOS:000315684600202 ER PT J AU Riggs, J Woodby, L Burgio, K Bailey, FA Williams, B AF Riggs, Jennifer Woodby, Lesa Burgio, Kathryn Bailey, F. Amos Williams, Beverly TI Don't Get Weak in Your Compassion: Bereaved Next-of-Kin's Suggestions for Improving End-of-Life Care in VA Medical Centers SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 13-16, 2013 CL New Orleans, LA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Riggs, Jennifer] Birmingham Atlanta VA Geriatr Res Educ & Clin Cnt, Birmingham, AL USA. [Woodby, Lesa] Birmingham VA Med Ctr, Birmingham, AL USA. [Burgio, Kathryn; Williams, Beverly] Univ Alabama Birmingham, Birmingham, AL USA. [Bailey, F. Amos] Univ Alabama Birmingham, Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2013 VL 45 IS 2 BP 450 EP 450 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 100GE UT WOS:000315684600223 ER PT J AU Williams, B Bailey, FA Woodby, L Wittich, A Burgio, K AF Williams, Beverly Bailey, F. Amos Woodby, Lesa Wittich, Angelina Burgio, Kathryn TI We Thought We Had More Time: Exploring Next-of-Kin Accounts of Hospice and Palliative Care Discussions for Veterans Who Died in VA Medical Centers SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 13-16, 2013 CL New Orleans, LA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Williams, Beverly; Burgio, Kathryn] Univ Alabama Birmingham, Birmingham, AL USA. [Bailey, F. Amos] Univ Alabama Birmingham, Birmingham VA Med Ctr, Birmingham, AL USA. [Woodby, Lesa; Wittich, Angelina] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2013 VL 45 IS 2 BP 458 EP 459 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 100GE UT WOS:000315684600236 ER PT J AU Jakupcak, M Hoerster, KD Blais, RK Malte, CA Hunt, S Seal, K AF Jakupcak, Matthew Hoerster, Katherine D. Blais, Rebecca K. Malte, Carol A. Hunt, Stephen Seal, Karen TI Readiness for Change Predicts VA Mental Healthcare Utilization Among Iraq and Afghanistan War Veterans SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; TRANSTHEORETICAL MODEL; RISK-FACTORS; DIAGNOSES; PTSD; PSYCHOTHERAPY; ASSOCIATION; ENGAGEMENT; SERVICES; COMBAT AB Many veterans present to Veteran Affairs (VA) care intending to seek mental health treatment for symptoms of posttraumatic stress disorder (PTSD), depression, and/or alcohol misuse, yet most subsequently underutilize mental health care. This study examined the association of readiness for change with outpatient VA mental health care utilization in 104 treatment-seeking Iraq and Afghanistan war veterans who screened positive for PTSD, depression, and/or alcohol misuse at intake. Multivariate analyses demonstrated that readiness for change assessed at intake was positively associated (Incident Rate Ratio [IRR] = 1.22) with prospective outpatient mental health care utilization with demographic factors, military characteristics, and mental health burden in the model. Results suggest that interventions that target readiness to change, such as motivational interviewing, may improve treatment utilization in veterans presenting for mental health care. C1 [Jakupcak, Matthew; Hoerster, Katherine D.; Blais, Rebecca K.; Malte, Carol A.; Hunt, Stephen] VA Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA USA. [Jakupcak, Matthew; Hoerster, Katherine D.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Blais, Rebecca K.] Univ Utah, Dept Psychol, Salt Lake City, UT 84112 USA. [Seal, Karen] San Francisco VA Med Ctr, San Francisco, CA USA. [Seal, Karen] Univ Calif San Francisco, Dept Med & Psychiat, San Francisco, CA 94143 USA. RP Jakupcak, M (reprint author), VA Puget Sound Hlth Care Syst, Deployment Hlth Serv, 1660 S Columbian Way, Seattle, WA 98108 USA. EM matthew.jakupcak@va.gov NR 22 TC 4 Z9 4 U1 1 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD FEB PY 2013 VL 26 IS 1 BP 165 EP 168 DI 10.1002/jts.21768 PG 4 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 092CH UT WOS:000315095900021 PM 23319359 ER PT J AU Molineros, JE Maiti, AK Sun, C Looger, LL Han, SZ Kim-Howard, X Glenn, S Adler, A Kelly, JA Niewold, TB Gilkeson, GS Brown, EE Alarcon, GS Edberg, JC Petri, M Ramsey-Goldman, R Reveille, JD Vila, LM Freedman, BI Tsao, BP Criswell, LA Jacob, CO Moore, JH Vyse, TJ Langefeld, CL Guthridge, JM Gaffney, PM Moser, KL Scofield, RH Alarcon-Riquelme, ME Williams, SM Merrill, JT James, JA Kaufman, KM Kimberly, RP Harley, JB Nath, SK AF Molineros, Julio E. Maiti, Amit K. Sun, Celi Looger, Loren L. Han, Shizhong Kim-Howard, Xana Glenn, Stuart Adler, Adam Kelly, Jennifer A. Niewold, Timothy B. Gilkeson, Gary S. Brown, Elizabeth E. Alarcon, Graciela S. Edberg, Jeffrey C. Petri, Michelle Ramsey-Goldman, Rosalind Reveille, John D. Vila, Luis M. Freedman, Barry I. Tsao, Betty P. Criswell, Lindsey A. Jacob, Chaim O. Moore, Jason H. Vyse, Timothy J. Langefeld, Carl L. Guthridge, Joel M. Gaffney, Patrick M. Moser, Kathy L. Scofield, R. Hal Alarcon-Riquelme, Marta E. Williams, Scott M. Merrill, Joan T. James, Judith A. Kaufman, Kenneth M. Kimberly, Robert P. Harley, John B. Nath, Swapan K. CA BIOLUPUS Network TI Admixture Mapping in Lupus Identifies Multiple Functional Variants within IFIH1 Associated with Apoptosis, Inflammation, and Autoantibody Production SO PLOS GENETICS LA English DT Article ID CLASS-SWITCH RECOMBINATION; WHOLE-GENOME ASSOCIATION; BINDING-PROTEIN; RIG-I; POPULATION-STRUCTURE; AFRICAN-AMERICANS; REVISED CRITERIA; GENE DISCOVERY; DISEASE GENES; GENOTYPE DATA AB Systemic lupus erythematosus (SLE) is an inflammatory autoimmune disease with a strong genetic component. African-Americans (AA) are at increased risk of SLE, but the genetic basis of this risk is largely unknown. To identify causal variants in SLE loci in AA, we performed admixture mapping followed by fine mapping in AA and European-Americans (EA). Through genome-wide admixture mapping in AA, we identified a strong SLE susceptibility locus at 2q22-24 (LOD = 6.28), and the admixture signal is associated with the European ancestry (ancestry risk ratio similar to 1.5). Large-scale genotypic analysis on 19,726 individuals of African and European ancestry revealed three independently associated variants in the IFIH1 gene: an intronic variant, rs13023380 [P-meta = 5.20x10(-14); odds ratio, 95% confidence interval = 0.82 (0.78-0.87)], and two missense variants, rs1990760 (Ala946Thr) [P-meta = 3.08x10(-7); 0.88 (0.84-0.93)] and rs10930046 (Arg460His) [P-dom = 1.16x10(-8); 0.70 (0.62-0.79)]. Both missense variants produced dramatic phenotypic changes in apoptosis and inflammation-related gene expression. We experimentally validated function of the intronic SNP by DNA electrophoresis, protein identification, and in vitro protein binding assays. DNA carrying the intronic risk allele rs13023380 showed reduced binding efficiency to a cellular protein complex including nucleolin and lupus autoantigen Ku70/80, and showed reduced transcriptional activity in vivo. Thus, in SLE patients, genetic susceptibility could create a biochemical imbalance that dysregulates nucleolin, Ku70/80, or other nucleic acid regulatory proteins. This could promote antibody hypermutation and auto-antibody generation, further destabilizing the cellular network. Together with molecular modeling, our results establish a distinct role for IFIH1 in apoptosis, inflammation, and autoantibody production, and explain the molecular basis of these three risk alleles for SLE pathogenesis. C1 [Molineros, Julio E.; Maiti, Amit K.; Sun, Celi; Han, Shizhong; Kim-Howard, Xana; Glenn, Stuart; Adler, Adam; Kelly, Jennifer A.; Guthridge, Joel M.; Gaffney, Patrick M.; Moser, Kathy L.; Scofield, R. Hal; Alarcon-Riquelme, Marta E.; James, Judith A.; Kaufman, Kenneth M.; Nath, Swapan K.] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Res Program, Oklahoma City, OK 73104 USA. [Looger, Loren L.] Howard Hughes Med Inst, Ashburn, VA USA. [Han, Shizhong] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Niewold, Timothy B.] Mayo Clin, Div Rheumatol, Rochester, MN USA. [Niewold, Timothy B.] Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA. [Gilkeson, Gary S.] Med Univ S Carolina, Div Rheumatol, Charleston, SC 29425 USA. [Brown, Elizabeth E.; Alarcon, Graciela S.; Edberg, Jeffrey C.; Kimberly, Robert P.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Petri, Michelle] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Ramsey-Goldman, Rosalind] Northwestern Univ, Div Rheumatol, Feinberg Sch Med, Chicago, IL 60611 USA. [Reveille, John D.] Univ Texas Hlth Sci Ctr Houston, Dept Rheumatol & Clin Immunogenet, Houston, TX USA. [Vila, Luis M.] Univ Puerto Rico, Div Rheumatol, Dept Med, San Juan, PR 00936 USA. [Freedman, Barry I.] Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC USA. [Tsao, Betty P.] Univ Calif Los Angeles, Dept Med, Div Rheumatol, Los Angeles, CA 90024 USA. [Criswell, Lindsey A.] Univ Calif San Francisco, Rosalind Russell Med Res Ctr Arthrit, San Francisco, CA 94143 USA. [Jacob, Chaim O.] Univ So Calif, Dept Med, Los Angeles, CA USA. [Moore, Jason H.] Dartmouth Med Sch, Dept Genet, Lebanon, NH USA. [Vyse, Timothy J.] Kings Coll London, Div Genet & Mol Med, London WC2R 2LS, England. [Vyse, Timothy J.] Kings Coll London, Div Immunol Infect & Inflammatory Dis, London WC2R 2LS, England. [Langefeld, Carl L.] Wake Forest Univ Hlth Sci, Dept Biostat Sci, Wake Forest, NC USA. [Moser, Kathy L.; James, Judith A.] Univ Oklahoma, Hlth Sci Ctr, Coll Med, Oklahoma City, OK 73190 USA. [Alarcon-Riquelme, Marta E.] Univ Granada, Ctr Genom & Invest Oncol GENyO Pfizer, Granada, Spain. [Williams, Scott M.] Dartmouth Coll, Dept Genet, Geisel Sch Med, Hanover, NH 03755 USA. [Merrill, Joan T.] Oklahoma Med Res Fdn, Clin Pharmacol Res Program, Oklahoma City, OK 73104 USA. [Harley, John B.] Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH USA. [Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. RP Molineros, JE (reprint author), Oklahoma Med Res Fdn, Arthrit & Clin Immunol Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA. EM Swapan-Nath@omrf.org OI Kimberly, Robert/0000-0002-5330-3086; Alarcon Riquelme, Marta Eugenia/0000-0002-7632-4154; Niewold, Timothy/0000-0003-3532-6660 FU National Institutes of Health [AR060366, AR049084, AI094377, AR053483, AR33062, RR020143, RR0155577, AI082714, AR058554, AI083194, AI024717, GM103510, AR057172]; U.S. Department of Defense [AI082714, AI024717, PR094002, AR002138, AR30692, RR025741, AR042460, AI031584, AI101934, AR062277, AR048940, AR043814, DE018209, AI062629, DE015223, RR027190, P60 AR053308, R01 AR44804, M01 RR-00079, UL1 TR000165]; U.S. Department of Veterans Affairs [IMMA 9]; Alliance for Lupus Research; Swedish Research Council; Kirkland Scholar Award; Instituto de Salud Carlos III (European Union Fonds Europeen de Developpement Regional (FEDER)) [PS09/00129]; European Science Foundation (BIOLUPUS) FX This work was supported by grants from the National Institutes of Health (AR060366, AR049084, AI094377, AR053483, AR33062, RR020143, RR0155577, AI082714, AR058554, AI083194, AI024717, GM103510, AR057172), the U.S. Department of Defense (PR094002, AR002138, AR30692, RR025741, AR042460, AI024717, AI031584, AI101934, AR062277, AR048940, AR043814, DE018209, AI082714, AI062629, DE015223, RR027190, PR094002, P60 AR053308, R01 AR44804, M01 RR-00079, UL1 TR000165), the U.S. Department of Veterans Affairs (IMMA 9), the Alliance for Lupus Research, the Swedish Research Council, Kirkland Scholar Award, Instituto de Salud Carlos III (PS09/00129, co-financed through the European Union Fonds Europeen de Developpement Regional (FEDER)), and European Science Foundation (BIOLUPUS). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 77 TC 37 Z9 38 U1 0 U2 10 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7404 J9 PLOS GENET JI PLoS Genet. PD FEB PY 2013 VL 9 IS 2 AR e1003222 DI 10.1371/journal.pgen.1003222 PG 19 WC Genetics & Heredity SC Genetics & Heredity GA 099RG UT WOS:000315638300005 PM 23441136 ER PT J AU Eriksson, S Graf, EH Dahl, V Strain, MC Yukl, SA Lysenko, ES Bosch, RJ Lai, J Chioma, S Emad, F Abdel-Mohsen, M Hoh, R Hecht, F Hunt, P Somsouk, M Wong, J Johnston, R Siliciano, RF Richman, DD O'Doherty, U Palmer, S Deeks, SG Siliciano, JD AF Eriksson, Susanne Graf, Erin H. Dahl, Viktor Strain, Matthew C. Yukl, Steven A. Lysenko, Elena S. Bosch, Ronald J. Lai, Jun Chioma, Stanley Emad, Fatemeh Abdel-Mohsen, Mohamed Hoh, Rebecca Hecht, Frederick Hunt, Peter Somsouk, Ma Wong, Joseph Johnston, Rowena Siliciano, Robert F. Richman, Douglas D. O'Doherty, Una Palmer, Sarah Deeks, Steven G. Siliciano, Janet D. TI Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies SO PLOS PATHOGENS LA English DT Article ID IMMUNODEFICIENCY-VIRUS TYPE-1; CD4(+) T-CELLS; ACTIVE ANTIRETROVIRAL THERAPY; BLOOD MONONUCLEAR-CELLS; LOW-LEVEL VIREMIA; LATENT HIV-1; IN-VIVO; INFECTED INDIVIDUALS; PERIPHERAL-BLOOD; PLASMA VIREMIA AB HIV-1 reservoirs preclude virus eradication in patients receiving highly active antiretroviral therapy (HAART). The best characterized reservoir is a small, difficult-to-quantify pool of resting memory CD4(+) T cells carrying latent but replication-competent viral genomes. Because strategies targeting this latent reservoir are now being tested in clinical trials, well-validated high-throughput assays that quantify this reservoir are urgently needed. Here we compare eleven different approaches for quantitating persistent HIV-1 in 30 patients on HAART, using the original viral outgrowth assay for resting CD4(+) T cells carrying inducible, replication-competent viral genomes as a standard for comparison. PCR-based assays for cells containing HIV-1 DNA gave infected cell frequencies at least 2 logs higher than the viral outgrowth assay, even in subjects who started HAART during acute/early infection. This difference may reflect defective viral genomes. The ratio of infected cell frequencies determined by viral outgrowth and PCR-based assays varied dramatically between patients. Although strong correlations with the viral outgrowth assay could not be formally excluded for most assays, correlations achieved statistical significance only for integrated HIV-1 DNA in peripheral blood mononuclear cells and HIV-1 RNA/DNA ratio in rectal CD4(+) T cells. Residual viremia was below the limit of detection in many subjects and did not correlate with the viral outgrowth assays. The dramatic differences in infected cell frequencies and the lack of a precise correlation between culture and PCR-based assays raise the possibility that the successful clearance of latently infected cells may be masked by a larger and variable pool of cells with defective proviruses. These defective proviruses are detected by PCR but may not be affected by reactivation strategies and may not require eradication to accomplish an effective cure. A molecular understanding of the discrepancy between infected cell frequencies measured by viral outgrowth versus PCR assays is an urgent priority in HIV-1 cure research. C1 [Eriksson, Susanne; Dahl, Viktor; Palmer, Sarah] Swedish Inst Communicable Dis, Dept Diagnost & Vaccinol, Solna, Sweden. [Eriksson, Susanne; Dahl, Viktor; Palmer, Sarah] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Solna, Sweden. [Graf, Erin H.; Lysenko, Elena S.; O'Doherty, Una] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA. [Strain, Matthew C.; Richman, Douglas D.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Strain, Matthew C.; Richman, Douglas D.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA. [Yukl, Steven A.; Wong, Joseph] San Francisco VA Med Ctr, San Francisco, CA USA. [Yukl, Steven A.; Abdel-Mohsen, Mohamed; Hoh, Rebecca; Hecht, Frederick; Hunt, Peter; Somsouk, Ma; Wong, Joseph; Deeks, Steven G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Bosch, Ronald J.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Lai, Jun; Chioma, Stanley; Emad, Fatemeh; Siliciano, Robert F.; Siliciano, Janet D.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Johnston, Rowena] Fdn AIDS Res, AmfAR, New York, NY USA. [Siliciano, Robert F.] Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA. RP Eriksson, S (reprint author), Swedish Inst Communicable Dis, Dept Diagnost & Vaccinol, Solna, Sweden. EM jsilicia@jhmi.edu OI Dahl, Viktor/0000-0001-9921-5172 FU ARCHE Collaborative Research Grant from the Foundation for AIDS Research [amFAR 108165-50-RGRL]; Martin Delaney CARE and DARE Collaboratories(NIH) [AI096113, 1U19AI096109]; NIH [43222]; Howard Hughes Medical Institute; Department of Veterans Affairs [1 IK2 CX000520-01]; James Pendleton Charitable Trust; National Institutes of Health [AI 080193, AI74621, AI69432-S]; CFAR [AI306214]; NIAID [RO1AIO87145, K24AIO69994]; UCSF/Gladstone CFAR [P30 AIO27763]; UCSF Clinical and Translational Research Institute Clinical Research Center [UL 1 RR024131]; Center for AIDS Prevention Studies [P30 MH62246] FX This work was supported by an ARCHE Collaborative Research Grant from the Foundation for AIDS Research (amFAR 108165-50-RGRL), by the Martin Delaney CARE and DARE Collaboratories(NIH grants AI096113 and 1U19AI096109), and by NIH grant 43222 (RFS), and by the Howard Hughes Medical Institute (RFS). For MS and DDR, this work was supported by the Department of Veterans Affairs, the James Pendleton Charitable Trust, National Institutes of Health (AI 080193, AI74621, AI69432-S), and CFAR grant AI306214. For SAY, this work was supported by the Department of Veterans Affairs (VA Career Development Award 1 IK2 CX000520-01). The UCSF SCOPE cohort was supported in part by the NIAID (RO1AIO87145, K24AIO69994), the UCSF/Gladstone CFAR (P30 AIO27763), the UCSF Clinical and Translational Research Institute Clinical Research Center (UL 1 RR024131) and the Center for AIDS Prevention Studies (P30 MH62246). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 84 TC 160 Z9 161 U1 5 U2 30 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7374 J9 PLOS PATHOG JI PLoS Pathog. PD FEB PY 2013 VL 9 IS 2 AR e1003174 DI 10.1371/journal.ppat.1003174 PG 17 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA 099UU UT WOS:000315648900024 PM 23459007 ER PT J AU Chan, ED Iseman, MD AF Chan, Edward D. Iseman, Michael D. TI Underlying Host Risk Factors for Nontuberculous Mycobacterial Lung Disease SO SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Review DE Marfan syndrome; environmental mycobacteria; bronchiectasis; pectus excavatum; scoliosis; nontuberculous mycobacteria ID PULMONARY ALVEOLAR PROTEINOSIS; ANTITUMOR NECROSIS FACTOR; RAPIDLY GROWING MYCOBACTERIA; CHRONIC MYELOGENOUS LEUKEMIA; WILLIAMS-CAMPBELL-SYNDROME; AVIUM COMPLEX DISEASE; MITRAL-VALVE-PROLAPSE; MOUNIER-KUHN-SYNDROME; AFRICAN GOLD MINERS; GROWTH-FACTOR-BETA AB Nontuberculous mycobacteria (NTM) are environmental microbes that cause a variety of human diseases, particularly chronic lung infections. Despite the fact that NTM are widespread in the environment, relatively few people develop NTM lung disease, suggesting intrinsic vulnerability in some individuals. This paper reviews the evidence that underlying disorders predispose to NTM lung disease, in particular primary conditions that result in bronchiectasis, chronic obstructive pulmonary disease, alpha-1-antitrypsin anomalies, pneumoconiosis, pulmonary alveolar proteinosis, and frank immunosuppressive states such as that associated with the use of anti-tumor necrosis factor-alpha biologics, posttransplantation immunosuppression, and HIV infection. Over the past several decades, NTM lung disease has been increasingly identified in postmenopausal women with slender body habitus. Thus we will also review the clinical and experimental evidence which supports the observation that such individuals are predisposed to NTM lung disease. C1 [Chan, Edward D.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Chan, Edward D.; Iseman, Michael D.] Natl Jewish Hlth, Dept Med, Denver, CO 80206 USA. [Chan, Edward D.] Natl Jewish Hlth, Cell Biol Program, Denver, CO 80206 USA. [Chan, Edward D.; Iseman, Michael D.] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Denver, CO USA. [Iseman, Michael D.] Univ Colorado Denver, Div Infect Dis, Denver, CO USA. RP Chan, ED (reprint author), Natl Jewish Hlth, D509,Neustadt Bldg,1400 Jackson St, Denver, CO 80206 USA. EM chane@njhealth.org NR 139 TC 34 Z9 35 U1 0 U2 8 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 1069-3424 EI 1098-9048 J9 SEMIN RESP CRIT CARE JI Semin. Respir. Crit. Care Med. PD FEB PY 2013 VL 34 IS 1 BP 110 EP 123 DI 10.1055/s-0033-1333573 PG 14 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 101RY UT WOS:000315793300011 PM 23460011 ER PT J AU Mata, IF Alvarez, V Ribacoba, R Infante, J Sierra, M Gomez-Garre, P Mir, P Waldherr, S Yearout, D Zabetian, CP AF Mata, Ignacio F. Alvarez, Victoria Ribacoba, Renee Infante, Jon Sierra, Maria Gomez-Garre, Pilar Mir, Pablo Waldherr, Sarah Yearout, Dora Zabetian, Cyrus P. CA Latin Amer Res Consortium Genetics TI Novel Lrrk2-p.S1761R mutation is not a common cause of Parkinson's disease in Spain SO MOVEMENT DISORDERS LA English DT Letter C1 [Mata, Ignacio F.; Waldherr, Sarah; Yearout, Dora; Zabetian, Cyrus P.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Mata, Ignacio F.; Zabetian, Cyrus P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Alvarez, Victoria] Hosp Univ Cent Asturias, Lab Genet Mol, Inst Invest Nefrol, Oviedo, Spain. [Ribacoba, Renee] Hosp Univ Cent Asturias, Dept Neurol, Oviedo, Spain. [Infante, Jon; Gomez-Garre, Pilar; Mir, Pablo] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Neurodegenerat, Barcelona, Spain. [Infante, Jon; Sierra, Maria] Marques de Valdecilla Univ Hosp, Dept Neurol, Santander, Spain. [Gomez-Garre, Pilar; Mir, Pablo] Univ Seville, Hosp Univ Virgen del Rocio, Unidad Trastornos Movimiento, CSIC,Serv Neurol & Neurofisiol Clin,Inst Biomed S, Seville, Spain. RP Mata, IF (reprint author), VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr S182, 1660 S Columbian Way, Seattle, WA 98108 USA. EM nachofm@u.washington.edu RI IBIS, MOVIMIENTO/P-3309-2015; Mir, Pablo/C-8662-2013 OI Mir, Pablo/0000-0003-1656-302X; Fernandez Mata, Ignacio/0000-0003-1198-0633; Gomez-Garre, Pilar/0000-0002-0437-6182; Zabetian, Cyrus/0000-0002-7739-4306 FU BLRD VA [I01 BX000531]; FIC NIH HHS [R25 TW009345]; NINDS NIH HHS [P50 NS062684, R01 NS065070] NR 3 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD FEB PY 2013 VL 28 IS 2 BP 248 EP 248 DI 10.1002/mds.25293 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 096JF UT WOS:000315399300026 PM 23389884 ER PT J AU Murray, AL Morgenroth, DC Czerniecki, JM AF Murray, Andrew L. Morgenroth, David C. Czerniecki, Joseph M. TI Residual Limb Claudication in a Traumatic Transtibial Amputee SO PM&R LA English DT Article ID BACK-PAIN; PHANTOM PAIN; AMPUTATION AB Residual limb pain is a common symptom in the lower extremity amputee population with a fairly broad differential diagnosis. One etiology of residual limb pain that has previously received limited discussion in the literature is that of vascular claudication. Increased awareness of this etiology is important given the prevalence of vascular disease in both the general population and in lower extremity amputees. This article discusses a presentation of residual limb vascular claudication, describes a clinical approach to the problem, and discusses a potential pathophysiologic mechanism for vascular claudication in the amputee that differs from the nonamputee. PM R 2013;5:152-154 C1 [Murray, Andrew L.; Morgenroth, David C.; Czerniecki, Joseph M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Morgenroth, David C.; Czerniecki, Joseph M.] VA Puget Sound Hlth Care Syst, Rehabil Care Serv, Seattle, WA 98108 USA. RP Morgenroth, DC (reprint author), VA Puget Sound Hlth Care Syst, Rehabil Care Serv, 1660 S Columbian Way,RCS 117, Seattle, WA 98108 USA. EM dmorgen@uw.edu OI Morgenroth, David/0000-0002-0226-7775 NR 15 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1934-1482 J9 PM&R JI PM&R PD FEB PY 2013 VL 5 IS 2 BP 152 EP 154 DI 10.1016/j.pmrj.2012.08.003 PG 3 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 095VP UT WOS:000315363400011 PM 23415251 ER PT J AU Mishra, RK Li, YM Ricardo, AC Yang, W Keane, M Cuevas, M Christenson, R DeFilippi, C Chen, J He, J Kallem, RR Raj, DS Schelling, JR Wright, J Go, AS Shlipak, MG AF Mishra, Rakesh K. Li, Yongmei Ricardo, Ana C. Yang, Wei Keane, Martin Cuevas, Magdalena Christenson, Robert DeFilippi, Christopher Chen, Jing He, Jiang Kallem, Radhakrishna R. Raj, Dominic S. Schelling, Jeffrey R. Wright, Jackson Go, Alan S. Shlipak, Michael G. CA Chronic Renal Insufficiency Cohort TI Association of N-Terminal Pro-B-Type Natriuretic Peptide With Left Ventricular Structure and Function in Chronic Kidney Disease (from the Chronic Renal Insufficiency Cohort [CRIC]) SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID HEART-FAILURE; CARDIOVASCULAR EVENTS; DIASTOLIC FUNCTION; MORTALITY; BNP; HEMODIALYSIS; HYPERTROPHY; MASS; CKD; ECHOCARDIOGRAPHY AB We evaluated the cross-sectional associations of N-terminal pro-B-type natriuretic peptide (NT-proBNP) with cardiac structural and functional abnormalities in a cohort of patients with chronic kidney disease without clinical heart failure, the Chronic Renal Insufficiency Cohort (n = 3,232). The associations of NT-proBNP with echocardiographically determined left ventricular (LV) mass and LV systolic and diastolic function were evaluated using multivariate logistic and linear regression models. Reclassification of participants' predicted risk of LV hypertrophy (LVH), systolic and diastolic dysfunction was performed using a category-free net reclassification improvement index that compared a clinical model with and without NT-proBNP. The median NT-proBNP was 126.6 pg/ml (interquartile range 55.5 to 303.7). The greatest quartile of NT-proBNP was associated with a nearly threefold odds of LVH (odds ratio 2.7, 95% confidence interval [CI] 1.8 to 4.0) and LV systolic dysfunction (odds ratio 2.7, 95% CI 1.7 to 4.5) and a twofold odds of diastolic dysfunction (odds ratio 2.0, 95% CI 1.3 to 2.9) in the fully adjusted models. When evaluated alone as a screening test, NT-proBNP functioned modestly for the detection of LVH (area under the curve 0.66) and LV systolic dysfunction (area under the curve 0.62) and poorly for the detection of diastolic dysfunction (area under the curve 0.51). However, when added to the clinical model, NT-proBNP significantly reclassified participants' likelihood of having LVH (net reclassification improvement 0.14, 95% CI 0.13-0.15; p < 0.001) and LV systolic dysfunction (net reclassification improvement 0.28, 95% CI 0.27 to 0.30; p < 0.001) but not diastolic dysfunction (net reclassification improvement 0.10, 95% CI 0.10 to 0.11; p = 0.07). In conclusion, in this large chronic kidney disease cohort without heart failure, NT-proBNP had strong associations with prevalent LVH and LV systolic dysfunction. (C) 2013 Elsevier Inc. All rights reserved. (Am J Cardiol 2013;111:432-438) C1 [Mishra, Rakesh K.; Shlipak, Michael G.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Mishra, Rakesh K.; Li, Yongmei; Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA. [Ricardo, Ana C.] Univ Illinois, Chicago, IL USA. [Yang, Wei] Univ Penn, Sci & Data Coordinating Ctr, Philadelphia, PA 19104 USA. [Keane, Martin; Cuevas, Magdalena] Hosp Univ Penn, Philadelphia, PA 19104 USA. [Christenson, Robert; DeFilippi, Christopher] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA. [Chen, Jing; He, Jiang] Tulane Univ, Sch Publ Hlth & Trop Med, New Orleans, LA USA. [Kallem, Radhakrishna R.] Univ Penn, Philadelphia, PA 19104 USA. [Raj, Dominic S.] George Washington Univ, Washington, DC USA. [Schelling, Jeffrey R.] MetroHlth Med Ctr, Cleveland, OH USA. [Schelling, Jeffrey R.; Wright, Jackson] Case Western Univ, Cleveland, OH USA. [Go, Alan S.] Kaiser Permanente Div Res, Oakland, CA USA. RP Mishra, RK (reprint author), Univ Calif San Francisco, San Francisco, CA 94143 USA. EM rakesh.mishra@ucsf.edu RI Yang, Wei/A-9223-2009 OI Yang, Wei/0000-0001-8984-4389 FU Chronic Renal Insufficiency Cohort General Clinical Research Center and Clinical and Translational Science Award [UL1 RR-024134, UL1 RR-025005, M01RR-16500, UL1 RR-024989, M01 RR-000042, UL1 RR-024986, UL1 RR-029879, 2 U01 DK060902]; [R01 DK066488] FX This project was supported by R01 DK066488 award (to principal investigator M. G. Shlipak); and in part by the Chronic Renal Insufficiency Cohort General Clinical Research Center and Clinical and Translational Science Award grants: UL1 RR-024134 to the University of Pennsylvania (Philadelphia, Pennsylvania), UL1 RR-025005 to Johns Hopkins University (Baltimore, Maryland), M01RR-16500 to University of Maryland (College Park, Maryland), UL1 RR-024989 to Case Western Reserve University (Cleveland, Ohio), M01 RR-000042 and UL1 RR-024986 to University of Michigan (Ann Arbor, Michigan), UL1 RR-029879 to University of Illinois at Chicago (Chicago, Illinois), and 2 U01 DK060902 to the Kaiser Permanente Division of Research in Oakland (Oakland, California). NR 28 TC 16 Z9 18 U1 0 U2 3 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD FEB 1 PY 2013 VL 111 IS 3 BP 432 EP 438 DI 10.1016/j.amjcard.2012.10.019 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 083BM UT WOS:000314437700022 PM 23178053 ER PT J AU Mikuls, TR Padala, PR Sayles, HR Yu, F Michaud, K Caplan, L Kerr, GS Reimold, A Cannon, GW Richards, JS Lazaro, D Thiele, GM Boscarino, JA AF Mikuls, Ted R. Padala, Prasad R. Sayles, Harlan R. Yu, Fang Michaud, Kaleb Caplan, Liron Kerr, Gail S. Reimold, Andreas Cannon, Grant W. Richards, J. Steuart Lazaro, Deana Thiele, Geoffrey M. Boscarino, Joseph A. TI Prospective study of posttraumatic stress disorder and disease activity outcomes in US veterans with rheumatoid arthritis SO ARTHRITIS CARE & RESEARCH LA English DT Article ID GULF-WAR VETERANS; CHRONIC PAIN; ANXIETY DISORDERS; VIETNAM VETERANS; PTSD SYMPTOMS; CARE; ASSOCIATION; MORTALITY; EXPOSURE; ILLNESS AB Objective To examine the relationship between posttraumatic stress disorder (PTSD) and disease activity in US veterans with rheumatoid arthritis (RA). Methods US veterans with RA were enrolled in a longitudinal observational study and were categorized as having PTSD, other anxiety/depression disorders, or neither of these psychiatric diagnoses using administrative codes. Generalized linear mixed-effects models were used to examine the associations of the diagnostic groups with outcomes measured over a mean followup period of 3.0 years. Results At enrollment, 1,522 patients had a mean age of 63 years, they were primarily men (91%), and a majority (78%) reported white race. A diagnosis of PTSD was observed in 178 patients (11.7%), and other anxiety/depression diagnoses (excluding PTSD) were found in 360 patients (23.7%). The presence of a PTSD diagnosis was independently associated with higher values of self-reported pain, physical impairment, tender joint count, and worse patient global well-being scores compared to patients with no psychiatric diagnosis. There were no significant group differences in swollen joint count, erythrocyte sedimentation rate, or Disease Activity Score in 28 joints. There were no differences between any outcomes comparing those with PTSD and those with other anxiety/depression diagnoses. Conclusion In this RA cohort, the diagnosis of PTSD was associated with worse patient-reported outcomes and tender joint counts, but not with other physician- or laboratory-based measures of disease activity. These results suggest that PTSD, along with other anxiety/depression disorders, may affect RA disease activity assessments that rely on patient-reported outcomes and the resulting treatment decisions. C1 [Mikuls, Ted R.; Thiele, Geoffrey M.] Omaha VAMC, Omaha, NE 68198 USA. [Mikuls, Ted R.; Sayles, Harlan R.; Yu, Fang; Michaud, Kaleb; Thiele, Geoffrey M.] Univ Nebraska Med Ctr, Omaha, NE 68198 USA. [Padala, Prasad R.] Little Rock VAMC, Little Rock, AR USA. [Caplan, Liron] Denver VAMC, Denver, CO USA. [Caplan, Liron] Univ Colorado, Sch Med, Denver, CO USA. [Kerr, Gail S.; Richards, J. Steuart] DC VAMC, Washington, DC USA. [Kerr, Gail S.] Georgetown Univ Hosp, Washington, DC 20007 USA. [Reimold, Andreas] Dallas VAMC, Dallas, TX USA. [Reimold, Andreas] Univ Texas SW, Dallas, TX USA. [Cannon, Grant W.] George E Wahlen VAMC, Salt Lake City, UT USA. [Cannon, Grant W.] Univ Utah, Salt Lake City, UT USA. [Lazaro, Deana] Brooklyn VAMC, Brooklyn, NY USA. [Boscarino, Joseph A.] Weis Ctr Res, Geisinger Clin, Danville, PA 17822 USA. RP Mikuls, TR (reprint author), Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE 68198 USA. EM tmikuls@unmc.edu RI Yu, Fang/B-9874-2013 OI Thiele, Geoffrey/0000-0001-5688-8596 FU Nebraska Arthritis Outcomes Research Center at the University of Nebraska Medical Center; Veterans Health Administration; Abbott Laboratories; Bristol-Myers Squibb; Veterans Affairs Health Services Research and Development Program Career Development Award [CDA 07-221] FX Supported by the Nebraska Arthritis Outcomes Research Center at the University of Nebraska Medical Center. The Veterans Affairs Rheumatoid Arthritis registry is supported by the Veterans Affairs Health Services Research and Development Program of the Veterans Health Administration and unrestricted research grants from Abbott Laboratories and Bristol-Myers Squibb. Dr. Mikuls' work was supported by the Veterans Health Administration (Veterans Affairs Merit award). Dr. Caplan's work was supported by a Veterans Affairs Health Services Research and Development Program Career Development Award (CDA 07-221). NR 36 TC 9 Z9 9 U1 4 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X J9 ARTHRIT CARE RES JI Arthritis Care Res. PD FEB PY 2013 VL 65 IS 2 BP 227 EP 234 DI 10.1002/acr.21778 PG 8 WC Rheumatology SC Rheumatology GA 083LW UT WOS:000314466600008 PM 22740431 ER PT J AU Fryer, SL Jorgensen, KW Yetter, EJ Daurignac, EC Watson, TD Shanbhag, H Krystal, JH Mathalon, DH AF Fryer, Susanna L. Jorgensen, Kasper W. Yetter, Elizabeth J. Daurignac, Elsa C. Watson, Todd D. Shanbhag, Harshad Krystal, John H. Mathalon, Daniel H. TI Differential brain response to alcohol cue distractors across stages of alcohol dependence SO BIOLOGICAL PSYCHOLOGY LA English DT Article DE Abstinence; Alcoholism; Amygdala; Anterior cingulate; Cognitive control; Distraction; Inferior parietal lobule ID ANTERIOR CINGULATE CORTEX; PREFRONTAL CORTEX; ABSTINENT ALCOHOLICS; VENTRAL STRIATUM; ODDBALL TASK; ACTIVATION; FMRI; AMYGDALA; STIMULI; EMOTION AB Altered attention to alcohol-related cues is implicated in the craving and relapse cycle characteristic of alcohol dependence (ALC). Prior cue reactivity studies typically invoke explicit attention to alcohol cues, so the neural response underlying incidental cue exposure remains unclear. Here, we embed infrequent, task-irrelevant alcohol and non-alcohol cues in an attention-demanding task, enabling evaluation of brain responses to distracting alcohol cues. Alcohol dependent individuals, across illness phase (n = 44), and controls (n = 20) performed a cue-reactivity fMRI target detection task. Significant Group-by-Distractor effects were observed in dorsal anterior cingulate cortex (ACC), inferior parietal lobule, and amygdala. Controls and long-term abstainers increased recruitment of attention and cognitive control regions, while recent and long-term abstainers decreased limbic recruitment to alcohol distractors. Across phases of ALC, self-reported craving positively correlated with cue-related activations in ventral ACC, medial prefrontal cortex, and cerebellum. Results indicate that brain responses elicited by incidental alcohol cues differentiate phases of ALC. (C) 2012 Elsevier B.V. All rights reserved. C1 [Fryer, Susanna L.; Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Fryer, Susanna L.; Jorgensen, Kasper W.; Yetter, Elizabeth J.; Shanbhag, Harshad; Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Daurignac, Elsa C.] SUNY Buffalo, Dept Psychiat, Buffalo, NY 14260 USA. [Watson, Todd D.] Lewis & Clark Coll, Dept Psychol, Portland, OR 97219 USA. [Krystal, John H.; Mathalon, Daniel H.] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA. RP Mathalon, DH (reprint author), San Francisco VA Med Ctr, Psychiat Serv 116D, 4150 Clement St, San Francisco, CA 94121 USA. EM daniel.mathalon@ucsf.edu OI Mathalon, Daniel/0000-0001-6090-4974 FU NIAAA [P50-AA-12870]; Alcohol Beverage Medical Research Foundation; NIMH [T32 MH089920] FX This work was supported by grants from NIAAA P50-AA-12870 (to J.H. Krystal), the Alcohol Beverage Medical Research Foundation (to D.H. Mathalon), and NIMH T32 MH089920 (to J.M. Ford). The authors thank Drs. Mark George and Andreas Heinz for facilitating access to stimulus sets developed in their laboratories. NR 63 TC 10 Z9 10 U1 5 U2 20 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0301-0511 J9 BIOL PSYCHOL JI Biol. Psychol. PD FEB PY 2013 VL 92 IS 2 BP 282 EP 291 DI 10.1016/j.biopsycho.2012.10.004 PG 10 WC Psychology, Biological; Behavioral Sciences; Psychology; Psychology, Experimental SC Psychology; Behavioral Sciences GA 095DU UT WOS:000315315700025 PM 23131612 ER PT J AU Fox, ER Musani, SK Barbalic, M Lin, HH Yu, B Ogunyankin, KO Smith, NL Kutlar, A Glazer, NL Post, WS Paltoo, DN Dries, DL Farlow, DN Duarte, CW Kardia, SL Meyers, KJ Sun, YV Arnett, DK Patki, AA Sha, J Cui, XQ Samdarshi, TE Penman, AD Bibbins-Domingo, K Buzkova, P Benjamin, EJ Bluemke, DA Morrison, AC Heiss, G Carr, JJ Tracy, RP Mosley, TH Taylor, HA Psaty, BM Heckbert, SR Cappola, TP Vasan, RS AF Fox, Ervin R. Musani, Solomon K. Barbalic, Maja Lin, Honghuang Yu, Bing Ogunyankin, Kofo O. Smith, Nicholas L. Kutlar, Abdullah Glazer, Nicole L. Post, Wendy S. Paltoo, Dina N. Dries, Daniel L. Farlow, Deborah N. Duarte, Christine W. Kardia, Sharon L. Meyers, Kristin J. Sun, Yan V. Arnett, Donna K. Patki, Amit A. Sha, Jin Cui, Xiangqui Samdarshi, Tandaw E. Penman, Alan D. Bibbins-Domingo, Kirsten Buzkova, Petra Benjamin, Emelia J. Bluemke, David A. Morrison, Alanna C. Heiss, Gerardo Carr, J. Jeffrey Tracy, Russell P. Mosley, Thomas H. Taylor, Herman A. Psaty, Bruce M. Heckbert, Susan R. Cappola, Thomas P. Vasan, Ramachandran S. TI Genome-Wide Association Study of Cardiac Structure and Systolic Function in African Americans The Candidate Gene Association Resource (CARe) Study SO CIRCULATION-CARDIOVASCULAR GENETICS LA English DT Article DE echocardiography; ethnic; genome-wide association studies; left atrium genetics; left ventricular mass genetics ID LEFT-VENTRICULAR MASS; COMMON DISEASES; HYPERTROPHY; VARIANTS; SUSCEPTIBILITY; CONTRACTILITY; HYPERTENSION; HYPERGEN; LINKAGE; MARKERS AB Background-Using data from 4 community-based cohorts of African Americans, we tested the association between genome-wide markers (single-nucleotide polymorphisms) and cardiac phenotypes in the Candidate-gene Association Resource study. Methods and Results-Among 6765 African Americans, we related age, sex, height, and weight-adjusted residuals for 9 cardiac phenotypes (assessed by echocardiogram or magnetic resonance imaging) to 2.5 million single-nucleotide polymorphisms genotyped using Genome-wide Affymetrix Human SNP Array 6.0 (Affy6.0) and the remainder imputed. Within the cohort, genome-wide association analysis was conducted, followed by meta-analysis across cohorts using inverse variance weights (genome-wide significance threshold=4.0x10(-7)). Supplementary pathway analysis was performed. We attempted replication in 3 smaller cohorts of African ancestry and tested lookups in 1 consortium of European ancestry (EchoGEN). Across the 9 phenotypes, variants in 4 genetic loci reached genome-wide significance: rs4552931 in UBE2V2 (P=1.43x10(-7)) for left ventricular mass, rs7213314 in WIPI1 (P=1.68x10(-7)) for left ventricular internal diastolic diameter, rs1571099 in PPAPDC1A (P=2.57x10(-8)) for interventricular septal wall thickness, and rs9530176 in KLF5 (P=4.02x10(-7)) for ejection fraction. Associated variants were enriched in 3 signaling pathways involved in cardiac remodeling. None of the 4 loci replicated in cohorts of African ancestry was confirmed in lookups in EchoGEN. Conclusions-In the largest genome-wide association study of cardiac structure and function to date in African Americans, we identified 4 genetic loci related to left ventricular mass, interventricular septal wall thickness, left ventricular internal diastolic diameter, and ejection fraction, which reached genome-wide significance. Replication results suggest that these loci may be unique to individuals of African ancestry. Additional large-scale studies are warranted for these complex phenotypes. (Circ Cardiovasc Genet. 2013;6:37-46.) C1 [Fox, Ervin R.; Musani, Solomon K.; Yu, Bing; Samdarshi, Tandaw E.; Penman, Alan D.; Mosley, Thomas H.; Taylor, Herman A.] Univ Mississippi, Sch Med, Dept Med, Jackson, MS 39216 USA. [Barbalic, Maja; Morrison, Alanna C.] Univ Texas Hlth Sci Ctr, Sch Publ Hlth, Ctr Human Genet, Houston, TX USA. [Lin, Honghuang; Glazer, Nicole L.; Vasan, Ramachandran S.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [Ogunyankin, Kofo O.] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA. [Smith, Nicholas L.] Univ Washington, Dept Epidemiol, Sch Med, Seattle, WA 98195 USA. [Smith, Nicholas L.] US Dept Vet Affairs, Seattle Epidemiol Res & Informat Ctr, Off Res & Dev, Grp Hlth Res Inst,Grp Hlth Cooperat, Seattle, WA USA. [Kutlar, Abdullah] Georgia Hlth Sci Univ, Dept Med, Augusta, GA USA. [Post, Wendy S.] Johns Hopkins Sch Med, Dept Med, Div Cardiol, Baltimore, MD USA. [Paltoo, Dina N.] NHLBI, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA. [Dries, Daniel L.] Yale Univ, Sch Med, Dept Med, Div Cardiovasc, New Haven, CT 06510 USA. [Farlow, Deborah N.] Broad Inst Massachusetts Inst Technol & Harvard U, Boston, MA USA. [Duarte, Christine W.; Patki, Amit A.; Cui, Xiangqui] Univ Alabama Birmingham, Sch Publ Hlth, Dept Biostat, Birmingham, AL 35294 USA. [Arnett, Donna K.; Sha, Jin] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA. [Kardia, Sharon L.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Meyers, Kristin J.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53706 USA. [Sun, Yan V.] Emory Univ, Sch Med, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA USA. [Bibbins-Domingo, Kirsten] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Buzkova, Petra] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Benjamin, Emelia J.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Bluemke, David A.] NIH, Ctr Clin, Bethesda, MD 20892 USA. [Heiss, Gerardo] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Carr, J. Jeffrey] Wake Forest Univ, Sch Med Publ Hlth & Translat Sci, Salem, NC USA. [Tracy, Russell P.] Univ Vermont, Coll Med, Dept Pathol & Lab Med, Burlington, VT 05405 USA. [Psaty, Bruce M.; Heckbert, Susan R.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA. [Psaty, Bruce M.; Heckbert, Susan R.] Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Psaty, Bruce M.; Heckbert, Susan R.] Univ Washington, Dept Hlth Serv, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Carr, J. Jeffrey] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. RP Fox, ER (reprint author), Univ Mississippi, Med Ctr, Dept Med, 2500 North State St, Jackson, MS 39216 USA. EM efox@medicine.umsmed.edu RI Carr, John/A-1938-2012 OI Carr, John/0000-0002-4398-8237; Lin, Honghuang/0000-0003-3043-3942; Ramachandran, Vasan/0000-0001-7357-5970; Benjamin, Emelia/0000-0003-4076-2336; Bluemke, David/0000-0002-8323-8086 FU National Institutes of Health (NIH)/National Institute on Minority Health and Health Disparities (NIMHD) [P20]; Novartis; Celgene Corp; Global Iron Summit; NIH [HL 100245, R01 HL09257, RC1 HD101056, R01 HL102214, R01 AG028321]; Candidate Gene Association Resource Study, Exome Sequencing Project; ARIC, NIH; NIH; National Heart, Lung, and Blood Institute [HL 087652]; University of North Carolina at Chapel Hill [N01-HC-55015]; Baylor Medical College [N01-HC-55016]; University of Mississippi Medical Center [N01-HC-55021]; University of Minnesota [N01-HC-55019, N01-HC-48048]; Johns Hopkins University [N01-HC-55020, N01-HC-85081, N01 HC-15103]; University of Texas, Houston [N01-HC-55017]; University of North Carolina, Forsyth County [N01-HC-55018]; University of Washington [N01-HC-85079, N01 HC-55222, U01 HL080295, N01-HC-95159]; Wake Forest University [N01-HC-85080, N01-HC-45205]; University of Pittsburgh [N01-HC-85082]; University of California, Davis [N01-HC-85083]; University of California, Irvine [N01-HC-85084, N01-HC-45134, N01-HC-95100]; New England Medical Center [N01-HC-85085]; University of Vermont [N01-HC-85086]; Georgetown University [N01-HC-35129]; University of Wisconsin [N01-HC-75150]; Geisinger Clinic [N01-HC-45133]; Case Western Reserve University [RO1 HL46380-01-16]; University of Illinois [N01-HB-72982, N01-HB-97062]; Howard University [N01-HB-72991, N01-HB-97061]; University of Miami [N01-HB-72992, N01-HB-97064]; Duke University [N01-HB-72993]; George Washington University [N01-HB-72994]; University of Tennessee [N01-HB-72995, N01-HB-97070]; Yale University [N01-HB-72996, N01-HB-97072]; Children's Hospital-Philadelphia [N01-HB-72997, N01-HB-97056]; University of Chicago [N01-HB-72998, N01-HB-97053]; Medical College of Georgia [N01-HB-73000, N01-HB-97060]; Washington University [N01-HB-73001, N01-HB-97071]; Jewish Hospital and Medical Center of Brooklyn [N01-HB-73002]; Trustees of Health and Hospitals of the City of Boston, Inc. [N01-HB-73003]; Children's Hospital-Oakland [N01-HB-73004, N01-HB-97054]; University of Mississippi [N01-HB-73005, N01-HC-95171]; St. Luke's Hospital-New York [N01-HB-73006]; Alta Bates-Herrick Hospital [N01-HB-97051]; Columbia University [N01-HB-97058]; St. Jude's Children's Research Hospital [N01-HB-97066]; Research Foundation, State University of New York-Albany [N01-HB-97068, N01-HB-97069]; New England Research Institute [N01-HB-97073]; Interfaith Medical Center-Brooklyn [N01-HB-97085]; University of Alabama at Birmingham [N01-HC-48047, N01-HC-95095]; Northwestern University [N01-HC-48049]; Kaiser Foundation Research Institute [N01-HC-48050]; Tufts-New England Medical Center [N01-HC-45204]; Harbor-UCLA Research and Education Institute [N01-HC-05187]; Boston University [N01-HC-25195]; Jackson State University [N01-HC-95170]; Tougaloo College [N01-HC-95172]; Regents of the University of California [N01-HC-95160]; [R01 HD067264]; [RC4 AG039029]; [R01 HL101161-01-A1]; [R01 DK077950-03]; [RC1 HL100185]; [P60 MD002249] FX Dr Kutlar received research grants from National Institutes of Health (NIH)/National Institute on Minority Health and Health Disparities (NIMHD)-P20, Novartis, Celgene Corp. (>=$10000), and Global Iron Summit (<$10000). Dr Paltoo has ownership interest in a 529 College Plan and a Thrift Saving Plan (>$10000). Dr Kardia received research grants from R01 HD067264, RC4 AG039029, R01 HL101161-01-A1, R01 DK077950-03, RC1 HL100185, and P60 MD002249 (>$10000). Dr Sun received research grants from NIH HL 100245, Genetics of Hypertension Risk Factors, and Sequela in African Americans (>$10000). Dr Benjamin received research grants from R01 HL09257, RC1 HD101056, R01 HL102214, and R01 AG028321 (all NIH grants >$10000). Dr Tracy received research grants from Candidate Gene Association Resource Study, Exome Sequencing Project (>$10000). Dr Mosley received research grants from ARIC, ARIC-Neurocognitive Study, Predictors of Coronary Artery Calcification in an African American Cohort, GWAS of Ischemic Brain Vascular Injury, ARIC PET Amyloid Imaging Study, the Intracranial Atherosclerosis Disease and Cognitive Impairment Study, Parkinson Disease and Olfactory Function in the ARIC Study, and Identify Epidemiological Risk Factors for Abdominal Aortic Aneurysm Study (all NIH grants >$10000). Dr Taylor received research grants for the Jackson Heart Study (NIH grant >$10000). Dr Psaty received NIH grants (<$10000); he serves on the Data and Safety Monitoring Board for a clinical trial for a device (Zoll Life Cor <$10000) and service on the Steering Committee for Yale Open Data Project (Medtronic <$10000). Dr Heckbert received research grants from HL 087652 Whole Genome Association Study in the Cardiovascular Health Study (National Heart, Lung, and Blood Institute >$10000). Dr Vasan received an NIH grant (>$10000). The other authors report no conflicts.; Atherosclerotic Risk in Communities: University of North Carolina at Chapel Hill (N01-HC-55015), Baylor Medical College (N01-HC-55016), University of Mississippi Medical Center (N01-HC-55021), University of Minnesota (N01-HC-55019), Johns Hopkins University (N01-HC-55020), University of Texas, Houston (N01-HC-55017), and University of North Carolina, Forsyth County (N01-HC-55018); Cardiovascular Health Study: University of Washington (N01-HC-85079), Wake Forest University (N01-HC-85080), Johns Hopkins University (N01-HC-85081), University of Pittsburgh (N01-HC-85082), University of California, Davis (N01-HC-85083), University of California, Irvine (N01-HC-85084), New England Medical Center (N01-HC-85085), University of Vermont (N01-HC-85086), Georgetown University (N01-HC-35129), Johns Hopkins University (N01 HC-15103), University of Wisconsin (N01-HC-75150), Geisinger Clinic (N01-HC-45133), and University of Washington (N01 HC-55222, U01 HL080295); Cleveland Family Study: Case Western Reserve University (RO1 HL46380-01-16); Cooperative Study of Sickle Cell Disease: University of Illinois (N01-HB-72982, N01-HB-97062), Howard University (N01-HB-72991, N01-HB-97061), University of Miami (N01-HB-72992, N01-HB-97064), Duke University (N01-HB-72993), George Washington University (N01-HB-72994), University of Tennessee (N01-HB-72995, N01-HB-97070), Yale University (N01-HB-72996, N01-HB-97072), Children's Hospital-Philadelphia (N01-HB-72997, N01-HB-97056), University of Chicago (N01-HB-72998, N01-HB-97053), Medical College of Georgia (N01-HB-73000, N01-HB-97060), Washington University (N01-HB-73001, N01-HB-97071), Jewish Hospital and Medical Center of Brooklyn (N01-HB-73002), Trustees of Health and Hospitals of the City of Boston, Inc. (N01-HB-73003), Children's Hospital-Oakland (N01-HB-73004, N01-HB-97054), University of Mississippi (N01-HB-73005), St. Luke's Hospital-New York (N01-HB-73006), Alta Bates-Herrick Hospital (N01-HB-97051), Columbia University (N01-HB-97058), St.; Jude's Children's Research Hospital (N01-HB-97066), Research Foundation, State University of New York-Albany (N01-HB-97068, N01-HB-97069), New England Research Institute (N01-HB-97073), and Interfaith Medical Center-Brooklyn (N01-HB-97085); Coronary Artery Risk in Young Adults: University of Alabama at Birmingham (N01-HC-48047), University of Minnesota (N01-HC-48048), Northwestern University (N01-HC-48049), Kaiser Foundation Research Institute (N01-HC-48050), University of Alabama at Birmingham (N01-HC-95095), Tufts-New England Medical Center (N01-HC-45204), Wake Forest University (N01-HC-45205), Harbor-UCLA Research and Education Institute (N01-HC-05187), and University of California, Irvine (N01-HC-45134, N01-HC-95100); Framingham Heart Study: Boston University (N01-HC-25195); Jackson Heart Study: Jackson State University (N01-HC-95170), University of Mississippi (N01-HC-95171), and Tougaloo College (N01-HC-95172); Multi-Ethnic Study of Atherosclerosis: University of Washington (N01-HC-95159), Regents of the University of California (N01-HC-95160), Columbia University (N01-HC-95161), Johns Hopkins University (N01-HC-95162), University of Minnesota (N01-HC-95163), Northwestern University (N01-HC-95164), Wake Forest University (N01-HC-95165), University of Vermont (N01-HC-95166), New England Medical Center (N01-HC-95167), Johns Hopkins University (N01-HC-95168), and Harbor-UCLA Research and Education Institute (N01-HC-95169); Sleep Heart Health Study: Johns Hopkins University (U01 HL064360), Case Western University (U01 HL063463), University of California, Davis (U01 HL053916), University of Arizona (U01 HL053938), University of Minnesota (relocating in 2006 to University Arizona) (U01 HL053934), University of Pittsburgh (U01 HL077813), Boston University (U01 HL053941), MedStar Research Institute (U01 HL063429), and Johns Hopkins University (U01 HL053937). NR 28 TC 15 Z9 15 U1 1 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1942-325X J9 CIRC-CARDIOVASC GENE JI Circ.-Cardiovasc. Genet. PD FEB PY 2013 VL 6 IS 1 BP 37 EP 46 DI 10.1161/CIRCGENETICS.111.962365 PG 10 WC Cardiac & Cardiovascular Systems; Genetics & Heredity SC Cardiovascular System & Cardiology; Genetics & Heredity GA 094YL UT WOS:000315301500008 PM 23275298 ER PT J AU Halpern, SD Loewenstein, G Volpp, KG Cooney, E Vranas, K Quill, CM McKenzie, MS Harhay, MO Gabler, NB Silva, T Arnold, R Angus, DC Bryce, C AF Halpern, Scott D. Loewenstein, George Volpp, Kevin G. Cooney, Elizabeth Vranas, Kelly Quill, Caroline M. McKenzie, Mary S. Harhay, Michael O. Gabler, Nicole B. Silva, Tatiana Arnold, Robert Angus, Derek C. Bryce, Cindy TI Default Options In Advance Directives Influence How Patients Set Goals For End-Of-Life Care SO HEALTH AFFAIRS LA English DT Article ID TREATMENT PREFERENCES; DECISION-MAKING; MEDICAL-CARE; HEALTH-CARE; CARDIOPULMONARY-RESUSCITATION; ASYMMETRIC PATERNALISM; BEHAVIORAL ECONOMICS; FAMILY; OUTCOMES; SATISFACTION AB Although decisions regarding end-of-life care are personal and important, they may be influenced by the ways in which options are presented. To test this hypothesis, we randomly assigned 132 seriously ill patients to complete one of three types of advance directives. Two types had end-of-life care options already checked-a default choice-but one of these favored comfort-oriented care, and the other, life-extending care. The third type was a standard advance directive with no options checked. We found that most patients preferred comfort-oriented care, but the defaults influenced those choices. For example, 77 percent of patients in the comfort-oriented group retained that choice, while 43 percent of those in the life-extending group rejected the default choice and selected comfort-oriented care instead. Among the standard advance directive group, 61 percent of patients selected comfort-oriented care. Our findings suggest that patients may not hold deep-seated preferences regarding end-of-life care. The findings provide motivation for future research examining whether using default options in advance directives may improve important outcomes, including patients' receipt of wanted and unwanted services, resource use, survival, and quality of life. C1 [Halpern, Scott D.] Univ Penn, Fostering Improvement End Of Life Decis Sci Progr, Philadelphia, PA 19104 USA. [Loewenstein, George] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA. [Volpp, Kevin G.] Univ Penn, Leonard Davis Inst Hlth Econ, Wharton Sch, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA. [Vranas, Kelly] Philadelphia Vet Affairs Med Ctr, Med Intens Care Unit, Philadelphia, PA USA. [Quill, Caroline M.; McKenzie, Mary S.] Hosp Univ Penn, Div Pulm Allergy & Crit Care, Philadelphia, PA 19104 USA. [Harhay, Michael O.] Univ Penn, Philadelphia, PA 19104 USA. [Gabler, Nicole B.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Silva, Tatiana] Univ Mannheim, Mannheim, Germany. [Arnold, Robert] Univ Pittsburgh, Inst Doctor Patient Commun, Pittsburgh, PA 15260 USA. [Angus, Derek C.] Univ Pittsburgh, Clin Res Invest & Syst Modeling Acute Illness, Pittsburgh, PA 15260 USA. [Bryce, Cindy] Univ Pittsburgh, Pittsburgh, PA 15260 USA. RP Halpern, SD (reprint author), Univ Penn, Fostering Improvement End Of Life Decis Sci Progr, Philadelphia, PA 19104 USA. EM shalpern@exchange.upenn.edu RI Angus, Derek/E-9671-2012 OI Bryce, Cindy/0000-0001-6356-6675 FU Greenwall Foundation; Kornfeld Foundation; Leonard Davis Institute of Health Economics at the University of Pennsylvania; Center for Excellence in Cancer Communication Research of the University of Michigan; Center for Excellence in Cancer Communication Research of the University of Pennsylvania FX This work was supported by research grants from the Greenwall Foundation, Kornfeld Foundation, Leonard Davis Institute of Health Economics at the University of Pennsylvania, and Center for Excellence in Cancer Communication Research of the Universities of Michigan and Pennsylvania. The authors thank Susan Metzger for her assistance with patient recruitment. NR 45 TC 28 Z9 28 U1 2 U2 23 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD FEB PY 2013 VL 32 IS 2 BP 408 EP 417 DI 10.1377/hlthaff.2012.0895 PG 10 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 093QQ UT WOS:000315206900027 PM 23381535 ER PT J AU Win, AK Lindor, NM Winship, I Tucker, KM Buchanan, DD Young, JP Rosty, C Leggett, B Giles, GG Goldblatt, J Macrae, FA Parry, S Kalady, MF Baron, JA Ahnen, DJ Le Marchand, L Gallinger, S Haile, RW Newcomb, PA Hopper, JL Jenkins, MA AF Win, Aung Ko Lindor, Noralane M. Winship, Ingrid Tucker, Katherine M. Buchanan, Daniel D. Young, Joanne P. Rosty, Christophe Leggett, Barbara Giles, Graham G. Goldblatt, Jack Macrae, Finlay A. Parry, Susan Kalady, Matthew F. Baron, John A. Ahnen, Dennis J. Le Marchand, Loic Gallinger, Steven Haile, Robert W. Newcomb, Polly A. Hopper, John L. Jenkins, Mark A. TI Risks of Colorectal and Other Cancers After Endometrial Cancer for Women With Lynch Syndrome SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID DNA MISMATCH REPAIR; GERMLINE MUTATIONS; MOLECULAR ANALYSIS; FAMILY REGISTRY; MSH6 MUTATION; COLON-CANCER; CARRIERS; HNPCC; NONCARRIERS; GUIDELINES AB Background Lynch syndrome is an autosomal dominantly inherited disorder caused by germline mutations in DNA mismatch repair (MMR) genes. Previous studies have shown that MMR gene mutation carriers are at increased risk of colorectal, endometrial, and several other cancers following an initial diagnosis of colorectal cancer. We estimated cancer risks following an endometrial cancer diagnosis for women carrying MMR gene mutations. Methods We obtained data from the Colon Cancer Family Registry for a cohort of 127 women who had a diagnosis of endometrial cancer and who carried a mutation in one of four MMR genes (30 carried a mutation in MLH1, 72 in MSH2, 22 in MSH6, and 3 in PMS2). We used the Kaplan-Meier method to estimate 10- and 20-year cumulative risks for each cancer. We estimated the age-, country-, and calendar period-specific standardized incidence ratios (SIRs) for each cancer, compared with the general population. Results Following endometrial cancer, women carrying MMR gene mutations had the following 20-year risks of other cancer cancers: colorectal cancer (48%, 95% confidence interval [CI] = 35% to 62%); cancer of the kidney, renal pelvis, or ureter (11%, 95% CI = 3% to 20%); urinary bladder cancer (9%, 95% CI = 2% to 17%); and breast cancer (11%, 95% CI = 4% to 19%). Compared with the general population, these women were at statistically significantly elevated risks of colorectal cancer (SIR = 39.9, 95% CI = 27.2 to 58.3), cancer of the kidney, renal pelvis, or ureter (SIR = 28.3, 95% CI = 11.9 to 48.6), urinary bladder cancer (SIR = 24.3, 95% CI = 8.56 to 42.9), and breast cancer (SIR = 2.51, 95% CI = 1.17 to 4.14). Conclusions Women with Lynch syndrome who are diagnosed with endometrial cancer have increased risks of several cancers, including breast cancer. J Natl Cancer Inst;2013;105:274-279 C1 [Win, Aung Ko; Hopper, John L.; Jenkins, Mark A.] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Parkville, Vic 3010, Australia. [Winship, Ingrid] Univ Melbourne, Dept Med, Parkville, Vic 3010, Australia. [Lindor, Noralane M.] Mayo Clin Arizona, Dept Hlth Sci Res, Scottsdale, AZ USA. [Winship, Ingrid; Macrae, Finlay A.] Royal Melbourne Hosp, Parkville, Vic 3050, Australia. [Tucker, Katherine M.] Prince Wales Hosp, Hereditary Canc Clin, Randwick, NSW 2031, Australia. [Buchanan, Daniel D.; Young, Joanne P.; Rosty, Christophe] Queensland Inst Med Res, Canc & Populat Studies Grp, Herston, Qld 4006, Australia. [Leggett, Barbara] Royal Brisbane & Womens Hosp Res Fdn, Queensland Inst Med Res, Clin Res Ctr, Conjoint Gastroenterol Lab,Pathol Queensland, Herston, Qld, Australia. [Rosty, Christophe] Univ Queensland, Dept Mol & Cellular Pathol, Herston, Qld, Australia. [Leggett, Barbara] Univ Queensland, Sch Med, Herston, Qld, Australia. [Leggett, Barbara] Royal Brisbane & Womens Hosp, Dept Gastroenterol & Hepatol, Brisbane, Qld, Australia. [Giles, Graham G.] Canc Council Victoria, Canc Epidemiol Ctr, Carlton, Vic, Australia. [Goldblatt, Jack] Univ Western Australia, Genet Serv Western Australia, Perth, WA 6009, Australia. [Goldblatt, Jack] Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA 6009, Australia. [Parry, Susan] Auckland City Hosp, New Zealand Familial Gastrointestinal Canc Regist, Auckland, New Zealand. [Parry, Susan] Middlemore Hosp, Dept Gastroenterol, Auckland 6, New Zealand. [Kalady, Matthew F.] Cleveland Clin, Dept Colorectal Surg, Inst Digest Dis, Cleveland, OH 44106 USA. [Kalady, Matthew F.] Cleveland Clin, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44106 USA. [Baron, John A.] Univ N Carolina, Dept Med, Chapel Hill, NC USA. [Ahnen, Dennis J.] Univ Colorado, Sch Med, Denver VA Med Ctr, Denver, CO USA. [Le Marchand, Loic] Univ Hawaii, Ctr Canc, Honolulu, HI 96822 USA. [Gallinger, Steven] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada. [Gallinger, Steven] Canc Care Ontario, Toronto, ON, Canada. [Haile, Robert W.] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA. [Newcomb, Polly A.] Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA 98104 USA. RP Jenkins, MA (reprint author), Univ Melbourne, Melbourne Sch Populat Hlth, Ctr Mol Environm Genet & Analyt Epidemiol, Level 3,207 Bouverie St, Parkville, Vic 3010, Australia. EM m.jenkins@unimelb.edu.au RI Gallinger, Steven/E-4575-2013; Rosty, Christophe/F-1796-2010; Jenkins, Mark/P-7803-2015; Leggett, Barbara/D-3579-2011 OI Jenkins, Mark/0000-0002-8964-6160; Giles, Graham/0000-0003-4946-9099; Win, Aung Ko/0000-0002-2794-5261; Buchanan, Daniel/0000-0003-2225-6675; Winship, Ingrid/0000-0001-8535-6003 FU National Cancer Institute, National Institutes of Health under RFA [CA-95-011]; Picchi Brothers Foundation Cancer Council Victoria Cancer Research Scholarship, Australia FX This work was supported by the National Cancer Institute, National Institutes of Health under RFA CA-95-011, and through cooperative agreements with members of the Colon Cancer Family Registry and principal investigators. AKW is supported by the Picchi Brothers Foundation Cancer Council Victoria Cancer Research Scholarship, Australia. JLH is a National Health and Medical Research Council Australia Fellow. MAJ is a National Health and Medical Research Council Senior Research Fellow. JPY is a Cancer Council Queensland Senior Research Fellow. CR is a Jass Pathology Fellow. NR 34 TC 36 Z9 39 U1 0 U2 11 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 J9 JNCI-J NATL CANCER I JI JNCI-. Natl. Cancer Inst. PD FEB PY 2013 VL 105 IS 4 BP 274 EP 279 DI 10.1093/jnci/djs525 PG 6 WC Oncology SC Oncology GA 093PD UT WOS:000315202900008 PM 23385444 ER PT J AU Shin, SS Bales, JW Yan, HQ Kline, AE Wagner, AK Lyons-Weiler, J Dixon, CE AF Shin, Samuel S. Bales, James W. Yan, Hong Q. Kline, Anthony E. Wagner, Amy K. Lyons-Weiler, James Dixon, C. Edward TI The Effect of Environmental Enrichment on Substantia Nigra Gene Expression after Traumatic Brain Injury in Rats SO JOURNAL OF NEUROTRAUMA LA English DT Article DE dopamine; EE; microarray; TBI ID CLOSED HEAD-INJURY; MEDIATED FUNCTIONAL IMPROVEMENT; RANDOMIZED CONTROLLED-TRIAL; CONTROLLED CORTICAL IMPACT; WATER MAZE PERFORMANCE; LONG-TERM POTENTIATION; PARKINSONS-DISEASE; MESSENGER-RNA; AXONAL INJURY; NEUROBEHAVIORAL RECOVERY AB Experimental investigations into the effects of traumatic brain injury (TBI) have demonstrated significant alterations in dopaminergic systems. Dopaminergic fibers originating within the substantia nigra and ventral tegmental area (VTA) are important for reward learning, addiction, movement, and behavior. However, little is known about the effect of TBI on substantia nigra and VTA function. Environmental enrichment (EE) has been shown to improve functional outcome after TBI, and a number of studies suggest that it may exert some benefits via dopaminergic signaling. To better understand the role of dopamine in chronic TBI pathophysiology and the effect of EE, we examined the mRNA expression profile within the substantia nigra and VTA at 4 weeks post-injury. Specifically, three comparisons were made: 1) TBI versus sham, 2) sham + EE versus sham + standard (STD) housing, and 3) TBI + EE versus TBI + STD. There were differential expressions of 25, 4, and 40 genes in these comparisons, respectively. Chronic alterations in genes post-injury within the substantia nigra and VTA included genes important for cellular membrane homeostasis and transcription. EE-induced gene alterations after TBI included genes important for signal transduction, in particular calcium signaling pathways, membrane homeostasis, and metabolism. Elucidation of these alterations in gene expression within the substantia nigra and VTA provides new insights into chronic changes in dopamine signaling post-TBI, and the potential role of EE in TBI rehabilitation. C1 [Shin, Samuel S.; Bales, James W.; Yan, Hong Q.; Dixon, C. Edward] Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA. [Shin, Samuel S.; Bales, James W.; Yan, Hong Q.; Kline, Anthony E.; Wagner, Amy K.; Dixon, C. Edward] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15260 USA. [Shin, Samuel S.; Bales, James W.; Yan, Hong Q.; Dixon, C. Edward] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA. [Shin, Samuel S.; Bales, James W.; Yan, Hong Q.; Kline, Anthony E.; Wagner, Amy K.; Dixon, C. Edward] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA. [Kline, Anthony E.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. [Kline, Anthony E.; Wagner, Amy K.; Dixon, C. Edward] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA. [Lyons-Weiler, James] Univ Pittsburgh, Genom & Prote Core Labs Bioinformat Anal Core, Pittsburgh, PA 15260 USA. [Dixon, C. Edward] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Dixon, CE (reprint author), Univ Pittsburgh, 201 Hill Bldg,3434 Fifth Ave, Pittsburgh, PA 15260 USA. EM dixonec@upmc.edu OI Lyons-Weiler, James/0000-0001-9343-7508 FU National Institutes of Health (NIH) [R21NS047919, P01NS030318, R01NS060672, 5F30NS067731-03]; Pittsburgh Copeland Foundation; [R01NS060005] FX This research was supported by National Institutes of Health (NIH) grants R21NS047919, P01NS030318, R01NS060672, NIH F30 grant 5F30NS067731-03, and the Pittsburgh Copeland Foundation (CED), and R01NS060005 (AEK). NR 92 TC 10 Z9 11 U1 0 U2 12 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 J9 J NEUROTRAUM JI J. Neurotrauma PD FEB PY 2013 VL 30 IS 4 BP 259 EP 270 DI 10.1089/neu.2012.2462 PG 12 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA 093CM UT WOS:000315169300003 PM 23094804 ER PT J AU Schoenborn, NL Arbaje, AI Eubank, KJ Maynor, K Carrese, JA AF Schoenborn, Nancy L. Arbaje, Alicia I. Eubank, Kathryn J. Maynor, Kenric Carrese, Joseph A. TI Clinician Roles and Responsibilities During Care Transitions of Older Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE care transitions; older adults; qualitative study; clinician roles; healthcare professionals ID HOSPITAL DISCHARGE; FOLLOW-UP; COMMUNICATION; PHYSICIANS; CONTINUITY; TRIAL; OPPORTUNITIES; INTERVENTION; READMISSION; INFECTIONS AB OBJECTIVES: To identify the perceived roles and responsibilities of clinicians during care transitions of older adults. DESIGN: Qualitative study involving 1-hour in-depth semistructured interviews. Audiotapes of interviews were transcribed, coded, and analyzed, and themes and sub-themes were generated. SETTING: An acute care hospital, a skilled nursing facility, two community-based outpatient practices, and one home healthcare agency. PARTICIPANTS: Forty healthcare professionals directly involved in care transitions of older adults (18 physicians, 11 home healthcare administrative and field staff, four social workers, three nurse practitioners, three physician assistants, and one hospital case manager). MEASUREMENTS: Perspectives of healthcare professionals regarding clinicians' roles and responsibilities during care transitions were examined and described. RESULTS: Content analysis revealed several themes: components of clinicians' roles during care transitions; congruence between self- and others' perceived ideal roles but incongruence between ideal and routine roles; ambiguity in accountability in the postdischarge period; factors prompting clinicians to act closer to ideal roles; and barriers to performing ideal roles. A conceptual framework was created to summarize clinicians' roles during care transitions. CONCLUSION: This study reports differences between what healthcare professionals perceive as ideal roles of clinicians during care transitions and what clinicians actually do routinely. Certain patient and clinician factors prompt clinicians to act closer to the ideal roles. Multiple barriers interfere with consistent practice of ideal roles. Future investigations could evaluate interventions targeting various components of the conceptual framework and relevant outcomes. J Am Geriatr Soc 61:231-236, 2013. C1 [Schoenborn, Nancy L.; Arbaje, Alicia I.] Johns Hopkins Univ, Sch Med, Dept Med, Div Geriatr Med & Gerontol, Baltimore, MD 21224 USA. [Eubank, Kathryn J.] Univ Calif San Francisco, Dept Med, San Francisco Vet Affairs Med Ctr, Div Geriatr, San Francisco, CA USA. [Maynor, Kenric] Geisinger Hlth Syst, Wyoming Valley Med Ctr, Dept Hospitalist Med, Wilkes Barre, PA USA. [Carrese, Joseph A.] Johns Hopkins Univ, Sch Med, Dept Med, Div Gen Internal Med, Baltimore, MD 21205 USA. RP Schoenborn, NL (reprint author), Johns Hopkins Univ, Sch Med, Johns Hopkins Bayview Med Ctr, Div Geriatr Med & Gerontol, 5200 Eastern Ave,Mason F Lord Bldg,Ctr Tower,Suit, Baltimore, MD 21224 USA. EM nancyli@jhmi.edu FU Robert Wood Johnson Foundation Clinical Scholars Program; Harold Amos Medical Faculty Development Program FX This project was supported by the Robert Wood Johnson Foundation Clinical Scholars Program and Harold Amos Medical Faculty Development Program. NR 30 TC 10 Z9 10 U1 2 U2 22 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2013 VL 61 IS 2 BP 231 EP 236 DI 10.1111/jgs.12084 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 094HY UT WOS:000315254800008 PM 23320747 ER PT J AU Brown, AF Vassar, SD Connor, KI Vickrey, BG AF Brown, Arleen F. Vassar, Stefanie D. Connor, Karen I. Vickrey, Barbara G. TI Collaborative Care Management Reduces Disparities in Dementia Care Quality for Caregivers with Less Education SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE dementia; caregivers; care management ID NURSING-HOME PLACEMENT; ALZHEIMERS-DISEASE; OF-CARE; INTERVENTION; OUTCOMES; HEALTH; PATIENT; BURDEN; INSTITUTIONALIZATION; PREDICTORS AB OBJECTIVES: To examine educational gradients in dementia care and whether the effect of a dementia collaborative care management intervention varied according to the educational attainment of the informal caregiver, DESIGN: Analysis of data from a cluster-randomized controlled trial. SETTING: Eighteen clinics in three healthcare organizations in southern California. PARTICIPANTS: Dyads of Medicare recipients aged 65 and older with a diagnosis of dementia and an eligible caregiver. INTERVENTION: Collaborative care management for dementia. MEASUREMENTS: Caregiver educational attainment, adherence to four dimensions of guideline-recommended processes of dementia care (assessment, treatment, education and support, and safety) before and after the intervention, and the adjusted intervention effect (IE) for each dimension stratified according to caregiver education. Each IE, was estimated by subtracting the difference between pre- and postintervention scores for the usual care participants from the difference between pre- and postintervention scores in the intervention participants. RESULTS: At baseline, caregivers with lower educational attainment provided poorer quality of dementia care for the Treatment and Education dimensions than those with more education, but less-educated caregivers had significantly more improvement after the intervention on the assessment, treatment, and safety dimensions. The IEs for those who had not graduated from high school were 44.4 for the assessment dimension, 36.9 for the treatment dimension, and 52.7 for the safety dimension, versus 29.5, 15.7, and 40.9 respectively, for college graduates (P < .001 for all three). CONCLUSIONS: Collaborative care management was associated with smaller disparities in dementia care quality between caregivers with lower educational attainment and those with more education. J Am Geriatr Soc 61:243-251, 2013. C1 [Brown, Arleen F.] Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90024 USA. [Vassar, Stefanie D.; Connor, Karen I.; Vickrey, Barbara G.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Vassar, Stefanie D.; Connor, Karen I.; Vickrey, Barbara G.] Greater Los Angeles Vet Affairs Hlth Care Syst, Los Angeles, CA USA. RP Brown, AF (reprint author), Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, 911 Broxton Plaza,Room 205, Los Angeles, CA 90024 USA. EM abrown@mednet.ucla.edu FU California Healthcare Foundation [99-3020]; State of California Department of Aging [IG-0001-22]; State of California Department of Health Services; Alzheimer's Disease Education Initiative [00-91, 316]; Archstone Foundation [00-04-37]; University of California at Los Angeles (UCLA) Resource Centers for Minority Aging Research Center for Health Improvement of Minority Elderly under National Institutes of Health, National Institute on Aging [P30-AG021684]; UCLA/Drew Project EXPORT; National Center on Minority Health and Health Disparities [2P20MD000182]; National Center for Advancing Clinical Sciences; UCLA Clinical and Translational Research Institute [UL1TR000124] FX Funding for the original study was provided by the California Healthcare Foundation (99-3020), the State of California Department of Aging (IG-0001-22), the State of California Department of Health Services, the Alzheimer's Disease Education Initiative (00-91,316), and the Archstone Foundation (00-04-37). Dr. Brown received support from the University of California at Los Angeles (UCLA) Resource Centers for Minority Aging Research Center for Health Improvement of Minority Elderly under National Institutes of Health, National Institute on Aging Grant P30-AG021684, from UCLA/Drew Project EXPORT, National Center on Minority Health and Health Disparities, 2P20MD000182, and from the National Center for Advancing Clinical Sciences, UCLA Clinical and Translational Research Institute, UL1TR000124. The content does not necessarily represent the official views of the sponsoring organizations. NR 28 TC 4 Z9 4 U1 1 U2 18 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2013 VL 61 IS 2 BP 243 EP 251 DI 10.1111/jgs.12079 PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 094HY UT WOS:000315254800010 PM 23320655 ER PT J AU Koyama, A Steinman, M Ensrud, K Hillier, TA Yaffe, K AF Koyama, Alain Steinman, Michael Ensrud, Kristine Hillier, Teresa A. Yaffe, Kristine TI Ten-Year Trajectory of Potentially Inappropriate Medications in Very Old Women: Importance of Cognitive Status SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE cognitive function; dementia; potentially inappropriate medication; anticholinergic ID CHOLINESTERASE-INHIBITORS; BENZODIAZEPINE USE; ELDERLY-PATIENTS; CONTROLLED-TRIAL; BEERS CRITERIA; RISK-FACTORS; DRUG-USE; ANTICHOLINERGICS; IMPAIRMENT; DEMENTIA AB OBJECTIVES: To determine which older adults tend to receive potentially inappropriate medications (PIMs), how this may differ according to cognitive status, and how the trajectories of PIM use change over time. DESIGN: Ten-year longitudinal cohort study. SETTING: Three clinical sites in the United States. PARTICIPANTS: One thousand four hundred eighty-four community-dwelling women aged 75 and older. MEASUREMENTS: At follow-up, cognitive status was ascertained and classified as normal, mild cognitive impairment (MCI), or dementia. Beers 2003 criteria and other literature were used to identify PIMs from,detailed medication inventory performed at three time points. Anticholinergic load was measured using the Anticholinergic Cognitive Burden Scale (ACB), which assigns medications a value from 0 to 3 depending on anticholinergic properties. RESULTS: At baseline, 23.9% of women were taking at least one PIM and the mean +/- SD ACB score was 1.41 +/- 1.69. The most frequently reported PIMs were anticholinergics (15.2%), benzodiazepines (8.6%), and antispasmodics (8.0%). Over 10 years, PIM use increased for women with dementia (24.9-33.1%; P = .02) but remained fairly constant for women with MCI (23.9-23.0%; P = .84) and normal cognitive status (22.2-19.8%; P = .17). Mean ACB score increased significantly (P < .001) over time for all groups (dementia: 1.28-2.05; MCI: 0.98-1.66; normal: 0.99-1.48). CONCLUSION: PIM use and anticholinergic load in a community-dwelling population of older women was high, especially in women who later developed dementia. Future guidelines should limit PIM use and seek safer alternatives. J Am Geriatr Soc 61:258-263, 2013. C1 [Koyama, Alain] No Calif Inst Res & Educ, San Francisco, CA USA. [Koyama, Alain; Steinman, Michael; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Steinman, Michael] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Ensrud, Kristine] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA. [Ensrud, Kristine] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Ensrud, Kristine] Minneapolis Vet Affairs Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Hillier, Teresa A.] Kaiser Permanente Northwest Hawaii, Ctr Hlth Res, Honolulu, HI USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Koyama, A (reprint author), 4150 Clement St,VAMC 116H, San Francisco, CA 94121 USA. EM alain.koyama@va.gov FU National Institute of Aging (NIA) [K24 AG 031155, R01 AG 026720]; Alzheimer's Association [IIRG-08-88872]; National Institutes of Health (NIH); NIA [R01 AG005407, R01 AR35582, R01 AR35583, R01 AR35584, R01 AG005394, R01 AG027574, R01 AG027576] FX Funded in part by Grants K24 AG 031155 and R01 AG 026720 from the National Institute of Aging (NIA) and Grant IIRG-08-88872 from the Alzheimer's Association. The Study of Osteoporotic Fractures is supported by the National Institutes of Health (NIH). NIA provides support under Grants R01 AG005407, R01 AR35582, R01 AR35583, R01 AR35584, R01 AG005394, R01 AG027574, and R01 AG027576. NR 30 TC 16 Z9 16 U1 0 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2013 VL 61 IS 2 BP 258 EP 263 DI 10.1111/jgs.12093 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 094HY UT WOS:000315254800012 PM 23320787 ER PT J AU Thai, JN Walter, LC Eng, C Smith, AK AF Thai, Julie N. Walter, Louise C. Eng, Catherine Smith, Alexander K. TI Every Patient Is an Individual: Clinicians Balance Individual Factors When Discussing Prognosis with Diverse Frail Elderly Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE prognosis; geriatrics; end of life ID DECISION-MAKING; OLDER; LIFE; END; COMMUNICATION; MAMMOGRAPHY; BURDENS; WOMEN; CARE; AGE AB BACKGROUND: To explore clinician choice of whether to discuss prognosis with their frail older patients. DESIGN: Qualitative interview study. SETTING: Primary care clinicians were recruited from nursing homes, community-based clinics, and academic medical centers. PARTICIPANTS: Three geriatric nurse practitioners, nine geriatricians, five general internists, and three family medicine physicians with a mean age of 44 and a mean 12 years in practice. Seventeen clinicians had patient panels with 80% or more community-dwelling outpatients, 13 had patient panels with 50% or more patients aged 85 and older, and 16 had patient panels with 25% or more of patients in a minority group (Asian, African American, Hispanic). MEASUREMENTS: Clinicians were asked to describe their practice of discussing long-term (<5-year) and short-term (<1-year and 3-month) prognosis. Responses were analyzed qualitatively using constant comparison until thematic saturation was reached. RESULTS: Clinicians reported individualizing the decision to discuss prognosis with their frail older patients based on clinical circumstances. Common reasons for discussing prognosis included patient had a specific condition with a limited prognosis, to give patients time to prepare, to promote informed medical decision-making, and when patients or families prompted the conversation. Common reasons not to discuss included maintaining hope and avoiding anxiety, cognitive impairment or patient unable to understand prognosis, respect for patients' cultural values, and long-term prognosis too uncertain to be useful. CONCLUSION: Clinicians caring for frail older adults are generally willing to discuss short- but not long-term prognosis. Clinicians balance individual factors when deciding whether to discuss prognosis. J Am Geriatr Soc 61:264-269, 2013. C1 [Thai, Julie N.; Walter, Louise C.; Eng, Catherine; Smith, Alexander K.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94121 USA. [Thai, Julie N.; Walter, Louise C.; Smith, Alexander K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Eng, Catherine] On Lok Lifeways, San Francisco, CA USA. RP Smith, AK (reprint author), Univ Calif San Francisco, Dept Med, Div Geriatr, 4150 Clement St 181G, San Francisco, CA 94121 USA. EM aksmith@ucsf.edu FU Center for Aging in Diverse Communities of the Resource Centers for Minority Aging Research program [P30-AG15272]; National Institute on Aging, National Institutes of Health; National Center for Research Resources UCSF-CTSI [UL1 RR024131]; Atlantic Philanthropies; Society of General Internal Medicine; John A. Hartford Foundation; Association of Specialty Professors FX Dr. Smith was supported by pilot Grant P30-AG15272 from the Center for Aging in Diverse Communities of the Resource Centers for Minority Aging Research program funded by the National Institute on Aging, National Institutes of Health. The National Center for Research Resources UCSF-CTSI (UL1 RR024131), Atlantic Philanthropies, the Society of General Internal Medicine, the John A. Hartford Foundation, and the Association of Specialty Professors provided additional support. NR 17 TC 8 Z9 8 U1 0 U2 16 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2013 VL 61 IS 2 BP 264 EP 269 DI 10.1111/jgs.12098 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 094HY UT WOS:000315254800013 PM 23320808 ER PT J AU Vorasubin, N Wu, AW Day, C Suh, JD AF Vorasubin, Nopawan Wu, Arthur W. Day, Christina Suh, Jeffrey D. TI Invasive sinonasal actinomycosis: Case Report and Literature Review SO LARYNGOSCOPE LA English DT Article DE sinonasal actinomycosis; cervicofacial actinomycosis ID SINUS ACTINOMYCOSIS; MAXILLARY SINUS; MANAGEMENT; INFECTION AB Actinomycosis is a rare anaerobic bacterial infection typically caused by Actinomyces israelii. Although part of normal flora in the oral cavity, and respiratory and digestive tracts, A israelii can give rise to pathologic infections most commonly reported in the oral cavity from odontogenic causes. We present a rare case of invasive actinomycosis presenting with extensive midface destruction involving the maxilla and paranasal sinuses, with mucosal necrosis mimicking an aggressive neoplasm. The diagnosis is usually reached only after histopathologic analysis showing characteristic sulfur granules with filamentous gram-positive, nonacid-fast bacteria. We review the literature on its epidemiology, clinical presentation, diagnosis, treatment, and prognosis. C1 [Vorasubin, Nopawan; Wu, Arthur W.; Suh, Jeffrey D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Head & Neck Surg, Los Angeles, CA 90095 USA. [Day, Christina] W Los Angeles Vet Affairs Hosp, Dept Pathol, Los Angeles, CA USA. RP Vorasubin, N (reprint author), 10833 Le Conte Ave,62-132 CHS, Los Angeles, CA 90095 USA. EM nvorasubin@mednet.ucla.edu NR 24 TC 5 Z9 5 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD FEB PY 2013 VL 123 IS 2 BP 334 EP 338 DI 10.1002/lary.23477 PG 5 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 090NH UT WOS:000314985400009 PM 23008010 ER PT J AU Weiner, MW AF Weiner, Michael W. TI Further insights into Alzheimer disease pathogenesis SO NATURE REVIEWS NEUROLOGY LA English DT Editorial Material ID PRIONS; TAU AB In 2012, studies of autosomal dominant Alzheimer disease (AD), late-onset AD, and a rare genetic mutation of amyloid precursor protein provided support for the critical role of amyloid in AD pathogenesis. Increasing evidence implicated cell-to-cell transmission in the spread of tau and amyloid, highlighting novel targets for therapeutic intervention. Weiner, M. W. Nat. Rev. Neurol. 9, 65-66 (2013); published online 22 January 2013; doi:10.1038/nrneurol.2012.275 C1 Univ Calif San Francisco, Ctr Imaging Neurodegenerat Dis, Dept Radiol, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Weiner, MW (reprint author), Univ Calif San Francisco, Ctr Imaging Neurodegenerat Dis, Dept Radiol, San Francisco VA Med Ctr, 4150 Clement St 114M, San Francisco, CA 94121 USA. EM michael.weiner@ucsf.edu NR 8 TC 17 Z9 19 U1 1 U2 25 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-4758 J9 NAT REV NEUROL JI Nat. Rev. Neurol. PD FEB PY 2013 VL 9 IS 2 BP 65 EP 66 DI 10.1038/nrneurol.2012.275 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 094GG UT WOS:000315250400002 PM 23338285 ER PT J AU Kenton, K Mueller, ER Tarnay, C Brubaker, L Rosenman, A Smith, B Stroupe, K Bresee, C Anger, JT AF Kenton, Kimberly Mueller, Elizabeth R. Tarnay, Christopher Brubaker, Linda Rosenman, Amy Smith, Bridget Stroupe, Kevin Bresee, Catherine Anger, Jennifer T. TI COMPARATIVE EFFECTIVENESS OF ROBOTIC AND LAPAROSCOPIC SACROCOLPOPEXY FOR APICAL VAGINAL PROLAPSE: ONE YEAR OUTCOMES SO NEUROUROLOGY AND URODYNAMICS LA English DT Meeting Abstract CT Winter Meeting of the Society-for-Urodynamics-and-Female-Urology (SUFU) CY FEB 26-MAR 02, 2013 CL Las Vegas, NV SP Soc Urodynam & Female Urol (SUFU) C1 [Kenton, Kimberly; Mueller, Elizabeth R.; Brubaker, Linda] Loyola Univ, Med Ctr, Maywood, IL 60153 USA. [Tarnay, Christopher; Rosenman, Amy] UCLA Med Ctr, Los Angeles, CA USA. [Smith, Bridget; Stroupe, Kevin] US Dept Vet Affairs, Hines, IL USA. [Bresee, Catherine; Anger, Jennifer T.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. RI Bresee, Catherine/A-9148-2015 OI Bresee, Catherine/0000-0002-5710-4906 NR 0 TC 0 Z9 0 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0733-2467 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PD FEB PY 2013 VL 32 IS 2 BP 112 EP 113 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 093WG UT WOS:000315223200016 ER PT J AU Munoz, A Boone, TB Smith, CP Salas, NA Somogyi, GT AF Munoz, Alvaro Boone, Timothy B. Smith, Christopher P. Salas, Nilson A. Somogyi, George T. TI BLADDER OVERACTIVITY FOLLOWING SPINAL CORD INJURY IS IMPROVED BY INCREASING NITRIC OXIDE LEVELS SO NEUROUROLOGY AND URODYNAMICS LA English DT Meeting Abstract CT Winter Meeting of the Society-for-Urodynamics-and-Female-Urology (SUFU) CY FEB 26-MAR 02, 2013 CL Las Vegas, NV SP Soc Urodynam & Female Urol (SUFU) C1 [Munoz, Alvaro; Boone, Timothy B.; Salas, Nilson A.] Methodist Hosp, Res Inst, Houston, TX 77030 USA. [Munoz, Alvaro; Smith, Christopher P.; Salas, Nilson A.; Somogyi, George T.] Baylor Coll Med, Houston, TX 77030 USA. [Boone, Timothy B.; Smith, Christopher P.] VA Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0733-2467 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PD FEB PY 2013 VL 32 IS 2 BP 128 EP 129 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 093WG UT WOS:000315223200053 ER PT J AU Munoz, A Boone, TB Sun, YX AF Munoz, Alvaro Boone, Timothy B. Sun, Yuxiang TI GHRELIN-SIGNALING AFFECTS NEURALLY EVOKED BLADDER CONTRACTIONS BUT NOT DETRUSOR PERFORMANCE SO NEUROUROLOGY AND URODYNAMICS LA English DT Meeting Abstract CT Winter Meeting of the Society-for-Urodynamics-and-Female-Urology (SUFU) CY FEB 26-MAR 02, 2013 CL Las Vegas, NV SP Soc Urodynam & Female Urol (SUFU) C1 [Munoz, Alvaro; Boone, Timothy B.] Methodist Hosp, Res Inst, Houston, TX 77030 USA. [Munoz, Alvaro; Sun, Yuxiang] Baylor Coll Med, Houston, TX 77030 USA. [Boone, Timothy B.] VA Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0733-2467 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PD FEB PY 2013 VL 32 IS 2 BP 134 EP 134 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 093WG UT WOS:000315223200064 ER PT J AU Polland, A Meckel, K Trop, C AF Polland, Allison Meckel, Katherine Trop, Cynthia TI INCIDENCE OF PLACEMENT AND REMOVAL OR REVISION OF TRANSVAGINAL MESH FOR PROLAPSE AND STRESS URINARY INCONTINENCE BEFORE AND AFTER THE 2011 FDA NOTIFICATION SO NEUROUROLOGY AND URODYNAMICS LA English DT Meeting Abstract CT Winter Meeting of the Society-for-Urodynamics-and-Female-Urology (SUFU) CY FEB 26-MAR 02, 2013 CL Las Vegas, NV SP Soc Urodynam & Female Urol (SUFU) C1 [Polland, Allison] Mt Sinai Med Ctr, New York, NY 10029 USA. [Meckel, Katherine] Columbia Univ, New York, NY USA. [Trop, Cynthia] James J Peters VA Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0733-2467 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PD FEB PY 2013 VL 32 IS 2 BP 200 EP 200 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 093WG UT WOS:000315223200215 ER PT J AU Krishnan, JA Lindenauer, PK Au, DH Carson, SS Lee, TA McBurnie, MA Naureckas, ET Vollmer, WM Mularski, RA AF Krishnan, Jerry A. Lindenauer, Peter K. Au, David H. Carson, Shannon S. Lee, Todd A. McBurnie, Mary Ann Naureckas, Edward T. Vollmer, William M. Mularski, Richard A. TI Stakeholder Priorities for Comparative Effectiveness Research in Chronic Obstructive Pulmonary Disease A Workshop Report SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE health services research; research priorities; care coordination; stakeholders ID COPD AB Comparative effectiveness research (CER) is intended to address the expressed needs of patients, clinicians, and other stakeholders. Representatives of 54 stakeholder groups with an interest in chronic obstructive pulmonary disease (COPD) participated in workshops convened by the COPD Outcomes-based Network for Clinical Effectiveness and Research Translation (CONCERT) over a 2-year period. Year 1 focused on chronic care and care coordination. Year 2 focused on acute care and transitions in care between healthcare settings. Discussions and provisional voting were conducted via teleconferences and e-mail exchanges before the workshop. Final prioritization votes occurred after in-person discussions at the workshop. We used a modified Delphi approach to facilitate discussions and consensus building. To more easily quantify preferences and to evaluate the internal consistency of rankings, the Analytic Hierarchy Process was incorporated in Year 2. Results of preworkshop and final workshop voting often differed, suggesting that prioritization efforts relying solely on requests for topics from stakeholder groups without in-person discussion may provide different research priorities. Research priorities varied across stakeholder groups, but generally focused on studies to evaluate different approaches to healthcare delivery (e.g., spirometry for diagnosis and treatment, integrated healthcare strategies during transitions in care) rather than head-to-head comparisons of medications. This research agenda may help to inform groups intending to respond to CER funding opportunities in COPD. The methodologies used, detailed in the online supplement, may also help to inform prioritization efforts for CER in other health conditions. C1 [Krishnan, Jerry A.; Lee, Todd A.] Univ Illinois, Chicago, IL 60612 USA. [Lindenauer, Peter K.] Baystate Med Ctr, Ctr Qual Care Res, Springfield, MA USA. [Lindenauer, Peter K.] Tufts Univ, Sch Med, Boston, MA 02111 USA. [Au, David H.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Au, David H.] Univ Washington, Seattle, WA 98195 USA. [Carson, Shannon S.] Univ N Carolina, Div Pulm & Crit Care Med, Chapel Hill, NC USA. [McBurnie, Mary Ann; Vollmer, William M.; Mularski, Richard A.] Kaiser Permanente Ctr Hlth Res, Ctr Hlth Res, Portland, OR USA. [Naureckas, Edward T.] Univ Illinois, Sect Pulm & Crit Care, Chicago, IL 60612 USA. RP Krishnan, JA (reprint author), Univ Illinois, Hosp & Hlth Sci Syst, Med Ctr Adm Bldg,MC 973,914 S Wood St, Chicago, IL 60612 USA. EM jakris@uic.edu FU Agency for Healthcare Research and Quality [AHRQ R13 HS017894]; National Institutes of Health/National Heart, Lung, and Blood Institute [NIH/NHLBI RC2 HL1011618]; Health Services Research and Development, Department of Veterans Affairs FX Supported by Agency for Healthcare Research and Quality grant AHRQ R13 HS017894 and National Institutes of Health/National Heart, Lung, and Blood Institute grant NIH/NHLBI RC2 HL1011618. D.H.A. is supported through Health Services Research and Development, Department of Veterans Affairs. NR 16 TC 15 Z9 17 U1 0 U2 2 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD FEB 1 PY 2013 VL 187 IS 3 BP 320 EP 326 DI 10.1164/rccm.201206-0994WS PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 088TT UT WOS:000314860700014 PM 23155144 ER PT J AU Miller, YE Karoor, V Dempsey, EC AF Miller, York E. Karoor, Vijaya Dempsey, Edward C. TI Sleep-disordered Breathing, Hypoxemia, and Cancer Mortality SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Letter ID DISEASE; MECHANISM; APNEA C1 [Miller, York E.] Denver Vet Affairs Med Ctr, Denver, CO USA. Univ Colorado Denver, Aurora, CO USA. RP Miller, YE (reprint author), Denver Vet Affairs Med Ctr, Denver, CO USA. NR 6 TC 4 Z9 4 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD FEB 1 PY 2013 VL 187 IS 3 BP 330 EP 331 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 088TT UT WOS:000314860700021 PM 23378442 ER PT J AU O'Hare, AM Vig, EK Hebert, PL AF O'Hare, Ann M. Vig, Elizabeth K. Hebert, Paul L. TI Initiation of Dialysis at Higher Levels of Estimated GFR and Subsequent Withdrawal SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Editorial Material ID STAGE RENAL-DISEASE; LONG-TERM DIALYSIS; UNITED-STATES; ELDERLY-PATIENTS; KIDNEY-FUNCTION; OLDER-ADULTS; END; LIFE; DISCONTINUATION; INTENSITY C1 VA Puget Sound Healthcare Syst, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. RP O'Hare, AM (reprint author), VA Med Ctr, 1160 S Columbian Way, Seattle, WA 98108 USA. EM ann.ohare@va.gov NR 29 TC 5 Z9 5 U1 0 U2 1 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD FEB PY 2013 VL 8 IS 2 BP 179 EP 181 DI 10.2215/CJN.12841212 PG 3 WC Urology & Nephrology SC Urology & Nephrology GA 083TT UT WOS:000314488800003 PM 23349332 ER PT J AU Alge, JL Karakala, N Neely, BA Janech, MG Tomlin, JA Chawla, LS Shaw, AD Arthur, JM AF Alge, Joseph L. Karakala, Nithin Neely, Benjamin A. Janech, Michael G. Tomlin, James A. Chawla, Lakhmir S. Shaw, Andrew D. Arthur, John M. CA SAKInet Investigators TI Urinary Angiotensinogen and Risk of Severe AKI SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID ACUTE KIDNEY INJURY; ACUTE-RENAL-FAILURE; GELATINASE-ASSOCIATED LIPOCALIN; ADULT CARDIAC-SURGERY; POOR OUTCOMES; OBSERVATIONAL COHORT; STATISTICAL-MODEL; CYSTATIN-C; BIOMARKERS; SYSTEM AB Background Biomarkers of AKI that can predict which patients will develop severe renal disease at the time of diagnosis will facilitate timely intervention in populations at risk of adverse outcomes. Design, setting, participants, & measurements Liquid chromatography/tandem mass spectrometry was used to identify 30 potential prognostic urinary biomarkers of severe AKI in a group of patients that developed AKI after cardiac surgery. Angiotensinogen had the best discriminative characteristics. Urinary angiotensinogen was subsequently measured by ELISA and its prognostic predictive power was verified in 97 patients who underwent cardiac surgery between August 1, 2008 and October 6, 2011. Results The urine angiotensinogen/creatinine ratio (uAnCR) predicted worsening of AKI, Acute Kidney Injury Network (AKIN) stage 3, need for renal replacement therapy, discharge >7 days from sample collection, and composite outcomes of AKIN stage 2 or 3, AKIN stage 3 or death, and renal replacement therapy or death. The prognostic predictive power of uAnCR was improved when only patients classified as AKIN stage 1 at the time of urine sample collection (n=79) were used in the analysis, among whom it predicted development of stage 3 AKI or death with an area under the curve of 0.81. Finally, category free net reclassification improvement showed that the addition of uAnCR to a clinical model to predict worsening of AM improved the predictive power. Conclusions Elevated uAnCR is associated with adverse outcomes inpatients with AKI. These data are the first to demonstrate the utility of angiotensinogen as a prognostic biomarker of AKI after cardiac surgery. Clin J Am Soc Nephrol 8: 184-193, 2013. doi: 10.2215/CJN.06280612 C1 [Alge, Joseph L.; Karakala, Nithin; Neely, Benjamin A.; Janech, Michael G.; Arthur, John M.] Med Univ S Carolina, Charleston, SC 29425 USA. [Karakala, Nithin; Janech, Michael G.; Arthur, John M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Tomlin, James A.] Univ Tennessee, Coll Med, Chattanooga, TN USA. [Chawla, Lakhmir S.] George Washington Univ, Washington, DC USA. [Shaw, Andrew D.] Duke Univ, Durham, NC USA. [Shaw, Andrew D.] Durham Vet Affairs Med Ctr, Durham, NC USA. RP Arthur, JM (reprint author), Med Univ S Carolina, Dept Med, Div Nephrol, 96 Jonathan Lucas St,POB 250623, Charleston, SC 29425 USA. EM arthurj@musc.edu RI Velez, Juan Carlos/N-3782-2016 OI Janech, Michael/0000-0002-3202-4811; Neely, Benjamin/0000-0001-6120-7695; Alge, Joseph/0000-0002-2491-1066 FU National Institutes of Health [R01 DK080234, UL1 RR029882]; Department of Veterans Affairs; Nephcure Foundation FX This study was supported by the National Institutes of Health (Grants R01 DK080234 and UL1 RR029882) and by a Merit Review award from the Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs. M.J. was supported by the Nephcure Foundation as a young investigator. The contents do not necessarily represent the views of the Department of Veterans Affairs or the US Government. NR 36 TC 26 Z9 27 U1 0 U2 3 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD FEB PY 2013 VL 8 IS 2 BP 184 EP 193 DI 10.2215/CJN.06280612 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 083TT UT WOS:000314488800005 PM 23143504 ER PT J AU Johansen, KL Kaysen, GA Dalrymple, LS Grimes, BA Glidden, DV Anand, S Chertow, GM AF Johansen, Kirsten L. Kaysen, George A. Dalrymple, Lorien S. Grimes, Barbara A. Glidden, David V. Anand, Shuchi Chertow, Glenn M. TI Association of Physical Activity with Survival among Ambulatory Patients on Dialysis: The Comprehensive Dialysis Study SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID STAGE RENAL-DISEASE; DOSE-RESPONSE; MORTALITY; METAANALYSIS; COHORT; HEMODIALYSIS AB Background and objectives Despite high mortality and low levels of physical activity (PA) among patients starting dialysis, the link between low PA and mortality has not been carefully evaluated. Design, setting, participants, & measurements The Comprehensive Dialysis Study was a prospective cohort study that enrolled patients who started dialysis between June 2005 and June 2007 in a random sample of dialysis facilities in the United States. The Human Activity Profile (HAP) was administered to estimate PA among 1554 ambulatory enrolled patients in the Comprehensive Dialysis Study. Patients were followed until death or September 30, 2009, and the major outcome was all-cause mortality. Results The average age was 59.8 (14.2) years; 55% of participants were male, 28% were black, and 56% had diabetes mellitus. The majority (57.3%) had low fitness estimated from the HAP score. The median follow-up was 2.6 (interquartile range, 2.2-3.1) years. The association between PA and mortality was linear across the range of scores (1-94). After multivariable adjustment, lower adjusted activity score on the HAP was associated with higher mortality (hazard ratio, 1.30; 95% confidence interval, 1.23-1.39 per 10 points). Patients in the lowest level of fitness experienced a 3.5-fold (95% confidence interval, 2.54-4.89) increase in risk of death compared with those with average or above fitness. Conclusions Low levels of PA are strongly associated with mortality among patients new to dialysis. Interventions aimed to preserve or enhance PA should be prospectively tested. Clin J Am Soc Nephrol 8: 248-253, 2013. doi: 10.2215/CJN.08560812 C1 [Johansen, Kirsten L.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Johansen, Kirsten L.] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA 94121 USA. [Kaysen, George A.; Dalrymple, Lorien S.] Univ Calif Davis, Div Nephrol, Davis, CA 95616 USA. [Grimes, Barbara A.; Glidden, David V.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Anand, Shuchi; Chertow, Glenn M.] Stanford Univ, Div Nephrol, Stanford, CA 94305 USA. RP Johansen, KL (reprint author), San Francisco VA Med Ctr, Nephrol Sect, 111J,4150 Clement St, San Francisco, CA 94121 USA. EM Kirsten.johansen@ucsf.edu FU National Institutes of Health [N01-DK-1-2450, N01-DK-7-0005]; Abbott Laboratories Inc FX This study was supported by the National Institutes of Health (Contracts N01-DK-1-2450 to G.M.C. and N01-DK-7-0005 to K.L.J.). The interpretation and reporting of the data presented here are the responsibility of the authors and in no way should be seen as an official policy or interpretation of the US government.; K.L.J. has received grant support from Abbott Laboratories Inc and has served on Amgen's National Nephrology Advisory Board. NR 21 TC 27 Z9 28 U1 0 U2 3 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD FEB PY 2013 VL 8 IS 2 BP 248 EP 253 DI 10.2215/CJN.08560812 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 083TT UT WOS:000314488800013 PM 23124787 ER PT J AU Pomeroy, J Renstrom, F Gradmark, AM Mogren, I Persson, M Bluck, L Wright, A Kahn, SE Domellof, M Franks, PW AF Pomeroy, Jeremy Renstrom, Frida Gradmark, Anna M. Mogren, Ingrid Persson, Margareta Bluck, Les Wright, Antony Kahn, Steven E. Domellof, Magnus Franks, Paul W. TI Maternal Physical Activity and Insulin Action in Pregnancy and Their Relationships With Infant Body Composition SO DIABETES CARE LA English DT Article ID SENSITIVITY; WOMEN; SECRETION AB OBJECTIVE-We sought to assess the association between maternal gestational physical activity and insulin action and body composition in early infancy. RESEARCH DESIGN AND METHODS-At 28-32 weeks' gestation, pregnant women participating in an observational study in Sweden underwent assessments of height, weight, and body composition, an oral glucose tolerance test, and 10 days of objective physical activity assessment. Thirty mothers and infants returned at 11-19 weeks postpartum. Infants underwent assessments of weight, length, and body composition. RESULTS-Early insulin response was correlated with total physical activity (r = 0.47; P = 0.007). Early insulin response (r = -0.36; P = 0.045) and total physical activity (r = 0.52; P = 0.037) were also correlated with infant fat-free mass. No maternal variable was significantly correlated with infant adiposity. CONCLUSIONS-The relationships between maternal physical activity, insulin response, and infant fat-free mass suggest that physical activity during pregnancy may affect metabolic outcomes in the mother and her offspring. Diabetes Care 36:267-269, 2013 C1 [Pomeroy, Jeremy; Renstrom, Frida; Franks, Paul W.] Lund Univ, Skane Univ Hosp, Dept Clin Sci, Genet & Mol Epidemiol Unit, Malmo, Sweden. [Pomeroy, Jeremy] NIH, Phoenix Epidemiol & Clin Res Branch, Phoenix, AZ USA. [Renstrom, Frida; Franks, Paul W.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Renstrom, Frida; Gradmark, Anna M.; Franks, Paul W.] Umea Univ, Med Sect, Genet Epidemiol & Clin Res Grp, Dept Publ Hlth & Clin Med, Umea, Sweden. [Mogren, Ingrid; Persson, Margareta] Umea Univ, Dept Clin Sci, Obstet & Gynecol Unit, Umea, Sweden. [Persson, Margareta] Dalarna Univ, Sch Hlth & Social Studies, Falun, Sweden. [Bluck, Les; Wright, Antony] MRC Human Nutr Res, Cambridge, England. [Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. [Domellof, Magnus] Umea Univ, Dept Pediat, Umea, Sweden. RP Franks, PW (reprint author), Lund Univ, Skane Univ Hosp, Dept Clin Sci, Genet & Mol Epidemiol Unit, Malmo, Sweden. EM jeremy.pomeroy@nih.gov; paul.franks@med.lu.se RI Domellof, Magnus/E-5307-2011 OI Domellof, Magnus/0000-0002-0726-7029; Mogren, Ingrid/0000-0003-2985-1135; Franks, Paul/0000-0002-0520-7604; Kahn, Steven/0000-0001-7307-9002 FU Torsten Soderberg foundation; Ragnar Soderberg foundation; Fredrik and Ingrid Thurings Foundation; Vasterbotten regional health authority; Medical Research Council Unit [U1059]; National Institute of Diabetes and Digestive and Kidney Diseases; U.S. Department of Veterans Affairs FX This study was a preparatory project for the LifeGene Study (www.lifegene.se) and was funded by the Torsten and Ragnar Soderberg foundations, Fredrik and Ingrid Thurings Foundation, and Vasterbotten regional health authority (all grants to P.W.F.). The stable isotope measurements were conducted under the Medical Research Council Unit Program U1059. J.P. was supported by the National Institute of Diabetes and Digestive and Kidney Diseases Intramural Research Program. S.E.K. was supported in part by the U.S. Department of Veterans Affairs. NR 9 TC 8 Z9 8 U1 0 U2 11 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD FEB PY 2013 VL 36 IS 2 BP 267 EP 269 DI 10.2337/dc12-0885 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 083MA UT WOS:000314467100023 PM 22966095 ER PT J AU Wander, PL Boyko, EJ Leonetti, DL McNeely, MJ Kahn, SE Fujimoto, WY AF Wander, Pandora L. Boyko, Edward J. Leonetti, Donna L. McNeely, Marguerite J. Kahn, Steven E. Fujimoto, Wilfred Y. TI Change in Visceral Adiposity Independently Predicts a Greater Risk of Developing Type 2 Diabetes Over 10 Years in Japanese Americans SO DIABETES CARE LA English DT Article ID BODY-FAT DISTRIBUTION; IMPAIRED GLUCOSE-TOLERANCE; INSULIN-RESISTANCE; LIFETIME RISK; MELLITUS; OBESITY; MEN; CLASSIFICATION; DISEASE; WEIGHT AB OBJECTIVE-Visceral adiposity is an important risk factor for cardiovascular disease and type 2 diabetes. We sought to determine whether change in intraabdominal fat area (IAF) over time predicts subsequent development of diabetes. RESEARCH DESIGN AND METHODS-We followed up 436 nondiabetic Japanese-American subjects (mean age 51.9 years, mean BMI 24.2 kg/m(2), 54% male) for development of diabetes. We fit a logistic regression model to examine the association over a 10-year follow-up between change in IAF at 5-year follow-up and other fat areas (measured by computed tomography) and development of incident diabetes, adjusted for age, sex, family history of diabetes in a first-degree relative, second-generation versus third-generation Japanese American (Nisei vs. Sansei), baseline IAF, BMI, weight change over time, smoking status, physical activity level, and subcutaneous fat (SCF) depot areas. RESULTS-Cumulative incidence of diabetes was 20.4% at 10 years. Mean change in IAF was 10.9 cm(2). An increase of 1 SD in IAF was associated with a 1.65-fold increase in the odds of diabetes over 10 years (OR = 1.65, 95% CI 1.21-2.25) after adjusting for the above covariates. This association was also independent of changes in thoracic, thigh, and abdominal SCF, as well as change in weight. CONCLUSIONS-We conclude that baseline IAF and accumulation of fat in this area over time are independent predictors of the development of type 2 diabetes in Japanese Americans. Diabetes Care 36:289-293, 2013 C1 [Wander, Pandora L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Boyko, Edward J.; McNeely, Marguerite J.; Kahn, Steven E.; Fujimoto, Wilfred Y.] Univ Washington, Dept Med, Seattle, WA USA. [Boyko, Edward J.; Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Leonetti, Donna L.] Univ Washington, Dept Anthropol, Seattle, WA 98195 USA. RP Wander, PL (reprint author), Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. EM lwander@u.washington.edu OI Wander, Pandora/0000-0003-3671-1464; Kahn, Steven/0000-0001-7307-9002; Boyko, Edward/0000-0002-3695-192X FU National Institutes of Health [DK-31170, HL-49293, DK-02654]; Diabetes Research Center [DK-17047]; Clinical Nutrition Research Unit [DK-35816]; General Clinical Research Center at the University of Washington [RR-00037] FX This work was supported by National Institutes of Health grants DK-31170, HL-49293, and DK-02654 and by facilities and services provided by the Diabetes Research Center (DK-17047), Clinical Nutrition Research Unit (DK-35816), and the General Clinical Research Center (RR-00037) at the University of Washington. VA Puget Sound Health Care System provides support for the involvement of E.J.B. and S.E.K. in this research. NR 33 TC 22 Z9 22 U1 0 U2 4 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD FEB PY 2013 VL 36 IS 2 BP 289 EP 293 DI 10.2337/dc12-0198 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 083MA UT WOS:000314467100028 PM 22966093 ER PT J AU Willette, AA Xu, GF Johnson, SC Birdsill, AC Jonaitis, EM Sager, MA Hermann, BP La Rue, A Asthana, S Bendlin, BB AF Willette, Auriel A. Xu, Guofan Johnson, Sterling C. Birdsill, Alex C. Jonaitis, Erin M. Sager, Mark A. Hermann, Bruce P. La Rue, Asenath Asthana, Sanjay Bendlin, Barbara B. TI Insulin Resistance, Brain Atrophy, and Cognitive Performance in Late Middle-Aged Adults SO DIABETES CARE LA English DT Article ID GRAY-MATTER VOLUME; ALZHEIMERS-DISEASE; RHESUS-MONKEYS; DYSFUNCTION; RECEPTOR; GLUCOSE; BETA; MORPHOMETRY; METABOLISM; MECHANISMS AB OBJECTIVE-Insulin resistance dysregulates glucose uptake and other functions in brain areas affected by Alzheimer disease. Insulin resistance may play a role in Alzheimer disease etiopathogenesis. This longitudinal study examined whether insulin resistance among late middle-aged, cognitively healthy individuals was associated with 1) less gray matter in Alzheimer disease-sensitive brain regions and 2) worse cognitive performance. RESEARCH DESIGN AND METHODS-Homeostasis model assessment of insulin resistance, gray matter volume, and the Rey Auditory Verbal Learning Test (RAVLT) were acquired in 372 participants at baseline and a consecutive subset of 121 individuals similar to 4 years later. Voxel-based morphometry and tensor-based morphometry were used, respectively, to test the association of insulin resistance with baseline brain volume and progressive gray matter atrophy. RESULTS-Higher insulin resistance predicted less gray matter at baseline and 4 years later in medial temporal lobe, prefrontal cortices, precuneus, and other parietal gyri. A region-of-interest analysis, independent of the voxel-wise analyses, confirmed that higher insulin resistance was related to medial temporal lobe atrophy. Atrophy itself corresponded to cognitive deficits in the RAVLT. Temporal lobe atrophy that was predicted by higher insulin resistance significantly mediated worse RAVLT encoding performance. CONCLUSIONS-These results suggest that insulin resistance in an asymptomatic, late middle-aged cohort is associated with progressive atrophy in regions affected by early Alzheimer disease. Insulin resistance may also affect the ability to encode episodic information by negatively influencing gray matter volume in medial temporal lobe. Diabetes Care 36:443-449, 2013 C1 [Willette, Auriel A.; Xu, Guofan; Johnson, Sterling C.; Birdsill, Alex C.; Asthana, Sanjay; Bendlin, Barbara B.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Willette, Auriel A.; Johnson, Sterling C.] Univ Wisconsin, Waisman Lab Brain Imaging & Behav, Madison, WI USA. [Willette, Auriel A.; Xu, Guofan; Johnson, Sterling C.; Birdsill, Alex C.; Jonaitis, Erin M.; Sager, Mark A.; Hermann, Bruce P.; La Rue, Asenath; Asthana, Sanjay; Bendlin, Barbara B.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Dis Res Ctr, Madison, WI USA. [Xu, Guofan] Univ Wisconsin, Dept Nucl Med, Madison, WI USA. [Jonaitis, Erin M.; Sager, Mark A.; Hermann, Bruce P.; La Rue, Asenath; Asthana, Sanjay] Wisconsin Sch Med & Publ Hlth, Wisconsin Alzheimers Inst, Madison, WI USA. RP Bendlin, BB (reprint author), William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. EM bbb@medicine.wisc.edu OI Bendlin, Barbara/0000-0002-0580-9875 FU National Institutes of Health [R01AG21155, R01AG027161, P50AG033514] FX This study was supported by National Institutes of Health grants R01AG21155, R01AG027161, and P50AG033514. Portions of data collection and analysis were facilitated by resources from the Veterans Administration at the William S. Middleton Memorial Veterans Hospital and Geriatric Research Education and Clinical Center in Madison, Wisconsin. NR 40 TC 52 Z9 52 U1 1 U2 12 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD FEB PY 2013 VL 36 IS 2 BP 443 EP 449 DI 10.2337/dc12-0922 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 083MA UT WOS:000314467100050 PM 23069842 ER PT J AU Dominitz, JA Baldwin, LM Green, P Kreuter, WI Ko, CW AF Dominitz, Jason A. Baldwin, Laura-Mae Green, Pamela Kreuter, William I. Ko, Cynthia W. TI Regional Variation in Anesthesia Assistance During Outpatient Colonoscopy Is Not Associated With Differences in Polyp Detection or Complication Rates SO GASTROENTEROLOGY LA English DT Article DE Colorectal Cancer Screening; Cost Efficacy; Quality; Pain ID DEEP SEDATION; UNITED-STATES; GI ENDOSCOPY; PROPOFOL; POPULATION; MEDICARE; ECONOMICS; SERVICES; QUALITY; SYSTEM AB BACKGROUND & AIMS: We investigated the rate and predictors of anesthesia assistance during outpatient colonoscopy and whether anesthesia assistance is associated with colonoscopy interventions and outcomes. METHODS: We performed a retrospective cohort study using a 20% sample of Medicare administrative claims submitted during the 2003 calendar year. We analyzed data from 328,177 adults, 66 years old or older, who underwent outpatient colonoscopy examinations. RESULTS: Overall, 8.7% of outpatient colonoscopies were performed with anesthesia assistance. In multivariate analysis, independent predictors of anesthesia assistance included black race, female sex, and a nonscreening indication; anesthesia assistance increased with median income and comorbidities. General and colorectal surgeons, fewer years in their practice, and nonhospital site of service were also significantly associated with anesthesia assistance. The strongest predictor of anesthesia assistance was the Medicare carrier, with odds ratios ranging from 0.22 (95% confidence interval: 0.12-0.43) for the Arkansas carrier (crude rate 0.9%) to 9.90 (95% confidence interval: 7.92-12.39) for the Empire carrier in New York area (crude rate 35.3%) compared with the Wisconsin carrier (crude rate 4.3%). There was also considerable variation among endoscopists; 75% of providers had no colonoscopies with anesthesia assistance recorded in their dataset, and 4.5% of providers had anesthesia assistance in at least three quarters of their examinations. Anesthesia assistance was not associated with the diagnosis of polyps, the performance of biopsy or polypectomy, or complications in multivariate analyses. CONCLUSIONS: There are significant variations among regions and sites of service in anesthesia assistance during outpatient colonoscopies of Medicare beneficiaries. Although this variation has considerable economic implications, it was not associated with measures of patient risk or outcomes, such as polyp detection or procedure-related complications. C1 [Dominitz, Jason A.; Green, Pamela] VA Puget Sound Hlth Care Syst, NW Ctr Outcomes Res Older Adults, Seattle, WA USA. [Dominitz, Jason A.; Ko, Cynthia W.] Univ Washington, Sch Med, Dept Med, Div Gastroenterol, Seattle, WA 98195 USA. [Baldwin, Laura-Mae] Univ Washington, Sch Med, Dept Family Med, Seattle, WA 98195 USA. [Kreuter, William I.] Univ Washington, Dept Hlth Serv, Sch Med, Seattle, WA 98195 USA. RP Dominitz, JA (reprint author), VA Puget Sound Hlth Care Syst S111 GI, 1660 S Columbian Way, Seattle, WA 98108 USA. EM Jason.Dominitz@va.gov OI Dominitz, Jason/0000-0002-8070-7086 FU American College of Gastroenterology; NIH [CA127659]; American Society for Gastrointestinal Endoscopy Endoscopic Research Career Development Award; VA Puget Sound Health Care System, Department of Veterans Affairs FX This material is based on work supported by the VA Puget Sound Health Care System, Department of Veterans Affairs. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs.; Support was received from the American College of Gastroenterology (CWK), NIH CA127659 (CWK), and American Society for Gastrointestinal Endoscopy Endoscopic Research Career Development Award (JAD). NR 30 TC 14 Z9 15 U1 1 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD FEB PY 2013 VL 144 IS 2 BP 298 EP 306 DI 10.1053/j.gastro.2012.10.038 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 086VL UT WOS:000314716300023 PM 23103615 ER PT J AU Shalbueva, N Mareninova, OA Gerloff, A Yuan, JZ Waldron, RT Pandol, SJ Gukovskaya, AS AF Shalbueva, Natalia Mareninova, Olga A. Gerloff, Andreas Yuan, Jingzhen Waldron, Richard T. Pandol, Stephen J. Gukovskaya, Anna S. TI Effects of Oxidative Alcohol Metabolism on the Mitochondrial Permeability Transition Pore and Necrosis in a Mouse Model of Alcoholic Pancreatitis SO GASTROENTEROLOGY LA English DT Article DE Tissue Damage; Ethanol Toxicity; Cell Death; Exocrine Pancreas ID KAPPA-B ACTIVATION; ACINAR-CELLS; CYCLOPHILIN-D; ACETALDEHYDE METABOLISM; MOLECULAR-MECHANISMS; CYCLOSPORINE-A; ETHANOL; CALCIUM; DEATH; APOPTOSIS AB BACKGROUND & AIMS: Opening of the mitochondrial permeability transition pore (MPTP) causes loss of the mitochondrial membrane potential (Delta Psi m) and, ultimately, adenosine triphosphate depletion and necrosis. Cells deficient in cyclophilin D (CypD), a component of the MPTP, are resistant to MPTP opening, loss of Delta Psi m, and necrosis. Alcohol abuse is a major risk factor for pancreatitis and is believed to sensitize the pancreas to stressors, by poorly understood mechanisms. We investigated the effects of ethanol on the pancreatic MPTP, the mechanisms of these effects, and their role in pancreatitis. METHODS: We measured Delta Psi m in mouse pancreatic acinar cells incubated with ethanol alone and in combination with physiologic and pathologic concentrations of cholecystokinin-8 (CCK). To examine the role of MPTP, we used ex vivo and in vivo models of pancreatitis, induced in wild-type and CypD(-/-) mice by a combination of ethanol and CCK. RESULTS: Ethanol reduced basal Delta Psi m and converted a transient depolarization, induced by physiologic concentrations of CCK, into a sustained decrease in Delta Psi m, resulting in reduced cellular adenosine triphosphate and increased necrosis. The effects of ethanol and CCK were mediated by MPTP because they were not observed in CypD(-/-) acinar cells. Ethanol and CCK activated MPTP through different mechanisms-ethanol by reducing the ratio of oxidized nicotinamide adenine dinucleotide to reduced nicotinamide adenine dinucleotide, as a result of oxidative metabolism, and CCK by increasing cytosolic Ca2+. CypD(-/-) mice developed a less-severe form of pancreatitis after administration of ethanol and CCK. CONCLUSIONS: Oxidative metabolism of ethanol sensitizes pancreatic mitochondria to activate MPTP, leading to mitochondrial failure; this makes the pancreas susceptible to necrotizing pancreatitis. C1 [Shalbueva, Natalia; Mareninova, Olga A.; Gerloff, Andreas; Yuan, Jingzhen; Waldron, Richard T.; Pandol, Stephen J.; Gukovskaya, Anna S.] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, So Calif Res Ctr Alcohol Liver & Pancreat Dis & C, Los Angeles, CA 90073 USA. [Shalbueva, Natalia] Russian Acad Sci, Inst Gen & Expt Biol, Siberian Branch, Ulan Ude, Russia. RP Gukovskaya, AS (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, W Los Angeles VA Healthcare Ctr, 11301 Wilshire Blvd,Bldg 258,Room 340, Los Angeles, CA 90073 USA. EM agukovsk@ucla.edu FU Southern California Research Center for ALPD and Cirrhosis (National Institutes of Health) [P50AA11999]; Department of Veterans Affairs; National Institutes of Health [R01 DK59936, R01 AA19730] FX Supported by the Southern California Research Center for ALPD and Cirrhosis (National Institutes of Health grant P50AA11999), Department of Veterans Affairs, and in part by the National Institutes of Health (R01 grants DK59936 and AA19730). NR 42 TC 14 Z9 14 U1 1 U2 11 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD FEB PY 2013 VL 144 IS 2 BP 437 EP + DI 10.1053/j.gastro.2012.10.037 PG 16 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 086VL UT WOS:000314716300037 PM 23103769 ER EF